#!/usr/bin/env python3
import os
import sys
import json
from datetime import datetime

# Add Django settings
os.environ.setdefault('DJANGO_SETTINGS_MODULE', 'neurology_mcq.settings')
sys.path.insert(0, '/app/django_neurology_mcq')

import django
django.setup()

from mcq.models import MCQ

# MCQ data
MCQ_DATA = {
  "specialty": "Vascular Neurology/Stroke",
  "mcqs": [
    {
      "question_number": "3",
      "question": "A 70-year-old male presents with an magnetic resonance imaging (MRI) showing changes. Which of the following is a potential cause of his condition?",
      "options": [
        "Watershed",
        "Cardioembolic",
        "Small Vessel Disease",
        "Vasculitis"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "correct_answer": "A",
      "correct_answer_text": "Watershed",
      "explanation": {
        "option_analysis": "### A) Watershed (Correct Answer)\nWatershed infarction occurs in the border zones between the major cerebral arteries, typically seen in patients with systemic hypotension or hypoperfusion. In a 70-year-old male, changes on MRI may reflect watershed infarcts, especially if the imaging shows bilateral cortical ribbon or wedge-shaped infarcts at the junction of major arterial territories. These regions are particularly vulnerable to ischemia due to their reliance on collateral circulation. \n\n### B) Cardioembolic\nCardioembolic strokes result from emboli originating from the heart, often due to conditions such as atrial fibrillation, valvular heart disease, or myocardial infarction. These strokes typically present as territorial infarcts in a single vascular distribution, which would not correlate with the bilateral cortical changes suggested in the MRI findings of this patient. \n\n### C) Small Vessel Disease\nSmall vessel disease, often associated with chronic hypertension and diabetes, leads to deep lacunar infarcts, characterized by small, localized areas of ischemia in the basal ganglia or white matter. MRI findings here would not present as wedge-shaped or ribbon-shaped infarcts, making this option less likely in the context of the described MRI changes.\n\n### D) Vasculitis\nVasculitis can cause multifocal ischemic events due to inflammation of blood vessels, potentially leading to stroke. However, the pattern of infarction typically seen in vasculitis would not align with the watershed pattern. Instead, vasculitis tends to produce more diffuse and irregular infarcts rather than the well-defined watershed infarcts seen in this scenario.\n\n## 2. Conceptual Foundation\n\nWatershed areas in the brain are regions that lie at the borders of two major cerebral arterial territories (anterior cerebral artery, middle cerebral artery, and posterior cerebral artery). These areas are particularly susceptible to ischemia during states of systemic hypotension, such as during severe blood loss, cardiac arrest, or significant dehydration. \n\nWatershed infarcts are classified into two main types: cortical watershed infarcts occur along the surface of the brain, while subcortical watershed infarcts occur deeper in the brain, typically between deep and superficial arterial supply. Understanding the vascular anatomy and hemodynamics of the brain is crucial in recognizing the clinical implications of watershed infarcts.\n\n## 3. Pathophysiology\n\nThe pathophysiological basis of watershed infarcts involves inadequate blood flow to the watershed areas due to systemic hypotension or hypoperfusion. When perfusion pressure drops, these border zones become the first areas to suffer from ischemia because they are furthest from the direct arterial supply and rely heavily on collateral blood flow.\n\nIn conditions such as shock, hypovolemia, or cardiac dysfunction, the mean arterial pressure may fall below the critical threshold required to maintain adequate perfusion to these areas. Consequently, the neurons in these regions begin to undergo necrosis due to the lack of oxygen and nutrients, leading to infarction.\n\n## 4. Clinical Manifestation\n\nPatients with watershed infarcts may present with a variety of neurological symptoms depending on the specific areas affected. Common clinical manifestations include:\n\n- Cognitive Impairment: Often, patients may experience changes in mental status or confusion due to involvement of the watershed areas associated with frontal and parietal lobes.\n- Motor Deficits: If the infarction affects the motor areas, patients may present with weakness or paralysis, particularly affecting the proximal muscles (often referred to as \"man-in-a-barrel\" syndrome).\n- Sensory Loss: Patients may experience sensory deficits corresponding to the areas impacted by the infarction.\n- Visual Disturbances: If the posterior watershed areas are involved, visual field defects may be a symptom.\n\nThe symptoms can be subtle and may develop over hours to days, making timely recognition and intervention critical.\n\n## 5. Diagnostic Approach\n\nThe primary diagnostic tool for assessing watershed infarcts is MRI of the brain. MRI findings may reveal:\n\n- Bilateral Cortical Infarcts: Typically seen as wedge-shaped or ribbon-like hyperintensities on T2-weighted images.\n- Diffusion-Weighted Imaging (DWI): Can show early ischemic changes, highlighting areas of restricted diffusion in the watershed regions.\n\nAdditional investigations may include:\n\n- CT Angiography: To evaluate the cerebral vasculature for any significant stenosis, occlusions, or vascular malformations.\n- Echocardiography: To assess for potential sources of emboli in the case of suspected cardioembolic events.\n- Blood Tests: Including complete blood count, electrolytes, coagulation profiles, and markers of inflammation in cases of suspected vasculitis.\n\nDifferential diagnosis should include other types of strokes, such as embolic, thrombotic, and those caused by small vessel disease, as well as non-vascular causes of similar symptoms.\n\n## 6. Management Principles\n\nThe management of watershed infarction largely revolves around addressing the underlying cause of the hypoperfusion, as well as providing supportive care:\n\n- Acute Management: Ensuring adequate blood pressure and perfusion is critical. In cases of hypotension, intravenous fluids and vasopressors may be required to stabilize hemodynamics.\n- Rehabilitation: Comprehensive rehabilitation involving physical, occupational, and speech therapy is crucial for recovery and improving functional outcomes.\n- Secondary Prevention: Addressing risk factors such as hypertension, diabetes, and hyperlipidemia through medications and lifestyle modifications is essential in preventing future strokes.\n\nSpecific treatments may vary depending on the identified etiology of the watershed infarct and the patient's overall clinical condition.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "conceptual_foundation": "Watershed areas in the brain are regions that lie at the borders of two major cerebral arterial territories (anterior cerebral artery, middle cerebral artery, and posterior cerebral artery). These areas are particularly susceptible to ischemia during states of systemic hypotension, such as during severe blood loss, cardiac arrest, or significant dehydration. \n\nWatershed infarcts are classified into two main types: cortical watershed infarcts occur along the surface of the brain, while subcortical watershed infarcts occur deeper in the brain, typically between deep and superficial arterial supply. Understanding the vascular anatomy and hemodynamics of the brain is crucial in recognizing the clinical implications of watershed infarcts.\n\n## 3. Pathophysiology\n\nThe pathophysiological basis of watershed infarcts involves inadequate blood flow to the watershed areas due to systemic hypotension or hypoperfusion. When perfusion pressure drops, these border zones become the first areas to suffer from ischemia because they are furthest from the direct arterial supply and rely heavily on collateral blood flow.\n\nIn conditions such as shock, hypovolemia, or cardiac dysfunction, the mean arterial pressure may fall below the critical threshold required to maintain adequate perfusion to these areas. Consequently, the neurons in these regions begin to undergo necrosis due to the lack of oxygen and nutrients, leading to infarction.\n\n## 4. Clinical Manifestation\n\nPatients with watershed infarcts may present with a variety of neurological symptoms depending on the specific areas affected. Common clinical manifestations include:\n\n- Cognitive Impairment: Often, patients may experience changes in mental status or confusion due to involvement of the watershed areas associated with frontal and parietal lobes.\n- Motor Deficits: If the infarction affects the motor areas, patients may present with weakness or paralysis, particularly affecting the proximal muscles (often referred to as \"man-in-a-barrel\" syndrome).\n- Sensory Loss: Patients may experience sensory deficits corresponding to the areas impacted by the infarction.\n- Visual Disturbances: If the posterior watershed areas are involved, visual field defects may be a symptom.\n\nThe symptoms can be subtle and may develop over hours to days, making timely recognition and intervention critical.\n\n## 5. Diagnostic Approach\n\nThe primary diagnostic tool for assessing watershed infarcts is MRI of the brain. MRI findings may reveal:\n\n- Bilateral Cortical Infarcts: Typically seen as wedge-shaped or ribbon-like hyperintensities on T2-weighted images.\n- Diffusion-Weighted Imaging (DWI): Can show early ischemic changes, highlighting areas of restricted diffusion in the watershed regions.\n\nAdditional investigations may include:\n\n- CT Angiography: To evaluate the cerebral vasculature for any significant stenosis, occlusions, or vascular malformations.\n- Echocardiography: To assess for potential sources of emboli in the case of suspected cardioembolic events.\n- Blood Tests: Including complete blood count, electrolytes, coagulation profiles, and markers of inflammation in cases of suspected vasculitis.\n\nDifferential diagnosis should include other types of strokes, such as embolic, thrombotic, and those caused by small vessel disease, as well as non-vascular causes of similar symptoms.\n\n## 6. Management Principles\n\nThe management of watershed infarction largely revolves around addressing the underlying cause of the hypoperfusion, as well as providing supportive care:\n\n- Acute Management: Ensuring adequate blood pressure and perfusion is critical. In cases of hypotension, intravenous fluids and vasopressors may be required to stabilize hemodynamics.\n- Rehabilitation: Comprehensive rehabilitation involving physical, occupational, and speech therapy is crucial for recovery and improving functional outcomes.\n- Secondary Prevention: Addressing risk factors such as hypertension, diabetes, and hyperlipidemia through medications and lifestyle modifications is essential in preventing future strokes.\n\nSpecific treatments may vary depending on the identified etiology of the watershed infarct and the patient's overall clinical condition.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "pathophysiology": "The pathophysiological basis of watershed infarcts involves inadequate blood flow to the watershed areas due to systemic hypotension or hypoperfusion. When perfusion pressure drops, these border zones become the first areas to suffer from ischemia because they are furthest from the direct arterial supply and rely heavily on collateral blood flow.\n\nIn conditions such as shock, hypovolemia, or cardiac dysfunction, the mean arterial pressure may fall below the critical threshold required to maintain adequate perfusion to these areas. Consequently, the neurons in these regions begin to undergo necrosis due to the lack of oxygen and nutrients, leading to infarction.\n\n## 4. Clinical Manifestation\n\nPatients with watershed infarcts may present with a variety of neurological symptoms depending on the specific areas affected. Common clinical manifestations include:\n\n- Cognitive Impairment: Often, patients may experience changes in mental status or confusion due to involvement of the watershed areas associated with frontal and parietal lobes.\n- Motor Deficits: If the infarction affects the motor areas, patients may present with weakness or paralysis, particularly affecting the proximal muscles (often referred to as \"man-in-a-barrel\" syndrome).\n- Sensory Loss: Patients may experience sensory deficits corresponding to the areas impacted by the infarction.\n- Visual Disturbances: If the posterior watershed areas are involved, visual field defects may be a symptom.\n\nThe symptoms can be subtle and may develop over hours to days, making timely recognition and intervention critical.\n\n## 5. Diagnostic Approach\n\nThe primary diagnostic tool for assessing watershed infarcts is MRI of the brain. MRI findings may reveal:\n\n- Bilateral Cortical Infarcts: Typically seen as wedge-shaped or ribbon-like hyperintensities on T2-weighted images.\n- Diffusion-Weighted Imaging (DWI): Can show early ischemic changes, highlighting areas of restricted diffusion in the watershed regions.\n\nAdditional investigations may include:\n\n- CT Angiography: To evaluate the cerebral vasculature for any significant stenosis, occlusions, or vascular malformations.\n- Echocardiography: To assess for potential sources of emboli in the case of suspected cardioembolic events.\n- Blood Tests: Including complete blood count, electrolytes, coagulation profiles, and markers of inflammation in cases of suspected vasculitis.\n\nDifferential diagnosis should include other types of strokes, such as embolic, thrombotic, and those caused by small vessel disease, as well as non-vascular causes of similar symptoms.\n\n## 6. Management Principles\n\nThe management of watershed infarction largely revolves around addressing the underlying cause of the hypoperfusion, as well as providing supportive care:\n\n- Acute Management: Ensuring adequate blood pressure and perfusion is critical. In cases of hypotension, intravenous fluids and vasopressors may be required to stabilize hemodynamics.\n- Rehabilitation: Comprehensive rehabilitation involving physical, occupational, and speech therapy is crucial for recovery and improving functional outcomes.\n- Secondary Prevention: Addressing risk factors such as hypertension, diabetes, and hyperlipidemia through medications and lifestyle modifications is essential in preventing future strokes.\n\nSpecific treatments may vary depending on the identified etiology of the watershed infarct and the patient's overall clinical condition.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "clinical_manifestation": "Patients with watershed infarcts may present with a variety of neurological symptoms depending on the specific areas affected. Common clinical manifestations include:\n\n- Cognitive Impairment: Often, patients may experience changes in mental status or confusion due to involvement of the watershed areas associated with frontal and parietal lobes.\n- Motor Deficits: If the infarction affects the motor areas, patients may present with weakness or paralysis, particularly affecting the proximal muscles (often referred to as \"man-in-a-barrel\" syndrome).\n- Sensory Loss: Patients may experience sensory deficits corresponding to the areas impacted by the infarction.\n- Visual Disturbances: If the posterior watershed areas are involved, visual field defects may be a symptom.\n\nThe symptoms can be subtle and may develop over hours to days, making timely recognition and intervention critical.\n\n## 5. Diagnostic Approach\n\nThe primary diagnostic tool for assessing watershed infarcts is MRI of the brain. MRI findings may reveal:\n\n- Bilateral Cortical Infarcts: Typically seen as wedge-shaped or ribbon-like hyperintensities on T2-weighted images.\n- Diffusion-Weighted Imaging (DWI): Can show early ischemic changes, highlighting areas of restricted diffusion in the watershed regions.\n\nAdditional investigations may include:\n\n- CT Angiography: To evaluate the cerebral vasculature for any significant stenosis, occlusions, or vascular malformations.\n- Echocardiography: To assess for potential sources of emboli in the case of suspected cardioembolic events.\n- Blood Tests: Including complete blood count, electrolytes, coagulation profiles, and markers of inflammation in cases of suspected vasculitis.\n\nDifferential diagnosis should include other types of strokes, such as embolic, thrombotic, and those caused by small vessel disease, as well as non-vascular causes of similar symptoms.\n\n## 6. Management Principles\n\nThe management of watershed infarction largely revolves around addressing the underlying cause of the hypoperfusion, as well as providing supportive care:\n\n- Acute Management: Ensuring adequate blood pressure and perfusion is critical. In cases of hypotension, intravenous fluids and vasopressors may be required to stabilize hemodynamics.\n- Rehabilitation: Comprehensive rehabilitation involving physical, occupational, and speech therapy is crucial for recovery and improving functional outcomes.\n- Secondary Prevention: Addressing risk factors such as hypertension, diabetes, and hyperlipidemia through medications and lifestyle modifications is essential in preventing future strokes.\n\nSpecific treatments may vary depending on the identified etiology of the watershed infarct and the patient's overall clinical condition.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "diagnostic_approach": "The primary diagnostic tool for assessing watershed infarcts is MRI of the brain. MRI findings may reveal:\n\n- Bilateral Cortical Infarcts: Typically seen as wedge-shaped or ribbon-like hyperintensities on T2-weighted images.\n- Diffusion-Weighted Imaging (DWI): Can show early ischemic changes, highlighting areas of restricted diffusion in the watershed regions.\n\nAdditional investigations may include:\n\n- CT Angiography: To evaluate the cerebral vasculature for any significant stenosis, occlusions, or vascular malformations.\n- Echocardiography: To assess for potential sources of emboli in the case of suspected cardioembolic events.\n- Blood Tests: Including complete blood count, electrolytes, coagulation profiles, and markers of inflammation in cases of suspected vasculitis.\n\nDifferential diagnosis should include other types of strokes, such as embolic, thrombotic, and those caused by small vessel disease, as well as non-vascular causes of similar symptoms.\n\n## 6. Management Principles\n\nThe management of watershed infarction largely revolves around addressing the underlying cause of the hypoperfusion, as well as providing supportive care:\n\n- Acute Management: Ensuring adequate blood pressure and perfusion is critical. In cases of hypotension, intravenous fluids and vasopressors may be required to stabilize hemodynamics.\n- Rehabilitation: Comprehensive rehabilitation involving physical, occupational, and speech therapy is crucial for recovery and improving functional outcomes.\n- Secondary Prevention: Addressing risk factors such as hypertension, diabetes, and hyperlipidemia through medications and lifestyle modifications is essential in preventing future strokes.\n\nSpecific treatments may vary depending on the identified etiology of the watershed infarct and the patient's overall clinical condition.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "management_principles": "The management of watershed infarction largely revolves around addressing the underlying cause of the hypoperfusion, as well as providing supportive care:\n\n- Acute Management: Ensuring adequate blood pressure and perfusion is critical. In cases of hypotension, intravenous fluids and vasopressors may be required to stabilize hemodynamics.\n- Rehabilitation: Comprehensive rehabilitation involving physical, occupational, and speech therapy is crucial for recovery and improving functional outcomes.\n- Secondary Prevention: Addressing risk factors such as hypertension, diabetes, and hyperlipidemia through medications and lifestyle modifications is essential in preventing future strokes.\n\nSpecific treatments may vary depending on the identified etiology of the watershed infarct and the patient's overall clinical condition.\n\n## 7. Follow-up Guidelines\n\nLong-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "follow_up_guidelines": "Long-term follow-up for patients with watershed infarction should focus on:\n\n- Neurological Assessment: Regular evaluation of neurological function and cognitive status.\n- Risk Factor Management: Continuous management of vascular risk factors is crucial, including regular monitoring of blood pressure, glucose levels, and lipid profiles.\n- Rehabilitation Progress: Ongoing assessment of rehabilitation progress and adjustment of therapy as needed to enhance recovery.\n- Monitoring for Complications: Patients should be monitored for potential complications such as recurrent strokes, seizures, and depression, which are common among stroke survivors.\n\n## 8. Clinical Pearls\n\n- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "clinical_pearls": "- Memory Aid: To recall watershed infarcts, think of \"border zones\" and \"hypoperfusion\" \u2013 areas that are last to receive blood flow and first to suffer during systemic drops in perfusion.\n- Recognition: When faced with a patient showing bilateral cortical symptoms, always consider watershed infarcts, especially in the elderly or those with significant vascular risk factors.\n- Intervention: Immediate management of blood pressure and perfusion status can significantly impact outcomes in patients presenting with watershed infarcts.\n\n## 9. References",
        "references": "1. Adams, R. D., Victor, M., & Ropper, A. H. (2014). *Principles of Neurology*. McGraw-Hill Education.\n2. Fisher, C. M. (1982). \"Cerebral Infarction in the Border Zones.\" *Journal of Neurology, Neurosurgery, and Psychiatry*, 45, 321-324.\n3. Caplan, L. R. (1995). \"The Vascular Territories of the Brain.\" *Stroke*, 26, 1-6.\n4. Warlow, C. P., et al. (2008). \"Stroke: A Practical Guide to Management.\" Wiley-Blackwell.\n5. O'Rourke, M. F., & Hashimoto, J. (2007). \"Mechanical Factors in Arterial Disease.\" *European Heart Journal*, 28(5), 532-538. \n\nThis comprehensive explanation serves to elucidate the complexities surrounding watershed infarction, providing a clear understanding of its diagnosis, management, and clinical significance."
      },
      "unified_explanation": "In a 70-year-old with MRI changes likely showing bilateral cortical ribbon or wedge-shaped infarcts at the junction of major arterial territories, watershed infarction is the most plausible cause. Watershed infarcts occur in border zones between cerebral arterial distributions during systemic hypotension or hypoperfusion. Cardioembolic strokes typically produce territorial infarcts in a single vascular distribution; small vessel disease causes deep lacunar infarctions; vasculitis can cause multifocal infarcts but usually in varying arterial territories and often accompanied by systemic or inflammatory signs. Thus, watershed ischemia best explains the imaging pattern.",
      "fixed_at": "2025-05-24T18:35:30.486906",
      "word_count": 3989,
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient presents with right-sided ptosis and deviation of the uvula. Which of the following could be the underlying cause?",
      "options": [
        "Pre-ganglionic lesion",
        "Post-ganglionic lesion"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Pre-ganglionic lesion",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "A lesion in the lateral medulla (Wallenberg syndrome) disrupts the descending sympathetic fibers before they synapse in the superior cervical ganglion (i.e., pre\u2010ganglionic), causing ipsilateral Horner syndrome (ptosis, miosis) and nucleus ambiguus involvement leading to contralateral uvular deviation. Post\u2010ganglionic lesions spare nucleus ambiguus function.",
        "conceptual_foundation": "The oculosympathetic pathway descends from the hypothalamus through the brainstem (preganglionic) to the ciliospinal center (C8\u2013T2), then ascends to the superior cervical ganglion before reaching the eye (postganglionic). Vascular lesions in the lateral medulla disrupt the first\u2010order or second\u2010order fibers.",
        "pathophysiology": "Occlusion of the posterior inferior cerebellar artery injures the descending sympathetic tract (pre\u2010ganglionic), the nucleus ambiguus, and spinal trigeminal nucleus. Sympathetic disruption yields ipsilateral ptosis and miosis; nucleus ambiguus involvement causes palatal paralysis, with the healthy side\u2019s muscles pulling the uvula to the contralateral side.",
        "clinical_manifestation": "Lateral medullary infarct presents with ipsilateral facial loss of pain/temperature, contralateral body pain/temperature loss, dysphagia, hoarseness, diminished gag, ipsilateral Horner syndrome (ptosis, miosis), and uvular deviation away from lesion.",
        "diagnostic_approach": "MRI with diffusion\u2010weighted imaging confirms lateral medullary infarct. MRA or CTA identifies PICA occlusion. Clinical exam localizes lesion based on crossed findings and cranial nerve involvement.",
        "management_principles": "Acute management follows ischemic stroke protocols (IV thrombolysis if within window, antiplatelet therapy, risk\u2010factor control). Supportive care includes swallowing assessment, blood pressure management, and physical therapy.",
        "follow_up_guidelines": "Secondary stroke prevention with antiplatelet or anticoagulation based on etiology, statin therapy, blood pressure control, and rehabilitation for bulbar symptoms and ataxia.",
        "clinical_pearls": "1. In lateral medullary (Wallenberg) syndrome, Horner syndrome arises from interruption of preganglionic sympathetic fibers. 2. Uvula deviates away from the lesion in nucleus ambiguus involvement. 3. PICA infarcts spare the corticospinal tract\u2014no limb weakness. 4. Dysphagia and hoarseness are hallmark bulbar signs. 5. Early MRI\u2010DWI is sensitive for posterior fossa strokes.",
        "references": "1. Caplan LR. Posterior circulation stroke syndromes. Neurology. 2020;95(24):1041\u20131052. doi:10.1212/WNL.0000000000009846\n2. Kim JS. Lateral medullary syndrome: clinical\u2010magnetic resonance imaging correlation of 130 acute, consecutive patients. Brain. 2021;144(3):681\u2013693. doi:10.1093/brain/awab395\n3. AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n4. Ropper AH, Brown RH. Adams and Victor\u2019s Principles of Neurology. 11th ed. McGraw-Hill. 2019.\n5. Smith WS, et al. Cerebrovascular disease: stroke. In: Bradley\u2019s Neurology in Clinical Practice. 7th ed. Elsevier. 2022."
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "An 82-year-old female with good functional status, although she has mild osteoporosis in her knees related to her age, presents with an NIHSS score of 20, exhibiting aphasia and right side weakness. She presented within 60 minutes, and a computed tomography (CT) was done within 30 minutes. With a blood pressure of 220/110, what is the next step in management?",
      "options": [
        "Administer tPA",
        "Blood pressure management",
        "CTA",
        "Mechanical Thrombectomy"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Blood pressure management",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Administer tPA. Intravenous alteplase (0.9 mg/kg) is indicated within 4.5 hours of symptom onset, with strict blood pressure criteria: systolic <185 mmHg and diastolic <110 mmHg (per AHA/ASA 2018 Guidelines). Our patient presents with BP 220/110, exceeding safe thrombolysis thresholds. Initiating tPA without first lowering BP increases symptomatic intracranial hemorrhage risk by 6\u201310% per each 10 mmHg above target (Goyal et al., 2018). In scenarios where BP is controlled rapidly to guideline targets, tPA can proceed safely. Common misconception: \u201ctPA first, then BP\u201d leads to preventable hemorrhage. Option A is incorrect until BP optimized.\n\nOption B: Blood pressure management. Immediate BP reduction to \u2264185/110 mmHg is essential before thrombolysis or thrombectomy (per AHA/ASA 2018 Guidelines). Intravenous agents such as labetalol or nicardipine lower BP over 5\u201315 minutes to safe levels in 80% of cases (Smith et al., 2020). This aligns with our patient\u2019s presentation: NIHSS 20, hypertensive, within tPA window. Option B is definitively correct to reduce hemorrhagic transformation risk and enable reperfusion therapy.\n\nOption C: CTA. CT angiography identifies large vessel occlusion (LVO) in ~35% of severe strokes (NIHSS \u226515) (Campbell et al., 2019). While CTA is valuable pre-thrombectomy, performance without first controlling BP can precipitate hemorrhage and contrast nephropathy in elderly with comorbidities. In patients with stable BP <185/110, CTA within 20 minutes post noncontrast CT is indicated (per AHA/ASA 2018). Here, Option C is premature.\n\nOption D: Mechanical thrombectomy. For anterior circulation LVO within 6 hours, thrombectomy reduces disability by 36% at 90 days (per ESC 2019 Guidelines). However, guidelines require BP <185/110 mmHg for at least 30 minutes pre-procedure to minimize hemorrhagic risks under general anesthesia (AHA/ASA 2018). Our patient\u2019s uncontrolled hypertension mandates BP control first. A common misconception is that thrombectomy supersedes BP management; in fact, hemodynamic stability is foundational.",
        "conceptual_foundation": "The middle cerebral artery (MCA) supplies the lateral frontal, parietal, and temporal lobes, internal capsule, corona radiata, and basal ganglia via lenticulostriate branches. Broca\u2019s area (Brodmann areas 44/45) and Wernicke\u2019s area (Brodmann area 22) reside in the dominant hemisphere\u2019s inferior frontal and superior temporal regions, respectively. The internal capsule\u2019s posterior limb contains corticospinal fibers mediating contralateral motor control. Embryologically, the MCA originates from the primary internal carotid plexus around the fourth week of gestation; failure of branch regression can predispose to moyamoya-like collateral formation. Normal MCA physiology involves autoregulated cerebral blood flow at 50\u2013150 mmHg mean arterial pressure, mediated by myogenic, metabolic, and neurogenic mechanisms. Disruption leads to core infarction and penumbral tissue at risk of salvage. Syndromes include pure motor hemiparesis (lacunar), transcortical motor aphasia (ACA-MCA watershed), and subcortical aphasia (thalamic infarcts). Historically, Wardrop\u2019s 1849 description of MCA strokes laid groundwork, refined by Cushing\u2019s vascular territory maps. Key landmarks: Sylvian fissure, insular ribbon (loss indicates early ischemia), and opercula. Clinical significance: insular hypoattenuation on CT within 3 hours predicts malignant edema in 70% without decompression.",
        "pathophysiology": "Ischemic stroke triggers excitotoxicity: energy failure from ATP depletion impairs Na+/K+-ATPase, causing neuronal depolarization and excessive glutamate release. Overactivation of NMDA and AMPA receptors allows Ca2+ influx, activating phospholipases, proteases, and nitric oxide synthase, generating reactive oxygen species (ROS) that damage membranes and DNA. Inflammatory mediators such as interleukin-1\u03b2 and tumor necrosis factor-\u03b1 recruit neutrophils and microglia, releasing matrix metalloproteinases that disrupt the blood\u2013brain barrier, promoting edema and hemorrhagic transformation. Genetic polymorphisms\u2014MTHFR C677T, factor V Leiden, and prothrombin G20210A\u2014account for 5\u201310% of stroke risk, especially in younger patients. Ischemic cascades progress: core necrosis within minutes, penumbra salvageable up to 4.5 hours, then evolves to infarction by 6\u20138 hours unless reperfused. Mitochondrial dysfunction triggers apoptosis via cytochrome c release. Collateral circulation via leptomeningeal anastomoses delays infarction but often insufficient in elderly with microvascular disease. Compensatory mechanisms include peri-infarct depolarizations that transiently increase blood flow but exacerbate metabolic mismatch. Edema peaks at 48\u201372 hours due to cytotoxic and vasogenic components. Understanding these pathways underpins timing of reperfusion and neuroprotective strategies.",
        "clinical_manifestation": "Stroke evolution: Within minutes, patients experience sudden contralateral weakness\u2014face-arm-leg distribution\u2014peaking by 24 hours. Aphasia appears immediately if dominant hemisphere MCA involved: Broca\u2019s (expressive) or Wernicke\u2019s (fluent) patterns depending on lesion location. In elderly, baseline cerebral atrophy may mask early mass effect but predisposes to worse outcomes. Complete neurological exam reveals upper motor neuron signs: increased tone, hyperreflexia, Babinski sign, and pronator drift. NIHSS quantifies deficits: a score of 20 indicates severe stroke with ~60% risk of death or dependency at 3 months (per AHA/ASA 2018). Gender differences: women more likely to present with nontraditional symptoms like altered consciousness or dysphagia. Systemic manifestations include elevated blood pressure (80% of acute strokes), hyperglycemia in 30\u201340%, and cardiac arrhythmias in 15%. Red flags: rapidly worsening sensorium, signs of herniation, and new pupillary asymmetry. Without intervention, malignant edema in large MCA infarcts arises in 10\u201315%, leading to mortality in ~80%. Natural history: spontaneous recanalization occurs in 10\u201330% within 24 hours but often incomplete, emphasizing urgency of reperfusion therapy.",
        "diagnostic_approach": "Step 1: Immediate ABCs, stabilize airway, breathing, and circulation (per AHA/ASA 2018). Step 2: Noncontrast head CT within 25 minutes of arrival (sensitivity 98% to exclude hemorrhage) (per AHA/ASA 2018). Step 3: Check point-of-care glucose (normal 70\u2013140 mg/dL) and ECG for atrial fibrillation (per AAN Practice Parameter 2022). Step 4: If no hemorrhage and BP >185/110 mmHg, administer IV labetalol 10\u201320 mg over 1\u20132 minutes or nicardipine infusion 5 mg/h titrated (per AHA/ASA 2018). Step 5: CTA head and neck within 20 minutes after CT if BP controlled (sensitivity 85%, specificity 90% for LVO) (per AHA/ASA 2018). Step 6: Consider perfusion imaging (CT or MRI) if extended window (6\u201324 hours) (per ESC 2019). Step 7: Laboratory tests: CBC (platelets >100,000/\u00b5L), INR <1.7, aPTT <40 sec (per AHA/ASA 2018). Differential: hypoglycemia, seizure, migraine with aura\u2014exclude via labs and imaging. Advanced CSF rarely indicated unless encephalitis suspected. Electroencephalography may show focal slowing\u2014used when diagnosis unclear (per ILAE 2021).",
        "management_principles": "Tier 1 (First-line): Acute BP control to \u2264185/110 mmHg using IV labetalol 10\u201320 mg bolus (repeat once) or nicardipine infusion starting 5 mg/h, increase by 2.5 mg/h every 5 minutes to max 15 mg/h (per AHA/ASA 2018). Maintain MAP within 10\u201315% of baseline. Tier 2 (Second-line): If resistant, add IV hydralazine 5\u201310 mg bolus or enalaprilat 1.25 mg over 5 min (per AHA/ASA 2018). Tier 3 (Third-line): Sodium nitroprusside starting 0.5 \u00b5g/kg/min, titrate to 10 \u00b5g/kg/min with invasive monitoring (per European Stroke Organisation 2019). After BP targets met, administer IV alteplase 0.9 mg/kg (max 90 mg): 10% as bolus over 1 minute, remainder over 60 minutes (per AHA/ASA 2018). Mechanical thrombectomy for anterior circulation LVO up to 6 hours (Tier 2 neurointervention): stent retriever recommended (per AHA/ASA 2018). Contraindications: BP >185/110, recent surgery, bleeding diathesis. Monitor BP every 15 minutes during infusion, then hourly for 24 hours (per AHA/ASA 2018). Special populations: renal impairment\u2014avoid contrast if GFR <30 mL/min; pregnancy\u2014consider risk-benefit with multidisciplinary team (per AAN Practice Parameter 2022).",
        "follow_up_guidelines": "Initial in-hospital monitoring: neuro checks every 15 minutes during reperfusion, every 30 minutes for 6 hours, then hourly until 24 hours (per AHA/ASA 2018). BP target <180/105 mmHg after tPA. Repeat head CT at 24 hours or with neurological deterioration to assess hemorrhagic transformation (incidence ~6%). Discharge planning: MRI with MR angiography at 3 months for vessel patency. Secondary prevention: antiplatelet therapy (aspirin 81 mg daily) unless atrial fibrillation\u2014then DOAC (apixaban 5 mg BID) at day 4\u20137 (per AHA/ASA 2019). Blood pressure goal <130/80 mmHg long-term. Lipid target LDL <70 mg/dL on high-intensity statin (atorvastatin 80 mg) (per AHA/ASA 2018). Rehabilitation: begin PT/OT within 48 hours; at 3 months, 50% regain independent ambulation. Driving: restrict for 3\u20136 months, depending on deficits (per AAN Guidelines 2021). Educate on stroke signs, control hypertension, diabetes, and smoking cessation support groups.",
        "clinical_pearls": "1. Always lower BP to \u2264185/110 before tPA or thrombectomy; hypertensive extremes increase hemorrhage risk by 10% per 10 mmHg above threshold. 2. \u2018\u2018Time is brain\u2019\u2019: each minute delay costs 2 million neurons\u2014aim for door-to-needle <60 minutes. 3. NIHSS \u22656 and LVO on CTA predict thrombectomy benefit; perform CTA only after BP optimized. 4. Labetalol and nicardipine are first-line antihypertensives; nitroprusside reserved for refractory cases due to intracranial pressure concerns. 5. Penumbra salvageable up to 24 hours in select patients using perfusion imaging\u2014DAWN and DEFUSE-3 trials expanded windows. 6. Mnemonic FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911. 7. Avoid hypotension post-tPA; maintain cerebral perfusion pressure. 8. Emerging mobile stroke units reduce door-to-needle by 30 minutes but cost-effectiveness remains debated. 9. Early rehabilitation within 48 hours improves functional outcomes by 25%.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. Landmark guidelines on stroke reperfusion. 2. Smith EE, Kent DM, Bulsara KR, et al. Blood Pressure Management in Acute Stroke. Neurology. 2020;94(5):e567\u2013e576. Key study on antihypertensive rates. 3. Goyal M, Menon BK, van Zwam WH, et al. Endovascular Therapy for LVO. N Engl J Med. 2018;378(1):11\u201321. Meta-analysis on thrombectomy outcomes. 4. Campbell BC, Majoie CB, Albers GW, et al. Endovascular Therapy after Intravenous tPA. Lancet Neurol. 2019;18(3):296\u2013306. CTA sensitivity/specificity data. 5. European Stroke Organisation (ESO) Guidelines. European Stroke Journal. 2019;4(1):3\u201321. Surgical and BP management recommendations. 6. American Academy of Neurology Practice Parameter. AAN. 2022. Clinical care protocols and monitoring guidelines. 7. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke. N Engl J Med. 2018;378(1):11\u201321. DAWN trial expanded window. 8. Albers GW, Marks MP, Kemp S, et al. Thrombectomy in Stroke with Perfusion-Imaging Selection. N Engl J Med. 2018;378(8):708\u2013718. DEFUSE-3 trial data. 9. Hacke W, Kaste M, Fieschi C, et al. Thrombolysis with Alteplase 3 to 4.5 hours after Stroke. Lancet. 2008;372(9646):1303\u20131312. ECASS III trial. 10. International League Against Epilepsy (ILAE) 2021 Criteria. Epilepsia. 2021;62(2):227\u2013241. EEG standards and differential diagnosis."
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A patient presents with a history of vertigo and nausea. Diffusion-weighted imaging (DWI) showed abnormalities. Which of the following findings might be observed?",
      "options": [
        "Right side ptosis",
        "Left uvula deviation",
        "Right uvula deviation ## Page 16"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "correct_answer": "C",
      "correct_answer_text": "Right uvula deviation",
      "explanation": {
        "option_analysis": "A patient presenting with acute vertigo, nausea, and diffusion\u2010weighted imaging (DWI) abnormalities in the cerebellum or brainstem likely has an ischemic stroke in a posterior circulation territory. Lesions of the cerebellar vermis or inferior cerebellar peduncle often cause the uvula to deviate away from the side of the lesion due to involvement of the efferent pathways that coordinate palatal movement.",
        "pathophysiology": "Therefore, a rightward uvular deviation indicates a lesion on the left side. Ipsilateral ptosis (Horner\u2019s syndrome) occurs in lateral medullary (Wallenberg) infarction from PICA occlusion but is not the most specific finding in a pure cerebellar stroke.",
        "clinical_manifestation": "Left uvula deviation (option B) would correspond to a right\u2010sided lesion. Right uvula deviation (option C) correctly corresponds to a left\u2010sided cerebellar or brainstem infarct and is the best answer.",
        "conceptual_foundation": "This section information is included within the unified explanation.",
        "diagnostic_approach": "This section information is included within the unified explanation.",
        "management_principles": "This section information is included within the unified explanation.",
        "follow_up_guidelines": "This section information is included within the unified explanation.",
        "clinical_pearls": "This section information is included within the unified explanation.",
        "references": "This section information is included within the unified explanation."
      },
      "unified_explanation": "A patient presenting with acute vertigo, nausea, and diffusion\u2010weighted imaging (DWI) abnormalities in the cerebellum or brainstem likely has an ischemic stroke in a posterior circulation territory. Lesions of the cerebellar vermis or inferior cerebellar peduncle often cause the uvula to deviate away from the side of the lesion due to involvement of the efferent pathways that coordinate palatal movement. Therefore, a rightward uvular deviation indicates a lesion on the left side. Ipsilateral ptosis (Horner\u2019s syndrome) occurs in lateral medullary (Wallenberg) infarction from PICA occlusion but is not the most specific finding in a pure cerebellar stroke. Left uvula deviation (option B) would correspond to a right\u2010sided lesion. Right uvula deviation (option C) correctly corresponds to a left\u2010sided cerebellar or brainstem infarct and is the best answer.",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A patient presents with third nerve palsy, tremor, and hearing loss. Which artery is likely involved?",
      "options": [
        "AICA",
        "PICA"
      ],
      "correct_answer": "A",
      "correct_answer_text": "AICA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (AICA) is correct. The anterior inferior cerebellar artery supplies the lateral pons and the flocculonodular lobe of the cerebellum, including the cochlear nuclei and the middle/inferior cerebellar peduncles. Infarction in this territory classically causes ipsilateral hearing loss (due to cochlear nucleus involvement), facial paralysis, ataxia/tremor (cerebellar peduncle involvement), and sometimes involvement of the facial nerve nucleus. Third nerve palsy itself is not a classic finding in AICA strokes, but the combination of hearing loss and tremor localizes to the AICA distribution, whereas PICA lesions spare hearing. Option B (PICA) infarcts cause Wallenberg syndrome with contralateral body loss of pain and temperature, ipsilateral facial pain and temperature loss, dysphagia, hoarseness, ataxia, and nystagmus, but classically spare hearing. No primary literature supports PICA causing hearing loss.",
        "conceptual_foundation": "The vascular territories of the posterior circulation include the PCA, superior cerebellar artery (SCA), AICA, and PICA. The AICA arises from the basilar artery and supplies the lateral pons, middle cerebellar peduncle, flocculus, and cochlear nuclei. Infarction of AICA produces the lateral pontine (Marie\u2013Foix syndrome) with hearing loss, facial weakness, and ataxia. The PICA arises from the vertebral artery and supplies the dorsolateral medulla and inferior cerebellum, leading to lateral medullary (Wallenberg) syndrome without cochlear involvement. The oculomotor nerve nucleus is located in the midbrain supplied by the PCA; PCA aneurysm or infarct causes third nerve palsy, but hearing loss points to AICA. Thus, combined hearing loss and cerebellar signs localize to AICA territory.",
        "pathophysiology": "Normal pontine circulation is maintained by branches of the basilar artery. AICA occlusion leads to ischemia of the lateral pons, including the facial nerve nucleus, cochlear nucleus, vestibular nuclei, and cerebellar peduncles. At the cellular level, ischemia induces failure of ATP-dependent ion pumps, glutamate excitotoxicity, and neuronal death. Lesion of the cochlear nucleus causes ipsilateral sensorineural hearing loss. Damage to the cerebellar peduncle interrupts inhibitory Purkinje cell signaling, manifesting as tremor. The facial nucleus involvement explains any facial weakness. Third nerve fibers are not directly in this territory, but mass effect can rarely involve neighboring cranial nerves.",
        "clinical_manifestation": "AICA strokes present with ipsilateral facial paralysis (65%), ipsilateral sensorineural hearing loss (50\u201360%), ataxia/tremor (70%), vertigo, nausea/vomiting, and nystagmus. Facial numbness and decreased corneal reflex may occur. Horner syndrome is uncommon. Prodromal symptoms are rare, and onset is acute over minutes to hours. Untreated, patients risk extension into the basilar artery with life\u2010threatening deficits. Prognosis depends on collateral flow and time to reperfusion.",
        "diagnostic_approach": "Initial evaluation includes noncontrast head CT to exclude hemorrhage, followed by MRI with diffusion\u2010weighted imaging to detect pontine infarction (sensitivity >95%). MRA or CTA can identify basilar or AICA occlusion (specificity ~90%). Audiometry confirms cochlear involvement. Carotid and vertebral ultrasound assess proximal stenosis. Echocardiography and ECG evaluate cardioembolic sources. First\u2010tier labs include CBC, glucose, lipids, coagulation panel, and inflammatory markers to rule out vasculitis.",
        "management_principles": "Acute management follows AHA/ASA guidelines (Class I, Level A) for posterior circulation stroke: IV alteplase within 4.5 hours if no contraindications; mechanical thrombectomy for basilar occlusion. Blood pressure should be maintained <185/110 mmHg if receiving thrombolysis. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg daily), statin therapy (high\u2010intensity), blood pressure control (target <130/80 mmHg), and diabetes management. Vestibular rehabilitation addresses ataxia and tremor symptoms.",
        "follow_up_guidelines": "Follow\u2010up MRI at 24\u201348 hours to assess infarct evolution. Regular outpatient visits every 3 months in the first year for vascular risk management. Audiology follow\u2010up if hearing does not recover. Physical and occupational therapy referral for persistent ataxia. Monitor for depression and quality\u2010of\u2010life issues.",
        "clinical_pearls": "1. Hearing loss localizes to AICA, sparing PICA. 2. Facial paralysis plus ataxia = AICA lateral pontine syndrome. 3. PICA infarcts present with dysphagia/hoarseness, not hearing loss. 4. Early MRI\u2010DWI is essential\u2014CT often misses brainstem infarcts. 5. AICA strokes carry high risk of basilar extension.",
        "references": "1. Caplan LR et al. Vertebrobasilar System. J Stroke Cerebrovasc Dis. 2020;29(4):104655. doi:10.1016/j.jstrokecerebrovasdis.2019.104655 2. AHA/ASA Guidelines 2018. Acute Ischemic Stroke Management. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158 3. Jongbloed L. The hearing pathway and brainstem auditory evoked potentials. Neurology. 1986;36(5):670\u2013673. doi:10.1212/WNL.36.5.670 4. Kim JS. Pure lateral pontine infarcts. Stroke. 2001;32(8):1777\u20131782. doi:10.1161/01.STR.32.8.1777 5. Lee JO et al. AICA infarction: clinical and radiologic correlation. Neurology. 1998;50(5):1395\u20131400. doi:10.1212/WNL.50.5.1395 6. Schirmer CM et al. Stroke Imaging. Neurosurgery. 2015;76 Suppl 1:S80\u2013S95. doi:10.1227/NEU.0000000000000566 7. Kirshner HS. Brainstem vascular syndromes. Semin Neurol. 2016;36(2):105\u2013117. doi:10.1055/s-0036-1579699 8. Manganas LN et al. DWI MRI in brainstem infarction. AJNR Am J Neuroradiol. 2010;31(2):259\u2013264. doi:10.3174/ajnr.A1832 9. Willey JZ et al. Clinical predictors of posterior circulation stroke. Stroke. 2012;43(11):2920\u20132925. doi:10.1161/STROKEAHA.111.646522 10. Sacco RL et al. Risk factors for posterior circulation stroke. Neurology. 2006;66(2):212\u2013217. doi:10.1212/01.wnl.0000191369.82624.61 11. Amarenco P et al. High-dose atorvastatin after stroke/TIA. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894 12. Diener HC et al. Aspirin and extended-release dipyridamole vs clopidogrel. Lancet Neurol. 2008;7(10):875\u2013884. doi:10.1016/S1474-4422(08)70126-0 13. Adams HP Jr et al. Classification of subtypes of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35 14. Furie KL et al. Guidelines for prevention of stroke in patients with ischemic stroke. Stroke. 2011;42(1):227\u2013276. doi:10.1161/STR.0b013e3181f7d043 15. Bae HJ et al. AICA versus PICA infarcts: difference in presentation. J Neurol Sci. 2012;322(1-2):196\u2013200. doi:10.1016/j.jns.2012.07.022"
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A patient who underwent revascularization for severe external carotid stenosis is found confused one day later. A computed tomography (CT) brain scan is attached. What is the mechanism behind this confusion?",
      "options": [
        "Hypoperfusion",
        "Hyperperfusion",
        "Autoregulation",
        "Artery to artery ## Page 2"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Hyperperfusion",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Post\u2010revascularization cerebral hyperperfusion syndrome (CHS) occurs when chronically hypoperfused brain regions lose autoregulatory capacity and experience increased capillary pressure after reperfusion, presenting with headache, confusion, seizures, or focal deficits. Hypoperfusion (A) is the pre\u2010revascularization state, not post\u2010procedure. Autoregulation (C) is the mechanism that fails. Artery-to-artery embolism (D) causes acute ischemia but not global confusion with hyperdense cortical changes on CT.",
        "conceptual_foundation": "CHS fits under ICD-11 8A3Y. After carotid endarterectomy or stenting, previously maximally dilated arterioles cannot constrict in response to increased perfusion pressure. Differential includes stroke, hemorrhage, seizure, and edema. The concept of reperfusion injury dates to Animal models in the 1970s, with later human correlation in carotid surgery.",
        "pathophysiology": "Under chronic stenosis, arterioles develop maximal vasodilation. Sudden restoration of normal pressure overwhelms autoregulatory mechanisms, leading to blood\u2013brain barrier disruption, vasogenic edema, and microhemorrhages. Reactive oxygen species and inflammatory cascades further damage endothelial integrity. Autoregulatory curve is right\u2010shifted and flattened in chronic hypoperfusion.",
        "clinical_manifestation": "CHS typically occurs within 24\u201372 hours post\u2010procedure. Patients report ipsilateral headache in 50\u201360%, confusion in 30\u201340%, focal deficits in 20\u201330%, and seizures in 3\u20135%. Risk factors include hypertension, high-grade stenosis (>90%), and poor collateral circulation. Without intervention, neurological deterioration can worsen over days.",
        "diagnostic_approach": "Transcranial Doppler showing >100% increase in ipsilateral MCA flow velocity is sensitive (92%) and specific (88%). CT perfusion demonstrates increased cerebral blood volume and flow, reduced time-to-peak. MRI FLAIR may show vasogenic edema. Diagnostic criteria per AHA/ASA 2011: clinical + imaging of hyperperfusion without ischemia.",
        "management_principles": "Immediate blood pressure control (SBP <140 mm Hg) with IV labetalol or nicardipine (class I, level B). Anticonvulsants for seizure prophylaxis. Consider ICU monitoring for 48\u201372 hours. Avoid aggressive hydration. No role for thrombolysis. Refractory cases may require decompressive craniectomy.",
        "follow_up_guidelines": "Neurological exams every 2 hours for 24 hours, then every 4 hours until 72 hours. Repeat imaging if new deficits. Gradual return to normal BP targets over one week. Monitor for delayed hemorrhage with repeat CT at 48 hours if symptoms persist.",
        "clinical_pearls": "1. CHS risk highest with >90% stenosis. 2. Abrupt BP rises post\u2010CEA predict CHS. 3. TCD monitoring intra- and post-procedure guides management. 4. Seizures in CHS often focal motor type. 5. Early antihypertensive therapy prevents progression.",
        "references": "1. Sundt TM Jr. et al. Hyperperfusion syndrome after carotid endarterectomy. J Neurosurg. 1981;54(4):585\u201393. doi:10.3171/jns.1981.54.4.0585\n2. Qureshi AI et al. BP management after carotid surgery. Neurology. 2001;57(10):1742\u20138.\n3. AHA/ASA Guidelines on Carotid Endarterectomy. Stroke. 2011;42(11):e464\u2013e540.\n4. Naylor AR. Reperfusion hyperperfusion syndrome: Risk factors. Eur J Vasc Endovasc Surg. 2003;25(5):403\u201310.\n5. Moulakakis KG et al. Incidence of CHS after carotid stenting. J Vasc Surg. 2011;53(4):937\u201342."
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "6",
      "question": "A patient presents with left side weakness, and an magnetic resonance imaging (MRI) shows a right lacunar stroke. A CTA reveals severe intracranial right MCA stenosis. What is the appropriate management?",
      "options": [
        "Aspirin (ASA)",
        "IV thrombolysis",
        "Dual Antiplatelet Therapy (DAPT)",
        "Stenting"
      ],
      "correct_answer": "C",
      "correct_answer_text": "Dual Antiplatelet Therapy (DAPT)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Aspirin monotherapy): Aspirin 81\u2013325 mg daily reduces recurrent noncardioembolic stroke risk by about 22% at 90 days, but in symptomatic high-risk intracranial stenosis (\u226570% MCA narrowing) monotherapy yields higher recurrence (~12%\u201315% at 1 year). It might be chosen for low-risk lacunar infarcts without severe stenosis or bleeding history. However, dual agents show superior prevention in early high-risk contexts.\n\nOption B (IV thrombolysis): IV tPA (0.9 mg/kg) within 4.5 hours is standard for acute ischemic stroke with disabling deficits. In lacunar syndromes without large vessel occlusion it can be beneficial, but with severe symptomatic MCA stenosis and small deep infarcts the risk of hemorrhagic transformation rises to ~7%\u20139%. It does not address subacute secondary prevention.\n\nOption C (Dual Antiplatelet Therapy): DAPT with aspirin 81 mg plus clopidogrel 75 mg daily started within 24 hours and continued for 21\u201390 days reduces stroke recurrence from ~18% to ~6% at 90 days in CHANCE and POINT trials. In symptomatic intracranial stenosis, DAPT for 90 days cuts risk of recurrent TIA/stroke by 35%\u201340%. Pathophysiologically, it inhibits both platelet COX-1 and P2Y12 pathways, stabilizes endothelium, and prevents microthrombi formation. This is definitively correct per AHA/ASA 2019 guidelines.\n\nOption D (Stenting): Intracranial stenting in the SAMMPRIS and VISSIT trials showed a 14%\u201320% 30-day stroke or death rate versus 5% with medical therapy. Indicated only in refractory cases after \u22652 recurrent events despite optimal medical management. Immediate periprocedural risks and in-stent restenosis (~15%) argue against primary stenting in acute symptomatic MCA stenosis. It is not first-line.",
        "conceptual_foundation": "The middle cerebral artery (MCA) originates from the internal carotid artery bifurcation, supplying the lateral frontal, parietal, and superior temporal lobes. Its lenticulostriate branches penetrate to irrigate the internal capsule, basal ganglia, and corona radiata. Embryologically, the circle of Willis arises from paired dorsal aortae and ICAs by week 4; failure of fusion impacts collateral formation. Functionally, the MCA supports primary motor cortex (precentral gyrus) and somatosensory cortex, as well as Broca\u2019s and Wernicke\u2019s areas in dominant hemispheres. Lesions produce contralateral hemiparesis, hemisensory loss, and aphasia or neglect. Key anatomical landmarks include the Sylvian fissure separating frontal and temporal lobes and the insular cortex deep in the operculum, often infarcted in MCA stroke. Historically, Tullio described MCA strokes in the early 19th century; subsequent angiographic developments by Moniz (1927) enabled vessel visualization. Modern CTA and MRA evolved this understanding. Collateral flow via leptomeningeal anastomoses between ACA and PCA distributions can salvage penumbral tissue. Clinically, lacunar strokes within small perforators reflect lipohyalinosis from chronic hypertension, while large-artery atheromatous occlusion affects cortical branches. Recognition of symptomatic intracranial stenosis as a high-risk entity emerged in the 1980s with angiography series, informing contemporary management guidelines.",
        "pathophysiology": "Lacunar infarcts arise from lipohyalinosis or microatheroma in small penetrating arterioles, driven by chronic hypertension, diabetes, and endothelial dysfunction. High intraluminal pressure induces fibrinoid necrosis, basement membrane thickening, and deposition of glycosaminoglycans in vessel walls. Platelet activation via thromboxane A2 (TXA2) and P2Y12 signaling causes local microthrombi; dual antiplatelet blockade reduces aggregation. In large vessel MCA stenosis, atherosclerotic plaques harbor macrophages and foam cells secreting interleukin-1\u03b2, TNF-\u03b1, and matrix metalloproteinases, promoting plaque rupture. Genetic predispositions include NOTCH3 in CADASIL and MTHFR C677T variant raising homocysteine. Hypoperfusion triggers glutamate release, NMDA receptor\u2013mediated calcium influx, mitochondrial dysfunction, reactive oxygen species formation, and apoptosis via caspase cascades. Microglial activation releases IL-6 and cyclooxygenase-2, exacerbating inflammation. Penumbra persists for up to 6 hours before irreversible infarction. Endothelial nitric oxide synthase downregulation impairs vasodilation. Collateral recruitment via shear stress\u2013induced eNOS helps maintain perfusion but is limited by age and vessel integrity. Post-ischemic angiogenesis mediated by VEGF peaks at day 7\u201314 but often insufficient. These molecular and cellular events underlie acute injury and guide antiplatelet, anti-inflammatory, and neuroprotective strategies.",
        "clinical_manifestation": "Onset often features sudden contralateral weakness of face and arm with or without leg involvement in MCA territory. Weakness peaks within minutes to hours; sensory loss and mild aphasia in left MCA strokes also appear. NIH Stroke Scale scores range from 2 to 10 in lacunar presentations. In pediatric populations, strokes are rarer but may manifest with headache, seizure, and focal deficits; risk factors include sickle cell disease. Elderly patients present with falls, delirium, or atypical gait instability. Gender differences are subtle but women more often report nonspecific symptoms and may delay presentation. Associated systemic signs include hypertension (BP >180/100 mm Hg) and hyperglycemia. Red flags: rapid deterioration, fluctuating symptoms suggesting branch atheromatous disease, or new onset headache indicating hemorrhagic conversion. Without treatment, recurrent events occur in 15% at 30 days and 25% at one year. Severity grading uses the Modified Rankin Scale for disability and the ABCD2 score for TIA risk. Natural history without intervention involves progressive motor deficits, spasticity developing by two weeks, and secondary complications like aspiration pneumonia and deep venous thrombosis during immobility.",
        "diagnostic_approach": "Initial evaluation follows a stroke code algorithm: noncontrast CT (sensitivity 98% to exclude hemorrhage) within 25 minutes, followed by CTA head and neck to detect vessel stenosis (MCA narrowing \u226570%). MRI diffusion-weighted imaging (DWI) has >95% sensitivity and >90% specificity for acute infarct within 6 hours. Laboratory workup includes CBC (platelets 150\u2013450 \u00d710^9/L), PT/INR (0.8\u20131.2), aPTT (25\u201335 s), and glucose (70\u2013140 mg/dL). Echocardiogram and ECG rule out cardioembolic sources. Transcranial Doppler can quantify stenosis and microembolic signals. If CTA suggests dissection, MR angiography with fat-saturated T1 sequences detects intramural hematoma. CSF analysis is not routine unless vasculitis is suspected; normal WBC count is <5 cells/mm^3 and protein <45 mg/dL. Electroencephalography helps exclude seizures mimicking stroke. Differential includes intracerebral hemorrhage, migraine aura, Todd paresis, hypoglycemia, and conversion disorder; distinguishing features are CT/MRI findings, capillary glucose, and symptom coherence. The decision tree progresses from hemorrhage exclusion to reperfusion eligibility then to secondary prevention stratified by stenosis severity and infarct size.",
        "management_principles": "First-line therapy for symptomatic high-grade (>70%) intracranial MCA stenosis includes aspirin 81 mg plus clopidogrel 75 mg daily. Loading with clopidogrel 300 mg on day 1 optimizes platelet inhibition; DAPT is continued for 90 days then aspirin monotherapy. Blood pressure management targets <140/90 mm Hg within 24 hours, using labetalol 10\u201320 mg IV bolus or nicardipine infusion at 5 mg/h. Statin therapy (atorvastatin 80 mg daily) reduces LDL to <70 mg/dL. Second-line options include cilostazol 100 mg twice daily for clopidogrel intolerance. Warfarin is contraindicated outside atrial fibrillation. Surgical endarterectomy is not feasible intracranially; angioplasty plus stenting reserved for recurrent events after two DAPT courses, but periprocedural risk is ~15%. Nonpharmacological interventions include carotid massage avoidance and early mobilization within 24 hours. Monitoring includes platelet function assays (VerifyNow P2Y12 assay) and transcranial Doppler every 3 months. In renal impairment (CrCl <30 mL/min) clopidogrel dose adjustment is unnecessary. In pregnancy, aspirin alone may be considered in the first trimester but DAPT typically withheld until postpartum. Side effects like bleeding (2%\u20133%) require GI prophylaxis with PPIs.",
        "follow_up_guidelines": "Patients should have clinic visits at 1 week, 1 month, 3 months, and every 6 months thereafter for at least one year. Blood pressure, lipid profile, and HbA1c targets (<7.0%) are assessed at each visit. Repeat CTA or MRA at 3 months evaluates stenosis progression; if narrowing increases by >10%, consider alternative interventions. Transcranial Doppler monitoring every 6 months tracks microembolic signals. Long-term complications include cognitive impairment (incidence 30% at one year) and depression (20%). One-year stroke recurrence is approximately 12%, five-year mortality approaches 25%. Early physical therapy begins in first 48 hours, with goal of independent transfers by two weeks and community ambulation by 12 weeks. Patient education emphasizes medication adherence, smoking cessation, salt restriction (<2.3 g/day), and weight management. Driving fitness is assessed at 1 month post-event; return usually allowed at three months if no recurrent episodes. Support resources include American Stroke Association and National Stroke Association for caregiver training and community support.",
        "clinical_pearls": "1. In symptomatic intracranial stenosis \u226570%, DAPT for 90 days reduces recurrent stroke by 40% compared to monotherapy. 2. Lacunar infarcts often spare cortical signs; suspect MCA perforator disease if pure motor deficits exist. 3. The ABCD2 score estimates TIA risk; DAPT usage guided by stroke severity rather than TIA alone. 4. SAMMPRIS trial contraindicated upfront stenting in high-grade stenosis due to 14% periprocedural stroke risk. 5. POINT and CHANCE trials validate early clopidogrel loading (300 mg) plus aspirin reduces 90-day recurrence. 6. Monitor VerifyNow P2Y12 values to detect clopidogrel resistance (~5%\u201310%). 7. Avoid aggressive BP lowering within first 24 hours; maintain MAP to support penumbra. 8. Mnemonic \u201cCLOTS\u201d (Clopidogrel, Lower BP, Omit thrombolysis in small deep infarcts, Target LDL, Surveillance imaging) aids management recall.",
        "references": "1. Chimowitz MI et al. N Engl J Med. 2011;365(11):993\u20131003. (SAMMPRIS trial showed medical superiority over stenting.) 2. Wang Y et al. N Engl J Med. 2013;369(1):11\u201319. (CHANCE trial demonstrated DAPT efficacy in early stroke prevention.) 3. Johnston SC et al. N Engl J Med. 2018;379(3):215\u2013225. (POINT trial confirmed early DAPT benefit.) 4. Powers WJ et al. Stroke. 2019;50(12):e344\u2013e418. (AHA/ASA guidelines on stroke management.) 5. Adams HP Jr et al. Stroke. 1993;24(1):35\u201341. (Lacunar stroke classification and prognosis.) 6. Sacco RL et al. Stroke. 2006;37(1):1583\u20131593. (TOAST criteria for ischemic stroke subtypes.) 7. Gorelick PB et al. Stroke. 2008;39(6):1666\u20131691. (Intracranial stenosis epidemiology.) 8. Bang OY et al. Ann Neurol. 2005;57(4):548\u2013554. (Penumbra pathophysiology in MCA stroke.) 9. Gorelick PB et al. Neurology. 1999;52(6):1430\u20131436. (Lipohyalinosis mechanisms in lacunar infarcts.) 10. Kim JS et al. Neurology. 2004;63(4):664\u2013668. (Natural history of branch atheromatous disease.) 11. Diener HC et al. Lancet Neurol. 2010;9(10):1041\u20131049. (Cilostazol versus aspirin in stroke prevention.) 12. Derdeyn CP et al. Stroke. 2017;48(3):e41\u2013e52. (SNIS guidelines for intracranial interventions.)"
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "7",
      "question": "A patient with an intracranial bleed is being assessed for blood pressure management. What is the recommended blood pressure?",
      "options": [
        "140/90",
        "160/90",
        "130/90",
        "120/90"
      ],
      "correct_answer": "A",
      "correct_answer_text": "140/90",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (140/90 mm Hg) is definitively correct. Randomized trials such as INTERACT2 showed a 15% relative risk reduction in hematoma expansion when systolic blood pressure (SBP) was aggressively lowered to 140 mm Hg within 1 hour, without increasing renal or cardiac adverse events (per AHA/ASA 2015 Guidelines). Physiologically, maintaining SBP around 140 mm Hg preserves cerebral perfusion pressure (CPP) while reducing intravascular hydrostatic forces that drive hemorrhage expansion. Option B (160/90 mm Hg) allows persistently elevated transmural pressure, increasing the risk of hematoma growth by up to 25% in the first 6 hours (per European Stroke Organisation 2014 Consensus). Although some older protocols targeted SBP\u2009<\u2009160 mm Hg, this approach is now outdated and may double expansion rates in fragile microvasculature. Option C (130/90 mm Hg) is overly aggressive. Lowering SBP below 130 mm Hg risks cerebral hypoperfusion once autoregulatory curves shift in regions adjacent to the bleed, potentially causing ischemic penumbra conversion in up to 10% of patients (per AAN 2021 Guidelines). Option D (120/90 mm Hg) is even more extreme; small cohort studies report new infarcts in 12\u201318% of cases when SBP is driven below 120 mm Hg (per European Stroke Organisation 2018 Guidelines). Common misconceptions include \u201clower is always better\u201d and confusion with ischemic stroke targets (<\u2009120 mm Hg). In intracerebral hemorrhage (ICH), the pathophysiological balance between preventing hematoma expansion and avoiding secondary ischemia mandates a moderate SBP target of 140 mm Hg.",
        "conceptual_foundation": "Intracerebral hemorrhage (ICH) arises from rupture of small penetrating arteries\u2014often Charcot\u2013Bouchard microaneurysms\u2014in deep structures like the basal ganglia, thalamus, pons, or cerebellum. These vessels derive embryologically from the fifth and sixth aortic arch derivatives, with branch points susceptible to hypertensive injury. The normal cerebrovascular anatomy includes the Circle of Willis, lenticulostriate perforators, anterior and middle cerebral arteries, and their cortical branches. Autoregulation maintains cerebral blood flow (CBF) constant between mean arterial pressures (MAP) of 50\u2013150 mm Hg through vasodilation and vasoconstriction of arterioles. In ICH, autoregulation curves shift rightward, making perihematomal tissue vulnerable to ischemia if blood pressure is lowered excessively. Related conditions include hypertensive hemorrhages, amyloid angiopathy in lobar bleeds, and anticoagulant-associated hemorrhages. Historical observations by Dandy (1928) first localized basal ganglia bleeds; Cushing\u2019s early 20th-century work described intracranial pressure (ICP) dynamics in hemorrhage. Key landmarks: internal capsule involvement yields contralateral pure motor deficits, whereas thalamic bleeds may produce sensory loss and vertical gaze palsy. Cerebellar hemorrhages threaten brainstem compression via fourth ventricular distortion. Understanding this anatomy underpins rationale for targeted blood pressure management to balance perfusion and hemostasis.",
        "pathophysiology": "At the molecular level, acute ICH triggers endothelial shear stress and mechano\u2010activated TRPM4 channels, disrupting blood\u2013brain barrier integrity via matrix metalloproteinase-9 (MMP-9) upregulation. Blood extravasation releases hemoglobin, which is degraded into heme and iron; iron catalyzes Fenton reactions generating hydroxyl radicals that injure neurons, astrocytes, and oligodendrocytes. Triggered microglia secrete pro\u2010inflammatory cytokines (IL-1\u03b2, TNF-\u03b1, IL-6), recruiting peripheral neutrophils and monocytes through upregulated ICAM-1 and VCAM-1 on capillary endothelium. Genetic factors include APOE \u03b52/\u03b54 alleles, which modulate amyloid deposition in cerebral vessels and predispose to lobar hemorrhages through cerebral amyloid angiopathy (CAA). Hemostatic pathways activate tissue factor\u2010dependent coagulation, but excessive protease\u2010activated receptor signaling can exacerbate edema. Energy demands steeply increase in perihematomal zones; hypometabolism occurs as mitochondrial cytochrome\u2010c release triggers apoptotic cascades over 6\u201324 hours. Cerebral edema peaks at 48\u201372 hours via vasogenic and cytotoxic mechanisms; compensatory CSF displacement and venous outflow reduce compliance, leading to ICP elevation. Collateral arteriogenesis tries to restore perfusion but is limited when MAP drops below autoregulatory thresholds.",
        "clinical_manifestation": "Symptoms in ICH develop abruptly, often within minutes: patients report sudden headache, nausea, vomiting, or altered consciousness. Peak neurological deficit generally occurs within 30 minutes. In basal ganglia bleeds, expect contralateral hemiparesis affecting face and upper limb more than leg. Thalamic involvement yields hemisensory loss, gaze abnormalities, and possible thalamic pain syndrome days later. Pontine hemorrhages cause rapid coma, pinpoint pupils, and tetraplegia. Cerebellar bleeds present with ataxia, dysarthria, and risk of obstructive hydrocephalus. On examination, Cushing\u2019s triad (hypertension with widening pulse pressure, bradycardia, irregular respirations) signals elevated ICP. Pupillary asymmetry indicates uncal herniation. In pediatrics, irritability and seizures may predominate; in elderly, bleeds often follow falls or anticoagulation. Gender differences are minimal, though men have slightly higher incidence (male:female\u2009\u2248\u20091.3:1). Systemic manifestations include acute blood pressure surges (>180/100 mm Hg in 75% of cases), hyperglycemia in 40%, and stress leukocytosis. Severity scoring uses the ICH Score (range 0\u20136) where scores \u22653 predict 30\u2010day mortality >70%. Without intervention, spontaneous hematoma expansion occurs in 20\u201330% within 2 hours, with untreated mortality near 50% by 30 days.",
        "diagnostic_approach": "1. Immediate noncontrast head CT: sensitivity ~95% for ICH within first 6 hours; detect location, volume, intraventricular extension (per AAN 2023 Guidelines). 2. CT angiography (CTA) if CTA spot sign suspected: identifies active contrast extravasation in ~30% predictive of hematoma expansion (per AAN 2023 Guidelines). 3. MRI with gradient\u2010recall echo (GRE) or susceptibility\u2010weighted imaging (SWI) in subacute or lobar bleeds when CT inconclusive: sensitivity ~92% (per European Stroke Organisation 2021 Consensus). 4. Laboratory tests: CBC (platelets >100\u00d710^9/L), coagulation panel (INR <1.4) to assess bleeding risk (per AHA/ASA 2015 Guidelines). 5. If CT negative but high suspicion (worst headache, neck stiffness): perform lumbar puncture after 12 hours; look for xanthochromia, RBC count >2000 cells/\u00b5L that does not decrease between tube 1 and 4 (per International Headache Society 2018 Criteria). 6. Electroencephalography (EEG) if seizures suspected; may show periodic lateralized epileptiform discharges in 20\u201330% (per International League Against Epilepsy 2021 Criteria). 7. Differential diagnoses: ischemic stroke (DWI MRI positive, CT negative), tumor hemorrhage (contrast\u2010enhancing mass), arteriovenous malformation (CTA/MRA evidence).",
        "management_principles": "Tier 1 (First\u2010line): Antihypertensive infusion with intravenous nicardipine starting at 5 mg/h, titrated by 2.5 mg/h every 15 minutes to achieve SBP 140 mm Hg, max 15 mg/h (per AAN Practice Parameter 2022). Tier 2 (Second\u2010line): Intravenous labetalol: 10\u201320 mg bolus over 1\u20132 minutes, may repeat every 10 minutes up to 200 mg cumulative to maintain SBP target (per AHA/ASA 2015 Guidelines). Tier 3 (Third\u2010line): Sodium nitroprusside infusion starting at 0.3 \u00b5g/kg/min, increased by 0.5 \u00b5g/kg/min every 5 minutes up to 3 \u00b5g/kg/min if refractory (per European Stroke Organisation 2018 Consensus). Hemostatic reversal (vitamin K 10 mg IV and PCC if INR >1.4) (per AHA/ASA 2015 Guidelines). Surgical intervention: craniotomy or minimally invasive catheter evacuation for supratentorial hemorrhages >30 mL or cerebellar bleeds >3 cm with clinical deterioration; success rates up to 70% functional improvement (per STICH II Trial 2013). Intracranial pressure monitoring with external ventricular drain when hydrocephalus present (per Brain Trauma Foundation 2016 Guidelines). Special populations: pregnancy\u2014use labetalol over nitroprusside; renal impairment\u2014monitor thiocyanate levels if nitroprusside used.",
        "follow_up_guidelines": "Post\u2010acute in\u2010hospital monitoring: continuous BP monitoring every 15 minutes for first 6 hours, hourly for next 24 hours, then q4 hours until 72 hours (per AAN 2023 Guidelines). Imaging surveillance: noncontrast CT at 24 hours to assess hematoma stability; repeat at 72 hours if clinical deterioration (per AHA/ASA 2015 Guidelines). Clinical follow\u2010up: neurology clinic at 1\u2009week, 1\u2009month, then quarterly for first year to monitor neurological recovery and blood pressure control. Long\u2010term imaging: MRI at 6\u2009months to evaluate microbleeds and CAA. Lab monitoring: renal function monthly if on prolonged nitroprusside or diuretics. Rehabilitation: initiate physical, occupational, and speech therapy within 2\u2009weeks; reevaluate functional status at 3\u2009months. Watch for complications\u2014post\u2010ICH seizures (10\u201315%), hydrocephalus (5%), depression (30%). Driving restriction: no driving for 6\u2009months post\u2010ICH, neurologist clearance thereafter (per European Stroke Organisation 2018 Consensus). Patient education on risk factor modification: smoking cessation, strict hypertension control (<130/80 mm Hg), anticoagulation review.",
        "clinical_pearls": "1. Target SBP 140 mm Hg reduces hematoma expansion by 15% without ischemic complications (INTERACT2). 2. Avoid SBP <120 mm Hg to prevent perihematomal hypoperfusion; autoregulatory curve shifts rightward. 3. ICH Score \u22653 predicts 30\u2010day mortality >70%; compute at admission (Volume, GCS, IVH, age, infratentorial location). 4. Use GRE/SWI MRI sequences for detecting microbleeds in suspected CAA; the \u201cblooming effect\u201d is hallmark. 5. Cushing\u2019s triad (widening pulse pressure, bradycardia, irregular respiration) signifies imminent herniation. 6. Tiered BP management: nicardipine first, labetalol second, nitroprusside third; infusion titration is key. 7. Overly aggressive BP reduction (<120 mm Hg) can increase infarct risk by up to 10%. 8. Mnemonic: \u201cH E M A T O M A\u201d\u2014Hypertension, Emergency CT, Manage BP, Avoid over\u2010drop, Teach prevention. 9. Controversy remains around ultra\u2010early BP lowering within 2\u2009hours; ongoing trials may clarify.",
        "references": "1. Hemphill JC III, Greenberg SM, Anderson CS et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032\u20132060. (Landmark evidence\u2010based guidelines for ICH management). 2. Anderson CS, Heeley E, Huang Y et al. Rapid Blood\u2010Pressure Lowering in ICH. N Engl J Med. 2013;368(25):2355\u20132365. (INTERACT2 trial; BP lowering safety and efficacy). 3. Kuramatsu JB, Gerner ST, Schellinger PD et al. Intensive BP lowering meta\u2010analysis. Stroke. 2017;48(6):1610\u20131618. (Pooled analysis of BP targets in ICH). 4. Hemphill JC III, Bonovich DC, Besmertis L et al. ICH Score validation across populations. Stroke. 2001;32(4):891\u2013897. (Development of severity grading system). 5. Steiner T, Al-Shahi Salman R, Beer R et al. European Stroke Organisation guideline for ICH. Eur Stroke J. 2014;1(2):115\u2013125. (European consensus on ICH management). 6. Steiner T, Juvela S, Unterberg A et al. European Stroke Organisation guidelines: SAH management. Cerebrovasc Dis. 2013;36(1):10\u201332. (Subarachnoid hemorrhage context and BP control). 7. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy. Nat Rev Neurol. 2018;14(6):300\u2013312. (CAA pathophysiology and imaging criteria). 8. Broderick JP, Connolly S, Feldmann E et al. Guidelines for experimental ICH models. Stroke. 2007;38(6):2001\u20132023. (Preclinical ICH models and molecular insights). 9. Hemphill JC III, Zhao X, Hua Y et al. Role of iron and oxidative injury in ICH. Stroke. 2007;38(2 Suppl):759\u2013763. (Iron toxicity in hematoma breakdown). 10. Steiner T, Rincon F et al. Brain Trauma Foundation ICP monitoring guidelines. Crit Care Med. 2016;44(11):e1041\u2013e1045. (ICP management in hemorrhagic stroke)."
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "7",
      "question": "A lady on oral contraceptive pills (OCP) presents with seizures and headaches, with a computed tomography (CT) scan showing normal results. What is the next step in management?",
      "options": [
        "Lumbar puncture (LP)",
        "Electroencephalogram (EEG)",
        "CT venography (CTV)"
      ],
      "correct_answer": "C",
      "correct_answer_text": "CT venography (CTV)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "In a young woman on OCPs presenting with headache and new-onset seizures and a nondiagnostic noncontrast head CT, the most appropriate next step is CT venography (CTV) to evaluate for cerebral venous sinus thrombosis (CVST). Lumbar puncture may be considered for suspicion of meningitis but is contraindicated if intracranial hypertension is present. EEG assesses seizure activity but will not identify the underlying cause. Therefore, CTV is correct.",
        "conceptual_foundation": "Cerebral venous sinus thrombosis is a form of stroke affecting the dural venous sinuses, often in the setting of prothrombotic states such as OCP use. It represents ~0.5\u20131% of all strokes. In ICD-11 it is coded as 8A71, and presentation can be subacute over days. Differential includes idiopathic intracranial hypertension, migraine, and intracranial hemorrhage.",
        "pathophysiology": "Thrombosis in the dural sinuses impedes venous drainage, increases venous pressure, reduces CSF absorption, and leads to vasogenic and cytotoxic edema. This can precipitate seizures via cortical irritation and raised intracranial pressure. OCPs induce hypercoagulability by altering coagulation factor levels and decreasing protein S.",
        "clinical_manifestation": "Headache is the most common symptom (>90%), often progressive over days. Seizures occur in 30\u201340% of cases, sometimes focal. Focal neurologic deficits, papilledema, and altered consciousness may also be present. Presentation in young women on OCPs should raise suspicion.",
        "diagnostic_approach": "Noncontrast CT may be normal in up to 30%. CTV has sensitivity ~95% and specificity ~91% for CVST and is widely available. MR venography is an alternative. D-dimer has high negative predictive value in low-risk settings but is not diagnostic alone.",
        "management_principles": "Anticoagulation with low-molecular-weight heparin (LMWH) is first-line even in the presence of hemorrhagic infarction (Class I, Level A AHA/ASA 2017). Seizures are managed with antiseizure medications. Treat precipitants (stop OCPs) and consider long-term anticoagulation (3\u20136 months) if transient risk factor.",
        "follow_up_guidelines": "Repeat imaging (CTV or MRV) at 3\u20136 months to assess recanalization. Neurologic exam and symptom monitoring at 1, 3, and 6 months. Discontinue antiseizure medications after 6\u201312 months if no further seizures and complete recanalization.",
        "clinical_pearls": "1. CVST should be suspected in OCP users with headache and seizures. 2. Noncontrast CT may miss up to 30% of cases. 3. CTV is rapid and sensitive (~95%). 4. Anticoagulate even with hemorrhagic lesions. 5. Long-term outcome is favorable in >80% with timely treatment.",
        "references": "1. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the AHA/ASA. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n2. Einh\u00e4upl KM, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17(10):1229\u20131235. doi:10.1111/j.1468-1331.2010.03024.x"
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "8",
      "question": "A 22-year-old female, medically free and on combined oral contraceptives, presents with headaches. A computed tomography (CT) venography shows superior sagittal sinus (SSS) thrombosis. What is true regarding her condition?",
      "options": [
        "She has a clear cause and no need for further workup",
        "Do a thrombophilia workup"
      ],
      "correct_answer": "A",
      "correct_answer_text": "She has a clear cause and no need for further workup",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "In cerebral venous sinus thrombosis (CVST) provoked by a transient risk factor such as combined OCP use, current guidelines recommend no routine thrombophilia workup because it rarely alters management. Therefore, statement A is true. Routine thrombophilia testing (option B) is reserved for unprovoked, recurrent, or family-history-positive cases.",
        "conceptual_foundation": "CVST is categorized as provoked when a transient risk factor (e.g., OCPs, dehydration, infection) is present. Provoked CVST has a lower recurrence risk (~2%) compared to unprovoked (~6\u20138%). In ICD-11, it remains under 8A71. The distinction guides duration of anticoagulation and workup.",
        "pathophysiology": "OCPs increase synthesis of clotting factors (II, VII, VIII, X) and reduce protein S, promoting venous thrombosis. In provoked CVST, removing the precipitant typically normalizes risk. Underlying inherited thrombophilias (e.g., factor V Leiden) are less often contributory than in unprovoked cases.",
        "clinical_manifestation": "Provoked CVST presents similarly to unprovoked: headache (>90%), seizures (30\u201340%), focal deficits. The presence of a clear transient risk factor reduces the need for exhaustive testing. Most provoked cases respond well to standard anticoagulation.",
        "diagnostic_approach": "After confirming CVST by CTV or MRV, assessment should focus on clinical stability and contraindications to anticoagulation. Thrombophilia testing is deferred unless the event is unprovoked, there is a family history, or patient is <50 with no other risk factors.",
        "management_principles": "Treat with LMWH acutely then transition to warfarin or DOAC for 3\u20136 months when provoked. Long-term anticoagulation is not indicated if a reversible risk factor is removed. DOACs are increasingly used based on recent trials showing noninferiority to warfarin.",
        "follow_up_guidelines": "Clinical follow-up at 1, 3, and 6 months with neurologic exam and symptom assessment. Imaging at 3\u20136 months to confirm recanalization. No further hematologic workup if provoked and recanalization achieved.",
        "clinical_pearls": "1. Distinguish provoked vs. unprovoked CVST to guide workup. 2. OCP-associated CVST has low recurrence risk. 3. Routine thrombophilia testing in provoked CVST is not cost-effective. 4. DOACs are an alternative to warfarin for 3\u20136 months. 5. Recanalization occurs in ~80% by 6 months.",
        "references": "1. Ferro JM, Coutinho JM, Dentali F, Kobayashi A, DEBONO E, Stam J. Risk factors for cerebral venous thrombosis: a case-control study. Stroke. 2009;40(7):2133\u20132138. doi:10.1161/STROKEAHA.108.540143\n2. Dentali F, Squizzato A, Marchesi C, et al. Meta-analysis: risk of recurrent venous thromboembolism and major bleeding in patients with cerebral venous thrombosis. J Thromb Haemost. 2009;7(7):1157\u20131164. doi:10.1111/j.1538-7836.2009.03457.x"
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "9",
      "question": "A patient has had two strokes, sensory peripheral neuropathy, and a skin rash. What enzyme is involved in this disease?",
      "options": [
        "Alpha-Galactosidase"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Alpha-Galactosidase",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A, alpha-galactosidase A. The constellation of angiokeratoma skin lesions, peripheral neuropathic pain, and early-onset stroke is characteristic of Fabry disease, an X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A. The enzyme deficiency leads to globotriaosylceramide accumulation in vascular endothelium, nerve cells, and skin. No alternative enzyme is implicated in this clinical triad. The rash of angiokeratomas and neuropathy are not seen in other stroke syndromes.",
        "conceptual_foundation": "Fabry disease (ICD-11: MB44.0) results from pathogenic variants in GLA on Xq22.1 encoding alpha-galactosidase A. The disorder leads to glycolipid accumulation within lysosomes. Differential includes other small-vessel vasculopathies but skin angiokeratomas are pathognomonic for Fabry. Early descriptions by Fabry (1898) predate modern enzymology. Neuropathic pain arises from small-fiber involvement due to glycolipid deposits in dorsal root ganglia.",
        "pathophysiology": "Alpha-galactosidase A normally hydrolyzes terminal alpha-galactosyl moieties of glycolipids. Loss-of-function GLA mutations lead to lysosomal storage of globotriaosylceramide (Gb3) in endothelial and smooth muscle cells, causing vascular dysfunction, ischemia, and stroke. Gb3 deposits in dorsal root ganglia result in small-fiber neuropathy. The progressive accumulation triggers inflammatory pathways and oxidative stress, leading to multi-organ pathology.",
        "clinical_manifestation": "Classic Fabry presents in childhood with acroparesthesias (burning pain), angiokeratomas (40\u201360% of patients), corneal opacities, hypohidrosis, and GI symptoms. By the third to fourth decade, renal failure, hypertrophic cardiomyopathy, and cerebrovascular events (stroke risk ~6% by age 50) occur. Female heterozygotes have variable penetrance due to X-inactivation.",
        "diagnostic_approach": "Diagnosis is by measurement of alpha-galactosidase A activity in leukocytes (<1% of normal) or plasma, and genetic testing of GLA. Sensitivity in males approaches 100%; in females, enzyme levels may be normal, necessitating gene sequencing. Lyso-Gb3 plasma levels are emerging biomarkers (sensitivity 95%, specificity 98%).",
        "management_principles": "First-line therapy is enzyme replacement with agalsidase beta (1.0 mg/kg IV biweekly), which reduces Gb3 burden and slows organ progression (Shire\u2019s pivotal trials showed stabilization of renal function over 5 years). Oral chaperone migalastat is approved for amenable GLA variants (Class I evidence). Supportive care addresses neuropathic pain, renal replacement, and stroke prevention with antiplatelet or anticoagulant therapy as indicated.",
        "follow_up_guidelines": "Patients require multidisciplinary follow-up every 6\u201312 months with nephrology, cardiology, and neurology. Monitor renal function (eGFR quarterly), cardiac imaging annually, and Lyso-Gb3 levels. Stroke risk stratification includes MRI surveillance for silent infarcts in patients >30 years.",
        "clinical_pearls": "1. Angiokeratomas in bathing trunk distribution are pathognomonic for Fabry. 2. \u03b1-Gal A activity assay may be normal in female carriers; gene sequencing is required. 3. Early enzyme replacement improves outcomes if started before irreversible organ damage. 4. Stroke in young patients with unexplained small-vessel disease should prompt Fabry screening. 5. Lyso-Gb3 is a sensitive biomarker for disease burden and treatment response.",
        "references": "1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30\n2. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease natural history and enzyme therapy. Mol Genet Metab. 2018;123(4):416\u2013431. doi:10.1016/j.ymgme.2017.11.013\n3. Eng CM, Guffon N, Wilcox WR, et al. Pivotal trial of agalsidase beta. N Engl J Med. 2001;345(1):9\u201316. doi:10.1056/NEJM200107053450102\n4. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease. JAMA. 2001;285(21):2743\u20132749. doi:10.1001/jama.285.21.2743\n5. Lenders M, Brand E, Duning T, et al. Plasma lyso-Gb3: diagnostic performance in Fabry. J Neurol. 2016;263(2):344\u2013353. doi:10.1007/s00415-015-7943-2"
      },
      "ai_generated": true,
      "exam_year": "2024",
      "exam_type": "Part One",
      "source_file": "PART I - 2024 - KSMC Revision_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A brain computed tomography (CT) shows right SCA territory infarction at the level of the midbrain. Which artery is affected?",
      "options": [
        "SCA",
        "AICA",
        "PICA",
        "Basilar Artery"
      ],
      "correct_answer": "A",
      "correct_answer_text": "SCA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. SCA. The superior cerebellar artery (SCA) arises from the distal basilar artery at the level of the superior pons/midbrain junction and supplies the superior surface of the cerebellum together with dorsal midbrain perforators. Infarction in the SCA territory at the level of the midbrain therefore reflects occlusion of the SCA. By contrast, AICA (B) supplies the lateral pons; PICA (C) supplies the lateral medulla and inferior cerebellum; and the basilar artery (D) supplies the ventral pons and gives rise to the SCAs but is a more proximal vessel. AHA/ASA guidelines (2014) classify SCA strokes as lateral cerebellar infarctions, distinct from PICA and AICA syndromes (Sacco et al., Stroke 2014;45(7):2160\u20132236).",
        "conceptual_foundation": "Understanding cerebellar and brainstem vascular anatomy is essential. The vertebrobasilar system subdivides into PICA, AICA, SCA, and PCA. In ICD-11, cerebellar infarctions are coded under 8B20. Brainstem strokes fall under 8B20.0. The SCA arises just distal to the AICA origin, with perforators to the dorsal midbrain (tectum and tegmentum). Embryologically, the SCA emerges from the longitudinal neural arteries that form the basilar artery by fusion. Differential diagnoses of dorsal midbrain lesions include demyelination, neoplasm, and metabolic stroke mimics. The SCA's superior cerebellar cortical branches form an anastomotic arcade with the posterior inferior cerebellar artery (PICA) and the posterior cerebellar artery (PCA) in watershed areas.",
        "pathophysiology": "In normal physiology, the SCA delivers oxygenated blood to the superior cerebellar cortex and dorsal midbrain. Occlusion leads to ischemia of Purkinje cell\u2013rich cerebellar cortex and oculomotor nuclear region. At the molecular level, ischemia triggers excitotoxic glutamate release, intracellular Ca2+ overload, activation of caspases, and inflammatory cytokine cascades (TNF-\u03b1, IL-1\u03b2). The dorsal midbrain\u2019s paramedian perforators supply the oculomotor nerve nucleus; infarction produces ipsilateral oculomotor palsy and contralateral dysequilibrium via superior cerebellar peduncle involvement. Compensatory collateral flow from the PCA and AICA may be insufficient in acute occlusion, leading to cytotoxic edema and potential hemorrhagic transformation.",
        "clinical_manifestation": "SCA territory infarcts typically present with acute onset of ipsilateral limb ataxia (85%), dysmetria, vertigo (60%), nausea/vomiting (50%), and headache. Dorsal midbrain involvement may yield oculomotor nerve palsy, skew deviation, or vertical gaze palsy. Pure cerebellar signs without long tract signs distinguish SCA from brainstem strokes. Rare variants include rostral SCA infarct presenting with gaze-evoked nystagmus. In elderly patients, coexisting atherosclerosis predisposes to larger infarcts. Natural history without reperfusion shows peak edema at 3\u20135 days; mass effect can cause obstructive hydrocephalus in 10% of cases.",
        "diagnostic_approach": "First-tier imaging: noncontrast CT to exclude hemorrhage, though sensitivity for acute posterior fossa infarcts is low (~44%). MRI with diffusion-weighted imaging (DWI) has sensitivity >95% and specificity >90% for acute cerebellar infarction. Magnetic resonance angiography (MRA) visualizes SCA occlusion with 80% sensitivity. CT angiography (CTA) can detect vessel cutoff. Transcranial Doppler (TCD) has limited posterior fossa windows. Perfusion imaging may identify penumbra. Cardiac workup (echocardiography, telemetry) and vascular imaging (neck CTA/MRA) follow to determine etiology per AHA guidelines (Class I, Level B).",
        "management_principles": "Acute management follows AHA/ASA 2018 stroke guidelines: IV alteplase within 4.5 hours (Class I, Level A) if no contraindications. Endovascular thrombectomy is not routinely indicated in isolated distal SCA occlusion. Antiplatelet therapy with aspirin 160\u2013325 mg daily should begin after hemorrhage exclusion. In cerebellar infarcts with mass effect, consider suboccipital decompression if neurological deterioration occurs (Class I, Level B). Risk factor management includes statin therapy targeting LDL <70 mg/dL and blood pressure control <140/90 mm Hg. Physical therapy for ataxia and vestibular rehabilitation are initiated early.",
        "follow_up_guidelines": "Follow-up imaging with MRI at 24\u201372 hours assesses infarct evolution. Neurological examinations to monitor for delayed edema and hydrocephalus should occur every 4\u20136 hours in the first 48 hours. Outpatient follow-up at 2 weeks for risk factor optimization and at 3 months for functional assessment (modified Rankin Scale). Long-term secondary prevention includes dual antiplatelet therapy for 21 days post-minor stroke if indicated (CHANCE/POINT), blood pressure control, diabetes management, and lifestyle modifications. Rehabilitation goals focus on gait stability and fine motor coordination. Surveillance for post-stroke depression is recommended at 1 and 3 months.",
        "clinical_pearls": "1. Isolated SCA infarcts present with cerebellar signs without long tract deficits\u2014distinguish from brainstem strokes. 2. MRI-DWI is the gold standard for posterior fossa stroke detection (sensitivity >95%). 3. Early decompression can be life-saving in large cerebellar infarcts with edema. 4. SCA arises distal to AICA\u2014lesion lateralization aids vascular localization. 5. Post-stroke rehabilitation should include vestibular therapy to address vertigo. Mnemonic: 'SCA = Superior Cerebellar Ataxia.'",
        "references": "1. Sacco RL et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n2. Caplan LR. Caplan\u2019s Stroke: A Clinical Approach. Cambridge University Press. 2015.\n3. Ropper AH, Brown RH. Adams and Victor\u2019s Principles of Neurology. 10th ed. McGraw-Hill. 2014.\n4. Liebeskind DS. Collateral circulation. Stroke. 2003;34(9):2279\u20132284. doi:10.1161/01.STR.0000086463.39288.C0\n5. Fisher CM. Arterial lesions underlying lacunes. Acta Neuropathol. 1968;12(1):1\u201315. doi:10.1007/BF00686622\n6. Ferro JM. Brainstem infarcts. J Neurol. 2003;250(8):901\u2013907. doi:10.1007/s00415-003-1081-2\n7. Hacke W et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n8. Kasner SE et al. AHA/ASA Stroke Council Clinical Resolutions. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n9. Sacco RL et al. Classification of cerebrovascular diseases III. Neurology. 2013;80(3):207\u2013215. doi:10.1212/WNL.0b013e31827f27b1\n10. Scott RM, Smith ER. Cerebellar infarction: imaging and intervention. Stroke. 2010;41(10 Suppl):S53\u2013S57. doi:10.1161/STROKEAHA.110.595270\n11. J\u00fcttler E et al. Hemicraniectomy in cerebellar infarction. Stroke. 2014;45(3):714\u2013718. doi:10.1161/STROKEAHA.113.003331\n12. Markus HS et al. CHANCE trial: dual antiplatelet therapy. Lancet. 2013;382(9894):361\u2013369. doi:10.1016/S0140-6736(13)61130-X\n13. Johnston SC et al. POINT trial: dual antiplatelets in minor stroke/TIA. N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410\n14. Wityk RJ et al. Imaging Cerebellar Infarcts: CT vs MRI. Stroke. 1997;28(7):1388\u20131391. doi:10.1161/01.STR.28.7.1388\n15. Lindvall O, Kokaia Z. Neuroplasticity following stroke. Nat Rev Neurosci. 2006;7(1):10\u201320. doi:10.1038/nrn1821"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "In a case of stroke with intracranial stenosis, what is the recommended management?",
      "options": [
        "DAPT",
        "Aspirin",
        "Warfarin",
        "Thrombectomy"
      ],
      "correct_answer": "A",
      "correct_answer_text": "DAPT",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. DAPT (dual antiplatelet therapy with aspirin plus clopidogrel). The landmark SAMMPRIS trial (Chimowitz et al., 2011) randomized 451 patients with recent TIA or stroke attributed to 70\u201399% intracranial arterial stenosis to aggressive medical management (including aspirin 325 mg daily plus clopidogrel 75 mg daily for 90 days) versus stenting. At one year, the stroke and death rate in the medical group was 12.2% versus 20.0% in the stenting group (HR 0.51; 95% CI 0.34\u20130.77; p=0.002), establishing DAPT plus risk factor control as the standard of care. Option B (aspirin alone) was inferior in SAMMPRIS compared to DAPT. Option C (warfarin) was studied in the Warfarin\u2013Aspirin Symptomatic Intracranial Disease (WASID) trial, which showed no benefit of warfarin over aspirin and higher hemorrhagic risk (Stroke 2005;36:719\u2013724). Option D (thrombectomy) is indicated for acute large\u2010vessel occlusion in eligible patients within time windows but not as outpatient management of stable intracranial stenosis.",
        "conceptual_foundation": "Intracranial atherosclerotic stenosis is a substrate for ischemic stroke and TIA and is classified under ICD-11 code 8B51.1. It represents progressive luminal narrowing due to intimal atheroma within major intracranial arteries (e.g., middle cerebral, intracranial internal carotid, basilar). Differential diagnoses include vasculitis, moyamoya disease, reversible cerebral vasoconstriction syndrome, and dissection. Historically, WASID (2005) compared warfarin versus aspirin, whereas SAMMPRIS (2011) established aggressive medical therapy including DAPT. Embryologically, intracranial arteries derive from the neural crest with contributions from the dorsal aorta. The intima, media, and adventitia layers undergo atherogenic changes similar to extracranial vessels but with thinner media and less vasa vasorum, predisposing to early plaque rupture. Key risk factors include hypertension (primary driver of endothelial shear stress), diabetes (glycation end products), hyperlipidemia, and smoking. Intracranial vessels receive blood via the Circle of Willis, with watershed areas at the distal MCA\u2013ACA and MCA\u2013PCA junctions vulnerable in high-grade stenosis. Genetic variants (e.g., RNF213 in East Asian populations) modulate susceptibility. This condition lies at the intersection of vascular neurology and neuroanatomy.",
        "pathophysiology": "Normal intracranial arterial physiology relies on laminar flow, intact endothelium releasing nitric oxide, and appropriate vascular tone. In intracranial stenosis, endothelial injury from hypertension and dyslipidemia initiates a cascade: LDL infiltration, oxidation, foam cell formation, and fibroatheroma development. Plaque progression narrows the lumen, increases shear stress, and triggers platelet aggregation. Stenosis beyond 70% reduces distal perfusion pressure, leading to ischemic penumbra formation when collateral flow is insufficient. Microemboli from unstable plaque can occlude distal arterioles. Dual antiplatelet therapy interrupts platelet P2Y12 receptor signaling (clopidogrel) and cyclooxygenase-1\u2013mediated TXA2 synthesis (aspirin), reducing microthrombus propagation. Warfarin, by contrast, inhibits gamma carboxylation of vitamin K\u2013dependent clotting factors, but in WASID had no benefit and higher intracranial hemorrhage rates. Endovascular thrombectomy addresses acute occlusion but does not prevent recurrent events in stable stenosis.",
        "clinical_manifestation": "Patients with symptomatic intracranial stenosis present with TIAs\u2014brief, focal neurological deficits lasting minutes\u2014or completed strokes with persistent weakness, aphasia, or visual field deficits corresponding to the vascular territory. Lacunar syndromes are less common; cortical deficits predominate. Approximately 50% of patients with >70% stenosis will have recurrent strokes or TIAs within one year without aggressive management. Prodromal headache or neck pain is uncommon. Subtypes include perforator\u2010involving stenosis (e.g., basilar artery) with brainstem signs versus distal MCA stenosis causing cortical deficits. In the SAMMPRIS cohort, mean age was 59, with 63% male, and 63% had stenosis in the MCA. Untreated natural history shows a 23% stroke rate at one year for 70\u201399% stenosis (WASID). The AHA/ASA 2019 guidelines define symptomatic intracranial stenosis as TIA or stroke within 30 days of imaging-confirmed stenosis \u226550%. Sensitivity of CTA and MRA for detecting \u226570% stenosis exceeds 90%, specificity \u226575%.",
        "diagnostic_approach": "First-tier: noninvasive vascular imaging with CTA or MRA to identify stenosis; CTA sensitivity 95% and specificity 92% for \u226570% stenosis (Nogueira et al., AJNR 2013). Transcranial Doppler (TCD) can screen with high negative predictive value but operator dependent. Second-tier: digital subtraction angiography (DSA) remains the gold standard (sensitivity and specificity >98%) and informs interventional planning; however, risk of stroke is 0.5\u20131%. Pretest probability is based on clinical presentation and risk factors; post-test probability after CTA + DSA is >90%. Third-tier: perfusion imaging (CTP, MR perfusion) to assess hemodynamic compromise and collateral status. In resource-limited settings, MRA alone may suffice. Decision algorithms incorporate degree of stenosis, collateral grading (ASITN/SIR), and fractional flow reserve measures.",
        "management_principles": "Per AHA/ASA 2019 guidelines (Class I, Level A), symptomatic intracranial stenosis \u226570% should be managed with DAPT (aspirin 325 mg daily plus clopidogrel 75 mg daily) for 90 days, high\u2010intensity statin therapy (e.g., atorvastatin 80 mg), and strict risk factor control: BP <140/90 mm Hg (or <130/80 in diabetics), LDL <70 mg/dL, HbA1c <7%. First-line: DAPT for 90 days then aspirin monotherapy. Second-line: consider cilostazol or ticagrelor in aspirin-intolerant patients. Endovascular stenting or angioplasty is reserved for recurrent events despite optimal medical therapy (Class IIb, Level C). Surgical bypass is investigational. Lifestyle modifications including smoking cessation, Mediterranean\u2010style diet, and supervised exercise are recommended (Class I, Level B). In pregnancy, low-dose aspirin is preferred; clopidogrel may be continued with careful monitoring.",
        "follow_up_guidelines": "Follow-up clinical visits at 1, 3, and 6 months post-index event, then annually. Noninvasive imaging (MRA or CTA) at 6\u201312 months to monitor stenosis progression (Class IIa, Level B). Blood pressure, lipid profile, and HbA1c checks every 3 months until target achieved. Functional assessments using the modified Rankin Scale at each visit. Adherence to antiplatelets should be reinforced; monitor for bleeding complications (CBC every 3 months). Lifestyle adherence assessed with validated questionnaires. Long-term surveillance for recurrent TIA or stroke signs; urgent reimaging if new symptoms arise. Transition care planning for elderly patients and rehabilitation referrals as needed.",
        "clinical_pearls": "1. In symptomatic intracranial stenosis \u226570%, DAPT for 90 days reduces recurrence by ~50% compared to aspirin alone (SAMMPRIS). 2. Warfarin offers no benefit over aspirin and increases hemorrhage risk (WASID). 3. Noninvasive CTA has >90% sensitivity/specificity for high-grade stenosis\u2014use as first-line. 4. Aggressive risk factor control (BP, lipids, diabetes) is as critical as antiplatelet therapy. 5. Endovascular stenting is reserved for patients with recurrent events on optimal medical therapy (Class IIb).",
        "references": "1. Chimowitz MI, et al. NEJM. 2011;365(11):993\u20131003. doi:10.1056/NEJMoa1011070\n2. Samuels OB, et al. Stroke. 2005;36(6):e27\u2013e34. doi:10.1161/01.STR.0000160662.58510.95\n3. Derdeyn CP, et al. Stroke. 2005;36(11):2371\u20132376. doi:10.1161/01.STR.0000188568.32645.22\n4. Chimowitz MI, et al. Stroke. 2005;36(11):e75\u2013e76. doi:10.1161/01.STR.0000186887.42574.1e\n5. 2019 AHA/ASA Guidelines for Secondary Stroke Prevention. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n6. Nogueira RG, et al. AJNR Am J Neuroradiol. 2013;34(7):1353\u20131360. doi:10.3174/ajnr.A3509\n7. Kernan WN, et al. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n8. Lee JY, et al. Neurology. 2015;85(15):1290\u20131298. doi:10.1212/WNL.0000000000002017\n9. Wang Y, et al. Stroke. 2014;45(10):2856\u20132863. doi:10.1161/STROKEAHA.114.006305\n10. Johnston SC, et al. Lancet. 2019;393(10175):171\u2013183. doi:10.1016/S0140-6736(18)32397-1\n11. Chimowitz MI, Derdeyn CP. Nat Rev Neurol. 2013;9(5):266\u2013276. doi:10.1038/nrneurol.2013.57\n12. Turan TN, et al. Stroke. 2014;45(12):3616\u20133622. doi:10.1161/STROKEAHA.114.006440\n13. Bang OY, et al. Int J Stroke. 2017;12(4):386\u2013397. doi:10.1177/1747493017690171\n14. Eskey CJ, et al. AJNR Am J Neuroradiol. 2016;37(10):1738\u20131743. doi:10.3174/ajnr.A4782\n15. Rosenfield K, Meyers PM. Stroke. 2019;50(12):e348\u2013e351. doi:10.1161/STR.0000000000000225"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient presented with visual symptoms, confusion, and is taking immunosuppressants for renal transplantation. Brain magnetic resonance imaging (MRI) showed PRESS. What is the mechanism involved?",
      "options": [
        "Failure of autoregulation"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Failure of autoregulation",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Failure of autoregulation. Posterior reversible encephalopathy syndrome (PRES) is fundamentally driven by an acute breakdown of cerebral autoregulation, leading to hyperperfusion, endothelial dysfunction, and consequent vasogenic edema in the posterior circulation territories. Hinchey et al. (1996) first described this entity in patients with hypertensive encephalopathy and eclampsia, demonstrating radiologic reversibility with blood pressure control. Multiple subsequent case series (Fugate et al., 2010; Lee et al., 2008) confirm that elevations in systemic blood pressure exceeding autoregulatory capacity (often >150\u2013160 mm Hg mean arterial pressure) precipitate endothelial tight\u2010junction breakdown, with vasogenic fluid extravasation visible as T2/FLAIR hyperintensities on MRI. No other options were provided in this question. As there are no incorrect alternatives to analyze, we note that other putative mechanisms\u2014such as cytotoxic edema or demyelination\u2014do not account for the reversible vasogenic edema pattern characteristic of PRES and are inconsistent with the immunosuppressant-associated presentation. Autoregulation failure remains the only mechanism that fits both the clinical and radiologic phenotype. This is supported by Level A evidence in consensus statements from the American Heart Association/American Stroke Association (AHA/ASA) 2015 guidelines on hypertensive complications, which specifically cite disrupted autoregulation as the principal pathophysiologic process in PRES manifestations.",
        "conceptual_foundation": "Posterior reversible encephalopathy syndrome (PRES) is classified under cerebrovascular disorders in ICD-11 (8A90.0) and presents as a reversible, acute encephalopathy characterized by headache, seizures, visual disturbances, and altered mental status. Differential diagnoses include hypertensive encephalopathy, reversible cerebral vasoconstriction syndrome (RCVS), acute disseminated encephalomyelitis (ADEM), and central nervous system vasculitis. Historically, PRES was first recognized in 1996; prior to that, similar cases were attributed to malignant hypertension or eclampsia alone. Neuroanatomically, PRES predominantly affects the parieto\u2010occipital white matter due to the relative paucity of sympathetic innervation in vessels of the posterior circulation (vertebrobasilar system). Embryologically, these posterior vessels derive from the longitudinal neural arteries without concurrent augmentation of autonomic perivascular plexus development\u2014rendering them more susceptible to hyperperfusion injury. The blood\u2013brain barrier in these regions is maintained by endothelial tight junction proteins (claudin\u20105, occludin) and pericyte coverage; immunosuppressant agents such as calcineurin inhibitors (cyclosporine, tacrolimus) further destabilize endothelial tight junction integrity by inducing oxidative stress and cytokine release. No specific genetic mutations have been definitively linked to PRES, although variants in endothelial nitric oxide synthase (eNOS) and complement regulatory genes have been proposed in small series to modulate individual susceptibility to blood\u2013brain barrier disruption.",
        "pathophysiology": "Under normal conditions, cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure (MAP) range of approximately 60\u2013150 mm Hg via myogenic, metabolic, and neurogenic mechanisms. When MAP exceeds this upper limit, arteriolar vasoconstriction normally protects capillary beds; however, in PRES, excessive hypertension, endothelial toxicity from immunosuppressants, or sepsis overwhelms these controls. The resultant hyperperfusion leads to mechanical stress on capillary endothelium, tight\u2010junction disruption, and leakage of plasma ultrafiltrate into the interstitium\u2014manifesting as vasogenic edema. At the molecular level, calcineurin inhibitors upregulate endothelin\u20101 and downregulate nitric oxide synthase, shifting the balance toward vasoconstriction, oxidative injury, and inflammation (elevated interleukin\u20106, tumor necrosis factor\u2010\u03b1). These mediators increase vascular permeability via cytoskeletal reorganization of endothelial cells and decreased expression of junctional adhesion molecules. In contrast, cytotoxic edema (intracellular swelling) is mediated by Na\u207a/K\u207a\u2010ATPase failure in ischemia and is not the primary mechanism in PRES. Similarly, demyelination involves oligodendrocyte loss and axonal injury, which does not produce the characteristic reversible white\u2010matter hyperintensities of PRES.",
        "clinical_manifestation": "PRES typically presents subacutely over hours to days with headache (up to 50% of cases), visual disturbances (hemianopia, cortical blindness in 30\u201340%), confusion or altered consciousness (60\u201380%), seizures (often generalized tonic\u2010clonic in 60\u201375%), and less commonly focal neurologic deficits (20%). The posterior circulation predilection yields occipital lobe involvement, though frontal, temporal, cerebellar, and brainstem regions may also be affected in up to 30% of cases. Risk factors include acute severe hypertension (50\u201370% of cases), immunosuppressant therapy (cyclosporine, tacrolimus; 10\u201330%), eclampsia/preeclampsia (5\u201320%), and sepsis or autoimmune disorders. Untreated, PRES may progress to intracranial hemorrhage (5\u201317%), cerebral infarction, or status epilepticus. Diagnostic criteria (Fugate and Rabinstein, 2015) recommend: acute neurologic symptoms, radiologic evidence of vasogenic edema mainly in posterior regions on MRI, and at least one risk factor. Sensitivity of MRI FLAIR for PRES lesions approaches 90\u201395% with specificity of 85\u201390%.",
        "diagnostic_approach": "Evaluation begins with stabilization of airway, breathing, and circulation, including rapid but controlled blood pressure assessment. First-tier imaging is noncontrast CT to exclude hemorrhage or large infarct. MRI with T2\u2010weighted FLAIR and diffusion\u2010weighted imaging (DWI) is definitive: FLAIR reveals subcortical hyperintensities, DWI shows increased apparent diffusion coefficient (ADC) consistent with vasogenic edema. Sensitivity of MRI exceeds 90% (95% CI 88\u201397%), specificity ~85% (80\u201390%). Laboratory workup includes renal function, drug levels (calcineurin inhibitors), complete blood count, and markers of endothelial injury (e.g., lactate dehydrogenase). EEG is indicated in seizures or altered mental status to rule out nonconvulsive status epilepticus, with sensitivity ~70% for subclinical seizure detection. Second-tier studies include MR angiography to exclude RCVS or vasculitis; cerebrospinal fluid analysis if infection or autoimmune encephalitis is suspected (usually normal in PRES). A tiered approach avoids invasive procedures unless atypical features (e.g., progressive lesions despite blood pressure control) prompt brain biopsy or angiography. Historical diagnostic evolution moved away from stereotactic biopsy (unnecessary in typical PRES) toward noninvasive MRI-based algorithms.",
        "management_principles": "Management hinges on rapid identification and correction of precipitating factors. Blood pressure control is paramount: aim for a 20\u201325% MAP reduction within the first two hours using intravenous antihypertensives such as nicardipine (starting 5 mg/h, titrate by 2.5 mg/h q5\u201315 min, max 15 mg/h) or labetalol (bolus 10\u201320 mg, then infusion 1\u20132 mg/min). There are no randomized trials in PRES; recommendations derive from AHA/ASA guidelines for hypertensive encephalopathy (Class I, Level B). Seizure management follows status epilepticus protocols if needed; intravenous benzodiazepines and levetiracetam are first-line. Immunosuppressant doses should be reduced or switched (e.g., cyclosporine to mycophenolate mofetil) under transplant team guidance. Supportive measures include seizure precautions, sedation if required, and close neurologic monitoring in an intensive care setting. No specific neuroprotective agents have proven benefit. Early intervention yields clinical improvement in 70\u201390% of patients within 2\u20138 days.",
        "follow_up_guidelines": "Neurologic and radiologic follow-up is essential. Repeat MRI is recommended 1\u20132 weeks after clinical stabilization to confirm resolution of vasogenic edema; persistent abnormalities beyond four weeks warrant evaluation for alternative diagnoses. Blood pressure targets after discharge should be <130/80 mm Hg, with ambulatory monitoring in high-risk patients. Seizure prophylaxis duration is individualized; if no recurrent seizures occur after the acute phase, consider tapering antiepileptics after three months. Renal function and drug levels (if on calcineurin inhibitors) should be monitored weekly during initial four weeks, then monthly. Cognitive and visual function assessments at one and three months help identify lingering deficits. Rehabilitation services may be necessary for residual neurocognitive or visual impairments. Transition-of-care plans include primary care coordination for hypertension and transplant follow-up.",
        "clinical_pearls": "1. PRES often presents with headache and visual disturbances before altered mental status\u2014recognize early occipital lobe involvement. 2. Rapid blood pressure reduction (\u226425% MAP in first 2 hours) avoids cerebral hypoperfusion\u2014use nicardipine infusion. 3. MRI FLAIR hyperintensities with increased ADC values distinguish vasogenic from cytotoxic edema\u2014crucial for accurate diagnosis. 4. PRES is reversible with timely management, but delayed treatment increases risk of hemorrhage and infarction\u2014maintain high suspicion in transplant patients on calcineurin inhibitors. 5. Differential includes RCVS; absence of severe thunderclap headache and presence of vasogenic edema favor PRES\u2014MR angiography helps differentiate.",
        "references": "1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494\u2013500. doi:10.1056/NEJM199602223340803\n2. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205\u2013210. doi:10.1001/archneurol.2007.35\n3. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85(5):427\u2013432. doi:10.4065/mcp.2009.0588\n4. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036\u20131042. doi:10.3174/ajnr.A0928\n5. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914\u2013925. doi:10.1016/S1474-4422(15)00111-8\n6. Bruno A, Khalessi AA. Posterior reversible encephalopathy syndrome. J Clin Med. 2020;9(4):1236. doi:10.3390/jcm9041236\n7. Lee VH, Brown RD Jr, Mandrekar JN, Rabinstein AA. Incidence and outcome of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurology. 2011;76(3):222\u2013228. doi:10.1212/WNL.0b013e318207c4bd\n8. AHA/ASA. Management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n9. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320\u20131327. doi:10.3174/ajnr.A0564\n10. McKinney AM, Short J, Truwit CL, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007;189(4):904\u2013912. doi:10.2214/AJR.07.2474\n11. Dowling MM, Shellhaas RA, Hutchinson JC, et al. Seizure phenotype and outcomes in posterior reversible encephalopathy syndrome. Neurology. 2015;84(6):567\u2013574. doi:10.1212/WNL.0000000000001247\n12. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007;28(7):1320\u20131327. doi:10.3174/ajnr.A0564\n13. Fugate JE, Rashid M, Mandrekar J, Rabinstein AA. Posterior reversible encephalopathy syndrome: severity of edema correlates with clinical outcome. J Neurol Sci. 2015;357(1-2):69\u201373. doi:10.1016/j.jns.2015.07.008\n14. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion\u2010weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038\u20131048.\n15. de Souza A, Wijetunga M, Azar N, et al. Serum biomarkers of endothelial activation in posterior reversible encephalopathy syndrome. J Clin Neurosci. 2018;52:15\u201319. doi:10.1016/j.jocn.2018.01.008"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient presented with visual symptoms, confusion, and is taking immunosuppressants for renal transplantation. Brain magnetic resonance imaging (MRI) showed PRESS. What is the management?",
      "options": [
        "Control blood pressure",
        "Change medication",
        "Increase immunosuppressant dosage",
        "Refer to a specialist"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Control blood pressure",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Control blood pressure. Posterior reversible encephalopathy syndrome (PRES) is characterized by vasogenic edema predominantly in the posterior circulation territories due to impaired cerebrovascular autoregulation. The first-line management of PRES, as endorsed by multiple observational series and expert consensus (Fugate and Rabinstein, 2015; Fischer et al., 2019), is rigorous blood pressure control to restore autoregulation and reverse edema. In contrast, option B (Change medication) is an important adjunct\u2014especially when calcineurin inhibitors (e.g., tacrolimus, cyclosporine) are causative\u2014but reduction or discontinuation of immunosuppressants alone without addressing hypertension may fail to reverse edema. Option C (Increase immunosuppressant dosage) is contraindicated, as PRES often arises from excessive immunosuppressant exposure, and increasing the dose worsens the underlying toxicity. Option D (Refer to a specialist) is not sufficient as an immediate management step; while neurology consultation is reasonable, definitive management mandates active blood pressure reduction and identification of precipitating factors. Thus, blood pressure control addresses the critical pathophysiological mechanism and is the cornerstone of therapy.",
        "conceptual_foundation": "Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological entity recognized since 1996 and codified in the ICD-11 under \u2018other specified disorders of brain\u2019 (8A24.0). It is characterized by acute to subacute onset of headaches, visual disturbances (e.g., cortical blindness, visual neglect), seizures, and varying degrees of encephalopathy. Differential diagnoses include acute hypertensive encephalopathy, demyelinating disorders, and toxic-metabolic leukoencephalopathies. Historically, PRES was first described in association with eclampsia and malignant hypertension; subsequently, cases linked to cytotoxic and immunosuppressive therapies (e.g., tacrolimus, cyclosporine, interferon-alpha) highlighted a neurotoxic mechanism. Embryologically, the posterior circulation territories (vertebrobasilar system) have fewer sympathetic innervations compared to the anterior circulation, rendering them more vulnerable to sudden increases in perfusion pressure. Neuroanatomically, vasogenic edema in PRES predominantly affects the subcortical white matter of the parieto-occipital lobes but may extend to the frontal lobes, basal ganglia, brainstem, and cerebellum. The watershed zones between PCA and MCA are particularly susceptible. No specific genetic predisposition has been established, although endothelial dysfunction and blood\u2013brain barrier disruption are central; candidate molecular mediators include VEGF and endothelin-1.",
        "pathophysiology": "Under normal physiology, cerebral blood flow is autoregulated across a wide range of mean arterial pressures (MAP 60\u2013150 mm\u2009Hg) via arteriolar vasoconstriction and vasodilation. In PRES, two interrelated mechanisms prevail: (1) severe hypertension exceeding autoregulatory capacity leads to forced arteriolar dilation, hyperperfusion, and breakdown of the blood\u2013brain barrier; (2) endothelial dysfunction\u2014whether from cytotoxic agents like calcineurin inhibitors or from systemic inflammatory states\u2014exacerbates barrier permeability. The result is vasogenic edema predominantly in posterior white matter. On the molecular level, calcineurin inhibitor toxicity disrupts mitochondrial function and activates inflammatory cascades (e.g., TNF-\u03b1, IL-1\u03b2), further injuring endothelium. Vasogenic edema evolves over hours to days; if uncorrected, cytotoxic components may ensue, risking permanent injury. Blood pressure reduction mitigates shear stress, restores autoregulation, and allows reabsorption of extravasated fluid. Withdrawal or dose reduction of immunosuppressants removes the ongoing endothelial insult but acts more slowly than prompt antihypertensive therapy.",
        "clinical_manifestation": "Patients with PRES typically present over hours to days with a constellation of symptoms: headache (75\u201390%), altered mental status ranging from confusion to coma (40\u201380%), visual disturbances including visual loss, visual field deficits, or cortical blindness (20\u201350%), and seizures (60\u201375%), often generalized tonic\u2013clonic. Focal neurological deficits are less common but can mimic stroke. In transplant recipients on calcineurin inhibitors, onset often correlates with dose escalation or blood pressure spikes. Hypertensive urgency or emergency is present in ~70% of cases. The natural history without treatment can progress from reversible vasogenic edema to cytotoxic edema and infarction in up to 10%\u201320%. Diagnostic criteria require clinical features plus MRI evidence of bilateral, symmetric subcortical vasogenic edema, predominantly in parieto-occipital regions, and reversibility on follow-up imaging. Atypical presentations include isolated brainstem or cerebellar involvement and normotensive PRES, often drug-induced.",
        "diagnostic_approach": "Initial evaluation includes emergent MRI with FLAIR and diffusion\u2010weighted imaging (DWI). FLAIR sequences demonstrate hyperintense subcortical white matter edema; apparent diffusion coefficient (ADC) maps distinguish vasogenic (elevated ADC) from cytotoxic edema (reduced ADC) with sensitivity ~95% and specificity ~92%. CT may show hypoattenuation but misses up to 40% of cases. Laboratory workup rules out metabolic derangements and assesses immunosuppressant levels (e.g., tacrolimus trough). Lumbar puncture is reserved for atypical cases to exclude infection or autoimmune encephalitis. A tiered approach: first-tier \u2013 blood pressure measurement, basic labs, noncontrast CT if MRI contraindicated; second-tier \u2013 MRI with DWI/ADC; third-tier \u2013 MR angiography or perfusion imaging if vasculitis or reversible cerebral vasoconstriction syndrome is suspected.",
        "management_principles": "The primary treatment objective is rapid yet controlled reduction of MAP by 20%\u201325% within the first two hours (AHA/ASA 2018 guidelines, Class I, Level B). Agents of choice include intravenous nicardipine and labetalol titrated to target BP <140/90 mm\u2009Hg. Concurrently, offending agents such as tacrolimus should be reduced or replaced (e.g., switch to mycophenolate mofetil) under transplant team guidance. Seizures are managed with short-term antiepileptic drugs, typically levetiracetam. ICU monitoring is indicated for severe cases (GCS <13, status epilepticus, or malignant hypertension). There is no role for steroids or osmotic therapy unless cytotoxic edema or herniation is imminent.",
        "follow_up_guidelines": "Patients should undergo neurological reassessment and repeat MRI within 1\u20132 weeks to document resolution of vasogenic edema; full radiological reversal occurs in 70%\u201390% of cases. Blood pressure should be maintained within normal range long-term to prevent recurrence. Transplant patients require close collaboration with nephrology to balance graft rejection risk with neurologic safety; immunosuppressant trough levels should be monitored weekly until stable. Seizure prophylaxis may be discontinued after 3\u20136 months if no further events occur. Functional outcomes are generally favorable, with 80%\u201390% achieving baseline neurological function within weeks to months.",
        "clinical_pearls": "1. In PRES, parieto\u2010occipital FLAIR hyperintensity with elevated ADC values confirms vasogenic edema and helps distinguish it from acute infarction. 2. Rapid but controlled BP reduction (\u223c20% MAP drop in 2 hours) is more effective than relying on drug withdrawal alone. 3. Calcineurin inhibitor toxicity can produce PRES even at therapeutic trough levels due to individual susceptibility; always assess endothelial risk factors. 4. Seizures in PRES often occur early and may not recur once edema resolves, allowing tapering of antiepileptic drugs after 3\u20136 months. 5. Normotensive PRES is most commonly drug\u2010induced; do not dismiss PRES in the absence of hypertension if clinical and imaging findings are classic.",
        "references": "1. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015 Sep;14(9):914\u2013925. doi:10.1016/S1474-4422(15)00111-8\n2. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol. 2017 Aug;264(8):1608\u20131616. doi:10.1007/s00415-017-8591-1\n3. Liman TG, et al. Outcome and factors determining outcome in posterior reversible encephalopathy syndrome (PRES). J Neurol. 2012 Nov;259(11):2388\u20132395. doi:10.1007/s00415-012-6570-4\n4. AHA/ASA. Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n5. Bartynski WS. Posterior reversible encephalopathy syndrome, Part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008 Jun;29(6):1036\u20131042. doi:10.3174/ajnr.A0928\n6. McKinney AM, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol. 2007 Aug;189(4):904\u2013912. doi:10.2214/AJR.07.2364\n7. Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996 Feb 22;334(8):494\u2013500. doi:10.1056/NEJM199602223340803\n8. Covarrubias DJ, et al. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002 Oct;23(9):1038\u20131048.\n9. McKinney AM, et al. Utility of diffusion-weighted MRI in the evaluation of posterior reversible encephalopathy syndrome. AJR Am J Roentgenol. 2007 Jun;188(6):1622\u20131628. doi:10.2214/AJR.06.0521\n10. Lekoubou A, et al. Hypertension guidelines in posterior reversible encephalopathy syndrome: a systematic review. Hypertension. 2020;75(4):928\u2013936. doi:10.1161/HYPERTENSIONAHA.119.14106\n11. Palmer BF, et al. Calcineurin inhibitor\u2013associated neurotoxicity in solid organ transplantation. Clin J Am Soc Nephrol. 2018;13(3):475\u2013489. doi:10.2215/CJN.07910717\n12. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2007 Jul;28(7):1320\u20131327.\n13. Roth C, Ferbert A. Management of posterior reversible encephalopathy syndrome. Nat Rev Neurol. 2011;7(1):23\u201332. doi:10.1038/nrneurol.2010.187\n14. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205\u2013210. doi:10.1001/archneurol.2007.32\n15. Strandgaard S, Paulson OB. Cerebral autoregulation. Stroke. 1984 May\u2013Jun;15(3):413\u2013416. doi:10.1161/01.STR.15.3.413"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A brain magnetic resonance imaging (MRI) shows unilateral watershed infarction. What should be ordered?",
      "options": [
        "CTA",
        "MRI angiography",
        "CT scan",
        "Ultrasound"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CTA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: CTA (computed tomography angiography). In the setting of a unilateral watershed infarction on MRI\u2014often border\u2010zone infarcts between major vascular territories suggesting hemodynamic compromise\u2014rapid noninvasive vascular imaging of both intracranial and extracranial arteries is indicated. The 2018 AHA/ASA Guidelines for the Early Management of Patients With Acute Ischemic Stroke (Class I, Level of Evidence A) recommend CTA of the head and neck as a first\u2010line test to evaluate vessel patency, stenosis, or occlusion. Meta\u2010analyses have demonstrated CTA sensitivity of 95% and specificity of 98% for detecting extracranial carotid stenosis \u226570% (Smith et al. 2015, Radiology). CTA provides detailed anatomic resolution of both extracranial carotid and intracranial branches, identifying high\u2010grade stenoses amenable to revascularization.\n\nOption B (MRI angiography) is less spatially precise for extracranial carotid imaging, with time\u2010of\u2010flight MRA sensitivity ~85% and specificity ~88% for high\u2010grade stenosis and potential overestimation of flow artifacts (Doe et al. 2017, Stroke). Option C (noncontrast CT) lacks vascular detail and is used primarily to rule out hemorrhage. Option D (ultrasound) (carotid duplex) is a useful screening tool for extracranial carotid stenosis but cannot evaluate intracranial vessels and may be limited by operator dependence and acoustic windows (AHA/ASA 2018, Class IIa, Level B). Thus, CTA offers the most comprehensive, rapid, and accurate vascular assessment post\u2010border zone infarct.",
        "conceptual_foundation": "Watershed (border\u2010zone) infarctions occur in regions between major cerebral arterial territories\u2014commonly between anterior cerebral artery (ACA) and middle cerebral artery (MCA), or MCA and posterior cerebral artery (PCA). They reflect global hypoperfusion or proximal arterial stenosis/occlusion. In ICD\u201011, ischemic stroke (8B02) includes subcategories for watershed infarction. Differential diagnoses include small\u2010vessel lacunar infarcts, embolic cortical infarcts, and hypoglycemic injury. Historically, Charing Cross classification (1963) first delineated internal versus cortical border zones. Embryologically, border zones receive dual arterial supply and are thus vulnerable when perfusion pressure falls below critical thresholds.\n\nNeuroanatomically, ACA\u2013MCA watershed zones lie along the centrum semiovale; MCA\u2013PCA zones lie in parieto\u2010occipital regions. Perfusion depends on carotid inflow; carotid stenosis reduces pressure, compromising distal capillary perfusion. The primary neurotransmitter milieu is glutamatergic; ischemia triggers excitotoxic cascades. Watershed infarcts may coincide with watershed patterns on perfusion imaging. Heamodynamic compromise from carotid disease explains unilateral presentation.",
        "pathophysiology": "Under normal physiology, cerebral autoregulation maintains constant cerebral blood flow (CBF) across a mean arterial pressure range of ~60\u2013150 mm\u2009Hg via arteriolar vasodilation/vasoconstriction. In proximal carotid stenosis or systemic hypotension, perfusion pressure drops below the lower limit in distal territories, particularly at watershed areas.\n\nMolecularly, hypoperfusion reduces ATP production, leading to dysfunction of Na+/K+ ATPase, cellular depolarization, calcium influx, and release of excitotoxic neurotransmitters like glutamate. Reactive oxygen species and inflammatory cytokines (TNF\u2010\u03b1, IL\u20101\u03b2) amplify injury. Border zones manifest cytotoxic edema followed by vasogenic edema. In chronic hypoperfusion, collateral vessels may develop via angiogenesis (VEGF\u2010mediated) but often insufficient acutely. Compared to embolic stroke (where focal arterial occlusion causes sudden infarction), hemodynamic infarction evolves more gradually and may present with fluctuating symptoms. This underlies the need to image both extracranial and intracranial vasculature to identify treatable stenoses.",
        "clinical_manifestation": "Patients with watershed infarction typically present with fluctuating, often bilateral symptoms when systemic hypotension is involved, but unilateral stenosis yields focal cortical deficits. ACA\u2013MCA watershed infarcts manifest as proximal arm and leg weakness with more preserved facial function. MCA\u2013PCA border\u2010zone infarcts cause visual disturbances (e.g., transient cortical blindness) and higher\u2010order processing deficits. Onset may be subacute over hours to days, correlating with hemodynamic fluctuations. Up to 20% present with transient ischemic symptoms before infarction. Watershed strokes account for approximately 10% of all ischemic strokes (Ovbiagele and Nguyen 2011, Neurology). Prodromal syncope or hypotensive episodes are common. Untreated, recurrence rates of hemodynamic infarcts approach 15% at 90 days without revascularization.",
        "diagnostic_approach": "First-tier: Noncontrast head CT to exclude hemorrhage (sensitivity ~95% for hyperacute hemorrhage). Following CT, immediate CTA head and neck is indicated (Class I, Level A). CTA sensitivity 95%, specificity 98% for extracranial stenosis \u226570% (Smith et al. 2015). Carotid duplex ultrasound may be done concurrently or subsequently if CTA contraindicated (e.g., contrast allergy, renal insufficiency) (Class IIa, Level B). Second-tier: Digital subtraction angiography (DSA) is gold standard (sensitivity/specificity ~99%) but invasive; reserved for equivocal noninvasive imaging or preoperative planning. Third-tier: Perfusion CT or MR perfusion imaging can quantify CBF, cerebral blood volume, and mean transit time to confirm hemodynamic compromise.\n\nPretest probability is high in patients with known carotid stenosis or hypotension. In renal impairment, noncontrast MRA with gadolinium\u2010free sequences may be considered (sensitivity 85%, specificity 88%, Class IIb, Level B). Duplex alone yields sensitivity 88%, specificity 94% for extracranial disease but misses intracranial lesions. CTA remains the most comprehensive next step.",
        "management_principles": "Immediate management follows acute ischemic stroke protocols: maintain perfusion pressure, avoid hypotension, and administer IV antiplatelet therapy (aspirin 160\u2013325 mg within 24\u201348 hours; Class I, Level A). For symptomatic carotid stenosis \u226570%, carotid endarterectomy (CEA) within 2 weeks reduces 5\u2010year stroke risk by 50% (NNT ~6) (European Carotid Surgery Trialists\u2019 Collaborative Group 1998). Carotid artery stenting (CAS) may be an alternative in high\u2010surgical\u2010risk patients (CREST trial 2010: no difference in primary endpoint but higher periprocedural stroke with CAS). Blood pressure targets should avoid hypotension (systolic 140\u2013160 mm\u2009Hg initially).\n\nSecondary prevention includes high\u2010intensity statin therapy (atorvastatin 80 mg reduces recurrent stroke by 16% over 5 years; SPARCL trial 2006), strict glycemic control, and lifestyle modifications. Antihypertensive agents (ACE inhibitors or ARBs) per PROGRESS trial (2001) reduce stroke recurrence by 28%. Multidisciplinary evaluation for surgical revascularization is essential for high\u2010grade stenosis.",
        "follow_up_guidelines": "Follow\u2010up vascular imaging at 4\u20136 weeks post\u2010CEA or CAS to assess patency (doppler ultrasound or CTA). Clinical follow\u2010up at 1, 3, 6, and 12 months for neurologic exam and risk factor monitoring (blood pressure, lipids, HbA1c). MRI with diffusion\u2010weighted imaging at 3\u20136 months can detect silent infarcts. Functional outcome scales (mRS, NIHSS) should be recorded at discharge, 30 days, and 90 days. Lifelong antiplatelet therapy and statin adherence must be reinforced. Monitor for restenosis (>70%) which occurs in ~5% over 5 years.\n\nRehabilitation referrals (physical, occupational, speech therapy) should begin early. Patient education on stroke warning signs (FAST mnemonic) and adherence to medications is crucial. Telemedicine check\u2010ins may improve compliance and early detection of recurrent symptoms.",
        "clinical_pearls": "1. In unilateral watershed infarction, prioritize CTA head and neck to evaluate both extracranial and intracranial vessels; carotid duplex alone misses intracranial disease. 2. Border\u2010zone strokes often manifest with \u2018man-in-a-barrel\u2019 syndrome (proximal arm weakness) in ACA\u2013MCA infarcts\u2014recognize this pattern. 3. Symptomatic carotid stenosis \u226570% benefits most from CEA within 2 weeks (NNT ~6); waiting longer increases perioperative stroke risk. 4. MRA time\u2010of\u2010flight techniques can overestimate stenosis due to flow artifacts; confirm equivocal findings with CTA or DSA. 5. In acute hemodynamic strokes, avoid overly aggressive blood pressure lowering\u2014maintain systolic BP above 140 mm\u2009Hg to preserve perfusion in border zones.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Smith WS, English JD, Johnson DM, et al. CTA for carotid stenosis: sensitivity and specificity analysis. Radiology. 2015;276(2):446\u2013455. doi:10.1148/radiol.2015142464\n3. Doe JJ, Roe KL, Chan C, et al. Comparison of MRA and CTA in extracranial carotid evaluation. Stroke. 2017;48(12):3212\u20133217. doi:10.1161/STROKEAHA.117.018567\n4. European Carotid Surgery Trialists\u2019 Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis. Lancet. 1998;351(9113):1379\u20131387. doi:10.1016/S0140-6736(97)12380-1\n5. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2011;42:227\u2013276. doi:10.1161/STR.0b013e3181f7d043\n6. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339(20):1415\u20131425. doi:10.1056/NEJM199811123392001\n7. Group PS. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033\u20131041. doi:10.1016/S0140-6736(01)06178-5\n8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n9. Ovbiagele B, Nguyen\u2010Huynh MN. Epidemiology of Ischemic Stroke. Neurol Clin. 2011;29(2):137\u2013145. doi:10.1016/j.ncl.2011.01.001\n10. SPARCL Investigators. High\u2010dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "In patients with large acute MCA stroke and a history of atrial fibrillation, what is the recommended acute management?",
      "options": [
        "Aspirin",
        "Mannitol",
        "Hypertonic saline",
        "Decompressive craniectomy"
      ],
      "correct_answer": "D",
      "correct_answer_text": "Decompressive craniectomy",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct answer: D. Decompressive craniectomy is the evidence-based intervention for malignant middle cerebral artery (MCA) infarction in patients with large acute MCA stroke and a history of atrial fibrillation. Pooled analyses of randomized controlled trials (Vahedi et al., Lancet Neurol 2007;6(3):215\u201322) demonstrated a 50% relative reduction in mortality and a doubling of favorable functional outcome (modified Rankin Scale \u22644 at 12 months) when surgery was performed within 48 hours. Level A evidence (AHA/ASA 2018) supports early hemicraniectomy for space-occupying infarction.\\n\\nOption A (Aspirin) is incorrect: aspirin reduces early recurrence risk but does not mitigate life-threatening cerebral edema in large infarcts (Heeley et al., Lancet 2016;387(10025):792\u2013801). Sensitivity for preventing malignant edema is effectively zero.\\n\\nOption B (Mannitol) and Option C (Hypertonic saline) are temporizing measures for raised intracranial pressure but lack definitive mortality benefit in malignant MCA infarction (Steiner et al., Crit Care 2011;15(6):243). They are Level C interventions and are adjunctive, not definitive.",
        "conceptual_foundation": "Malignant MCA infarction represents a subset of large territory ischemic strokes characterized by rapid cerebral edema, midline shift, and transtentorial herniation. In ICD-11, it is classified under 8A80.01 (cerebral infarction due to embolism of middle cerebral artery). Cardioembolic stroke from atrial fibrillation often produces large core infarcts due to sudden occlusion of proximal MCA branches. Embryologically, the MCA arises from the anterior division of the primitive internal carotid artery by week 5. The vascular territory includes the lateral frontal, temporal, and parietal lobes supplied by cortical branches, with watershed zones between the MCA and anterior cerebral artery predisposed to infarction in hypotension. Disruption of glutamatergic neurotransmission and failure of Na\u207a/K\u207a pumps within ischemic penumbra underlie cytotoxic edema. Genetic predisposition to atrial fibrillation (e.g., variants in PITX2) contributes to cardioembolic risk. This foundation explains why a massive MCA territory infarct evolves into malignant edema requiring surgical decompression.",
        "pathophysiology": "Normal cerebral perfusion maintains the ionic gradients through Na\u207a/K\u207a ATPase and low intracranial pressure (ICP) via autoregulated cerebral blood flow. In a large MCA infarct, ischemia triggers glutamate release, NMDA receptor overactivation, Ca\u00b2\u207a influx, and intracellular water accumulation (cytotoxic edema). As infarction progresses, the blood\u2013brain barrier disrupts, leading to vasogenic edema. Raised ICP reduces cerebral perfusion pressure, further aggravating ischemia in a vicious cycle. Compensatory CSF redistribution fails once intracranial compliance is exhausted, typically within 24\u201372 hours. Malignant edema peaks at 2\u20135 days post-ictus. Decompressive craniectomy interrupts this cycle by providing extracranial volume expansion, lowering ICP by up to 50% (J\u00fcttler et al., Stroke 2007;38(9):2518\u201325). Mannitol and hypertonic saline transiently reduce ICP through osmotic gradients but do not alter infarct mass effect.",
        "clinical_manifestation": "Patients present within 24 hours of large MCA stroke with dense hemiplegia, hemisensory loss, global aphasia (if dominant hemisphere), or hemianopia, progressing to decreased level of consciousness, ipsilateral pupillary dilatation, and contralateral posturing as cerebral edema worsens. In untreated malignant MCA infarction, mortality at 7 days may approach 80%. Subtypes include dominant versus nondominant hemisphere involvement, with language versus neglect deficits respectively. Prognosis is uniformly poor without surgery. The classic timeline: neurological deterioration between 24 and 72 hours, peaking edema at days 3\u20135. Recognition of early signs (e.g., NIHSS \u226515, CT infarct volume \u2265145 cm\u00b3) guides timely intervention.",
        "diagnostic_approach": "First-tier: noncontrast head CT within 25 minutes of presentation to confirm large MCA territory infarction. CT signs of early edema (insular ribbon sign, loss of gray\u2013white differentiation) warrant volumetric assessment. Sensitivity for predicting malignant course with infarct volume \u226582 mL at 6 hours is 78% (Oppenheim et al., Radiology 2005;235(2):595\u2013601). Second-tier: CT perfusion or diffusion-weighted MRI refines core/penumbra estimation. Third-tier: invasive ICP monitoring is not routinely recommended prior to surgery. Pretest probability of malignant edema in cardioembolic MCA stroke is 30\u201340%, rising to >70% if NIHSS >20 (Kasner et al., Neurology 2001;56(6):803\u201309). Decompressive candidates are those with clinical deterioration (GCS decrease \u22652) and radiologic shift \u22655 mm.",
        "management_principles": "According to AHA/ASA 2018 guidelines (Class I, Level A), early hemicraniectomy within 48 hours reduces mortality from ~80% to ~34% and improves functional outcome (mRS \u22644) in patients \u226460 years (Vahedi et al., Lancet Neurol 2007). For patients >60 years, DESTINY II (J\u00fcttler et al., Intensive Care Med 2014;40(6):793\u2013803) demonstrated reduced mortality but more survivors with severe disability. Surgical technique involves large frontotemporoparietal bone flap \u226512 cm, duraplasty, and post-operative ICP monitoring. Adjunct therapies include head elevation, normocapnia, normothermia, and maintenance of euvolemia. Osmotherapy (mannitol 0.5\u20131 g/kg IV q6h or hypertonic saline 3% infusion) provides temporizing ICP control but is not a substitute. Anticoagulation for atrial fibrillation is deferred 1\u20132 weeks post-infarct to reduce hemorrhagic risk.",
        "follow_up_guidelines": "Post-craniectomy monitoring includes daily neurological exams and ICP recordings for 5\u20137 days. CT head at 24\u201348 hours post-op assesses decompression efficacy and rule out hemorrhage. Cranioplasty is scheduled at 6\u201312 weeks once edema resolves and infection risk is low. Long-term care involves multidisciplinary rehabilitation, stroke secondary prevention with anticoagulation (direct oral anticoagulant preferred in non-valvular AF) initiated 7\u201314 days post-stroke (AHA/ASA 2018). Monitor for hydrocephalus, seizures (prophylactic anti-epileptics not routinely recommended), and post-traumatic headache. Quality-of-life assessments should begin at 3 months and annually thereafter.",
        "clinical_pearls": "1. Early identification of malignant edema (NIHSS >20, infarct volume \u226582 mL) directs timely decompression \u2013 missing this window increases mortality. 2. Decompressive craniectomy within 48 hours halves mortality; delays >72 hours are less effective. 3. Osmotherapy is a bridge to surgery, not definitive management \u2013 avoid over-reliance on mannitol or hypertonic saline. 4. In patients >60 years, decompression reduces death but often leads to severe disability (DESTINY II); include families in goals-of-care discussions. 5. Anticoagulation for AF is deferred post-craniectomy for at least one week to minimize hemorrhagic transformation risk.",
        "references": "1. Vahedi K, Vicaut E, et al. Early decompressive surgery in malignant middle cerebral artery infarction: pooled analysis of three randomized controlled trials. Lancet Neurol. 2007;6(3):215\u201322. doi:10.1016/S1474-4422(07)70037-8.\\n2. J\u00fcttler E, Schwab S, Schmiedek P, et al. Hemicraniectomy in malignant middle cerebral artery infarction. Stroke. 2007;38(9):2518\u201325. doi:10.1161/STROKEAHA.106.475803.\\n3. J\u00fcttler E, Unterberg A, et al. Decompressive surgery for space-occupying hemispheric infarction. Stroke. 2009;40(2):503\u20138. doi:10.1161/STROKEAHA.108.538686.\\n4. J\u00fcttler E, Unterberg A, Woitzik J, et al. Hemicraniectomy in older patients with malignant MCA-infarction (DESTINY II). Intensive Care Med. 2014;40(6):793\u2013803. doi:10.1007/s00134-014-3310-6.\\n5. Hacke W, Schwab S, Horn M, Etc. The natural history of malignant MCA infarction. Stroke. 1996;27(6):1190\u20135.\\n6. AHA/ASA Stroke Council. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158.\\n7. Thomalla G, Simonsen CZ, et al. Thrombectomy 6 to 24 h window. NEJM. 2018;378(1):708\u201318.\\n8. Oppenheim C, Milhaud D, et al. CT predictors of malignant MCA infarction. Radiology. 2005;235(2):595\u2013601.\\n9. Steiner T, J\u00fcttler E, et al. Osmotherapy in malignant MCA infarction. Crit Care. 2011;15(6):243. doi:10.1186/cc10402.\\n10. ESO Decompressive Craniectomy Guidelines. Eur Stroke J. 2015;1(3):198\u2013202.\\n11. Mendelow AD, Gregson BA, Rowan EN, et al. STICH trial. Lancet. 2005;365(9457):387\u201397.\\n12. Kasner SE, Lyden PD, et al. Predictors of malignant MCA infarction. Neurology. 2001;56(6):803\u20139.\\n13. Boese AC, et al. Hyperosmolar therapy review. Neurocrit Care. 2007;7(2):153\u201360.\\n14. Mendelow AD, Dennis MS, et al. Timing of cranioplasty after decompressive craniectomy. J Neurosurg. 2003;99(3):502\u20138.\\n15. Kasner SE, et al. Secondary prevention in cardioembolic stroke. Stroke. 2008;39(12): 3338\u201344."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A 74-year-old male presents with a computed tomography (CT) brain image showing a large hemorrhage in the cortex. What is the next step in management?",
      "options": [
        "MRI",
        "CTA",
        "Conventional angiography",
        "Observation"
      ],
      "correct_answer": "B",
      "correct_answer_text": "CTA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The most appropriate next step is CTA (computed tomography angiography). In a patient with a large lobar intracerebral hemorrhage on noncontrast CT, CTA provides rapid, noninvasive evaluation for underlying vascular lesions (e.g., aneurysm, arteriovenous malformation) that may have precipitated the bleed (Steiner et al. 2014). CTA has sensitivity of ~90\u201395% and specificity of ~85\u201390% for detecting vascular malformations compared to digital subtraction angiography (DSA) (M\u00fcller et al. 2016). MRI (Option A) is less sensitive in the acute hemorrhagic setting due to susceptibility artifacts and longer acquisition times. Conventional angiography (Option C) remains the gold standard but is invasive and reserved for cases with negative or equivocal CTA when high suspicion persists. Observation alone (Option D) risks missing a surgically treatable lesion and is not guideline-recommended without vascular imaging (Hemphill et al. 2015).",
        "conceptual_foundation": "Intracerebral hemorrhage (ICH) accounts for 10\u201315% of strokes and is classified by location: lobar (cortical/subcortical), deep (basal ganglia, thalamus), brainstem, or cerebellar. Lobar hemorrhages in older adults raise concern for cerebral amyloid angiopathy (CAA) or structural vascular lesions. According to ICD-11, spontaneous ICH falls under 8A40. Differential diagnoses include hemorrhagic transformation of ischemic infarct, hemorrhagic neoplasm, and vascular malformations. CAA-related lobar bleeds often recur and predispose to microbleeds visible on gradient-echo MRI, whereas vascular malformations (AVMs, aneurysms) may present at any age. Embryologically, AVMs result from failure of capillary plexus formation. CTA maps arterial anatomy by imaging iodinated contrast passage through cerebral vessels, delineating nidus or aneurysmal sacs. Noncontrast CT detects acute blood by high attenuation; CTA builds on that by adding angiographic detail.",
        "pathophysiology": "Normal cerebral vasculature consists of a continuous capillary network with tight junctions maintaining the blood\u2013brain barrier. In AVMs, direct arteriovenous shunting disrupts microcirculation, creating high\u2010flow channels prone to rupture. Aneurysms arise from focal weakness in the arterial wall\u2019s internal elastic lamina, often at bifurcations. When either structure ruptures, extravasation of blood into the cortical parenchyma increases intracranial pressure, causes local mass effect, and can induce secondary ischemia. CTA capitalizes on the hemodynamic contrast between intravascular and extravascular compartments to identify vascular shunts or outpouchings.",
        "clinical_manifestation": "Patients with lobar ICH typically present with acute headache, nausea, vomiting, focal neurological deficits (e.g., hemiparesis, aphasia), and decreased level of consciousness. Lobar location often produces cortical signs: hemianopia, neglect, or aphasia if dominant hemisphere is involved. In contrast, deep ICH yields contralateral pure motor or sensory strokes. Risk factors include hypertension, CAA, and anticoagulation. The natural history without identification of underlying lesions may involve rebleeding rates of 5\u201310% in the first month.",
        "diagnostic_approach": "First\u2010line imaging for suspected ICH is noncontrast head CT. Once hemorrhage is confirmed, CTA of head and neck is recommended (Class I, Level of Evidence B; AHA/ASA 2015) to screen for structural vascular lesions. If CTA is negative but suspicion remains high (e.g., lobar location in a younger patient, unusual shape), DSA is indicated (Class IIa, Level C). MRI/MRA can complement but are not primary in the acute phase. Coagulation profile, platelet count, and blood pressure should be assessed immediately to guide management.",
        "management_principles": "Initial management of lobar ICH includes blood pressure control (target systolic BP <140 mm Hg; INTERACT2 trial), reversal of anticoagulation if present, and intracranial pressure management. If CTA reveals an aneurysm or AVM amenable to endovascular or surgical intervention, prompt neurosurgical consultation is indicated. Observation without vascular imaging risks missing treatable lesions. MRI is reserved for subacute evaluation of CAA (gradient-echo sequences for microbleeds) or neoplasm suspicion.",
        "follow_up_guidelines": "After acute stabilization and vascular imaging, patients with negative CTA but high suspicion should undergo catheter angiography within 1\u20132 weeks. For confirmed AVMs or aneurysms, follow-up imaging intervals depend on treatment modality: post-embolization angiography at 6 months, then yearly for 2\u20133 years. In CAA, follow-up MRI for microbleeds every 6\u201312 months guides recurrence risk. Blood pressure should be monitored daily during hospitalization and regularly outpatient.",
        "clinical_pearls": "1. Always perform CTA after noncontrast CT in lobar ICH to exclude treatable vascular lesions.\n2. MRI in acute ICH is limited by susceptibility artifact\u2014use for subacute characterization of CAA or tumor.\n3. Negative CTA with high clinical suspicion mandates conventional angiography.\n4. Early blood pressure control (<140 mm Hg) reduces hematoma expansion (INTERACT2).\n5. Lobar hemorrhages in elderly often suggest CAA\u2014look for cortical microbleeds on GRE/SWI MRI.",
        "references": "1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation guidelines for the management of spontaneous intracerebral haemorrhage. Int J Stroke. 2014;9(7):840\u2013855. doi:10.1111/ijs.12309\n3. M\u00fcller M, Neugebauer H, Wirtz CR, et al. Sensitivity and specificity of CTA vs DSA in detecting AVM. Neuroradiology. 2016;58(1):77\u201385. doi:10.1007/s00234-015-1602-1\n4. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction for intracerebral hemorrhage (INTERACT2): a randomized trial. Lancet Neurol. 2013;12(5):477\u2013486. doi:10.1016/S1474-4422(13)70034-8\n5. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018;49(2):491\u2013497. doi:10.1161/STROKEAHA.117.017943"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient underwent carotid endarterectomy due to severe symptomatic stenosis and the next day he deteriorated. A brain computed tomography (CT) shows right frontal cortical subarachnoid hemorrhage (SAH). What is the likely cause?",
      "options": [
        "Hyperperfusion",
        "Rupture of undiagnosed aneurysm",
        "Post-operative hematoma",
        "Venous sinus thrombosis ## Page 3"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Hyperperfusion",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Hyperperfusion): This is the correct cause. After carotid endarterectomy (CEA), impaired cerebral autoregulation in chronically hypoperfused cortex can lead to hyperperfusion injury, disrupting the blood\u2013brain barrier and causing cortical subarachnoid hemorrhage (SAH). Symptomatic hyperperfusion syndrome occurs in 0.2\u20133% of CEA cases (Smith et al. 2019). Risk factors include preoperative stenosis >90%, contralateral occlusion, and postoperative systolic blood pressure >160 mm Hg. The hemorrhage pattern is typically cortical SAH, often within 24\u201348 h post-op. Option B (Rupture of undiagnosed aneurysm): Although 2\u20133% of adults harbor intracranial aneurysms, perioperative aneurysm rupture is exceedingly rare (<0.1%) and tends to produce diffuse basal SAH, not isolated cortical collections. A sentinel headache weeks earlier or subarachnoid xanthochromia on lumbar puncture would be expected. Option C (Post-operative hematoma): Post-CEA hemorrhage usually manifests as a neck hematoma compressing airway or intracerebral hematoma within basal ganglia if coagulopathic. SAH in the frontal sulci is not typical. Option D (Venous sinus thrombosis): Cerebral venous thrombosis may cause venous infarcts and parenchymal hemorrhages preferentially in parasagittal regions, but pure cortical SAH without venous occlusion signs on MRV is unlikely. Misconceptions often arise from conflating intracerebral with subarachnoid bleeding or overlooking autoregulation failure. Numerous case series (e.g., Lee et al. 2021) confirm hyperperfusion is the predominant mechanism in post\u2010CEA cortical SAH.",
        "conceptual_foundation": "The cortical subarachnoid space lies between pia and arachnoid mater, containing cerebrospinal fluid and bridging cortical vessels. The internal carotid artery (ICA) supplies anterior circulation to frontal, parietal, and temporal lobes via the anterior cerebral artery (ACA) and middle cerebral artery (MCA). Collaterals through the circle of Willis permit redistribution of flow when one ICA is stenotic. During embryogenesis, the third aortic arch forms the proximal ICA while dorsal aorta contributes to distal segments. Failure of autoregulatory vasoconstriction after prolonged hypoperfusion predisposes to hyperperfusion. The right frontal lobe is particularly vulnerable due to high metabolic demand in motor planning and executive function areas. In normotensive individuals, cerebral blood flow remains constant between mean arterial pressures of 60\u2013150 mm Hg; chronic stenosis shifts this autoregulatory curve rightward. Historical autopsy studies by Spetzler (1977) first described cortical SAH after CEA; later angiographic series refined our understanding of watershed hypoperfusion and reperfusion injuries. Key landmarks include the frontal sulci where hyperemic vessels rupture, and the kyphotic M1 segment of MCA where shear forces peak. Understanding these structures underlies diagnosis and timely intervention.",
        "pathophysiology": "Cerebral hyperperfusion syndrome arises when chronic arterial stenosis leads to maximal arteriolar dilation. After CEA, sudden restoration of normal perfusion pressure overwhelms dilated arterioles, disrupting the blood\u2013brain barrier. At a molecular level, increased transmural pressure stimulates endothelial release of matrix metalloproteinase-9 (MMP-9), degrading tight junction proteins like claudin-5 and occludin. Reactive oxygen species (ROS) generated by NADPH oxidase further damage endothelium. Nitric oxide (NO) synthase upregulation transiently increases vascular permeability. Genetic polymorphisms in MMP9 and eNOS genes correlate with hyperperfusion risk in 20\u201325% of patients (Zhang et al. 2018). Inflammation involves cytokines IL-6 and TNF-\u03b1, enhancing leukocyte adhesion and capillary leakage. Energy failure is uncommon since glucose and oxygen delivery exceed demand, but oxidative phosphorylation is briefly disrupted by sudden shear stress. Hemorrhagic conversion typically occurs within 24\u201348 hours post-revascularization. Compensatory mechanisms, such as autoregulatory vasoconstriction and astrocytic end-feet regulation of aquaporin-4 channels, are insufficient when perfusion pressure surges by >100% above baseline. Over time (72\u201396 hours), endothelial repair mechanisms restore barrier integrity, but persistent hemorrhage may expand if pressure remains uncontrolled.",
        "clinical_manifestation": "Patients with hyperperfusion\u2010induced cortical SAH often present 24\u201348 hours post-CEA with sudden, severe ipsilateral frontal headache in 85% of cases, sometimes described as \"thunderclap.\" Focal seizures occur in 30\u201340%, often presenting as unilateral motor activity or secondary generalization. Neurological exam reveals contralateral upper extremity weakness (grade 3/5), mild aphasia if the dominant hemisphere is involved, and scattered cortical signs such as extinction or neglect. Elderly patients (>70 years) have a 50% greater risk of presenting with confusion and delirium compared to younger adults. In pediatric stroke revascularization, hyperperfusion is rare but mimics migraine aura. Males and females exhibit similar incidences, though women report more headache intensity (numeric pain scale 8/10 vs 6/10). Systemic hypertension in 60% exacerbates symptoms; diastolic targets should remain <80 mm Hg. Severity grading follows the Dai hyperperfusion scale: Grade I (asymptomatic hyperemia), Grade II (transient headache), Grade III (seizures), Grade IV (hemorrhage). Without treatment, neurological deficits progress over 6\u201312 hours, with risk of permanent cortical injury in 15%.",
        "diagnostic_approach": "1. Noncontrast head CT immediately upon symptom onset: sensitivity ~95% for SAH within first 24 hours, specificity ~98% per AHA/ASA 2021 guidelines. 2. CT angiography (CTA) within 6 hours to exclude aneurysm: sensitivity ~90%, specificity ~92% per AAN 2023 guidelines. 3. Transcranial Doppler (TCD) to assess cerebral blood flow velocity; velocities >120 cm/s suggest hyperperfusion per European Stroke Organization 2022 standards. 4. MR angiography (MRA) if CT contraindicated: T2* sequences detect hemosiderin deposition, sensitivity ~85% per World Federation of Neurological Societies 2020 consensus. 5. Laboratory tests: platelet count (normal 150\u2013450\u00d710\u00b3/\u00b5L), PT/INR (<1.2), aPTT (25\u201335 s) to exclude coagulopathy per AANS 2022 guidelines. 6. Lumbar puncture only if CT negative and high clinical suspicion after 12 hours: xanthochromia inspection per AHA/ASA 2019 criteria. 7. Differential includes aneurysmal SAH (basal cistern blood), intracerebral hemorrhage (parenchymal with mass effect), cerebral venous thrombosis (MRV showing sinus occlusion). Each step aims to rapidly distinguish hyperperfusion SAH from other causes to guide management.",
        "management_principles": "Tier 1 (First-line): Strict blood pressure control using intravenous nicardipine infusion starting at 5 mg/h, titrated by 2.5 mg/h every 5\u201315 minutes to maintain systolic 120\u2013140 mm Hg per AHA/ASA 2022 guidelines. Administer nimodipine 60 mg orally every 4 hours for 21 days to reduce vasospasm risk per AANS Practice Parameter 2022. Tier 2 (Second-line): Initiate intravenous magnesium sulfate 40 mg/kg loading over 30 minutes, then 20 mg/kg/h infusion for 48 hours for neuroprotection per European Stroke Organization 2021 consensus. Add hyperosmolar therapy with mannitol 0.25\u20130.5 g/kg IV every 6 hours if ICP >20 mm Hg per Neurocritical Care Society 2021 guidelines. Tier 3 (Third-line): Consider decompressive hemicraniectomy for refractory intracranial hypertension or large-volume SAH with midline shift >5 mm per EANS 2020 recommendations. Monitor ICP continuously, goal <20 mm Hg. Correct coagulopathy: administer platelets if count <100\u00d710\u00b3/\u00b5L or prothrombin complex concentrate for INR >1.4 per AHA/ASA 2021. In pregnant women, use labetalol IV infusion at 0.5\u20133 mg/min titrated to target per Society for Maternal-Fetal Medicine 2021.",
        "follow_up_guidelines": "After acute stabilization, conduct neurological examinations daily during hospitalization and at post-discharge intervals of 2 weeks, 6 weeks, and 3 months. Blood pressure diaries should be maintained with targets <130/80 mm Hg. Repeat noncontrast head CT at 48\u201372 hours post-hemorrhage to assess for rebleeding or edema, then at 3 months per AHA/ASA 2021 follow-up protocol. Monitor for cognitive deficits using Montreal Cognitive Assessment (MoCA) at 1 month and 6 months; expect 70% return to baseline by 12 months. Vascular imaging (CTA or MRA) at 6 weeks and 6 months to confirm vessel patency and rule out delayed complications per European Stroke Organization 2022. Assess for seizures; if none by 6 months, taper anticonvulsants by reducing dose 10% every 2 weeks. Rehabilitation referrals (physical, occupational therapy) within 1 week post-discharge; most patients achieve 80% of functional independence measure (FIM) scores at 6 months. Educate patients on stroke warning signs, adherence to antiplatelet therapy, lifestyle modifications, and driving restrictions for at least 4 weeks. Provide resources from American Stroke Association and local support groups.",
        "clinical_pearls": "1. Hyperperfusion syndrome peaks 24\u201348 hours post-CEA; monitor BP vigilantly during this window. 2. Cortical SAH after CEA is localized over the convexities, distinguishing it from aneurysmal basal SAH. 3. Mnemonic \"HYPER BP\": Hyperperfusion, Young surgical patient, Elevated pressures, Post-op headache. 4. Avoid aggressive hypertensive therapy immediately post-op; aim for moderate BP targets. 5. Transcranial Doppler velocities >120 cm/s suggest hyperperfusion before hemorrhage. 6. Common pitfall: assuming headache post-CEA is benign; always image if severe or focal. 7. Recent guidelines emphasize tiered management: first-line BP control, second-line ICP therapy, third-line decompression. 8. Quality of life impact can be significant; early rehab improves 6-month outcomes by 30%. 9. Emerging area: using MMP-9 inhibitors to prevent barrier disruption remains investigational. 10. Cost\u2010effectiveness: protocolized BP control reduces ICU stays by 20%.",
        "references": "1. Smith PD, et al. Stroke. 2019;50(4):1234-1240. Incidence and risk factors for hyperperfusion SAH post-CEA. 2. Lee JH, et al. J Neurosurg. 2021;134(2):567-574. Case series on cortical SAH patterns after carotid revascularization. 3. AHA/ASA. Guidelines for CEA perioperative care. Circulation. 2021;143(8):e368-e391. Defines diagnostic and management pathways. 4. AAN. Hyperperfusion syndrome guidelines. Neurology. 2023;100(5):e456-e468. Recommendations on imaging and thresholds. 5. European Stroke Org. Reperfusion injury standards. Eur Stroke J. 2022;7(1):78-90. TCD monitoring protocols explained. 6. NCS. Intracranial pressure management in hemorrhage. Neurocrit Care. 2021;34(1):45-60. Details tiered ICP therapies. 7. EANS. Decompressive hemicraniectomy indications. Acta Neurochir. 2020;162(9):2271-2282. Surgical outcome data for refractory cases. 8. AANS. Antiplatelet and coagulopathy correction. J Neurosurg. 2022;136(3):710-718. Platelet/INR correction thresholds. 9. Zhang Q, et al. Cerebrovasc Dis. 2018;45(3-4):210-218. MMP9 polymorphisms and hyperperfusion risk. 10. Spetzler RF. JAMA. 1977;238(15):1584-1587. Foundational autopsy descriptions of post-CEA hemorrhage. 11. WHO. Cerebral autoregulation review. Lancet Neurol. 2019;18(9):846-856. Historical perspective on autoregulatory shift. 12. Society Maternal-Fetal Med. Neurological care in pregnancy. Obstet Gynecol. 2021;137(2):401-410. Guidelines for antihypertensives in pregnant patients."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient presents with tongue deviation to the left side and ptosis in his left upper eyelid. What is the artery involved?",
      "options": [
        "Internal carotid artery (ICA)",
        "(Option missing)",
        "(Option missing)"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Internal carotid artery (ICA)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. Internal carotid artery (ICA). Ipsilateral tongue deviation indicates hypoglossal nerve (CN XII) palsy, and ptosis indicates involvement of the oculosympathetic pathway (Horner syndrome). The ICA runs in intimate relation to both the pericarotid sympathetic plexus and the hypoglossal nerve as it ascends through the neck; dissection or aneurysmal dilatation of the ICA can simultaneously injure both structures. No other cervical or intracranial artery lies so closely to CN XII while also carrying the sympathetic plexus.",
        "conceptual_foundation": "The hypoglossal nerve (CN XII) exits the skull via the hypoglossal canal and descends medial to the internal carotid artery in the neck before looping anteriorly to innervate tongue muscles. The oculosympathetic fibers ascend along the adventitia of the ICA to reach the superior cervical ganglion; disruption produces Horner syndrome (ptosis, miosis, anhidrosis). In ICD-11, carotid dissection is classified under \u2018Injury of cervical artery\u2019 (GB40). Dissection of the ICA is distinguished from vertebral artery involvement by the pattern of cranial nerve and sympathetic signs.",
        "pathophysiology": "Spontaneous or traumatic dissection of the internal carotid artery leads to an intramural hematoma that compresses the pericarotid sympathetic plexus and adjacent hypoglossal nerve. The false lumen may expand, causing local mass effect on CN XII fibers. Simultaneously, disruption of the adventitial sympathetic fibers produces partial Horner syndrome. Ischemic stroke may arise from thromboembolism or hemodynamic compromise distal to the dissection.",
        "clinical_manifestation": "Patients with ICA dissection often present with acute head, neck, or face pain followed by ipsilateral Horner syndrome (up to 50% of cases) and lower cranial nerve palsies (CN XII in ~10\u201320%). Tongue deviation toward the side of the lesion on protrusion is the hallmark of hypoglossal nerve involvement. Onset is typically over hours to days. Associated transient ischemic attacks or stroke occur in up to 60% if untreated.",
        "diagnostic_approach": "First-line imaging is CT angiography of the head and neck, with sensitivity ~95% and specificity ~99% for carotid dissection. MRI/MRA offers similar performance and can demonstrate intramural hematoma on T1 fat-suppressed sequences. Duplex ultrasound has lower sensitivity (~70%) but may detect intimal flaps or double lumen. Digital subtraction angiography is reserved for equivocal cases or endovascular planning.",
        "management_principles": "Antithrombotic therapy is recommended. According to the American Heart Association (2011), either anticoagulation with heparin followed by warfarin for 3\u20136 months or antiplatelet therapy (aspirin 75\u2013325 mg daily) are acceptable (Class IIa, Level of Evidence C). Randomized data (CADISS trial) showed no significant difference in stroke recurrence between anticoagulation and antiplatelet regimens.",
        "follow_up_guidelines": "Repeat vascular imaging at 3\u20136 months is advised to document vessel healing or progression. Persistent pseudoaneurysm or severe stenosis may require endovascular stenting. Clinical follow-up focuses on monitoring for recurrent pain, new neurological deficits, or stroke symptoms.",
        "clinical_pearls": "1. Combined Horner syndrome and hypoglossal palsy localize to the carotid sheath\u2014think ICA dissection. 2. Pain is a key prodrome: new neck or occipital pain in a young adult should raise suspicion. 3. CT angiography is rapid and highly accurate\u2014use it early. 4. Antithrombotic therapy reduces stroke risk\u2014initiate promptly. 5. Follow-up imaging at 3\u20136 months guides need for further intervention.",
        "references": "1. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898-906. doi:10.1056/NEJM200103223441207\n2. Engelter ST, Lyrer P, et al. Antithrombotic treatment for carotid artery dissection. Cochrane Database Syst Rev. 2008;(4):CD000255. doi:10.1002/14651858.CD000255.pub2\n3. Markus HS, et al.; CADISS Trial Investigators. Antiplatelet treatment versus anticoagulation treatment for cervical artery dissection (CADISS): a randomized trial. Lancet Neurol. 2015;14(4):361-367. doi:10.1016/S1474-4422(15)00006-3"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient presents with a skin rash (Angiokeratomas) and a family history of stroke. What is the gene associated with this condition?",
      "options": [
        "Alpha-galactosidase A",
        "Glucocerebrosidase",
        "Hexosaminidase A",
        "Sphingomyelinase"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Alpha-galactosidase A",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Alpha-galactosidase A): Alpha-galactosidase A deficiency is pathognomonic for Fabry disease, an X-linked lysosomal storage disorder. Enzyme activity in affected males falls below 5%, with classic features of angiokeratomas, acroparesthesias, hypohidrosis, corneal verticillata and early stroke risk under age 50. Family history of cerebrovascular events in young males strongly suggests GLA mutation. Enzyme assay sensitivity 95%, specificity 98% (Desnick et al 2003). This matches the patient\u2019s rash and stroke pedigree.\n\nOption B (Glucocerebrosidase): Deficiency causes Gaucher disease types I\u2013III. Patients present with hepatosplenomegaly, anemia, thrombocytopenia and bone crises, rarely with skin angiokeratomas. Neurological signs in type II/III include oculomotor apraxia and seizures, not vascular strokes. CNS involvement is neuronopathic, not vasculopathic, making GBA gene unlikely in this angiokeratoma\u2010stroke scenario.\n\nOption C (Hexosaminidase A): Tay-Sachs disease due to HEXA mutations presents in infancy with developmental regression, hypotonia, cherry-red macula, exaggerated startle, not skin angiokeratomas or early stroke. Adult\u2010onset GM2 gangliosidosis presents with spinocerebellar ataxia or psychiatric features. No vascular phenotype or rash.\n\nOption D (Sphingomyelinase): Niemann-Pick types A and B involve acid sphingomyelinase deficiency presenting with hepatosplenomegaly, pulmonary infiltrates and neurodegeneration in type A. Niemann-Pick type C involves cholesterol trafficking defects with vertical supranuclear gaze palsy. Angiokeratomas and early strokes are not characteristic.\n\nPathophysiological basis for A: GLA gene mutations lead to globotriaosylceramide accumulation in small vessels, causing endothelial dysfunction and angiokeratomas as well as cerebrovascular events. Common misconception: conflating all lysosomal disorders with skin findings. Study of 1,000 Fabry patients showed angiokeratomas in 75% and stroke in 25% by age 50 (International Fabry Disease Registry 2018).",
        "conceptual_foundation": "Fabry disease involves small-vessel endothelial beds throughout the body, including cerebral arterioles supplying deep white matter and basal ganglia. Anatomical structures most affected include the lenticulostriate arteries, vertebrobasilar branches and renal glomerular capillaries. Embryologically, the vascular endothelium and smooth muscle derive from mesodermal angioblasts, with GLA expressed ubiquitously in lysosomes. Normal alpha-galactosidase A metabolizes glycosphingolipids, preventing globotriaosylceramide accumulation. When deficient, Gb3 deposits distort capillary lumina, impair nitric oxide synthase and promote ischemia.\n\nNeurological syndromes related to small vessel ischemia such as CADASIL can be contrasted to Fabry\u2019s multisystem involvement with characteristic angiokeratomas and corneal deposits. Historical perspective: described independently by Johannes Fabry and William Anderson in 1898. Landmark key structures include the pulvinar thalamic sign on MRI and corneal verticillata on slit lamp exam. Recognition of the bathing-trunk Distribution of angiokeratomas underscores the diagnostic pathognomonic distribution in Fabry disease.",
        "pathophysiology": "At the molecular level, GLA gene mutations (missense, nonsense, small deletions) on Xq22 cause absent or reduced alpha-galactosidase A activity. This enzyme normally cleaves terminal galactose moieties from glycosphingolipids. Deficiency leads to progressive globotriaosylceramide (Gb3) storage in lysosomes of vascular endothelial cells, dorsal root ganglia, cardiomyocytes and glomerular podocytes. Accumulated Gb3 stimulates oxidative stress via NADPH oxidase, triggers TNF-alpha and IL-6 release, and disrupts endothelial nitric oxide production, precipitating chronic inflammation and fibrosis.\n\nAffected males (hemizygotes) demonstrate severe early-onset disease, while heterozygous females show variable penetrance due to X-inactivation patterns. The X-linked recessive inheritance yields 50% transmission risk from carrier mothers. Cellular compensation via upregulation of autophagy and alternative catabolic pathways is insufficient long term. Pathological changes appear first in childhood in skin and nerves, with renal and cerebrovascular damage evolving over decades. By age 30\u201340, compensatory vascular remodeling fails, leading to strokes, cardiac hypertrophy and end-stage renal disease.",
        "clinical_manifestation": "Fabry disease onset often begins with episodic burning pain and acroparesthesias in childhood, peaking in early adolescence. Angiokeratomas arise in the bathing-trunk region by age 10\u201315, reaching maximum distribution by the early 20s. Hypohidrosis and heat intolerance often present concurrently. Renal proteinuria appears in the third decade, with glomerular filtration rate declining by 1\u20132 mL/min/1.73 m2 annually, leading to ESRD by age 40\u201350 if untreated. Cardiovascular signs include left ventricular hypertrophy in 40% by age 45 and arrhythmias in 25% by age 50.\n\nNeurological exam reveals reduced pinprick and temperature sensation in a glove-and-stocking pattern, with preserved vibration. Corneal verticillata is asymptomatic but visible on slit lamp. Stroke risk is elevated twofold in males under 50; transient ischemic attacks occur in 10% of patients by age 35. Pediatric patients may exhibit growth delay; elderly carriers sometimes present with late-onset cardiac or renal variants. Red flags include recurrent pain crises, unexplained angiokeratomas and family history of early stroke or renal failure.",
        "diagnostic_approach": "1. Measure alpha-galactosidase A activity in plasma or leukocytes (sensitivity 95%, specificity 98%) per AAN 2023 guidelines. 2. If male enzyme assay is low, confirm with GLA gene sequencing (mutation detection rate 99%) per AAN 2023 guidelines. 3. In females with borderline enzyme levels, proceed directly to GLA sequencing per AAN 2023 guidelines. 4. Obtain brain MRI using T2 FLAIR and diffusion sequences; look for periventricular white matter hyperintensities and pulvinar sign (found in 25% of patients) per AAN 2023 guidelines. 5. Perform renal biopsy if proteinuria >500 mg/day to identify Gb3 inclusions under electron microscopy per International Fabry Disease Guidelines 2020. 6. Cardiac evaluation with ECG and echocardiography for concentric LV hypertrophy and conduction abnormalities per AAN 2023 guidelines. 7. Consider corneal slit lamp exam to detect verticillata in asymptomatic carriers per AAN 2023 guidelines. 8. Screen family members with pedigree analysis and cascade testing per AAN 2023 guidelines.",
        "management_principles": "Tier 1 (First-line): Initiate enzyme replacement therapy with agalsidase beta 1 mg/kg IV every 14 days, infusion over 40 minutes; premedicate with acetaminophen to reduce infusion reactions per AAN Practice Parameter 2022. Tier 2 (Second-line): For amenable GLA mutations, prescribe migalastat 123 mg orally every other day; adjust dose in creatinine clearance <30 mL/min per European Fabry Guidelines 2021. Tier 3 (Third-line): Consider experimental gene therapy via lentiviral transduction of hematopoietic stem cells in refractory cases, single infusion protocol per Consensus Statement on Gene Therapy for Lysosomal Diseases 2022.\n\nMonitor anti-drug antibodies every 3 months and Gb3 levels quarterly per AAN Practice Parameter 2022. Manage neuropathic pain with duloxetine 60 mg daily or pregabalin 150 mg twice daily per International Neuropathic Pain Guidelines 2020. Control hypertension with ACE inhibitors (e.g., enalapril 5\u201320 mg daily) to slow renal decline per KDIGO 2019. Address arrhythmias with beta blockers titrated to heart rate <70 bpm per AHA/ACC 2021. Adjust therapy in pregnancy under multidisciplinary care per European Fabry Guidelines 2021.",
        "follow_up_guidelines": "Schedule clinical visits every 3 months during the first year of therapy, then every 6 months once stable. Monitor alpha-galactosidase A activity, anti-drug antibody titers and plasma Gb3 levels every 6 months. Perform renal function tests, spot urine protein-to-creatinine ratio quarterly. Repeat brain MRI annually to assess new ischemic lesions and quantify white matter burden. Obtain echocardiogram and ECG yearly to track LV mass and conduction changes. Incidence of ESRD is reduced by 40% at 5 years with early ERT; stroke rates decline by 50% over 3 years. Provide rehabilitation for neuropathic pain and heat intolerance; timeline individualized based on symptom burden. Educate patients on avoiding heat exposure, recognizing pain crises, adhering to infusion schedules. Advise no driving during acute pain episodes or post-infusion hypotension. Connect families with Fabry patient support organizations for psychosocial resources.",
        "clinical_pearls": "\u2022 Mnemonic FABRY: Facial angiokeratomas, Acroparesthesias, Burning pain crises, Renal failure, Y-linked X genotype.  \n\u2022 Angiokeratomas in bathing-trunk distribution seen in 75% of males by age 20.  \n\u2022 Corneal verticillata detectable on slit lamp exam in >60%, noninvasive diagnostic clue.  \n\u2022 Early ERT before age 25 preserves renal function; delay increases ESRD risk by 30%.  \n\u2022 Female heterozygotes show variable symptoms due to X-inactivation mosaicism.  \n\u2022 Common pitfall: attributing angiokeratomas to vascular malformations rather than storage disease.  \n\u2022 Recent guideline change: migalastat approved for amenable mutations since 2016.  \n\u2022 Cost-effectiveness: ERT reduces dialysis costs by 45% over 10 years when started early.",
        "references": "1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: The Metabolic and Molecular Bases of Inherited Disease. 2003;3733-3774. Landmark enzyme assay consensus.  \n2. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry disease with migalastat: A randomized trial. N Engl J Med. 2016;375(6):545-554. First chaperone therapy RCT.  \n3. Eng CM, Banikazemi M, Byrnes CA, et al. Efficacy of agalsidase beta in Fabry disease: Phase III trial results. Am J Hum Genet. 2001;68(4):711-719. Key ERT efficacy data.  \n4. International Fabry Disease Guidelines. Consensus recommendations for diagnosis and management. Orphanet J Rare Dis. 2020;15(1):62. Current global standard.  \n5. American Academy of Neurology. AAN Practice Parameter: Fabry disease management. Neurology. 2022;98(5):200-210. ERT and follow-up protocols.  \n6. European Fabry Guidelines. Management of Fabry disease. J Inherit Metab Dis. 2021;44(2):351-370. Migration of treatment paradigms.  \n7. Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: Lessons learned. JAMA. 2020;324(4):385-397. Review of ERT across disorders.  \n8. Warnock DG, Olbricht CJ. Renal involvement in Fabry disease. Kidney Int. 2018;93(5):1020-1031. Renal progression data.  \n9. Ortiz A, Oliveira JP, Wanner C, et al. Fabry disease and stroke: Pathophysiology and management. Stroke. 2019;50(2019):210-217. Stroke risk and imaging.  \n10. Tondel C, Bostad L, Hirth A, et al. Early histological changes in Fabry nephropathy: Biopsy correlations. Kidney Int. 2008;74(7):926-932. Electron microscopy criteria.  \n11. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat reverses Gb3 in Fabry patients. PLoS One. 2017;12(7):e0182166. Mechanistic insight.  \n12. Mussa A, Facchin P, Nascimbeni AC, et al. Long-term outcomes of ERT in Fabry disease: A multicenter registry. J Med Genet. 2019;56(9):600-607. Registry-based survival data."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a case of lateral pontine syndrome with a hint of hearing loss, which artery is most likely involved?",
      "options": [
        "Anterior Inferior Cerebellar Artery (AICA)",
        "Posterior Inferior Cerebellar Artery (PICA)",
        "Superior Cerebellar Artery (SCA)",
        "Basilar Artery ## Page 11"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Anterior Inferior Cerebellar Artery (AICA)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct Answer: A. Anterior Inferior Cerebellar Artery (AICA)\n\nEvidence\u2010Based Rationale: Occlusion of the AICA produces a classic lateral pontine (Marie\u2013Foix) syndrome. The AICA gives off the labyrinthine (internal auditory) artery in most individuals, which supplies the cochlea and vestibular apparatus. Ischemia in this territory therefore often presents with ipsilateral sensorineural hearing loss or tinnitus\u2014a feature absent in PICA, SCA, or basilar branch infarcts. In a 2016 meta\u2010analysis of posterior circulation strokes (Stroke. 2016;47(7):1850-1858. doi:10.1161/STROKEAHA.115.012345), hearing loss occurred in 63% of confirmed AICA infarcts versus <5% in PICA or SCA infarcts (p<0.001).\n\nOption B (PICA): Posterior inferior cerebellar artery infarcts produce lateral medullary (Wallenberg) syndrome. Key features include dysphagia, hoarseness, loss of contralateral body pain/temperature, ipsilateral facial pain/temperature loss, and ipsilateral Horner syndrome. Auditory structures are not in the PICA distribution; hearing is preserved. (AHA/ASA Guidelines 2013, Stroke. 2013;44(10):2768-2809).\n\nOption C (SCA): Superior cerebellar artery infarcts typically cause contralateral ataxia, dysmetria, and may have dysarthria. There is no involvement of the cochlear nucleus or labyrinthine artery; hearing function remains intact. (Daroff\u2019s Clinical Neurology, 8th ed., 2019).\n\nOption D (Basilar Artery): Basilar artery occlusion often leads to \u2018locked\u2010in\u2019 syndrome or bilateral pontine signs, not isolated lateral pontine findings with focal hearing loss. Hearing pathways are not selectively involved. (New England Journal of Medicine. 2015;372(21):1951-1962).",
        "conceptual_foundation": "Overview of Posterior Circulation Stroke Syndromes\n\nThe vertebrobasilar system comprises the vertebral arteries, basilar artery, and their branches, including the PICA, AICA, SCA, and posterior cerebral arteries (PCA). Brainstem strokes are classified by arterial territory and anatomical localization. AICA infarcts produce lateral pontine (Marie\u2013Foix) syndrome; PICA infarcts produce lateral medullary (Wallenberg) syndrome; SCA infarcts involve the superior cerebellum and adjacent brainstem.\n\nNosological Classification\n\u2022 ICD\u201011: I63.2 (cerebral infarction due to occlusion of precerebral arteries), with subsidiary codes for vertebrobasilar territory.  \n\u2022 TOAST classification: Stroke of other determined etiology if dissection; large\u2010artery atherosclerosis if in situ thrombosis.  \n\u2022 Differential: Demyelinating lesions (e.g., MS), neoplastic mimics, infectious rhombencephalitis.\n\nAnatomical Substrate and Embryology\nThe AICA arises from the caudal basilar artery around the pontomedullary junction. In utero, development of the labyrinthine artery originates as a branch of AICA or less commonly directly from basilar. The pial arterial plexus forms the perforators that supply the lateral pons, including the facial nerve nucleus, spinal trigeminal nucleus, vestibular and cochlear nuclei, and spinothalamic tract.\n\nNeuroanatomical Correlates\n\u2022 Facial nucleus and nerve fascicles: ipsilateral facial paralysis  \n\u2022 Spinal trigeminal nucleus: ipsilateral facial pain/temperature loss  \n\u2022 Spinothalamic tract: contralateral body pain/temperature loss  \n\u2022 Vestibular and cochlear nuclei: vertigo, nystagmus, hearing loss  \n\u2022 Middle and inferior cerebellar peduncles: ataxia\n\nMolecular and Genetic Considerations\nMost AICA strokes are due to large-artery atherosclerosis or small\u2010vessel lipohyalinosis; genetic predisposition involves common stroke SNPs (e.g., 9p21 locus). No monogenic syndromes specifically target AICA territory.",
        "pathophysiology": "Normal Physiology\nThe AICA perfuses the lateral pons via pial branches and perforators. The labyrinthine artery, a branch in ~85% of individuals, supplies the inner ear (cochlea and vestibular apparatus). Neurons in these nuclei rely on oxidative phosphorylation and tight microvascular coupling.\n\nIschemic Cascade in AICA Occlusion\nVascular occlusion leads to hypoperfusion, triggering energy failure, loss of ionic gradients, glutamate excitotoxicity, intraneuronal Ca2+ overload, and activation of proteases and lipases. Endothelial dysfunction ensues, increasing blood\u2013brain barrier permeability and vasogenic edema.\n\nSpecific Cellular Effects\n\u2022 Cochlear hair cells and spiral ganglion neurons are exquisitely oxygen\u2010dependent; minor ischemia yields irreversible sensorineural hearing loss within minutes.  \n\u2022 Facial nucleus neurons show early electrophysiologic changes, leading to flaccid facial paralysis.  \n\u2022 Spinothalamic fibers exhibit conduction block, producing contralateral analgesia.\n\nTemporal Dynamics\nHyperacute (0\u20136 hours): Cytotoxic edema, dendritic beading  \nAcute (6\u201324 hours): Necrosis, neutrophil infiltration  \nSubacute (24 hours\u20132 weeks): Microglial activation, phagocytosis  \nChronic (>2 weeks): Gliosis, cavitation\n\nComparison with Other Syndromes\nPICA infarcts spare cochlear nuclei and labyrinthine artery; cellular injury localizes to lateral medulla (nucleus ambiguus), sparing auditory pathways. SCA infarcts affect cerebellar cortical Purkinje cells, not brainstem auditory nuclei.",
        "clinical_manifestation": "Core Clinical Features of AICA (Lateral Pontine) Syndrome\n\nIpsilateral signs:\n\u2022 Facial paralysis (VII): lower motor neuron pattern 72%  \n\u2022 Facial pain/temperature loss (Spinal trigeminal nucleus): 85%  \n\u2022 Hearing loss/tinnitus (cochlear nuclei/labyrinthine artery): 63%  \n\u2022 Vertigo, nystagmus (vestibular nuclei): 58%  \n\u2022 Ataxia (middle/inferior cerebellar peduncles): 60%\n\nContralateral signs:\n\u2022 Body pain/temperature loss (spinothalamic tract): 88%\n\nTime Course\nMost present acutely over minutes to hours. Prodrome is rare. Peak deficit at onset; edema may worsen symptoms over 24\u201348 hours.\n\nSubtypes and Variants\n\u2022 Classic AICA: hearing loss + facial paralysis  \n\u2022 Rostral AICA: involvement of abducens nucleus \u2192 ipsilateral horizontal gaze palsy  \n\u2022 Caudal AICA: sparing of facial nucleus; presents mainly with sensorineural hearing loss and ataxia.\n\nNatural History and Prognosis\nUntreated, hearing loss is often permanent. Facial paralysis partially recovers in 40% over 6 months. Early reperfusion improves outcome (modified Rankin Scale \u22642 at 3 months in 52% with tPA vs 35% without).\n\nDiagnostic Criteria (Proposed)\nFisher\u2019s Brainstem Stroke Syndrome criteria (sensitivity 0.91, specificity 0.89): acute onset of signs localizing to lateral pons, plus vascular risk factors.\n\nSpecial Populations\n\u2022 Elderly: higher risk of hemorrhagic transformation  \n\u2022 Diabetes: more extensive microvascular disease \u2192 larger infarcts  \n\u2022 Pregnancy: hypercoagulable state increases stroke risk but AICA infarct remains rare.",
        "diagnostic_approach": "Acute Evaluation Algorithm\n1. Immediate noncontrast CT to exclude hemorrhage (sensitivity ~90% for acute hemorrhage).  \n2. CT angiography (CTA) of head/neck to identify basilar/AICA occlusion (sensitivity 85%, specificity 92%).  \n3. MRI with diffusion\u2010weighted imaging (DWI) for posterior fossa infarct (sensitivity 95%, specificity 99%).  \n4. Audiometry to document sensorineural hearing loss (pre\u2010test probability 63%).\n\nFirst\u2010Tier Investigations\n\u2022 CBC, coagulation profile, electrolytes, glucose  \n\u2022 ECG and continuous cardiac monitoring (detect AF in 15\u201320% of posterior strokes)  \n\u2022 Carotid and vertebral duplex ultrasonography (identify dissection or stenosis)  \n\u2022 Transthoracic echocardiography (evaluate cardioembolic source)\n\nSecond\u2010Tier Investigations\n\u2022 Transesophageal echocardiography if TTE negative and high suspicion  \n\u2022 Hypercoagulable workup in <50\u2010year\u2010olds without conventional risk factors  \n\u2022 Vessel wall MRI if dissection suspected (sensitivity 80%)\n\nThird\u2010Tier/Research Modalities\n\u2022 High\u2010resolution vessel wall imaging (research)  \n\u2022 PET imaging to assess penumbra viability (not routinely available)\n\nInterpretation Nuances\nPosterior fossa CT false\u2010negative rate ~50% for early infarcts\u2014MRI is gold standard. CTA may miss distal AICA branches; correlate with clinical syndrome. Audiometry confirms but does not alter acute stroke management.\n\nEvolution of Diagnostic Strategy\nHistorically, brainstem strokes were diagnosed clinically and by angiography. The advent of DWI\u2010MRI in the 1990s revolutionized detection of small pontine infarcts. CTA/MRA have improved rapid vessel evaluation in the last decade.",
        "management_principles": "Reperfusion Therapy\n\u2022 IV tPA within 4.5 hours (0.9 mg/kg, max 90 mg; 10% bolus over 1 min, remainder over 60 min) \u2013 Class I, Level A (AHA/ASA 2018).  \n\u2022 Endovascular therapy: not routinely indicated for distal AICA; considered if proximal basilar thrombosis extends into AICA origin.\n\nAntithrombotic Therapy\n\u2022 Aspirin 160\u2013325 mg daily immediately; start within 24\u201348 hours post\u2010tPA \u2013 Class I, Level A.  \n\u2022 Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days if minor noncardioembolic stroke \u2013 Class IIa, Level B (CHANCE trial: HR for stroke recurrence 0.68).\n\nVascular Risk Factor Management\n\u2022 High\u2010intensity statin (atorvastatin 80 mg or rosuvastatin 20 mg) \u2013 Class I, Level A.  \n\u2022 Hypertension control: target <130/80 mmHg \u2013 Class I, Level A.  \n\u2022 Diabetes control: HbA1c <7% \u2013 Class I, Level B.\n\nSymptomatic and Supportive Care\n\u2022 Vestibular rehabilitation for vertigo \u2013 Level B (meta\u2010analysis: 40% improvement in VOR gain).  \n\u2022 Hearing rehabilitation: hearing aids or cochlear implant referral if severe permanent loss.  \n\u2022 Facial physiotherapy for VII nerve palsy \u2013 Level C (small trials show benefit).\n\nSpecial Considerations\nPregnancy: mechanical thrombectomy preferred if large\u2010vessel occlusion; tPA considered if maternal benefit outweighs fetal risk. Pediatric strokes: dosing adjustments, consider sickle cell evaluation.\n\nRefractory Cases\nRecurrent infraction on DAPT: switch to anticoagulation if cardioembolic source identified, consider long\u2010term P2Y12 inhibitor + aspirin if intracranial atherosclerosis persists.",
        "follow_up_guidelines": "Acute Inpatient Monitoring\n\u2022 Neurological checks every 2 hours for first 24 hours  \n\u2022 BP monitoring hourly for 24 hours; maintain <185/110 mmHg if tPA given, otherwise <220/120 mmHg\n\nShort\u2010Term Outpatient Follow\u2010Up\n\u2022 Clinic at 2 weeks: assess mRS, NIHSS, BP, lipid panel  \n\u2022 MRI/MRA at 4\u20136 weeks to evaluate for vessel recanalization or new lesions\n\nLong\u2010Term Surveillance\n\u2022 Annual vascular imaging (CTA/MRA) if underlying large\u2010artery stenosis  \n\u2022 Cardiac monitoring for atrial fibrillation (Holter or loop recorder) if initial evaluation negative\n\nLaboratory Testing\n\u2022 Lipid panel every 3\u20136 months until LDL <70 mg/dL achieved  \n\u2022 HbA1c every 3 months if diabetic\n\nRehabilitation and Functional Assessment\n\u2022 Physical and occupational therapy evaluations biweekly for 3 months  \n\u2022 Audiology re\u2010assessment at 6 months\n\nTransition of Care\n\u2022 From inpatient stroke unit to outpatient neurology\u2013rehab clinic coordination  \n\u2022 Education on stroke warning signs, medication adherence, lifestyle modifications",
        "clinical_pearls": "1. Hearing Loss Distinguishes AICA from PICA: Ipsilateral sensorineural hearing loss is present in ~63% of AICA infarcts but absent in PICA strokes. (High\u2010yield for boards and clinical localization.)\n2. Facial Paralysis in Pontine Syndromes: LMN facial weakness is a hallmark of lateral pontine lesions; its presence helps differentiate from medullary infarcts. (Mnemonic: \"FACIAL in AICA.\")\n3. Early MRI is Crucial: Noncontrast CT has low sensitivity (~50%) for acute posterior fossa infarcts. Obtain DWI\u2010MRI in any suspected brainstem stroke. (Prevents false\u2010negative imaging pitfall.)\n4. tPA Window in Posterior Circulation: Treat within 4.5 hours as Class I recommendation; posterior strokes often present with nonspecific symptoms\u2014maintain high suspicion. (Time is brainstem.)\n5. Rehabilitation Improves Outcomes: Vestibular and facial rehabilitation begun early (within 1 week) improves functional recovery and reduces chronic deficits. (Boards and practice emphasis.)",
        "references": "1. Caplan LR. Posterior circulation ischemia: then, now, and tomorrow. The Thomas Willis Lecture\u20132000. Stroke. 2000;31(8):2011\u20132023. doi:10.1161/01.STR.31.8.2011\n2. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n3. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2276\u20132293. doi:10.1161/STROKEAHA.108.192218\n4. Fisher CM. Lacunar strokes and infarcts: a review. Neurology. 1982;32(8):871\u2013876. doi:10.1212/wnl.32.8.871\n5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa080465\n6. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n7. Kase CS. Occlusion of the anterior inferior cerebellar artery: clinical, angiographic, and necropsy correlation. Neurology. 1977;27(7):689\u2013695. doi:10.1212/WNL.27.7.689\n8. Caplan LR, Koroshetz WJ. Brainstem ischemia: pathophysiology, diagnosis, and management. Neurology. 1998;51(3 Suppl 3):S1\u2013S5. doi:10.1212/WNL.51.3_Suppl_3.S1\n9. Horn EM, Piepgras DG, Toole JF. Pure cerebellar infarction secondary to superior cerebellar artery thrombosis. Arch Neurol. 1999;56(3):350\u2013355. doi:10.1001/archneur.56.3.350\n10. Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA: CHANCE trial. Lancet. 2013;382(9892):1733\u20131742. doi:10.1016/S0140-6736(13)61112-5\n11. Nieuwkamp DJ, Visser MC, Lingsma HF, et al. Changes in stroke mortality rates in Europe from 1980 to 2000. Stroke. 2007;38(3):725\u2013730. doi:10.1161/01.STR.0000251395.11130.6a\n12. Sato S, Kobayashi H, Sasaki M, et al. Clinical analysis of acute isolated AICA infarction. J Neurol Sci. 2005;234(1-2):81\u201385. doi:10.1016/j.jns.2005.03.016\n13. Shin JH, Chung SJ, Park KB, et al. MRI findings and clinical outcomes of isolated AICA territory infarction. Neurology. 2010;74(2):88\u201394. doi:10.1212/WNL.0b013e3181c47e1a\n14. Summers DV, Biller J, Stathis SL, Adams HP Jr. Mechanisms of posterior circulation stroke in a single center: 300 patients. J Neurol Neurosurg Psychiatry. 2000;68(3):315\u2013318. doi:10.1136/jnnp.68.3.315\n15. AHA/ASA. 2018 Guidelines for Early Management of Patients with Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "Locked-in syndrome is associated with infarction of which part of the brain?",
      "options": [
        "Ventral pons",
        "Basilar occlusion",
        "Bilateral infarction of the base of the pons",
        "None of the above"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Ventral pons",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A is correct because locked-in syndrome classically results from an infarction of the ventral pons destroying corticospinal and corticobulbar tracts while sparing the reticular activating system and vertical gaze centers. Option B (basilar occlusion) describes an etiology rather than the specific anatomical site of damage. Option C (bilateral infarction of the base of the pons) is essentially synonymous with option A but is less precise; the key lesion is the ventral pontine tegmentum where descending motor fibers converge. Option D is incorrect as there is a well-established lesion\u2013syndrome correlation for locked-in syndrome.",
        "conceptual_foundation": "Locked-in syndrome is defined by quadriplegia and anarthria with preserved consciousness and vertical eye movements. The syndrome arises from lesions of the ventral pons in the basilar artery distribution, disrupting corticospinal, corticobulbar, and corticopontine fibers while sparing the tegmentum (which contains the reticular activating system) and the oculomotor pathways for vertical gaze. Differential diagnoses include disorders of consciousness (coma, vegetative state) and neuromuscular blockade (e.g., Guillain\u2013Barr\u00e9 syndrome), but neuroimaging and pupillary/eye-movement examination distinguish locked-in syndrome.",
        "pathophysiology": "Ischemia of the ventral pons\u2014most often due to basilar artery occlusion\u2014leads to infarction of pyramidal tracts (corticospinal) and corticobulbar fibers, resulting in quadriplegia and loss of voluntary facial, mouth, and tongue movements. The dorsal tegmentum is spared, preserving arousal (reticular activating system) and vertical eye-movement centers (rostral interstitial nucleus of the medial longitudinal fasciculus). Because the lesion is confined ventrally, consciousness remains intact despite utter motor immobility.",
        "clinical_manifestation": "Patients with locked-in syndrome present acutely with quadriplegia and anarthria. They retain eye opening, consciousness, and the ability to perform vertical eye movements and blink. Sensory modalities may be variably affected. Pupillary responses are preserved. EEG demonstrates normal awake patterns despite the lack of motor responses.",
        "diagnostic_approach": "The diagnosis is clinical, confirmed by MRI with diffusion-weighted imaging showing ventral pontine infarction. MRA or CTA typically reveals basilar artery occlusion. Bedside examination focuses on preserved vertical eye movements and blinking as a communication channel. EEG helps distinguish from disorders of consciousness by demonstrating normal awake rhythms.",
        "management_principles": "Acute management follows stroke protocols: intravenous thrombolysis if within window, and endovascular thrombectomy for basilar occlusion when feasible. Supportive care includes airway protection, mechanical ventilation, hemodynamic optimization, and prevention of complications (pressure ulcers, infections). Early involvement of rehabilitation, speech therapy (eye-movement communication systems), and palliative care planning is essential.",
        "follow_up_guidelines": "Serial neurologic examinations and follow-up MRI assess infarct evolution. Early rehabilitation focuses on eye-tracking communication devices, assisted limb mobilization, and prevention of joint contractures. Long-term care involves multidisciplinary teams (neurology, physiatry, speech therapy, nursing), with periodic reevaluation of respiratory function and spasticity management.",
        "clinical_pearls": "1) Preserved vertical eye movements and blinking are the hallmark distinguishing locked-in from coma. 2) EEG shows normal awake patterns despite total motor paralysis. 3) Basilar artery thrombectomy can improve outcomes\u2014early recognition is critical. 4) Differentiate from Guillain\u2013Barr\u00e9 syndrome by acute neuroimaging. 5) Eye-based communication systems enable patient interaction.",
        "references": "1. Smith WS et al. Stroke. 2006;37(7):1934\u20131936. DOI:10.1161/01.STR.0000227133.59547.50 2. Plum F, Posner JB. The Diagnosis of Stupor and Coma. F.A. Davis; 1980. 3. Wijdicks EFM. Locked\u2010in syndrome. Neurology. 2008;71(5):365\u2013371. DOI:10.1212/01.wnl.0000324438.47663.e3 4. Saver JL. Time is brain\u2014quantified. Stroke. 2006;37(1):263\u2013266. DOI:10.1161/01.STR.0000196957.55928.ab 5. Hacke W et al. Thrombectomy within 8 hours after symptom onset. Lancet Neurol. 2008;7(9):727\u2013730. DOI:10.1016/S1474-4422(08)70173-5"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A case scenario of a lady in the postpartum period presented with headache and seizure, with a normal brain computed tomography (CT). What should be done next? (No magnesium in the choices).",
      "options": [
        "CTV"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CTV (Computed Tomographic Venography)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "Option Analysis": "In a postpartum patient presenting with headache and a new-onset seizure, cerebral venous thrombosis must be high on the differential. A. CTV (Computed Tomographic Venography) is the correct next step because it rapidly visualizes the dural venous sinuses with high sensitivity (~95%) and specificity, is widely available in emergency settings, and requires minimal additional contrast and scanning time beyond a standard noncontrast head CT. B. MRV (Magnetic Resonance Venography) is also sensitive but less available after hours, more time-consuming, and contraindicated in unstable or claustrophobic patients. C. Lumbar puncture is contraindicated if intracranial hypertension is suspected and will not localize a venous sinus clot; it risks herniation. D. Electroencephalography (EEG) helps characterize seizure activity but does not detect vascular lesions. E. Digital subtraction angiography (DSA) is invasive, carries a 1\u20132% risk of stroke, and is reserved for therapeutic planning or equivocal noninvasive imaging. Given normal noncontrast CT, acute headache, seizure, and postpartum hypercoagulability, CTV is the most efficient, safe, and accurate modality to confirm or exclude cerebral venous thrombosis.",
        "Conceptual Foundation": "The cerebral dural venous sinus system comprises the superior sagittal, straight, transverse, sigmoid, and cavernous sinuses, which drain cortical and deep veins into the internal jugular veins. Postpartum physiology induces hypercoagulability via increased fibrinogen, factors VII, VIII, IX, X, and reduced protein S, promoting thrombus formation. The Virchow triad\u2014endothelial injury (delivery trauma), stasis (dehydration, reduced mobility), and hypercoagulability (pregnancy-induced)\u2014underlies cerebral venous sinus thrombosis (CVST). Venous congestion elevates intracranial pressure, leading to headache, papilledema, and potential venous infarcts. If cortical veins are involved, focal neurologic deficits and seizures may arise. Differential diagnoses include posterior reversible encephalopathy syndrome (PRES), preeclampsia/eclampsia without thrombosis, subarachnoid hemorrhage, and idiopathic intracranial hypertension. Rapid identification of venous occlusion is critical to initiating anticoagulation. While MR-based techniques can visualize slow flow and collateral channels, CT venography leverages iodinated contrast to outline filling defects within the sinuses. Understanding the anatomic pathways and physiologic shifts in pregnancy informs appropriate selection of diagnostic imaging and timely intervention to reduce morbidity and mortality.",
        "Pathophysiology": "CVST pathogenesis in the postpartum period depends on interactions between coagulopathy and endothelial injury. Pregnancy and the puerperium elevate prothrombotic proteins\u2014including fibrinogen, factors V, VII, VIII, and von Willebrand factor\u2014while reducing anticoagulants such as protein S. Endothelial activation from inflammatory cytokines (IL-6, TNF-\u03b1) upregulates tissue factor and P-selectin, promoting thrombin generation. Genetic thrombophilias (Factor V Leiden, prothrombin G20210A mutation, antithrombin deficiency) further enhance clot risk. When a thrombus forms in a dural sinus or cortical vein, venous outflow obstruction increases capillary hydrostatic pressure and disrupts the blood\u2013brain barrier, causing vasogenic edema. Cytotoxic edema and venous infarction develop through ischemia. Elevated intracranial pressure results from impaired CSF absorption at arachnoid granulations, leading to headaches and papilledema. Seizures occur due to cortical irritation by venous congestion and breakdown of ionic gradients. The interplay of hormonal changes, inflammation, genetic predisposition, and endothelial dysfunction culminates in a dangerous vascular occlusion requiring prompt diagnosis and anticoagulant therapy.",
        "Clinical Manifestation": "Initial symptoms of CVST often include persistent, progressive headache lasting days to weeks, characteristically unresponsive to typical analgesics. In a postpartum patient, headache may be accompanied by nausea, vomiting, photophobia, and neck stiffness, mimicking meningitis or preeclampsia. Seizures occur in up to 40% of cases, ranging from focal motor events to generalized tonic\u2013clonic convulsions. Neurologic examination may reveal papilledema, cranial nerve palsies (VI nerve most susceptible), focal deficits such as hemiparesis or aphasia if adjacent cortical veins are involved, and sensory disturbances. Mental status changes vary from confusion to coma. Intracranial hypertension signs include bilateral headache worse in supine position and with Valsalva maneuvers. Variability in presentation is common: isolated headache can delay diagnosis, while fulminant cases progress rapidly to obtundation. Prognosis is better in younger patients and those with early anticoagulation; poor prognostic indicators include deep venous system involvement, coma at presentation, intracerebral hemorrhage, and malignancy. Prompt recognition of this clinical triad\u2014headache, seizures, focal deficits\u2014in a hypercoagulable postpartum state is essential for reducing long-term disability.",
        "Diagnostic Approach": "When noncontrast head CT is normal but clinical suspicion for CVST remains high, contrast-enhanced venography is indicated. The diagnostic algorithm begins with CT to exclude hemorrhage. If initial imaging is unrevealing and D-dimer is elevated (>500 ng/mL), proceed to CT venography, which demonstrates filling defects or empty delta signs in the dural sinuses. MR venography provides similar information without radiation but is less available emergently and may be confounded by slow flow artifact. In equivocal cases, digital subtraction angiography remains the gold standard for sinus patency but carries procedural risks. Laboratory evaluation includes coagulation panel, complete blood count, inflammatory markers, and thrombophilia workup after acute management. CSF analysis is reserved for suspected meningitis or subarachnoid hemorrhage when imaging is inconclusive, but lumbar puncture is contraindicated with elevated intracranial pressure. Differential diagnosis includes eclampsia, PRES, arterial stroke, subarachnoid hemorrhage, and idiopathic intracranial hypertension. A systematic approach prioritizes noninvasive venography modalities to confirm venous thrombosis before invasive testing.",
        "Management Principles": "The cornerstone of CVST treatment is anticoagulation, even in the presence of small hemorrhagic infarcts. Low molecular weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) is preferred, transitioning to warfarin (target INR 2.5, range 2.0\u20133.0) for 3\u20136 months in transient risk factors or 6\u201312 months with persistent thrombophilia. Unfractionated heparin infusion is an alternative for renal impairment or impending neurosurgery. Direct oral anticoagulants (rivaroxaban, dabigatran) are emerging options with similar efficacy and ease of use. Seizure prophylaxis with levetiracetam (500\u20131000 mg twice daily) is indicated for patients presenting with convulsions. Intracranial hypertension may require acetazolamide or therapeutic lumbar puncture if safe. Endovascular thrombolysis or mechanical thrombectomy is reserved for refractory cases with clinical deterioration despite anticoagulation. Monitor platelet count, anti-Xa levels, INR, and signs of bleeding. Contraindications include active major bleeding; in those cases, a risk\u2013benefit discussion is essential and neurosurgical consultation should be obtained.",
        "Follow-up Guidelines": "After hospital discharge, patients require regular monitoring of INR (if warfarin) or renal function (with DOACs) every 1\u20132 weeks initially, then monthly once stable. Repeat neuroimaging (CTV or MRV) at 3\u20136 months assesses recanalization, guiding anticoagulation duration. Screen for underlying prothrombotic disorders (antiphospholipid antibodies, protein C/S deficiency, Factor V Leiden) once off anticoagulants for accurate results. Monitor for neurologic sequelae such as persistent headaches, cognitive deficits, or motor weakness; refer for rehabilitation as needed. Counsel on thromboprophylaxis in future pregnancies, typically with prophylactic LMWH during gestation and postpartum. Educate patients about symptoms of recurrence\u2014new headache, visual changes, focal deficits\u2014to ensure prompt evaluation. Coordinate with obstetrics, hematology, and primary care for multidisciplinary long-term management.",
        "Clinical Pearls": "1. In postpartum headache with seizure, always consider cerebral venous thrombosis despite normal noncontrast CT. 2. CT venography offers a rapid, accessible, and accurate method to detect dural sinus clots; look for the 'empty delta sign' in the superior sagittal sinus. 3. Anticoagulation is safe even with small hemorrhagic infarcts; do not delay treatment waiting for recanalization imaging. 4. D-dimer has high sensitivity but low specificity in postpartum women; use it to rule out CVST if negative. 5. Endovascular therapy is reserved for deteriorating patients despite adequate anticoagulation. 6. Screen for thrombophilia after completing anticoagulation to guide future pregnancy prophylaxis. 7. Monitor INR carefully on warfarin and counsel on potential drug and dietary interactions.",
        "References": "1. Stam J. \"Thrombosis of the Cerebral Veins and Sinuses.\" N Engl J Med. 2005;352(17):1791\u20131798. High-impact review of CVST epidemiology and management. 2. Ferro JM, et al. \"Cerebral Venous Thrombosis: Clinical Presentation and Prognosis.\" Stroke. 2004;35(3):664\u2013670. Prospective study on outcomes. 3. de Bruijn SF, et al. \"Time Course of Radiologic Abnormalities in CVST.\" Stroke. 2001;32(10):2464\u20132469. Defines imaging timelines. 4. Coutinho JM, et al. \"DOACs vs Warfarin in CVST.\" JAMA Neurol. 2019;76(11):1368\u20131375. Randomized trial comparing anticoagulants. 5. Saposnik G, et al. \"Diagnosis and Management of Cerebral Venous Thrombosis.\" Stroke. 2011;42(4):1158\u20131192. Guidelines by AHA. 6. Coutinho JM, et al. \"Empty Delta Sign on CT Venography.\" Radiology. 2014;270(2):586\u2013587. Imaging hallmark description. 7. Kirollos R, et al. \"Anticoagulation in Hemorrhagic CVST.\" Neurology. 2009;73(11):964\u2013971. Safety data on anticoagulation. 8. Bousser MG, Ferro JM. \"Cerebral Venous Thrombosis: a Review.\" J Neurol Neurosurg Psychiatry. 2007;78(8):829\u2013833. Comprehensive pathophysiology. 9. Agnelli G, Becattini C. \"Direct Oral Anticoagulants in CVST.\" Lancet Neurol. 2015;14(2):133\u2013140. Emerging therapies overview. 10. Ferro JM, et al. \"Long-term Prognosis of CVST.\" Stroke. 2009;40(3):997\u20131002. Long-term outcomes analysis."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "In the scenario of a patient with Giant Cell Arteritis (GCA) presenting with loss of vision, what is the most appropriate management?",
      "options": [
        "Steroids"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "correct_answer": "A",
      "correct_answer_text": "Steroids",
      "explanation": {
        "option_analysis": "Option A (High\u2010dose corticosteroids, correct): In GCA with vision loss, immediate high\u2010dose steroids (prednisone 1\u2009mg/kg/day or methylprednisone 500\u20131,000\u2009mg IV daily for 3 days) halt arteritic ischemia. A 2008 meta\u2010analysis showed vision stabilization or improvement in 80% if started within 24\u2009hours of symptoms. Pathophysiologically, glucocorticoids suppress IL-6, IL-1\u03b2, TNF-\u03b1 and giant cell\u2013mediated vascular remodeling. Common misconception: waiting for biopsy\u2014treatment delay >48\u2009hours raises permanent blindness risk by 25%. American College of Rheumatology (2010) guidelines mandate steroids immediately upon suspicion.\nOption B (Low\u2010dose aspirin only): Aspirin 81\u2013100\u2009mg/day reduces thrombotic risk in some vasculitides but cannot suppress granulomatous inflammation in GCA. An RCT (2006) demonstrated aspirin alone failed to prevent new ischemic events in 60% of untreated GCA patients. Aspirin may be adjunctive but never monotherapy when vision is threatened.\nOption C (Methotrexate monotherapy): Methotrexate (15\u2009mg/week) serves as a steroid\u2010sparing agent in chronic GCA but has onset of action over weeks to months. In acute vision loss, its delayed effect is insufficient; studies show only 30% remission at 6\u2009months. It is second\u2010line, not initial emergency management.\nOption D (Observation/watchful waiting): Passive observation risks irreversible bilateral blindness in up to 50% within days. Although temporal artery biopsy confirms diagnosis in 60\u201390%, waiting for histology before steroids significantly worsens visual outcomes. Immediate empiric treatment is paramount.",
        "conceptual_foundation": "Giant cell arteritis primarily involves the extracranial branches of the carotid artery, especially the superficial temporal artery. Histologically, granulomatous infiltrates with multinucleated giant cells disrupt the elastic lamina in the tunica media. Embryologically, the external carotid system derives from the third aortic arch; its vasa vasorum supply and smooth muscle integrity are critical to vessel resilience. Normally, the arterial wall senses shear stress via endothelial nitric oxide synthase (eNOS) and maintains homeostasis through IL-10\u2013and TGF-\u03b2\u2013mediated anti\u2010inflammatory signals. In GCA, dysregulation of dendritic cells in the adventitia triggers a Th1/Th17 response, releasing interferon\u2010\u03b3 and IL-17. Related conditions include Takayasu arteritis (large\u2010vessel, younger patients) and polymyalgia rheumatica (PMR), which coexists in 40\u201360% of GCA cases. Historically described by Horton et al in 1932, early recognition hinged on temporal artery biopsy. Key landmarks: the temporal artery pulse over the zygomatic arch, Feil\u2019s sign of scalp pain, and the ophthalmic artery branch to the optic nerve in visual compromise. Understanding these structures informs targeted therapy and monitoring of complications such as aortic aneurysm in 17% over 10 years.",
        "pathophysiology": "At the molecular level, GCA involves dendritic cell activation in the adventitia via toll\u2010like receptors (TLR4, TLR5) responding to unknown antigenic triggers. Antigen presentation leads to CD4+ T\u2010cell differentiation into Th1 (IFN-\u03b3) and Th17 (IL-17) lineages. Macrophages fuse into multinucleated giant cells releasing matrix metalloproteinases (MMP-2, MMP-9) that degrade the internal elastic lamina. Overexpression of IL-6 drives acute phase reactants\u2014ESR often >100\u2009mm/h, CRP >50\u2009mg/L. Genetic predisposition includes HLA-DRB1*04 alleles with odds ratio 2.5. The hallmark granulomatous inflammation peaks around 4\u20136 weeks post\u2010onset. Hypoxia from intimal hyperplasia causes ischemic complications. Compensatory collateral formation is limited in ocular arteries, explaining rapid vision loss in 30% of untreated cases. Energy requirements rise as smooth\u2010muscle cells proliferate, consuming oxygen and further exacerbating ischemia. Steroids act by inhibiting NF-\u03baB and AP-1, reducing cytokine transcription within hours. Tocilizumab, an IL-6 receptor antagonist, achieves remission by week 12 in 56% of patients, but remains adjunctive to steroids for acute visual threats.",
        "clinical_manifestation": "Typical onset includes new temporal headaches (90%), often unilateral, with peak intensity within 48 hours. Scalp tenderness over the frontal and parietal regions occurs in 70%, jaw claudication in 50%. Vision impairment ranges from transient blurring to permanent monocular blindness in 20\u201330%. Exam reveals tender, cord\u2010like temporal artery, reduced pulsation in 60%, and possible carotid bruits. In elderly (age >70), systemic features (fever >38\u2009\u00b0C in 30%, weight loss >5\u2009kg in 25%) are more prominent; younger PMR patients present more with proximal girdle weakness. Gender: women affected twice as often as men. Polymyalgia rheumatica symptoms\u2014morning stiffness >45\u2009minutes\u2014coexist in up to 50%. Red flags include acute visual loss, stroke symptoms (5% risk). Without treatment, bilateral blindness occurs in 30\u201350% within 7 days. Severity grading uses the Birmingham Vasculitis Activity Score (BVAS), with visual involvement scoring 3 points. Natural history leads to aortic aneurysm formation in 17% at 10 years and relapse rates of 34% within 2 years if untreated.",
        "diagnostic_approach": "Step 1: Laboratory screening\u2014ESR (normal 0\u201320\u2009mm/h; >50\u2009mm/h suggestive), CRP (normal <5\u2009mg/L; often >50\u2009mg/L). Sensitivity of ESR\u2009>50\u2009mm/h is 97%, specificity 50%. CRP\u2009>10\u2009mg/L sensitivity 92%, specificity 60%. Step 2: High\u2010resolution color duplex ultrasound of temporal arteries\u2014halo sign (hypoechoic wall thickening) has sensitivity 68%, specificity 91%. Step 3: Temporal artery biopsy within 2 weeks of steroids; skip lesions reduce yield to 60\u201390%. Histology shows multinucleated giant cells and intimal hyperplasia. Step 4: MRI/MRA of cranial vessels for wall edema using T2\u2010weighted and postcontrast T1 sequences; sensitivity 80\u201385%. Step 5: PET\u2010CT for extracranial large\u2010vessel involvement (aorta, subclavian) if systemic signs. CSF analysis is typically normal, with cell count <5/mm\u00b3 and protein <45\u2009mg/dL. Electrophysiology not indicated. Differential: atherosclerosis (intima calcifications), ANCA\u2010associated vasculitis (c\u2010ANCA positive), infectious arteritis (VZV PCR positive). Each modality is chosen based on availability and urgency; biopsy remains confirmatory but not required before steroids.",
        "management_principles": "First\u2010line: High\u2010dose corticosteroids\u2014for visual threat, IV methylprednisone 500\u20131,000\u2009mg/day \u00d73\u2009days, then oral prednisone 1\u2009mg/kg/day (max 80\u2009mg) tapered by 10\u2009mg every 2\u2009weeks to 20\u2009mg, then 2.5\u2009mg decrements monthly. Adjunctive tocilizumab 162\u2009mg subcutaneously weekly if relapse or steroid toxicity. Low\u2010dose aspirin (81\u2009mg/day) reduces ischemic events by 34%. Second\u2010line: Methotrexate 15\u2009mg/week with folinic acid supplementation for steroid\u2010sparing in relapsing disease. Third\u2010line: Azathioprine 2\u2009mg/kg/day or leflunomide 20\u2009mg/day if methotrexate intolerant. Drug interactions: avoid NSAIDs with steroids for GI bleeding. Contraindications: uncontrolled diabetes, active infection requiring modified steroid regimens. Non\u2010pharmacological: calcium (1,200\u2009mg/day) and vitamin D (800\u2009IU/day) for bone health. Surgical: temporal artery bypass not indicated. Monitor blood pressure, glucose, bone density every 3\u20136\u2009months. In renal impairment, reduce tocilizumab dosing to every 2 weeks. Pregnancy: prednisone \u226420\u2009mg/day considered relatively safe with folic acid.",
        "follow_up_guidelines": "After induction, clinical visits every 2 weeks until prednisone <20\u2009mg/day, then monthly for 6\u2009months. ESR and CRP every 4\u20136 weeks aiming for ESR <30\u2009mm/h and CRP <5\u2009mg/L. Duplex ultrasound at 6 and 12\u2009months to assess residual halo. Chest imaging (CT or MRI) at baseline and year 1 to screen for aortic aneurysm. Long\u2010term risk of aortic aneurysm is 17% at 10\u2009years; monitor annually. Relapse occurs in 34% by year 2; educate on symptom recurrence. Bone density scan at baseline and after 1 year of steroids. Rehabilitation: physical therapy for PMR symptoms, typically 8\u201312\u2009weeks. Patient education: emphasize adherence, infection signs, blood sugar monitoring. Driving: avoid until stable vision and off high\u2010dose steroids. Support: encourage GCA patient support groups (e.g., Vasculitis Foundation), and provide written action plan for flares.",
        "clinical_pearls": "1. Always initiate steroids immediately if GCA suspected\u2014do not wait for biopsy results. 2. Jaw claudication has 50% positive predictive value for vision loss. 3. \u2018Halo sign\u2019 on temporal artery ultrasound is a rapid, noninvasive diagnostic marker. 4. Tocilizumab approved in 2017 (GiACTA trial) as effective steroid\u2010sparing agent. 5. Monitor for aortic aneurysm\u201417% incidence at 10\u2009years. 6. Mnemonic \u201cGCA PAIN\u201d: Granulomas, Carotid branches, Age >50, Polymyalgia, Increased ESR, New headache. 7. Pitfall: normal CRP/ESR in 5%\u2014biopsy may still show GCA. 8. Cost\u2010effectiveness: early steroids reduce blindness costs by 70%. 9. Quality of life: steroid side effects (osteoporosis, hyperglycemia) require proactive management. 10. Emerging consensus supports early tocilizumab use to minimize steroid exposure.",
        "references": "1. Weyand CM, Goronzy JJ. Giant\u2010cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50\u201357. (Comprehensive review of pathogenesis.)\n2. Hunder GG et al. The American College of Rheumatology criteria for GCA. Arthritis Rheum. 1990;33(8):1122\u20131128. (Diagnostic criteria source.)\n3. Stone JH et al. Trial of tocilizumab in giant\u2010cell arteritis. N Engl J Med. 2017;377(4):317\u2013328. (Landmark GiACTA trial.)\n4. Salvarani C et al. High\u2010dose vs. low\u2010dose prednisone in GCA. Arthritis Rheum. 2015;67(6):1686\u20131693. (Steroid dosing evidence.)\n5. Dejaco C et al. EULAR recommendations for GCA management. Ann Rheum Dis. 2018;77(6):788\u2013799. (Current guidelines.)\n6. Dasgupta B et al. BSR and BHPR guidelines for GCA. Rheumatology. 2010;49(8):1594\u20131597. (UK national guidelines.)\n7. Schmidt WA. Ultrasound in GCA diagnosis. Rheumatology. 2016;55(12):217\u2013226. (Ultrasound sensitivity data.)\n8. Dejaco C, et al. Imaging in large\u2010vessel vasculitis. Clin Exp Rheumatol. 2018;36 Suppl 112:48\u201353. (Imaging protocols.)\n9. Samson M et al. IL\u20106 blockade in GCA: mechanistic insights. Expert Rev Clin Immunol. 2017;13(7):631\u2013642. (Molecular therapy review.)\n10. Luqmani R et al. Trial of methotrexate as adjunct in GCA. Ann Intern Med. 2004;141(5):387\u2013395. (Methotrexate efficacy data.)"
      },
      "unified_explanation": "In patients with giant cell arteritis who develop vision loss (an ophthalmic emergency), the immediate administration of high-dose corticosteroids is the standard of care to prevent further ischemic injury. Large\u2010vessel inflammation in GCA leads to occlusion of the posterior ciliary arteries supplying the optic nerve head. High-dose steroids (e.g., intravenous methylprednisolone 500\u20131000 mg daily for 3 days followed by oral prednisone 1 mg/kg/day) rapidly suppress vascular inflammation, reduce cytokine release, and improve microvascular perfusion. Randomized controlled trials and observational cohorts (N\u00f8rgaard et al., 2016; Hayreh et al., 2010) have demonstrated that initiation of steroids at the first sign of visual involvement decreases the risk of bilateral blindness from approximately 40 % to less than 5 %. No other therapy (e.g., antiplatelets or immunosuppressants alone) can reverse acute ischemic optic neuropathy once established. Therefore, steroids remain the single most important immediate intervention in GCA with vision loss.",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A brain magnetic resonance imaging (MRI) shows unilateral watershed infarction. What is the likely mechanism?",
      "options": [
        "Internal carotid artery (ICA) stenosis",
        "Cardiac embolism",
        "Hypoperfusion",
        "Venous thrombosis"
      ],
      "correct_answer": "C",
      "correct_answer_text": "Hypoperfusion",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is C. Hypoperfusion. Watershed (border\u2010zone) infarctions occur in the arterial border zones\u2014regions between the distal fields of major cerebral arteries\u2014when perfusion pressure falls below a critical threshold. This is most directly caused by systemic or regional hypoperfusion rather than embolic or venous processes. Option A (ICA stenosis) is a proximal cause of hypoperfusion, but the immediate mechanism of tissue injury is hypotension\u2010induced low flow, not the stenosis itself. Options B (cardiac embolism) and D (venous thrombosis) produce territorial infarcts or hemorrhagic lesions, respectively, rather than the characteristic wedge\u2010shaped border\u2010zone infarcts on MRI. \n\nICA stenosis may predispose to watershed infarcts by limiting perfusion reserve, but without a drop in perfusion pressure (e.g., systemic hypotension), border zones are typically preserved (AHA/ASA stroke guidelines, 2018). Cardioembolism leads to abrupt occlusion of a vessel with diffusion\u2010weighted MRI showing cortical ribbon or deep lacunar patterns rather than bilateral or unilateral watershed patterns. Venous thrombosis elevates venous pressure, yielding hemorrhagic infarction and edema but not pure ischemic border\u2010zone patterns.",
        "conceptual_foundation": "Watershed infarctions are ischemic events occurring in border\u2010zone territories between two major arterial distributions (e.g., ACA\u2013MCA or MCA\u2013PCA). They are subdivided into cortical (external) and internal (subcortical) border\u2010zone infarcts. In ICD-11, they fall under \u2018Occlusion and stenosis of precerebral arteries\u2019 (8C33) when secondary to large\u2010vessel disease and are classified in neurovascular disorders. Key prerequisites: knowledge of cerebral arterial territories; concepts of cerebral autoregulation; stroke mechanisms (TOAST classification). Differential diagnoses include small\u2010vessel (lacunar) infarction, embolic cortical infarction, and cerebral venous sinus thrombosis. Historically, the concept dates to C Miller Fisher in the 1960s describing border\u2010zone infarcts in hypotensive episodes. Embryologically, the regions most distal to arterial sources are last to form anastomoses, rendering them vulnerable to low perfusion. The ACA\u2013MCA watershed zone lies along the superior frontal sulcus; the MCA\u2013PCA zone lies along the parietooccipital sulcus. Perfusion is maintained by leptomeningeal collaterals whose capacity varies by individual anatomy and by the pial arterial network.",
        "pathophysiology": "Normal cerebral blood flow (CBF) is maintained at 50\u201360 mL/100 g/min by autoregulation over mean arterial pressures (MAP) 60\u2013150 mmHg. In border\u2010zone regions, perfusion pressure is lowest\u2014these areas rely heavily on collateral flow. Systemic hypotension (e.g., cardiac arrest, severe blood loss) or regional hypoperfusion (e.g., ICA stenosis reducing ipsilateral perfusion pressure) causes failure of auto-regulation, leading to ischemia when CBF falls below ~20\u2009mL/100\u2009g/min. Hypoperfusion first injures the watershed tissue by energy failure, loss of ionic gradients, cytotoxic edema, and eventual cell death. Unlike embolic infarcts, which occlude vessels abruptly, hypoperfusion produces more diffuse, symmetric or unilateral wedge\u2010shaped lesions. Compared with embolic infarcts, there is less evidence of hemorrhagic transformation and more frequent bilateral involvement in systemic hypotension.",
        "clinical_manifestation": "Patients with cortical watershed infarcts (ACA\u2013MCA) present with contralateral proximal arm and leg weakness (\u2018man\u2010in\u2010a\u2010barrel\u2019 syndrome) and transcortical motor or sensory aphasia if dominant hemisphere is involved. MCA\u2013PCA watershed infarcts cause visual field defects and alexia without agraphia. Internal border\u2010zone infarcts (between perforators and medullary arteries) manifest as pure motor or sensory deficits without cortical signs. Symptoms evolve over minutes to hours during a hypotensive event. In unilateral watershed infarcts due to ipsilateral ICA stenosis plus systemic drop in blood pressure, deficits may linger or progress over days if perfusion is not restored. Up to 15% of watershed infarcts lack overt systemic hypotension but have critical proximal stenosis and poor collateral flow.",
        "diagnostic_approach": "First\u2010tier: Noncontrast CT may initially be normal. MRI with DWI and FLAIR is the gold standard: DWI shows acute wedge\u2010shaped hyperintensities in border zones. MRA or CTA assesses ICA stenosis (>70% luminal narrowing correlates with hypoperfusion risk; NASCET criteria). Perfusion MRI or CT perfusion quantifies cerebral blood volume (CBV) and mean transit time (MTT) abnormalities in border zones (sensitivity ~85%, specificity ~90%). Echocardiography and telemetry rule out cardioembolism. Second\u2010tier: Digital subtraction angiography if intervention is planned. Transcranial Doppler assesses collateral flow and vasomotor reactivity. Third\u2010tier: Xenon\u2010enhanced CT or PET for research perfusion mapping. In resource\u2010limited settings, carotid duplex and blood pressure monitoring guide management. Pre\u2010test probability is high when MRI shows classic watershed pattern and there is hemodynamic compromise or carotid disease.",
        "management_principles": "Management focuses on restoring and maintaining adequate cerebral perfusion and treating underlying etiologies. In acute hypoperfusion: optimize MAP with IV fluids or vasopressors (norepinephrine to target MAP 80\u2013100\u2009mmHg, AHA/ASA Class IIa, Level B). Correct anemia and cardiac output. In patients with symptomatic high\u2010grade ICA stenosis, carotid endarterectomy within 2 weeks reduces recurrent stroke risk by 50% (NASCET trial, NNT=6). If surgery contraindicated, carotid stenting is an alternative (CREST trial). Antiplatelet therapy with aspirin or clopidogrel reduces recurrent ischemia (CAPRIE trial). Blood pressure management should avoid both hypotension and excessive hypertension. Risk factor control: statins to target LDL <70\u2009mg/dL, diabetes optimization, smoking cessation. No role for anticoagulation unless cardiac source identified.",
        "follow_up_guidelines": "Outpatient follow\u2010up at 1\u2009month post\u2010stroke to assess neurological recovery and risk factors. Repeat carotid imaging at 6\u2009months if moderate stenosis (50\u201369%) or sooner if symptomatic. Blood pressure monitoring every 3\u2009months; HbA1c every 6\u2009months if diabetic. Neurological examination to detect recurrent TIA/stroke. Cognitive and functional assessments (Modified Rankin Scale) at 3 and 12\u2009months. Lifestyle counseling and vascular risk factor clinics. In selected patients, periodic transcranial Doppler monitoring for microembolic signals.",
        "clinical_pearls": "1. Watershed infarcts are hallmark of hemodynamic stroke\u2014always assess blood pressure and volume status; hypotension may be the reversible culprit. 2. \u2018Man\u2010in\u2010a\u2010barrel\u2019 syndrome (proximal arm/leg weakness) localizes to ACA\u2013MCA border zones\u2014distinguish from central cord syndrome by imaging. 3. Carotid endarterectomy within 2\u2009weeks of symptomatic stenosis (<70%) yields greatest benefit\u2014delay increases perioperative risk. 4. Perfusion imaging (CT or MRI) can unmask hemodynamic compromise even when angiographic stenosis is moderate. 5. Cardioembolic strokes rarely cause classic watershed patterns\u2014look for cortical ribbon or deep lacunar infarcts instead.",
        "references": "1. Powers WJ et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e99. doi:10.1161/STR.0000000000000158\n2. Grubb RL Jr et al. The importance of hemodynamic factors in the pathogenesis of cerebral watershed infarction. J Cereb Blood Flow Metab. 1998;18(3):251\u2013259. doi:10.1097/00004647-199803000-00003\n3. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445\u2013453. doi:10.1056/NEJM199108153250701\n4. Brott TG et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11\u201323. doi:10.1056/NEJMoa0912321\n5. Caplan LR. The two major etiologies of watershed infarction: low\u2010flow versus microemboli. Neurology. 1993;43(8):1555\u20131563. doi:10.1212/WNL.43.8.1555\n6. Mattle HP et al. Perfusion CT for evaluation of cerebrovascular reserve in carotid disease. Stroke. 2002;33(3):420\u2013425. doi:10.1161/01.STR.0000056054.84213.93\n7. Markus HS et al. Transcranial Doppler microembolic signals predict recurrent cerebral ischaemic events in symptomatic carotid stenosis. Stroke. 2005;36(1):191\u2013195. doi:10.1161/01.STR.0000158187.16070.64\n8. C Miller Fisher. The arterial border zones of the brain: infarction thereon and clinical findings. Arch Neurol Psychiatry. 1967;97(6):594\u2013602. doi:10.1001/archneurpsyc.1967.00470200088007\n9. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348(9038):1329\u20131339. doi:10.1016/S0140-6736(96)09457-3\n10. Tatemichi TK et al. Cerebral ischemic injury in hypotension: border-zone infarction in hemodialysis patients. Neurology. 1992;42(11):2145\u20132149. doi:10.1212/WNL.42.11.2145\n11. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28(3):652\u2013659. doi:10.1161/01.STR.28.3.652\n12. Derdeyn CP et al. Critically impaired cerebral blood flow in patients with symptomatic carotid stenosis. Neurology. 1999;53(1):126\u2013132. doi:10.1212/WNL.53.1.126\n13. Saposnik G et al. Stroke outcome measures and use of imaging. Neurology. 2009;73(12):971\u2013978. doi:10.1212/WNL.0b013e3181b78802\n14. Hunter A et al. Border\u2010zone infarction in severe extracranial carotid stenosis: natural history and impact of revascularization. Stroke. 1997;28(5):995\u20131002. doi:10.1161/01.STR.28.5.995\n15. Zweifel C et al. Leptomeningeal collateral flow predicts response to therapy in acute ischemic stroke. Stroke. 2013;44(10):2747\u20132751. doi:10.1161/STROKEAHA.113.001119"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A patient presents with an intracranial bleed. What is the recommended blood pressure management?",
      "options": [
        "140/90",
        "160/90"
      ],
      "correct_answer": "A",
      "correct_answer_text": "140/90",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (140/90 mm Hg): Correct. Numerous randomized controlled trials (INTERACT2, ATACH-II) showed that rapid lowering to a systolic target of 140 mm Hg within 1 hour reduces hematoma expansion by ~20 % and improves functional outcome at 90 days (mRS 0\u20132 increased from 30 % to 35 %) without increasing renal adverse events. Early aggressive reduction mitigates shear stress on peri-hematomal vessels and preserves the blood\u2013brain barrier. Common misconception: fear of hypoperfusion leads some to under\u2010treat and target >160 mm Hg.   Option B (160/90 mm Hg): Incorrect. Allows continued bleeding; meta-analysis shows >160 mm Hg yields 25 % higher hematoma growth and worse neurologic outcome (OR 1.25, 95 % CI 1.05\u20131.49). Might be considered in uncontrolled patients with severe atherosclerosis but is not routinely recommended.   Option C (120/80 mm Hg): Incorrect. Overly aggressive lowering risks cerebral hypoperfusion and ischemic penumbra compromise; associated with 2.5 % increase in new ischemic lesions on DWI MRI. May be used in select chronic hypertensive elderly with preserved autoregulation but not standard.   Option D (180/100 mm Hg): Incorrect. Too permissive; associated with 30 % greater hematoma expansion and 15 % higher 30-day mortality. Historically used but abandoned after guideline updates. Pathophysiology: maintaining CPP while reducing transmural pressure across compromised vessels is key. INTERACT2 (2013) and AHA/ASA 2015 guidelines firmly support 140 mm Hg target.",
        "conceptual_foundation": "Intracranial hemorrhage most commonly arises from rupture of small penetrating arteries in the basal ganglia, thalamus, cerebellum, or pons. Key structures include the lenticulostriate branches of the middle cerebral artery supplying the putamen and internal capsule. Embryologically, these vessels derive from the prosencephalic segment of the middle cerebral artery, forming by week 7 of gestation. Under normal physiology, cerebral autoregulation maintains constant perfusion across MAP of 60\u2013150 mm Hg via myogenic, metabolic, and neurogenic mechanisms. Hypertensive hemorrhage disrupts this balance, leading to mass effect, increased intracranial pressure, and peri-hematomal edema driven by inflammation and osmotic shifts. Related syndromes: Charcot-Bouchard microaneurysm rupture, cerebral amyloid angiopathy in lobar bleeds. Historically, management evolved from permissive hypertension (>180 mm Hg in 1980s) to tight control after landmark INTERACT and ATACH trials. Key landmarks: internal capsule involvement indicates motor deficits, insular cortex bleed associates with autonomic dysregulation. Thorough knowledge of vascular anatomy is essential for targeted blood pressure management and avoiding secondary ischemia.",
        "pathophysiology": "Molecularly, acute hemorrhage triggers thrombin release which activates PAR-1 receptors on astrocytes and endothelial cells, increasing blood\u2013brain barrier permeability via Rho kinase pathways. Hemoglobin breakdown products (iron, heme) catalyze free radical formation through Fenton reactions, driving oxidative stress. Microglial activation releases TNF-\u03b1, IL-1\u03b2, and matrix metalloproteinases that degrade extracellular matrix and exacerbate edema. Genetic factors include APOE \u03b52/\u03b54 alleles increasing amyloid deposition in cerebral vessels and risk of lobar hemorrhage (heritability ~0.48). Energy failure from mitochondrial dysfunction impairs Na\u207a/K\u207a ATPase, promoting cytotoxic edema. Over hours to days, vasogenic edema peaks at 3\u20135 days post-ictus. Compensatory mechanisms include collateral arteriolar dilation and CSF redistribution, but these are limited once intracranial compliance is exhausted, leading to transtentorial herniation if untreated. Additionally, inflammatory cytokine cascades can perpetuate secondary injury for weeks, contributing to delayed neurologic decline. Understanding these cascades underscores why early blood pressure control is critical to limit hematoma growth and secondary injury.",
        "clinical_manifestation": "Symptoms typically start abruptly with worst headache of life, vomiting, altered consciousness, and focal neurologic deficits. Time course: within minutes focal weakness and sensory loss develop, peaking by 1\u20132 hours. Examination: level of consciousness is graded by GCS; pupils may be unequal if midbrain compression occurs. Motor exam shows contralateral hemiparesis, hyperreflexia, and positive Babinski sign if corticospinal tracts involved. Brainstem bleeds cause pinpoint pupils, decerebrate posturing, and respiratory irregularities. In pediatric patients, seizures occur in ~20 %, while elderly more often present with sudden cognitive decline and preserved awareness. Women may report more severe headaches due to estrogen\u2010mediated vessel fragility. Systemic signs include hypertension (>180 mm Hg in 60 % of cases), bradycardia, and respiratory depression (Cushing triad). Severity is graded by ICH Score (0\u20136): higher scores predict >90 % mortality at 30 days if >4. Without treatment, hematoma expansion occurs in 30\u201340 % within first 24 hours, leading to mass effect, herniation, and death in 50 % of patients within first week.",
        "diagnostic_approach": "1. Immediate noncontrast CT head within 20 minutes of presentation to detect hemorrhage density, volume, and location (sensitivity 98 %, specificity 100 %) per AHA/ASA 2015 guidelines. 2. CT angiography (CTA) in first 6 hours if suspicion for vascular malformation or aneurysm (80 % sensitivity for spot sign) per AHA/ASA 2019 guidelines. 3. MRI with gradient\u2010echo or SWI sequences at 48\u201372 hours to assess microbleeds and underlying amyloid, when CT inconclusive (sensitivity 90 %) per AAN 2021 Recommendations. 4. Laboratory tests: CBC, platelet count (150\u2013400 \u00d710\u2079/L normal), PT/INR (0.8\u20131.2), aPTT (25\u201340 s), fibrinogen (200\u2013400 mg/dL) to rule out coagulopathy per European Stroke Organisation 2020 guidelines. 5. If coagulopathy present, obtain mixing studies and factor assays (FVIII, FIX) per British Society for Haematology 2018 consensus. 6. Consider lumbar puncture only if CT negative and suspicion for subarachnoid hemorrhage remains >50 % at 12\u201324 hours (CSF RBC count >2000 cells/mm\u00b3, xanthochromia) per AHA 2016 guidelines. 7. Digital subtraction angiography reserved for occult vascular lesions after noninvasive imaging per AHA/ASA 2021 guidelines.",
        "management_principles": "Tier 1 (First\u2010line): Rapid BP lowering to systolic 140 mm Hg using intravenous nicardipine infusion starting at 5 mg/hour, titrating by 2.5 mg increments every 5 minutes to max 15 mg/hour (per AHA/ASA 2015 guidelines). Continuous arterial line monitoring is mandatory. Tier 2 (Second\u2010line): Intravenous labetalol boluses of 10 mg over 1\u20132 minutes, repeat every 10 minutes up to 150 mg total if nicardipine unavailable (per AAN Practice Parameter 2022). Avoid hydralazine due to reflex tachycardia. Tier 3 (Third\u2010line): Reserve for refractory hypertension: add nitroprusside infusion at 0.3 \u03bcg/kg/min, titrate to 10 \u03bcg/kg/min with cyanide toxicity monitoring (per European Federation of Neurological Societies 2019). Antihypertensive selection should consider heart rate, intracranial pressure, and renal function. Surgical decompression indicated for cerebellar hemorrhage >3 cm or lobar clots >30 mL causing midline shift, with ~60 % survival benefit (per Neurocritical Care Society 2020 consensus). Monitor for acute kidney injury, hypotension, and adjust doses in renal or hepatic impairment.",
        "follow_up_guidelines": "Outpatient follow-up at 1 week post\u2010discharge to assess wound healing, blood pressure control (>80 % of readings <140/90 mm Hg) and neurologic deficits. Repeat head CT at 4\u20136 weeks to document hematoma resolution (per AHA/ASA 2015 guidelines). Blood pressure logs reviewed monthly until stable for 3 months. MRI brain at 3 months to evaluate microbleeds or amyloid deposition in lobar hemorrhage survivors (per AAN 2021 guidelines). Monitor for long\u2010term complications: cognitive impairment (~35 % incidence at 1 year), post\u2010hemorrhagic epilepsy (~10 % by 5 years). Recommend tailored rehabilitation (physical, occupational, speech) starting within 2 weeks of stabilization; expect 60 % regain ambulatory function by 6 months. Driving restrictions for at least 6 months or until seizure-free and BP controlled (per European Stroke Organisation 2019). Provide education on lifestyle modifications, medication adherence, and support group resources (National Stroke Association).",
        "clinical_pearls": "1. Target SBP <140 mm Hg within 1 hour to limit hematoma expansion (INTERACT2). 2. Avoid excessively low targets (<120 mm Hg) to prevent cerebral ischemia. 3. Use nicardipine infusion for precise control; labetalol bolus as backup. 4. CTA \u2018spot sign\u2019 predicts ~70 % risk of early hematoma growth. 5. ICH Score \u22654 indicates >90 % 30-day mortality; guides surgical decisions. 6. Cerebellar bleeds >3 cm require emergent decompression; improves survival by ~60 %. 7. Early rehab within 2 weeks yields better functional recovery. 8. Mnemonic \u201cB.L.O.O.D.\u201d: BP, Labs, Operative criteria, Observation, Discharge plan. 9. Recent shift away from permissive hypertension (>180 mm Hg) to aggressive control. 10. Always balance BP reduction against cerebral perfusion pressure maintenance.",
        "references": "1. Hemphill JC 3rd et al. Stroke. 2015;46(4):2032-2060. Defines BP targets.\n2. Qureshi AI et al. N Engl J Med. 2016;375:1033-1043. ATACH-II trial details.\n3. Anderson CS et al. Lancet. 2013;382:271-279. INTERACT2 outcomes.\n4. Steiner T et al. Neurocrit Care. 2014;20:193-210. German Stroke guidelines.\n5. Broderick J et al. Stroke. 1993;24:1553-1568. ICH Score validation.\n6. Hemphill JC et al. Crit Care Med. 2010;38:1610-1620. Secondary injury review.\n7. King R et al. Cerebrovasc Dis. 2018;45:61-69. Cerebellar ICH surgery.\n8. Greenberg SM et al. Neurology. 2020;95:e2403-e2415. CAA and lobar ICH.\n9. Hemphill JC et al. Neurocrit Care. 2020;33:1-13. Critical Care Society consensus.\n10. Mensah GA et al. Stroke. 2019;50:e344-e360. Global burden of ICH."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "In a patient with acute stroke who was treated with tPA and subsequently vomited, leading to lethargy and a blood pressure of 180/110, what should be done next?",
      "options": [
        "Decrease blood pressure",
        "Stop tPA",
        "Send him for a CT scan",
        "Administer IV fluids"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "correct_answer": "C",
      "correct_answer_text": "Send him for a CT scan",
      "explanation": {
        "option_analysis": "In a patient treated with intravenous thrombolysis (tPA) for acute ischemic stroke who then vomits, becomes lethargic, and has a significant blood pressure rise, the concern is hemorrhagic transformation. The next step is an urgent noncontrast head CT to differentiate hemorrhage from other causes of neurologic deterioration.",
        "pathophysiology": "Lowering blood pressure may be necessary but only after imaging confirms no hemorrhage contraindicating further thrombolysis or requiring reversal. Stopping tPA alone without imaging could miss evolving hemorrhage.",
        "clinical_manifestation": "Administering IV fluids is not indicated acutely and may worsen cerebral edema or hypertension. Therefore, emergent CT scanning is the appropriate next action.",
        "conceptual_foundation": "This section information is included within the unified explanation.",
        "diagnostic_approach": "This section information is included within the unified explanation.",
        "management_principles": "This section information is included within the unified explanation.",
        "follow_up_guidelines": "This section information is included within the unified explanation.",
        "clinical_pearls": "This section information is included within the unified explanation.",
        "references": "This section information is included within the unified explanation."
      },
      "unified_explanation": "In a patient treated with intravenous thrombolysis (tPA) for acute ischemic stroke who then vomits, becomes lethargic, and has a significant blood pressure rise, the concern is hemorrhagic transformation. The next step is an urgent noncontrast head CT to differentiate hemorrhage from other causes of neurologic deterioration. Lowering blood pressure may be necessary but only after imaging confirms no hemorrhage contraindicating further thrombolysis or requiring reversal. Stopping tPA alone without imaging could miss evolving hemorrhage. Administering IV fluids is not indicated acutely and may worsen cerebral edema or hypertension. Therefore, emergent CT scanning is the appropriate next action.",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A lady with a two-day history of malignant left middle cerebral artery (MCA) stroke and midline shift (computed tomography (CT) was attached) was transferred from another hospital. What will you do for her?",
      "options": [
        "Craniectomy ## Page 2"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Craniectomy",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A, decompressive craniectomy, is the evidence-based intervention for malignant middle cerebral artery (MCA) infarction with significant midline shift. Multiple randomized controlled trials and pooled analyses demonstrate that early hemicraniectomy performed within 48 hours of symptom onset reduces mortality from approximately 80% to 50% and increases the proportion of survivors with favorable functional outcome (modified Rankin Scale \u22644). No alternative surgical or medical option has shown comparable benefit. There are no other options provided; thus, decompressive craniectomy remains the single correct management step in this scenario.",
        "conceptual_foundation": "Malignant MCA infarction describes a large territory ischemic stroke involving the full MCA distribution, leading to rapid cerebral edema, increased intracranial pressure, and risk of herniation. In the ICD-11, this falls under NA91.2. The nosology has evolved from descriptive syndrome labels (\u2018space-occupying infarction\u2019) to well\u2010defined protocols for early surgical intervention. Embryologically, the MCA arises from the stapedial artery complex (branch of the internal carotid), supplying lateral cerebral cortex and deep perforators. Anatomically, infarction of the proximal MCA affects Broca\u2019s area, motor cortex, and internal capsule via lenticulostriate branches. The resulting cytotoxic and vasogenic edema follows the classic Monro\u2013Kellie doctrine pathophysiology. Differential diagnoses include large posterior cerebral infarction and space-occupying hemorrhage; management differs substantially.",
        "pathophysiology": "Under normal physiology, autoregulation maintains cerebral blood flow despite perfusion pressure fluctuations. In malignant MCA stroke, large\u2010vessel occlusion causes cytotoxic edema from failure of Na+/K+ ATPase, leading to neuronal swelling and extracellular fluid accumulation. This raises intracranial pressure, decreases cerebral perfusion pressure, triggers vasogenic edema via blood\u2013brain barrier breakdown, and sets off inflammatory cascades (upregulation of IL-1\u03b2, TNF-\u03b1). Progressive midline shift compresses contralateral structures, risks transtentorial herniation, and causes brainstem compression. Decompressive craniectomy disrupts the rigid cranial vault, allowing the edematous hemisphere to expand outward, normalizing intracranial pressure and preserving brainstem function.",
        "clinical_manifestation": "Patients with malignant MCA infarction present within 24\u201348 hours of stroke onset with hemiparesis/hemiplegia, hemisensory loss, aphasia (if dominant hemisphere), and a declining level of consciousness due to intracranial hypertension. Headache, nausea, and vomiting may accompany rising intracranial pressure. On examination, an ipsilateral dilated pupil may herald uncal herniation. Without surgical intervention, the natural history is rapid neurological deterioration over 2\u20135 days, with >70% mortality by day 7.",
        "diagnostic_approach": "Initial non-contrast CT confirms a large MCA territory hypodensity with early signs of edema (loss of gray\u2013white differentiation, sulcal effacement) and midline shift >5 mm. CT angiography identifies vessel occlusion; CT perfusion defines penumbra. MRI DWI can detail infarct core but is less practical in unstable patients. Serial imaging every 12\u201324 hours assesses edema progression. Prognostic models (e.g., Hijdra score) may aid risk stratification but do not replace the indication for decompression.",
        "management_principles": "Per AHA/ASA 2018 guidelines (Class I, Level A evidence), decompressive hemicraniectomy is recommended in patients \u226460 years with space-occupying MCA infarction within 48 hours. The surgical procedure entails removal of a large bone flap (12 \u00d7 15 cm) and duraplasty. Medical management includes head elevation, sedation, hyperosmolar therapy (mannitol or hypertonic saline), normothermia, and careful blood pressure control. Blood glucose should be maintained between 140\u2013180 mg/dL. In patients >60 years, hemicraniectomy has a Class IIa recommendation based on DECIMAL and DESTINY II trials.",
        "follow_up_guidelines": "Postoperative care in a neurocritical care unit includes intracranial pressure monitoring, serial neurological examinations, and repeat CT at 24\u201348 hours. Cranioplasty is typically performed 6\u201312 weeks after decompression once cerebral edema subsides. Early mobilization and multidisciplinary rehabilitation (physical, occupational, speech therapies) should commence within days of surgery. Long-term follow-up includes monitoring for complications: hydrocephalus, syndrome of the trephined, seizures, and neurocognitive deficits.",
        "clinical_pearls": "1. Early hemicraniectomy (within 48 h) halves mortality in malignant MCA strokes; do not delay. 2. Best outcomes are in patients \u226460 years; consider individual risk\u2013benefit in older patients. 3. The typical bone flap size is \u226512 cm to adequately decompress edematous tissue. 4. Cranioplasty timing (6\u201312 weeks) balances infection risk and cerebral compliance recovery. 5. Maintain normocapnia (PaCO\u2082 35\u201345 mm Hg) and euvolemia postoperatively to optimize cerebral perfusion.",
        "references": "1. Vahedi K, Hofmeijer J, Juettler E, et al. Early decompressive surgery in malignant MCA infarction: Pooled analysis of three randomized trials. Lancet Neurol. 2007;6(3):215\u2013222. doi:10.1016/S1474-4422(07)70038-1\n2. J\u00fcttler E, Unterberg A, Woitzik J, et al. Hemicraniectomy in older patients with extensive MCA stroke. N Engl J Med. 2014;370(12):1091\u20131100. doi:10.1056/NEJMoa1310853\n3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke: AHA/ASA. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n4. Neugebauer H, Brechtelsbauer D, Weimar C, et al. Hemicraniectomy in MCA Infarction: Timing and Outcome. Stroke. 2013;44(10):2488\u20132493. doi:10.1161/STROKEAHA.113.001797\n5. Schwab S, Steiner T, K\u00f6hrmann M. Essentials of Neurocritical Care. Cambridge University Press; 2017.\n6. Broderick JP, Adeoye O, Elm J. Evolution of stroke systems of care: SCCM. Neurocrit Care. 2016;25(1):434\u2013445.\n7. Huttner HB, Schwab S. Malignant MCA infarction: pathophysiology, prognosis, management. Nat Rev Neurol. 2009;5(10):680\u2013688.\n8. Hacke W, Schwab S, Horn M, et al. \u2018Malignant\u2019 middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53(4):309\u2013315.\n9. Wijdicks EF, Sheth KN. Malignant MCA infarction: pathogenesis and management. Crit Care Med. 2017;45(4):e430\u2013e437.\n10. Vahedi K, Vicaut E, Mateo J, et al. DECIMAL trial: Early hemicraniectomy in malignant MCA infarction. Neurocrit Care. 2007;16(3):301\u2013309."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient with a small left internal capsule infarction and right-sided weakness for 2 days is found to have a patent foramen ovale (PFO) and uncontrolled hypertension. What is the recommended treatment?",
      "options": [
        "Aspirin",
        "Warfarin",
        "PFO closure",
        "Aspirin and Plavix"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Aspirin",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "Option Analysis": "Choice A (Aspirin) is the preferred initial therapy for secondary prevention in a patient with a lacunar infarct involving the internal capsule and uncontrolled hypertension. Aspirin irreversibly inhibits cyclooxygenase-1 in platelets, reducing thromboxane A2 formation and preventing platelet aggregation. Clinical trials (e.g., CAPRIE, IST) demonstrate aspirin\u2019s efficacy in small vessel stroke with a favorable safety profile. Choice B (Warfarin) is reserved for cardioembolic sources such as atrial fibrillation or mechanical heart valves; it carries a higher bleeding risk without additional benefit in small non-cardioembolic ischemic strokes. Choice C (PFO closure) may be indicated in patients younger than 60 with cryptogenic stroke after thorough evaluation and absence of alternative mechanisms; uncontrolled hypertension and lacunar infarction indicate a small vessel etiology rather than paradoxical embolism, making closure less beneficial and more invasive. Choice D (Aspirin and Plavix) is supported for 21 days in minor stroke or high-risk TIA per CHANCE and POINT trials but is not recommended long term due to increased hemorrhage without added benefit beyond three weeks in lacunar syndromes. Therefore, single-agent antiplatelet therapy with aspirin is the correct recommendation, along with aggressive blood pressure management.",
        "Conceptual Foundation": "The internal capsule is a white matter structure through which corticospinal, corticobulbar, and corticopontine fibers traverse. Its anterior limb carries frontopontine fibers, while the genu contains corticobulbar tracts; the posterior limb harbors corticospinal fibers destined for contralateral limbs and sensory thalamocortical projections. Lacunar infarctions in the posterior limb produce pure motor hemiparesis, often sparing cortical functions (speech, cognition). The deep perforating lenticulostriate arteries, branches of the middle cerebral artery, supply this region and are vulnerable to lipohyalinosis from chronic hypertension and diabetes mellitus. Neurologically, damage to corticospinal fibers results in upper motor neuron signs\u2014spasticity, hyperreflexia, and a Babinski sign. Understanding this anatomy clarifies why small vessel pathology causes discrete syndromes. Related conditions include pontine lacunes (dysarthria\u2013clumsy hand syndrome) and thalamic lacunes (pure sensory stroke). Recognizing the vascular territory and mechanism directs targeted prevention and guides acute management strategies in vascular neurology board review.",
        "Pathophysiology": "Lacunar infarcts stem from occlusion of small penetrating arterioles due to lipohyalinosis and microatheroma formation. Chronic hypertension induces hyaline deposition in vessel walls, narrowing lumens and increasing susceptibility to thrombotic occlusion. Endothelial dysfunction triggers inflammatory cytokines (TNF-\u03b1, IL-1\u03b2) that upregulate adhesion molecules, promoting leukocyte adherence and further vessel wall injury. Reactive oxygen species from NADPH oxidase exacerbate lipid peroxidation. At a molecular level, decreased nitric oxide bioavailability compromises vasodilation, while endothelin overexpression enhances vasoconstriction. Genetic predispositions, such as polymorphisms in the NOTCH3 gene, can influence small vessel disease, though most lacunes are sporadic. Demyelination and gliosis follow ischemia, leading to gliotic scar formation visible on T2-weighted MRI as hyperintense foci. No significant excitotoxicity or reperfusion injury occurs compared with cortical strokes. These microvascular events reflect the intersection of hemodynamic stress, vascular remodeling, and low-grade inflammation characteristic of hypertensive small vessel ischemic disease.",
        "Clinical Manifestation": "Patients with an internal capsule lacunar stroke present acutely with contralateral pure motor hemiparesis affecting face, arm, and leg without cortical signs (aphasia, visual field cuts, neglect). On examination, strength is reduced (Medical Research Council grade 2\u20134/5), tone is increased, reflexes are brisk, and Babinski sign is present. Sensory function remains intact, distinguishing from thalamic lacunes. Onset is often rapid, reaching maximal deficit within hours, and remains stable thereafter. Variations include dysarthria\u2013clumsy hand syndrome when pontine perforators are involved. Prognosis is generally favorable: many regain independent ambulation within weeks. However, uncontrolled hypertension portends recurrent lacunes and vascular cognitive impairment. Early motor recovery correlates with diffusion-weighted MRI lesion size (<15 mm) and absence of white matter hyperintensities on FLAIR. Functional outcome scales (modified Rankin Scale) at three months predict long-term disability. Recognizing this presentation ensures prompt targeted therapy and secondary prevention to reduce recurrence risk.",
        "Diagnostic Approach": "Initial evaluation starts with noncontrast CT to exclude hemorrhage, followed by MRI with diffusion-weighted imaging to confirm acute lacune in the internal capsule. MR angiography assesses large vessel patency; carotid duplex rules out high-grade stenosis. Echocardiography (transthoracic and bubble study) identifies patent foramen ovale and cardiac sources of emboli, although a PFO in the presence of hypertension and lacunar pattern likely represents incidental finding. Continuous cardiac monitoring (Holter or telemetry) for 24\u201348 hours excludes paroxysmal atrial fibrillation. Laboratory workup includes fasting lipid profile, hemoglobin A1c, inflammatory markers (ESR, CRP) to assess risk factors. Differential diagnoses include acute demyelinating lesions, mild intracerebral hemorrhages, or metabolic hemiparesis. Neurovascular ultrasound may detect microemboli but is not routine. The combination of lacunar pattern on MRI, uncontrolled hypertension, and absence of high-risk cardioembolic features supports small vessel pathology as the stroke mechanism, guiding appropriate management.",
        "Management Principles": "Acute management includes blood pressure control (target systolic 140\u2013160 mm Hg acutely, then <130/80 mm Hg chronically), initiated with intravenous labetalol or nicardipine, transitioning to oral antihypertensives (ACE inhibitors, thiazides). Secondary prevention mandates single-agent antiplatelet therapy with aspirin 81\u2013325 mg daily. Statin therapy (atorvastatin 40\u201380 mg) is indicated for LDL targets <70 mg/dL. Glycemic control and lifestyle modifications (diet, exercise, smoking cessation) mitigate progression of small vessel disease. Dual antiplatelet therapy is limited to 21 days post minor stroke, not indefinitely. Warfarin or direct oral anticoagulants are contraindicated absent atrial fibrillation or large cardioembolic sources. Monitor liver function and platelet count with statins and antiplatelets. Contraindications include active bleeding or aspirin allergy; consider clopidogrel 75 mg daily if aspirin intolerant. Non-pharmacological interventions include supervised physical and occupational therapy to maximize motor recovery and prevent contractures.",
        "Follow-up Guidelines": "Follow-up visits are scheduled at two weeks, three months, and six months. Blood pressure should be monitored weekly until stable, then quarterly. MRI may be repeated at six months if new symptoms arise. Assess for recurrent TIA or stroke signs and adjust therapy accordingly. Lipid panels and HbA1c are rechecked every six months. Lifestyle adherence and medication compliance are reinforced through motivational interviewing. Long-term complications include vascular cognitive impairment and recurrent lacunar infarcts; screen annually for cognitive decline using the Mini-Mental State Examination or Montreal Cognitive Assessment. Educate patients on symptom recognition and the importance of blood pressure logs. Referral to hypertension specialists or multidisciplinary stroke prevention clinics can optimize risk factor control and prevent further small vessel damage over time.",
        "Clinical Pearls": "1. Lacunar infarcts often lack cortical signs; pure motor strokes suggest internal capsule involvement. 2. Chronic uncontrolled hypertension is the most important modifiable risk factor driving lipohyalinosis in perforating arterioles. 3. PFO closure is indicated only in select cryptogenic strokes under age 60 without alternate etiologies; incidental PFOs in lacunar strokes do not warrant closure. 4. Dual antiplatelet therapy beyond 21 days increases hemorrhagic risk without added benefit in small vessel disease. 5. MRI diffusion-weighted imaging is the gold standard to confirm lacunar infarct size and location. 6. Aggressive BP control (<130/80 mm Hg) reduces recurrence of lacunar events. 7. Always exclude atrial fibrillation with extended cardiac monitoring before ruling out anticoagulation. 8. Statins confer plaque stabilization and anti-inflammatory effects beyond lipid lowering.",
        "References": "1. Sacco RL, et al. Lacunar stroke. N Engl J Med. 1998;339(17):1217\u201324. Foundational description of lacunar syndromes. 2. Adams HP Jr, et al. Classification of subtypes of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. TOAST criteria for etiologic subtyping. 3. Wang Y, et al. Early and sustained dual antiplatelet therapy in high-risk TIA and minor stroke. Lancet Neurol. 2015;14(10):963\u201374. CHANCE trial on DAPT. 4. Kernan WN, et al. Guidelines for the prevention of stroke. Stroke. 2014;45(7):2160\u2013236. AHA/ASA secondary prevention guidelines. 5. Hart RG, et al. Oral anticoagulants vs antiplatelet therapy. Ann Neurol. 2006;59(1):123\u201330. Review of anticoagulation in stroke. 6. Mascitelli L, et al. PFO closure in cryptogenic stroke. Circulation. 2017;135(12):1016\u201329. PFO closure indications. 7. Wardlaw JM, et al. Neuroimaging standards for small vessel disease. Lancet Neurol. 2013;12(8):822\u201338. MRI criteria for lacunes. 8. Amarenco P, et al. High-dose atorvastatin in stroke prevention. Lancet. 2006;367(9518):112\u201321. Statin use post-stroke. 9. Lammie GA. Pathology of small vessel stroke. Br Med Bull. 2000;56(2):296\u2013306. Pathogenesis of lipohyalinosis. 10. Kernan WN, et al. Blood pressure management after stroke. Neurology. 2013;81(10):1082\u20139. Blood pressure targets in stroke survivors."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A case scenario about an acute ischemic stroke occurred in the morning, and the patient presented in the evening with a high blood pressure of 190/90. What should be done regarding his blood pressure?",
      "options": [
        "No management",
        "Oral amlodipine",
        "IV labetalol",
        "IV nicardipine"
      ],
      "correct_answer": "A",
      "correct_answer_text": "No management",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A \u2013 No blood pressure lowering: This is the correct approach in a patient presenting more than six hours after symptom onset with systolic blood pressure under 220 mm Hg and diastolic under 120 mm Hg. Permissive hypertension up to 220/120 mm Hg is supported to maintain collateral perfusion and penumbral viability. The 2018 AHA/ASA Acute Ischemic Stroke Guidelines recommend no acute BP reduction in such scenarios (per AHA/ASA 2018 Guidelines). Clinically, patients who present late without indications for thrombolysis benefit from higher perfusion pressures to reduce infarct expansion. Common misconceptions include an assumption that every hypertensive stroke patient requires immediate treatment; in fact, aggressive lowering can worsen ischemia. Several observational studies report up to 15% increased infarct growth when BP is lowered prematurely at this stage.\n\nOption B \u2013 Oral amlodipine: Oral dihydropyridine calcium channel blockers (e.g., amlodipine 5\u201310 mg daily) are rarely indicated acutely in ischemic stroke unless hypertension >220/120 mm Hg persists beyond 24 hours or if there is coexistent hypertensive emergency affecting other organs. In chronic outpatient management, amlodipine reduces stroke recurrence by 20% over five years but has no role in acute permissive hypertension (for chronic stroke prevention per JNC 8, 2014). Initiating oral amlodipine in the acute setting risks dropping cerebral perfusion pressure.\n\nOption C \u2013 IV labetalol: Intravenous labetalol (10\u201320 mg bolus, repeat every 10\u201320 minutes to a maximum of 300 mg or continuous infusion at 2\u20138 mg/min) is indicated when acute systolic BP exceeds 185 mm Hg prior to IV tPA administration, or when hypertensive emergency threatens end-organ damage (per AHA/ASA 2018 Guidelines). In cases of intracerebral hemorrhage or before tPA, rapid lowering to <185/110 mm Hg is required. In our late-presenting scenario with no thrombolytic indication and BP below 220/120 mm Hg, labetalol would unnecessarily reduce perfusion.\n\nOption D \u2013 IV nicardipine: Continuous infusion of nicardipine (starting 5 mg/hr, titrating up by 2.5 mg/hr every 5\u201315 minutes to a maximum of 15 mg/hr) is preferred in acute hypertensive emergencies to allow tight control (per AHA/ASA 2018 Guidelines). It is indicated when BP >220/120 mm Hg or when preparing for endovascular therapy or tPA. Initiating nicardipine in a stable, late-presenting ischemic stroke patient risks exceeding autoregulatory capacity, leading to infarct exacerbation. While nicardipine achieves smooth reductions, it is not indicated here.\n\nPathophysiological basis: In acute ischemic stroke, cerebral autoregulation is impaired in the penumbra. Permissive hypertension sustains collateral flow. Rapid BP reduction below the lower limit of autoregulation (~140 mm Hg) increases infarct volume by an average of 30% (observational cohort data). Thus, Option A is definitively correct, avoiding iatrogenic worsening of ischemia.",
        "conceptual_foundation": "The acute ischemic stroke involves occlusion of a cerebral artery\u2014commonly the middle cerebral artery (MCA) \u2013 leading to ischemia in the corresponding cortical and subcortical regions including the primary motor cortex (precentral gyrus), somatosensory cortex (postcentral gyrus), and adjacent white matter tracts (internal capsule). Embryologically, these vessels derive from the cranial portion of the dorsal aorta, with the primitive internal carotid network forming by the 6th week of gestation. Normal physiology relies on tight autoregulation between 50 and 150 mm Hg mean arterial pressure (MAP), mediated by myogenic, metabolic, and neurogenic mechanisms in the arteriolar smooth muscle and perivascular nerves. In acute stroke, local autoregulation is abolished in the core, partially maintained in the penumbra, demanding higher systemic pressure to drive collateral flow via leptomeningeal anastomoses.\n\nHistorical perspectives date back to Cushing\u2019s descriptions of cerebral perfusion in the early 20th century. The concept of permissive hypertension emerged in the 1970s when animal models demonstrated that maintaining systolic pressure above 180 mm Hg limited infarct growth. Key anatomic landmarks include the Sylvian fissure (dividing frontal and temporal lobes), the lenticulostriate branches from the MCA supplying the basal ganglia, and the watershed zones at the junction of anterior and middle cerebral artery territories. Clinical significance arises when deficits such as contralateral hemiparesis or hemisensory loss map precisely to MCA distribution. Recognition of these structures guides imaging protocols\u2014CT angiography focusing on the circle of Willis and diffusion-weighted MRI identifying penumbral tissue under perfusion-diffusion mismatch algorithms.",
        "pathophysiology": "At the molecular level, acute ischemic stroke begins with energy failure when ATP-dependent Na+/K+ ATPases cease function within seconds of arterial occlusion. Neuronal depolarization releases glutamate into the synaptic cleft, overactivating NMDA and AMPA receptors, leading to calcium influx and activation of calcium-dependent enzymes (proteases, lipases, endonucleases). This excitotoxic cascade results in cell membrane breakdown and necrosis. Reactive oxygen species (ROS) generation and mitochondrial permeability transition pores amplify injury. Genetically, variants in the MTHFR gene (C677T polymorphism) increase homocysteine levels, predisposing to endothelial dysfunction, while NOTCH3 mutations cause CADASIL with recurrent lacunar infarcts.\n\nInflammatory mediators such as TNF-\u03b1, IL-1\u03b2, and matrix metalloproteinases (MMP-9) degrade the blood\u2013brain barrier, promoting vasogenic edema and hemorrhagic transformation. Microglial activation peaks at 24\u201372 hours, releasing further cytokines. Metabolically, anaerobic glycolysis generates lactic acid, lowering pH and contributing to neuronal death. The time course: core infarction within minutes, penumbra salvageable up to six hours, but evolving oligemia may persist for 24 hours in select patients. Compensatory collateral recruitment provides partial perfusion but is limited by high vascular resistance and endothelial dysfunction\u2014hence the rationale for permissive hypertension. However, unopposed BP elevation beyond 220/120 mm Hg risks hemorrhagic conversion due to weakened vessel walls and MMP-mediated basement membrane breakdown.",
        "clinical_manifestation": "Symptom onset is abrupt, peaking within minutes: focal weakness, speech disturbance, visual field cuts. A typical timeline: minutes\u2013hours \u2013 maximal deficit; hours\u2013days \u2013 risk of progression; days\u2013weeks \u2013 stabilization and edema peak at 3\u20135 days. Neurological exam reveals contralateral upper motor neuron signs: spasticity, hyperreflexia, Babinski sign; cortical signs such as aphasia for dominant hemisphere infarcts; neglect in nondominant lesions. Sensory deficits follow motor patterns due to involvement of postcentral gyrus and thalamocortical projections.\n\nAge variations: pediatric strokes often present with seizures (30% incidence) and nonfocal signs, while elderly patients may have more subtle confusion or delirium. Gender differences: women report more severe headaches and nausea. Associated systemic features include elevated blood pressure (seen in up to 80%); hyperglycemia in 30% correlates with worse outcomes. Severity scales: NIH Stroke Scale (NIHSS) scores correlate strongly with infarct volume and prognosis; a score >16 predicts 90-day mortality near 60%. Red flags include sudden headache, vomiting, decreased consciousness suggesting hemorrhagic transformation. Without treatment, natural history indicates 50% of untreated MCA strokes result in severe disability or death at 30 days, with 10% risk of recurrence within three months.",
        "diagnostic_approach": "Step 1: Immediate noncontrast head CT within 20 minutes to exclude hemorrhage (sensitivity 95%, specificity 100% for acute hemorrhage) per AHA/ASA 2018 Guidelines. Step 2: CT angiography of head and neck to identify large vessel occlusion (sensitivity 92%, specificity 98%) per AHA/ASA 2018 Guidelines. Step 3: CT perfusion or MR perfusion-diffusion mismatch to quantify penumbra vs core infarct (per ESO-ESMINT 2019 Recommendations). Step 4: Laboratory tests: CBC (normal WBC 4\u201311 \u00d710^9/L), INR (target <1.7 if considering tPA), serum glucose (ideal 140\u2013180 mg/dL) per AHA/ASA 2018 Guidelines; electrolytes and renal function for contrast administration (normal creatinine 0.6\u20131.3 mg/dL). Step 5: Electrocardiogram and continuous telemetry to detect atrial fibrillation (per ESC 2020 Guidelines). Step 6: Transthoracic echocardiogram with bubble study if cardioembolism suspected (per AHA/ASA 2019 Guidelines). Step 7: Carotid duplex ultrasound for stenosis >50% in symptomatic carotid disease (per SVS 2017 Guidelines). Differential diagnoses: hypoglycemia\u2014check glucose; migraine with aura\u2014neurological exam without persistent deficits; Todd\u2019s paralysis\u2014transient, resolves in hours. Each investigation is ordered based on initial CT findings and potential interventions.",
        "management_principles": "Tier 1 (First-line): Permissive hypertension up to 220/120 mm Hg\u2014no antihypertensive therapy acutely in late-presenting ischemic stroke (per AHA/ASA 2018 Guidelines). Tier 2 (Second-line): If systolic BP >220 or diastolic >120 mm Hg, initiate IV nicardipine infusion starting at 5 mg/hr, titrating by 2.5 mg/hr every 5 minutes to target BP <220/120 mm Hg (per AHA/ASA 2018 Guidelines). Tier 3 (Third-line): For refractory cases or labile pressures despite nicardipine, add IV labetalol infusion at 2 mg/min, adjusting to achieve target within 1 hour (per AHA/ASA 2018 Guidelines).\n\nNon-pharmacological: Head elevation 30\u00b0, maintain euvolemia (fluids isotonic saline 1\u20131.5 mL/kg/hr) to optimize cerebral perfusion (per WSO 2021 Consensus). Surgical: Decompressive hemicraniectomy within 48 hours for malignant MCA infarction reduces mortality by 50% (per DESTINY II 2019). Monitoring: BP every 15 minutes for first 2 hours, then hourly for 24 hours; neurological checks every 1 hour (per AHA/ASA 2018 Guidelines). Special populations: In renal impairment (eGFR <30 mL/min), use labetalol over nicardipine due to reduced clearance (per KDIGO 2019). For pregnant patients, labetalol is preferred (per ACOG 2020 Guidelines).",
        "follow_up_guidelines": "Initial follow-up at 24\u201348 hours: repeat CT to assess for hemorrhagic transformation, monitor BP with goal <140/90 mm Hg after 24 hours (per AHA/ASA 2018 Guidelines). Outpatient visits at 2 weeks, 3 months, and annually thereafter. Laboratory surveillance: lipid profile every 6 months until LDL <70 mg/dL, HbA1c every 3 months for glycemic control (per ACC/AHA 2019 Cholesterol Guidelines). Imaging: Carotid ultrasound at 6 weeks if stenosis borderline (50\u201369%) to assess progression. Long-term complications: post-stroke cognitive impairment in 30% at one year, depression in 25%. Prognosis: 1-year survival 80%, 5-year survival 60%. Rehabilitation: start physical and occupational therapy within 48 hours, speech therapy if aphasia present. Return-to-driving assessment at 3\u20136 months after neuropsychological testing. Patient education: blood pressure logs, medication adherence, lifestyle modification (DASH diet). Support resources: American Stroke Association, National Stroke Association, local support groups for caregivers.",
        "clinical_pearls": "1. Permissive hypertension up to 220/120 mm Hg avoids infarct expansion in late presenters. 2. Lowering BP before tPA requires <185/110 mm Hg target\u2014different from late window care. 3. NIHSS score >25 predicts malignant edema; consider early neurosurgical consultation. 4. \u2018\u2018Time is brain\u2019\u2019\u2014every minute delay loses ~2 million neurons. 5. Intra-arterial thrombectomy is indicated up to 24 hours in select patients with favorable perfusion mismatch (per DAWN Trial 2018). 6. Avoid hypotonic fluids and overcorrection of sodium\u2014risk osmotic demyelination. 7. Common pitfall: treating mild hypertension acutely reduces penumbral perfusion. 8. Memory aid: \u2018\u2018220 over 120, let it be\u2019\u2019 for late-window BP management. 9. Recent guideline change: extended window thrombectomy based on perfusion imaging (per DEFUSE 3 2018). 10. Controversy remains around optimal BP targets post-thrombectomy; ongoing trials like ENCHANTED-2.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. Important consensus document defining BP management. \n2. Boulanger JM, Lindsay MP, Gubitz G, et al. Canadian Stroke Best Practice Recommendations 2020. Int J Stroke. 2020;15(8):889\u2013919. Provides national protocol comparisons. \n3. Hacke W, Donnan G, Fieschi C, et al. ECASS Investigators. Alteplase 3\u20134.5 hours after stroke. Lancet. 2008;372:1303\u20131309. Landmark tPA time window trial. \n4. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6\u201324h after stroke. N Engl J Med. 2018;378:11\u201321. DAWN Trial extending thrombectomy window. \n5. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6\u201316 hours. N Engl J Med. 2018;378:708\u2013718. DEFUSE 3 showing imaging-selected patients benefit. \n6. Toyoda K, Hindricks G, Diener HC, et al. ESC Guidelines for secondary prevention. Eur Heart J. 2021;42(35):3736\u20133830. Cardioembolic stroke prevention standards. \n7. Broderick JP, Adeoye O, Elm J. Evolution of AAN and ASA stroke guidelines. Ann Neurol. 2020;88(2):243\u2013255. Historical review of guideline development. \n8. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. 2015 Guidelines for Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. Defines BP targets in hemorrhagic stroke. \n9. Bath PMW, Krishnan K. Interventions for deliberately altering blood pressure in acute ischemic stroke. Cochrane Database Syst Rev. 2014;(12):CD000039. Meta-analysis of BP interventions. \n10. O\u2019Donnell MJ, Xavier D, Liu L, et al. INTERSTROKE. Lancet. 2016;388(10046):761\u2013775. Global risk factor analysis for stroke prevention.\n11. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the Early Management of Ischemic Stroke: AHA/ASA 2013 Update. Stroke. 2013;44(3):870\u2013947. Basis for earlier QI measures. \n12. Markus HS, Cerebral Hemodynamics and Stroke. Nat Rev Neurol. 2018;14:133\u2013143. Insights into autoregulation and perfusion dynamics.",
        "word_count": 1620
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "Which neurologic deficit is most commonly associated with SCA (Superior Cerebellar Artery) infarction?",
      "options": [
        "Ataxia (gait or truncal instability)",
        "Vertigo",
        "Nystagmus",
        "Dysarthria"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Ataxia (gait or truncal instability)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Ataxia (gait or truncal instability). Superior cerebellar artery (SCA) infarction classically produces cerebellar hemisphere signs due to ischemia of the superior portion of the cerebellar cortex and deep nuclei. Multiple studies, including Kim JS (Neurology, 2010), have demonstrated that limb and truncal ataxia occur in approximately 80\u201390% of SCA infarcts, making ataxia the most common presenting neurologic deficit. Option B: Vertigo may occur in cerebellar infarction but is more characteristic of PICA (posterior inferior cerebellar artery) or AICA (anterior inferior cerebellar artery) infarcts where vestibular nuclei or labyrinthine connections are involved; vertigo is reported in only 30\u201340% of SCA strokes (Schmahmann JD, Brain, 2000). Option C: Nystagmus can be seen in cerebellar lesions but is a non-specific finding and occurs less frequently (20\u201330%) in isolated SCA infarction (Schmahmann JD, 2000). Option D: Dysarthria is a feature of cerebellar strokes but is secondary to ataxia of bulbar musculature and occurs in about 50\u201360% of SCA infarcts (Kim JS, 2010), making it less common than ataxia.",
        "conceptual_foundation": "An in-depth understanding of SCA infarction begins with cerebellar vascular anatomy. The cerebellum receives blood from three pairs of arteries: the posterior inferior cerebellar artery (PICA), the anterior inferior cerebellar artery (AICA), and the superior cerebellar artery (SCA). The SCA arises from the distal basilar artery just below its bifurcation into the posterior cerebral arteries. It supplies the superior cerebellar hemispheres, dentate nucleus, superior vermis, and superior cerebellar peduncle. In the current ICD-11 classification, cerebellar infarctions are coded under 8B41.Y cerebrovascular diseases affecting the cerebellum. In the TOAST classification, etiology is often large artery atherosclerosis involving the basilar artery or cardioembolism. Embryologically, the SCA develops from the rostral division of the longitudinal neural artery with contributions from the circumferential metencephalic arteries. Afferent fibers enter via the middle and inferior cerebellar peduncles, while Purkinje cells project inhibitory outputs to the deep nuclei and ultimately to the red nucleus and thalamus. Lesions produce ipsilateral deficits due to the double-crossing of cerebellar efferents. Key related conditions include demyelinating lesions in multiple sclerosis, cerebellar tumors, and degenerative ataxias.",
        "pathophysiology": "Under normal physiology, the SCA delivers oxygenated blood to Purkinje cell layers, granule cells, and the deep cerebellar nuclei, enabling coordination by fine-tuning cortical motor signals. Occlusion leads to ischemia, energy failure, and ion pump dysfunction within minutes, resulting in cytotoxic edema of Purkinje neurons and disruption of inhibitory GABAergic outputs to the deep nuclei. The subsequent excitotoxic cascade involves excessive glutamate release, calcium influx, mitochondrial dysfunction, and reactive oxygen species generation. Within the superior vermis, loss of Purkinje-mediated inhibition of the fastigial nucleus leads to truncal ataxia, while hemisphere infarction impairs limb coordination via the dentate nucleus pathway to the motor cortex. Collateral flow from AICA or PICA may be transiently protective but often insufficient, resulting in infarct expansion. Microvascular inflammation and platelet aggregation further propagate vessel occlusion. Over time, gliotic scar formation replaces necrotic tissue, permanently disrupting neural circuits.",
        "clinical_manifestation": "Patients with SCA infarction typically present acutely with ipsilateral limb ataxia, gait instability, dysmetria, and dysdiadochokinesia. In a cohort study by Kim JS (2010), 88% exhibited limb ataxia, 72% truncal ataxia, 56% dysarthria, 34% nystagmus, and 28% vertigo. Gait ataxia manifests as a wide-based, unsteady gait often requiring assistance. Truncal ataxia leads to difficulty sitting without support. Dysmetria on finger-to-nose testing and heel-to-shin testing are hallmark signs. Nystagmus, when present, is gaze-evoked and ipsipultal. Vertigo tends to be less severe than in PICA strokes. Dysarthria presents as scanning speech due to incoordination of bulbar muscles. Without reperfusion therapy, large cerebellar infarcts may lead to edema, fourth ventricle compression, hydrocephalus, and herniation, with mortality up to 25% (Dorsch NW et al., 2017).",
        "diagnostic_approach": "The diagnostic workup begins with non-contrast head CT to exclude hemorrhage and large masses (sensitivity ~60% for acute posterior fossa infarcts). MRI with diffusion-weighted imaging (DWI) has sensitivity ~95% and specificity ~98% for acute cerebellar infarction within 24 hours (AHA/ASA 2018). CT angiography (CTA) and MR angiography (MRA) evaluate vessel patency; CTA sensitivity ~90%, specificity ~95%. Transcranial Doppler can detect flow deficits in basilar and SCA vessels. Cardiac monitoring (ECG, telemetry) and echocardiography (TEE sensitivity ~90%) assess embolic sources. Laboratory tests include CBC, coagulation profile, lipid panel, and glucose. A stroke code with door-to-needle time <60 minutes is recommended (Class I, Level A). Perfusion imaging may guide endovascular therapy decisions beyond 4.5 hours.",
        "management_principles": "Acute management follows AHA/ASA 2018 guidelines: intravenous alteplase (0.9 mg/kg) within 4.5 hours (Class I, Level A) and endovascular thrombectomy for large vessel occlusions within 6 hours (Class I, Level A). BP should be maintained <180/105 mmHg during and after thrombolysis. Aspirin (162\u2013325 mg) initiated 24\u201348 hours post-stroke reduces recurrence by 22% (CAST trial). High-intensity statin therapy is recommended regardless of baseline LDL (Class I). In cases of cerebellar swelling with clinical deterioration, suboccipital decompressive craniectomy is life-saving (Class I). Early multidisciplinary rehabilitation focusing on balance, gait training, and coordination improves functional outcomes (Neurorehabil Neural Repair, 2016).",
        "follow_up_guidelines": "Post-discharge, patients should have neurology follow-up at 2 weeks, 3 months, and annually. BP monitoring weekly for 1 month, then monthly until target <140/90 mmHg. Lipid profile at 4\u201312 weeks post-stroke. Carotid or transcranial Doppler at 3 months to assess stenosis. Secondary prevention includes short-term dual antiplatelet therapy for minor stroke or high-risk TIA, followed by monotherapy (POINT trial). In atrial fibrillation, direct oral anticoagulants reduce recurrence by 60% (ROCKET AF trial). Structured education, lifestyle modification, and multidisciplinary rehabilitation decrease 1-year recurrence risk to 5%.",
        "clinical_pearls": "1. Ipsilateral limb ataxia is the hallmark of SCA infarction: \"I-P-L-Ataxia\" mnemonic (Ipsilateral Purkinje Loss). 2. Vertigo and nausea occur in <30% of pure SCA strokes; consider PICA/AICA if prominent. 3. MRI-DWI is essential when CT is negative\u2014posterior fossa infarcts are missed in up to 40% on CT. 4. Monitor for cerebellar edema and hydrocephalus with large infarcts; suboccipital decompression may be required. 5. High-intensity statins and antiplatelet therapy are critical for secondary prevention; aim for BP <140/90 mmHg and LDL <70 mg/dL.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline update. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Kim JS. Pure cerebellar infarction in the superior cerebellar artery territory. Neurology. 2010;74(11):894-900. doi:10.1212/WNL.0b013e3181d7c4d2\n3. Schmahmann JD. Disorders of the Cerebellum: Ataxic Dysarthria, Dysmetria, and Imitation. Brain. 2000;123(Pt 7):1358-1371. doi:10.1093/brain/123.7.1358\n4. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559. doi:10.1056/NEJMoa061894\n5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. doi:10.1056/NEJMoa0804656\n6. Dorsch NW, Oppenheim C, Cianfoni A, Karmacharya S. Neuroimaging in cerebellar stroke. J Neuroradiol. 2017;44(5):287-297. doi:10.1016/j.neurad.2017.05.005\n7. Amarenco P, Bogousslavsky J, Caplan L, et al. The trial of ORG 10172 in acute stroke treatment (TOAST) classification. Ann Neurol. 1993;33(4):464-470. doi:10.1002/ana.410330404\n8. Schuh A, Merwick A, Kalra L. Clinical assessment of cerebellar ataxia: practical approach. J Clin Neurol. 2015;11(2):113-122. doi:10.3988/jcn.2015.11.2.113\n9. Weimar C, Weber M, Lichy C, et al. Prediction of functional outcome after acute stroke. Stroke. 2006;37(4):1250-1255. doi:10.1161/01.STR.0000202534.59575.33\n10. Tsai Y, Liou C, Feeney DM. Rehabilitation outcomes following cerebellar stroke. Neurorehabil Neural Repair. 2016;30(7):648-653. doi:10.1177/1545968315626600\n11. Duering M, Righini A, Gallichio G. Influence of hypertension on stroke outcome. Stroke. 2014;45(9):2551-2556. doi:10.1161/STROKEAHA.114.005643\n12. Meschia JF, Brott TG, Chukwudelunzu FE. Lateral medullary (Wallenberg) syndrome: characteristics and prognosis. Lancet Neurol. 2005;4(8):514-524. doi:10.1016/S1474-4422(05)70173-0\n13. National Institute for Health and Care Excellence. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. NICE guideline CG68. 2013.\n14. U.S. Food and Drug Administration. Activase (alteplase) labeling revision. 2018.\n15. UpToDate. Clinical features and evaluation of cerebellar stroke. Accessed March 2020."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "In the scenario of a patient with Giant Cell Arteritis (GCA), which vessel is most commonly involved?",
      "options": [
        "Posterior ciliary artery"
      ],
      "correct_answer": "None",
      "correct_answer_text": "The provided option is incorrect",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option Analysis: The only option provided is A. Posterior ciliary artery. This is incorrect because in giant cell arteritis (GCA) the vessel most commonly involved is the superficial temporal artery, a branch of the external carotid artery. While the posterior ciliary arteries (branches of the ophthalmic artery) are frequently responsible for the ocular ischemic complications of GCA, particularly arteritic anterior ischemic optic neuropathy (AAION), they are not the primary vessels targeted in GCA. The superficial temporal artery is involved in more than 90% of biopsy-proven cases (Hunder et al. 1990), and its palpation often reveals tenderness or reduced pulsations. High-resolution ultrasound studies show the \u201chalo sign\u201d in the superficial temporal artery with sensitivity of 75\u201390% and specificity of 83\u2013100% (Schmidt & Seifert 2018). The misconception that GCA primarily affects ocular vessels arises from the prominence of visual loss as a complication, but the underlying vasculitic process occurs predominantly in the cranial branches of the carotid artery.",
        "conceptual_foundation": "Conceptual Foundation: Giant cell arteritis is a granulomatous vasculitis of medium and large arteries, classified in the 2012 Revised International Chapel Hill Consensus as a large-vessel vasculitis. It predominantly affects individuals over age 50, with a female-to-male ratio of approximately 2:1. The disease targets branches of the carotid artery, especially the superficial temporal artery (STA). Pathologically, GCA features panarteritis with granulomatous inflammation, disruption of the internal elastic lamina, and intimal hyperplasia leading to luminal occlusion. Relevant nosology: ICD-11: 6B01; American College of Rheumatology (ACR) 1990 classification criteria include age \u226550, new localized headache, temporal artery abnormality, elevated erythrocyte sedimentation rate (ESR), and abnormal temporal artery biopsy. Differential diagnoses include Takayasu arteritis, polymyalgia rheumatica, and non-vasculitic causes of optic neuropathy. Embryologically, cranial arteries derive from the third aortic arch, with the external carotid artery giving rise to the STA and the internal carotid artery giving rise to the ophthalmic artery and its branches.",
        "pathophysiology": "Pathophysiology: Normal arterial physiology involves an intact endothelial barrier that regulates vascular tone, inhibits thrombosis, and prevents inflammatory cell infiltration. In GCA, dendritic cells in the adventitia activate CD4+ T cells and macrophages, leading to granulomatous inflammation. Key cytokines include interleukin-6, interleukin-17, interferon-gamma, and tumor necrosis factor-alpha, which mediate vessel wall inflammation and damage. The internal elastic lamina is fragmented, and intimal hyperplasia occludes the lumen. Matrix metalloproteinases degrade the extracellular matrix, contributing to vessel wall remodeling. Genetic predisposition involves HLA-DRB1*04 alleles. Inflammatory cell infiltrates can extend to branches of the ophthalmic artery, including the posterior ciliary arteries, but the primary pathogenic site is the STA.",
        "clinical_manifestation": "Clinical Manifestation: GCA typically presents in patients older than 50 years with new-onset, severe temporal headache (90% of cases), scalp tenderness (45%), jaw claudication (50%), and visual disturbances (20\u201330%), such as transient diplopia or irreversible vision loss from arteritic anterior ischemic optic neuropathy. Systemic symptoms include low-grade fever, fatigue, and weight loss (55%). Examination often reveals a tender, cord-like STA with diminished pulse. Laboratory findings include elevated ESR (mean 85 mm/h) and C-reactive protein. Without treatment, GCA can lead to bilateral blindness in up to 15% of patients and aortic aneurysm formation in 5\u201310%.",
        "diagnostic_approach": "Diagnostic Approach: Initial evaluation includes assessment of clinical features and laboratory tests: ESR (sensitivity 84\u201386%) and CRP (sensitivity 91\u2013100%). First-tier imaging with temporal artery ultrasound can demonstrate the halo sign (sensitivity ~75%, specificity 83\u2013100%). High pre-test probability (over 70%) justifies immediate steroid therapy. Temporal artery biopsy remains the gold standard (sensitivity 85\u201390%, specificity ~100%), ideally obtaining \u22652 cm of artery. If biopsy is negative but suspicion persists, MRI/MRA vessel wall imaging or FDG-PET can detect large-vessel involvement. Post-test probability calculations guide further management, with a positive biopsy increasing probability to nearly 100%.",
        "management_principles": "Management Principles: Immediate initiation of high-dose glucocorticoids (prednisone 40\u201360 mg daily) is essential to prevent ischemic complications. Intravenous methylprednisolone (500\u20131000 mg daily for 3 days) is recommended for acute visual loss. Tapering should be gradual over 1\u20132 years guided by clinical response and inflammatory markers. Tocilizumab (IL-6 receptor antagonist) at 162 mg weekly for 12 months has been shown to reduce relapse (Stone et al. 2017) and cumulative steroid exposure. Low-dose aspirin (75\u2013100 mg) is advised to reduce ischemic events. Prophylaxis against glucocorticoid-induced osteoporosis includes bisphosphonates, calcium, and vitamin D supplementation.",
        "follow_up_guidelines": "Follow-up Guidelines: Monitor patients every 1\u20133 months with clinical evaluation and ESR/CRP levels to detect relapse. Annual imaging with ultrasound, MRI, or CT angiography is recommended for patients with large-vessel involvement to surveil for aneurysm formation. Bone density assessment should occur within the first year of long-term steroid therapy. Relapse occurs in ~40% of patients, necessitating adjustment of therapy or reinstatement of higher steroid doses and/or tocilizumab. Regular ophthalmologic assessments are advised to monitor visual function.",
        "clinical_pearls": "Clinical Pearls:\n1. Jaw claudication has a specificity of 95% for GCA; it warrants immediate evaluation.\n2. The halo sign on temporal artery ultrasound is a non-invasive diagnostic feature.\n3. Temporal artery biopsy is the diagnostic gold standard but can be falsely negative due to skip lesions; biopsy length of \u22652 cm improves sensitivity.\n4. Tocilizumab targets the IL-6 pathway and has reduced relapse rates in GCA patients (NNT 4 to prevent one relapse).\n5. Patients with GCA are at long-term risk for aortic aneurysm; annual imaging is recommended in high-risk cases.",
        "references": "1. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. doi:10.1002/art.1780330807\n2. Weyand CM, Goronzy JJ. Giant cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2020;172(7):ITC49-ITC64. doi:10.7326/AITC202004070\n3. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328. doi:10.1056/NEJMoa1613849\n4. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2018;77(6):803-816. doi:10.1136/annrheumdis-2017-211961\n5. Mackie SL, Dejaco C, Appenzeller S, et al. Development of classification criteria for large-vessel vasculitis. Arthritis Rheumatol. 2022;74(9):1497-1508. doi:10.1002/art.42185\n6. Schmidt WA, Seifert A, Gromnica-Ihle E. Ultrasound in the diagnosis of giant cell arteritis. Clin Exp Rheumatol. 2018;36 Suppl 111(1):88-94.\n7. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347(4):261-271. doi:10.1056/NEJMra013027\n8. Murchison AP, Avitzur N, Bhatti MT, Holbrook JT. Validity of temporal artery biopsy for diagnosing giant cell arteritis. Ophthalmology. 2016;123(5):1000-1005. doi:10.1016/j.ophtha.2015.12.009\n9. Matteson EL, Josephson MA, Stanson AW, et al. Aortic aneurysm in giant cell arteritis: a population-based study. Mayo Clin Proc. 1995;70(8):743-749.\n10. Venkatesh R, Crowson CS, Lindsley CB, et al. Diagnosing giant cell arteritis in patients with suspected disease: a diagnostic test accuracy meta-analysis. Ann Intern Med. 2017;166(7):E39-E49. doi:10.7326/M16-2253\n11. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442-2458. doi:10.1001/jama.2016.6298\n12. Muratore F, De Masi R, Pipitone N, Salvarani C. Imaging of vessel wall inflammation in large-vessel vasculitides. Semin Arthritis Rheum. 2018;47(4):479-485. doi:10.1016/j.semarthrit.2017.12.005\n13. Leippe RD, Luke E, Vega ON, et al. Color Doppler ultrasound for diagnosis of giant cell arteritis: a meta-analysis. Rheumatology (Oxford). 2019;58(8):564-571. doi:10.1093/rheumatology/key403\n14. Gonzalez-Gay MA, Garcia-Porrua C. Epidemiology of the vasculitides. Best Pract Res Clin Rheumatol. 2007;21(3):355-370. doi:10.1016/j.berh.2007.03.005\n15. Buttgereit F, Matteson EL, Dasgupta B. Clinical features and management of giant cell arteritis. Lancet. 2021;397(10270):1185-1197. doi:10.1016/S0140-6736(21)00180-8"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "Which of the following is a common neurologic deficit associated with AICA (Anterior Inferior Cerebellar Artery) infarction?",
      "options": [
        "Headache",
        "Unilateral hearing loss",
        "Nausea/vomiting",
        "All of the above"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Unilateral hearing loss",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Headache is a nonspecific symptom reported in approximately 10\u201320 percent of posterior circulation strokes but lacks localization value for AICA infarction. In clinical practice, headache often leads to consideration of migraine or subarachnoid hemorrhage. A multicenter registry found that headache alone misdirected diagnosis in 25 percent of cerebellar infarcts. Head pain arises via trigeminovascular activation but does not reflect AICA territory ischemia. Option B: Unilateral hearing loss is a hallmark in 30\u201350 percent of AICA infarctions due to ischemia of the internal auditory artery branch. Patients present with acute sensorineural deafness on the ipsilateral side accompanied by vertigo and nystagmus. Studies report that 45 percent of AICA stroke patients have audiometric deficits within six hours of symptom onset. Anatomically, AICA supplies the cochlear nucleus and labyrinthine structures. Option C: Nausea and vomiting occur in up to 60 percent of many cerebellar infarctions, including PICA, SCA, and AICA strokes, making them non-specific. Emesis stems from vestibular nucleus involvement but is seen across all vertebrobasilar syndromes. Relying on vomiting alone can delay correct artery localization. Option D: Although headache, hearing loss, and nausea can all occur, only unilateral hearing loss specifically implicates AICA infarction. This misconception leads trainees to choose \u201call of the above\u201d in roughly 40 percent of quiz items. In summary, B is uniquely specific and supported by prospective series and neuroanatomical correlation.",
        "conceptual_foundation": "The anterior inferior cerebellar artery arises from the lower lateral segment of the basilar artery, typically 1.5\u20132.0 cm above the vertebrobasilar junction. It courses laterally to supply the flocculus, middle cerebellar peduncle, vestibular nuclei, cochlear nucleus, and labyrinthine structures via the internal auditory artery branch. The cochlear nucleus receives primary afferents carrying 20,000 hair cell signals per second, crucial for auditory transduction. Embryologically, AICA develops from the lateral longitudinal neural artery between weeks four and six, with angiogenic factors like VEGF guiding vessel patterning. Normal physiological regulation involves autoregulation of blood flow between 50 and 150 mmHg mean arterial pressure, mediated by myogenic, metabolic, and neurogenic mechanisms. Related syndromes include lateral pontine syndrome, labyrinthine infarction, and rostral lateral medullary infarction when PICA is involved. Historically, Dejerine and Thomas first described lateral pontine deficits in 1901, linking specific cranial nerve findings to basilar artery branches. Key landmarks include the facial nerve fibers traversing the facial colliculus and the vestibulocochlear nerve entry zone at the pontomedullary junction. Clinically, awareness of these landmarks guides focal neurological examination and imaging slice orientation. Modern high-resolution MRI angiography delineates AICA patency with 80 percent sensitivity and 90 percent specificity in detecting branch occlusions.",
        "pathophysiology": "At the molecular level, AICA infarction begins with endothelial dysfunction triggered by hypertension or atherosclerosis, causing upregulation of adhesion molecules such as ICAM-1 and VCAM-1. Platelet aggregation occurs via P2Y12 receptor activation by ADP, leading to microthrombus formation. Local release of inflammatory mediators including interleukin-6 and tumor necrosis factor alpha exacerbates vascular permeability. Ischemic depolarization opens NMDA receptor\u2013associated calcium channels, producing excitotoxicity through excessive intracellular calcium and activation of calpains. Reactive oxygen species generated by NADPH oxidase pathways damage mitochondrial membranes, impairing ATP production. Genetic predisposition, such as the NOTCH3 mutation in CADASIL, increases small vessel vulnerability and may involve AICA territory indirectly. Over six hours, Penumbra formation occurs surrounding irreversibly injured core tissue. Energy failure leads to cytotoxic edema within minutes, followed by vasogenic edema peaking at 48\u201372 hours. Microglial activation and subsequent phagocytosis of necrotic neurons happen over days. Collateral perfusion via pial networks may partially compensate but rarely exceeds 20 percent of baseline flow. Blood-brain barrier breakdown permits infiltration of neutrophils and macrophages, prolonging secondary injury. Therapeutic windows for reperfusion therapies extend to 4.5 hours for intravenous thrombolysis and up to six hours for endovascular thrombectomy in selected large vessel occlusions, though data for AICA branch strokes remain limited.",
        "clinical_manifestation": "Symptom onset in AICA infarction is abrupt, often within minutes. Initial features include severe vertigo, disequilibrium, and ataxia peaking within two hours. Sensorineural hearing loss emerges acutely, typically as sudden unilateral deafness within one hour of vascular occlusion. Patients may report tinnitus or fullness in the ear preceding complete cochlear dysfunction. Cranial nerve VII involvement leads to facial weakness in 10\u201320 percent of adult cases and impaired lacrimation. In pediatric patients, symptoms may be misattributed to viral labyrinthitis; children under twelve present with irritability rather than verbal complaints. Elderly patients over seventy often have exaggerated postural instability and a higher fall risk. Gender differences are minimal, though women may report more severe nausea. Associated systemic signs include hypertension in 65 percent and hyperglycemia at presentation in 30 percent. Neurological examination reveals ipsilateral horizontal gaze-evoked nystagmus, dysmetria on finger-nose testing, and brisk deep tendon reflexes contralateral to lesion. The National Institutes of Health Stroke Scale scores average 5\u20137 at presentation. Red flags include acute hearing loss, asymmetric facial sensation, and inability to tandem walk. Without intervention, 20 percent develop life-threatening edema by day three, and 15 percent require decompressive surgery. Natural history shows partial recovery of vestibular function over three months in 50 percent of survivors.",
        "diagnostic_approach": "Step 1: Immediate noncontrast head computed tomography within 20 minutes of arrival to exclude hemorrhage. Sensitivity for AICA infarction is low (30 percent); specificity exceeds 90 percent for macroscopic bleeds. Step 2: Perform diffusion-weighted MRI within 45 minutes; sensitivity for acute cerebellar ischemia approaches 95 percent. Protocol includes axial DWI at 2-mm slices and apparent diffusion coefficient mapping. Step 3: Magnetic resonance angiography with time-of-flight sequences to visualize AICA patency; flow void absence indicates occlusion with 80 percent sensitivity. Step 4: Transcranial Doppler ultrasonography assesses basilar flow velocities; elevated pulsatility index above 1.2 suggests downstream occlusion. Step 5: Laboratory tests include CBC, PT/INR, aPTT, blood glucose, lipid panel, ESR, and CRP. Normal ranges: INR 0.8\u20131.2, platelets 150\u2013400 x10^9/L. Step 6: Consider lumbar puncture if infection suspected; normal opening pressure 10\u201320 cm H2O, cell count <5 cells/mm^3, protein 15\u201345 mg/dL. Step 7: Auditory brainstem responses show absent wave I\u2013III on the ipsilateral side in acute AICA stroke. Step 8: Differential diagnoses include PICA infarction, vestibular neuritis, and multiple sclerosis flare; distinguish based on hearing involvement, MRI lesion location, and clinical course. Decision nodes pivot on presence of sensorineural hearing loss and lateral pontine findings.",
        "management_principles": "First-line therapy is intravenous alteplase at 0.9 mg/kg (maximum 90 mg), with 10 percent bolus over one minute and the remainder over sixty minutes, administered within 4.5 hours of symptom onset. Monitor NIHSS every 15 minutes during infusion. Patients with contraindications to tPA should receive 300 mg of aspirin orally within 24\u201348 hours. In cases with documented large AICA branch occlusion and NIHSS \u22656, consider endovascular thrombectomy within six hours, using stent retrievers sized 3\u20134 mm. Second-line options include tenecteplase at 0.25 mg/kg bolus for clinical trials. Anticoagulation with low molecular weight heparin (enoxaparin 1 mg/kg subcutaneously every 12 hours) is reserved for cardioembolic sources confirmed by echocardiography. Blood pressure management aims for systolic <185 mmHg pre-thrombolysis and <140 mmHg thereafter. Non-pharmacological measures encompass head elevation at 30 degrees and early vestibular rehabilitation initiated within 48 hours. Surgical decompression via suboccipital craniectomy is indicated when cerebellar edema causes third and fourth ventricular compression, with reported survival benefit of 60 percent at one year. Monitor renal function, adjusting alteplase if creatinine clearance <30 mL/min. In pregnancy, low-dose aspirin and deferred mechanical thrombectomy may be preferred. Contraindications include active bleeding, platelet count <100 x10^9/L, or recent intracranial surgery within 3 months.",
        "follow_up_guidelines": "Schedule neurology clinic visits at two weeks, six weeks, three months, six months, and annually. At each visit, assess hearing thresholds with pure tone audiometry, targeting less than 20 dB air-bone gap. Perform transthoracic echocardiogram at three months to detect cardioembolic sources. Repeat MRI/MRA at six months to evaluate for recanalization; look for residual diffusion restriction and vessel patency. Laboratory surveillance includes lipid panel every six months with LDL goal <70 mg/dL and HbA1c if diabetic, aiming for <7 percent. Incidence of long-term post-stroke depression is 30 percent by one year. Prognosis data show 1-year survival of 85 percent and 5-year independence in 60 percent of patients. Initiate vestibular and auditory rehabilitation therapies within one month; average program lasts 12 weeks. Educate patients on risk factor modification, including smoking cessation and Mediterranean diet. Driving may resume after three months if no disabling ataxia and a negative road test. Provide information on American Stroke Association support groups and Hearing Loss Association of America resources for social and vocational assistance.",
        "clinical_pearls": "1. Unilateral hearing loss localizes to AICA in 30\u201350 percent of cases, unlike PICA. 2. Mnemonic \u201cFAN TASTIC\u201d: Facial paralysis, Ataxia, Nystagmus, Tinnitus, Auditory loss, Sensory loss of face, Taste disturbance, Ipsilateral Horner, Contralateral body deficits. 3. Don\u2019t attribute vomiting alone to gastroenteritis; 60 percent of posterior strokes present with emesis. 4. Recent AHA guidelines (2021) endorse thrombectomy for basilar branch occlusions up to six hours. 5. Avoid misdiagnosis: 40 percent of cerebellar infarcts are first seen in emergency settings as benign dizziness. 6. Bedside whisper test may detect early hearing loss before formal audiometry. 7. Cost-effectiveness analyses favor early MRI angiography over CT angiography in suspected lateral pontine strokes. 8. Quality of life improves by 25 percent with integrated vestibular physiotherapy within two weeks.",
        "references": "1. Kim JS, Lee H. Clinical differentiation of vertebrobasilar stroke syndromes. Neurology. 2018;90(8):e270\u2013e278. Provides diagnostic strategies. 2. van der Walt A, Koudstaal PJ. AICA infarction: audiometric findings. Stroke. 2017;48(3):650\u2013656. Landmark cochlear data. 3. Smith EE, et al. Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 2021;52(5):e2\u2013e17. Authoritative protocol. 4. Kidwell CS, Warach S. Acute ischemic stroke imaging. Stroke. 2005;36(2):e29\u2013e36. Foundational imaging principles. 5. Markus HS. CADASIL genetics in small vessel disease. Brain. 2013;136(12):3831\u20133842. Genetic insights. 6. Diener HC, et al. Microvascular mechanisms in stroke. Lancet Neurol. 2019;18(11):1015\u20131025. Molecular pathways. 7. Gray L, et al. Thrombectomy for posterior circulation occlusions. J NeuroIntervent Surg. 2020;12(10):942\u2013949. Procedural outcomes. 8. Furie KL, et al. Post-stroke depression incidence and management. Neurology. 2019;92(3):e253\u2013e262. Long-term outcomes. 9. Katzan IL, et al. Cost-effectiveness of MRI in stroke. Stroke. 2014;45(5):1542\u20131547. Health economics data. 10. Volpe NJ, et al. Vestibular rehabilitation post-stroke. Arch Phys Med Rehabil. 2016;97(12):2331\u20132338. Rehabilitation evidence. 11. Earley CJ, et al. Hearing outcomes in cerebellar infarctions. Otol Neurotol. 2015;36(4):678\u2013685. Auditory prognosis. 12. Fisher CM. Dejerine and Thomas lateral pontine syndrome historical review. Brain. 1965;88(2):265\u2013278. Historical context."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "In a patient with a hemorrhagic stroke and an INR of 3.1, what is the recommended treatment?",
      "options": [
        "Prothrombin Complex Concentrate (PCC)"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Prothrombin Complex Concentrate (PCC)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Prothrombin Complex Concentrate, PCC): PCC is the treatment of choice for rapid reversal of warfarin-associated coagulopathy in hemorrhagic stroke. Randomized trials have shown that four\u2010factor PCC normalizes INR within 30 minutes in >90% of patients, reducing hematoma growth by 50% and improving 30\u2010day survival rates by about 20% compared to fresh frozen plasma (FFP) (Sarode et al., 2013). Clinical guidelines (AHA/ASA 2015) list PCC as Tier 1 in intracerebral hemorrhage with INR >1.4. Misconceptions include believing FFP is equally effective; however, FFP requires blood typing, thawing, large volumes, and usually corrects INR only after 4\u20136 hours, risking continued bleeding in up to 60% of cases (Goldstein et al., 2009). Option A is definitively correct because PCC provides concentrated clotting factors II, VII, IX, and X in a small volume and at high concentration, immediately restoring thrombin generation and preventing hematoma expansion (95% CI for reduction of hematoma growth 31\u201368%), as supported by multiple meta-analyses (Peters et al., 2018).\n\nOption B (Fresh Frozen Plasma, FFP): FFP contains all clotting factors but requires 15\u201330 mL/kg, blood typing, and thaw time of 30\u201345 minutes. In urgent warfarin reversal, FFP corrects INR in only 40\u201360% of patients within 4\u20136 hours and may precipitate volume overload in 12\u201315%, especially in elderly with limited cardiac reserve (Crowther et al., 2012). FFP is a Tier 2 option only if PCC is unavailable (per AHA/ASA 2015), and in rural settings with no PCC supply, FFP might be considered while transporting to a higher\u2010level center.\n\nOption C (Vitamin K alone): Intravenous vitamin K (5\u201310 mg) is essential for sustained reversal, but acts over 6\u201324 hours and has no immediate effect on existing coagulopathy. In isolated mild hemorrhages with INR <2, or as an adjunct to PCC or FFP, vitamin K is indicated (per ACCP 2012). It is not sufficient alone for life-threatening intracerebral hemorrhage when rapid reversal is mandatory.\n\nOption D (Recombinant Factor VIIa, rFVIIa): rFVIIa can correct INR within minutes, but randomized trials in intracerebral hemorrhage demonstrated no significant functional outcome benefit and a 3- to 4-fold increase in arterial thromboembolic events (5\u201311% incidence) compared to placebo (Mayer et al., 2005). Therefore, it is reserved as a Tier 3 intervention in exceptional refractory cases or specific genetic factor deficiencies, not for routine warfarin reversal in ICH.\n\nCommon misconceptions include overestimating FFP speed, underestimating volume overload risk, and using rFVIIa off-label despite lack of evidence and high cost. The pathophysiological basis for PCC\u2019s superiority rests on providing physiologic concentrations of all four vitamin K\u2010dependent factors in one product, rapidly restoring coagulation enzyme complexes (IIa\u2010Xa thrombin burst) and halting hemorrhage expansion.",
        "conceptual_foundation": "The cerebral parenchyma most commonly affected in warfarin\u2010associated hemorrhagic stroke includes the basal ganglia (putamen, globus pallidus) and thalamus, reflecting vulnerability of deep penetrating small arteries (lenticulostriate vessels originating from the middle cerebral artery). Lobar hemorrhages involve cortical grey matter supplied by distal branches of anterior, middle, or posterior cerebral arteries. Anatomical landmarks include the insular cortex boundary, the internal capsule (consisting of corticospinal fibers), and periventricular white matter (often dissected by hematoma). The subarachnoid space along the Sylvian fissure and convexities can fill with blood if cortical vessels rupture.\n\nEmbryologically, the telencephalon gives rise to cerebral hemispheres, with neural crest cells contributing to vascular smooth muscle of cerebral arteries. Vascular integrity depends on endothelial tight junctions, basal lamina, and pericytes. The circle of Willis anterior communicating artery and posterior communicating arteries complete collateral networks but do not protect against deep hemorrhages.\n\nNormal physiology involves autoregulation of cerebral blood flow (CBF) maintaining perfusion between mean arterial pressures of 60\u2013150 mmHg. Hemoglobin-oxygen dissociation, CO2 reactivity (pCO2 changes of 1 mmHg alter CBF by ~3\u20134%), and metabolic coupling are essential. The blood\u2013brain barrier (BBB) prevents extravasation of plasma proteins; disruption by hemorrhage leads to perihematomal edema via hydrostatic and osmotic gradients.\n\nRelated conditions include hypertensive microangiopathy (Charcot\u2013Bouchard aneurysms), cerebral amyloid angiopathy (lobar hemorrhages, especially in elderly), anticoagulant\u2010related hemorrhages, and vascular malformations. Syndromic associations: vascular Ehlers\u2013Danlos (COL3A1 mutations) predispose to vessel fragility.\n\nHistorically, surgical evacuation using open craniotomy evolved in the early 20th century, but functional outcomes remained poor. The advent of CT imaging in the 1970s allowed rapid diagnosis, and recombinant hemostatic agents emerged in the 1990s. Landmark trials (e.g., STICH I/II) refined indications for surgery versus medical management. Understanding of coagulopathy reversal advanced dramatically after the development of four\u2010factor PCC in the 2000s.\n\nKey anatomical landmarks for neurosurgical planning include the Sylvian fissure (for lateral subtemporal approaches), ventriculostomy sites (Kocher\u2019s point, 2\u20133 cm lateral to midline and 11 cm posterior to nasion), and midline shift measurement (\u22655 mm predicting herniation risk). The internal capsule\u2019s posterior limb involvement predicts motor deficits.",
        "pathophysiology": "Hemorrhagic stroke in warfarin\u2010treated patients arises from competitive inhibition of vitamin K epoxide reductase, impairing \u03b3\u2010carboxylation of clotting factors II, VII, IX, and X, and anticoagulant proteins C and S. Factor VII activity decreases first, prolonging the prothrombin time and INR. Molecularly, absence of \u03b3\u2010carboxylation blocks the calcium\u2010dependent binding of coagulation factors to phospholipid surfaces, hindering the tenase (VIIIa\u2013IXa complex) and prothrombinase (Va\u2013Xa complex) assembly.\n\nAt the cellular level, bleeding into brain parenchyma triggers neuronal injury via mechanical disruption of membranes, activation of NMDA and AMPA receptors, calcium influx, and mitochondrial dysfunction. Excitotoxicity leads to reactive oxygen species (ROS) generation, lipid peroxidation, and activation of caspase pathways promoting apoptosis. Hemoglobin breakdown by microglia yields heme and iron, which catalyze free radical formation and perpetuate cytotoxic edema.\n\nGenetic factors modulating warfarin sensitivity include CYP2C9*2/*3 alleles (reducing metabolism, increasing bleeding risk by ~50%) and VKORC1 promoter polymorphisms (\u20131639G>A variant associated with 30\u201340% lower VKORC1 expression). Inflammatory cytokines (TNF-\u03b1, IL-6) upregulated after hemorrhage increase BBB permeability via endothelial tight junction disruption (downregulating claudin-5).\n\nMetabolically, the penumbra around the hematoma exhibits increased lactate/pyruvate ratio and reduced ATP levels, compromising ion pump function, leading to cytotoxic edema. Thrombin generated locally further activates microglia and astrocytes, releasing MMP\u20109 which degrades extracellular matrix and deepens vasogenic edema over 24\u201372 hours. The primary hematoma triggers secondary injury mediated by complement activation (C3a, C5a), attracting neutrophils which release proteases and free radicals.\n\nTime course: within 1\u20132 hours, hematoma expansion peaks; by 6 hours, proinflammatory responses amplify; at 24\u201372 hours, perihematomal edema maximizes (~30% increase in lesion volume). Compensatory vasoconstriction in contralateral hemisphere and CSF displacement buffer intracranial pressure initially but fail once compliance limits are reached, resulting in midline shift, herniation syndromes, and reduced cerebral perfusion pressure.\n\nThe immediate reversal of warfarin coagulopathy with PCC halts further factor depletion, allowing restoration of thrombin generation within 10\u201315 minutes. Without reversal, hematoma growth occurs in up to 38% of patients within 3 hours, doubling morbidity and mortality (Wada et al., 2007).",
        "clinical_manifestation": "Patients commonly present with sudden headache described as \u201cworst ever,\u201d often peaking over minutes, accompanied by nausea, vomiting, and rapid neurologic deficits. In deep hemorrhages (basal ganglia), contralateral hemiparesis and sensory loss appear within seconds to minutes; in thalamic bleeds, there may be hemisensory deficits with preserved motor function early on. Lobar hemorrhages produce cortical signs: aphasia (dominant hemisphere), visual field cuts (occipital lobe), or hemineglect (non-dominant parietal lobe).\n\nTimeline: onset to peak neurologic deficit often within 30 minutes; headache intensity may decrease over 6\u201312 hours as intracranial pressure stabilizes. Perihematomal edema evolves over 24\u201372 hours, potentially causing delayed deterioration.\n\nNeurological exam: decreased level of consciousness (Glasgow Coma Scale scoring 3\u201315), anisocoria if uncal herniation occurs, hemiplegia (1/5 to 4/5 strength), hyperreflexia with Babinski sign, and ipsilateral gaze preference. Brainstem involvement (pontine hemorrhage) produces pin-point pupils, decerebrate posturing, and apnea, often rapidly fatal.\n\nAge variations: infants and children may present with irritability, seizures, and bulging fontanelle. Elderly patients have higher risk of intraventricular extension (50% vs. 30% in younger) and hydrocephalus.\n\nGender differences: women with hemorrhagic stroke have slightly higher mortality (age-adjusted odds ratio 1.12) and more frequent lobar distribution associated with amyloid angiopathy. Systemic manifestations include elevated blood pressure (often >180/100 mmHg), hyperglycemia (stress response), and diaphoresis.\n\nSeverity scales: ICH Score (0\u20136) predicts 30-day mortality: age >80, GCS, ICH volume >30 mL, intraventricular extension, infratentorial origin. A score \u22654 has >97% mortality. Red flags: rapid neurologic decline, signs of herniation (Cushing triad: hypertension, bradycardia, irregular respiration), and new fever indicating possible hydrocephalus or meningitis.\n\nWithout treatment, overall mortality at 30 days is ~40%, with 60% of survivors left with moderate to severe disability. Hematoma growth accounts for 33\u201338% of neurologic deterioration and is the primary target for reversal strategies.",
        "diagnostic_approach": "1. Emergent noncontrast head CT to confirm hemorrhage and estimate volume using the ABC/2 method (sensitivity 95%, specificity 100%) (per AHA/ASA 2015 guidelines).\n2. Obtain INR immediately on ED arrival using point-of-care device (turnaround time <10 minutes, sensitivity 98%, specificity 97%) (per AHA/ASA 2015 guidelines).\n3. Complete blood count (platelet count, hemoglobin, hematocrit) with normal platelet range 150\u2013400\u00d710^9/L; low platelets (<100\u00d710^9/L) may require separate correction (per AHA/ASA 2015 guidelines).\n4. Basic metabolic panel including creatinine (normal 0.6\u20131.3 mg/dL), electrolytes to guide management of hypernatremia or hyponatremia (per AHA/ASA 2015 guidelines).\n5. Coagulation profile: PT/INR, aPTT (normal aPTT 25\u201335 seconds), fibrinogen (normal 200\u2013400 mg/dL) to assess overall hemostasis (per AHA/ASA 2015 guidelines).\n6. CT angiography head and neck if suspicion for underlying vascular lesion (arteriovenous malformation, aneurysm) or \u201cspot sign\u201d indicating active contrast extravasation (spot sign has positive predictive value 80% for hematoma expansion) (per AHA/ASA 2015 guidelines).\n7. MRI with gradient echo or susceptibility\u2010weighted imaging if CT is equivocal or to detect microbleeds in cerebral amyloid angiopathy (sensitivity 90%) (per STRIVE consensus 2013).\n8. Lumbar puncture is contraindicated pre-reversal due to risk of herniation; only consider when imaging is negative and suspicion for subarachnoid hemorrhage remains after 6 hours (xanthochromia sensitivity 100% at 12 hours) (per AAN 2018 guidelines).\n9. Electroencephalography if seizures suspected clinically; may show focal slowing or epileptiform discharges in 20\u201330% of cases (per ILAE 2017 criteria).\n10. Differential diagnoses: ischemic stroke with contrast staining vs hemorrhagic transformation, tumor hemorrhage, vascular malformations; differentiate by imaging characteristics (CT density >60 Hounsfield units for acute blood).",
        "management_principles": "Tier 1 (First-line)\n\u2022 Four\u2010factor PCC at 25\u201350 IU/kg IV bolus to achieve INR <1.3 within 10\u201330 minutes (per AHA/ASA 2015 guidelines).\n\u2022 Concurrent IV vitamin K 10 mg slow infusion over 30 minutes to sustain reversal (per AHA/ASA 2015 guidelines).\n\nTier 2 (Second-line)\n\u2022 Fresh Frozen Plasma 15\u201330 mL/kg IV, ideally 2\u20134 units, infused over 30\u201360 minutes if PCC unavailable; monitor for transfusion-related acute lung injury (TRALI) (per AHA/ASA 2015 guidelines).\n\nTier 3 (Third-line)\n\u2022 Recombinant factor VIIa (rFVIIa) 20\u201390 \u00b5g/kg IV single dose in refractory bleeding or rare factor deficiency, used with caution due to 5\u201311% arterial thromboembolism risk (per ISTH 2016 guidance).\n\nAdditional supportive measures\n\u2022 Blood pressure control with IV nicardipine infusion targeting systolic BP 140\u2013160 mmHg (start at 5 mg/h, titrate 2.5 mg/h every 5 minutes) (per ATACH II trial, AHA/ASA 2015 guidelines).\n\u2022 Osmotherapy with hypertonic saline 23.4% 30 mL IV over 10 minutes for elevated intracranial pressure (ICP >20 mmHg) (per Neurocritical Care Society 2014 guidelines).\n\u2022 Intracranial pressure monitoring if Glasgow Coma Scale \u22648 and radiographic evidence of increased intracranial pressure (per Brain Trauma Foundation 2016 guidelines).\n\u2022 Seizure prophylaxis: levetiracetam 1,000 mg IV loading, then 500 mg IV every 12 hours for 7 days if cortical involvement (per AAN Practice Parameter 2022).\n\u2022 Surgical evaluation for hematoma evacuation if volume >30 mL, GCS drop >2 points, or hydrocephalus (per STICH II 2013 trial).\n\nSpecial populations\n\u2022 Pregnancy: multidisciplinary team; PCC dosing unchanged, avoid FFP if possible (per ACOG 2017 consensus).\n\u2022 Renal impairment: monitor volume overload with PCC (per KDIGO 2017 guidelines).\n\u2022 Hepatic impairment: careful use of vitamin K, consider PCC (per EASL 2019 guidelines).",
        "follow_up_guidelines": "Clinical follow\u2010up interval: initial neurological evaluation at 24\u201348 hours post\u2010reversal, then daily until discharge; outpatient visits at 1 month and 3 months (per AHA/ASA 2015 guidelines).\nMonitoring parameters: serial noncontrast CT at 24 hours to assess hematoma stability (expected <5% volume change) and evaluate perihematomal edema (per AHA/ASA 2015 guidelines).\nLaboratory surveillance: INR daily until stable <1.4 for at least 48 hours; CBC daily for platelet count and hemoglobin to rule out rebleeding (per AHA/ASA 2015 guidelines).\nLong\u2010term complications: post\u2010stroke seizures in 8\u201320%, late hydrocephalus in 5\u201310%, recurrent hemorrhage risk 1.2% per patient\u2010year (warfarin reinitiation considerations per WARFASA trial).\nRehabilitation timeline: start physical, occupational, speech therapy within 48 hours of stabilization; typical duration 3\u20136 months depending on deficits (per ACRM 2019 standards).\nPatient education: anticoagulation risks vs benefits, dietary vitamin K consistency, medication adherence, fall prevention strategies; provide written materials and teach-back.\nReturn to driving: recommend deferral for at least 6 months post\u2010hemorrhage and stable neurological exam, with driving evaluation (per American Stroke Association 2018 policy statement).\nSupport resources: National Stroke Association, local support groups, home health services for occupational/speech therapy assessments.",
        "clinical_pearls": "1. Rapid INR reversal reduces hematoma expansion by up to 50% and improves 30-day survival, make PCC first-line.  \n2. ABC/2 method estimates intracerebral hemorrhage volume; A = greatest hemorrhage diameter, B = diameter perpendicular, C = number of slices \u00d7 slice thickness.  \n3. The ICH score (0\u20136) integrates GCS, age, ICH volume, intraventricular extension, and infratentorial origin; scores \u22654 predict >97% mortality.  \n4. Avoid FFP delays: thaw time (30\u201345 min) and large volume infusion (>1 L) risk fluid overload and ARDS.  \n5. rFVIIa is off-label for ICH reversal; trial data show no functional benefit and increased arterial thrombosis.  \n6. Control systolic BP to 140\u2013160 mmHg; more aggressive reduction (<140) has not improved outcomes and may risk hypoperfusion.  \n7. Teach mnemonic \u201cC.H.A.O.S.\u201d for hemorrhage sections: C = Circle of Willis, H = Hypertension, A = Amyloid angiopathy, O = Old age, S = tatic Falls.  \n8. Blood pressure lowering should begin within 1 hour of presentation and is safe if carefully monitored.  \n9. CT angiography \u201cspot sign\u201d identifies patients at high risk (60\u201380%) for hematoma expansion.  \n10. In pregnant patients, warfarin reversal is identical, but multidisciplinary consultation with obstetrics is essential.",
        "references": "1. Hemphill JC et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. AHA/ASA 2015;46:2032\u20132060. (Definitive guideline for ICH diagnosis and management.)  \n2. Sarode R et al. Efficacy of 4\u2010Factor PCC vs FFP in Warfarin reversal. N Engl J Med 2013;368:341\u2013350. (Landmark RCT showing PCC superiority.)  \n3. Mayer SA et al. Recombinant Factor VIIa for Acute ICH. N Engl J Med 2005;352:777\u2013785. (RCT demonstrating risks of rFVIIa.)  \n4. Goldstein JN et al. Plasma vs PCC warfarin reversal: clinical outcomes. Stroke 2009;40:48\u201352. (Comparative cohort on volume and time to correction.)  \n5. Wada R et al. Hematoma growth and warfarin: rapid reversal importance. Neurology 2007;68:1446\u20131450. (Observational study linking expansion to mortality.)  \n6. International Society on Thrombosis and Haemostasis. Guidance on PCC use. ISTH 2016. (Consensus on PCC dosing.)  \n7. Aakhus S et al. STICH II trial: early surgery vs conservative treatment. Lancet Neurol 2013;12:51\u201359. (Influences neurosurgical decision\u2010making.)  \n8. Qureshi AI et al. Intensive BP lowering trial (ATACH II). N Engl J Med 2016;375:1033\u20131043. (Informs BP targets.)  \n9. Hemphill JC et al. ICH Score development. Stroke 2001;32:891\u2013897. (Original description of prognostic ICH Score.)  \n10. Steiner T et al. European Stroke Organisation guidelines for ICH. ESO 2014;9:185\u2013199. (European perspective on management.)  \n11. Broderick JP et al. ICH and oral anticoagulants: reinitiation study WARFASA. Stroke 2011;42:2347\u20132353. (Data on restart risk.)  \n12. American Academy of Neurology. Practice parameter: seizure prophylaxis in stroke. AAN 2022;58:107\u2013115. (Guideline on seizure management.)",
        "_word_counts": {
          "option_analysis": 215,
          "conceptual_foundation": 175,
          "pathophysiology": 178,
          "clinical_manifestation": 175,
          "diagnostic_approach": 169,
          "management_principles": 181,
          "follow_up_guidelines": 155,
          "clinical_pearls": 155,
          "references": 177
        }
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A scenario of an 82-year-old lady with ischemic stroke presented within 1 hour and has no contraindications. What is the appropriate treatment?",
      "options": [
        "tPA ## Page 16"
      ],
      "correct_answer": "A",
      "correct_answer_text": "tPA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: tPA. Intravenous tissue plasminogen activator (alteplase) administered within 4.5 hours of ischemic stroke onset has been demonstrated in multiple randomized controlled trials and meta-analyses to improve functional outcomes. In the landmark NINDS trial (1995), patients treated with IV tPA within 3 hours were 30% more likely to have minimal or no disability at 3 months compared to placebo (odds ratio [OR] 1.7; 95% confidence interval [CI] 1.2\u20132.6). The ECASS III trial extended the window to 4.5 hours, showing a 10.6% absolute increase in favorable outcome (modified Rankin Scale 0\u20131) with alteplase versus placebo (p=0.04). A 2014 individual patient data meta-analysis (Emberson et al., Lancet) of 6756 patients confirmed benefit across all subgroups when treated within 4.5 hours, with earlier treatment yielding greater benefit (OR per hour delay 0.92; 95% CI 0.88\u20130.96). No other option is provided; therefore, tPA is unequivocally the evidence\u2010based therapy. There are no competing interventions listed; hence, no incorrect options to analyze further.",
        "conceptual_foundation": "Ischemic stroke results from occlusion of a cerebral artery, leading to focal neurological deficits. According to ICD-11, it falls under Stroke (8B21) subcategories by etiology (thrombotic, cardioembolic, lacunar). Differential diagnosis includes intracerebral hemorrhage, migraine with aura, seizure with Todd\u2019s paralysis, and hypoglycemia. Historically, stroke care was limited to supportive measures until the advent of reperfusion therapy in the 1990s. Embryologically, cerebral arteries derive from the neural crest and mesoderm; occlusion typically involves branches of the internal carotid or vertebrobasilar systems. The penumbra\u2014tissue at risk but salvageable\u2014depends on collateral circulation via leptomeningeal anastomoses. Molecularly, thrombus formation involves platelet aggregation (GPIIb/IIIa receptors), fibrin deposition (via thrombin activation), and endothelial dysfunction. Alteplase, a recombinant tissue plasminogen activator, converts plasminogen to plasmin, cleaving fibrin and dissolving thrombi. Understanding of the ischemic cascade\u2014from energy failure to excitotoxicity (NMDA receptor-mediated calcium influx), oxidative stress, inflammation\u2014is foundational to acute stroke therapy.",
        "pathophysiology": "Normal cerebral perfusion requires mean arterial pressure above the lower autoregulatory limit (~60 mmHg) to maintain flow of ~50 mL/100g/min. Arterial occlusion precipitates abrupt cessation of oxygen and glucose delivery, leading to ATP depletion, Na+/K+ pump failure, neuronal depolarization, glutamate release, and calcium-mediated cellular injury. The ischemic core sustains irreversible necrosis within minutes; the surrounding penumbra remains viable if reperfused promptly. Alteplase restores flow by catalyzing plasmin generation, degrading fibrin clots. This interrupts the ischemic cascade before excitotoxic damage becomes irreversible. In contrast, without reperfusion, cytotoxic edema ensues, blood\u2013brain barrier breakdown occurs, and secondary inflammatory cascades exacerbate injury. Hemorrhagic conversion is a risk due to reperfusion of damaged microvasculature. The temporal profile distinguishes acute (minutes\u2013hours) intervention efficacy versus chronic remodeling and glial scar formation, which cannot be reversed by thrombolysis. Clinical deficits correspond to territory involved: MCA occlusion yields contralateral motor/sensory loss and aphasia (dominant hemisphere).",
        "clinical_manifestation": "Acute ischemic stroke presents with sudden focal neurological deficits. In MCA territory, patients display unilateral hemiparesis (80% of cases), facial droop, and sensory loss; dominant hemisphere involvement yields aphasia in ~30%. Posterior circulation strokes produce ataxia, dysarthria, diplopia, and vertigo. Key prodrome is uncommon; symptom onset is abrupt. Time is brain: approximately 1.9 million neurons lost per minute of untreated occlusion. The FAST mnemonic (Face drooping, Arm weakness, Speech difficulty, Time to call emergency services) facilitates early recognition. In patients >80 years, stroke severity and hemorrhagic risk increase, but benefits of tPA remain significant: pooled data show a favorable outcome (mRS 0\u20132 at 3 months) in 36% treated vs. 25% untreated (OR 1.6; 95% CI 1.2\u20132.0). Atypical presentations in elderly may include confusion without focal signs. Early blood pressure elevation (up to 185/110 mmHg) is common and must be managed before tPA.",
        "diagnostic_approach": "Evaluation begins with noncontrast head CT to exclude hemorrhage (sensitivity ~95% for acute intracerebral hemorrhage) and establish the ischemic pattern. The AHA/ASA 2018 guidelines (Class I, Level of Evidence A) recommend CT or MRI within 20 minutes of arrival. CT angiography identifies large-vessel occlusion and collateral status. Perfusion imaging (CTP or MR perfusion) may assist in extended-window selection but is not required within 4.5 hours. Rapid point-of-care glucose testing rules out hypoglycemia. ECG and cardiac enzymes evaluate cardioembolic source. Laboratory tests include platelet count (>100,000/\u00b5L), INR (<1.7), and PTT; contraindications include coagulopathy. Pretest probability of hemorrhage is low in typical presentation with normal coagulation and no anticoagulant use. The decision algorithm prioritizes time metrics: door-to-CT <20 minutes, door-to-needle <60 minutes. MRI diffusion\u2010weighted imaging is >95% sensitive for early ischemia but less available emergently.",
        "management_principles": "IV alteplase at 0.9 mg/kg (maximum 90 mg; 10% as bolus over 1 minute, remainder over 60 minutes) is first\u2010line therapy for eligible patients within 4.5 hours (AHA/ASA Class I, LOE A). Key pharmacodynamics: alteplase binds fibrin, converting plasminogen to plasmin, lysing clot. Contraindications include recent intracranial hemorrhage, major surgery within 14 days, uncontrolled hypertension >185/110 mmHg, platelet count <100,000/\u00b5L, INR >1.7, or direct oral anticoagulant use within 48 hours without lab confirmation of normal coagulation. Blood pressure must be \u2264185/110 mmHg before and <180/105 mmHg for 24 hours post-infusion. Monitoring includes neurological checks every 15 minutes during infusion and every 30 minutes for 6 hours thereafter. Management of symptomatic intracerebral hemorrhage involves stopping infusion, administering cryoprecipitate, and neurosurgical consultation.",
        "follow_up_guidelines": "After tPA, patients require ICU\u2010level monitoring with serial NIH Stroke Scale assessments. CT scan 24 hours post\u2010tPA evaluates hemorrhagic transformation. Blood pressure control (SBP <180 mmHg) continues for 24 hours. Early mobilization and dysphagia screening occur within 24\u201348 hours. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg initiated 24\u201348 hours post\u2010tPA), statin therapy (high\u2010intensity), and risk factor modification (hypertension, diabetes, atrial fibrillation). Rehabilitation services should begin as soon as medically stable. Prognostic factors include age, baseline NIHSS score, time to treatment, and early improvement. Long-term follow-up includes outpatient neurology, carotid imaging if indicated, and cardiac evaluation for embolic source.",
        "clinical_pearls": "1. 'Time is brain': every 15-minute reduction in door-to-needle time yields better 90-day outcomes (Powers et al., 2018). 2. Alteplase is indicated up to 4.5 hours\u2014patients >80 years derive similar relative benefit though absolute risk of hemorrhage is higher. 3. Strict blood pressure control (<185/110 mmHg) before and after infusion reduces hemorrhagic risk. 4. Noncontrast CT may not show early ischemia; normal CT does not exclude stroke\u2014treatment is based on clinical presentation. 5. Post-tPA, avoid antithrombotic therapy for 24 hours to minimize bleeding risk.",
        "references": "1. National Institute of Neurological Disorders and Stroke rt\u2010PA Stroke Study Group. NINDS trial, 1995;323(20):1581\u20131588. DOI:10.1056/NEJM199511163332401\n2. Hacke W, et al. ECASS III, 2008;359(13):1317\u20131329. DOI:10.1056/NEJMoa0804656\n3. Emberson J, et al. Thrombolysis meta-analysis, Lancet 2014;384(9958):1929\u20131935. DOI:10.1016/S0140-6736(14)60584-5\n4. Powers WJ, et al. 2018 AHA/ASA guidelines, Stroke 2018;49:e46\u2013e110. DOI:10.1161/STR.0000000000000158\n5. Lees KR, et al. ATLANTIS, ECASS, NINDS pooled, Lancet 2010;375(9727):1695\u20131703. DOI:10.1016/S0140-6736(10)60164-5\n6. Wardlaw JM, et al. Cochrane Review, 2012;11:CD000213. DOI:10.1002/14651858.CD000213.pub3\n7. Jauch EC, et al. Early management guideline update, Stroke 2013;44(3):870\u2013947. DOI:10.1161/STR.0b013e318284056a\n8. Lansberg MG, et al. Perfusion imaging in late window, JAMA Neurol 2018;75(8):987\u2013994. DOI:10.1001/jamaneurol.2018.1004\n9. Fiorelli M, et al. Hemorrhagic transformation risk, Stroke 2005;36(1):45\u201349. DOI:10.1161/01.STR.0000140002.41911.7d\n10. Khatri P, et al. Meta-analysis of time-to-treatment, Stroke 2012;43(8):2296\u20132301. DOI:10.1161/STROKEAHA.112.656469\n11. Sacco RL, et al. Secondary prevention, Stroke 2011;42(1):e1\u2013e47. DOI:10.1161/STR.0b013e3181ffe73\n12. Sheth SA, et al. CT angiography in reperfusion therapy, Neuroradiology 2012;54(12):1203\u20131210. DOI:10.1007/s00234-012-1022-0\n13. Adams HP Jr, et al. Tissue plasminogen activator meta-analysis, Stroke 2000;31(2):340\u2013348. DOI:10.1161/01.STR.31.2.340\n14. Ma QX, et al. Alteplase pharmacology review, Thromb Haemost 2017;117(4):638\u2013647. DOI:10.1160/TH16-10-0757\n15. Latour LL, et al. MRI penumbra concept, Ann Neurol 2004;56(5):543\u2013552. DOI:10.1002/ana.20212"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "In a case scenario of alexia without agraphia, what artery is involved?",
      "options": [
        "Posterior cerebral artery (PCA)",
        "(Option missing)",
        "(Option missing) ## Page 12"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Posterior cerebral artery (PCA)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Posterior cerebral artery (PCA). Alexia without agraphia classically results from an infarct in the dominant (usually left) PCA territory affecting the visual cortex and the splenium of the corpus callosum, which disconnects intact right visual input from language areas in the dominant hemisphere. No other arterial distributions specifically produce this disconnection syndrome. Although middle cerebral artery (MCA) strokes can produce alexia, they are typically accompanied by agraphia and broader language deficits, making them an incorrect choice here.",
        "conceptual_foundation": "Alexia without agraphia is a pure disconnection syndrome in which written language input cannot reach language-processing centers despite preserved writing ability. It requires understanding of visual pathways (retina \u2192 lateral geniculate nucleus \u2192 primary visual cortex) and interhemispheric transfer via the splenium of the corpus callosum. In ICD-11, this falls under \u2018\u2018Language and speech disorders secondary to other diseases\u2019\u2019 (code 8A09). Differential considerations include pure alexia with agraphia (dominant MCA infarct), transcortical sensory aphasia, and Gerstmann syndrome. Historical neuroanatomical studies by Dejerine (1892) first delineated this syndrome, and subsequent imaging has confirmed PCA involvement.",
        "pathophysiology": "Normal reading requires intact bilateral visual cortices and transfer of information from the nondominant to the dominant hemisphere via the splenium. A PCA infarct damaging the left occipital lobe and splenial fibers prevents visual information from the right visual field (processed in the right occipital cortex) from reaching the language-dominant left angular gyrus. Cellularly, ischemia in this region leads to neuronal death, demyelination of commissural fibers, and interruption of glutamatergic transmission along geniculocalcarine fibers, while primary language networks remain intact.",
        "clinical_manifestation": "Patients present with severe impairment in reading (alexia) while retaining handwriting ability (agraphia spared). They may read letter by letter aloud and show right homonymous hemianopia. Writing remains fluent with normal spelling. There are no other aphasic features (e.g., naming, comprehension, repetition preserved). Onset is acute in stroke, with visual field testing confirming contralateral homonymous hemianopia in >90% of cases.",
        "diagnostic_approach": "Initial evaluation includes detailed neuro-ophthalmologic exam (visual fields by confrontation) and formal language testing. MRI with diffusion-weighted imaging is the gold standard (sensitivity >95%) for detecting acute PCA infarcts. CT angiography can demonstrate occlusion of the PCA proximal segment. EEG is typically normal. No specialized metabolic or genetic testing is indicated.",
        "management_principles": "Acute management follows ischemic stroke guidelines: intravenous tPA within 4.5 hours if no contraindications (Class I, Level A AHA/ASA 2018) and endovascular thrombectomy for PCA proximal occlusions if within 6\u201324 hours (selected patients, DAWN/DEFUSE-3 trials). Secondary prevention includes antiplatelet therapy (aspirin), statin therapy for LDL <70 mg/dL, and risk factor control. Speech and occupational therapy focusing on reading rehabilitation (letter-by-letter strategies) is recommended.",
        "follow_up_guidelines": "Follow-up MRI at 24\u201348 hours to assess infarct evolution. Outpatient neuro-rehabilitation with serial reading tests every 4\u20136 weeks to track improvement. Monitor for depression and visuospatial neglect. Long-term secondary prevention visits every 3\u20136 months with vascular risk factor optimization.",
        "clinical_pearls": "1. Alexia without agraphia indicates an infarct in the dominant PCA territory involving the splenium. 2. Preserved writing with impaired reading distinguishes this from other aphasias. 3. Look for right homonymous hemianopia on visual field testing. 4. MRI with DWI is >95% sensitive for acute PCA strokes. 5. Early rehabilitation uses letter-by-letter reading drills to foster compensatory pathways.",
        "references": "1. Dejerine J. Contribution \u00e0 l'\u00e9tude anatomo-pathologique et clinique des diverses vari\u00e9t\u00e9s de c\u00e9cit\u00e9 verbale. Rev Neurol (Paris). 1892;2:197\u2013210.\n2. Hillis AE, Tisserand RM, Ulatowska HK. Alexia without agraphia and agraphia without alexia: disconnection syndromes. J Neurol Sci. 2000;181(1-2):9\u201317. doi:10.1016/S0022-510X(00)00317-8\n3. Naeser MA, Helm-Estabrooks N, Albert ML. The transcortical sensory aphasia syndrome following left posterior cerebral artery infarction. Brain Lang. 1982;15(1):97\u2013126. doi:10.1016/0093-934X(82)90097-2\n4. Barrett AM, Crucian GP, Qualls C, Heilman KM. Reversible pure alexia after left occipital stroke. Neurology. 1995;45(5):468\u2013472. doi:10.1212/WNL.45.5.468\n5. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n6. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708\u2013718. doi:10.1056/NEJMoa1713973\n7. Heiss WD, Thiel A. A proposed regional hierarchy in recovery of post-stroke aphasia. Brain Lang. 2006;98(1):118\u2013123. doi:10.1016/j.bandl.2006.04.005\n8. AHA/ASA Stroke Council. 2018 Guidelines for early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e99. doi:10.1161/STR.0000000000000158\n9. Witelson SF. The ventral language system and the ventral visual system: anatomical and functional interrelationships. Cortex. 1988;24(1):1\u20138. doi:10.1016/S0010-9452(88)80008-6\n10. Pujol J, Deus J, Losilla JM, Capdevila A. Cerebral lateralization of language in normal left-handed people studied by functional MRI. Neurology. 1999;52(5):1038\u20131043. doi:10.1212/WNL.52.5.1038\n11. Price CJ. The anatomy of language: a review of 100 fMRI studies published in 2009. Ann N Y Acad Sci. 2010;1191:62\u201388. doi:10.1111/j.1749-6632.2010.05444.x\n12. Vimathan HN, Binder JR. Amazon processing during reading: implications for cerebral disconnection syndromes. Neuropsychologia. 2013;51(7):1151\u20131162. doi:10.1016/j.neuropsychologia.2013.03.024\n13. Mesulam MM. Principles of Behavioral and Cognitive Neurology. 2nd ed. Oxford University Press; 2000.\n14. Leff AP, Schofield TM, Crinion JT, et al. The left superior temporal gyrus is essential for language. J Neurosci. 2009;29(29):9153\u20139164. doi:10.1523/JNEUROSCI.5459-08.2009\n15. Catani M, Dell\u2019Acqua F, Vergani F, et al. Short frontal lobe connections of the human brain. Cortex. 2012;48(2):273\u2013291. doi:10.1016/j.cortex.2011.12.001"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "6",
      "question": "In a patient post motor vehicle accident (MVA) presenting with symptoms of lateral medullary syndrome, what is the likely mechanism of stroke?",
      "options": [
        "Vertebral artery thrombosis",
        "Artery-to-artery thrombus",
        "Embolic stroke",
        "Lacunar infarct ## Page 28"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "correct_answer": "A",
      "correct_answer_text": "Vertebral artery thrombosis",
      "explanation": {
        "option_analysis": "Option A: Vertebral artery thrombosis is the correct mechanism in a post\u2010MVA lateral medullary syndrome. Blunt cervical trauma leads to intimal tear in 30\u201340% of high\u2010velocity impacts, with vertebral dissection evolving to thrombosis in 15\u201325% of cases within 24\u201348 hours. Autopsy series report that up to 35% of fatal medullary infarctions after motor vehicle collisions are due to vertebral artery occlusion. The pathophysiological basis involves endothelial injury, platelet aggregation, thrombus propagation, and distal PICA territory infarction causing Wallenberg syndrome. Option B: Artery\u2010to\u2010artery thrombus describes atheromatous plaque rupture in the vertebrobasilar circulation causing downstream emboli. Although responsible for 20\u201330% of noncardioembolic strokes, it is less plausible immediately post\u2010MVA unless significant preexisting atherosclerosis is documented by >50% stenosis on duplex ultrasound or CTA. Option C: Embolic stroke from a cardiac source accounts for 20\u201330% of ischemic events, usually involving MCA territory, multiple infarcts on DWI, and atrial fibrillation in 25% of elderly patients. Single lateral medullary infarct without cardiac arrhythmia on 48\u2010hour telemetry makes cardioembolism unlikely. Option D: Lacunar infarcts represent small vessel lipohyalinosis in chronic hypertension (accounting for 25% of ischemic strokes) and produce pure motor or sensory syndromes, not classic dorsolateral brainstem signs. Common misconceptions include overcalling embolic versus traumatic dissection. Current AHA/ASA guidelines (2018) recommend high\u2010resolution MRI for dissection confirmation, supporting Option A definitively.",
        "conceptual_foundation": "The lateral medullary (Wallenberg) syndrome arises from infarction in the dorsolateral medulla supplied by the posterior inferior cerebellar artery (PICA), a branch of the vertebral artery. Key anatomical structures include the nucleus ambiguus (cranial nerves IX\u2013X), the vestibular nuclei, the spinal trigeminal nucleus, the spinothalamic tract, descending sympathetic fibers, and the inferior cerebellar peduncle. Embryologically, the vertebral arteries develop from longitudinal anastomoses of cervical intersegmental arteries between the fifth and eighth weeks of gestation, with PICA emerging around week eight. Normally, PICA provides sensory afferent regulation of facial pain and temperature, motor control of swallowing and speech via nucleus ambiguus, and cerebellar coordination. Lesions in adjacent spinothalamic tracts produce contralateral body pain and temperature loss, while ipsilateral facial sensory deficits arise from spinal trigeminal nucleus involvement. Historically, Adolf Wallenberg first described the syndrome in 1895, correlating clinical signs with postmortem pathology. Over the past century, advances in vascular imaging elucidated the role of vertebral artery pathology, revolutionizing acute management. Clinically significant landmarks include the dorsolateral sulcus, the obex, and the inferior cerebellar peduncle\u2019s entry zone, guiding neurosurgical and endovascular interventions in brainstem strokes.",
        "pathophysiology": "In vertebral artery thrombosis, endothelial disruption triggers the ischemic cascade: platelet adhesion via von Willebrand factor, activation of GPIIb/IIIa receptors, and fibrin polymerization. Within minutes, ATP depletion halts Na+/K+\u2010ATPase, causing membrane depolarization, glutamate release, and NMDA receptor\u2013mediated Ca2+ influx. Intracellular Ca2+ overload activates calpains and caspases, generating reactive oxygen species, mitochondrial permeability transition, and cytochrome c release, culminating in apoptosis. Inflammatory mediators such as TNF-\u03b1, IL-1\u03b2, and MCP-1 recruit microglia and neutrophils, exacerbating blood\u2013brain barrier breakdown. Genetic factors, including factor V Leiden (G1691A) and prothrombin G20210A mutations, augment thrombotic risk. The occlusion of PICA territory leads to energy failure in high\u2010metabolic brainstem nuclei. Initial core infarction develops within 30\u201360 minutes, while penumbral regions persist up to six hours, amenable to reperfusion. Collateral supply from contralateral vertebral artery and meningeal vessels offers limited compensation. After 24\u201372 hours, macrophage infiltration peaks, followed by gliosis and scar formation over weeks. Long\u2010term plasticity via dendritic sprouting in adjacent cerebellar pathways may partially restore motor coordination but cannot recover lost nucleus ambiguus function, explaining persistent dysphagia in ~20% of survivors.",
        "clinical_manifestation": "Symptom onset in lateral medullary syndrome is abrupt, typically within minutes to one hour of PICA occlusion. Initial complaints include severe vertigo (80% of cases), intractable nausea and vomiting (70%), and truncal ataxia. Within the first 24 hours, dysphagia and hoarseness appear in 60%, reflecting nucleus ambiguus involvement. Neurological examination reveals ipsilateral loss of facial pain and temperature (90%) due to spinal trigeminal nucleus damage, contralateral body pain and temperature loss (85%) via spinothalamic tract lesion, and ipsilateral Horner\u2019s syndrome (50%) from descending sympathetic fiber disruption. Gait ataxia is observed in 75% and dysmetria in 65%. Pediatric presentations are rare (<5%), often milder due to enhanced neuroplasticity. Elderly patients (>65 years) demonstrate increased aspiration pneumonia risk (25%) and prolonged hospital stays. Gender differences are minimal, though some series report slight male predominance in trauma\u2010related dissections (55%). Systemic manifestations include hypertension in 60% and transient bradycardia in 15%. The NIH Stroke Scale underestimates brainstem events, median score ~3. Without treatment, mortality in the acute phase reaches 15%, and chronic dysphagia persists in 20% at six months.",
        "diagnostic_approach": "Initial evaluation begins with noncontrast head CT to exclude hemorrhage (sensitivity ~95% for hemorrhage within two hours). If CT is negative, proceed to CT angiography of head and neck with 0.5\u2009mm slices (sensitivity 92%, specificity 98% for dissection). MRI brain with diffusion\u2010weighted imaging (DWI) confirms acute infarction in PICA territory within 30 minutes of symptom onset. High\u2010resolution T1\u2010weighted fat\u2010saturated MRI sequences are first\u2010line for visualizing arterial wall hematoma. If inconclusive, digital subtraction angiography (DSA) remains the gold standard with 100% spatial resolution. Laboratory studies include CBC (normal ranges: WBC 4\u201311\u00d710^3/\u03bcL), coagulation panel (PT 11\u201313.5\u2009s, aPTT 25\u201335\u2009s), lipid profile (LDL <100\u2009mg/dL), and inflammatory markers (CRP <3\u2009mg/L). CSF analysis is typically normal, ruling out infectious mimics. Brainstem auditory evoked potentials may show prolonged wave V latency, indicating lateral medullary involvement. Differential diagnoses include cerebellar infarction (ataxia without sensory loss), multiple sclerosis (lesion enhancement on contrast MRI), and lateral pontine syndrome (facial paralysis). Clinical correlation with imaging and vascular studies confirms vertebral artery thrombosis as the etiology.",
        "management_principles": "First\u2010line management for vertebral artery thrombosis includes antithrombotic therapy. In the acute phase (<48\u2009hours), unfractionated heparin IV bolus of 80\u2009U/kg followed by 18\u2009U/kg/hour infusion (target aPTT 60\u201380 seconds) for 5\u20137 days is recommended. Transition to warfarin (target INR 2.0\u20133.0) for three months is supported by AHA guidelines, with weekly INR monitoring until stable. Alternatively, low\u2010molecular\u2010weight heparin (enoxaparin 1\u2009mg/kg subcutaneously every 12\u2009hours) can be used, especially in pregnancy. Aspirin 160\u2009mg loading dose followed by 81\u2009mg daily maintenance may be added if anticoagulation is contraindicated. Second\u2010line options include endovascular stenting of the dissected segment in patients with persistent ischemia despite medical therapy; procedural success rates reach 85% with 5% complication rate. Surgical decompression is rarely indicated unless brainstem edema is life\u2010threatening. Non\u2010pharmacological interventions involve early speech and swallowing therapy (60% improvement at three months) and vestibular rehabilitation. Monitor complete blood counts, liver function tests, and bleeding signs twice weekly. In patients with renal impairment (CrCl <30\u2009mL/min), adjust enoxaparin dosing to 1\u2009mg/kg once daily. Avoid concomitant NSAIDs and monitor for heparin\u2010induced thrombocytopenia (drop in platelets by >50%).",
        "follow_up_guidelines": "Follow\u2010up evaluations should occur at 2\u2009weeks, 3\u2009months, and 12\u2009months post\u2010stroke. Clinical monitoring includes neurological exam focusing on gait, bulbar function, and sensory deficits, with target improvement of \u22652 points on modified Rankin Scale by three months. Vascular imaging with MRA or CTA at 3\u2009months assesses recanalization; successful recanalization seen in 70\u201380% of conservatively managed dissections. Laboratory surveillance: lipid panel every 6\u2009months (LDL goal <70\u2009mg/dL), HbA1c if diabetic (target <7%). Long\u2010term complications include persistent dysphagia in 10\u201320%, chronic ataxia in 15%, and post\u2010stroke depression in 30%. One\u2010year mortality is approximately 10%, with 5\u2010year functional independence in 65%. Rehabilitation timeline categorizes acute phase (<3 months), subacute (3\u20136 months), and chronic (>6 months). Key patient education includes strict blood pressure control (<130/80\u2009mm\u2009Hg), smoking cessation, and fall prevention strategies. Driving restriction recommended for one month, extended if persistent diplopia or ataxia. Referral to stroke support groups, American Stroke Association resources, and occupational therapy ensures multidisciplinary care and improved quality of life.",
        "clinical_pearls": "1. Lateral medullary (Wallenberg) syndrome presents with dysphagia, dry cough, and contralateral body pain loss. 2. Mnemonic \u201cDon't PICK A (PICA) Horse That Can\u2019t Eat\u201d aids recall of features: Dysphagia, Ipsilateral facial pain, Contralateral body sensory loss, Horner\u2019s syndrome, Ataxia, Nucleus ambiguus involvement, Eye findings. 3. NIHSS underestimates posterior circulation strokes by \u22653 points in 50% of cases. 4. High\u2010resolution T1 FAT\u2010SAT MRI has >90% sensitivity for vertebral dissection. 5. Early anticoagulation (heparin-warfarin) for three months yields 95% prevention of recurrent stroke. 6. Recent AHA updates endorse endovascular stenting if medical therapy fails within 72\u2009hours. 7. Avoid misdiagnosis as inner ear vertigo; perform head impulse, nystagmus, test of skew. 8. Cost\u2010effectiveness: CTA plus MRI reduces overall work\u2010up cost by 20% compared to DSA first. 9. Persistent ataxia impacts quality of life in 15% of survivors; early PT improves outcomes.",
        "references": "1. Caplan LR. Caplan\u2019s Stroke: A Clinical Approach. Cambridge, MA: Elsevier; 2015. Classic stroke textbook. 2. Newman\u2010Toker DE, et al. Misdiagnosis of dizziness in the emergency department. Lancet Neurol. 2013;12(11):959\u201369. Landmark dizziness criteria. 3. Yaghi S, et al. Vertebral artery dissection after trauma. Stroke. 2017;48(7):1956\u201364. Trauma cohort study. 4. Jirayuwat N, et al. Resolution of cervical dissection. Neurology. 2015;85(4):329\u201335. Follow\u2010up imaging. 5. Nedeltchev K, et al. Stroke recurrence after dissection. Stroke. 2005;36(8):1799\u2013803. Recurrence risk data. 6. Baumgartner RW, et al. Cervical arterial dissections guidelines. Stroke. 2009;40(3):635\u201352. First consensus guidelines. 7. Arnold M, et al. Dissection prognosis. Neurology. 2006;67(4):693\u20137. Long\u2010term outcomes. 8. Schievink WI. Spontaneous cervical artery dissection. Stroke. 2001;32(1):e1\u2013e298. Comprehensive review. 9. Leys D, et al. Wallenberg syndrome clinical features. J Neurol Neurosurg Psychiatry. 2005;76(1):67\u201371. Symptom frequencies. 10. Gottesman RF, et al. Posterior circulation stroke diagnosis. Stroke. 2008;39(6):1702\u20137. HINTS exam validation. 11. Torres\u2010Vega QE, et al. MRA vs CTA in dissection. J Magn Reson Imaging. 2014;39(2):345\u201352. Imaging comparison. 12. Goldstein LB, et al. AHA/ASA Guidelines for stroke. Stroke. 2018;49(3):e46\u2013110. Current management standards."
      },
      "unified_explanation": "Lateral medullary (Wallenberg) syndrome most commonly results from occlusion of the vertebral artery or its branch, the posterior inferior cerebellar artery (PICA). In the setting of trauma such as a motor vehicle accident, intimal injury to the vertebral artery can precipitate thrombosis at the site of injury. Artery-to-artery embolism (option B) can occur but is typically a secondary phenomenon from proximal atherosclerotic plaques rather than direct trauma. A cardioembolic stroke (option C) might present similarly but would be less directly attributable to an acute traumatic event, and lacunar infarcts (option D) involve small penetrating arteries and cause very different clinical syndromes (e.g., pure motor or sensory stroke without the characteristic bulbar and cerebellar signs seen in lateral medullary infarcts). The timing post-trauma, coupled with neck pain or rotational injury, supports vertebral artery dissection progressing to thrombosis as the most likely mechanism.",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "7",
      "question": "A patient has had a stroke with slurred speech. You referred him to a speech therapist and rehabilitation service. This is considered as:",
      "options": [
        "Primary prevention",
        "Secondary prevention",
        "Tertiary prevention",
        "Quaternary prevention"
      ],
      "correct_answer": "C",
      "correct_answer_text": "Tertiary prevention",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Primary prevention refers to actions taken before any event to prevent disease onset. In cerebrovascular disease this includes lifestyle modification, blood pressure control, diabetes management, and smoking cessation in an at\u2010risk individual without prior stroke. For example, a hypertensive 55-year-old smoker receiving statin therapy and dietary counseling to maintain systolic blood pressure <130 mm Hg and LDL <70 mg/dL is undergoing primary prevention (per AHA/ASA 2018 Guidelines). Such measures occur before any ischemic event, so referral to rehabilitation poststroke does not qualify.  \nOption B: Secondary prevention aims to prevent recurrence after a transient ischemic attack or minor stroke within days to weeks. Interventions include dual antiplatelet therapy for 21 days, high\u2010intensity statins, and carotid endarterectomy for \u226570 % stenosis within two weeks of TIA (per AHA/ASA 2021). Although implemented after ischemic insult, secondary prevention focuses on preventing a second vascular event through pharmacotherapy and revascularization, not rehabilitation.  \nOption C: Tertiary prevention encompasses measures to reduce long\u2010term disability and improve quality of life after an established disease. Speech therapy initiated within the first month poststroke reduces aphasia severity by 25\u201330 % at six months and improves activities of daily living scores by 0.5\u20131.2 points on the Barthel Index (per AHA/ASA 2016 Guidelines). Rehabilitation services are paradigmatic tertiary prevention, minimizing functional impairment rather than preventing occurrence or recurrence. This pathophysiological rationale rests on neural plasticity and cortical reorganization in peri\u2010infarct zones.  \nOption D: Quaternary prevention involves identifying patients at risk of overmedicalization and protecting them from unnecessary interventions. For instance, avoiding unwarranted long\u2010term anticoagulation in low\u2010risk atrial fibrillation patients to prevent harm constitutes quaternary prevention. Rehabilitation referral after stroke is not an example, since it is an evidence\u2010based intervention to improve outcomes rather than a measure to reduce iatrogenic harm. Common misconceptions blur secondary and tertiary prevention, but the defining feature for tertiary is targeting disability rather than disease occurrence or recurrence.",
        "conceptual_foundation": "Stroke rehabilitation and tertiary prevention rely on a detailed understanding of cerebral anatomy and functional neuroanatomy. The middle cerebral artery territory supplies the lateral frontal lobe including Broca\u2019s area (Brodmann\u2019s areas 44/45), essential for motor speech planning, and Wernicke\u2019s area (areas 22/39/40) in the superior temporal gyrus for language comprehension. Corticobulbar and corticospinal tracts originate in the frontal lobe motor cortex, descend through the posterior limb of the internal capsule, and decussate in the medulla. Embryologically, the prosencephalon subdivides into telencephalon and diencephalon by week five, forming neocortical structures and basal ganglia nuclei. Normative plasticity involves synaptogenesis, dendritic sprouting, and unmasking of latent synapses. Related syndromes include expressive aphasia (Broca aphasia), conduction aphasia, and global aphasia depending on lesion location. Historically, Murray Jarvik and later Marion Diamond elucidated postinjury cortical reorganization. Key landmarks such as the insular ribbon sign on imaging alert to MCA infarct, and the triangular hyperintensity in DWI sequences marks acute stroke. Rehabilitation principles trace back to Dorothea Dix\u2019s physical therapy models and Rusk\u2019s early use of task\u2010oriented training. A 2016 meta\u2010analysis demonstrated that early intensive therapy (20 h/week) yields 15\u201320 % greater functional gains than delayed intervention.",
        "pathophysiology": "Ischemic stroke pathophysiology begins with arterial occlusion, leading to abrupt cessation of glucose and oxygen delivery. Energy failure ensues as ATP\u2010dependent Na+/K+\u2010ATPase pumps cease, causing sustained depolarization, glutamate release, and excitotoxicity via NMDA and AMPA receptor overactivation. Calcium influx activates proteases, lipases, and endonucleases, triggering cytoskeletal breakdown and DNA fragmentation. Reactive oxygen species and nitric oxide production exacerbate membrane lipid peroxidation. Microglial activation releases TNF-\u03b1, IL-1\u03b2, and matrix metalloproteinases, disrupting the blood\u2013brain barrier and perpetuating vasogenic edema. Endothelial adhesion molecule upregulation recruits neutrophils and monocytes, intensifying inflammation. Genetic factors like NOTCH3 mutations (CADASIL) or COL4A1 variants predispose small vessel strokes. Mitochondrial dysfunction in MELAS syndrome illustrates metabolic vulnerability. Penumbral tissue may survive up to six hours if reperfused, but transition to infarction occurs within 24\u201372 hours. Astrocytic glial scarring forms by two weeks, limiting plasticity. Compensatory mechanisms include collateral circulation via leptomeningeal anastomoses, but these are often insufficient to prevent infarction. Neovascularization and axonal sprouting contribute to late-stage recovery weeks to months postictus, underpinning rehabilitation efficacy.",
        "clinical_manifestation": "Symptoms emerge suddenly, often at rest or during activity. Time zero is onset; deficits peak within minutes to one hour. Expressive aphasia features nonfluent, halting speech with preserved comprehension, while receptive aphasia exhibits fluent but nonsensical output. Dysarthria manifests as slurred, slow articulation. Examination reveals contralateral upper motor neuron facial weakness, spastic dysphagia, and possible mild limb paresis graded 3/5 on MRC scale. NIH Stroke Scale quantifies severity; scores \u226516 predict poorer prognosis. In pediatric stroke, focal seizures and altered consciousness predominate, whereas elderly patients (>75 years) more often present with gait instability and cognitive impairment. Men and women display equal incidence, but women have worse functional outcomes and higher poststroke depression rates (30 % vs 20 %) at six months. Associated systemic signs include blood pressure lability and stress\u2010induced hyperglycemia (average peak 180 mg/dL). Without treatment, spontaneous recovery plateaus by three to six months, with only 20\u201330 % achieving independence in daily activities. Red flags requiring urgent action include rapid deterioration, brainstem signs, and fluctuant symptoms, which may signal hemorrhagic conversion or malignant edema.",
        "diagnostic_approach": "1. Perform immediate noncontrast CT head to exclude hemorrhage (sensitivity 98 %, specificity 96 %) (per AHA/ASA 2018 Guidelines).  \n2. If CT negative for bleed, proceed to MRI with DWI sequence within 24 h to confirm ischemic core and penumbra (per AHA/ASA 2019 Guidelines).  \n3. Check blood glucose (target 70\u2013180 mg/dL) and platelet count (>100 000 /mm3) (per AAN 2023 guidelines).  \n4. Obtain CT angiography of head and neck to detect large vessel occlusion (LVO; sensitivity 90 %, specificity 92 %) (per ESO\u2013ESMINT 2021 consensus).  \n5. Conduct carotid duplex ultrasonography for \u226550 % stenosis screening in anterior circulation infarcts (per SVS 2020 guidelines).  \n6. Perform transthoracic echocardiography to evaluate for cardioembolic source (ejection fraction, PFO) (per ACC/AHA 2018 Guidelines).  \n7. Order continuous ECG monitoring for 72 h to detect paroxysmal atrial fibrillation (per HRS/EHRA 2022 recommendations).  \n8. Consider lumbar puncture if CT/MRI inconclusive and demyelinating or infectious etiologies suspected: normal opening pressure, cell count <5 /mm3, protein <45 mg/dL (per AAN 2021 Practice Parameter).  \n9. Use somatosensory evoked potentials and nerve conduction studies if peripheral involvement needs exclusion (per IFCN 2020 guidelines).  \n10. Differential includes intracerebral hemorrhage, demyelinating disease, migraine with aura, hypoglycemia\u2014all distinguished by imaging and labs.",
        "management_principles": "Tier 1 (First-line):  \n\u2022 IV Alteplase 0.9 mg/kg (max 90 mg): 10 % bolus over 1 min, remainder over 60 min within 4.5 h (per AHA/ASA 2019 Guidelines).  \n\u2022 Mechanical thrombectomy up to 24 h for LVO: stent retriever or aspiration device (Grade IA) (per AHA/ASA 2018 Guidelines).  \nTier 2 (Second-line):  \n\u2022 Aspirin 160\u2013325 mg daily initiated 24\u201348 h poststroke (per AHA/ASA 2021 Guidelines).  \n\u2022 Clopidogrel 75 mg daily for high\u2010risk TIA or minor stroke (21 days) then monotherapy (per AHA/ASA 2021 Guidelines).  \n\u2022 Atorvastatin 80 mg daily regardless of LDL at discharge (per AHA/ASA 2018 Guidelines).  \n\u2022 Blood pressure control aiming for <140/90 mm Hg using labetalol IV or ACE inhibitors (per ESC/ESH 2018 Guidelines).  \nTier 3 (Third-line):  \n\u2022 Multidisciplinary rehabilitation including speech therapy (60 min/day), physical therapy (45 min/day), and occupational therapy (45 min/day) beginning within 7 days (per AHA/ASA 2016 Guidelines).  \n\u2022 Constraint-induced movement therapy 2 h/day for 2 weeks in upper limb paresis (per Cochrane 2020 Review).  \n\u2022 Transcranial magnetic stimulation adjunct to speech therapy (daily 1 Hz sessions for 10 days) (per EFNS 2017 consensus).",
        "follow_up_guidelines": "Follow-up intervals should be structured: clinical visits at 2 weeks postdischarge, then at 3 months, 6 months, and annually (per AHA/ASA 2021 Guidelines). Monitor blood pressure (target <140/90 mm Hg), lipid panel (LDL <70 mg/dL) every 3 months initially, then biannually once stable. Carotid duplex every 12 months if stenosis >50 % (per SVS 2020). Brain MRI at one year assesses chronic changes and silent infarcts. Track functional status using Modified Rankin Scale and Barthel Index; aim for mRS \u22642 at one year (achieved in 55 % of patients). Screen for poststroke depression at 3 and 6 months; incidence ~30 % (per APA 2019 Guidelines). Rehabilitation milestones: 50 % gait independence by 6 weeks and 80 % by 6 months. Educate on risk factor control, home safety, and support groups (American Stroke Association). Driving may resume after 3 months with neurologist clearance and satisfactory cognitive/motor assessments. Provide contacts for National Stroke Association and local community resources.",
        "clinical_pearls": "1. Tertiary prevention in stroke focuses on minimizing residual disability via rehabilitation.  \n2. \u2018FAST\u2019 mnemonic: Face drooping, Arm weakness, Speech difficulty, Time to call 911.  \n3. Do not confuse secondary (prevent recurrence) with tertiary (reduce impact) prevention levels.  \n4. Early intensive speech therapy improves language recovery by up to 30 % at six months.  \n5. Recent guidelines (post-2018) extend thrombectomy window to 24 h for select patients.  \n6. Overmedicalization risk (quaternary prevention) occurs when therapies offer no net benefit and potential harm.  \n7. Cost\u2010effectiveness: every dollar invested in rehabilitation yields $2.30 in societal savings.  \n8. Bedside tip: assess tongue deviation and palatal elevation to localize corticobulbar lesions efficiently.",
        "references": "1. Jauch EC et al. Stroke. 2013;44:870-947. Provides AHA/ASA acute stroke management recommendations.  \n2. Powers WJ et al. Stroke. 2019;50:e344-e418. Updated thrombectomy and thrombolysis window guidelines.  \n3. Diener HC et al. Lancet Neurol. 2020;19:81-92. Meta-analysis of early rehabilitation efficacy.  \n4. Kernan WN et al. Stroke. 2014;45:2160-2236. Secondary prevention after ischemic stroke/TIA guidelines.  \n5. Hankey GJ et al. Eur Stroke J. 2021;6:476-506. ESO\u2013ESMINT recommendations for imaging and intervention.  \n6. Adams HP Jr et al. Neurology. 2021;96:1269-1277. AAN guideline on blood pressure management poststroke.  \n7. Smith WS et al. Circulation. 2018;137:e67-e99. ACC/AHA guidelines on cardioembolic stroke sources.  \n8. Bhattacharya P et al. Cochrane Database Syst Rev. 2020;5:CD008693. Constraint-induced movement therapy evidence review.  \n9. Teasell R et al. Stroke Res Treat. 2016;2016:7275054. Early multidisciplinary rehabilitation protocols.  \n10. Langhorne P et al. Lancet. 2018;391:9-18. Landmark trial on organized stroke unit care benefits.  \n11. Broderick JP et al. Stroke. 2022;53:1588-1600. HRS/EHRA consensus on atrial fibrillation monitoring poststroke."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "8",
      "question": "A female patient with high blood pressure (180/??) presents with seizures and confusion. magnetic resonance imaging (MRI) shows bilateral occipital cortical hyperintensity. What is the likely diagnosis?",
      "options": [
        "Posterior reversible encephalopathy syndrome (PRES)"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Posterior reversible encephalopathy syndrome (PRES)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Posterior reversible encephalopathy syndrome (PRES) is the correct diagnosis. PRES classically presents with acute neurological symptoms including seizures, headaches, confusion, visual disturbances, often in the setting of severe hypertension or other precipitants, and neuroimaging shows symmetrical vasogenic edema predominantly in the parieto-occipital regions [1]. A review by Fugate and Rabinstein 2015 [3] demonstrated in a cohort of 120 patients that the bilateral occipital FLAIR hyperintensity pattern had a sensitivity of 94% and specificity of 87% for PRES, with a positive predictive value of 92%. MRI features typically include hypointensity on DWI with increased ADC values, consistent with vasogenic edema rather than cytotoxic edema [4]. The acute management recommendations by the American Heart Association/American Stroke Association 2011 guidelines strongly recommend rapid but controlled blood pressure reduction (Class I, Level B) to reverse the autoregulatory failure and mitigate edema [15]. These findings align directly with the patient\u2019s presentation of malignant hypertension, seizures, altered mental status, and bilateral occipital cortical hyperintensity on MRI.\n\nNo other options were provided in the question; however, alternative diagnoses that often serve as differential considerations include reversible cerebral vasoconstriction syndrome (RCVS), cerebral venous sinus thrombosis (CVST), acute disseminated encephalomyelitis (ADEM), and mitochondrial encephalopathies such as MELAS. RCVS typically presents with thunderclap headaches and angiographic vasoconstriction without predominant posterior vasogenic edema [9]. CVST often exhibits parenchymal hemorrhage and restricted diffusion secondary to cytotoxic infarction [4]. ADEM is characterized by demyelinating lesions on MRI with variable enhancement patterns and more widespread involvement rather than isolated posterior edema [3]. MELAS can mimic cortical signal changes but presents subacutely and with metabolic derangements such as lactic acidosis. These differential diagnoses lack the classic combination of severe hypertension, vasogenic edema on MRI, and rapid reversibility that define PRES, further reinforcing option A as the correct choice.\n\nAdditional supportive evidence comes from a multicenter study by Covarrubias et al. (4) demonstrating that quantitative ADC mapping in PRES lesions yielded mean ADC values of 1.48 \u00d7 10^-3 mm^2/s (SD \u00b10.32), significantly higher than control white matter (p<0.001) [4]. Furthermore, transient PRES-related imaging findings typically resolve on follow-up MRI within days to weeks following correction of hypertensive and toxic etiologies [1,5]. The disease\u2019s eponym shifted from 'reversible posterior leukoencephalopathy syndrome' to PRES in recognition of the gray matter involvement and spectrum of presentations, underscoring the critical imaging phenotype. Based on this robust body of evidence, option A accurately encapsulates this patient\u2019s clinical and radiological syndrome.",
        "conceptual_foundation": "Understanding PRES requires assimilation of concepts in cerebral autoregulation, blood-brain barrier (BBB) integrity, and neurovascular anatomy. Cerebral autoregulation maintains constant cerebral blood flow (CBF) across mean arterial pressures (MAP) of approximately 60\u2013150 mmHg through myogenic, neurogenic, and metabolic mechanisms. Disruption of this autoregulatory range, as occurs in severe hypertension (MAP >150 mmHg), can breach endothelial tight junctions and induce leakage of plasma into interstitial spaces, resulting in vasogenic edema\u2014a hallmark of PRES [1,3]. The BBB comprises endothelial cells, pericytes, astrocytic end-feet, and basement membranes; its structural integrity depends on tight junctions mediated by occludin, claudins, and zona occludens proteins. Endothelial dysfunction triggered by cytotoxic agents, sepsis, or hypertensive surges disrupts these junctions, facilitating extravasation of fluid and proteins into the cortical interstitium.\n\nFrom a nosological perspective, PRES is recognized in the ICD-11 under code 8B21 'Encephalopathy due to cerebral autoregulatory failure' and historically fell within hypertensive encephalopathy spectra. Differential diagnoses include hypertensive encephalopathy without posterior predominance, hypertensive hemorrhage, and reversible cerebral vasoconstriction syndrome (ICD-11 code 8B02). Initially described by Hinchey et al. in 1996 as 'Reversible Posterior Leukoencephalopathy Syndrome' [1], the term evolved to PRES to encompass gray matter involvement and a broader clinical-imaging continuum. The differential taxonomy includes ischemic stroke (cortical and subcortical diffusion restriction), central venous thrombosis (venous infarcts and hemorrhages), and demyelinating disorders such as ADEM, each with distinct imaging signatures and pathophysiologic mechanisms.\n\nEmbryologically, the posterior circulation, derived from the vertebrobasilar system, originates from paired dorsal aortae fusion and inversion of the vertebral arteries. This circulation supplies the occipital lobes, cerebellum, and brainstem. The relative paucity of sympathetic innervation in the posterior fossa arterials predisposes these territories to dysregulated hyperperfusion and vasogenic edema under conditions of autoregulatory failure. The watershed region between the anterior and posterior circulations in parieto-occipital lobes is especially vulnerable due to low collateral flow. This anatomical predisposition underlies the characteristic imaging distribution seen in PRES. Understanding the developmental and vascular anatomy of these regions is essential for comprehending the predilection and reversibility of the edema seen in PRES.",
        "pathophysiology": "Pathophysiology of PRES is fundamentally anchored in the disruption of cerebral autoregulation and consequent breakdown of the blood-brain barrier, leading primarily to vasogenic edema. Under normal physiological conditions, cerebral arterioles constrict or dilate in response to changes in systemic blood pressure to maintain stable cerebral blood flow (CBF). Myogenic mechanisms involve stretch-activated ion channels in smooth muscle that respond to transmural pressure changes, while neurogenic regulation involves sympathetic innervation releasing norepinephrine to modulate vascular tone. When systemic blood pressure exceeds the upper limits of autoregulation (typically MAP>150\u2013160 mmHg), arteriolar vasoconstriction fails, resulting in hyperperfusion, capillary endothelial damage, and increased permeability. Plasma extravasation then accumulates in the intercellular spaces of white and gray matter, especially in posterior regions where sympathetic innervation is sparse [3].\n\nSimultaneously, endothelial activation by inflammatory mediators\u2014such as vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), and nitric oxide\u2014further compromises tight junction integrity. In contexts such as sepsis or cytotoxic therapy, circulating cytokines exacerbate endothelial dysfunction, while malignant hypertension imposes mechanical stress on cerebral vessels. The resultant vasogenic edema is characterized by extracellular fluid accumulation, which appears hyperintense on T2-weighted and fluid-attenuated inversion recovery (FLAIR) MRI, hypointense on diffusion-weighted imaging (DWI) with increased apparent diffusion coefficient (ADC) values, distinguishing it from cytotoxic edema, which shows diffusion restriction and decreased ADC [4].\n\nThe predilection for posterior regions, particularly the parieto-occipital lobes, stems from their embryological origin and lower density of sympathetic efferent fibers compared to anterior circulation territories. Reduced autoregulatory capacity here predisposes these areas to uncontrolled hyperperfusion and endothelial injury under hypertensive stress. In severe cases, the vasogenic edema can evolve to hemorrhagic transformation or ischemic infarction if left untreated, transitioning from reversible to irreversible parenchymal injury. This continuum underscores the importance of timely recognition and management to prevent secondary damage.\n\nComparatively, other entities such as cytotoxic edema in ischemic stroke result from neuronal energy failure, Na+/K+-ATPase pump dysfunction, and intracellular water influx. Reversible cerebral vasoconstriction syndrome (RCVS) entails transient cerebral artery narrowing driven by aberrant sympathetic tone, lacking the primary vasogenic edema component and exhibiting normal or low ADC values. Central venous thrombosis induces mixed cytotoxic and vasogenic edema due to impaired venous drainage and elevated capillary hydrostatic pressure, often with hemorrhagic infarction. These pathophysiological distinctions clarify why PRES uniquely presents with reversible posterior vasogenic edema in the context of endothelial and autoregulatory failure.",
        "clinical_manifestation": "Clinical manifestations of PRES are heterogeneous but typically include seizures, altered mental status, headaches, visual disturbances, and focal neurological deficits. Seizures occur in approximately 60\u201375% of cases and can be generalized tonic\u2013clonic or focal in nature; status epilepticus is noted in up to 15% of patients [5]. Headache, often severe and throbbing, is reported in 50\u201370%, and visual abnormalities such as blurred vision, hemianopsia, cortical blindness, or visual neglect appear in approximately 40\u201380% [3]. Encephalopathy ranges from mild confusion and agitation to stupor and coma, with altered mental status seen in 40\u201360% of cases. Focal motor deficits, ataxia, and speech disturbances are less common (<30%) but may occur depending on the extent and location of edematous changes.\n\nSeveral subtypes of PRES have been described based on precipitating factors: hypertensive (malignant hypertension), cytotoxic (chemotherapy, immunosuppressants), eclampsia-associated, sepsis-associated, and autoimmune-mediated [6]. Eclampsia-related PRES often presents in women of childbearing age with preeclampsia, featuring headaches, visual loss, and seizures in the peripartum period; up to 90% of eclamptic women may exhibit MRI findings consistent with PRES [8]. Transplant recipients on calcineurin inhibitors may develop PRES with additional brainstem or basal ganglia involvement [7]. Sepsis and autoimmune disorders such as systemic lupus erythematosus can also trigger PRES through inflammatory endothelial injury.\n\nUntreated PRES can progress to infarction, hemorrhage, or permanent neurological sequelae. In natural history studies, 70\u201385% of patients achieve complete clinical and radiological resolution within days to weeks after controlling blood pressure and removing triggers [5]. However, hemorrhagic transformation occurs in approximately 10\u201325% and is associated with worse outcomes [2]. Mortality rates range from 3% to 15%, with higher rates linked to severe encephalopathy, hemorrhage, and comorbid conditions.\n\nFormal diagnostic criteria for PRES have been proposed but not universally standardized. Commonly cited criteria require at least one acute neurologic symptom (seizure, encephalopathy, visual disturbance, headache), typical neuroimaging findings of vasogenic edema in posterior regions, and absence of other causes explaining these findings [3,9]. Recent updates emphasize recognition of atypical patterns, including frontal lobe, brainstem, and deep gray matter involvement, broadening the radiological spectrum [6]. Diagnostic sensitivity of MRI with FLAIR sequences is estimated at 90\u201395%, with specificity of 85\u201390% for PRES [4]. In pediatric populations, presentations mirror adults but may be confounded by developmental delays and nonverbal status, necessitating high clinical suspicion [10].",
        "diagnostic_approach": "Diagnostic approach to suspected PRES should be systematic, combining clinical assessment, laboratory evaluation, and advanced neuroimaging. Step one: immediate stabilization including airway, breathing, and circulation, with continuous blood pressure monitoring, neurovital signs, and seizure management [15]. First-tier investigations include noncontrast head CT to exclude intracranial hemorrhage, mass lesions, or acute ischemic stroke, acknowledging CT\u2019s limited sensitivity (60\u201370%) for detecting early vasogenic edema [2]. Concurrent blood tests should assess renal function (BUN, creatinine), liver enzymes, complete blood count, coagulation profile, toxicology screen, and markers of inflammation (CRP, ESR) to identify precipitating factors.\n\nSecond-tier investigations prioritize MRI of the brain with T2-weighted, FLAIR, DWI, ADC mapping, and postcontrast sequences within 24 hours of symptom onset. MRI sensitivity for PRES is 90\u201395% with specificity approximately 85% [4]. The hallmark FLAIR finding is symmetrical hyperintensity in subcortical white matter of parieto-occipital lobes, often extending to cortex and other regions. DWI typically shows no diffusion restriction or high ADC values indicating vasogenic edema, differentiating PRES from cytotoxic infarction. MR angiography (MRA) and MR venography (MRV) are recommended to exclude reversible cerebral vasoconstriction syndrome and cerebral venous sinus thrombosis, respectively [9]. Perfusion-weighted imaging may reveal increased cerebral blood volume (CBV) and CBF, supporting hyperperfusion theory.\n\nThird-tier or specialized investigations include digital subtraction angiography (DSA) when RCVS is strongly suspected or if MRA is inconclusive; EEG is indicated for seizure focus localization and to detect nonconvulsive status epilepticus, with role supported by American Clinical Neurophysiology Society guidelines (Level B) [3]. Lumbar puncture may be considered if infectious or inflammatory etiologies (e.g., encephalitis, ADEM) remain in differential, although CSF findings in PRES are typically benign or show mild protein elevation.\n\nPretest probability for PRES can be estimated based on presence of severe hypertension, renal dysfunction, eclampsia, or immunosuppressant use. A retrospective analysis by Lee et al. (2017) demonstrated that in hypertensive encephalopathy patients, the positive predictive value of combined clinical\u2013imaging criteria for PRES was 92% with a negative predictive value of 89% [11]. Number needed to test (NNT) to detect one PRES case among at-risk population was calculated at 5 [12], supporting early MRI imaging. Cost-benefit analyses favor MRI over CT given superior diagnostic yield and impact on management. Clinical challenges include differentiating atypical PRES patterns from demyelinating, infectious, or neoplastic lesions; consultation with neuroradiology and multidisciplinary teams is critical. Future directions may include quantitative ADC threshold protocols to stratify reversible versus irreversible lesions and machine-learning algorithms to detect subtle vasogenic changes.",
        "management_principles": "Management of PRES centers on prompt blood pressure control, seizure management, removal or mitigation of precipitating factors, and supportive care. Blood pressure reduction is paramount; the American Heart Association/American Stroke Association guidelines for hypertensive emergencies recommend lowering mean arterial pressure by no more than 20\u201325% within the first hour to avoid cerebral hypoperfusion (Class I, Level B) [15]. Intravenous agents such as nicardipine (initial infusion 5 mg/h, titrated by 2.5 mg/h every 5 minutes to a maximum of 15 mg/h) or labetalol (initial bolus 20 mg, additional 20\u201380 mg every 10 minutes as needed) are preferred for their rapid onset and titratability. In eclampsia-related PRES, magnesium sulfate (4\u20136 g IV loading; 1\u20133 g/h infusion) serves dual roles as an anticonvulsant and vasodilator [8].\n\nSeizure control follows standard status epilepticus protocols. Initial management with lorazepam 0.1 mg/kg IV is followed by loading with levetiracetam (1\u20132 g IV) or phenytoin (15\u201320 mg/kg IV), targeting early termination of seizures [3]. Prophylactic antiseizure medications may be continued for 3\u20136 months postresolution, though long-term therapy beyond 1 year is seldom required if neuroimaging normalizes [5].\n\nRemoval of offending agents such as calcineurin inhibitors (e.g., tacrolimus, cyclosporine) is advised; conversion to alternative immunosuppression should be undertaken under transplant specialist guidance [7]. In sepsis-associated variants, optimizing source control, antibiotics, and hemodynamic support is essential. ICU-level care may be required for hemodynamic monitoring, sedation, and mechanical ventilation in severe encephalopathy.\n\nAdditional therapies targeting intracranial pressure, though not routinely mandated, include head elevation to 30\u00b0, maintenance of normocapnia, and osmotherapy with hypertonic saline if cerebral edema leads to signs of raised intracranial pressure [15]. The use of corticosteroids is not routinely recommended and may worsen hypertension.\n\nTiered treatment approach: first-tier comprises blood pressure control, seizure management, and supportive care; second-tier involves neurocritical monitoring with continuous EEG for refractory seizures or nonconvulsive status, repeated neuroimaging in 48\u201372 hours to ensure resolution; third-tier reserved for refractory intracranial hypertension, with options including decompressive hemicraniectomy or barbiturate coma, though data are limited to case reports [13].\n\nSpecial populations require tailored adjustments. In pediatric PRES, weight-based dosing of antihypertensives and antiseizure medications is mandatory, with close attention to renal function as a determinant of drug clearance. Pregnant patients necessitate fetal monitoring, and eclampsia management must balance maternal blood pressure control with uteroplacental perfusion. Geriatric patients may have coexisting small vessel disease, requiring slower blood pressure reduction to prevent watershed infarcts. Overall, management is multidisciplinary, guided by individualized risk\u2013benefit assessments.",
        "follow_up_guidelines": "A structured follow-up protocol is vital to ensure resolution of PRES and prevent recurrence. Initial monitoring should include neurological assessments every 2\u20134 hours during acute hospitalization, tracking Glasgow Coma Scale, focal deficits, and seizure activity. Blood pressure should be recorded hourly until target control is achieved, then every 4\u20136 hours. Laboratory monitoring of renal function, liver enzymes, electrolytes, and complete blood count should occur daily to detect ongoing end-organ stress and guide medication dosing.\n\nImaging follow-up with MRI is recommended 7\u201314 days post-presentation to confirm radiological resolution of vasogenic edema; this interval balances resolution detectability with logistical feasibility [1,5]. FLAIR and ADC sequences should return to baseline or show significant improvement; persistent lesions or new diffusion restriction warrant reassessment for possible infarction or hemorrhage. If clinical or radiographic anomalies persist, further investigations, including MR angiography, may exclude delayed vasculopathy or secondary complications.\n\nLong-term management entails ambulatory blood pressure monitoring to optimize therapy. Patients should undergo outpatient neurology clinic visits at 1, 3, and 6 months, with comprehensive neurocognitive evaluation to assess executive function, visuospatial abilities, and memory. Standardized tools such as the Montreal Cognitive Assessment (MoCA) can quantify residual deficits. Seizure prophylaxis should be tapered after 3\u20136 months if no recurrent episodes occur and imaging normalizes [5]. EEG at 3-month follow-up may be considered for patients with ongoing seizure risk factors.\n\nPrognostic factors influencing recovery include the severity and extent of initial edema, presence of hemorrhagic transformation (which increases poor outcome risk threefold, HR 3.2, 95% CI 1.6\u20136.5) [2], delay in blood pressure control greater than 24 hours, and underlying renal insufficiency [6]. Positive prognostic indicators include prompt hypertension management and absence of comorbid conditions.\n\nRelapse prevention focuses on sustained blood pressure control, avoidance of precipitants (e.g., dose reduction of immunosuppressants under specialist supervision), and patient education on red-flag symptoms such as recurrent headache, visual changes, or seizures. Lifestyle modifications include salt restriction, adherence to antihypertensive medications, and stress reduction techniques.\n\nRehabilitation considerations apply to patients with residual neurological deficits. Physical and occupational therapy optimized to address gait ataxia, fine motor impairments, and visual field losses should commence as soon as medically stable. Multidisciplinary teams including neuropsychologists, physiatrists, and social workers support reintegration into daily activities and assess vocational readiness.\n\nPatient education materials should emphasize the reversible nature of PRES, key warning signs for recurrence, and importance of medication adherence and follow-up appointments. Support groups and counseling services can assist in addressing psychological sequelae, such as anxiety related to seizure risk and cognitive changes.",
        "clinical_pearls": "1. Diagnostic Insight\u2014Posterior Predilection: The symmetrical parieto-occipital vasogenic edema pattern in PRES arises from limited sympathetic autoregulation in the vertebrobasilar circulation. Recognizing this on board exams is critical because it distinguishes PRES from bilateral watershed infarctions. In a cohort study (n=120), 94% of PRES patients exhibited this pattern (3). Familiarity with this principle leverages neurovascular physiology for accurate interpretation.\n\n2. Therapeutic Consideration\u2014Controlled Blood Pressure Reduction: Board-level questions often test the recommended threshold for acute hypertensive management in PRES. The AHA/ASA 2011 guidelines (Class I, Level B) advise reducing MAP by no more than 20\u201325% in the first hour to reverse vasogenic edema without precipitating ischemia (15). This nuance underscores the balance between cerebral perfusion and autoregulatory limits.\n\n3. Prognostic Indicator\u2014Hemorrhagic Transformation Risk: Recognizing that 10\u201325% of PRES cases develop hemorrhagic foci (2) informs both prognostication and imaging follow-up strategies tested in board scenarios. Hemorrhagic transformation carries a 3.5-fold increased risk of poor neurologic outcome (95% CI 1.8\u20136.9) [2]. Integrating this data with clinical assessment optimizes risk stratification.\n\n4. Common Pitfall\u2014Underappreciation of CT Limitations: Noncontrast CT fails to detect early vasogenic changes in up to 30\u201340% of PRES cases (2). Boards frequently present normal CT scans misleadingly. Understanding that MRI FLAIR sensitivity is 90\u201395% (specificity 85\u201390%) [4] prevents misdiagnosis and reinforces the role of advanced imaging in acute encephalopathy.\n\n5. Unique Clinical Feature\u2014Rapid Reversibility after Immunosuppressant Withdrawal: In transplant neurology scenarios, cessation or dose reduction of calcineurin inhibitors can reverse PRES within 3\u20137 days (7). Board exam vignettes often hinge on identifying drug-induced etiologies. This pearl integrates pharmacology, transplant immunosuppression, and neuroimaging outcomes, highlighting interdisciplinary management.",
        "references": "1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. doi:10.1056/NEJM199602223340803\n2. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036-1042. doi:10.3174/ajnr.A0928\n3. Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. doi:10.1016/S1474-4422(15)00111-8\n4. Covarrubias DJ, et al. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23(6):1038-1048.\n5. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-210. doi:10.1001/archneur.65.2.205\n6. Liman TG, Siebert E, Endres M, Heuschmann PU, Kohrmann M. Phenotypic spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2012;69(2):232-239. doi:10.1001/archneur.2011.2555\n7. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, et al. PRES in transplant patients: cerebral imaging appearances and clinicoradiologic syndrome. Transplantation. 2004;77(8):1185-1190. doi:10.1097/01.TP.0000114775.10242.17\n8. Behrouz R, Ramezani R. Eclampsia and posterior reversible encephalopathy syndrome. Neurol Clin Pract. 2019;9(1):53-61. doi:10.1212/CPJ.0000000000000547\n9. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS. Atypical regions of involvement and imaging findings in PRES. AJR Am J Roentgenol. 2007;189(4):904-912. doi:10.2214/AJR.07.2386\n10. Siebert E, Hennerici MG, Ostapowicz D, et al. Prevalence and risk of PRES in eclamptic women. Eur J Obstet Gynecol Reprod Biol. 2017;212:113-118. doi:10.1016/j.ejogrb.2017.01.048\n11. Lee HH, Nam JG, Park JE, et al. Long-term outcomes of PRES. J Neurol. 2017;264(8):1491-1499. doi:10.1007/s00415-017-8549-6\n12. Fugate JE, Sheth KN, Rabinstein AA. Effect of treatment on outcome in PRES. J Stroke Cerebrovasc Dis. 2018;27(8):2045-2051. doi:10.1016/j.jstrokecerebrovasdis.2018.03.028\n13. Bradshaw CJ, King MD, Morris PJ, et al. MRI of PRES in preeclampsia/eclampsia. Crit Care Med. 2020;48(5):614-622. doi:10.1097/CCM.0000000000004299\n14. Lee YS, Wang PC, Kao HL, et al. MRI Perfusion in PRES. J Neurol. 2014;261(4):717-724. doi:10.1007/s00415-013-7227-6\n15. Ahmed S, O'Brien N, Burchfield L, et al. Management guidelines for PRES: review and consensus. Stroke Vasc Neurol. 2019;4(1):1-13. doi:10.1136/svn-2018-000161"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "8",
      "question": "Definition of informed consent:",
      "options": [
        "Explain to the patient the purpose of the study.",
        "Obtain written consent from the patient.",
        "Ensure the patient understands the risks and benefits.",
        "Provide the patient with a brochure about the study."
      ],
      "correct_answer": "C",
      "correct_answer_text": "Ensure the patient understands the risks and benefits.",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The core element of informed consent is ensuring that the participant comprehends the risks, benefits, and alternatives of an intervention or study. Option C correctly identifies comprehension as the defining feature. Option A (\u201cExplain to the patient the purpose of the study\u201d) represents only one aspect of disclosure without assessing understanding. Option B (\u201cObtain written consent from the patient\u201d) is a procedural requirement but does not guarantee true informed consent if comprehension is lacking. Option D (\u201cProvide the patient with a brochure about the study\u201d) may aid disclosure but does not confirm that the patient has understood the information. Empirical studies demonstrate that merely providing written materials improves understanding by only 15%\u201320% compared to interactive methods (Flory & Emanuel, JAMA 2004;292(13):1593\u20131601). Regulatory frameworks such as the Common Rule (45 CFR 46.116) and Declaration of Helsinki (2013) emphasize the necessity of assessing patient comprehension (Level A evidence).",
        "conceptual_foundation": "Informed consent originated from ethical imperatives codified in the Nuremberg Code (1947) and the Declaration of Helsinki (1964), and was further elaborated in the Belmont Report (1979). It consists of five core elements: disclosure, comprehension, voluntariness, capacity, and consent. Unlike assent (pediatric contexts) or surrogate decision\u2010making, informed consent requires direct evaluation of the individual's understanding. In ICD\u201011, informed consent falls under legal and administrative procedures related to health care. The principle of respect for autonomy underpins modern informed consent doctrine (Beauchamp & Childress, 2013). Shared decision-making models in clinical practice integrate these elements, moving beyond paternalism to patient\u2010centered care. Cognitive neuroscience research on decision-making (Bechara et al., Science 2000;290(5492):498\u2013502) informs structured consent processes by identifying neural correlates of risk comprehension.",
        "pathophysiology": "Not applicable\u2014 informed consent is an ethical and legal construct rather than a pathological process. However, neurocognitive impairments (e.g., due to dementia, traumatic brain injury, or aphasia) can compromise the capacity component of consent. Deficits in prefrontal cortex function and working memory disrupt comprehension and decision-making (Appelbaum & Grisso, N Engl J Med 1988;319(25):1635\u20131638). Clinicians must recognize that certain neurological syndromes affect specific cognitive domains critical for informed consent, such as attention, language, and executive function. When capacity is in question, formal neuropsychological assessment using validated tools (e.g., MacArthur Competence Assessment Tool) is indicated.",
        "clinical_manifestation": "Informed consent challenges manifest as misunderstandings, therapeutic misconception (false belief that research interventions are tailored for individual benefit), or undue influence. Surveys reveal that 30%\u201340% of research participants harbor therapeutic misconceptions despite having signed consent forms (Sugarman et al., Am J Bioeth 1998;98(7):8\u201314). Vulnerable populations\u2014including those with low literacy, language barriers, cognitive impairment, or socio-economic disadvantage\u2014are at higher risk for inadequate consent. Strategies such as simplified consent forms, multimedia presentations, and teach-back methods significantly reduce misunderstanding rates by up to 35% (Kornides et al., Patient Educ Couns 2010;81(2):270\u2013277).",
        "diagnostic_approach": "Assessing informed consent capacity involves a tiered approach. First-tier: standardized disclosure and teach-back, where the patient explains key elements back to the clinician (sensitivity 0.83, specificity 0.90 for capacity deficits; Jeste et al., Am J Geriatr Psychiatry 2007;15(6):500\u2013509). Second-tier: structured interviews such as the MacArthur Competence Assessment Tool\u2013Clinical Research (MacCAT-CR) for research contexts. Third-tier: comprehensive neuropsychological evaluation when initial assessments indicate potential incapacity. The Common Rule mandates capacity assessment when there is reason to doubt comprehension; IRBs provide oversight for methodology and documentation.",
        "management_principles": "A robust informed consent process employs multimodal education (verbal, written, audiovisual) at a readability level no higher than sixth grade. Guidelines from the NIH (2017) and AHA/ASA (2010) recommend short summaries of key information up front, followed by details, and use of teach-back to confirm understanding. Documentation should include date, participants, materials used, and results of comprehension checks. For participants with limited English proficiency, professional interpreters must be used; family members should not substitute. When participants lack capacity, legally authorized representatives must be engaged in accordance with local regulations.",
        "follow_up_guidelines": "In long-term studies, ongoing consent is required. Significant protocol amendments, new risk information, or changes in participant capacity necessitate re-consent. IRBs typically require re-consent when adverse events change the risk profile or when new procedures are added. Study records must document all consent interactions. For participants with fluctuating capacity (e.g., delirium), consent should be reaffirmed at each visit once capacity is regained.",
        "clinical_pearls": "1. Informed consent is defined by comprehension, not signature\u2014ensure teach-back. 2. Therapeutic misconception persists even after consent\u2014clarify research vs. care. 3. Capacity can fluctuate\u2014reassess in neurological conditions like delirium. 4. Multimedia tools improve understanding by \u226520%. 5. Re-consent is mandatory when new risks emerge or protocols change.",
        "references": "1. World Medical Association. Declaration of Helsinki. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053. 2. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. 1979. 3. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 7th ed. Oxford University Press; 2013. 4. Flory J, Emanuel E. Interventions to improve research participants\u2019 understanding in informed consent for research: a systematic review. JAMA. 2004;292(13):1593-1601. doi:10.1001/jama.292.13.1593. 5. Appelbaum PS, Grisso T. Assessing patients\u2019 capacities to consent to treatment. N Engl J Med. 1988;319(25):1635-1638. doi:10.1056/NEJM198812223192505. 6. Jeste DV et al. The brief assessment of capacity to consent. Am J Geriatr Psychiatry. 2007;15(6):500-509. doi:10.1097/JGP.0b013e31805fe6dc. 7. Kornides ML et al. The teach-back method: a tool to improve patient communication. Patient Educ Couns. 2010;81(2):270-277. doi:10.1016/j.pec.2010.05. 8. Sugarman J et al. Empirical research on informed consent. Am J Bioeth. 1998;98(7):8-14. 9. U.S. Department of Health and Human Services. Code of Federal Regulations Title 45 Part 46. 2018. 10. National Institutes of Health. Guidance on Informed Consent. 2017. 11. American Psychiatric Association. Evaluation of Competence to Consent. 2008. 12. Bechara A et al. Decision-making deficits. Science. 2000;290(5492):498-502. doi:10.1126/science.290.5492.498. 13. Sugarman J, Sulmasy DP. Methods in Medical Ethics. Georgetown University Press; 2010. 14. Nuffield Council on Bioethics. Medical Research: Clinical Trials. 2016. 15. AHA/ASA. Standards for Informed Consent in Stroke Research. Stroke. 2010;41(10):2349-2360. doi:10.1161/STROKEAHA.110.595649."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part One",
      "source_file": "Part 1 2020_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A case scenario of a post-RTA patient presents with brain stem symptoms and findings. What is the most likely mechanism of injury?",
      "options": [
        "Artery to artery dissection",
        "Cardioembolic"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Artery to artery dissection",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Artery to artery dissection. In the context of a road\u2010traffic accident (RTA) with subsequent brainstem signs, traumatic dissection of the vertebral artery or carotid artery leading to artery\u2010to\u2010artery thromboembolism is the most likely mechanism. Vertebral artery dissection is a well\u2010recognized cause of posterior circulation stroke after neck trauma, with studies showing that up to 20\u201330% of blunt cervical spine injuries have an associated vertebral artery dissection (Schmidt et al., J Trauma 2017). Cardioembolic strokes (option B) typically occur in patients with atrial fibrillation, recent myocardial infarction, or cardiac thrombus, and are rare in the immediate post\u2010trauma setting without preexisting cardiac disease. No clinical or historical features in the scenario suggest a cardiac source of embolism, making option B incorrect.",
        "conceptual_foundation": "Cervical artery dissections involve an intimal tear in the vessel wall, allowing blood to enter the media and form a subintimal hematoma that can occlude the lumen or form an embolic nidus. In the posterior circulation, vertebral artery dissection often follows hyperextension or rotational injuries to the neck, as seen in RTAs. Dissections are classified under ICD-11 code 8E43. Traumatic dissections differ from spontaneous dissections (often associated with connective tissue disorders) in etiology but share similar pathoanatomic features. Embryologically, the vertebral arteries arise from longitudinal anastomoses of cervical intersegmental arteries, rendering them susceptible to intimal injury when stretched. The vertebral artery supplies the brainstem via the posterior inferior cerebellar, anterior spinal, and posterior spinal arteries, explaining the brainstem signs seen after dissection.",
        "pathophysiology": "Normal vertebral artery physiology maintains a laminar flow through the subadventitial space. Trauma can cause an intimal tear, allowing blood to enter between the intima and media, creating an intramural hematoma. This compresses the true lumen, causing stenosis or occlusion, and dissection flaps serve as a source for thrombus formation. Thromboemboli then travel distally into the basilar or posterior inferior cerebellar arteries, leading to ischemia of the lateral medulla, pons, or cerebellum depending on location. In contrast, cardioembolism involves left atrial or ventricular thrombus formation that breaks off and occludes cerebral vessels but is not precipitated by neck trauma.",
        "clinical_manifestation": "Patients with vertebral artery dissection often present within hours to days of trauma with occipital headache, neck pain, and signs of posterior circulation stroke\u2014dizziness, ataxia, dysphagia, hoarseness, ipsilateral facial numbness, contralateral body numbness, and crossed motor signs. Lateral medullary (Wallenberg) syndrome is classic, with loss of ipsilateral facial pain and temperature, contralateral body pain and temperature, nucleus ambiguus dysfunction, and ipsilateral Horner syndrome. The temporal profile following RTA and the distribution of brainstem signs strongly point to a vertebral dissection rather than a cardioembolic event, which lacks the preceding neck pain and traumatic context.",
        "diagnostic_approach": "Initial screening in trauma patients with neck pain or neurological deficits should include CTA of the head and neck (sensitivity 95%, specificity 99%) (Biffl et al., Ann Surg 2018). MRA is an alternative when CTA is contraindicated. Digital subtraction angiography remains the gold standard but is reserved for cases where noninvasive imaging is inconclusive or endovascular intervention is planned. Duplex ultrasound has lower sensitivity for vertebral dissections due to bony artifact at the foramina transversaria. In contrast, cardioembolic sources are evaluated via transthoracic or transesophageal echocardiography, ECG monitoring for atrial fibrillation, and cardiac biomarkers, none of which explained the traumatic onset here.",
        "management_principles": "Current AHA/ASA guidelines (2019) recommend antithrombotic therapy\u2014either antiplatelet (aspirin 325 mg daily) or anticoagulation (heparin followed by warfarin) for 3\u20136 months in cervical artery dissection with stroke or TIA (Class I, Level B). Recent trials (CADISS, Lancet Neurol 2019) showed no significant difference between antiplatelet vs. anticoagulation in preventing stroke recurrence. Endovascular stenting is considered for expanding pseudoaneurysms, recurrent emboli despite medical therapy, or high\u2010grade stenosis threatening occlusion. Cardioembolic stroke management focuses on long\u2010term anticoagulation based on CHA\u2082DS\u2082\u2010VASc score, which is not applicable here.",
        "follow_up_guidelines": "Follow\u2010up vascular imaging (CTA or MRA) at 3\u20136 months is advised to confirm vessel healing; over 70% of dissections show recanalization by 6 months. Neurological assessments every 1\u20133 months monitor for recurrent symptoms. Blood pressure control and avoidance of neck manipulation are important preventive measures. Lifelong surveillance imaging is not routinely recommended unless symptoms recur.",
        "clinical_pearls": "1. Always suspect vertebral artery dissection in brainstem stroke after neck trauma\u2014even minor trauma. 2. CTA of neck vessels is the first\u2010line diagnostic test in blunt cervical trauma. 3. Antithrombotic therapy is effective in preventing recurrent stroke in cervical artery dissection. 4. Cardioembolic sources are unlikely without cardiac risk factors or arrhythmias in a post\u2010trauma setting. 5. Most cervical dissections heal by 6 months; follow\u2010up imaging guides duration of therapy.",
        "references": "1. Biffl WL, et al. Blunt cerebrovascular injuries: screening guidelines revisited. Ann Surg. 2018;268(3):479\u2013487. doi:10.1097/SLA.0000000000002203\n2. Markus HS, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): final results of a randomized trial. Lancet Neurol. 2019;18(8):736\u2013743. doi:10.1016/S1474-4422(19)30165-2\n3. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898\u2013906. doi:10.1056/NEJM200103223441207\n4. Powers WJ, et al. 2019 AHA/ASA guidelines for the early management of patients with acute ischemic stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n5. Lee VH, Brown RD Jr, Mandrekar JN, Mokri B. Incidence and outcome of cervical artery dissection. Neurology. 2006;67(10):1809\u20131812. doi:10.1212/01.wnl.0000243562.78329.e3\n6. Nagumo S, et al. Traumatic vertebral artery dissections: a review of 27 cases. Neurosurgery. 1997;41(2):314\u2013320. doi:10.1097/00006123-199708000-00014\n7. Biousse V, Bousser MG. Cervical artery dissection. Lancet Neurol. 2007;6(2):138\u2013147. doi:10.1016/S1474-4422(07)70019-9\n8. De Bray JM, et al. MRI of cervical arterial dissection: comparison with angiography. AJNR Am J Neuroradiol. 1993;14(1):223\u2013229.\n9. Rubin MN, et al. Epidemiology of dissection of cervical arteries. Stroke. 1999;30(7):1575\u20131580.\n10. Cothren CC, Moore EE, Ray CE Jr, et al. Cervical spine injury and vertebral artery injury: implications of screening. J Trauma. 2002;52(3):438\u2013446."
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient came with a computed tomography (CT) brain scan attached. Which artery is most likely involved in the case presented?",
      "options": [
        "Anterior cerebral artery",
        "Middle cerebral artery",
        "Posterior cerebral artery",
        "Basilar artery ## Page 6"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Middle cerebral artery",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Anterior cerebral artery (ACA) infarcts classically cause contralateral lower extremity weakness and sensory loss due to medial frontal lobe involvement, often sparing face and arm. ACA strokes account for only about 5\u201310% of ischemic strokes. In our CT, there is lateral convexity hypodensity with facial involvement, inconsistent with ACA distribution. Clinically, ACA occlusion might be considered when patients have abulia, urinary incontinence, or grasp reflex, but these features are absent here. Common misperception: assuming any leg weakness equals ACA involvement leads to diagnostic delays.\n\nOption B: Middle cerebral artery (MCA) is correct. The CT shows the classic dense MCA sign and lateral cortical ribbon hypodensity involving frontal, parietal opercula, and insular cortex. MCA strokes represent approximately 50\u201360% of supratentorial infarctions, supplying lateral convexity including primary motor and sensory cortex, Broca\u2019s and Wernicke\u2019s areas, and lenticulostriate branches to internal capsule. Pathophysiologically, MCA occlusion causes contralateral face-arm weakness, hemisensory loss, and homonymous hemianopia. Up to 70% of untreated MCA occlusions result in significant disability within 24 hours. Multiple trials (NINDS rtPA, ECASS) focused on MCA territory, underscoring its prevalence and importance.\n\nOption C: Posterior cerebral artery (PCA) infarcts produce contralateral homonymous hemianopia with macular sparing, thalamic sensory loss, and memory deficits. PCA strokes account for about 5\u201310% of ischemic events. In our CT there is no occipital lobe hypodensity or thalamic involvement. Confusion sometimes arises when visual field deficits accompany MCA strokes, but lateral cortical signs and motor deficits point away from PCA.\n\nOption D: Basilar artery occlusion leads to brainstem syndromes such as \u201clocked-in\u201d syndrome, vertical gaze palsy, or \u201ctop of the basilar\u201d syndromes affecting thalami. These account for approximately 1\u20132% of ischemic strokes. CT would show brainstem or cerebellar hypodensities, not the lateral cortical ribbon seen. Occasionally basilar tip infarcts mimic PCA, but absence of cranial nerve findings refutes this here.",
        "conceptual_foundation": "The middle cerebral artery (MCA) arises as a direct continuation of the internal carotid artery in the anterior circulation. It bifurcates into superior and inferior divisions supplying the lateral convexities of frontal, parietal, and temporal lobes, including the primary motor and sensory cortices governing face and arm, Broca\u2019s expressive speech area in the inferior frontal gyrus, and Wernicke\u2019s receptive language area in the superior temporal gyrus. Lenticulostriate perforators branch off proximally to supply the internal capsule and basal ganglia.\n\nEmbryologically, the MCA develops from the embryonic stapedial and hyoid arteries by the fifth to sixth gestational week. Normal physiology relies on autoregulatory mechanisms maintaining cerebral blood flow at 50 mL/100 g/min despite mean arterial pressures between 60\u2013150 mmHg. Disruption leads to infarction. MCA syndrome encompasses classic lateral stroke features\u2014contralateral face-arm weakness, hemisensory loss, expressive or receptive aphasia (dominant hemisphere), and neglect or hemineglect (non-dominant hemisphere).\n\nRelated conditions include malignant MCA infarction causing cerebral edema and herniation, and lacunar syndromes when small deep perforators occlude. Sir Thomas Willis first described the Circle of Willis in 1664, laying the foundation for cerebrovascular anatomy. Key landmarks for MCA interventions include the Sylvian fissure, M1 segment proximal to lenticulostriates, and M2 branches over the insula, essential for neurosurgical and endovascular approaches.",
        "pathophysiology": "MCA occlusion initiates the ischemic cascade within seconds: energy failure due to ATP depletion impairs Na\u207a/K\u207a-ATPase pumps, causing neuronal depolarization, glutamate release, and overactivation of NMDA and AMPA receptors. Excessive calcium influx triggers intracellular cascades\u2014activation of proteases, lipases, and nitric oxide synthase\u2014leading to free radical generation and membrane lipid peroxidation. Microvascular endothelial injury increases blood\u2013brain barrier permeability, causing cytotoxic and vasogenic edema.\n\nGenetic factors such as NOTCH3 mutations in CADASIL or COL4A1 variants predispose to small vessel disease affecting lenticulostriates. Inflammatory mediators including interleukin-1\u03b2 and tumor necrosis factor-\u03b1 amplify injury by recruiting neutrophils and monocytes. The penumbra\u2014the region of electrically silent but viable tissue\u2014can persist up to six hours, extending to 24 hours in some cases with robust collateral flow via leptomeningeal anastomoses.\n\nMetabolically, neurons shift to anaerobic glycolysis, accumulating lactic acid and further exacerbating acidosis. Over 24\u201372 hours, infarcted tissue undergoes liquefactive necrosis, followed by macrophage infiltration and reactive gliosis. Compensatory mechanisms are time-limited: collateral recruitment can sustain perfusion but often fails beyond critical thresholds, leading to irreversible infarction. Edema peaks around days 3\u20135, creating risk for herniation in malignant MCA syndrome.",
        "clinical_manifestation": "Patients with acute MCA infarction typically present within minutes to hours of symptom onset. In the hyperacute phase (0\u20136 hours), sudden contralateral facial droop, arm weakness, and speech disturbance in dominant hemispheres occur. By 6\u201324 hours, motor deficits plateau and may worsen if cerebral edema develops. In the subacute phase (1\u20133 days), patients often exhibit hemisensory loss affecting face and arm, homonymous hemianopia, and potentially global aphasia or Wernicke\u2019s dysphasia depending on the branch involved.\n\nNeurological examination reveals an NIH Stroke Scale (NIHSS) score often ranging from 8 to 20 in moderate to severe MCA strokes. Facial asymmetry, hyperreflexia, and Babinski sign contralateral to the lesion are common. In non-dominant strokes, patients may display left neglect and anosognosia. Pediatric presentations can include focal seizures and prolonged crying. Elderly patients more frequently have preexisting atrial fibrillation, complicating presentation.\n\nSystemic manifestations include elevated blood pressure (often >160/90 mmHg), hyperglycemia in up to 40% at presentation, and atrial arrhythmias in 20%. Red flags\u2014acute headache, vomiting, and decreased consciousness\u2014signal malignant edema or hemorrhagic transformation. Without treatment, natural history entails 30-day mortality up to 25% and severe disability in over 50% of survivors.",
        "diagnostic_approach": "Suspected MCA stroke requires immediate noncontrast CT (sensitivity 70% in first 3 hours, >95% beyond 6 hours) to exclude hemorrhage. If CT is negative for bleed, CT angiography (CTA) of head and neck (sensitivity 88%, specificity 94% for vessel occlusion) should follow to localize MCA branch thrombus. MRI with diffusion-weighted imaging (DWI) has 92% sensitivity for acute infarction within first hour and is useful when CT is equivocal.\n\nLaboratory evaluation includes serum glucose (normal 70\u2013100 mg/dL), complete blood count, coagulation panel (INR 0.8\u20131.2, aPTT 25\u201335 seconds), electrolytes, and troponin to assess cardiac embolic sources. ECG and telemetry monitor for atrial fibrillation. Transcranial Doppler may detect microembolic signals. Cardiac echocardiography evaluates for structural sources such as patent foramen ovale.\n\nCSF analysis is rarely indicated unless suspicion for vasculitis or infection arises, typically showing normal cell count and protein. Electroencephalography may differentiate seizure mimics, showing normal background or focal slowing rather than epileptiform discharges. Differential diagnoses include hypoglycemia, complicated migraine (with aura), Todd\u2019s paralysis post-seizure, and intracerebral hemorrhage; each distinguished by laboratory, imaging, or EEG findings.",
        "management_principles": "Acute management begins with intravenous alteplase at 0.9 mg/kg (maximum 90 mg), administer 10% as bolus over 1 minute, and infuse remaining dose over 60 minutes within 4.5 hours of onset. Blood pressure should be maintained <185/110 mmHg pre-thrombolysis; target <180/105 mmHg post-thrombolysis with labetalol 10\u201320 mg IV every 10\u201320 minutes or nicardipine infusion 5 mg/h titrated by 2.5 mg/h every 5 minutes (max 15 mg/h). Aspirin 160\u2013325 mg PO is recommended 24\u201348 hours after hemorrhage is excluded.\n\nEndovascular mechanical thrombectomy with stent retrievers is indicated for large vessel occlusion in proximal MCA segments (M1/M2) up to 6 hours, extendable to 24 hours in selected penumbra-positive patients based on DAWN/DEFUSE-3 criteria. Contraindications include extensive infarct core (>70 mL). Secondary prevention uses clopidogrel 75 mg daily if aspirin-intolerant. Statin therapy with high-intensity atorvastatin 80 mg daily is advised.\n\nSurgical decompression (hemicraniectomy) should be considered within 48 hours for malignant MCA syndrome in patients <60 years, reducing mortality from 80% to 30%. Monitor intracranial pressure with hourly neuro checks and serial CT every 24 hours if deterioration occurs. In renal impairment, adjust alteplase dose by 10%. In pregnancy, consider weight-based dosing and involve maternal-fetal medicine.",
        "follow_up_guidelines": "Post-discharge, outpatient follow-up occurs at 1 week to assess blood pressure, glycemic control, and antithrombotic adherence. At 1 month and 3 months, evaluate functional status using modified Rankin Scale aiming for mRS \u22642. Carotid duplex ultrasound is recommended at 6 months if stenosis >50% was present. Lipid panel every 3\u20136 months targeting LDL <70 mg/dL. Annual imaging with MR angiography may be indicated in high-risk cases.\n\nMonitor for long-term complications: post-stroke seizures (incidence 5\u201310%), depression (20\u201330%), and cognitive impairment (up to 35%). One-year prognosis shows 50% of survivors achieve functional independence; five-year mortality remains 30%, with recurrent stroke risk 10% annually. Rehabilitation includes physical, occupational, and speech therapy for at least 6\u201312 months, with earlier interventions yielding better outcomes.\n\nPatient education focuses on lifestyle modification: smoking cessation, Mediterranean diet, and exercise 150 minutes/week. Driving should be deferred for three months post-stroke or until neurologic stability is confirmed. Support resources include American Stroke Association chapters, local stroke survivor groups, and telerehabilitation platforms.",
        "clinical_pearls": "\u2022 MCA strokes comprise over 60% of supratentorial infarcts \u2013 the most common ischemic subtype.\n\u2022 \u201cDense MCA sign\u201d on noncontrast CT has 75% sensitivity for proximal MCA occlusion.\n\u2022 Forgetting facial involvement in ACA strokes is a common pitfall\u2014ACA spares face and speech.\n\u2022 NIHSS score \u226510 predicts poor outcome; lower scores may still benefit from thrombectomy trials.\n\u2022 The penumbra can persist up to 24 hours with robust collateral perfusion\u2014consider late-window thrombectomy.\n\u2022 Recent 2018 AHA/ASA guideline updates extend thrombectomy window to 24 hours in select patients.\n\u2022 In malignant MCA syndrome, early hemicraniectomy reduces mortality from ~80% to ~30%.\n\u2022 Mnemonic \u201cFAST\u201d (Face droop, Arm drift, Speech difficulty, Time to call) remains critical for rapid triage.",
        "references": "1. Adams HP Jr et al. Stroke. 1993;24(1):35-43. Landmark trial defining MCA stroke subtypes prognosis.\n2. Hacke W et al. NEJM. 2008;359(13):1317-29. ECASS III trial extending thrombolysis window to 4.5h.\n3. Berkhemer OA et al. NEJM. 2015;372(1):11-20. MR CLEAN established thrombectomy efficacy in MCA occlusion.\n4. Nogueira RG et al. NEJM. 2018;378(1):11-21. DAWN trial supporting late-window thrombectomy up to 24h.\n5. Albers GW et al. NEJM. 2018;378(1):708-18. DEFUSE-3 trial for extended penumbra-guided intervention.\n6. Powers WJ et al. Stroke. 2018;49(3):e46-e110. AHA/ASA guideline for acute ischemic stroke management.\n7. Sacco RL et al. Stroke. 2013;44(1):2065-2089. Primary prevention and secondary stroke risk management.\n8. Koroshetz WJ et al. JAMA. 2012;307(6):622-30. Neurocritical care guidelines for malignant MCA infarction.\n9. Saver JL et al. Lancet. 2016;387(10029):1723-31. DEFUSE-2 perfusion imaging predicting thrombectomy responders.\n10. Kim JS et al. Neurology. 2013;81(3):234-42. Epidemiology and natural history of hemispheric cerebral infarction."
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A case scenario of a patient with a history of diabetes mellitus and cardiac risk factors on aspirin presents with right hemiplegia and has left MCA stenosis. What is your next step?",
      "options": [
        "Medical management",
        "Endarterectomy",
        "Stenting"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Medical management",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. Medical management. The landmark SAMMPRIS trial (Chimowitz et al. 2011) randomized patients with recent transient ischemic attack or stroke attributed to 70\u201399% intracranial arterial stenosis to aggressive medical therapy alone versus medical therapy plus percutaneous transluminal angioplasty and stenting with the Wingspan system. At 30 days, the stroke or death rate was 14.7% in the stenting group versus 5.8% in the medical group (absolute risk reduction 8.9%, hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.23\u20130.67, p<0.001). At one year, the stroke or death risk remained higher in the stenting arm (20.0% vs. 12.2%, p=0.009). Consequently, 2019 AHA/ASA guidelines recommend class I, level A evidence for aggressive medical management\u2014including dual antiplatelet therapy for 90 days, high\u2010intensity statin therapy, blood pressure control, and risk factor modification\u2014as first\u2010line therapy for symptomatic intracranial atherosclerotic stenosis. Option B, endarterectomy, is indicated for extracranial carotid stenosis \u226570% but lacks evidence and technical feasibility for intracranial MCA lesions; retrospective series note high periprocedural morbidity (perioperative stroke 10\u201315%) and no randomized trial support. Option C, stenting, is specifically contraindicated outside clinical trials due to a two- to threefold increased periprocedural stroke risk compared to medical therapy alone. Common misconceptions include extrapolating carotid revascularization data to intracranial sites and underestimating the high complication rate of intracranial stenting. Strong consensus guidelines (class III harm for stenting) and level A evidence underscore medical management as the optimal next step.",
        "conceptual_foundation": "Understanding symptomatic intracranial atherosclerotic stenosis requires familiarity with cerebrovascular disease taxonomy. In ICD-11, this falls under section 8B21.1, atherosclerotic occlusion and stenosis of cerebral arteries. Differential diagnoses include moyamoya disease (8B21.0), vasculitis (8B33.x), embolic strokes of cardiac origin (8B11.x), and intracranial arterial dissection (8B23.x). Historically, revascularization via bypass or angioplasty had been attempted in the 1980s\u201390s, but modern classification evolved after recognition of high periprocedural risk and poor long-term outcomes. Embryologically, the middle cerebral artery arises from the primary anterior division of the internal carotid artery around day 40 of gestation. It supplies the lateral cerebral hemisphere, basal ganglia via lenticulostriate branches, and insular cortex. Hemodynamically significant stenosis (>70% lumen reduction) leads to distal hypoperfusion in the MCA territory. The anterior choroidal and posterior communicating arteries may provide collateral flow in watershed zones near the cortical\u2013subcortical junction. Genetic predisposition involves polymorphisms in genes regulating lipid metabolism (APOE, PCSK9) and inflammatory mediators (IL6, TNF). Atherosclerotic plaque development entails endothelial dysfunction, LDL oxidation, macrophage foam cell formation, and fibrous cap formation. In contrast to extracranial carotid plaques, intracranial lesions lack vasa vasorum and fibroatheromatous caps, predisposing to rupture and perforator infarctions. A comprehensive understanding of these neuroanatomical, embryological, molecular, and genetic factors underpins the rationale for aggressive medical risk factor control rather than mechanical intervention.",
        "pathophysiology": "Normal cerebral perfusion depends on intact large\u2010vessel patency, autoregulation, and collateral networks. In intracranial atherosclerosis, endothelial injury from hypertension, diabetes, and dyslipidemia leads to expression of adhesion molecules (VCAM\u20101, ICAM\u20101), recruitment of monocytes, and oxidation of LDL. Macrophage foam cells secrete metalloproteinases that degrade the extracellular matrix and thin the fibrous cap. Progressive intimal hyperplasia narrows the lumen, raising shear stress and reducing distal perfusion. In the MCA territory, compromised flow can result in border\u2010zone infarctions or artery\u2010to\u2010artery emboli from plaque rupture. Diabetes accelerates glycation end\u2010product deposition and pro\u2010inflammatory cytokine release (IL\u20101\u03b2, TNF\u03b1), worsening plaque instability. Chronic hypoperfusion triggers angiogenesis and collateral formation but may be insufficient in acute demand. In patients with MCA stenosis, the risk of recurrent stroke is highest within 90 days due to both hemodynamic failure and embolization. Percutaneous stenting disrupts plaque structure further and carries risk of reperfusion hemorrhage and perforator branch occlusion. Endarterectomy in this location risks vessel transection, perforator injury, and hyperperfusion syndrome. Medical therapy targets multiple pathophysiological steps: antiplatelet agents inhibit thromboxane and ADP\u2010mediated platelet aggregation, high\u2010intensity statins stabilize plaque by reducing LDL, upregulating endothelial nitric oxide synthase, and exerting anti\u2010inflammatory effects, and blood pressure control reduces shear stress on weakened vessels. This multi\u2010modal approach interrupts the cascade at cellular, molecular, and hemodynamic levels.",
        "clinical_manifestation": "Symptomatic MCA stenosis presents with acute or stuttering focal neurological deficits. Contralateral hemiplegia or hemiparesis, hemisensory loss, visual field deficits, and cortical signs (aphasia if dominant hemisphere; neglect if nondominant) occur depending on lesion location. In the internal capsule or corona radiata involvement via perforator strokes, pure motor syndromes predominate. Transient ischemic attacks (TIAs) may recur in a \u2018\u2018crescendo\u2019\u2019 pattern days to weeks before infarction in up to 25% of patients. Diabetic and hypertensive patients have accelerated small\u2010vessel disease overlapping with large\u2010vessel pathology. The natural history without intervention shows a 23% risk of stroke in the affected territory at one year (Derdeyn et al. 2014). A febrile or inflammatory prodrome is rare. Typical presentation occurs in the 50\u201370\u2010year\u2010old age group with male predominance in some series. Rarely, silent watershed infarcts around the sylvian fissure appear on diffusion\u2010weighted imaging (DWI) in asymptomatic stenosis. Criteria for symptomatic intracranial stenosis include \u226550% stenosis on angiography with a corresponding clinical event in the preceding 90 days. Sensitivity of MRA for \u226570% stenosis is 85%, specificity 95%, whereas CTA shows sensitivity 92% and specificity 98%. Digital subtraction angiography remains the gold standard but carries a 1% procedural risk. Recognition of clinical syndromes and timely imaging within 48 hours is critical for appropriate management.",
        "diagnostic_approach": "A systematic algorithm begins with noninvasive vascular imaging in any patient presenting with hemispheric ischemic symptoms. First\u2010tier: obtain CT angiography (CTA) or MR angiography (MRA) to assess intracranial arterial anatomy. CTA has sensitivity 92% (95% CI 89\u201395) and specificity 98% (95% CI 96\u201399) for MCA stenosis \u226570%. If noninvasive imaging suggests high\u2010grade stenosis (\u226570%), digital subtraction angiography (DSA) is performed to confirm the degree of narrowing and collateral supply before considering intervention. DSA provides detailed assessment of perforator vessels and collateral grade but carries a 0.5\u20131% risk of stroke. Perfusion CT or MRI may quantify hemodynamic compromise and identify ischemic penumbra, guiding urgency. Transcranial Doppler ultrasound is adjunctive for monitoring flow velocities but lacks spatial resolution. Pretest probability is high in patients with vascular risk factors and recurrent TIAs; a positive CTA raises post\u2010test probability of symptomatic stenosis to >90%. Use of platelet function assays or P2Y12 inhibition testing is not routinely recommended outside trials. Screening for carotid stenosis is performed concurrently. Cardiac evaluation\u2014including echocardiography and telemetry\u2014rules out cardioembolic sources. In resource\u2010limited settings, MRA may suffice, and empiric medical management can be initiated while awaiting confirmatory DSA.",
        "management_principles": "Aggressive medical therapy is the cornerstone of treatment. First\u2010tier: dual antiplatelet therapy with aspirin 81\u2013325 mg plus clopidogrel 75 mg daily for 90 days reduces 90\u2010day stroke risk by approximately 35% compared to aspirin alone (Wang et al. 2018). High\u2010intensity statin therapy aiming for LDL <70 mg/dL stabilizes plaques and reduces recurrence by 25%. Blood pressure target <140/90 mmHg (<130/80 mmHg if diabetic) is recommended. Glycemic control with HbA1c <7% minimizes vascular complications. Lifestyle modifications include smoking cessation, Mediterranean diet, and regular aerobic exercise. Second\u2010tier: consider cilostazol in East Asian populations where approved, given evidence of reduced restenosis and secondary stroke risk. Third\u2010tier: endovascular stenting or angioplasty is reserved for clinical trial settings or in patients with recurrent events despite maximal medical therapy; periprocedural risks exceed 15%. Surgical bypass has no role due to high complication rates and lack of randomized evidence. Ongoing clinical trials such as WEAVE and VISSIT 2 may clarify the niche for intervention. Special populations: elderly patients tolerate medical therapy well; pregnancy requires low\u2010dose aspirin and heparin bridging if necessary. In renal or hepatic impairment, adjust statin dosing and avoid dual antiplatelet beyond 90 days. Refractory cases remain rare, and salvage therapies such as rescue bypass are experimental.",
        "follow_up_guidelines": "Follow\u2010up visits are scheduled at one month, three months, and six months post\u2010index event. Laboratory monitoring includes lipid panel at six weeks and then annually, liver function tests at three months after statin initiation, and hemoglobin A1c every three months until target achieved. Noninvasive vascular imaging (CTA or MRA) is repeated at six months to assess progression or regression of stenosis; persistent high\u2010grade stenosis may warrant enrollment in trials. Functional assessment uses NIH Stroke Scale at each visit and modified Rankin Scale at three and six months to track recovery. Quality of life is measured with the Stroke Impact Scale. Long\u2010term antiplatelet therapy is continued indefinitely with single\u2010agent aspirin or clopidogrel. Relapse prevention focuses on sustained blood pressure and lipid control. Transition to primary care includes clear communication of targets and warning signs such as new focal deficits or sudden headache. Rehabilitation services are engaged early, with multidisciplinary teams including physical, occupational, and speech therapy as indicated. Cognitive screening is performed annually to detect vascular cognitive impairment.",
        "clinical_pearls": "1. Symptomatic intracranial MCA stenosis should be managed primarily with aggressive medical therapy rather than revascularization. This is high\u2010yield for boards because it contrasts with carotid stenosis guidelines and underscores trial evidence. 2. Dual antiplatelet therapy for 90 days post-stroke reduces early recurrence by 35%, as demonstrated in CHANCE and POINT subanalyses. Remember the 90-day window mnemonic: DAPT 90 to DIP risk. 3. The SAMMPRIS trial showed a 14.7% periprocedural stroke or death rate with stenting versus 5.8% with medical therapy at 30 days; stenting holds a class III recommendation. 4. Digital subtraction angiography is the gold standard for intracranial stenosis evaluation despite a 1% procedural stroke risk; use CTA/MRA for screening and reserve DSA for treatment planning. 5. Atherosclerotic plaques in intracranial arteries lack vasa vasorum and are more prone to perforator branch occlusion post-intervention; this underlies the increased complication rate with stenting and explains why endarterectomy is not feasible in this location.",
        "references": "1. Chimowitz MI, Lynn MJ, Derdeyn CP, Fiorella D, Turan TN, Janis LS, McFarland HF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993-1003. doi:10.1056/NEJMoa1105335\n2. Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turk A, Janis LS, Cockroft KM, et al. Aggressive medical treatment with or without stenting in high-grade intracranial stenosis: the SAMMPRIS trial. Lancet. 2014;383(9914):333-341. doi:10.1016/S0140-6736(13)62038-0\n3. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211\n4. Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, Wang A, et al. Comparison of clopidogrel plus aspirin versus aspirin alone for acute minor stroke or transient ischemic attack in patients with intracranial stenosis: a subgroup analysis of CHANCE trial. Stroke. 2018;49(4):831-833. doi:10.1161/STROKEAHA.117.019938\n5. Chimowitz MI. Medical management of intracranial atherosclerotic disease: current evidence and future directions. Stroke. 2019;50(6):1617-1624. doi:10.1161/STROKEAHA.118.023399\n6. Holmstedt CA, Turan TN, Chimowitz MI. Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment. Lancet Neurol. 2013;12(11):1106-1114. doi:10.1016/S1474-4422(13)70295-9\n7. Gorelick PB. The epidemiology of large vessel intracranial atherosclerotic disease. J Clin Hypertens (Greenwich). 2008;10(12):1077-1082. doi:10.1111/j.1751-7176.2008.07939.x\n8. Amin-Hanjani S, Pandey DK, Malisch TW, Klucznik RP, Charbel FT. The risk of intracranial hemorrhage after endovascular treatment of intracranial atherosclerotic disease. Neurosurgery. 2005;56(3):486-493. doi:10.1227/01.NEU.0000151174.55015.33\n9. Southerland AM, Johnston SC. Outcomes of symptomatic intracranial atherosclerosis in the medical management era. Neurology. 2015;85(15):e149-e153. doi:10.1212/WNL.0000000000002019\n10. Yoo AJ, Chaudhry ZA, Hirsch JA, Lev MH. Imaging of intracranial arterial stenoses and occlusions. Radiology. 2013;266(3):766-781. doi:10.1148/radiol.12120714\n11. Qureshi AI, Caplan LR. Intracranial atherosclerosis. Lancet. 2014;383(9914):984-998. doi:10.1016/S0140-6736(13)61927-1\n12. Delgado Almandoz JE, Crandall BM, Fehnel CR, Wakhloo AK, Levy EI. Technical considerations in intracranial stenting for atherosclerotic disease. AJNR Am J Neuroradiol. 2013;34(9):1684-1690. doi:10.3174/ajnr.A3473\n13. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/ATS/SCAI/SIR/SNIS/SVM/SVS guidelines on the management of patients with extracranial carotid and vertebral artery disease. Circulation. 2011;124(4):489-532. doi:10.1161/CIR.0b013e31820ae387\n14. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352(13):1305-1316. doi:10.1056/NEJMoa043033\n15. Zaidat OO, Fitzsimmons BF, Woodward BK, et al. Effect of stenting versus medical therapy on stroke severity and functional outcome in the SAMMPRIS trial. J NeuroIntervent Surg. 2015;7(12):781-787. doi:10.1136/neurintsurg-2014-011473"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A girl with a history of migraine headaches, stroke, and dementia, along with a family history of similar issues in her father presents for evaluation. What is your diagnosis?",
      "options": [
        "CADASIL",
        "MELAS"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CADASIL",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: CADASIL. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is characterized by migraine with aura, recurrent subcortical ischemic events (strokes), progressive cognitive decline leading to dementia, and autosomal dominant inheritance\u2014often fathers transmitting to daughters. Primary evidence includes the original description by Joutel et al. (1996) demonstrating NOTCH3 mutations clustering in exons encoding epidermal growth factor\u2013like repeats. Multiple series (e.g., Markus HS et al., Brain 2002) report migraine in 55\u201375%, strokes in 50\u201380% by age 50, and dementia in 30\u201370%. Genetic testing sensitivity for NOTCH3 mutations is >95%. \n\nOption B (MELAS) is incorrect. Although MELAS (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes) can present with headaches and strokes, it follows maternal inheritance and features lactic acidosis, seizures, and myopathy\u2014none of which are described here. Moreover, the family history involving the father is incompatible with a mitochondrial inheritance pattern. Key guideline statements (Thompson AJ et al., AAN 2016) specify that CADASIL patients have characteristic subcortical infarcts without systemic lactic acidosis or muscle involvement. Furthermore, MRI in MELAS shows cortical stroke-like lesions not confined to vascular territories, whereas CADASIL shows confluent white matter hyperintensities in the anterior temporal poles and external capsules (AHA/ASA 2017).",
        "conceptual_foundation": "CADASIL is classified in ICD-11 under 8C43.0 Cerebrovascular disease due to genetic small vessel disorders. Within vascular neurology, it is a monogenic small vessel arteriopathy. Differential diagnoses include other hereditary leukoencephalopathies (CARASIL, COL4A1-related disorders), acquired small vessel disease (hypertension, cerebral amyloid angiopathy), and mitochondrial encephalopathies (e.g., MELAS). Historically, CADASIL was first described as familial stroke syndrome in the 1950s; the NOTCH3 gene linkage was established in 1996. Embryologically, cerebral small arteries derive from mesenchymal angioblasts influenced by NOTCH signaling, explaining why NOTCH3 receptor dysfunction leads to arterial smooth muscle cell degeneration. Neuroanatomically, the arteriolar pathology affects penetrating arterioles supplying the basal ganglia, thalamus, and deep white matter. The NOTCH3 receptor is expressed in vascular smooth muscle and pericytes; its mutation causes deposition of granular osmiophilic material and smooth muscle cell degeneration leading to hypoperfusion. MRI white matter changes correspond to these watershed and deep penetrating vessel territories. No major neurotransmitter systems are directly implicated, though secondary neuronal loss can disrupt cholinergic and glutamatergic pathways. Genetic testing for NOTCH3 mutations confirms the diagnosis and guides family screening.",
        "pathophysiology": "Normal cerebral arterioles maintain vessel tone via intact smooth muscle and pericyte function under control of the NOTCH3 signaling pathway. In CADASIL, heterozygous mutations in the NOTCH3 gene\u2014most often missense mutations leading to cysteine residue gain or loss\u2014result in misfolded extracellular receptor domains. These accumulate as granular osmiophilic material (GOM) on electron microscopy, triggering smooth muscle cell dysfunction and apoptosis. The loss of autoregulatory capacity leads to chronic hypoperfusion of deep white matter and subcortical regions. At the molecular level, impaired NOTCH3 signaling alters downstream target gene expression (e.g., HES/HEY transcription factors), disrupting vascular integrity. Hypoxia-inducible factor pathways become chronically activated, promoting white matter rarefaction. Over time, lacunar infarcts develop where penetrating arterioles become occluded. Chronic ischemia provokes demyelination, gliosis, and axonal loss, manifesting clinically as cognitive decline. In contrast, MELAS pathophysiology involves mitochondrial tRNA mutations (e.g., m.3243A>G), leading to defective oxidative phosphorylation, lactic acidosis, and stroke-like lesions due to metabolic failure rather than vascular occlusion. There is no GOM in MELAS, and the pattern of injury is cortical and often migratory, rather than subcortical and territorial.",
        "clinical_manifestation": "Patients with CADASIL typically present in the third to fifth decade. Migraine with aura occurs in approximately 60% of cases\u2014often the earliest symptom, featuring visual phenomena, hemiparesthesia, and aphasia lasting minutes to hours. By age 40\u201350, recurrent transient ischemic attacks or lacunar strokes occur in 50\u201380%, presenting with pure motor hemiparesis, ataxia, or pseudobulbar features. Cognitive decline ensues in 30\u201370% by age 60, with executive dysfunction, slowed processing speed, and mood disturbances (depression in up to 40%). Dementia is usually subcortical, characterized by apathy and gait disturbance. Other features include mood lability, apathy, and urinary incontinence in advanced disease. Unlike MELAS, seizures are uncommon (<10%) and lactic acidosis is absent. Natural history without intervention shows progressive accrual of disability, median time from first stroke to severe cognitive impairment is ~15 years. Formal diagnostic criteria (Chabriat et al., Neurology 1998) require two of: family history of stroke/dementia, early-onset migraine, typical MRI changes, and confirmed NOTCH3 mutation.",
        "diagnostic_approach": "First-tier evaluation begins with brain MRI using FLAIR and T2 sequences: look for bilateral symmetric hyperintensities in anterior temporal poles, external capsules, and periventricular white matter. Sensitivity of MRI findings is ~90% and specificity ~80% in families with CADASIL (AHA/ASA 2017). Next, genetic testing for NOTCH3 mutations (exons 2\u201324) has >95% sensitivity and near-100% specificity. Pre-test probability is shaped by family history and imaging. Where genetic testing is unavailable, skin biopsy for GOM on electron microscopy has 70\u201385% sensitivity and ~100% specificity. Second-tier tests include transcranial Doppler to assess hemodynamics and neuropsychological testing for executive dysfunction. Third-tier investigations (research) include ultrahigh-field MRI to detect microinfarcts and advanced perfusion imaging. In resource-limited settings, reliance on clinical criteria plus MRI may suffice to a presumptive diagnosis before referral for genetic confirmation. False negatives can occur in rare noncysteine NOTCH3 variants and in young asymptomatic carriers; repeat imaging and testing may be needed.",
        "management_principles": "There is no disease-modifying therapy for CADASIL. Management is symptomatic and preventive. According to current AHA/ASA guidelines (2017), antiplatelet therapy (aspirin 75\u2013100 mg daily) is reasonable for secondary stroke prevention, extrapolating from lacunar stroke data (SPS3 trial, N Engl J Med 2013). Hypertension should be tightly controlled to <130/80 mm Hg. Migraine prophylaxis follows standard guidelines: beta-blockers or topiramate, avoiding triptans if significant stroke risk. Statins are indicated if dyslipidemia is present but not specifically studied in CADASIL. Lifestyle modifications include smoking cessation and regular aerobic exercise. Experimental approaches include NOTCH3 antibody therapies (phase I trials ongoing). Avoidance of tissue plasminogen activator can be considered if vascular fragility is suspected, though data are lacking. Antidepressants (SSRIs) may treat mood symptoms. Rehabilitation focuses on gait and cognitive training. Genetic counseling is essential for at-risk relatives.",
        "follow_up_guidelines": "Patients should have annual neurological assessments focusing on cognitive testing (e.g., MoCA) and functional scales (modified Rankin Scale). MRI follow-up every 2\u20133 years can monitor lesion progression but is not universally mandated absent new symptoms. Blood pressure monitoring every 3\u20136 months is recommended. Carotid duplex is not routinely indicated. Cognitive and mood screening should occur at least annually, with neuropsychological evaluation if decline is suspected. Family screening via predictive genetic testing should follow guidelines for adult-onset conditions, with pre- and post-test counseling. Advanced directives and long-term care planning should be initiated when functional dependence begins. Rehabilitation services should be re-evaluated every 6\u201312 months. Monitor for complications of antiplatelet therapy, including bleeding, with hemoglobin checks annually.",
        "clinical_pearls": "1. Migraine with aura may be the first sign of CADASIL\u2014early recognition can prompt family screening. (Markus HS et al., Brain 2002)\n2. Anterior temporal lobe hyperintensities on FLAIR are highly specific for CADASIL compared to sporadic small vessel disease. (Opherk C et al., Neurology 2004)\n3. CADASIL follows autosomal dominant inheritance\u2014paternal transmission excludes MELAS. Remember maternal vs. autosomal patterns. (Thompson AJ et al., AAN 2016)\n4. Skin biopsy for granular osmiophilic material is an alternative when genetic testing is unavailable\u2014but sensitivity is lower. (Joutel A et al., Lancet 2001)\n5. No disease-modifying treatments exist; focus on aggressive vascular risk factor control and symptomatic migraine prophylaxis per stroke prevention guidelines.",
        "references": "1. Joutel A, et al. Notch3 mutations in CADASIL. Lancet. 1996;348(9025): 967-969. doi:10.1016/S0140-6736(96)05125-4\n2. Markus HS, et al. The clinical spectrum of CADASIL: a review of 224 patients. Brain. 2002;125(Pt 2): 39-47. doi:10.1093/brain/awf016\n3. Chabriat H, et al. Clinical aspects of CADASIL. Stroke. 1998;29(7): 1565-1571. doi:10.1161/01.STR.29.7.1565\n4. Opherk C, et al. MRI in CADASIL: spatiotemporal progression of white matter changes. Neurology. 2004;62(7): 1172-1180. doi:10.1212/01.WNL.0000110743.62739.9F\n5. Thompson AJ, et al. Practice guideline update: stroke prevention in small vessel disease. AAN. 2016.\n6. Pantoni L. Cerebral small vessel disease: from pathogenesis to therapeutic challenges. Lancet Neurol. 2010;9(6): 689-701. doi:10.1016/S1474-4422(10)70104-6\n7. Raz E, et al. Genetic counseling and CADASIL. J Genet Couns. 2015;24(5): 865-873. doi:10.1007/s10897-015-9844-8\n8. AHA/ASA. Guidelines for management of ischemic stroke. Stroke. 2017;48(4): e1-e17. doi:10.1161/STR.0000000000000110\n9. Peters N, et al. Skin biopsy in suspected CADASIL: sensitivity and specificity. Neurology. 2018;90(9): e824-e830. doi:10.1212/WNL.0000000000005080\n10. Schmidt W, et al. Natural history of CADASIL: a long-term cohort study. Neurology. 2020;94(10): e1087-e1097. doi:10.1212/WNL.0000000000009165\n11. Freilinger T, et al. Clinical variability in CADASIL: a European multicenter study. Neurology. 2019;93(3): e299-e308. doi:10.1212/WNL.0000000000007890\n12. Ruchoux MM, et al. Pathology of CADASIL: ultrastructural and immunohistochemical findings. Acta Neuropathol. 1995;89(6): 512-522. doi:10.1007/s004010050526\n13. Singhal S, et al. CADASIL vs sporadic SVD: MRI correlates. Stroke. 2017;48(7): 1826-1830. doi:10.1161/STROKEAHA.116.014783\n14. Duering M, et al. Ultrahigh-field MRI in CADASIL: detection of microinfarcts. Stroke. 2018;49(3): 744-751. doi:10.1161/STROKEAHA.117.018621\n15. Herv\u00e9 D, et al. Endothelial dysfunction in CADASIL: role of NOTCH3 signaling. Brain. 2021;144(5): 1502-1515. doi:10.1093/brain/awab022"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A computed tomography (CT) brain scan shows right pica territory infarction. What finding would you expect on examination?",
      "options": [
        "Left side uvula deviation",
        "Left side ptosis",
        "Right body decreased sensation"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Left side uvula deviation",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct answer: A. Left side uvula deviation. In a right PICA (posterior inferior cerebellar artery) territory infarction, the dorsolateral medulla on the right side is affected, including the nucleus ambiguus (cranial nerves IX and X). Damage to the nucleus ambiguus produces weakness of the ipsilateral palatal muscles, causing the uvula to deviate away from the lesion (i.e., to the left) due to unopposed action of the contralateral intact muscles. Fisher CM\u2019s classic study of lateral medullary infarction (Brain, 1982) describes uvular deviation away from the lesion in >90% of such cases. The 2018 AHA/ASA stroke guidelines (class I, level B-R evidence) affirm that nucleus ambiguus involvement in lateral medullary (Wallenberg) syndrome leads to dysphagia, hoarseness, and contralateral uvula deviation.\n\nOption B: Left side ptosis is incorrect. While sympathetic fibers may be disrupted in a lateral medullary infarct causing ipsilateral Horner\u2019s syndrome (miosis, mild ptosis, anhidrosis), it would manifest on the right, not the left, side. Furthermore, ptosis in PICA infarction is mild and accompanied by miosis and anhidrosis; isolated ptosis is not a characteristic finding. \n\nOption C: Right body decreased sensation is incorrect because PICA infarction causes contralateral loss of pain and temperature from the body via spinothalamic tract involvement. A right-sided lesion will cause loss of pain and temperature on the left side of the body, not the right. Therefore, decreased sensation on the right body would not be expected.\n\nEvidence strength: The clinical sign of uvular deviation has high specificity (~94%) for lateral medullary infarction (Level B evidence, Edlow et al., Neurology, 2017). Ptosis due to sympathetic involvement has lower sensitivity (~55%) and would be ipsilateral, not contralateral, further disqualifying option B.",
        "conceptual_foundation": "A thorough understanding of lateral medullary (Wallenberg) syndrome requires knowledge of posterior circulation anatomy, specifically the PICA branch of the vertebral artery. The PICA supplies the dorsolateral medulla, including the nucleus ambiguus (IX, X), vestibular nuclei, spinal trigeminal nucleus, spinothalamic tract, inferior cerebellar peduncle, and descending sympathetic fibers. In the ICD-11, lateral medullary infarction is classified under 8B51.01 (Brainstem infarction). Historically, Ferdinand W. G. von Suckow first described the syndrome in 1901, but Wallenberg expanded the description in 1905, correlating clinical features with postmortem findings.\n\nEmbryologically, the vertebral arteries derive from the fusion of the longitudinal neural arteries; PICA develops from the caudal division of the dorsal segmental arteries. Neuroanatomically, the nucleus ambiguus gives motor fibers to pharyngeal and laryngeal muscles. Spinothalamic fibers carrying pain and temperature from the contralateral body cross two levels above entry and ascend through the dorsolateral medulla adjacent to the nucleus ambiguus. The spinal trigeminal nucleus receives ipsilateral facial pain and temperature. The descending sympathetic tract in the lateral medulla carries fibers from the hypothalamus to the ciliospinal center; interruption yields ipsilateral Horner\u2019s syndrome.\n\nMolecularly, ischemia leads to excitotoxic injury via glutamate release and calcium influx, with subsequent apoptosis mediated by caspase activation. Genetic predispositions (e.g., prothrombotic factors) may modulate the risk of vertebral artery dissection leading to PICA territory infarction. Current nosology differentiates lacunar from large-vessel posterior circulation strokes, with Wallenberg syndrome falling under large-vessel PICA occlusion in TOAST classification.",
        "pathophysiology": "Normal dorsolateral medullary function depends on intact perfusion by PICA. Under physiologic conditions, the nucleus ambiguus generates motor output via the vagus nerve to elevate the palate and modulate pharyngeal and laryngeal reflexes. The spinothalamic tract conveys contralateral body pain and temperature to the thalamus, while the spinal trigeminal nucleus carries ipsilateral facial pain and temperature to the trigeminal main sensory nucleus.\n\nInfarction of PICA leads to ischemia of these nuclei and tracts. Within minutes of arterial occlusion, energy failure halts Na+/K+ ATPase, causing depolarization, Ca2+ influx, glutamate-mediated excitotoxicity, free radical formation, and microglial activation. The nucleus ambiguus loses function, resulting in palatal muscle weakness and uvular deviation away from the lesion. Spinothalamic tract disruption yields contralateral loss of pain/temperature in the body; spinal trigeminal nucleus involvement yields ipsilateral facial sensory loss. Infarction of descending sympathetic fibers causes ipsilateral Horner\u2019s syndrome. The inferior cerebellar peduncle may be involved, producing ipsilateral ataxia and dysmetria.\n\nTemporal evolution: Cytotoxic edema peaks at 24\u201348 hours post-infarction, with vasogenic edema expanding the lesion. Subacute inflammatory responses follow, with macrophage infiltration. Chronic gliosis occurs by weeks to months. Secondary neuronal network reorganization underlies partial recovery.",
        "clinical_manifestation": "Lateral medullary (Wallenberg) syndrome presents acutely with sudden vertigo, nausea, vomiting, and unsteady gait. Cardinal signs include:\n\u2022 Pseudobulbar findings: dysphagia (80\u201390%), hoarseness (68%), diminished gag reflex (70%), ipsilateral palatal droop, uvular deviation away from lesion (>90%) (Fisher CM, 1982).\n\u2022 Sensory disturbances: contralateral body pain/temperature loss (85%), ipsilateral facial pain/temperature loss (75%).\n\u2022 Cerebellar signs: ipsilateral limb ataxia, dysmetria (60\u201370%).\n\u2022 Vestibular signs: spontaneous ipsiversive nystagmus, vertigo (80%).\n\u2022 Autonomic signs: ipsilateral Horner\u2019s syndrome (40\u201355%).\n\nVariants: patients may present with isolated sensory or ataxic features without bulbar signs. In elderly or diabetic patients, presentation may be subtle, with predominant gait instability. Immunocompromised patients may exhibit atypical MRI patterns due to microvascular compromise.",
        "diagnostic_approach": "Initial evaluation should follow AHA/ASA stroke guidelines (2018 class I, level A). Noncontrast CT is performed emergently to exclude hemorrhage; however, CT sensitivity for posterior fossa infarction is ~26\u201342%. MRI with diffusion-weighted imaging (DWI) within 24 hours has sensitivity ~94% and specificity ~95% for acute infarction (Gottesman et al., 2010). CT angiography (CTA) or MR angiography (MRA) assesses vertebral and PICA patency. Echocardiography (TTE/TEE) and carotid Doppler evaluate embolic sources. Laboratory tests include CBC, coagulation profile, lipid panel, HbA1c, and hypercoagulability workup if indicated.\n\nFirst-tier: Noncontrast head CT, NIH Stroke Scale scoring, basic labs. Second-tier: MRI/MRA or CTA within 24 hours for infarct confirmation and vessel imaging. Third-tier: digital subtraction angiography for uncertain cases or endovascular planning; transcranial Doppler for hemodynamics; autoimmune panels if vasculitis suspected.",
        "management_principles": "Acute management follows AHA/ASA guidelines: intravenous alteplase within 4.5 hours if no contraindications (Class I, Level A). Mechanical thrombectomy is not routinely indicated for PICA but may be considered for proximal vertebral occlusion. Blood pressure should be maintained <185/110 mm Hg pre-thrombolysis and <220/120 mm Hg otherwise (Class I, Level B-NR).\n\nSecondary prevention: antiplatelet therapy with aspirin plus clopidogrel for 21 days post-minor stroke (POINT trial; NNT=40 for stroke prevention); long-term monotherapy thereafter. High-intensity statin therapy (atorvastatin 80 mg daily) reduces recurrent stroke risk by ~20% (SPARCL trial). Blood pressure control (<130/80 mm Hg), glycemic control (HbA1c <7%), and lifestyle modification are essential. Dysphagia should be evaluated by a speech-language pathologist; early enteral feeding if high aspiration risk.\n\nRehabilitation includes physical, occupational, and speech therapy. Patients with refractory dysphagia may require gastrostomy.",
        "follow_up_guidelines": "Follow-up imaging: MRI brain at 24\u201372 hours to assess infarct evolution; vascular imaging (CTA/MRA) at 1\u20132 weeks to reassess vessel patency. Outpatient neurology follow-up at 1 month, 3 months, and 6 months to monitor risk factor management and rehabilitation progress. Swallow study reevaluation at 4\u20136 weeks. Blood pressure, lipid profile, and glycemic control every 3\u20136 months. Secondary prevention adherence should be assessed at each visit.\n\nLong-term care: Evaluate for post-stroke depression and cognitive impairment. Orofacial and bulbar dysfunction may persist; ongoing speech therapy recommended. Monitor for late complications such as central pain syndrome.",
        "clinical_pearls": "1. Uvula deviation in lateral medullary infarction deviates away from the lesion due to nucleus ambiguus palsy; a high-specificity sign for PICA infarction. (Mnemonic: UVA=Uvula Away)\n2. Ipsilateral loss of facial pain/temperature with contralateral loss in the body localizes lesion to the dorsolateral medulla (\"crossed findings\").\n3. Horner\u2019s syndrome in lateral medullary syndrome is mild and ipsilateral; isolated ptosis without miosis suggests alternative diagnoses.\n4. CT head has low sensitivity for posterior fossa strokes\u2014obtain MRI DWI when clinical suspicion is high despite negative CT.\n5. Swallow evaluation is critical early to prevent aspiration pneumonia; 50% of lateral medullary patients require modified diets or enteral feeding.",
        "references": "1. Fisher CM. Infarction of the lateral medulla oblongata: clinical syndromes and vascular topography. Brain. 1982;105(2):167\u2013195. doi:10.1093/brain/105.2.167\n2. Sacco RL et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. AHA/ASA Stroke. 2011;42(1):227\u2013276. doi:10.1161/STR.0b013e3181f7d043\n3. Hacke W et al. Thrombolysis with alteplase 3\u20134.5 h after acute ischaemic stroke (ECASS III): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9646):1303\u20131315. doi:10.1016/S0140-6736(08)60191-2\n4. Edlow JA, et al. Clinical approach to the evaluation and diagnosis of posterior circulation stroke. Neurologist. 2017;22(1):28\u201336. doi:10.1097/NRL.0000000000000112\n5. Gottesman RF, et al. Early diffusion-weighted imaging and outcome after acute stroke. Ann Neurol. 2010;67(3):345\u2013355. doi:10.1002/ana.21997\n6. Adams HP Jr, et al. Classification of Subtype of Acute Ischemic Stroke. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35\n7. Johnston SC, et al. Early stroke risk and preventive therapy after transient ischemic attack. JAMA. 2000;284(22):2901\u20132906. doi:10.1001/jama.284.22.2901\n8. Amarenco P, et al. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2006;355(8):745\u2013754. doi:10.1056/NEJMoa063618\n9. SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n10. POINT Investigators. Clopidogrel and aspirin in acute minor stroke and high-risk TIA. N Engl J Med. 2018;379(3):215\u2013225. doi:10.1056/NEJMoa1800410\n11. Ropper AH, Samuels MA. Stroke: Clinical manifestations and diagnosis. N Engl J Med. 2009;361(13):1327\u20131335. doi:10.1056/NEJMra0810240\n12. Edlow JA, et al. Posterior circulation ischemic stroke: presentation, diagnosis, and management. Continuum (Minneap Minn). 2014;20(2):297\u2013313. doi:10.1212/01.CON.0000446716.21593.5e\n13. Kase CS, et al. Vertebrobasilar disease: pathophysiology and treatment. Stroke. 1990;21(1):14\u201322. doi:10.1161/01.STR.21.1.14\n14. Schwenk TL, et al. Dysphagia in lateral medullary (Wallenberg) syndrome: epidemiology and outcomes. Stroke. 2014;45(3):e47\u2013e49. doi:10.1161/STROKEAHA.113.001075\n15. Furie KL, et al. Guidelines for prevention of stroke in women. AHA/ASA Stroke. 2014;45(5):1545\u20131588. doi:10.1161/STR.0000000000000024"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "In a case of intracerebral hemorrhage (ICH), what is the target blood pressure (BP) for treatment?",
      "options": [
        "140/90",
        "160/90"
      ],
      "correct_answer": "A",
      "correct_answer_text": "140/90",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct target blood pressure in acute intracerebral hemorrhage (ICH) based on current AHA/ASA guidelines is a systolic blood pressure (SBP) of 140 mm Hg. This recommendation is supported by the INTERACT2 (Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2) trial, which randomized 2,794 patients presenting within 6 hours of ICH onset to a target SBP < 140 mm Hg versus < 180 mm Hg. Although the primary endpoint of death or severe disability (mRS 4\u20136 at 90 days) was not significantly different (adjusted OR 0.87; 95% CI, 0.75\u20131.01; P = 0.06), there was a favorable shift in distribution of mRS scores (ordinal analysis; adjusted OR 0.87; 95% CI, 0.77\u20131.00; P = 0.04) in the intensive group. The ATACH-2 (Antihypertensive Treatment of Acute Cerebral Hemorrhage II) trial tested an even lower SBP target (110\u2013139 mm Hg) versus standard (< 180 mm Hg) in 1,000 patients and found no significant benefit in death or disability (38.7% vs. 37.7%, HR 1.04; 95% CI, 0.85\u20131.27; P = 0.72) but did note higher renal adverse events in the intensive arm. Taken together, these high\u2010quality randomized trials (Level A evidence) support an SBP target of 140 mm Hg as both safe and potentially beneficial for functional outcome without undue harm. Option B (160/90) reflects older, less aggressive targets and is no longer recommended except when SBP < 140 cannot be safely achieved.",
        "conceptual_foundation": "Intracerebral hemorrhage (ICH) is classified under nontraumatic hemorrhagic stroke in ICD\u201011 coding (8B00.1). Elevated blood pressure is a major modifiable risk factor for both ICH occurrence and hematoma expansion. The path to ICH often involves chronic hypertension\u2013induced small vessel lipohyalinosis or Charcot\u2013Bouchard microaneurysms in deep structures (basal ganglia, thalamus). Rapid BP lowering aims to reduce hematoma growth, which occurs predominantly within the first 6 hours. Nosologically, ICH sits within cerebrovascular disorders (ICD-11 Chapter 8B) and contrasts with ischemic stroke subtypes (8B01). Differential diagnoses include hemorrhagic conversion of infarct, cerebral amyloid angiopathy, vascular malformations, and coagulopathy\u2010related bleeds. Embryologically, the deep perforating arteries arise from the mesencephalic branch of the posterior circulation and the striate branches of the MCA; chronic hypertension thins vessel walls. Key neurotransmitters (e.g., glutamate) mediate secondary injury after bleed, and genetic polymorphisms (e.g., APOE \u03b52/\u03b54 in amyloid angiopathy) modify risk. Understanding this framework clarifies why aggressive but safe BP lowering is central to acute management.",
        "pathophysiology": "Normal cerebral perfusion is maintained by autoregulation across a mean arterial pressure (MAP) range of approximately 60\u2013150 mm Hg. In chronic hypertension, this curve shifts rightward, rendering the brain susceptible to hypoperfusion at lower pressures and hyperperfusion at higher pressures. Acute ICH disrupts this balance through mass effect, increased intracranial pressure (ICP), and perihematomal edema driven by inflammatory cascades (microglial activation, cytokine release, free\u2010radical\u2013mediated injury). Hematoma expansion occurs via continued bleeding from ruptured small vessels, heavily influenced by transmural pressure; thus lowering MAP reduces vessel wall stress and the risk of extension. Excessive reduction below the autoregulatory threshold risks ischemia, especially in perihematomal zones. Trials have shown that targeting SBP ~140 mm Hg strikes an optimal balance between minimizing hematoma growth and preserving perihematomal perfusion.",
        "clinical_manifestation": "Patients with acute ICH commonly present with sudden focal neurological deficits (e.g., hemiparesis [up to 60%], speech disturbance [30%\u201350%], altered level of consciousness [20%\u201330%]). Headache occurs in ~50% and vomiting in ~25%. Deep hemorrhages (basal ganglia, thalamus) often manifest with contralateral sensorimotor deficits and altered consciousness, while lobar bleeds more commonly present with cortical signs (aphasia, visual field cuts, seizures). Hematoma expansion occurs in 20%\u201340% of cases, most often within the first 6 hours, and is a key determinant of early clinical worsening and poor outcome. Untreated hypertension promotes rebleeding and worsens edema and mass effect; early BP management can mitigate these processes.",
        "diagnostic_approach": "Initial evaluation includes noncontrast head CT (sensitivity > 95% for acute blood) obtained emergently. Blood pressure should be measured bilaterally, and a rapid\u2010acting IV antihypertensive agent (e.g., nicardipine, labetalol) initiated if SBP > 140 mm Hg. CTA may be added to identify spot sign (predicts hematoma growth; PPV ~60%, NPV ~90%). Laboratory tests include coagulation profile, platelet count, and toxicology as indicated. MRI is reserved for subacute or atypical presentations. Monitoring ICP and neurologic status in a stroke\u2010unit or ICU setting is recommended. No role for invasive cerebral autoregulation monitoring in routine care.",
        "management_principles": "AHA/ASA 2015 guidelines (Class I, Level A) recommend lowering SBP to 140 mm Hg in patients presenting with SBP between 150 and 220 mm Hg. First\u2010line agents include continuous\u2010infusion nicardipine or labetalol boluses, aiming for gradual reduction (no more than 60 mm Hg reduction within the first hour). Rapid\u2010acting oral agents (e.g., captopril) may be used if IV access is delayed. Blood pressure should be monitored invasively or every 5 minutes until stable. Aggressive reduction (SBP < 110 mm Hg) is not advised due to renal and ischemic risks. Management also includes intracranial pressure control, reversal of coagulopathy, and supportive care.",
        "follow_up_guidelines": "After stabilization, SBP goals may be relaxed to < 160 mm Hg. Ambulatory blood pressure monitoring and antihypertensive regimen optimization should begin prior to discharge to reduce recurrence risk. Follow\u2010up CT at 24 hours is indicated if clinical deterioration occurs; routine imaging at 24 hours may be considered to assess hematoma evolution. Long-term, secondary prevention includes strict BP control (< 130/80 mm Hg) per current stroke prevention guidelines (AHA/ASA 2021).",
        "clinical_pearls": "1. Early SBP reduction to 140 mm Hg in ICH is safe and may improve functional outcome (INTERACT2) \u2014 recall '140 is fine.' 2. Avoid rapid SBP drops below autoregulatory threshold; target no more than 20% MAP decrease in first hour. 3. Spot sign on CTA predicts hematoma expansion; negative predictive value ~90%. 4. Deep ICH from hypertensive vasculopathy contrasts with lobar ICH in amyloid angiopathy \u2014 note different recurrence risks. 5. Secondary prevention demands long-term SBP < 130/80 mm Hg to prevent recurrent ICH.",
        "references": "1. Hemphill JC 3rd, et al. 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Anderson CS, et al. Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). Lancet. 2013;382(9890):263\u2013273. doi:10.1016/S0140-6736(13)60487-6\n3. Qureshi AI, et al. Antihypertensive Treatment of Acute Cerebral Hemorrhage II (ATACH-2). N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603460\n4. Steiner T, et al. European Stroke Organisation (ESO) Guidelines for ICH. Eur Stroke J. 2014;1(2):77\u201388. doi:10.1177/2396987314534724\n5. Li Q, et al. Blood Pressure Lowering in ICH: Meta-analysis. JAMA Neurol. 2017;74(10):1169\u20131175. doi:10.1001/jamaneurol.2017.1667\n6. Krishnan K, et al. Spot Sign and Hematoma Expansion. Radiology. 2016;280(2):575\u2013581. doi:10.1148/radiol.2016160589\n7. Rodriguez-Luna D, et al. Blood Pressure Management Strategies. Neurol Clin Pract. 2018;8(4):341\u2013349. doi:10.1212/CPJ.0000000000000513\n8. McKinney JS, et al. Hematoma Expansion in ICH. Stroke. 2018;49(6):1358\u20131365. doi:10.1161/STROKEAHA.117.020841\n9. Goldstein JN, et al. Blood Pressure Control and Outcome. Neurology. 2017;88(7):643\u2013650. doi:10.1212/WNL.0000000000003622\n10. Wallace N, et al. Cerebral Autoregulation in ICH. Stroke. 2017;48(11):2923\u20132930. doi:10.1161/STROKEAHA.117.018339\n11. Steiner T, et al. Management of Elevated Intracranial Pressure. Crit Care Med. 2018;46(4):603\u2013611. doi:10.1097/CCM.0000000000002931\n12. Viera AJ, et al. Hypertension in Acute ICH. Am Fam Physician. 2019;100(2):111\u2013118.\n13. Broderick JP, et al. Secondary Prevention After ICH. Stroke. 2018;49(11):2622\u20132632. doi:10.1161/STROKEAHA.118.021632\n14. Sacco RL, et al. Stroke Prevention Guidelines. Stroke. 2021;52:e364\u2013e467. doi:10.1161/STR.0000000000000375\n15. Boehme AK, et al. Advances in ICH Management. Neurocrit Care. 2020;33(2):259\u2013272. doi:10.1007/s12028-020-00909-7"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A woman after a successful vaginal delivery complains of severe headache and hemiparesis. Her exam shows papilledema. What is the next step in management?",
      "options": [
        "CTV",
        "MRI",
        "Lumbar puncture",
        "Observation"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CTV",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "CT venography (CTV) is the most appropriate next step in this postpartum patient presenting with severe headache, hemiparesis, and papilledema. The clinical triad\u2014headache, focal neurological deficit, and signs of raised intracranial pressure\u2014in a woman in the puerperium is highly suggestive of cerebral venous sinus thrombosis (CVST). CTV has a sensitivity of approximately 95% and specificity of 91% for detecting venous sinus occlusion (Stam J. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354) and can be performed rapidly in most centers. MRI alone without dedicated venography may miss thrombosis in the superior sagittal or transverse sinuses, while lumbar puncture is contraindicated due to elevated intracranial pressure and risk of herniation. Observation without definitive imaging risks delay in diagnosis and treatment, potentially worsening outcomes.",
        "conceptual_foundation": "Cerebral venous sinus thrombosis is classified under ICD-11 8B71 (cerebrovascular disease, venous). It represents thrombosis of the dural venous sinuses leading to impaired venous drainage, venous hypertension, and possible infarction or hemorrhage. Risk factors include the hypercoagulable state of pregnancy and the puerperium, estrogen therapy, dehydration, infection, and prothrombotic disorders (Ferro JM et al. J Neurol. 2020;267(4):1053\u20131065). Differential diagnoses include idiopathic intracranial hypertension, arterial ischemic stroke, intracranial hemorrhage, eclampsia-related edema, and migraine. Historically, diagnostic classification evolved from angiography-based definitions to include noninvasive venographic imaging modalities such as CT and MR venography.",
        "pathophysiology": "Normal cerebral venous drainage involves dural sinuses that drain into the internal jugular veins. In thrombosis, clot formation occludes venous outflow, raising venous and capillary pressure. This leads to breakdown of the blood\u2013brain barrier, vasogenic edema, and potential venous infarction characterized by cytotoxic and vasogenic components (Coutinho JM et al. Curr Treat Options Neurol. 2017;19(2):6). Elevated intracranial pressure manifests as headache and papilledema. Focal deficits occur when venous infarcts involve motor cortex or deep structures. Puerperal hypercoagulability\u2014increased fibrinogen and factors VII, VIII, X, reduced fibrinolysis\u2014predisposes to CVST.",
        "clinical_manifestation": "Headache occurs in over 90% of CVST patients and can be the sole symptom. Focal neurological deficits, including hemiparesis, occur in approximately 40% of cases. Papilledema is present in ~30\u201340% and indicates raised intracranial pressure (Saposnik G et al. Stroke. 2011;42(4):1158\u20131192). Seizures occur in 30\u201340%. Onset is often subacute over days but may be acute. In postpartum women, the average time to presentation is within 1\u20132 weeks after delivery. Variants include isolated intracranial hypertension syndrome without focal signs, cavernous sinus thrombosis with cranial nerve palsies, and deep venous thrombosis presenting with diencephalic syndrome.",
        "diagnostic_approach": "Initial noncontrast head CT is performed emergently to exclude intracranial hemorrhage. Noncontrast CT may show the hyperdense sinus sign in ~25% of cases or indirect signs such as venous infarcts. Definitive diagnosis requires venous imaging with either CTV (sensitivity 95%, specificity 91%) or MR venography (MRV) (sensitivity 90%, specificity 87%). CTV is more widely available and faster; MRV offers superior soft tissue characterization. Lumbar puncture, once reserved for isolated intracranial hypertension syndrome, is contraindicated without prior imaging if raised pressure is suspected. Pre-test probability (clinical score) guides urgency; postpartum state confers high pre-test probability necessitating immediate imaging (Einh\u00e4upl K et al. Eur J Neurol. 2010;17(10):1229\u20131235).",
        "management_principles": "Anticoagulation with low-molecular-weight heparin (LMWH) is recommended even in the presence of small hemorrhagic venous infarcts (Class I, Level A) per AHA/ASA guidelines (Saposnik G et al. Stroke. 2011). LMWH reduces the odds of death or dependency by 60% (OR 0.40; 95% CI, 0.18\u20130.89). After initial heparin, transition to warfarin (INR 2.0\u20133.0) for 3\u20136 months if transient risk factors, or longer if thrombophilia present. Direct oral anticoagulants are emerging based on the RESPECT-CVT trial (Ferro JM et al. JAMA Neurol. 2019;76(12):1457\u20131465). Endovascular thrombolysis is reserved for deteriorating patients despite anticoagulation.",
        "follow_up_guidelines": "Follow-up neuroimaging (CTV or MRV) at 3\u20136 months assesses recanalization; ~85% will have partial or complete recanalization. Duration of anticoagulation: 3 months for transient risk factors, 6\u201312 months for idiopathic, and indefinite for severe thrombophilia. Monitor for chronic headache, cognitive impairment, and post-thrombotic syndrome. Neurological examination every 1\u20133 months initially, then yearly. Patient education on recurrence signs and thrombophilia workup is recommended.",
        "clinical_pearls": "1. In postpartum headache with focal deficits, always suspect CVST\u2014early imaging with venography is key. 2. Papilledema contraindicates lumbar puncture before imaging\u2014risk of herniation. 3. Anticoagulation benefits outweigh hemorrhage risk, even with hemorrhagic infarcts. 4. CTV is rapid, accessible, and highly sensitive for sinus thrombosis. 5. Restart prophylaxis in future pregnancies\u2014CVST recurrence risk ~2%.",
        "references": "1. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n2. Ferro JM, Bousser MG, Canh\u00e3o P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis \u2013 endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203\u20131213. doi:10.1111/ene.13329\n3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n4. Coutinho JM, Zuurbier SM, Aramideh M, Stam J. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012;43(12):3375\u20133377. doi:10.1161/STROKEAHA.112.668056\n5. Ferro JM, Canh\u00e3o P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664\u2013670. doi:10.1161/01.STR.0000117571.76197.26\n6. Einh\u00e4upl K, Stam J, Bousser MG, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2010;17(10):1229\u20131235. doi:10.1111/j.1468-1331.2010.03044.x\n7. Ferro JM, Dentali F, Kobayashi A, et al. Safety and efficacy of dabigatran versus warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol. 2019;76(12):1457\u20131465. doi:10.1001/jamaneurol.2019.2934\n8. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6(2):162\u2013170. doi:10.1016/S1474-4422(07)70029-7\n9. Canh\u00e3o P, Ferro JM, Lindgren AG, et al. Causes and predictors of death in cerebral venous thrombosis. Stroke. 2005;36(8):1720\u20131725. doi:10.1161/01.STR.0000172814.70091.23\n10. Saposnik G, de Veber G, Brown R, et al. Diagnosis and management of cerebral venous thrombosis: challenges, controversies, and future directions. Stroke. 2018;49(2):353\u2013361. doi:10.1161/STROKEAHA.117.016256\n11. Bhatt DL, et al. European guidelines for the management of CVST. Eur Heart J. 2020;41(41):3997\u20134008.\n12. Aguiar de Sousa D, et al. Pathophysiology of CVST. Front Neurol. 2018;9:1159.\n13. Coutinho JM, et al. Cerebral venous thrombosis: clinical presentation and prognostic factors. Stroke. 2019;50(5):1405\u20131412.\n14. Handley JD, et al. Headache in cerebral venous thrombosis: clinical review. Cephalalgia. 2017;37(9):801\u2013810.\n15. Dentali F, et al. Diagnosis and management of cerebral venous thrombosis in pregnancy. Thromb Res. 2019;179:29\u201335."
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A case scenario of a patient with a 1-day history of malignant MCA stroke is presented. The computed tomography (CT) brain shows \u2154 hypodensity without midline shift or hydrocephalus. What is the next step in management?",
      "options": [
        "Hemicraniectomy",
        "Osmotic therapy",
        "Aspirin",
        "Indications for hemicraniotomy"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Hemicraniectomy",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. Hemicraniectomy. Multiple randomized controlled trials including DECIMAL (2007), HAMLET (2009), and DESTINY (2007) have demonstrated that early decompressive hemicraniectomy in patients under age 60 with malignant middle cerebral artery infarction reduces mortality from approximately 80% to under 30% at 12 months (Vahedi et al. 2007, Hofmeijer et al. 2009, Juttler et al. 2007). The pooled relative risk reduction for death or severe disability (modified Rankin Scale >4) is 0.56 (95% CI 0.40\u20130.79, Level A evidence, AHA/ASA 2018 guidelines). Hemicraniectomy lowers intracranial pressure by creating additional intracranial volume and preventing herniation, directly addressing life\u2010threatening cerebral edema. Option B, osmotic therapy, may transiently lower intracranial pressure but has not been shown to improve mortality or functional outcome in malignant MCA infarction (Hofmeijer et al. 2008). Option C, aspirin, is indicated for secondary prevention but does not mitigate malignant cerebral edema or herniation risk. Option D, \u201cIndications for hemicraniotomy,\u201d is not a management step but rather a description of criteria; as such it is not an active intervention. Common misconceptions include overreliance on osmotic agents in place of definitive surgical decompression and delay of surgery pending midline shift, whereas guidelines recommend surgery based on infarct size (>50% MCA territory) and clinical deterioration within 48 hours irrespective of midline shift presence (AHA/ASA 2018).",
        "conceptual_foundation": "Malignant MCA infarction is characterized by cytotoxic and vasogenic edema affecting more than 50% of the middle cerebral artery territory, leading to increased intracranial pressure, midline shift, and risk of transtentorial herniation. In ICD-11, it is classified under 8B11.4 (ischemic stroke due to large artery occlusion). The condition evolves from core infarction and peri-infarct penumbra zones, with maximal edema formation between days 2 and 5 postictus. Historically, space-occupying cerebral infarction was recognized in the 1950s, but decompressive surgery was first systematically studied in the 2000s. Embryologically, the MCA arises from the prosencephalic branch of the internal carotid. Neuroanatomically, the MCA supplies the frontal, temporal, and parietal lobes plus basal ganglia via lenticulostriate arteries. Disruption of this territory affects motor and sensory cortices, language areas (dominant hemisphere), and uncovers internal capsule involvement. Differential diagnoses include large hemispheric hemorrhage, malignant edema from cortical vein thrombosis, and acute subdural hematoma. Molecular and genetic factors influencing cerebral edema include upregulation of aquaporin-4, activation of matrix metalloproteinases (MMP-9), and blood\u2013brain barrier breakdown mediated by vascular endothelial growth factor. Understanding this taxonomy and related pathobiology underpins the rationale for early surgical decompression rather than solely medical management.",
        "pathophysiology": "Under normal physiology, cerebral blood flow is autoregulated within a mean arterial pressure range of 60\u2013150 mmHg, and intracranial pressure (ICP) is maintained at 7\u201315 mmHg. In malignant MCA infarction, arterial occlusion results in energy failure leading to sodium\u2013potassium ATPase pump dysfunction, intracellular sodium accumulation, cytotoxic edema, and glutamate\u2010mediated excitotoxicity. Within several hours, blood\u2013brain barrier integrity is compromised, leading to vasogenic edema. This edema peaks 48\u201372 hours postinfarct, raising ICP, reducing cerebral perfusion pressure, and precipitating a vicious cycle of ischemia. Unrelieved intracranial hypertension causes midline shift, uncal herniation, and brainstem compression. Decompressive hemicraniectomy interrupts this cascade by expanding intracranial volume, lowering ICP, restoring perfusion to the penumbra, and preventing herniation. Compared to osmotic therapy, which provides transient ICP reduction by shifting water across an intact blood\u2013brain barrier, surgical decompression offers sustained ICP control and reduces mortality. The pathophysiological distinction between medical and surgical interventions clarifies why hemicraniectomy is the definitive treatment for life\u2010threatening malignant edema.",
        "clinical_manifestation": "Patients with malignant MCA stroke present within 24\u201348 hours of onset with sudden focal deficits consistent with large vessel occlusion: contralateral hemiplegia, hemisensory loss, gaze deviation toward the lesion, and global aphasia if the dominant hemisphere is involved. Early signs of increased ICP include severe headache, vomiting, declining level of consciousness, and Cushing\u2019s triad in advanced stages. Approximately 70\u201380% of large MCA infarcts develop malignant edema; of these, mortality exceeds 80% without decompression. Prodromal transient ischemic attacks are uncommon. The natural history involves neurological deterioration around day 2\u20133 postinfarct, correlating with peak edema. Untreated patients progress to coma and death. Rarely, subgroups with excellent collateral circulation may present more slowly. Formal diagnostic criteria per DECIMAL/DESTINY include: infarct volume >145 cm3 on CT or DWI, NIHSS \u226515, and deterioration within 48 hours. Sensitivity of CT-based infarct volume >145 cm3 for predicting malignant edema is 96%, specificity 86% (Vahedi et al. 2007).",
        "diagnostic_approach": "Initial evaluation includes noncontrast head CT to exclude hemorrhage and assess infarct size. Infarct volume >50% MCA territory or >145 cm3 on CT within 48 hours confers high risk of malignant edema (PPV 0.90; NPV 0.85). MRI with DWI can more accurately quantify infarct core but is less accessible emergently. CT angiography identifies proximal MCA occlusion and collateral status (grade 0\u20133 leptomeningeal collaterals; poor collaterals predict malignant course with OR 6.2, 95% CI 2.1\u201317.9). Transcranial Doppler may detect stagnation. Intracranial pressure monitoring is not routinely recommended before surgery (AHA/ASA 2018, Class III: no benefit). A tiered diagnostic approach begins with CT head (first tier), followed by CTA/CTP or MRI (second tier) if surgical planning requires vascular anatomy. Third-tier modalities like advanced MR perfusion are research tools. Clinical monitoring with NIHSS every 2\u20134 hours during the first 48 hours is critical. Pretest probability of malignant edema in large MCA infarct is ~50%; a CT infarct >145 cm3 posttest probability rises to >90%, justifying early surgical referral.",
        "management_principles": "The cornerstone of treatment is early decompressive hemicraniectomy within 48 hours of symptom onset. Surgical technique involves removal of a large bone flap (\u226512 cm), duraplasty with expansile graft, and lax dural closure. RCTs show number needed to treat (NNT) of 2\u20134 to prevent one death (Level A evidence). Class I, Level A recommendation by AHA/ASA 2018 supports hemicraniectomy in patients \u226460 years with NIHSS \u226515 and large infarct volume. Osmotic agents (mannitol 0.25\u20131 g/kg q6\u20138h, hypertonic saline 3% infusion) serve as temporizing measures but lack evidence for mortality reduction (Class IIb). Blood pressure should be maintained at systolic 140\u2013160 mmHg; permissive hypertension is allowed unless hemorrhagic transformation risk is high. Early rehabilitation, antithrombotic therapy with aspirin 160\u2013325 mg daily post hemorrhage exclusion, and prophylaxis for deep venous thrombosis (LMWH or intermittent pneumatic compression) are essential supportive measures. In refractory ICP elevation postcraniectomy, barbiturate coma or hypothermia are investigational.",
        "follow_up_guidelines": "Postoperative monitoring includes hourly neurological assessments and ICP measurement via intraparenchymal or external ventricular drain when indicated. Serial CT scans at 24\u201348 hours postcraniectomy assess residual edema and hematoma. Rehabilitation should begin within 72 hours; multidisciplinary input from physiotherapy, occupational and speech therapy optimizes functional recovery. Cranioplasty is typically performed 8\u201312 weeks after decompression, balancing infection risk and return of cerebral blood flow. Long-term follow-up includes assessments of functional status using mRS at 3, 6, and 12 months. Seizure prophylaxis is not routinely recommended beyond the first week unless clinical seizures occur. Bone flap resorption, hydrocephalus, and subdural hygroma are monitored by periodic imaging. Patient and family education regarding scalp hygiene, helmet use, and signs of intracranial hypertension are critical components of follow-up.",
        "clinical_pearls": "1. Early decompressive hemicraniectomy within 48 hours in malignant MCA infarct reduces mortality from ~80% to ~30% (NNT 2\u20134); think \u2018time is brain and bone\u2019. 2. Infarct volume >145 cm3 on CT within 24\u201348 hours predicts malignant edema with >90% specificity; use automated volumetry when available. 3. Osmotic therapy (mannitol, hypertonic saline) is a bridge but does not alter long-term outcomes; avoid delaying surgery. 4. Young patients (\u226460 years) derive the greatest functional benefit; careful selection based on NIHSS \u226515 and CT criteria is essential. 5. Post-craniectomy syndrome of trephined can manifest as neurological worsening; early cranioplasty (~8 weeks) often reverses symptoms. Mnemonic: \u201cBRAIN BONE\u201d (Brisk decompression, Rapid decision, Age \u226460, Infarct size >145 cm3, Neurological decline).",
        "references": "1. Vahedi K, Hofmeijer J, Juettler E, et al. Early Decompressive Surgery in Malignant Middle Cerebral Artery Infarction: A Randomized Trial. Lancet Neurol. 2007;6(3):215\u2013222. doi:10.1016/S1474-4422(07)70036-3\n2. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical Decompression for Space-Occupying Cerebral Infarction: A Systematic Review. Stroke. 2008;39(6):1495\u20131500. doi:10.1161/STROKEAHA.107.503580\n3. J\u00fcttler E, Schwab S, Schmiedek P, et al. DESTINY: Decompressive Surgery for the Treatment of Malignant Infarction of the MCA. Trial Design and First Results. Stroke. 2007;38(9):2506\u20132517. doi:10.1161/STROKEAHA.107.491713\n4. J\u00fcttler E, Schwab S, Schmiedek P, Unterberg A; DESTINY Study Group. Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke. N Engl J Med. 2014;370(12):1090\u20131098. doi:10.1056/NEJMoa1310210\n5. J\u00fcttler E, Grond M, Hacke W. Hamletal Trial Collaborators. Indication and Timing of Decompressive Craniectomy in Malignant MCA Infarction. Stroke. 2009;40(2):e402\u2013e404. doi:10.1161/STROKEAHA.108.532768\n6. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke. AHA/ASA. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n7. Vahedi K, Vicaut E, Mateo J, et al. Sequential Design, Two-Stage, Randomized, Controlled Trial of Decompressive Craniectomy with Medical Management in Malignant Middle Cerebral Artery Infarction (DECIMAL). Stroke. 2007;38(9):2506\u20132517. doi:10.1161/STROKEAHA.107.491713\n8. Schwab S, Schmeer C, Spr\u00fcgel MI, et al. Predictors of Outcome After Decompressive Hemicraniectomy in Malignant Middle Cerebral Artery Infarction. Stroke. 2018;49(1):225\u2013231. doi:10.1161/STROKEAHA.117.018566\n9. Hofmeijer J, Verbaan D, Munneke M, et al. Very Early Decompressive Hemicraniectomy in Malignant MCA Infarction: A Retrospective Cohort Study. Neurocrit Care. 2017;26(3):447\u2013455. doi:10.1007/s12028-016-0279-3\n10. Maas AIR, Choi SC, Shen Q, et al. Decompressive Craniectomy for Severe Traumatic Brain Injury: A Randomized Trial. N Engl J Med. 2005;352(4):366\u2013377. doi:10.1056/NEJMoa043663\n11. Bosche B, Bachmann G, Raabe A, Seifert V. Intracranial Pressure Changes During Decompressive Craniectomy. Acta Neurochir (Wien). 2009;151(7):793\u2013796. doi:10.1007/s00701-009-0409-9\n12. Strbian D, Sairanen T, Meretoja A, et al. Predicting Malignant Brain Edema From Ischemic Stroke With a Simple CT-Based Infarct Volume Measurement. Stroke. 2013;44(11):2736\u20132741. doi:10.1161/STROKEAHA.113.001117\n13. Hacke W, Schwab S, Horn M, Spranger M, de Georgia M, von Kummer R. \u2018\u2018Malignant\u2019\u2019 Middle Cerebral Artery Territory Infarction: Clinical Course and Prognosis. Arch Neurol. 1996;53(4):309\u2013315. doi:10.1001/archneur.1996.00550040037007\n14. Schaller B, Graf R. High-Dose Mannitol Management in the Treatment of Brain Edema: A Meta-Analysis of Randomized Controlled Trials. Neurosurgery. 2017;80(3):427\u2013435. doi:10.1093/neuros/nyx006\n15. Zaninovich OA, Marks MP, Bammer R, Campion E, Wilms G, Wintermark M. A Practical Guide to Assessing Leptomeningeal Collaterals by CT Angiography in Acute Ischemic Stroke: From Art to Science. AJNR Am J Neuroradiol. 2017;38(9):1635\u20131642. doi:10.3174/ajnr.A5253"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a patient with ICH on computed tomography (CT) brain and an International Normalized Ratio (INR) of 3.2, which treatment is recommended?",
      "options": [
        "PCC",
        "Vitamin K",
        "FFP"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "correct_answer": "A",
      "correct_answer_text": "PCC",
      "explanation": {
        "option_analysis": "Option A: Prothrombin complex concentrate (PCC) delivers concentrated vitamin K\u2013dependent clotting factors II, VII, IX, and X, allowing rapid INR correction within 15\u201330 minutes. In an acute intracerebral hemorrhage (ICH) with INR of 3.2, guidelines recommend 4-factor PCC at 25\u201350 IU/kg to achieve target INR \u22641.3, reducing hematoma expansion and improving outcomes (Sarode et al., 2013). The low infusion volume (<100 mL) minimizes risk of volume overload in hypertensive or elderly patients. Option B: Vitamin K (5\u201310 mg IV) is essential for sustained liver synthesis of factors, but onset is delayed (6\u201312 hours), insufficient for emergent hemorrhage. It should be co-administered with PCC, not used alone for rapid reversal. Option C: Fresh frozen plasma (FFP) contains all coagulation proteins but requires blood typing, thawing, and infusion of large volumes (10\u201315 mL/kg), delaying reversal by 1\u20134 hours and risking transfusion-related acute lung injury (TRALI) or circulatory overload. Comparative trials show FFP is inferior to PCC in speed and efficacy. Therefore, PCC is the optimal choice for urgent reversal in warfarin-associated ICH.",
        "conceptual_foundation": "Intracerebral hemorrhage (ICH) occurs when parenchymal vessels rupture, often within the basal ganglia, thalamus, cerebellum, or pons. These regions receive high-pressure arterial supply from lenticulostriate and perforating branches of the middle cerebral and basilar arteries. Blood accumulation increases intracranial volume, raising intracranial pressure (ICP) and causing perilesional edema. Mass effect may herniate brain structures, compressing vital centers in the midbrain or brainstem. Hematoma expansion in the first 24 hours correlates with neurologic decline and mortality. Warfarin impairs vitamin K\u2013dependent gamma-carboxylation of clotting factors, prolonging coagulation and heightening hemorrhage risk. Rapid reversal of anticoagulation restores hemostatic balance, stabilizing the hematoma. Adjacent neural pathways\u2014corticospinal tracts in the internal capsule, thalamocortical radiations, cerebellar peduncles\u2014determine focal deficits such as hemiparesis, sensory loss, or ataxia. Recognizing an anticoagulated patient with acute stroke symptoms warrants immediate imaging and coagulation factor replacement to minimize secondary injury from lesion expansion.",
        "pathophysiology": "Warfarin blocks vitamin K epoxide reductase, preventing regeneration of reduced vitamin K, which is essential for gamma-carboxylation of clotting factors II, VII, IX, and X. This modification at glutamic acid residues enables calcium binding and interaction with negatively charged phospholipid surfaces, critical for clot formation. In warfarin-associated ICH, the primary insult is vessel rupture; secondary injury arises from continued bleeding due to impaired thrombin generation. At the molecular level, reduced thrombin impairs fibrin polymerization and clot stabilization. PCC provides an exogenous source of prothrombin complex factors, bypassing hepatic synthesis, restoring factor concentrations to physiologic levels. FFP contains factor V and XI in addition to II, VII, IX, X, but in lower relative amounts and requires volumetric infusion. Vitamin K administration repletes hepatic stores but is limited by the half-life of factor synthesis (Factor II t\u00bd ~60 hours). Inflammatory cytokines released by hematoma expansion trigger microglial activation and blood\u2013brain barrier disruption, exacerbating edema and neurotoxicity.",
        "clinical_manifestation": "Patients with warfarin-associated ICH typically present with sudden headache, nausea, vomiting, and decreased level of consciousness due to rapid ICP elevation. Focal neurologic deficits correspond to hematoma location: putaminal bleeds cause contralateral hemiparesis and hemisensory loss, thalamic hemorrhages produce sensory deficits with possible ophthalmoplegia, cerebellar bleeds lead to truncal ataxia and dysmetria, and pontine hemorrhages yield pin-point pupils, quadriplegia, and \u201clocked-in\u201d syndrome. Initial Glasgow Coma Scale (GCS) score is a strong prognostic indicator; scores \u22648 predict high mortality. Blood pressure spikes (systolic >180 mm Hg) worsen bleeding risk. Seizures occur in ~10\u201320% of cases, especially with cortical involvement. Early neurological deterioration within the first 6 hours, often due to hematoma expansion, signals poor prognosis. Warfarin increases risk of hematoma growth by 1.7-fold. Monitoring changes in level of consciousness and new focal signs guides urgency of reversal therapy.",
        "diagnostic_approach": "In suspected ICH, noncontrast head CT is first-line, providing rapid detection of hyperdense blood collections and midline shift. CT angiography may identify active contrast extravasation (\u201cspot sign\u201d), predicting hematoma expansion. Laboratory evaluation includes coagulation studies: prothrombin time (PT), INR, activated partial thromboplastin time (aPTT), platelet count, and fibrinogen. INR >1.4 confirms overanticoagulation. A diagnostic algorithm: (1) stabilize airway/breathing/circulation; (2) obtain CT within 15 minutes; (3) draw labs concurrently; (4) if INR >1.4, administer PCC plus vitamin K immediately. MRI is reserved for subacute evaluation of underlying structural lesions. Differential diagnoses include ischemic stroke with hemorrhagic transformation (distinguished by clinical course and imaging timeline) and cerebral amyloid angiopathy (lobar bleeds in elderly without coagulopathy). Point-of-care INR assays expedite decision-making in emergent settings.",
        "management_principles": "Primary ICH management in anticoagulated patients focuses on rapid hemostatic correction, intracranial pressure control, and secondary prevention. PCC dosing: 25 IU/kg for INR 2\u20134, 35 IU/kg for INR 4\u20136, and 50 IU/kg for INR >6, infused over 10\u201330 minutes. Concurrent IV vitamin K 5\u201310 mg promotes sustained factor synthesis. Fresh frozen plasma (10\u201315 mL/kg) is reserved only when PCC is unavailable, due to risk of volume overload and slower reversal. Blood pressure should be lowered to systolic 140 mm Hg within 1 hour using IV nicardipine or labetalol. Intracranial pressure management includes head elevation, sedation, osmotic therapy (mannitol or hypertonic saline), and, when indicated, external ventricular drainage. Antiepileptic prophylaxis is not routine unless clinical seizures occur. Neurosurgical consultation is required for cerebellar hemorrhages >3 cm, significant mass effect, or deteriorating GCS. Monitor coagulation parameters every 30 minutes until target INR achieved.",
        "follow_up_guidelines": "After INR reversal and acute stabilization, repeat head CT at 6\u201324 hours assesses hematoma stability. Daily neurological exams monitor for delayed expansion or hydrocephalus. INR checks every 12\u201324 hours guide vitamin K dosing; aim for INR 2\u20133 if resuming warfarin or converting to direct oral anticoagulant (DOAC) after stabilization (>2 weeks). Blood pressure targets relax to systolic <160 mm Hg. Rehabilitation referral (physical, occupational, speech therapy) should commence early. Long-term complications include seizure risk (10\u201315%), cognitive impairment, and depression. Patients should receive fall prevention education and anticoagulation counseling, considering left atrial appendage occlusion or DOAC substitution if eligible. Routine neuroimaging at 3\u20136 months is indicated only for unresolved deficits or suspected secondary lesions.",
        "clinical_pearls": "\u2022 In warfarin-associated ICH, prioritize PCC over FFP and vitamin K alone for rapid INR correction and hematoma stabilization.  \n\u2022 Four-factor PCC corrects INR within 30 minutes, minimizing hematoma growth risk by up to 60%.  \n\u2022 Always co-administer IV vitamin K to sustain factor levels; omit oral dosing in emergencies.  \n\u2022 Monitor for thromboembolic complications post-PCC: rates are <2% but higher in atrial fibrillation cohorts.  \n\u2022 Avoid FFP when possible due to TRALI (0.1\u20131%) and volume overload, especially in heart failure.  \n\u2022 Rapid blood pressure control (systolic 140 mm Hg) reduces expansion.  \n\u2022 Board tip: If unavailable, 4-factor PCC is preferred over 3-factor PCC plus fresh frozen plasma.  \n\u2022 Recent 2022 AHA/ASA guidelines classify PCC as Class I, Level A evidence for warfarin reversal in ICH.",
        "references": "1. Sarode R et al. NEJM 2013;368:2071\u201381. (Phase III PCC vs FFP)  \n2. Steiner T et al. Stroke 2016;47:EE20. (AHA/ASA ICH guidelines)  \n3. Goldstein JN et al. Stroke 2020;51:601\u201311. (INR reversal outcomes)  \n4. Connolly SJ et al. Chest 2004;125:881\u201398. (FFP vs PCC risks)  \n5. Frontera JA et al. Crit Care Med 2008;36:2166\u201372. (Volume overload with FFP)  \n6. Hemphill JC et al. Stroke 2015;46:1121\u201334. (Blood pressure management)  \n7. Hemker HC et al. J Thromb Haemost 2016;14:18\u201323. (PCC pharmacokinetics)  \n8. Franchini M et al. Blood Transfus 2019;17:145\u201353. (PCC dosing)  \n9. Hart RG et al. JAMA Neurol 2014;71:1303\u20139. (Seizure prophylaxis)  \n10. Kuramatsu JB et al. Lancet Neurol 2015;14:1099\u2013106. (Hemorrhage expansion)  \n11. Wilson D et al. Thromb Haemost 2017;117:1816\u201324. (Thromboembolic risk PCC)  \n12. Paciaroni M et al. Stroke 2019;50:380\u20133. (Long-term outcomes after ICH)"
      },
      "unified_explanation": "In a patient with intracerebral hemorrhage (ICH) and an elevated INR of 3.2, rapid reversal of anticoagulation is paramount to limit hematoma expansion. Prothrombin complex concentrate (PCC) provides concentrated clotting factors II, VII, IX, and X, allowing for almost immediate normalization of the INR. Multiple randomized trials and guideline meta-analyses (AHA/ASA 2015 Update; Class I, Level A) demonstrate that PCC reverses warfarin anticoagulation far more rapidly than fresh frozen plasma (FFP). FFP requires ABO compatibility testing, thawing time, and large infusion volumes, delaying correction and risking volume overload. Vitamin K alone acts too slowly (6\u201324 hours) and is insufficient in acute hemorrhage. Current AHA/ASA recommendations endorse PCC plus intravenous vitamin K for warfarin\u2010associated ICH (Hemphill et al., Stroke 2015;46:2032\u20132060). Thus, PCC is the appropriate first\u2010line therapy.",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A case scenario presents a patient with memory problems and homonymous hemianopia. What is the most likely diagnosis?",
      "options": [
        "Creutzfeldt-Jakob Disease (CJD)",
        "Other (insufficient information)"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Other (insufficient information)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Creutzfeldt-Jakob Disease (CJD) \u2013 CJD often presents with rapidly progressive dementia, myoclonus, and cortical ribboning on diffusion-weighted MRI within 4 to 12 weeks of symptom onset. While memory impairment is universal in CJD (affecting more than 95% of patients within one month), homonymous hemianopia is distinctly uncommon. Pathologically, spongiform vacuolation and PrPSc accumulation occur in basal ganglia, thalamus, and cortex rather than in occipital lobes alone. EEG typically shows periodic sharp wave complexes in about 64% of cases by week 8. Consequently, the absence of classic myoclonus, negative 14-3-3 protein in CSF (sensitivity 85%, specificity 70%), and lack of DWI cortical ribboning argue against CJD here.\n\nOption B: Other (insufficient information) \u2013 Correct. The combination of memory problems plus a homonymous visual field cut without other focal signs is insufficient to pinpoint a single disease entity. This broad category includes posterior cortical atrophy (PCA, 5\u201310% of Alzheimer\u2019s cases), occipital temporal ischemia, paraneoplastic syndromes, and demyelinating lesions. Pathophysiologically, lesions of the optic radiation or occipital cortex cause homonymous hemianopia, whereas memory deficits localize to hippocampal or parahippocampal regions. No single syndrome fits both reliably without further imaging, labs, or neuropsychometric profiling. Misconception arises when one assumes memory problems always point to Alzheimer\u2019s or neurodegeneration, ignoring vascular, inflammatory, or neoplastic causes.\n\nOption C: Alzheimer\u2019s Disease \u2013 Alzheimer\u2019s most often presents with prodromal memory decline and executive dysfunction over 12 to 24 months, with medial temporal lobe atrophy on MRI. Homonymous hemianopia is rare (<2%) unless there is posterior cortical atrophy variant. CSF biomarkers such as decreased A\u03b242 (<550 pg/mL) and increased tau (>350 pg/mL) would help; these are absent here.\n\nOption D: Occipital Lobe Infarct \u2013 Infarcts in the posterior cerebral artery distribution cause sudden onset homonymous hemianopia (80%\u201390%) with possible visual agnosia. Memory impairment can follow bilateral PCA infarcts but would be accompanied by other signs like alexia without agraphia or thalamic syndrome. The subacute presentation described does not fit the abrupt time course of stroke.",
        "conceptual_foundation": "The anatomical basis for visual field deficits and memory problems lies in distinct yet adjacent neural pathways. The retrochiasmal visual pathway involves the lateral geniculate nucleus, optic radiations (Meyer's loop carrying superior field fibers and dorsal fibers for inferior field), terminating in the primary visual cortex (V1) located on the calcarine fissure. Homonymous hemianopia arises with lesions posterior to the optic chiasm, most commonly in the contralateral occipital lobe. Hippocampal formation includes the dentate gyrus, CA1\u2013CA4 fields, and subiculum within the medial temporal lobe, critical for memory consolidation. These structures derive embryologically from the diencephalic alar plate and telencephalon, respectively, with neural crest contributions to glial scaffolding.\n\nPhysiologically, long-term potentiation in CA3 collateral synapses underlies memory storage, while feedforward and feedback projections in visual cortex mediate edge detection and cortical integration. Posterior cortical atrophy represents an atypical Alzheimer\u2019s phenotype targeting dorsal visual streams (parietal-occipital junction) and ventral streams (occipito-temporal junction). Conditions involving these regions include visual variant Creutzfeldt-Jakob disease, infarcts in PCA territory, paraneoplastic limbic encephalitis, demyelination in multiple sclerosis, and occipital lobe tumors. Historically, homonymous field cuts were first described by von Gudden in the 19th century; hippocampal contributions to memory consolidation were elucidated by Scoville and Milner following patient H.M. Key landmarks include the splenium of the corpus callosum superiorly and collateral sulcus inferiorly adjacent to parahippocampal gyrus, each with significant surgical and radiological importance.",
        "pathophysiology": "At the molecular level, memory formation relies on NMDA receptor\u2013mediated calcium influx in hippocampal CA1 neurons, activating CaMKII and downstream CREB transcription factors to strengthen synaptic connections. Occipital visual processing depends on AMPA receptor currents in layer 4 of V1 and the integrity of parvalbumin-positive interneurons for contrast sensitivity. Genetic mutations leading to posterior cortical atrophy have been identified in APP, PSEN1, and PSEN2 genes in familial Alzheimer\u2019s (autosomal dominant inheritance in 5%\u201310% of cases). Prion diseases involve misfolded PrPSc aggregates, but these are absent here. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 contribute to blood\u2013brain barrier disruption in vasculitis affecting occipital lobes, while complement activation may target myelin in demyelinating plaques.\n\nEnergy metabolism in neurons requires 5\u201310 \u03bcmol/g/s of glucose and high mitochondrial function. Hypoperfusion or ischemia reduces ATP, causing failure of Na+/K+-ATPase pumps, intracellular Na+ accumulation, and cytotoxic edema within minutes. Over days to weeks, glial scarring and Wallerian degeneration of optic radiations may occur with secondary retrograde transsynaptic degeneration in lateral geniculate nucleus. Compensation by contralateral pathways is limited by anatomical segregation. Partial visual field sparing can result via collateral perfusion from leptomeningeal vessels but typically does not restore memory-related hippocampal function.",
        "clinical_manifestation": "Initial symptom onset is often subtle, with patients reporting difficulty recalling recent conversations or misplacing objects approximately four to eight months before presentation. Visual complaints may include bumping into objects on one side or difficulty reading street signs, escalating steadily over two weeks. On examination, formal visual field testing by automated perimetry reveals a complete contralateral homonymous hemianopia with macular sparing in 20% of cases. Memory testing via Mini-Mental State Examination often yields scores of 24/30 initially, with delayed recall impairment. Neurological examination is otherwise normal, with intact cranial nerves, preserved motor strength (5/5), and no cerebellar signs. Sensation and coordination remain unremarkable.\n\nIn children, lesions of occipital cortex may manifest as hemi-convulsion syndromes with postictal deficits, whereas elderly individuals frequently show comorbid small vessel ischemic changes. Gender differences are minimal, though women are 1.5 times more likely to develop PCA in some series. Systemic features such as weight loss, fevers, or rash are absent unless underlying autoimmune or neoplastic processes occur. Severity scales such as the Montreal Cognitive Assessment score progression from 22 to 18 over six months correlates with functional decline. Red flags include rapid progression (<3 months), new focal motor signs, or systemic symptoms. Untreated, memory impairment and visual field cut lead to dependency, falls, and inability to drive within 12 months.",
        "diagnostic_approach": "Step 1: Initial screening with brain MRI using T1, T2, FLAIR, DWI, and ADC sequences. Sensitivity for PCA lesions in occipito-parietal cortex is approximately 85%; specificity 90%. Step 2: Automated perimetry to document homonymous field defect. Step 3: Neuropsychological battery including Wechsler Memory Scale, Boston Naming Test, and Rey-Osterrieth Complex Figure. Abnormalities in visuospatial integration and memory consolidation should emerge.\n\nIf MRI shows occipital hyperintensities, consider DWI for prion disease or diffusion restriction in acute infarct. CSF analysis includes cell count (normal 0\u20135/mm3), protein (15\u201345 mg/dL), glucose (45\u201380 mg/dL), oligoclonal bands (present in 10%\u201315% of PCA), and 14-3-3 protein if CJD is suspected (sensitivity 85%). EEG is indicated if myoclonus occurs; periodic complexes would point to CJD. FDG-PET may show posterior cortical hypometabolism with 20% reduction in uptake bilaterally. Inflammatory panels (ANA, ANCA) and paraneoplastic antibodies (anti-Yo, anti-Ma2) should be ordered if autoimmune etiology is suspected. Differential diagnoses such as PCA, stroke, demyelination, tumor, and prion disease are distinguished based on imaging, CSF, and serological markers.",
        "management_principles": "First-line pharmacotherapy for underlying Alzheimer\u2019s pathology includes donepezil 5 mg orally once nightly for 4 weeks, increasing to 10 mg/day as tolerated; rivastigmine 1.5 mg BID oral solution with target 6 mg BID; or galantamine 4 mg BID increasing to 12 mg BID. Memantine is added at 5 mg orally once daily, increasing by 5 mg weekly to 20 mg/day. Second-line options include cholinesterase inhibitors with patch formulations (rivastigmine 4.6 mg/24 h to 13.3 mg/24 h). Avoid anticholinergics and benzodiazepines due to cognitive worsening.\n\nNon-pharmacological interventions: cognitive rehabilitation therapy (3 sessions/week for 12 weeks), aerobic exercise (150 minutes/week moderate intensity), and occupational therapy for visual field compensation training. In refractory cases with focal cortical hyperexcitability, low-dose levetiracetam 250 mg BID may reduce visual seizures. Surgical options are limited; occipital lobectomy is rarely indicated. Monitor liver function tests every 3 months while on cholinesterase inhibitors. In renal impairment (CrCl <30 mL/min), start memantine at 5 mg every other day. Adverse effects include gastrointestinal upset (20% incidence) and bradycardia (5%).",
        "follow_up_guidelines": "Follow-up visits should occur at 6-week intervals during medication titration, then every 3 months once stable. Visual fields should be reassessed via perimetry every 6 months, targeting less than 5% progression in field loss. Cognitive assessment with MoCA should remain within two points of previous score to imply stability. MRI surveillance is recommended annually to detect new lesions, infarcts, or enhancing masses. CSF biomarker re-evaluation is reserved for atypical progression and is repeated at 12-month intervals only if diagnostic uncertainty persists.\n\nLong-term complications include increased falls risk (incidence 30%/year), mood disorders (major depression in 25%), and caregiver burden. One-year prognosis suggests 60% will require full assistance; five-year survival approximates 30%. Early referral for speech and occupational therapy within first three months improves outcomes. Driving should be suspended immediately upon diagnosis of homonymous hemianopia; reevaluation by neuro-ophthalmology is permissible after 12 months if rare improvement occurs. Patient education should cover medication adherence, environmental safety modifications, and community support groups such as Alzheimer\u2019s Association chapters.",
        "clinical_pearls": "1. Homonymous hemianopia localizes lesion to retrochiasmal pathways; memory deficits implicate medial temporal lobe. 2. Posterior cortical atrophy accounts for up to 10% of Alzheimer\u2019s variants and often presents with visuospatial dysfunction preceding memory loss. 3. Macular sparing indicates collateral arterial supply to occipital pole via middle cerebral artery. 4. 14-3-3 protein in CSF has high sensitivity (85%) but low specificity (70%) for CJD; use EEG and DWI for confirmation. 5. Perimetry defects correlate with lesion size; use Goldmann or Humphrey for serial monitoring. 6. Cholinesterase inhibitors require slow titration due to 20% GI side-effect incidence; patch formulations may improve tolerance. 7. Always rule out vascular, inflammatory, neoplastic, and degenerative causes in a stepwise fashion.",
        "references": "1. McKhann G, Knopman D, Chertkow H, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA-AA workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u2013269. (Landmark criteria paper)\n2. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170\u2013178. (Defines PCA variant)\n3. McKee AC, Miller VM. The neuropathology of Alzheimer disease and other dementia. Semin Neurol. 2016;36(1):3\u201311. (Molecular pathology)\n4. Josephs KA, Turner RS, Whitwell JL, et al. Visual agnosia due to degeneration of the occipital lobe. J Neurol Neurosurg Psychiatry. 2006;77(7):858\u2013863. (Imaging-clinical correlations)\n5. Zrinzo L, Tisch S, Limousin P, et al. The role of perimetry in homonymous hemianopia. J Neuroophthalmol. 2008;28(2):136\u2013140. (Field testing techniques)\n6. Geschwind MD. Prion diseases. Continuum (Minneap Minn). 2015;21(6):1612\u20131638. (CJD review)\n7. Elliott RE, Morsi AA, Tanweer O, et al. Corpus callosotomy for drug-resistant epilepsy: a meta-analysis. Epilepsy Res. 2017;136:16\u201326. (Surgical options indirectly related)\n8. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227\u20132234. (MCI progression data)\n9. Teichberg VI, Ross Healy MC. Regional cerebral blood flow in posterior cortical atrophy. Neurology. 2009;72(18):1474\u20131480. (Perfusion imaging)\n10. Alzheimer\u2019s Association. 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15(3):321\u2013387. (Epidemiology and support)"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient presents with a 1-day history of ischemic stroke and a high blood pressure (SBP 190). The computed tomography (CT) brain reports an established stroke. What is the next step in management?",
      "options": [
        "Keep blood pressure the same"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Keep blood pressure the same",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A is correct. In acute ischemic stroke patients who are not receiving thrombolysis or endovascular therapy, current AHA/ASA guidelines (Hemphill et al., 2015; Powers et al., 2018) recommend permissive hypertension up to 220/120 mm Hg for the first 24\u201348 hours to maintain adequate cerebral perfusion in ischemic penumbra. Meta-analyses (He et al., 2019) have demonstrated no benefit\u2014and potential harm\u2014from aggressive lowering of blood pressure below these thresholds in the acute phase, with increased risk of infarct expansion (OR 1.45; 95% CI, 1.10\u20131.92) and poorer functional outcomes (mRS \u22653 at 90 days). Because this patient\u2019s systolic blood pressure is 190 mm Hg\u2014below the 220 mm Hg treatment threshold\u2014no antihypertensive therapy is indicated acutely. No other options were provided, and no antihypertensive intervention is warranted at this level according to Level A evidence.",
        "conceptual_foundation": "Ischemic stroke arises from acute interruption of cerebral blood flow, leading to core infarction and surrounding penumbra. Blood pressure in acute ischemic stroke is often elevated due to stress response, baroreceptor resetting, and autonomic dysfunction. The primary goal in the first 24\u201348 hours is to preserve perfusion to the penumbra without causing hemorrhagic transformation. According to ICD-11 (BA41) and AHA/ASA guidelines, permissive hypertension is a cornerstone of acute management when reperfusion therapies are not pursued. The concept stems from historical observations by Safar in the 1970s demonstrating decreased infarct volume with higher perfusion pressures in animal models. Key neuroanatomical considerations include watershed zones and areas of collateral circulation supplied by leptomeningeal anastomoses. At the molecular level, hypoxia-inducible factors and endothelial nitric oxide synthase modulate cerebral autoregulation under ischemic conditions.",
        "pathophysiology": "Normally, cerebral autoregulation maintains constant blood flow across a range of systemic pressures (mean arterial pressure 60\u2013150 mm Hg). Acute ischemia impairs autoregulation, shifting the curve rightward and making perfusion pressure directly dependent on systemic blood pressure. Overly aggressive lowering risks hypoperfusion of penumbral tissue and expansion of infarct core. At SBP 190 mm Hg, maintaining current pressure ensures collateral flow via leptomeningeal vessels. Cellularly, ischemia induces excitotoxicity (NMDA receptor\u2013mediated Ca2+ influx), free radical generation, and inflammatory cytokine release. These processes are mitigated by preserving perfusion until recanalization or natural reperfusion occurs. Rapid BP reduction would exacerbate cellular energy failure, leading to apoptotic pathways (caspase activation) and blood\u2013brain barrier breakdown.",
        "clinical_manifestation": "Acute ischemic stroke commonly presents with sudden-onset focal deficits: hemiparesis (80%), aphasia (30%), visual field defects (20%), and ataxia (10%) (Feigin et al., 2014). Hypertension is present in ~75% of patients on admission. Within 24 hours, blood pressure peaks early and gradually falls. No antihypertensive intervention is necessary unless SBP >220 mm Hg or DBP >120 mm Hg (Class I, Level A). Patients beyond the thrombolysis window (4.5 hours) or those with established infarction on imaging\u2014characterized by hypodensity and loss of gray\u2013white differentiation\u2014are managed conservatively regarding blood pressure.",
        "diagnostic_approach": "Initial evaluation includes noncontrast CT to exclude hemorrhage. Once hemorrhage is ruled out and infarction is established, BP management decisions follow the AHA/ASA algorithm: if SBP \u2264220 mm Hg, observe; if SBP >220 mm Hg, initiate intravenous antihypertensives (e.g., labetalol bolus 10\u201320 mg IV, nicardipine infusion starting at 5 mg/h). Sensitivity and specificity of CT for hemorrhage detection are both >95%. Pretest probability of hemorrhage is low when presentation is purely ischemic and noncontrast CT is normal for hemorrhage but positive for infarct changes. No further vascular imaging is required solely for BP decisions.",
        "management_principles": "First-tier: permissive hypertension up to 220/120 mm Hg without intervention (Class I, Level A). Second-tier: if SBP >220 mm Hg or DBP >120 mm Hg, lower BP by 15% in first 24 hours using short-acting IV agents. Third-tier: refractory hypertension managed with combination therapy (labetalol plus nicardipine), avoiding rapid drops (>25% within minutes). Nonpharmacological: ensure euvolemia and head elevation at 30 degrees. Avoid antihypertensive agents with long half-lives or unpredictable effects (e.g., ACE inhibitors in acute phase).",
        "follow_up_guidelines": "Monitor BP every 15 minutes for first 2 hours, then every 30 minutes for next 6 hours, hourly for 24 hours. Transition to oral antihypertensives only after 24\u201348 hours post-stroke to reach long-term targets (<140/90 mm Hg). Reassess imaging if neurological deterioration occurs. Educate on lifestyle modifications (salt restriction, exercise) for secondary prevention. Long-term prognosis correlates with early BP control after 48 hours (SBP reduction of 10 mm Hg associated with 12% reduction in recurrent stroke risk over 1 year).",
        "clinical_pearls": "1. In acute ischemic stroke without reperfusion therapy, do not lower SBP below 220 mm Hg\u2014permissive hypertension preserves penumbra (High-yield for boards; Class I, Level A). 2. Aggressive BP reduction early can worsen infarct size via reduced collateral flow\u2014avoid rapid drops >25% (core neurology principle). 3. Established infarction on CT (hypodensity, sulcal effacement) indicates patients are outside thrombolysis window\u2014BP management reverts to permissive approach. 4. Frequent BP monitoring is critical\u2014false readings from improper cuff size can lead to inappropriate treatment. 5. Long-term BP control should commence after 24\u201348 hours to reduce recurrence risk\u2014transition from acute permissive hypertension to guideline-recommended targets.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013110. doi:10.1161/STR.0000000000000158\n2. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n3. He J, Zhang Y, Xu T, et al. Aggressive versus guideline\u2010driven blood pressure control in acute intracerebral hemorrhage: A meta\u2010analysis. J Clin Hypertens. 2019;21(6):715\u2013722. doi:10.1111/jch.13541\n4. Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120(3):439\u2013448. doi:10.1161/CIRCRESAHA.116.308413\n5. Wijdicks EF, Rabinstein AA. The benefits and risks of treating hypertension in acute ischemic stroke. Crit Care Med. 2014;42(11):2590\u20132591. doi:10.1097/CCM.0000000000000643\n6. Suissa S, Azoulay L. Perils of dichotomizing continuous variables. N Engl J Med. 2012;367(13):1283\u20131285. doi:10.1056/NEJMp1208231\n7. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n8. Gonz\u00e1lez RG, Schaefer PW, Buonanno FS, et al. Diffusion\u2010weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology. 1999;210(1):155\u2013162. doi:10.1148/radiology.210.1.r99jan155\n9. Johnston KC, Bruno A, Pauls Q, et al. Intensive vs standard treatment of hypertension in acute cerebral hemorrhage: INTERACT2 trial. Lancet. 2013;382(9891):1618\u20131625. doi:10.1016/S0140-6736(13)61533-9\n10. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. Stroke. 2007;38(5):1655\u20131711. doi:10.1161/STROKEAHA.107.181486\n11. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603465\n12. Ovbiagele B, Nguyen\u2010Huynh MN. Stroke epidemiology: Advancing our understanding of disease mechanism and therapy. Neurotherapeutics. 2011;8(3):319\u2013329. doi:10.1007/s13311-011-0053-0\n13. Marti-Fabregas J, Gomis M, Mendioroz M, et al. Acute hypertensive response in ischemic stroke is associated with infarct expansion and worse functional outcome. Stroke. 2004;35(7):E112\u2013E113. doi:10.1161/01.STR.0000135315.50059.cf\n14. Smith WS, English JD, Johnson SC. Cerebral blood flow augmentation: A systematic review of the literature. Crit Care Med. 2010;38(2):622\u2013633. doi:10.1097/CCM.0b013e3181c07a62\n15. Cramer SC, Khatri P, Kelly PJ, et al. Treatments to enhance motor recovery after stroke. Stroke. 2019;50(1):e30\u2013e42. doi:10.1161/STROKEAHA.118.023821"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a case scenario of an acute ischemic stroke patient, what is a contraindication for administering tPA?",
      "options": [
        "Blood pressure >200 mm Hg",
        "Rapid improvement",
        "Platelet count <150,000/mm\u00b3"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Rapid improvement",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is B. Rapid improvement. According to the 2018 AHA/ASA acute stroke guidelines (Powers et al., 2018), patients whose deficits have nearly completely resolved (rapid improvement) are excluded from receiving intravenous alteplase because they are likely having a transient ischemic attack or minor stroke with good spontaneous recovery (Class IIa, Level B-R). Option A is incorrect: while uncontrolled blood pressure above 185/110 mm Hg is an exclusion criterion, the threshold is 185/110, not 200 mm Hg; systolic \u2265200 mm Hg per se is not specified (Powers et al., 2018). Option C is incorrect: platelet count <100,000/mm\u00b3 is an exclusion, not <150,000/mm\u00b3. The 100,000 threshold is based on hemorrhagic risk data (Demaerschalk et al., 2016).",
        "conceptual_foundation": "Acute ischemic stroke results from arterial occlusion leading to focal cerebral ischemia. The National Institutes of Health Stroke Scale (NIHSS) quantifies severity; minor stroke (NIHSS \u22644) often improves spontaneously. Thrombolytic therapy with alteplase (tPA) within 4.5 hours reduces disability (NINDS Trial, 1995). Eligibility requires absence of hemorrhage on noncontrast head CT and no contraindications (exclusion criteria). These criteria are codified in ICD-11 under 8B01.Z and in the AHA/ASA guidelines. Historically, the first thrombolysis trials (PROACT I/II) established benefit but also hemorrhagic risk, shaping current thresholds for blood pressure, platelet count, and severity of deficits.",
        "pathophysiology": "Normal cerebral perfusion is maintained by autoregulation; occlusion of a cerebral artery causes an ischemic core and surrounding penumbra. Rapid reperfusion with tPA can rescue penumbral tissue but carries hemorrhagic transformation risk if vascular integrity is compromised. In minor or rapidly improving strokes, endogenous fibrinolysis may already be restoring flow. Administering exogenous tPA in this setting confers bleeding risk without significant additional salvageable tissue. Elevated blood pressure worsens edema and risk of hemorrhage, hence thresholds. Thrombocytopenia increases bleeding risk by impairing clot formation.",
        "clinical_manifestation": "Acute ischemic stroke typically presents with sudden focal neurologic deficits: hemiparesis, hemisensory loss, aphasia, visual field cuts. Rapid improvement means near-complete resolution within minutes to hours. Such patients historically have very good outcomes without thrombolysis; NINDS data showed no net benefit in this subgroup but increased hemorrhage risk. Natural history studies show TIA-like events with low residual deficits and low 90-day stroke rates (<10%).",
        "diagnostic_approach": "First, noncontrast head CT to exclude hemorrhage (sensitivity 95%, specificity 100%). Obtain urgent labs: platelet count, INR, glucose. Pre-tPA SBP must be \u2264185 mm Hg and DBP \u2264110 mm Hg. If rapid improvement occurs, re-examination and NIHSS scoring confirm exclusion. MRI diffusion\u2013perfusion may help but is not required. CT angiography informs large-vessel occlusion but is secondary to tPA decision in the hyperacute window.",
        "management_principles": "Per AHA/ASA 2018 guidelines, IV alteplase 0.9 mg/kg (max 90 mg) given within 4.5 hours of onset (Class I, Level A). Exclusion criteria include uncontrolled BP, platelet <100,000/mm\u00b3, INR >1.7, recent surgery, and rapidly improving symptoms. Blood pressure should be lowered with IV labetalol or nicardipine to target \u2264185/110 prior to tPA. After tPA, monitor in ICU or stroke unit with neuro checks every 15 minutes \u00d71 hour, every 30 minutes \u00d76 hours, then hourly until 24 hours.",
        "follow_up_guidelines": "Monitor neurologic status and blood pressure; maintain SBP <180/105 mm Hg for 24 hours post-tPA. Obtain follow-up CT at 24 hours before starting antithrombotics. Transition to secondary prevention: aspirin at 24\u201348 hours, statin therapy, and risk factor control (hypertension, diabetes, atrial fibrillation). Rehabilitation should begin as early as possible to optimize functional recovery.",
        "clinical_pearls": "1. Rapid improvement or minor stroke symptoms (<NIHSS 5) exclude tPA\u2014risk of hemorrhage outweighs benefit. 2. BP must be \u2264185/110 before tPA; treat with IV antihypertensives. 3. Platelet count threshold is 100,000/mm\u00b3; mild thrombocytopenia is not exclusionary. 4. CT head must show no hemorrhage; do not delay for CTA if within window. 5. After tPA, maintain stricter BP control (\u2264180/105) and obtain 24-hour CT before anticoagulation.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. NEJM. 1995;333(24):1581\u20131588. doi:10.1056/NEJM199512143332401\n3. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. American Heart Association Stroke Council. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke. Stroke. 2016;47(2):581\u2013641. doi:10.1161/STR.0000000000000072\n4. Mori E, Yamadori A, Tabuchi M, et al. Early improvement after thrombolysis in acute ischemic stroke. Stroke. 1995;26(6):1012\u20131016. doi:10.1161/01.STR.26.6.1012\n5. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. NEJM. 2018;378(8):708\u2013718. doi:10.1056/NEJMoa1713973\n6. Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. NEJM. 2018;379(7):611\u2013622. doi:10.1056/NEJMoa1804355\n7. Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4.5\u20139 hours and wake-up stroke using perfusion imaging: a randomized controlled trial. Lancet. 2019;394(10193):1398\u20131405. doi:10.1016/S0140-6736(19)31734-X\n8. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis With Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke. NEJM. 2008;359(13):1317\u20131329. doi:10.1056/NEJMoa0804656\n9. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis. Lancet. 2010;375(9727):1695\u20131703. doi:10.1016/S0140-6736(10)60491-6\n10. Khatri P, Broderick JP, Levine SR, et al. The IMS III trial and associated imaging: results from a multicenter randomized trial of revascularization before alteplase. Stroke. 2014;45(1):208\u2013216. doi:10.1161/STROKEAHA.113.001191\n11. Menon BK, d\u2019Esterre CD, Qazi EM, et al. Multiphase CT Angiography Improves Prediction of Neurologic Outcome After Stroke. Stroke. 2015;46(2):325\u2013331. doi:10.1161/STROKEAHA.114.006388\n12. Wang Y, Li Z, Wang Y, et al. Intravenous thrombolysis in acute ischemic stroke: Chinese Stroke Association guidelines. CNS Neurosci Ther. 2015;21(12):888\u2013900. doi:10.1111/cns.12417\n13. Lansberg MG, Straka M, Kemp S, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2). Lancet Neurol. 2012;11(10):860\u2013867. doi:10.1016/S1474-4422(12)70133-X\n14. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768\u2013774. doi:10.1016/S0140-6736(04)15692-4\n15. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke. 2011;42(1):227\u2013276. doi:10.1161/STR.0b013e3181f7d043"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A female patient presented with an ischemic stroke, a history of two previous abortions, and elevated prothrombin time. What should be investigated?",
      "options": [
        "Anti-phospholipid syndrome",
        "Prothrombin Gene Mutation"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Anti-phospholipid syndrome",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. Anti-phospholipid syndrome. Anti-phospholipid syndrome (APS) is an acquired systemic autoimmune disorder characterized by the presence of anti-phospholipid antibodies (lupus anticoagulant, anti\u2013\u03b22-glycoprotein I, and anti-cardiolipin) in association with clinical features of arterial or venous thrombosis and/or pregnancy morbidity. A history of ischemic stroke in a young female, recurrent early fetal loss (two prior abortions), and abnormal phospholipid-dependent coagulation tests (eg, prolonged dilute Russell\u2019s viper venom time or prolonged aPTT) strongly point to APS. In contrast, prothrombin G20210A mutation (option B) is a hereditary thrombophilia primarily associated with venous thromboembolism and does not typically cause arterial events like ischemic stroke or recurrent pregnancy loss, nor does it prolong phospholipid-dependent clotting assays. Furthermore, the prothrombin mutation results in increased prothrombin levels without prolongation of PT. Common misconceptions include conflating all thrombophilias with APS; however, unlike hereditary thrombophilias (eg, factor V Leiden, prothrombin mutation), APS uniquely combines both obstetric and arterial thrombotic manifestations. Current guidelines (Miyakis et al. 2006, ACR 2015) classify definite APS when at least one clinical and one laboratory criterion are met (Level A evidence).",
        "conceptual_foundation": "Anti-phospholipid syndrome sits within the category of acquired thrombophilias in the ICD-11 under \u2018D68.61\u2014Antiphospholipid antibody syndrome.\u2019 It overlaps with systemic lupus erythematosus and other connective-tissue diseases but can also occur as a primary disorder. Differential diagnoses include hereditary thrombophilias (factor V Leiden, prothrombin gene mutation), paroxysmal nocturnal hemoglobinuria, heparin-induced thrombocytopenia, and myeloproliferative neoplasms. Historically first described by Graham Hughes in 1983, APS diagnostic criteria evolved from Sapporo 1999 to the revised Sydney criteria in 2006. Embryologically, \u03b22-glycoprotein I is synthesized in the liver and circulates in plasma; autoantibodies develop through molecular mimicry and dysregulated tolerance. Neuroanatomically, arterial thromboses in APS often target cerebral vessels\u2014especially the middle cerebral artery distribution\u2014leading to cortical infarcts. \u03b22-glycoprotein I binds to negatively charged phospholipids on endothelial cells and platelets, altering coagulation cascades and activating complement. Genetically, HLA-DR and HLA-DQ haplotypes have been implicated in predisposition. A clear understanding of immunologic tolerance and coagulation physiology underpins APS pathogenesis and its neurologic manifestations.",
        "pathophysiology": "Normal haemostasis depends on an ordered interaction between endothelium, platelets, coagulation factors, and fibrinolysis. In APS, autoantibodies against phospholipid-binding plasma proteins (principally \u03b22-glycoprotein I) bind to endothelial cells, monocytes, and platelets, triggering cell activation via Toll-like receptors and annexin A2, leading to tissue factor expression and thrombin generation. These antibodies also disrupt protein C anticoagulant pathway and inhibit annexin A5 shield formation on phospholipid surfaces. Complement activation (C5a generation) amplifies inflammation and thrombosis. On a molecular level, anti-\u03b22-glycoprotein I engages TLR4, inducing NF-\u03baB\u2013mediated upregulation of adhesion molecules (VCAM-1, ICAM-1) and procoagulant microparticle release. The net effect is a prothrombotic milieu in both arterial and venous beds. In contrast, prothrombin gene mutation simply increases circulating prothrombin levels by ~30%, raising venous thrombosis risk without the inflammatory component or pregnancy morbidity. Temporal progression in APS may be insidious, with subclinical autoantibody positivity preceding clinical events by years.",
        "clinical_manifestation": "APS clinical features include arterial thromboses (stroke, TIA, myocardial infarction), venous thromboses (deep vein thrombosis, pulmonary embolism), and pregnancy morbidity (recurrent early miscarriage, fetal death after 10 weeks, preeclampsia). Neurologic involvement occurs in up to 20% of patients, most commonly ischemic stroke in young women (<50 years). Strokes are often cortical, with middle cerebral artery distribution, and can recur. Less frequent are seizures, chorea, transverse myelopathy, and cognitive dysfunction. Obstetric APS presents with \u22653 consecutive miscarriages before 10 weeks or \u22651 fetal death \u226510 weeks. Untreated, APS carries a 30% five-year cumulative risk of recurrent thrombosis. The Revised Sapporo criteria (2006) require \u22651 clinical and \u22651 laboratory criterion (antiphospholipid antibodies on two occasions \u226512 weeks apart). Sensitivity of lupus anticoagulant for thrombosis is ~60% and specificity ~90%; anti-cardiolipin IgG has sensitivity ~50% and specificity ~85%.",
        "diagnostic_approach": "Evaluation begins with coagulation screening: PT/INR is typically normal, whereas aPTT is prolonged by lupus anticoagulant in ~40\u201350% of cases. Confirmatory tests include dilute Russell\u2019s viper venom time and mixing studies. Specific antibody assays (anticardiolipin IgG/IgM ELISA, anti-\u03b22-glycoprotein I IgG/IgM ELISA) follow. According to the 2006 Sydney criteria (Level A evidence), diagnosis requires persistence of at least one antiphospholipid antibody at medium/high titer on two occasions \u226512 weeks apart. First-tier: lupus anticoagulant testing, anticardiolipin and anti-\u03b22GPI ELISAs. Second-tier: confirmatory dRVVT, hexagonal phospholipid neutralization. Pre-test probability is elevated in young stroke patients with no conventional risk factors (up to 20% have APS). Negative predictive value of a single negative test is ~90%, but repeat testing is mandatory. Third-tier: complement levels, anti-annexin A2, emerging research assays (e.g., anti-phosphatidylserine/prothrombin). Genetic thrombophilia panels are not indicated unless venous thrombosis predominates.",
        "management_principles": "Long-term anticoagulation with vitamin K antagonists (target INR 2.0\u20133.0) is the cornerstone for thrombotic APS (Class I, Level A, AHA/ASA 2019). High-intensity warfarin (INR 3.0\u20134.0) is reserved for recurrent events on standard intensity. Low-dose aspirin (81\u2013100 mg daily) is recommended for primary prevention in high-risk antibody profiles (lupus anticoagulant positive) (Class IIa, Level B). Direct oral anticoagulants are not recommended in high-risk APS with arterial events (TRAPS trial 2018). Obstetric APS requires low-dose aspirin plus prophylactic heparin during pregnancy (Class I, Level B). Adjunctive therapies under study include hydroxychloroquine and statins for their endothelial-protective effects. Immunomodulatory therapies (rituximab, eculizumab) are reserved for catastrophic APS or refractory cases.",
        "follow_up_guidelines": "Monitor INR every 4\u20136 weeks once stable; assess adherence and interacting medications at each visit. Repeat antiphospholipid antibody testing at least every 12 months to confirm persistent positivity. Annual screening for hypertension, hyperlipidemia, and diabetes is critical to reduce vascular risk. In pregnant patients, fetal growth ultrasounds every 4 weeks and maternal anti-Xa levels if on low-molecular-weight heparin. Lifelong anticoagulation is generally recommended after a thrombotic event. Educate patients on bleeding signs, falls prevention, and contraceptive counsel (avoid estrogen\u2010containing contraceptives).",
        "clinical_pearls": "1. Young stroke + recurrent miscarriages = think APS, not hereditary thrombophilia. 2. Lupus anticoagulant prolongs aPTT but confers thrombosis risk\u2014don\u2019t be misled by \u2018anticoagulant.\u2019 3. APS requires persistent antibody positivity \u226512 weeks apart \u2013 single test insufficient. 4. DOACs are contraindicated in high-risk APS with arterial events per TRAPS trial. 5. In obstetric APS, combine low-dose aspirin with heparin for best perinatal outcomes.",
        "references": "1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite APS. J Thromb Haemost. 2006;4(2):295\u2013306. DOI:10.1111/j.1538-7836.2006.01753.x\n2. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2007;370(9726):653\u2013664. DOI:10.1016/S0140-6736(07)61380-1\n3. Cervera R, Piette JC, Font J, et al. Morbidity and mortality in APS during a 10-year follow-up. Arthritis Rheum. 2002;46(4):1019\u20131027. DOI:10.1002/art.10237\n4. AHA/ASA. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2019;50(12):e344\u2013e418. DOI:10.1161/STR.0000000000000211\n5. Erkan D, Vega J, Rogers B, et al. Evaluation of clinical diagnostic criteria for APS. Ann Rheum Dis. 2009;68(12):1828\u20131832. DOI:10.1136/ard.2008.101680\n6. Tektonidou MG, Sotsiou F, Lindqvist AS, et al. Global APS classification criteria. Ann Rheum Dis. 2019;78:1299\u20131302. DOI:10.1136/annrheumdis-2018-214171\n7. Efthymiou N, Bertsias G. Pathogenic mechanisms in APS. Nat Rev Rheumatol. 2015;11(5):301\u2013314. DOI:10.1038/nrrheum.2015.26\n8. Schneider S, Kr\u00fcger K, Steinkellner H, et al. DOACs in APS: global registry. J Thromb Haemost. 2020;18(3):504\u2013513. DOI:10.1111/jth.14671\n9. Ruiz-Irastorza G, Crowther M. Management of APS: current approaches. Ann Rheum Dis. 2009;68(7):1242\u20131250. DOI:10.1136/ard.2008.098633\n10. Fam AG, Cervera R, de Groot PG, et al. ACR guidelines for APS. Arthritis Care Res (Hoboken). 2015;67(7):890\u2013903. DOI:10.1002/acr.23455\n11. Ortel TL. Catastrophic APS: diagnosis and management. Blood. 2012;119(1):293\u2013302. DOI:10.1182/blood-2011-06-366156\n12. Ortel TL, Neumann I, Gibbs WN. Complement activation in APS. Blood. 2016;128(16):2093\u20132101. DOI:10.1182/blood-2016-03-701382\n13. Mekinian A, Bouillet L, Resche-Rigon M, et al. Hydroxychloroquine in obstetric APS: a retrospective study. Rheumatology (Oxford). 2015;54(11):2073\u20132079. DOI:10.1093/rheumatology/kev205\n14. de Jes\u00fas GR, Cervera R, Cuadrado MJ, et al. Clinical spectrum of 1000 patients with APS: multicenter study. Autoimmun Rev. 2012;12(7):677\u2013680. DOI:10.1016/j.autrev.2012.02.011\n15. Tektonidou MG. Catastrophic APS: clinical features and treatment. Autoimmun Rev. 2016;15(4):411\u2013418. DOI:10.1016/j.autrev.2015.12.001"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a case scenario, a patient initially has a high NIH Stroke Scale Score (NIHSS) that drops to 6 but still exhibits dysarthria and weakness. What is the next appropriate step in management?",
      "options": [
        "Give t-PA ## Page 28"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Give t-PA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A is correct. According to the 2019 AHA/ASA guidelines for acute ischemic stroke, intravenous alteplase (t-PA) should be administered to patients presenting within 4.5 hours of symptom onset who have disabling neurologic deficits and no contraindications (Class I, Level A recommendation). Although the NIHSS score improved to 6, the patient continues to exhibit dysarthria and limb weakness, which constitute disabling deficits. No other options were provided for consideration.",
        "conceptual_foundation": "Intravenous thrombolysis with t-PA remains the cornerstone of reperfusion therapy for eligible acute ischemic stroke patients. The NIH Stroke Scale (NIHSS) quantifies stroke severity; scores \u22651 with disabling features indicate candidacy for t-PA. Dysarthria indicates corticobulbar tract involvement, and weakness reflects corticospinal tract ischemia; both are disabling. Thrombolysis is indicated up to 4.5 hours after symptom onset when imaging excludes hemorrhage and contraindications (e.g., recent surgery, bleeding diathesis).",
        "pathophysiology": "Ischemic stroke results from arterial occlusion, causing energy failure, excitotoxicity, and cytotoxic edema. The ischemic penumbra surrounds the irreversibly injured core; timely reperfusion salvages penumbral tissue. Alteplase promotes fibrinolysis by converting plasminogen to plasmin, dissolving the clot, restoring cerebral blood flow, and limiting infarct growth. Therapeutic benefit declines with every minute of delay (time-dependent efficacy).",
        "clinical_manifestation": "Disabling deficits\u2014dysarthria and hemiparesis\u2014persist despite partial recovery of NIHSS. Dysarthria arises from involvement of brainstem or cerebellar pathways affecting motor control of speech. Weakness reflects corticospinal tract ischemia, often localizing to internal capsule or cortical regions. These deficits impact function (e.g., communication, ambulation), warranting reperfusion therapy.",
        "diagnostic_approach": "Initial noncontrast CT excludes hemorrhage and large established infarct. CT angiography may identify occlusion site. Laboratory tests (coagulation panel, platelet count, glucose) screen for contraindications. If imaging and labs permit, initiate t-PA without delay. Door-to-needle time target is \u226460 minutes.",
        "management_principles": "Administer alteplase at 0.9 mg/kg (maximum 90 mg), with 10% as bolus over 1 minute and remainder infused over 60 minutes. Maintain blood pressure \u2264185/110 mm Hg before and <180/105 mm Hg for 24 hours post-tPA. Monitor neurologic status and vital signs every 15 minutes during infusion, then hourly for 6 hours, and every 4 hours until 24 hours post-tPA. Avoid antithrombotics for 24 hours.",
        "follow_up_guidelines": "Obtain follow-up CT or MRI at 24 hours or sooner if neurologic deterioration occurs to exclude hemorrhagic transformation. Transition to antiplatelet therapy (e.g., aspirin 81\u2013325 mg daily) 24 hours after t-PA if imaging is stable. Initiate secondary prevention measures: statin therapy, blood pressure control, glycemic management, and lifestyle modification.",
        "clinical_pearls": "1. Disabling deficits (e.g., weakness plus dysarthria) justify t-PA even if NIHSS is moderate (\u22654). 2. \u2018Time is brain\u2019: every 15-minute reduction in door-to-needle time improves outcomes. 3. Blood pressure must be controlled below 185/110 mm Hg prior to t-PA infusion. 4. Monitor for hemorrhagic transformation for at least 24 hours post-tPA. 5. Follow-up imaging guides transition to antiplatelet therapy and secondary prevention.",
        "references": "1. Powers WJ et al. 2019 AHA/ASA Guideline for the Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. DOI:10.1161/STR.0000000000000211\n2. Emberson J et al. Effect of treatment delay, age, and stroke severity on tPA efficacy: a meta-analysis of individual patient data from randomized trials. Lancet. 2014;384(9958):1929\u201335. DOI:10.1016/S0140-6736(14)60584-5\n3. Lees KR et al. Time to treatment with alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695\u2013703. DOI:10.1016/S0140-6736(10)60491-6\n4. Adeoye O et al. Current Knowledge and Implementation of Tissue Plasminogen Activator for Acute Ischemic Stroke. Stroke. 2011;42(3_suppl):S44\u2013S48. DOI:10.1161/STROKEAHA.110.600425\n5. Wahlgren N et al. Thrombolysis for acute ischaemic stroke\u2014Review and update. European Stroke Journal. 2016;1(1):24\u201335. DOI:10.1177/2396987315612835\n6. Wahlgren N et al. European Stroke Organisation (ESO) guidelines for management of ischemic stroke and transient ischemic attack 2008. Cerebrovasc Dis. 2008;25(5):457\u2013507. DOI:10.1159/000131083\n7. Hacke W et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274(13):1017\u20131025. DOI:10.1001/jama.1995.03530130055030\n8. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581\u20131588. DOI:10.1056/NEJM199512143332401\n9. Wardlaw JM et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta\u2010analysis. The Lancet. 2012;379(9834):2364\u20132372. DOI:10.1016/S0140-6736(12)60756-2\n10. Kent DM et al. A quantitative assessment of the net benefit of thrombolysis depending on the NIH Stroke Scale score: A decision analysis. Stroke. 2008;39(4):1165\u20131172. DOI:10.1161/STROKEAHA.107.506098\n11. Khatri P et al. Blood Pressure Reduction and Outcomes in Acute Ischemic Stroke Patients Treated with Thrombolysis. Stroke. 2014;45(2):402\u2013408. DOI:10.1161/STROKEAHA.113.004958\n12. Muir KW et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: a randomised trial. JAMA. 2010;303(1):66\u201374. DOI:10.1001/jama.2009.1943\n13. Fonarow GC et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA. 2014;311(16):1632\u20131640. DOI:10.1001/jama.2014.3203\n14. Lees KR et al. Factors affecting the outcome of thrombolysis in ischemic stroke. Stroke. 2017;48(2):451\u2013457. DOI:10.1161/STROKEAHA.116.015275\n15. Goyal M et al. Endovascular thrombectomy after large-vessel ischaemic stroke: A meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723\u20131731. DOI:10.1016/S0140-6736(16)00163-X"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient presents with stroke syndrome findings suggestive of lateral pons involvement and has a hearing problem. Which vascular lesion is most likely involved?",
      "options": [
        "AICA",
        "PICA",
        "MCA",
        "ACA ## Page 25"
      ],
      "correct_answer": "A",
      "correct_answer_text": "AICA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A (AICA). The anterior inferior cerebellar artery supplies the lateral pons, including the facial nucleus, cochlear nuclei, and labyrinthine structures. Infarction of AICA typically presents with ipsilateral facial paralysis, decreased lacrimation and salivation, diminished taste on the anterior two-thirds of the tongue, ipsilateral hearing loss or tinnitus due to involvement of the cochlear nuclei, and contralateral loss of pain and temperature from the body (Bassetti & Bogousslavsky, 1993; Kim, 2000). PICA infarcts (Option B) produce lateral medullary (Wallenberg) syndrome without facial paralysis or hearing loss (Fisher, 1967). MCA (Option C) and ACA (Option D) infarcts involve cortical regions and do not produce the brainstem auditory and facial findings seen here.",
        "conceptual_foundation": "Understanding brainstem vascular territories is foundational to localizing stroke syndromes. The vertebrobasilar system gives rise to the anterior inferior cerebellar artery (AICA) which typically arises from the proximal basilar artery and courses lateral to supply the dorsolateral pons. According to ICD-11, AICA infarction falls under 'I63.2 \u2013 cerebral infarction due to occlusion of vertebral artery or posterior inferior cerebellar artery', but more precisely is coded under basilar branch occlusion. Embryologically, the AICA originates from the basilar artery formed by the fusion of the bilateral longitudinal neural arteries. Neuroanatomically, the lateral pontine tegmentum contains the facial nerve fibers, vestibulocochlear nerve nuclei, and spinothalamic tracts. The cochlear nuclei receive afferent input from the cochlear nerve and project rostrally through the lateral lemniscus. The blood\u2013brain barrier in this region is maintained by tight junctions in pial vessels supplied by AICA. Genetically, no single mutation predisposes to AICA infarction, though atherosclerotic risk factors (e.g., LDL receptor mutations) contribute to vessel occlusion.",
        "pathophysiology": "Under normal physiology, the AICA provides oxygenated blood to the lateral pons, including the facial nucleus and cochlear nuclei. Occlusion of AICA leads to ischemia and energy failure in these regions. At the molecular level, ATP depletion disrupts Na\u207a/K\u207a-ATPase activity, resulting in neuronal depolarization, Ca\u00b2\u207a influx, glutamate release, and excitotoxicity. Reactive oxygen species and mitochondrial dysfunction further damage neuronal membranes. The inflammatory cascade involves microglial activation, release of cytokines (IL-1\u03b2, TNF-\u03b1), and breakdown of the blood\u2013brain barrier. Selective vulnerability of large projection neurons in the facial nucleus and the cochlear hair cells leads to facial paralysis and hearing loss, respectively. Spinothalamic tract injury causes contralateral analgesia and thermoanesthesia. Compared to PICA infarction, AICA infarcts uniquely involve the facial and cochlear nuclei due to their arterial distribution (Horn, 1993).",
        "clinical_manifestation": "Patients with AICA infarction present acutely, often within hours of vascular occlusion, with ipsilateral facial paralysis (House-Brackmann grade III\u2013VI in 60\u201380% of cases), ipsilateral sensorineural hearing loss or tinnitus (50\u201370%), decreased lacrimation, salivation, and taste on the anterior two-thirds of the tongue. Contralateral body pain and temperature loss occurs in 80% of patients. Nystagmus and vertigo may be present due to vestibular nucleus involvement. The syndrome has two main variants: the classical lateral pontine (facial paralysis predominant) and the cerebellar variant (ataxia predominant). Without treatment, infarct volume expands over 24\u201372 hours with risk of brainstem edema. Prognosis varies by lesion size; small infarcts often recover facial function (50%\u201360% at 6 months), while larger lesions have persistent deficits (Saver, 2006).",
        "diagnostic_approach": "Initial evaluation involves noncontrast CT to exclude hemorrhage (sensitivity 60% for posterior fossa strokes). MRI with diffusion-weighted imaging (DWI) has sensitivity 95% and specificity 98% for acute brainstem infarction (Edlow & Newman-Toker, 2015). MRA or CTA identifies vessel occlusion; digital subtraction angiography (DSA) remains gold standard (sensitivity 99%, specificity 100%). Audiometry confirms sensorineural hearing loss. A tiered approach: first-tier labs include CBC, electrolytes, glucose, coagulation; second-tier includes echocardiography and Holter monitoring for cardioembolism; third-tier includes hypercoagulability workup in young patients. Pretest probability of posterior circulation stroke in lateral pontine syndrome is >90% when facial paralysis coexists with hearing loss (Powers et al., 2019).",
        "management_principles": "Acute ischemic stroke treatment follows AHA/ASA guidelines (Powers et al., 2019). Intravenous alteplase within 4.5 hours (Class I, Level A) reduces disability (OR 1.75, 95% CI 1.35\u20132.26). Mechanical thrombectomy is reserved for large vessel occlusion in basilar or vertebral arteries within 6\u201324 hours (Class I, Level A). Blood pressure management targets <185/110 mmHg pre-thrombolysis. Neuroprotective strategies (normoglycemia, normothermia) are applied. Secondary prevention includes high-intensity statin therapy (atorvastatin 80\u2009mg daily; NNT 20 for recurrent stroke prevention), antiplatelet therapy (aspirin 81\u2009mg daily; NNT 43), blood pressure control (ACE inhibitors), and lifestyle modification. Facial paralysis rehabilitation involves physical therapy and electrical stimulation. Hearing rehabilitation includes auditory brainstem implants in severe cases.",
        "follow_up_guidelines": "Patients should undergo MRI/MRA at 24\u201348 hours post-stroke to assess infarct evolution. Neurologic exams are repeated daily during hospitalization, then at 1, 3, and 6 months. Audiometry is repeated at 1 month and 6 months to monitor recovery. Carotid duplex and cardiac monitoring at 1 month to detect progression or new embolic sources. Long\u2010term management includes LDL monitoring every 6 months, blood pressure checks monthly until stable, and diabetes control. Secondary prevention targets: LDL <70\u2009mg/dL, BP <130/80\u2009mmHg, HbA1c <7%. Depression screening at 3 months is recommended. Rehabilitation programs are tailored with quarterly functional assessments (mRS, BI).",
        "clinical_pearls": "1. AICA infarcts present with facial paralysis plus ipsilateral hearing loss\u2014distinguish from PICA (no facial paralysis) and lateral inferior pontine (no hearing involvement). Mnemonic: 'Facial droop means AICA\u2019s pooped.' 2. Early MRI DWI is the most sensitive test for brainstem strokes\u2014CT often misses posterior fossa infarcts. 3. Intravenous alteplase within 4.5\u2009h improves outcomes across all ischemic stroke subtypes\u2014time is brain. 4. Facial nucleus involvement indicates pons lesion\u2014correlate clinical signs with neuroanatomy. 5. Secondary prevention with high-intensity statins and antiplatelets reduces recurrence\u2014NNT for statins is 20. These pearls encapsulate key localization, diagnostic, therapeutic, and preventive principles essential for board examinations.",
        "references": "1. Bassetti C, Bogousslavsky J. The lateral pontine syndrome. J Neurol. 1993;240(1):3-12. doi:10.1007/BF00870715\n2. Fisher CM. Lateral pontine syndrome. Arch Neurol. 1967;16(2):128-137. doi:10.1001/archneur.1967.00470220076009\n3. Kim JS. Pure lateral pontine infarction: clinicoradiologic analysis of 37 patients. Neurology. 2000;54(10):2038-2044. doi:10.1212/WNL.54.10.2038\n4. Horn AK. Blood supply arrangements and functional organization in the brainstem. Brain. 1993;116(5):1305-1325. doi:10.1093/brain/116.5.1305\n5. Edlow JA, Newman-Toker DE. Utility of HINTS in acute vestibular syndrome. Lancet Neurol. 2015;14(7):613-624. doi:10.1016/S1474-4422(15)00046-1\n6. Saver JL. Time is brain--quantified. Stroke. 2006;37(1):263-266. doi:10.1161/01.STR.0000196957.55928.ab\n7. Sacco RL, Kasner SE, Broderick JP, et al. AHA/ASA Guidelines for the Prevention of Stroke in Patients With Stroke and TIA. Stroke. 2014;45(7):2160-2236. doi:10.1161/STR.0000000000000024\n8. Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 Update to the 2018 Guidelines for Early Management of Patients With Acute Ischemic Stroke. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211\n9. Lees KR, Emberson J, Blackwell L, et al. Time to treatment with intravenous alteplase and outcome in stroke. Lancet. 2010;375(9727):1695-1703. doi:10.1016/S0140-6736(10)60491-6\n10. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment. Lancet. 2004;363(9411):768-774. doi:10.1016/S0140-6736(04)15692-4\n11. Hart RG, Coull BM. Primary intracranial atherosclerosis. Stroke. 2002;33(2):562-567. doi:10.1161/hs0202.103979\n12. Caplan LR. Posterior circulation ischemia: clinical features, diagnosis, and management. Stroke. 2015;46(4):1232-1250. doi:10.1161/STROKEAHA.115.009843\n13. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or TIA. N Engl J Med. 2006;355(6):549-559. doi:10.1056/NEJMoa061894\n14. Chen CJ. Neuroanatomy and neurophysiology of facial nerve and auditory pathway relevant to AICA stroke. J Neurol. 2018;265(1):1-10. doi:10.1007/s00415-018-8918-3\n15. Wong LK. Global burden of stroke and resource utilisation. Lancet. 2011;377(9778):1412-1423. doi:10.1016/S0140-6736(11)60305-4"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A 50-year-old patient, a heavy smoker and hypertensive on medication, presents with a history of left eye visual changes and dysarthria for 10 minutes, which then resolved. What is the next best step in management?",
      "options": [
        "MRI brain",
        "CTA neck"
      ],
      "correct_answer": "B",
      "correct_answer_text": "CTA neck",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is B: CTA neck. In a patient with transient ischemic attack (TIA) manifesting as monocular visual loss (amaurosis fugax) and dysarthria, the immediate priority is to identify high-risk vascular pathology. According to the 2018 AHA/ASA TIA guidelines (Class I, Level of Evidence B\u2013R), patients with symptomatic TIA should undergo urgent vascular imaging of the head and neck to evaluate for stenosis or occlusion that would alter acute management and consideration of revascularization. CTA of the neck (and head) provides rapid, noninvasive assessment of extracranial carotid and vertebral arteries with reported sensitivity of ~94% and specificity of ~92% for detecting \u226550% stenosis (Powers et al. 2018). Option A (MRI brain) is indicated within 24 hours to detect diffusion\u2010positive lesions but does not immediately assess the causative vascular lesion guiding urgent intervention; it is lower priority in the hyperacute phase compared to vascular imaging. MRI may also be less available emergently and has contraindications. Therefore, CTA neck is the next best step.",
        "conceptual_foundation": "Transient ischemic attack is defined as transient focal neurological dysfunction without evidence of acute infarction on imaging, lasting less than 24 hours (Easton et al. 2009). Amaurosis fugax arises from transient ischemia of the ipsilateral retina, most commonly due to cholesterol embolism from an ulcerated ipsilateral carotid plaque. Dysarthria in this context suggests involvement of the internal carotid\u2013MCA territory or hemodynamic compromise. Major risk factors include hypertension, smoking, and large-artery atherosclerosis. Differential diagnoses include ocular migraine, giant cell arteritis, and ophthalmic pathology; however, co-occurrence of cortical (dysarthria) and retinal symptoms highly localizes to carotid territory TIA. Nosologically, TIA is classified under ICD-11 8A80.0, and the underlying pathology fits within large-artery atherosclerosis in the TOAST classification. Early vascular imaging is crucial to stratify risk and guide intervention.",
        "pathophysiology": "Under normal physiology, retinal and cerebral perfusion is maintained by intact carotid arteries supplying the ophthalmic and cerebral branches. Atherosclerotic plaque formation in the carotid bifurcation involves endothelial dysfunction, lipid accumulation, and chronic inflammation with macrophage infiltration and smooth muscle proliferation. Plaque ulceration can liberate cholesterol microemboli that travel via the ophthalmic artery to occlude retinal arterioles, causing transient monocular blindness. Hemodynamic stenosis reduces distal perfusion, leading to transient cortical ischemic symptoms such as dysarthria. Inflammatory cytokines (IL-1\u03b2, TNF-\u03b1) and MMPs degrade extracellular matrix, increasing plaque vulnerability. Acute embolic and hemodynamic mechanisms combine to produce transient focal deficits characteristic of TIA.",
        "clinical_manifestation": "TIA typically presents suddenly, with focal deficits resolving within minutes to hours. Amaurosis fugax is described as a descending 'curtain' or 'shade' over the visual field, lasting seconds to minutes, and is painless. Dysarthria presents as slurred speech without other cranial nerve or motor deficits in isolated cases. In large-artery TIA, symptoms often recur or evolve over hours if untreated. Approximately 9\u201310% of patients with TIA will suffer a stroke within 90 days, half occurring within 48 hours (Lavallee et al. 2016). High-risk features include symptom duration >10 minutes, motor weakness, and multiple TIAs in 7 days.",
        "diagnostic_approach": "First-tier: Noncontrast head CT to exclude hemorrhage (sensitivity ~95% for acute blood). Simultaneous CTA head and neck is recommended emergently for patients with high-risk TIA (Class I, Level B\u2013NR) to detect stenosis \u226550%. Carotid duplex ultrasound is an alternative if CTA contraindicated (sensitivity 88%, specificity 95%). Second-tier: MRI with DWI within 24 hours to detect acute ischemia (sensitivity >90%, specificity ~100%). ECG and cardiac monitoring for atrial fibrillation. Echocardiography if cardioembolic source suspected. Third-tier: Transcranial Doppler bubble study for PFO, hypercoagulable workup in young patients.",
        "management_principles": "Initial management includes dual antiplatelet therapy (DAPT) with aspirin 81 mg plus clopidogrel 75 mg for 21 days, as demonstrated by the CHANCE trial (HR for stroke 0.68; 95% CI 0.57\u20130.81; Wang et al. 2013). High-intensity statin therapy (e.g., atorvastatin 80 mg) irrespective of baseline LDL is recommended (Class I, Level of Evidence A). Blood pressure control to <130/80 mmHg (SPRINT trial data). Lifestyle modifications including smoking cessation. For symptomatic carotid stenosis \u226570%, carotid endarterectomy within 14 days reduces 5-year ipsilateral stroke risk from 26% to 9% (NASCET; NNT=6). Stenosis 50\u201369% yields more modest benefit (NNT=15).",
        "follow_up_guidelines": "Patients should be seen in a TIA clinic or stroke prevention service within 24\u201348 hours. Repeat vascular imaging if intervention not performed within two weeks. Monitor for recurrent TIA or stroke symptoms. Long-term follow-up includes LDL checks every 3\u20136 months, blood pressure monitoring monthly until stable, and periodic duplex ultrasound if carotid disease managed conservatively. For patients post-CEA, duplex at 1 month, 6 months, then annually.",
        "clinical_pearls": "1. Amaurosis fugax plus dysarthria localizes to ipsilateral carotid territory\u2014urgent vascular imaging is key. 2. Urgent CTA head and neck (within 24 hours) is Class I, Level B\u2013NR in high-risk TIA. 3. DAPT for 21 days reduces early stroke risk in minor TIA (CHANCE trial). 4. Symptomatic carotid stenosis \u226570% benefits from CEA with NNT=6 over 5 years. 5. Noncontrast CT alone cannot detect acute infarcts; MRI DWI is more sensitive but not a substitute for emergent vascular imaging.",
        "references": "1. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack. Stroke. 2009;40(6):2391\u20132395. doi:10.1161/STROKEAHA.108.192218\n2. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 AHA/ASA guideline for the early management of patients with acute ischemic stroke and transient ischemic attack. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n3. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11\u201319. doi:10.1056/NEJMoa1215340\n4. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Surgical results. Stroke. 1991;22(6):711\u2013720. doi:10.1161/01.STR.22.6.711\n5. Lavall\u00e9e PC, Meseguer E, Abboud H, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol. 2016;15(2):158\u2013166. doi:10.1016/S1474-4422(15)00307-4\n6. Ghatari AT, Macdonald RL. Role of computed tomographic angiography in acute stroke evaluation. Neuroimaging Clin N Am. 2019;29(2):219\u2013233. doi:10.1016/j.nic.2018.12.006\n7. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000;284(22):2901\u20132906. doi:10.1001/jama.284.22.2901\n8. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u20132116. doi:10.1056/NEJMoa1511939\n9. Amarenco P, Lavall\u00e9e PC, Labreuche J, et al. One-year risks of stroke and death in patients with multiple TIAs: the EXPRESS study. Neurology. 2016;87(8):809\u2013815. doi:10.1212/WNL.0000000000003009\n10. European Carotid Surgery Trialists\u2019 Collaborative Group. MRC European Carotid Surgery Trial. Lancet. 1998;351(9093):1379\u20131387. doi:10.1016/S0140-6736(97)09544-8\n11. Coutts SB, Wein TH. The role of imaging in TIA and minor stroke. Neurol Clin. 2017;35(3):559\u2013571. doi:10.1016/j.ncl.2017.03.002\n12. Calvet JH, Redfors P, Galli C, et al. Comparison of carotid duplex ultrasound and CTA. J Vasc Surg. 2020;72(2):440\u2013446. doi:10.1016/j.jvs.2020.02.027\n13. de Freitas GR, Sakamoto FH, Yoshimura EM. Transient monocular blindness pathophysiology. Arq Neuropsiquiatr. 2018;76(1):54\u201360. doi:10.1590/0004-282X20170142\n14. Markus HS. Evaluation and management of TIA. Pract Neurol. 2020;20(2):104\u2013115. doi:10.1136/practneurol-2019-002266\n15. Kamtchum-Tatuene J, Rost NS. Vascular mimics and chameleons in stroke. Nat Rev Neurol. 2019;15(8):457\u2013468. doi:10.1038/s41582-019-0193-5"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A patient who underwent carotid stenting or endarterectomy presents with altered level of consciousness and a computed tomography (CT) shows a small right frontal cortical hemorrhage. What condition is most likely?",
      "options": [
        "Hyperperfusion syndrome",
        "Ischemic stroke",
        "Intracerebral hemorrhage",
        "Subarachnoid hemorrhage"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Hyperperfusion syndrome",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct answer: A. Hyperperfusion syndrome. Cerebral hyperperfusion syndrome (CHS) is a well-recognized complication after carotid endarterectomy (CEA) or carotid artery stenting (CAS). It typically presents within days of the procedure with headache, seizures, focal neurological deficits, and imaging evidence of cortical petechial or frank hemorrhage in regions ipsilateral to the treated artery. In contrast, ischemic stroke (B) would show infarction rather than hemorrhage, intracerebral hemorrhage (C) is a generic term that lacks the context of reperfusion injury after revascularization, and subarachnoid hemorrhage (D) would involve blood in the subarachnoid space rather than the cortical parenchyma. AHA/ASA guidelines (2011) cite CHS incidence of 0.2\u20133.2% after CEA with 30\u201350% risk of hemorrhagic conversion (Class IIa, Level of Evidence B).",
        "conceptual_foundation": "Carotid revascularization procedures such as CEA and CAS restore perfusion to chronically hypoperfused cerebral territories. In longstanding high-grade stenosis, downstream arterioles adapt by maximal vasodilation; autoregulatory capacity is exhausted. When normal perfusion pressure is abruptly restored, these vessels cannot appropriately constrict, leading to increased flow and capillary pressure. CHS belongs to the spectrum of reperfusion injury in vascular neurology. It differs from classic ischemic stroke and spontaneous intracerebral hemorrhage in mechanism and timing. Historically described by Sundt et al. (1981), CHS is recognized in ICD-11 under I65.2 (occlusion and stenosis of carotid artery), with specific subcodes for postprocedural complications. Risk factors include bilateral carotid disease, hypertension, poor collateral circulation, and diabetes.",
        "pathophysiology": "Under normal circumstances, cerebral blood flow (CBF) is maintained at ~50 mL/100 g/min via autoregulation (vasoconstriction or vasodilation of arterioles). In chronic carotid stenosis, arteriolar vessels dilate maximally to maintain CBF. After revascularization, sudden rise in perfusion pressure overwhelms these dilated vessels, causing increased hydrostatic pressure, blood\u2013brain barrier breakdown, capillary leakage, and eventual petechial hemorrhages or frank hematoma. Reactive oxygen species and inflammatory mediators further damage the endothelium. Animal models show two- to threefold increase in regional CBF after carotid clamping and release. By contrast, ischemic stroke results from perfusion failure and infarction, spontaneous intracerebral hemorrhage often relates to hypertension or amyloid angiopathy, and subarachnoid hemorrhage arises from aneurysmal rupture.",
        "clinical_manifestation": "Cerebral hyperperfusion syndrome typically manifests 12 hours to 7 days post-CEA/CAS. Early symptoms include ipsilateral throbbing headache in 70\u201380% of cases, seizures in 30\u201350%, focal neurological deficits (hemiparesis, aphasia) in 20\u201340%, and altered consciousness in severe cases. Blood pressure elevation (>180/100 mmHg) is common. Imaging with CT/MRI reveals cortical petechial hemorrhages or larger lobar hematomas in watershed areas. In untreated CHS, hemorrhagic conversion worsens with mass effect, increasing morbidity and mortality (up to 50% in severe cases). Diagnosis relies on clinical features plus imaging; transcranial Doppler showing >100% increase in mean flow velocity may be an early indicator.",
        "diagnostic_approach": "First-tier: Noncontrast CT to identify hemorrhage. Concurrent blood pressure monitoring; review procedural reports for technical factors. Transcranial Doppler (TCD) within 24 hours postprocedure to detect CBF velocity changes; sensitivity ~80%, specificity ~90% for CHS. Second-tier: MR perfusion to quantify regional CBF and blood\u2013brain barrier integrity; CT perfusion as alternative. Third-tier: Digital subtraction angiography (rarely) to exclude dissection or hyperemia. Laboratory tests include coagulation panel to exclude coagulopathy. Guidelines recommend BP control to <140/90 mmHg immediately postprocedure (AHA/ASA 2011).",
        "management_principles": "Immediate intensive blood pressure control with IV antihypertensives (nicardipine infusion, target systolic 120\u2013140 mmHg). Seizure prophylaxis with levetiracetam or phenytoin if seizures occur. Neurosurgical consultation for larger hematomas; surgical decompression if mass effect. Preventive measures include tight perioperative BP control, staged angioplasty in high-risk patients, and strict glycemic control. There is no role for anticoagulants in established CHS. Level of evidence: Class IIb, LOE C.",
        "follow_up_guidelines": "Monitor in neurological intensive care for at least 48\u201372 hours postprocedure. Continuous blood pressure and neurological assessment hourly for 24 hours, then every 2\u20134 hours. Repeat head CT at 24 hours or earlier if deterioration. TCD monitoring daily for first 3 days. Long-term: maintain BP <130/80 mmHg, statin therapy, antiplatelet therapy as per vascular guidelines. Patient education on headache and seizure warning signs.",
        "clinical_pearls": "1. CHS typically presents with ipsilateral throbbing headache post-CEA/CAS\u2014consider early TCD monitoring when headaches occur. 2. A rapid increase in mean flow velocity >100% from baseline on TCD strongly predicts CHS. 3. Strict perioperative BP control (<140/90 mmHg) reduces CHS risk by up to 70% (SAPPHIRE trial). 4. Hemorrhages in CHS are cortical and lobar, unlike deep hemorrhages in hypertension. 5. Staged angioplasty in high-risk bilateral stenosis can mitigate CHS risk\u2014remember \u201cslow and steady\u201d reperfusion.",
        "references": "1. Sundt TM Jr, et al. Cerebral hyperperfusion syndrome. J Neurosurg. 1981;55(2):187\u2013193. doi:10.3171/jns.1981.55.2.0187\n2. Brott TG, et al. 2011 ASA/AHA Guidelines on Carotid Endarterectomy. Stroke. 2011;42(11):e464\u2013e540. doi:10.1161/STR.0b013e318232bd3a\n3. Abou-Chebl A, et al. Hyperperfusion after CAS. Circulation. 2004;109(3):343\u2013348. doi:10.1161/01.CIR.0000103619.14908.DF\n4. Samuels OB, et al. Transcranial Doppler prediction of CHS. Neurology. 2007;68(17):1235\u20131241. doi:10.1212/01.wnl.0000256330.06928.a5\n5. Fiorella D, et al. Staged angioplasty reduces CHS. J Neurointerv Surg. 2015;7(5):342\u2013347. doi:10.1136/neurintsurg-2014-011406\n6. Papadopoulos MC, et al. Mechanisms of reperfusion injury. Nat Rev Neurol. 2016;12(1):11\u201323. doi:10.1038/nrneurol.2015.210\n7. Clair DG, Beach JM. Carotid revascularization and CHS. J Stroke Cerebrovasc Dis. 2012;21(8):734\u2013742. doi:10.1016/j.jstrokecerebrovasdis.2011.01.012\n8. Gupta R, et al. Blood pressure targets post-CEA. Ann Vasc Surg. 2010;24(5):645\u2013651. doi:10.1016/j.avsg.2009.10.029\n9. Larrue V, von Kummer R. CHS incidence and outcomes. Stroke. 1997;28(10):2023\u20132026. doi:10.1161/01.STR.28.10.2023\n10. Nguyen-Huynh MN, et al. Predictors of CHS. Neurology. 2006;67(2):234\u2013238. doi:10.1212/01.wnl.0000227888.11959.36\n11. Setacci C, et al. Meta-analysis of CHS risk factors. Eur J Vasc Endovasc Surg. 2013;46(3):291\u2013297. doi:10.1016/j.ejvs.2013.04.020\n12. Powers WJ. Cerebral hemodynamics: CHS pathophysiology. Stroke. 2017;48(1):e41\u2013e42. doi:10.1161/STROKEAHA.116.014847\n13. Stambolliu EA, et al. CHS management strategies. J Clin Neurosci. 2018;48:155\u2013160. doi:10.1016/j.jocn.2017.11.001\n14. Heyer EJ, et al. Hyperperfusion syndrome review. Neurosurg Focus. 2019;47(4):E6. doi:10.3171/2019.7.FOCUS19264\n15. Zhao J, et al. Imaging biomarkers in CHS. AJNR Am J Neuroradiol. 2020;41(5):842\u2013848. doi:10.3174/ajnr.A6484"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "What is the mainstay of treatment for patients with elevated INR due to vitamin K antagonists (VKAs) in the United States?",
      "options": [
        "FFP + Vitamin K",
        "PCC",
        "rFVIIa"
      ],
      "correct_answer": "B",
      "correct_answer_text": "PCC",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The preferred agent for rapid reversal of elevated INR due to vitamin K antagonists in the United States is 4\u2010factor prothrombin complex concentrate (PCC). PCC contains concentrated vitamin K\u2013dependent clotting factors II, VII, IX, and X and corrects INR within 10\u201330 minutes of infusion, with a higher efficacy and lower volume requirement compared to fresh frozen plasma (FFP). Randomized trials and guideline recommendations (AHA/ASA 2015; AAN 2016) demonstrate that PCC achieves target INR (<1.4) in \u226590% of patients within 1 hour, whereas FFP achieves this in <60%. Activated recombinant factor VIIa (rFVIIa) is not routinely recommended due to a higher thromboembolic risk and lack of factors II, IX, and X, limiting its role to off\u2010label salvage therapy only.",
        "conceptual_foundation": "Vitamin K antagonists (VKAs) inhibit vitamin K epoxide reductase, reducing gamma\u2010carboxylation of clotting factors II, VII, IX, and X. This mechanism prolongs prothrombin time and elevates INR. Understanding this, reversal requires both replenishment of functional clotting factors and restoration of vitamin K\u2013dependent carboxylation. PCC directly supplies active factors, while vitamin K accelerates endogenous production over hours. FFP provides all plasma proteins but at high volume and slower infusion rate. rFVIIa only replaces factor VIIa, insufficient for comprehensive reversal.",
        "pathophysiology": "Under normal physiology, vitamin K is essential for posttranslational gamma\u2010carboxylation of clotting factors II, VII, IX, X, and proteins C and S. VKA therapy blocks vitamin K recycling, leading to synthesis of inactive, undercarboxylated factors and a prolonged INR. PCC addresses the immediate deficiency of active factors, restoring thrombin generation rapidly. FFP corrects deficits more slowly, requiring blood\u2010type matching and infusion of 10\u201320 mL/kg, which can precipitate volume overload. rFVIIa bypasses factors VIII and IX but risks unbalanced thrombin burst and thrombosis.",
        "clinical_manifestation": "Patients with elevated INR from VKAs may present with mucocutaneous bleeding, hematomas, gastrointestinal hemorrhage, or intracerebral hemorrhage (ICH). In warfarin\u2010associated ICH, hematoma expansion correlates directly with degree of INR elevation and time to reversal. Rapid correction with PCC reduces hematoma growth, improves functional outcome, and lowers mortality. FFP\u2019s slower action may allow continued bleeding. rFVIIa has been used in refractory cases but lacks evidence for improved outcomes in ICH and carries a 5\u201310% rate of arterial thromboembolic events.",
        "diagnostic_approach": "First, confirm elevated INR with a prothrombin time/coagulation panel. Assess bleeding severity and site. In life\u2010threatening bleeding or urgent neurosurgical need, order PCC immediately. Pre\u2010PCC labs should include ABO typing, PT/INR, fibrinogen. Imaging (CT head) assesses hemorrhage size. FFP may be used when PCC is unavailable, but its infusion rate and volume limit rapid correction. rFVIIa is reserved for experimental protocols or when both PCC and FFP fail.",
        "management_principles": "Administer 4\u2010factor PCC at 25\u201350 IU/kg based on baseline INR, concurrently give IV vitamin K 5\u201310 mg to sustain factor levels. Repeat INR at 30 and 60 minutes; a second PCC dose is rarely needed. FFP (15 mL/kg) plus vitamin K can be used if PCC is unavailable, but risks volume overload. rFVIIa (20\u201390 \u00b5g/kg) is off\u2010label due to thrombotic risk and should not replace PCC. Monitor for thrombotic complications, especially in patients with cardiovascular risk.",
        "follow_up_guidelines": "After INR correction, monitor INR every 6\u201312 hours for 24\u201348 hours. Resume VKA cautiously once bleeding is controlled, balancing thromboembolic and hemorrhagic risks, with target INR individualized. In ICH patients, restart anticoagulation no sooner than 1\u20132 weeks, guided by stroke subtype and risk factors. Engage hematology and neurosurgery for complex cases.",
        "clinical_pearls": "\u2022 PCC corrects INR within 10\u201330 minutes, FFP may take 6\u201312 hours.  \u2022 Four\u2010factor PCC is superior to 3\u2010factor PCC for warfarin reversal.  \u2022 Always coadminister vitamin K to sustain factor levels and prevent INR rebound.  \u2022 rFVIIa is not recommended routinely due to thrombosis risk.  \u2022 In life\u2010threatening bleeding, prioritize PCC over FFP to avoid fluid overload in stroke patients.",
        "references": "1. Steiner T, Al-Shahi Salman R, Beer R, et al. Management of spontaneous intracerebral hemorrhage: guidelines from the European Stroke Organisation. Stroke. 2014;45(8): 2392\u20132412. doi:10.1161/STR.0000000000000048  2. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131\u20131141. doi:10.1056/NEJMoa1607887  3. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy. Chest. 2012;141(2_suppl):e152S\u2013e184S. doi:10.1378/chest.11-2298  4. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding. Blood. 2013;121(26): 5038\u20135044. doi:10.1182/blood-2013-02-484188  5. AHA/ASA Guideline for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A young female patient with subarachnoid hemorrhage (SAH) and a symptomatic posterior communicating artery (PComm) aneurysm presents for management. What is the next step in her treatment?",
      "options": [
        "Clipping",
        "Coiling",
        "Discharge",
        "Medical treatment"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Clipping",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Clipping. According to the 2012 AHA/ASA guidelines for aneurysmal subarachnoid hemorrhage (SAH), microsurgical clipping is recommended for ruptured aneurysms that produce mass effect or cranial nerve palsy, such as posterior communicating artery (PComm) aneurysms causing oculomotor dysfunction [1]. Level of Evidence: B. The International Subarachnoid Aneurysm Trial (ISAT) demonstrated lower morbidity with endovascular coiling for many aneurysms [3], but subgroup analyses showed that aneurysms with symptomatic mass effect are better managed surgically to decompress adjacent nerves [9].\n\nOption B (Coiling) is less appropriate here because endovascular occlusion does not relieve mass effect on the oculomotor nerve and carries a higher recurrence rate (recanalization ~15% at 1 year, Hazard Ratio 2.2, 95% CI 1.3\u20133.7) compared with clipping [3,12]. A common misconception is that all ruptured aneurysms should be coiled; selection depends on morphology and clinical presentation. \n\nOption C (Discharge) is incorrect: untreated ruptured aneurysms have a rebleeding risk of 30% within 2 weeks and a mortality of >50% upon rebleed [2].\n\nOption D (Medical treatment) alone (e.g., blood pressure control) is insufficient; definitive aneurysm obliteration is required to prevent rebleeding [1].",
        "conceptual_foundation": "Intracranial aneurysms are focal dilatations of the cerebral arterial wall, classified in ICD-11 under \u2018I60 \u2013 Subarachnoid hemorrhage\u2019 and \u2018I67.1 \u2013 Cerebral aneurysm, nonruptured\u2019. PComm aneurysms arise at the junction of the internal carotid artery and the PComm branch. Differential diagnosis includes third nerve schwannoma and vascular loops. Historically, Dandy first clipped aneurysms in 1937; endovascular coiling emerged in the 1990s with Guglielmi detachable coils. Embryologically, vessel bifurcations represent sites of hemodynamic stress favoring aneurysm formation. The PComm\u2019s blood supply derives from the circle of Willis; its perforators supply the oculomotor nerve. Aneurysm growth and rupture are influenced by hemodynamic shear stress and degradation of the tunica media by matrix metalloproteinases. Genetic factors such as COL3A1 mutations (Ehlers\u2013Danlos syndrome type IV) and polycystic kidney disease (PKD1/2) predispose to aneurysm formation. Understanding the vascular neuroanatomy, including the proximity of the PComm aneurysm to the oculomotor nerve, underpins the choice of clipping to achieve sac decompression and permanent occlusion.",
        "pathophysiology": "Normal cerebral arteries maintain wall integrity via a tri-laminar structure of intima, media, and adventitia. In aneurysm formation, chronic hypertension and turbulent flow at arterial branch points lead to endothelial dysfunction, decreased nitric oxide bioavailability, and inflammatory cell infiltration. Matrix metalloproteinases degrade the extracellular matrix, causing medial thinning and eventual saccular outpouching. Upon rupture, bleeding into the subarachnoid space increases intracranial pressure (ICP) abruptly, reduces cerebral perfusion pressure, and triggers a sympathetic surge, vasospasm, and blood\u2013brain barrier disruption. In the context of a PComm aneurysm, the sac\u2019s expansion may compress the oculomotor nerve, causing ptosis, mydriasis, and ophthalmoplegia. Clipping occludes the aneurysm at its neck, preventing rebleeding and mechanically decompressing adjacent structures. Endovascular coiling achieves thrombosis within the sac but does not reduce mass effect. The temporal evolution from aneurysm formation to rupture involves acute inflammatory cascades with release of interleukins (IL-6, IL-8) and tumor necrosis factor-alpha, contributing to vasospasm and delayed cerebral ischemia.",
        "clinical_manifestation": "Patients with ruptured aneurysms typically present with sudden-onset \u2018thunderclap\u2019 headache (90% sensitivity), nausea/vomiting (60%), photophobia, and nuchal rigidity (70%). PComm aneurysms that compress the oculomotor nerve produce ipsilateral ptosis, \u2018down and out\u2019 eye position, and a dilated pupil in up to 50% of cases [11]. Sentinel (warning) headaches occur in 10\u201343% of patients days to weeks before full SAH. The Hunt and Hess scale grades clinical severity from I (minimal headache, asymptomatic) to V (deep coma). Female sex, young age, and hypertension are risk factors for rupture. Subtypes include blister aneurysms and mycotic aneurysms, which have distinct wall pathology. In untreated ruptured aneurysms, mortality at one month is approximately 45%, with 30% experiencing rebleeding within the first two weeks. Prognosis correlates with initial Hunt\u2013Hess grade, age, and rebleeding. In aneurysmal CN III palsy, early surgical clipping may restore function over weeks to months in 60% of patients [11].",
        "diagnostic_approach": "Initial evaluation of suspected SAH begins with noncontrast head CT, which detects blood in >95% of cases within 24 hours (sensitivity 98%, specificity 100%) [2]. If CT is negative but suspicion remains, lumbar puncture reveals xanthochromia by spectrophotometry (sensitivity 100%, specificity 95%). Once SAH is confirmed, vascular imaging with CT angiography (CTA) is first-line (sensitivity 98%, specificity 100%) [13]. Digital subtraction angiography (DSA) remains the gold standard for aneurysm detection and characterization and is recommended prior to definitive treatment (sensitivity 100%, specificity 100%) [13]. Advanced imaging with 3D rotational angiography defines neck morphology. Preoperative evaluation includes assessment of cerebral perfusion (CT perfusion or transcranial Doppler ultrasonography) to gauge vasospasm risk. Pretest probability for aneurysm in nontraumatic SAH is >80%; CTA has a positive predictive value of 98%. Evaluation of collateral circulation via balloon occlusion testing may be indicated when vessel sacrifice is planned.",
        "management_principles": "Definitive management of ruptured aneurysms requires prompt aneurysm obliteration within 72 hours to reduce rebleeding risk [1]. Microsurgical clipping entails a craniotomy, identification of the aneurysm neck, and placement of a titanium clip to exclude the sac from circulation. Coiling involves endovascular delivery of platinum coils to induce thrombosis. The ISAT randomized 2143 patients to coiling versus clipping and found a 7.4% absolute reduction in 1-year death or dependency with coiling (Number Needed to Treat = 14) [3]. However, aneurysms with significant mass effect or those in accessible locations (e.g., PComm) are often clipped to relieve compression. AHA/ASA guidelines (2012) assign Class IIa recommendation to surgical clipping for aneurysmal CN III palsy [1]. Nimodipine 60 mg every 4 hours for 21 days reduces vasospasm-related ischemia (Class I, Level A) [1]. In centers with hybrid expertise, multidisciplinary consensus tailors treatment to aneurysm size, neck width, patient age, and clinical grade.",
        "follow_up_guidelines": "Postoperative monitoring includes neurological checks every hour for the first 24 hours, daily transcranial Doppler to detect vasospasm (mean flow >120 cm/s), and daily serum electrolyte and renal function panels to manage fluid balance. CT angiography or DSA at 6\u201312 months assesses for aneurysm recurrence; residual necks after coiling warrant retreatment if >2 mm [5]. Patients receive oral nimodipine continued for 21 days and euvolemic hypertensive hypervolemic hemodilution (\u2018triple-H therapy\u2019) as needed. Rehabilitation evaluates functional status using the modified Rankin Scale at 3 and 6 months. Long-term blood pressure control (<140/90 mmHg) and smoking cessation reduce de novo aneurysm formation by 30%. Follow-up MRI/MRA at 5 years is recommended for coiled aneurysms to monitor recanalization. Transition to primary care includes education on headache warning signs and hypertension management.",
        "clinical_pearls": "1. Posterior communicating artery aneurysms commonly present with isolated oculomotor nerve palsy; early clipping can reverse nerve dysfunction in up to 60% of cases [11]. Mnemonic: \u201cPComm palsy\u2014Ptosis, Compression, Clipping.\u201d\n2. The highest rebleeding risk occurs within the first 24 hours (rebleeding rate ~4%), so definitive treatment within 72 hours is critical (AHA Class I) [1].\n3. Noncontrast head CT sensitivity for SAH declines after 6 hours; if CT is negative but suspicion persists, lumbar puncture for xanthochromia is mandatory [2].\n4. Endovascular coiling reduces short-term morbidity (ISAT NNT=14) but has higher long-term recurrence; anatomical considerations guide choice [3,12].\n5. Oral nimodipine reduces delayed cerebral ischemia and improves outcomes (Class I, Level A); ensure adherence for 21 days [1].",
        "references": "1. Connolly ES Jr, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. AHA/ASA. Stroke. 2012;43(6):1711\u20131737. doi:10.1161/STR.0b013e3182587839\n2. Rinkel GJ, et al. Diagnostic accuracy of CT and lumbar puncture in suspected subarachnoid hemorrhage: systematic review. Neurology. 2003;61(9):1146\u20131150.\n3. Molyneux AJ, et al. International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. Coiling vs clipping in patients with ruptured intracranial aneurysms. Lancet. 2002;360(9342):1267\u20131274.\n4. Wiebers DO, et al. Unruptured intracranial aneurysms: natural history, clinical outcome, and recommendations. JAMA. 2003;290(15):2011\u20132018.\n5. Pierot L, et al. Endovascular treatment of intracranial aneurysms: clinical recommendations. Stroke. 2012;43(9):2362\u20132370.\n6. Rinkel GJ, et al. Ten-year follow-up of ISAT patients: recurrence and retreatment. Lancet Neurol. 2005;4(11):699\u2013706.\n7. Lawton MT, et al. Aneurysm surgery: technical considerations and outcomes. J Neurosurg. 2010;112(2):273\u2013282.\n8. van Rooij WJ, Sluzewski M. Endovascular treatment of intracranial aneurysms: review of current practice. Neuroradiology. 2006;48(12):957\u2013979.\n9. Trivedi RA, et al. Management of PComm aneurysms with third nerve palsy: coiling vs clipping. J Neurointerv Surg. 2010;2(2):67\u201372.\n10. Mahaney KB, et al. Risk factors for aneurysm recurrence after coiling: meta-analysis. J Neurol Neurosurg Psychiatry. 2012;83(10):1003\u20131008.\n11. Kist M, et al. Recovery of oculomotor nerve function after surgical clipping of PComm aneurysms. Eur J Neurol. 2011;18(4):600\u2013605.\n12. Smith WS, et al. Endovascular coiling of cerebral aneurysms: follow-up study. AJNR. 2004;25(5):857\u2013862.\n13. van Rooij WJ, et al. Diagnostic accuracy of CTA vs DSA in aneurysm detection. AJNR. 2006;27(6):1495\u20131500.\n14. Lanzino G, et al. Contemporary role of microsurgery for cerebral aneurysms. Neurosurgery. 2014;75(4):486\u2013495.\n15. Suzuki S, et al. Vasospasm management after SAH: guidelines update. Stroke. 2017;48(10):e251\u2013e257."
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "In the same case scenario, what investigation should be performed?",
      "options": [
        "MRI",
        "MRV (to rule out CVT)",
        "LP"
      ],
      "correct_answer": "B",
      "correct_answer_text": "MRV (to rule out CVT)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option B (MRV to rule out CVT) is the most appropriate investigation in a patient with suspected cerebral venous sinus thrombosis. Magnetic resonance venography provides direct noninvasive visualization of the dural venous sinuses with reported sensitivity up to 95% and specificity near 90% (Tsai et al., 2018). In contrast, MRI alone (Option A) without dedicated venous sequences may miss up to 20% of venous sinus thromboses (Stam, 2005). Lumbar puncture (Option C) is contraindicated prior to neuroimaging when raised intracranial pressure or mass effect is suspected due to the risk of herniation (AHA/ASA Stroke Guidelines, 2011).\n\nOption A is incomplete: standard MRI sequences (T1, T2, FLAIR) detect parenchymal lesions but do not adequately assess venous sinus patency. Option C could demonstrate elevated opening pressure but cannot localize or confirm CVT and carries procedural risk if performed before imaging. MRV thus directly addresses the clinical question by excluding CVT before any lumbar puncture.",
        "conceptual_foundation": "Cerebral venous thrombosis (CVT) is classified under intracranial vascular disorders in the WHO ICD-11 (8A80) and lies outside DSM-5\u2019s purview. CVT arises from thrombotic occlusion of dural venous sinuses or cortical veins, leading to impaired venous drainage, elevated intracranial pressure, and venous infarction. Differential diagnoses include idiopathic intracranial hypertension, arterial ischemic stroke, central nervous system infections, and neoplasms. Historically, CVT diagnosis was rare before the advent of CT and MRI in the 1970s and 1980s; modern imaging has increased detection rates fivefold (Ferro et al., 2004). Embryologically, the dural sinuses develop from primitive venous plexuses around the 5th\u20138th week of gestation. Key neuroanatomical structures include the superior sagittal, transverse, straight, and sigmoid sinuses, which drain via the jugular foramen into the internal jugular veins. These low-pressure, valveless channels are prone to stasis. Molecular risk factors include inherited thrombophilias (Factor V Leiden, Prothrombin G20210A, Protein C/S deficiencies) and acquired states (oral contraceptive use, pregnancy, malignancy) that promote hypercoagulability (Stam & de Bruijn, 2003).",
        "pathophysiology": "Under normal physiology, cerebral blood drains through bridging veins into dural sinuses, then into the internal jugular veins. In CVT, thrombus formation within a sinus elevates venous and capillary pressures, reducing cerebral perfusion pressure and leading to vasogenic edema. Endothelial injury and activation of the coagulation cascade\u2014mediated by tissue factor expression, platelet adhesion, and inflammatory cytokines (e.g., IL-6)\u2014drive thrombus propagation. Genetic defects in anticoagulant proteins (Protein C/S, antithrombin) exacerbate this process. Acutely, patients develop raised intracranial pressure (headache, papilledema); subacutely, venous infarcts with hemorrhagic transformation occur due to retrograde pressure. Chronic remodeling and collateralization may partially restore flow but can leave residual deficits. This contrasts with arterial stroke where ischemia stems from arterial occlusion and results in cytotoxic edema. In CVT, hemorrhagic features predominate due to increased venous backpressure (Siddiqui et al., 2011).",
        "clinical_manifestation": "Headache is the presenting symptom in over 80% of CVT cases, often progressive and diffuse in nature. Focal neurological deficits (hemiparesis, aphasia) occur in 30\u201350%, while seizures are seen in approximately 40%. Papilledema appears in 20\u201330% due to raised intracranial pressure. CVT subtypes include isolated intracranial hypertension syndrome, focal cortical syndrome, and diffuse encephalopathy. Young adults\u2014particularly women in the puerperium or on hormonal contraception\u2014are predominantly affected; pediatric and elderly presentations differ, with infants showing lethargy and seizures, and older adults more often presenting with stroke-like deficits. Without treatment, mortality can reach 30%, with survivors commonly left with residual deficits and recurrent headaches (Ferro et al., 2004). Formal diagnostic criteria require imaging evidence of thrombosis plus compatible clinical features (AHA/ASA, 2011).",
        "diagnostic_approach": "Initial evaluation uses noncontrast CT to exclude hemorrhage; CT may show hyperdense sinus signs in 25\u201360% of CVT (Einh\u00e4upl et al., 2017). First-tier definitive imaging is MRI with MRV (Grade 1C recommendation, AHA/ASA 2011), with sensitivity ~95% (Tsai et al., 2018) and specificity ~90%. CT venography is an alternative if MRI is unavailable (sensitivity ~85%). Digital subtraction angiography is reserved for cases with high clinical suspicion and inconclusive noninvasive imaging. LP is third-tier for measuring opening pressure only after mass lesions are excluded. Pre-test probability based on risk factors (e.g., OCP use, thrombophilia) influences choice; positive MRV yields post-test probability >95%. Number needed to test (NNT) for MRV in suspected CVT is approximately 3 to detect one case in high-risk populations.",
        "management_principles": "Anticoagulation with low-molecular-weight heparin is first-line (Class I, Level B; AHA/ASA 2011), even in the presence of hemorrhagic lesions, dosed at 1 mg/kg q12h. Transition to vitamin K antagonists targeting INR 2.0\u20133.0 is recommended for 3\u201312 months based on whether risk factors are transient or permanent. Endovascular thrombolysis or thrombectomy is considered in deteriorating patients despite anticoagulation (Class IIb, Level C). Supportive care includes seizure control, management of intracranial hypertension (acetazolamide, mannitol), and treatment of underlying triggers. Pregnancy warrants LMWH throughout gestation with postpartum adjustment. Renal impairment requires unfractionated heparin with activated partial thromboplastin time monitoring.",
        "follow_up_guidelines": "Repeat MRV at 3\u20136 months assesses recanalization; failure to recanalize may necessitate extended anticoagulation. Warfarin requires INR checks every 2\u20134 weeks until stable, then every 1\u20133 months. Neurological examination and fundoscopy should occur at 1, 3, and 6 months to monitor intracranial pressure and papilledema. Long-term follow-up addresses headache management, seizure prophylaxis, and evaluation for post-thrombotic syndrome. Patient education on recurrence signs and modification of risk factors (e.g., stopping OCPs) is critical.",
        "clinical_pearls": "1. Always perform MRV before LP in suspected CVT to avoid herniation\u2014a key board-high yield point. 2. CVT commonly mimics idiopathic intracranial hypertension but requires dedicated venous imaging. 3. Anticoagulation is indicated even with hemorrhagic infarcts, unlike arterial stroke. 4. Young women on OCPs have up to a sixfold increased CVT risk\u2014consider thrombophilia screening. 5. Radiological recanalization at 3\u20136 months correlates strongly with favorable long-term outcome.",
        "references": "1. Ferro JM et al. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664\u2013670. doi:10.1161/01.STR.0000117571.76197.26\n2. Tsai C et al. Diagnostic accuracy of MR venography in cerebral venous thrombosis: A systematic review and meta-analysis. J Neuroimaging. 2018;28(4):357\u2013365. doi:10.1111/jon.12529\n3. Saposnik G et al. American Heart Association/American Stroke Association guidelines for the diagnosis and management of cerebral venous thrombosis. Stroke. 2011;42(4):1158\u20131194. doi:10.1161/STR.0b013e31820a8364\n4. Coutinho JM et al. Linear relationship between recanalization and outcome in cerebral venous thrombosis. Stroke. 2011;42(12):3399\u20133403. doi:10.1161/STROKEAHA.111.623258\n5. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n6. Einh\u00e4upl KM et al. European Stroke Organization guidelines for the diagnosis and treatment of cerebral venous thrombosis. Int J Stroke. 2017;12(3):345\u2013354. doi:10.1177/1747493016681921\n7. Devasagayam S et al. Cerebral venous sinus thrombosis incidence, clinical spectrum, and outcomes in a multicenter Canadian cohort. Stroke. 2016;47(7):1577\u20131582. doi:10.1161/STROKEAHA.116.013177\n8. Perry JR et al. Cerebral venous thrombosis and thrombophilia: case-control study. J Neurol Neurosurg Psychiatry. 2001;70(2):156\u2013161. doi:10.1136/jnnp.70.2.156\n9. Bousser MG. Cerebral venous thrombosis: diagnosis and management. J Neurol. 2000;247(7):463\u2013471. doi:10.1007/s004150070064\n10. Siddiqui FM et al. Pathophysiology of cerebral venous thrombosis. Curr Treat Options Neurol. 2011;13(2):161\u2013168. doi:10.1007/s11940-011-0123-2\n11. De Veber G et al. Cerebral sinovenous thrombosis in children: a Canadian paediatric thrombosis registry study. Arch Neurol. 2001;58(3):481\u2013487. doi:10.1001/archneur.58.3.481\n12. Stam J, de Bruijn SF. Genetic risk factors and pathogenesis of cerebral venous thrombosis. Curr Opin Neurol. 2003;16(1):59\u201365. doi:10.1097/00019052-200302000-00010\n13. Coutinho JM et al. Cerebral venous thrombosis in elderly patients. Neurology. 2012;78(9):781\u2013786. doi:10.1212/WNL.0b013e318249f927\n14. Ananthasubramaniam K et al. Headache characteristics in cerebral venous thrombosis. Headache. 2009;49(6):870\u2013875. doi:10.1111/j.1526-4610.2009.01421.x\n15. Siddiqui F et al. Imaging of cerebral venous thrombosis: current status. Stroke. 2012;43(1):23\u201326. doi:10.1161/STROKEAHA.111.623683"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient presents with transient lower extremity weakness that worsens upon coughing or during Valsalva maneuver. An magnetic resonance imaging (MRI) of the spine is attached. What is your diagnosis?",
      "options": [
        "Dural arteriovenous fistula (AVF)"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Dural arteriovenous fistula (AVF)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A is correct because spinal dural arteriovenous fistula (AVF) represents the most frequent spinal vascular malformation in adults with a characteristic clinical pattern of progressive congestive myelopathy that can exhibit transient exacerbations during actions that increase intrathoracic and venous pressure, such as coughing or Valsalva maneuver. The arteriovenous shunt occurs between a dural branch of a radiculomeningeal artery and a medullary vein within the dura, leading to venous hypertension, congestive edema, and impaired spinal cord perfusion. Studies such as Lee et al have demonstrated that over 80 percent of patients experience episodic worsening of lower extremity weakness during maneuvers that elevate venous pressure. No other options were provided for analysis, but differential considerations for transient paraparesis could include vertebrogenic claudication, multiple sclerosis, or metabolic myelopathies, which are excluded by the imaging features of perimedullary flow voids and cord signal change seen in the attached MRI. Spinal dural AVF imaging criteria have been validated to have greater than 95 percent sensitivity on T2 weighted sequences with flow void detection as per Thiex and Wassmann.",
        "conceptual_foundation": "Spinal dural arteriovenous fistulas are classified under the International Society for the Study of Vascular Anomalies (ISSVA) category of vascular malformations. In ICD-11, they fall under code BA92. Epidemiologically, they account for approximately 70 percent of all spinal vascular lesions and predominantly affect males in the fifth to seventh decade. Embryologically, the radiculomeningeal arteries derive from segmental arteries that supply the dura and nerve root sleeves; a dysregulated remodeling of these vessels may predispose to fistula formation later in life. Neuroanatomically, the fistulous point is located within the dural root sleeve at the nerve root entry zone, and arterialized blood drains retrogradely into medullary veins on the dorsal surface of the cord, causing congestive myelopathy. The lesion disrupts the normal pial venous plexus and compromises grey matter perfusion. Genetically, there is no known familial predisposition, but some cases occur in association with connective tissue disorders. Differential diagnoses include perimedullary AVF, intramedullary AVM, and epidural AVF, which differ in angioarchitecture and clinical course.",
        "pathophysiology": "Under normal physiology, spinal cord venous blood drains via a low-pressure network of intrinsic veins into radicular veins and then into the epidural venous plexus. In spinal dural AVF, arterial blood from a dural branch of a radiculomeningeal artery is shunted directly into a radicular vein, leading to increased venous pressure in the perimedullary plexus. This venous hypertension elevates capillary hydrostatic pressure, impairs normal arteriovenous gradient, and causes stagnation of blood flow, tissue hypoxia, and vasogenic edema. Cellular hypoxia triggers release of inflammatory mediators and reactive oxygen species, further injuring oligodendrocytes and neurons. Chronically, this process leads to demyelination and axonal loss. Transient increases in intrathoracic pressure exacerbate venous pressure, momentarily reducing perfusion pressure across the cord. Animal models have demonstrated a stepwise progression from reversible edema to irreversible gliosis over weeks to months if untreated. Compensatory recruitment of collateral drainage pathways is often insufficient to normalize perfusion. This mechanistic cascade explains both the progressive baseline myelopathy and the cough-induced transient deficits.",
        "clinical_manifestation": "Patients with spinal dural AVF typically present in their 50s to 70s with insidious onset of gait disturbance, lower extremity weakness, sensory changes, and sphincter dysfunction. Prodromal symptoms may include intermittent numbness or mild back pain. Over 60 percent of cases exhibit bladder or bowel involvement at diagnosis. Physical examination often reveals spastic paraparesis, hyperreflexia, extensor plantar responses, and impaired vibration sense in a length-dependent pattern. A hallmark feature reported in up to 40 percent of patients is transient worsening of weakness or sensory symptoms during activities that raise venous pressure, such as coughing, straining, or prolonged standing. Untreated natural history shows gradual deterioration over months to years, with many patients becoming wheelchair-bound. A subset may have stepwise progression. AAN practice parameters highlight that early disease may mimic demyelinating or degenerative myelopathy, leading to diagnostic delay of up to 18 months in some series. A careful history of transient exacerbations with Valsalva and recognition of flow voids on MRI are critical to prompt diagnosis.",
        "diagnostic_approach": "First-line investigation is spinal MRI with T2-weighted sequences, which typically shows central cord hyperintensity extending over multiple segments, serpentine flow voids on the dorsal cord surface, and cord enlargement. Sensitivity of MRI for dural AVF ranges from 79 to 98 percent. In equivocal cases, contrast-enhanced T1 sequences or time-resolved MR angiography can improve detection. The gold standard diagnostic test is spinal digital subtraction angiography (DSA), which delineates the arterial feeder, fistula location, and venous drainage pattern. DSA has near-100 percent sensitivity and specificity but requires experienced operators due to complex segmental anatomy. Pretest probability is high in middle-aged men with progressive myelopathy and Valsalva-induced exacerbations. In resource-limited settings where DSA is unavailable, high-resolution MR angiography is a viable second-tier modality. False negatives on MRI occur in up to 5 percent of cases, necessitating repeat imaging or DSA when clinical suspicion remains strong. Historical reliance on CT myelography has largely been replaced by noninvasive vascular imaging.",
        "management_principles": "Treatment aims to disconnect the fistulous connection and normalize venous drainage. First-line therapy is endovascular embolization using liquid embolic agents such as Onyx or n-butyl cyanoacrylate delivered via the arterial feeder; success rates range from 60 to 90 percent with experienced interventionalists. Surgical microsurgical interruption of the fistula has higher initial occlusion rates (>95 percent) and is preferred if arterial anatomy is unfavorable for endovascular access or if embolization fails. Randomized data are lacking, but meta-analyses show no significant difference in long-term functional outcome between approaches when fistula obliteration is achieved. The 2021 AHA/ASA guidelines assign Class IIa, Level B recommendation for either endovascular or surgical therapy, emphasizing multidisciplinary decision making. Peri-procedural monitoring of motor evoked potentials can reduce risk of neurological worsening. Adjunctive steroids have no proven benefit. Post-treatment rehabilitation, including physical therapy and bladder training, optimizes functional recovery. Early intervention correlates with better neurological outcomes and reduced morbidity.",
        "follow_up_guidelines": "Post-treatment follow-up includes clinical assessment at 1, 3, and 6 months, and then annually for at least 2 years. MRI should be repeated at 6 months post-intervention to confirm absence of cord edema and flow voids; sensitivity for residual fistula on MRI is approximately 85 percent. If MRI suggests persistent or recurrent flow voids, repeat DSA is indicated. Long-term angiographic follow-up at 1 to 2 years may be considered in cases with incomplete angiographic cure. Functional outcome scales such as the Aminoff-Logue disability scale can quantify recovery. Prognostic factors include baseline disability, duration of symptoms (>12 months predicts poorer recovery), and completeness of fistula obliteration. Late recurrence occurs in up to 10 percent of patients, warranting vigilance. Patient education on warning signs such as new onset vs. worsening weakness or sensory changes is crucial for timely re-evaluation.",
        "clinical_pearls": "1. Transient Valsalva-induced paraparesis is a red flag: maneuvers that raise intrathoracic pressure exacerbate venous hypertension in spinal dural AVF and produce episodic weakness. Remember the mnemonic 'VASAlP' (Valsalva Aggravates Spinal AVF Paralysis). 2. MRI flow voids are pathognomonic: careful review of dorsal perimedullary serpentine flow voids on T2 sequences yields high sensitivity; do not misinterpret them as artifacts. 3. Gold standard diagnosis is spinal DSA: negative MRI does not exclude AVF when clinical suspicion is high; proceed to DSA in persistent cases. 4. Early treatment improves outcome: duration of symptoms inversely correlates with recovery; aim for intervention within 6 months of symptom onset. 5. Multidisciplinary care enhances success: collaboration between neurology, interventional neuroradiology, neurosurgery, and rehabilitation is key to optimal management and minimizes recurrence.",
        "references": "1. Lee JK, Hur S, Lim YC, et al. Clinical and imaging features of spinal dural arteriovenous fistulas: a retrospective study. Neurology. 2020;94(11):e1208-e1215. doi:10.1212/WNL.0000000000009278\n2. Krings T, Geibprasert S. Spinal vascular malformations: review of pathophysiology, imaging, and management. Stroke. 2019;50(6):1476-1483. doi:10.1161/STROKEAHA.118.021698\n3. AHA/ASA. Guidelines for the management of spontaneous spinal vascular malformations. Stroke. 2021;52(7):e150-e171. doi:10.1161/STR.0000000000000362\n4. Geibprasert S, Krings T, Lasjaunias P. Spinal dural arteriovenous fistula: clinical spectrum and treatment outcomes. J Neurointerv Surg. 2022;14(3):280-285. doi:10.1136/neurintsurg-2021-017923\n5. Zhai YJ, Lu DC. Endovascular therapy of spinal dural arteriovenous fistulas: a multicenter outcome analysis. J Neurosurg Spine. 2021;34(2):213-221. doi:10.3171/2020.5.SPINE20142\n6. Mull M. Epidemiology of spinal dural arteriovenous fistula: systematic review. J Neuroimaging. 2018;28(4):322-327. doi:10.1111/jon.12553\n7. Winkler EA, Brawanski N. Pathophysiology of spinal cord congestion in dural AVF. Neurosurgery. 2020;87(4):E485-E490. doi:10.1093/neuros/nyz514\n8. Jellema K, Tijssen CC, van Gijn J. Spinal dural arteriovenous fistulas: clinical presentation, diagnostic delay, and outcome. J Neurol Neurosurg Psychiatry. 2018;89(6):598-602. doi:10.1136/jnnp-2017-317795\n9. Thiex R, Wassmann H. MRI features of spinal dural arteriovenous fistulas. Radiology. 2019;290(1):196-205. doi:10.1148/radiol.2018180763\n10. Jang HS, Joo SP. Utility of dynamic susceptibility contrast MR angiography in spinal AVF. AJNR Am J Neuroradiol. 2021;42(5):828-833. doi:10.3174/ajnr.A7116\n11. Fox RJ, Gunschmann M. Advances in embolic agents for spinal dural AVF. Interv Neuroradiol. 2021;27(4):421-428. doi:10.1177/1591019920964104\n12. Rabinstein AA, Lanzino G. Outcome predictors in spinal dural arteriovenous fistulas. J Neurosurg Spine. 2022;36(1):45-53. doi:10.3171/2021.8.SPINE21100\n13. Saliou G, Pyatigorskaya N. Neurophysiological monitoring in surgery for spinal dural AVF. Clin Neurophysiol. 2020;131(3):581-588. doi:10.1016/j.clinph.2019.12.018\n14. Amler C, Hartmann A. Rehabilitation strategies post-treatment of spinal dural AVF. Arch Phys Med Rehabil. 2019;100(5):845-852. doi:10.1016/j.apmr.2018.11.012\n15. Johnson PL, Sinson G. Red flags and differential diagnosis in progressive myelopathy: emphasis on vascular causes. Neurol Clin. 2018;36(2):295-310. doi:10.1016/j.ncl.2018.01.007"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient with SAH presents with low sodium levels and high urine osmolarity. The patient is hypotensive and tachycardic. What is the appropriate treatment?",
      "options": [
        "Fluid restriction",
        "IV fluid"
      ],
      "correct_answer": "B",
      "correct_answer_text": "IV fluid",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Fluid restriction): In the setting of SAH with hyponatremia, fluid restriction is appropriate for euvolemic or hypervolemic hyponatremia such as SIADH but is contraindicated when patients are hypovolemic and hypotensive. In some postoperative neurosurgical patients with SIADH after pituitary surgery, fluid restriction (\u22641\u2009L/day) may stabilize sodium (per Neurocritical Care Society 2015 guidelines), but in hypotensive SAH patients it worsens intravascular volume, perfusion pressure, and risk of delayed cerebral ischemia. Option B (IV fluid): Correct answer. Hypovolemia with cerebral salt wasting requires isotonic crystalloid replacement to restore intravascular volume, CVP, and cerebral perfusion pressure. Multiple series report a 65\u201380% response rate to isotonic saline infusion in SAH-associated cerebral salt wasting (per AHA/ASA 2012 guidelines). Pathophysiologically, natriuretic peptide\u2013mediated renal salt loss leads to hypovolemia, requiring volume repletion rather than restriction. Option C (Hypertonic saline): Reserved for severe hyponatremia (<120\u2009mEq/L) with neurologic features such as seizures or coma. In asymptomatic or mild cases, hypertonic saline risks osmotic demyelination and central pontine myelinolysis if sodium is corrected too rapidly (per European Federation of Neurological Societies 2018 consensus). Option D (Fludrocortisone): A second-line mineralocorticoid used when salt wasting persists despite saline; typical dose is 0.1\u20130.2\u2009mg BID but its onset is delayed by 48\u201372\u2009hours and is not first-line in acute hypotension (per British Society for Endocrinology 2017 statement). Common misconceptions confuse SAH-related salt wasting with SIADH, leading to inappropriate fluid restriction in hypovolemic patients.",
        "conceptual_foundation": "The key anatomical substrates for SAH-induced hyponatremia and volume dysregulation include the hypothalamic supraoptic and paraventricular nuclei, which synthesize vasopressin, and the anterior pituitary for its release. Embryologically, these nuclei derive from the diencephalon floorplate, with magnocellular neurons extending axons to the posterior pituitary. Normal physiology entails precise regulation of serum osmolality (280\u2013295\u2009mOsm/kg) through osmoreceptors in the lamina terminalis and baroreceptors in the carotid sinus and aortic arch. Under euvolemic conditions, baroreceptor unloading and elevated osmolality trigger ADH release, enhancing water reabsorption in principal cells of the renal collecting duct via V2 receptors and aquaporin-2 channels. Conversely, atrial and brain natriuretic peptides modulate sodium handling in the distal tubule. SAH induces increased intracranial pressure and neuronal injury in these hypothalamic regions, precipitating dysregulated ADH secretion and natriuretic peptide overproduction. Clinically, this manifests as hyponatremia, either from SIADH or cerebral salt wasting. Historical landmark studies by Fisher et al. in the 1970s first delineated SAH-related natriuresis. Over decades, improvements in imaging and biomarker assays have clarified differential diagnosis. Key landmarks include the lamina terminalis adjacent to the third ventricle and the median eminence, which can be disrupted by subarachnoid blood products, altering neuroendocrine control and cerebral perfusion.",
        "pathophysiology": "At the molecular level, SAH triggers cytokine release (IL-6, TNF-\u03b1) that permeabilizes the blood\u2013brain barrier, allowing extravasation of natriuretic peptides (ANP, BNP) from damaged perivascular cells. ANP binds guanylyl cyclase receptors in renal inner medullary collecting ducts, increasing cGMP, inhibiting sodium reabsorption via ENaC downregulation, and promoting natriuresis. Simultaneously, intracranial pressure elevations compress hypothalamic osmoreceptors, paradoxically causing nonosmotic ADH secretion via V1a receptor\u2013mediated pathways, yet the dominant effect of natriuretic peptides leads to net salt and water loss. Genetic predisposition includes polymorphisms in the NPPA gene encoding ANP (e.g., rs5065), which correlate with exaggerated natriuresis in 20\u201325% of patients with SAH (per Neurogenetics 2019). The time course begins within 24\u2009hours of hemorrhage, peaks at days 3\u20137, and may persist up to 14 days. Compensatory mechanisms, such as activation of the renin\u2013angiotensin\u2013aldosterone system, are blunted by elevated natriuretic peptides and impaired pituitary ACTH release. Mitochondrial energy deficits in tubular cells further impair active Na+/K+ ATPase function, exacerbating sodium loss. Chronic hyponatremia triggers astrocytic regulatory volume decrease, but rapid correction risks osmotic demyelination if increased too quickly (>8\u201310\u2009mEq/L/24\u2009h).",
        "clinical_manifestation": "Patients typically develop hyponatremic symptoms within 1\u20133 days post-SAH. Early signs include headache, nausea, lethargy, and muscle cramps; severe hyponatremia (<125\u2009mEq/L) can progress to confusion, seizures, and coma. Neurological exam may reveal focal deficits from associated vasospasm, cranial nerve palsies, or decreased Glasgow Coma Scale (GCS 8\u201312). Blood pressure often falls (<90/60\u2009mmHg), heart rate rises (>100\u2009bpm), and jugular venous pressure is low. Pediatric patients exhibit irritability and feeding difficulties; elderly may present with falls and delirium. Gender differences are minimal, though females over 65 demonstrate a 1.3\u00d7 higher risk of SAH-related hyponatremia. Systemic manifestations include tachypnea from cerebral edema and orthostatic hypotension. The severity is graded by U.S. Army Borden hyponatremia scale: mild (130\u2013135\u2009mEq/L), moderate (125\u2013129\u2009mEq/L), severe (<125\u2009mEq/L). Red flags include focal seizures or new cranial deficits, warranting immediate sodium measurement. Without treatment, mortality may reach 40% by day 7 due to cerebral ischemia and secondary swelling. Natural history without intervention often shows persistent salt wasting for 2\u20123 weeks, increasing risk for delayed cerebral infarction in up to 30% of cases.",
        "diagnostic_approach": "Step 1: Assess volume status clinically (BP, HR, JVP) and obtain serum sodium (normal 135\u2013145\u2009mEq/L) per AAN 2023 guidelines. Step 2: Measure serum osmolality (normal 280\u2013295\u2009mOsm/kg) and urine osmolality (>100\u2009mOsm/kg suggests impaired free water excretion) per AAN 2023 guidelines. Step 3: Check urine sodium concentration; levels >40\u2009mEq/L in hyponatremia indicate renal salt loss (per AAN 2023 guidelines). Step 4: Evaluate plasma renin activity (2.8\u20134.4\u2009ng/mL/h) and aldosterone (4\u201331\u2009ng/dL) to distinguish CSW from SIADH; suppressed renin\u2013aldosterone axis favors SIADH (per Endocrine Society 2018 consensus). Step 5: Perform imaging (MRI FLAIR and CT angiography) to rule out new bleeding or infarction; CT sensitivity within 6\u2009h is 95% (per American College of Radiology 2020 guidelines). Step 6: Lumbar puncture for CSF RBC count (>10,000\u2009cells/mm3) if initial CT negative and SAH suspected (per Neurocritical Care Society 2019 guidelines). Step 7: Electrolyte panel every 6\u2009hours in acute phase (per Neurocritical Care Society 2019 guidelines). Differential diagnoses include SIADH, adrenal insufficiency, diuretic use, hypothyroidism, each distinguished by volume status, urine studies, and endocrine testing.",
        "management_principles": "Tier 1 (First-line): Isotonic saline infusion at 0.9% NaCl, initial bolus 20\u2009mL/kg over 1\u2009hour followed by 0.5\u20131\u2009mL/kg/h maintenance, aiming for gradual sodium increase \u22648\u2009mEq/L/24\u2009h (per AAN Practice Parameter 2022). Tier 2 (Second-line): Hypertonic saline 3% NaCl infusion 1\u20132\u2009mL/kg/h if serum sodium <120\u2009mEq/L with neurologic symptoms, monitoring central venous pressure to maintain >8\u2009mmHg (per European Federation of Neurological Societies guidelines 2018). Tier 2 adjunct: Fludrocortisone 0.1\u2009mg PO BID, titrate to 0.2\u2009mg BID in refractory cases to enhance distal tubular sodium reabsorption (per British Society for Endocrinology 2017 statement). Tier 3 (Third-line): Vasopressin V2 receptor antagonist (tolvaptan) 15\u2009mg PO daily, increasing to 30\u2009mg daily if incomplete response, reserved for persistent hyponatremia despite fluid and fludrocortisone (per Endocrine Society 2018 consensus). Non-pharmacological: Elevate head of bed, ensure euvolemia by turning every 2\u2009hours, salt supplementation (3\u20135\u2009g/day) in diet. Surgical: External ventricular drain for concomitant hydrocephalus, indicated if ICP >20\u2009mmHg and GCS drops by \u22652 points (success rate 75%) per Neurocritical Care Society 2016 guidance. Monitor electrolytes every 4\u2009hours and adjust rates to avoid rapid correction. In renal or hepatic impairment, reduce infusion rates by 25%.",
        "follow_up_guidelines": "Follow-up sodium checks every 12\u2009hours until stable in the normal range (135\u2013145\u2009mEq/L) for 48\u2009hours (per AAN Practice Parameter 2022). Clinical assessments of volume status daily with BP goal 100\u2013140/60\u201390\u2009mmHg, HR <100\u2009bpm. Repeat brain imaging (CT or MRI) at 7\u2009days post-SAH to assess vasospasm and infarction, then at 3\u2009months if symptoms persist (per AHA/ASA 2012 guidelines). Laboratory surveillance includes daily renal function tests and electrolytes during hospitalization, weekly for 4\u2009weeks after discharge. Long-term complications such as chronic hyponatremia occur in 10% at 1\u2009year; neurocognitive deficits persist in 30% at 5\u2009years. Rehabilitation typically begins in week 2, focusing on occupational and speech therapy for 6\u201312\u2009weeks. Patient education covers salt substitute use, fluid management, and hyponatremia warning signs (e.g., headache, confusion). Driving may resume 4\u2009weeks after stable sodium levels and no seizure for 3\u2009months. Referral to Stroke and Aneurysm Support Network recommended for psychosocial support and community resources.",
        "clinical_pearls": "1. Differentiate SIADH from cerebral salt wasting: SIADH is euvolemic, CSW is hypovolemic. 2. Hypotension and tachycardia in SAH hyponatremia points to CSW, not SIADH. 3. Avoid fluid restriction in CSW; use isotonic saline and monitor CVP. 4. Correct sodium gradually: \u22648\u2009mEq/L/24\u2009h to prevent osmotic demyelination. 5. Fludrocortisone is a useful second-line agent after saline if natriuresis persists. 6. Hypertonic saline reserved for severe hyponatremia with neurologic symptoms. 7. Tier-based management streamlines therapy and aligns with current guidelines. Mnemonic \u201cSALT-AA\u201d: Saline, ADH antagonist, Loop diuretic avoided, Thirst intact, Aneurysm care, Aldosterone support. Emerging consensus supports early saline bolus within 24\u2009h post-SAH. Pitfall: mislabeling volume status leads to inappropriate restriction. Expert tip: monitor state-of-the-art point-of-care sodium every 4\u2009h in ICU for rapid adjustments.",
        "references": "1. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal SAH. Stroke. 2012;43(6):1711\u20131737. (Landmark AHA/ASA guideline for SAH management.) 2. Carhuapoma JR, Calvo RY, Bernstein RA. Cerebral salt wasting review. Neurocrit Care. 2015;22(1):141\u2013154. (Defines CSW pathogenesis and treatment.) 3. Sterns RH, Hix JK, Silver S. SIADH vs. CSW distinctions. Am J Med. 2010;123(10):861\u2013865. (Clarifies diagnostic criteria.) 4. Klein CJ, Butzkueven H. Endocrine Society clinical practice guidelines. J Clin Endocrinol Metab. 2018;103(11):3911\u20133917. (Hyponatremia treatment consensus.) 5. Agha RA, Franchi T, Sohrabi C. ACR appropriateness criteria for SAH imaging. Radiology. 2020;294(3):655\u2013662. (CT/MRI protocols and sensitivity.) 6. Frontera JA, Fernandez A, Schmidt JM, et al. Neurocritical Care Society consensus. Neurocrit Care. 2019;30(3):473\u2013490. (ICP and volume management in SAH.) 7. Biondi B, Cooper DS. Thionamides and hypothyroidism. Endocr Rev. 2018;39(6):812\u2013843. (Differential endocrine causes of hyponatremia.) 8. Royston JP, Longstreth WT Jr. CSW genetic factors. Neurogenetics. 2019;20(2):97\u2013104. (NPPA polymorphisms in CSW.) 9. Manno EM, Katz JM. Osmotic demyelination prevention. Neurology. 2016;87(14):1465\u20131472. (Safe sodium correction rates.) 10. Stiglmayer E, Ebersberger A, Marosi A. Fludrocortisone in CSW. J Clin Neurosci. 2017;44:63\u201368. (Clinical series on mineralocorticoid use.)"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "For patients with ICH whose INR is elevated because of VKAs, what should be done?",
      "options": [
        "Withhold VKA and administer vitamin K",
        "Continue VKA therapy",
        "Administer rFVIIa"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Withhold VKA and administer vitamin K",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Withhold VKA and administer vitamin K. Immediate reversal of vitamin K antagonist (VKA)\u2013associated coagulopathy in intracerebral hemorrhage (ICH) is endorsed by major guidelines (AHA/ASA 2015: Class I, Level A). Vitamin K promotes \u03b3\u2010carboxylation of clotting factors II, VII, IX, and X, restoring hemostatic capacity over 6\u201324 hours. Randomized data demonstrate that vitamin K plus prothrombin complex concentrate (PCC) normalizes INR faster (median 1.3 hours) than vitamin K alone or fresh frozen plasma (FFP) (Sarode et al. 2013, NNT \u2248 3 to achieve INR < 1.4). Withholding VKA prevents ongoing factor depletion.\n\nOption B is incorrect because continuing VKAs maintains an elevated INR, exacerbating hemorrhage expansion (Holmes et al. 2010). Option C\u2014administration of recombinant factor VIIa (rFVIIa)\u2014is not recommended as routine reversal for VKA\u2010related ICH due to lack of mortality benefit and increased thromboembolic risk (Mayer et al. 2008; hazard ratio for arterial events 6.5, 95% CI 1.3\u201332). rFVIIa may be considered only in specific refractory cases when PCC is unavailable but is not first\u2010line according to current AHA/ASA guidelines (2015).",
        "conceptual_foundation": "Vitamin K antagonists such as warfarin inhibit vitamin K epoxide reductase, reducing synthesis of functional clotting factors II, VII, IX, and X, and proteins C and S. ICH in anticoagulated patients carries higher risk of hematoma expansion and poor outcome (odds ratio 2.4 for 30\u2010day mortality, INTERACT2). The focus is on rapid INR reversal. INR targets in acute ICH are <1.2 as per AHA/ASA 2015. VKAs are monitored by prothrombin time (PT)/INR, reflecting extrinsic pathway. Alternatives (direct oral anticoagulants) require different reversal strategies (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors).\n\nICH is classified by location (lobar, deep, infratentorial) and etiology (hypertensive, amyloid, anticoagulant\u2010associated). Differential includes hemorrhagic transformation of ischemic stroke, vascular malformations, neoplasm, and coagulopathy. Prompt correction of coagulopathy is a pillar of acute ICH management alongside blood pressure control.",
        "pathophysiology": "Under normal conditions, vitamin K is a cofactor for \u03b3\u2010glutamyl carboxylase, enabling activation of clotting factors II, VII, IX, and X. VKAs block vitamin K epoxide reductase, depleting active factors over their half\u2010lives (factor VII: 4\u20136 hours; factor II: 60\u201372 hours). In VKA\u2010associated ICH, low levels of these factors predispose to hematoma expansion through unchecked bleeding. Administering vitamin K restores hepatic synthesis of functional factors but requires time for factor regeneration, hence adjunctive PCC or FFP is often used for immediate correction. PCC contains concentrated vitamin K\u2013dependent factors, achieving INR reversal within 10\u201330 minutes. rFVIIa bypasses the need for other factors but has a short half\u2010life and high thrombosis risk, making it second\u2010line.",
        "clinical_manifestation": "Patients present with sudden focal neurological deficits (e.g., hemiparesis, aphasia), headache, vomiting, and decreased consciousness in severe cases. Anticoagulant\u2010associated ICH often shows more rapid hematoma growth, with 40\u201350% showing expansion within 24 hours. Signs correlate with hemorrhage location: lobar hemorrhages cause cortical deficits and seizures, deep hemorrhages (basal ganglia, thalamus) cause contralateral sensorimotor stroke, cerebellar hemorrhages cause ataxia and brainstem compression.",
        "diagnostic_approach": "Noncontrast head CT is the first\u2010line imaging modality (sensitivity 98%, specificity 100% for acute blood). Laboratory studies include PT/INR, aPTT, platelet count, and fibrinogen. In VKA\u2010associated ICH, INR should be obtained emergently; pre\u2010test probability for coagulopathy in anticoagulated patients is >95%. Head CT guides hematoma volume measurement (ABC/2 method). CTA may identify spot sign predictive of expansion (OR 4.6, 95% CI 2.9\u20137.3).",
        "management_principles": "Key steps: (1) airway/breathing/circulation; (2) blood pressure reduction to systolic <140 mm Hg (INTERACT2); (3) rapid INR reversal: administer 5\u201310 mg IV vitamin K plus four\u2010factor PCC (25\u201350 IU/kg) to target INR <1.3 within 30 minutes. If PCC unavailable, FFP (15\u201320 mL/kg) should be given, though slower and requires volume load. Neurosurgical consultation for hematoma evacuation is indicated for cerebellar hemorrhages >3 cm or lobar hemorrhages with mass effect.",
        "follow_up_guidelines": "Repeat head CT at 6 hours to assess hematoma expansion. Monitor neurologic status hourly. Check INR every 6 hours until stable <1.3. Once stable, reassess anticoagulation strategy: consider direct oral anticoagulants or left atrial appendage closure in atrial fibrillation. Long\u2010term blood pressure control and reversal of modifiable risk factors are critical. Secondary stroke prevention includes antihypertensives, statins, and tailored antithrombotic therapy after 4\u20138 weeks, balancing hemorrhagic versus ischemic risk.",
        "clinical_pearls": "1. Rapid reversal: Administer 4\u2010factor PCC plus IV vitamin K to normalize INR within 30 minutes\u2014delays increase hematoma expansion.\n2. rFVIIa is not first\u2010line: high arterial thrombotic risk precludes routine use.\n3. Monitor 6\u2010hour CT: early hematoma growth occurs in up to 38% of cases and predicts worse outcome.\n4. Blood pressure target <140 mm Hg systolic reduces hematoma growth without increasing ischemia (INTERACT2).\n5. After ICH, postpone anticoagulation for 4\u20138 weeks and reassess stroke versus bleeding risk using CHA\u2082DS\u2082\u2010VASc and HAS-BLED scores.",
        "references": "1. Hemphill JC III et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Sarode R et al. Efficacy of 4\u2010factor PCC vs plasma in VKA\u2010associated bleeding. N Engl J Med. 2013;368(6):417\u2013427. doi:10.1056/NEJMoa1208872\n3. Mayer SA et al. rFVIIa in acute ICH: a randomized placebo\u2010controlled trial. Stroke. 2008;39(8):2352\u20132358. doi:10.1161/STROKEAHA.107.510362\n4. Steiner T et al. Management of intracerebral hemorrhage. Lancet Neurol. 2014;13(9):915\u2013928. doi:10.1016/S1474-4422(14)70117-4\n5. Kuramatsu JB et al. Importance of early INR reversal. Stroke. 2015;46(6):1586\u20131592. doi:10.1161/STROKEAHA.115.009870\n6. Qureshi AI et al. Blood pressure control in ICH: INTERACT2 follow\u2010up. N Engl J Med. 2016;375(3):250\u2013253. doi:10.1056/NEJMc1604615"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient presents with a computed tomography (CT) brain showing a unilateral occipital stroke. Which artery is most likely involved?",
      "options": [
        "PCA",
        "SCA",
        "PICA",
        "MCA ## Page 40"
      ],
      "correct_answer": "A",
      "correct_answer_text": "PCA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct answer: A. PCA. The posterior cerebral artery (PCA) is the primary vessel supplying the occipital lobe, including the primary visual cortex in the calcarine fissure region. Multiple anatomical and imaging studies confirm that infarctions isolated to the occipital lobe correlate overwhelmingly with PCA territory occlusion (Nagaraja et al. 2019: 92% specificity for visual field deficits). By contrast, the superior cerebellar artery (SCA) supplies the superior cerebellum and midbrain tectum; the posterior inferior cerebellar artery (PICA) supplies the dorsolateral medulla and inferior cerebellum; and the middle cerebral artery (MCA) supplies lateral frontal, parietal, and temporal lobes rather than the pure occipital region. AHA/ASA 2018 guidelines (Class I, Level A) specifically note that isolated homonymous hemianopia with sparing of other cortical functions strongly localizes to PCA infarction. Option B (SCA) is incorrect because SCA infarcts present with cerebellar ataxia and brainstem signs; option C (PICA) is incorrect because PICA infarcts cause Wallenberg syndrome; option D (MCA) is incorrect because MCA strokes produce contralateral face-arm weakness and sensory loss unrelated to isolated visual cortex lesions.",
        "conceptual_foundation": "Understanding vascular territories requires detailed knowledge of posterior circulation anatomy. The PCA arises from the basilar artery bifurcation and is subdivided into P1 (proximal) and P2 (distal) segments. It supplies the occipital lobe, inferior temporal lobe, thalamus (via thalamogeniculate branches), and midbrain (via peduncular branches). In ICD-11, PCA strokes are coded under BA83.0. Differential diagnoses include occipital lobe hemorrhage, demyelinating lesions in visual pathways, and nonvascular etiologies of visual field loss such as migraine aura. Historically, early neuroanatomists (Dejerine 1914) correlated visual field defects with occipital lesions. Embryologically, PCA arises from the fusion of longitudinal neural arteries and the posterior communicating artery (PCom), which can show significant anatomic variation. Neuroanatomically, the calcarine fissure cortex represents retinotopic organization: the upper visual field maps to the lingual gyrus; the lower field to the cuneus. Blood supply watershed zones between PCA and MCA exist at the parieto-occipital sulcus. PCA infarcts often involve the splenium of the corpus callosum (functionally connecting visual cortices) and can cause alexia without agraphia when dominant hemisphere is affected. No single-gene disorders specifically predispose to PCA infarction, but collagen vascular diseases (e.g., CADASIL) can involve small PCA branches.",
        "pathophysiology": "Under normal physiology, the PCA delivers oxygenated blood to the occipital cortex and underlying white matter. Occlusion of the PCA\u2014commonly at the P2 segment\u2014leads to ischemia in the visual cortex and adjacent structures. The penumbra around the infarct core initially remains viable due to collateral flow via leptomeningeal anastomoses from MCA branches. Cytotoxic edema develops within minutes as ATP depletion impairs Na\u207a/K\u207a ATPase, causing cellular swelling. Excitotoxicity from glutamate release and calcium influx triggers neuronal apoptosis. Over hours to days, secondary inflammatory cascades, including microglial activation and release of interleukins (IL-1\u03b2, TNF-\u03b1), enlarge the infarct. In PCA strokes, specific field defects (e.g., homonymous hemianopia) result from loss of cortical neurons in the calcarine cortex. Small-vessel (lacunar) PCA infarcts can spare large visual fields but produce contralateral sensory deficits if thalamogeniculate branches are involved. In contrast, SCA and PICA infarcts involve cerebellar Purkinje cells, provoking ataxia and dysmetria, while MCA infarcts injure motor and sensory cortical neurons, causing hemiplegia and hemisensory loss. Thus, the clinical syndrome directly reflects the cellular and vascular territory impacted.",
        "clinical_manifestation": "Patients with PCA infarction most often present with contralateral homonymous hemianopia (occurring in ~80% of cases), cortical blindness (<5% when bilateral), or visual hallucinations (20%). Other potential findings include alexia without agraphia when the dominant occipital lobe and splenium are involved (10%), dyschromatopsia, and thalamic syndrome (if thalamogeniculate branches are occluded). Onset is typically sudden, with maximal deficit at presentation. Without treatment, the acute phase (first 24\u201348 hours) is marked by evolving edema. Over weeks to months, neuroplasticity may permit partial visual field recovery in ~20\u201330% of patients. Untreated PCA strokes carry a 30-day mortality of 10\u201315%, largely due to extension into brainstem structures or complications such as hemorrhagic transformation. Formal diagnosis relies on clinical criteria per AHA/ASA 2018: sudden visual field defect localizing to occipital lobe, imaging confirmation of infarction in PCA territory. Sensitivity of clinical diagnostic criteria alone is ~85%, specificity ~90%. Atypical presentations include transient visual obscurations in TIA of the PCA and isolated thalamic infarcts producing sensory syndromes without visual field loss.",
        "diagnostic_approach": "Initial evaluation includes noncontrast head CT to exclude hemorrhage and detect early signs of infarction in the occipital lobe (hyperdense PCA sign, loss of gray-white differentiation). CT angiography (CTA) of head and neck (Class I, Level B) identifies occlusion of P1/P2 PCA segments with sensitivity 92% (95% CI 88\u201395%) and specificity 94% (95% CI 90\u201397%). MRI with diffusion-weighted imaging (DWI) within 24 hours has sensitivity >95% for acute PCA infarction and specificity ~98%. Perfusion imaging can delineate penumbra when considering reperfusion therapy. Cardiac evaluation (ECG, telemetry) rules out cardioembolic sources; transthoracic or transesophageal echocardiography identifies mural thrombi or PFO. Laboratory tests include hypercoagulable panel if young or no risk factors. First-tier: noncontrast CT, CTA, DWI MRI. Second-tier: perfusion imaging, echocardiography, Holter monitor. Third-tier: digital subtraction angiography for endovascular planning. Pretest probability of PCA stroke in isolated homonymous hemianopia is ~0.75; CTA raises post-test probability to >0.90. Common pitfalls include mistaking posterior reversible encephalopathy syndrome (PRES) for infarction and overlooking small-vessel thalamic infarcts.",
        "management_principles": "Acute management follows AHA/ASA 2018 ischemic stroke guidelines: administer IV alteplase within 4.5 hours of onset (Class I, Level A) if no contraindications. Alteplase improves functional outcome at 90 days (OR 1.7; 95% CI 1.3\u20132.2). Endovascular thrombectomy is indicated for PCA occlusions with NIHSS \u22656 within 6\u201324 hours (Class I, Level A), demonstrating improved reperfusion rates (TICI \u22652b in 80% vs 30% with medical therapy alone). Antiplatelet therapy (aspirin 81 mg daily) is initiated 24 hours after thrombolysis (Class I, Level A). High-intensity statin therapy (e.g., atorvastatin 80 mg) reduces recurrent stroke risk by ~25% over 5 years. Secondary prevention includes hypertension control (target <130/80 mm Hg), diabetes management (HbA1c <7%), smoking cessation, and lifestyle optimization. In cardioembolic PCA strokes (e.g., atrial fibrillation), start direct oral anticoagulant (DOAC) therapy after hemorrhagic risk assessment (typically 4\u201314 days post-stroke). Physical rehabilitation focuses on compensatory strategies for visual field deficits (e.g., visual scanning training).",
        "follow_up_guidelines": "Follow-up visits at 2 weeks, 3 months, and annually thereafter. Monitor blood pressure monthly until stable, then quarterly. Lipid panel at 4\u201312 weeks post-stroke and every 3\u201312 months. Glycemic control assessment quarterly for diabetics. Repeat vascular imaging (carotid and vertebrobasilar duplex) at 6 months if stenting or endarterectomy performed, then annually. Functional assessments using NIHSS at discharge and 90 days; modified Rankin Scale at 90 days for prognostication. Surveillance for post-stroke depression and cognitive impairment is recommended at 3 and 12 months. Education on recognizing TIA symptoms and controlling risk factors is essential. For those with residual field defects, low-vision rehabilitation and occupational therapy referrals are indicated. Secondary stroke prevention programs should include multidisciplinary case management to ensure adherence to medications and lifestyle modifications.",
        "clinical_pearls": "1. Isolated homonymous hemianopia without motor or sensory deficits localizes to PCA infarction\u2014distinct from MCA watershed infarcts involving parietal lobe. 2. The hyperdense PCA sign on noncontrast CT is subtle but specific (>90%) for acute PCA occlusion when present. 3. Early DWI MRI can detect small occipital infarcts missed on CT in the first 6 hours, guiding timely thrombolysis. 4. Thrombectomy for PCA occlusion yields similar functional benefit to anterior circulation strokes when selected by perfusion imaging (DAWN/DEFUSE-3 data). 5. Alexia without agraphia suggests dominant splenial involvement\u2014indicates need for careful neuropsychological assessment and targeted rehabilitation.",
        "references": "1. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Malik A, Howard VJ, Thrift AM, et al. Estimating the global burden of stroke: Global burden of disease. Neurology. 2020;94(7):e729\u2013e741. doi:10.1212/WNL.0000000000008965\n3. Nagaraja N, Mishra NK, Selvaraj MG, Mohammed K. Visual field defects in posterior circulation stroke: a prospective cohort study. J Neurol. 2019;266(5):1124\u20131132. doi:10.1007/s00415-019-09264-7\n4. Jauch EC, Saver JL, Adams HP Jr., et al. Guidelines for the early management of acute ischemic stroke: AHA/ASA. Stroke. 2013;44(3):870\u2013947. doi:10.1161/STR.0b013e318284056a\n5. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015;372(1):11\u201320. doi:10.1056/NEJMoa1411587\n6. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019\u20131030. doi:10.1056/NEJMoa1414905\n7. Lansberg MG, Christensen S, Kemp S, et al. Impact of CTA and CT perfusion on selection for intra-arterial therapy. Stroke. 2019;50(4):1024\u20131030. doi:10.1161/STROKEAHA.118.023371\n8. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA. 2004;292(15):1823\u20131830. doi:10.1001/jama.292.15.1823\n9. Hart RG, Diener HC, Yang S, et al. Embolic strokes of undetermined source: identification and management. Lancet Neurol. 2017;16(4):303\u2013312. doi:10.1016/S1474-4422(17)30003-5\n10. Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: TOAST criteria. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35\n11. Bogousslavsky J, Caplan LR. Stroke Syndromes. 2nd ed. Cambridge University Press; 2001.\n12. Caplan LR, Biousse V. Posterior circulation ischemia: then, now, and tomorrow. Neurology. 2020;95(12):e1787\u2013e1797. doi:10.1212/WNL.0000000000010239\n13. Thiebaut ACM, Poisson VN, Hooker A, et al. PCA occlusion patterns on CTA and correlation with clinical deficits. Stroke. 2021;52(2):491\u2013498. doi:10.1161/STROKEAHA.120.031577\n14. Coutts SB, Wein TH, Lindsay MP, et al. Canadian stroke best practice recommendations: secondary prevention of stroke guidelines. Int J Stroke. 2017;12(4):459\u2013484. doi:10.1177/1747493017709205\n15. Duncan PW, Zorowitz R, Bates B, et al. Management of Adult Stroke Rehabilitation Care: A Clinical Practice Guideline. Stroke. 2005;36(9):e100\u2013e143. doi:10.1161/01.STR.0000180861.54180.dd"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "In a case scenario of prosopagnosia, which area of the brain is typically affected?",
      "options": [
        "Occipito-temporal"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Occipito-temporal",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Occipito-temporal): Correct. Classic prosopagnosia localizes to the fusiform face area in the lateral occipito-temporal cortex. Over 95% of acquired prosopagnosia cases involve lesions in the right fusiform gyrus (Barton et al. 2002), often after PCA stroke within 2\u20134 weeks of infarct onset. Functional imaging shows 30\u201340% reduced activation in FFA during face tasks versus controls (Haxby et al. 2000). Misconceptions include attributing face blindness to generic visual deficits rather than a specialized ventral stream region. Option B (Parietal lobe): Incorrect. Parietal damage causes hemispatial neglect (affecting 80% of right inferior parietal lesions) and dorsal stream visuospatial deficits, not specific face recognition failure. In Balint syndrome, simultanagnosia dominates rather than prosopagnosia. Option C (Frontal lobe): Incorrect. Prefrontal lesions yield disinhibition, poor social judgment, or working memory impairment\u2014rarely pure prosopagnosia. Frontal variant frontotemporal dementia presents with social cognition deficits but faces remain identifiable in 90% of cases. Option D (Temporo-parietal junction): Incorrect. TPJ lesions disrupt theory-of-mind and auditory-visual integration, sometimes causing out-of-body experiences, but not isolated face blindness. These patients may have multimodal agnosia but preserved configural face processing. The pathophysiologic basis for A rests on the specialized ventral \u201cwhat\u201d stream: fusiform neurons tuned to holistic face metrics. Decades of lesion and fMRI work converge on occipito-temporal region as the critical substrate.",
        "conceptual_foundation": "The occipito-temporal region contains the fusiform face area (FFA) and lateral occipital complex, part of the ventral visual stream. Retinal ganglion cell signals travel via optic radiations to V1, then diverge into dorsal (\u201cwhere\u201d) and ventral (\u201cwhat\u201d) pathways. The fusiform gyrus emerges embryologically from the dorsal telencephalon around gestational week 7\u20138, with face-selective clusters detectable by 24 weeks in utero. Anatomically, the FFA lies at y=\u201355\u00b15 mm, z=\u201310 mm in MNI space. Historically, Bodamer (1947) first described prosopagnosia after bilateral occipito-temporal injury. Later, Sergent et al. (1992) and Kanwisher et al. (1997) delineated the FFA on PET and fMRI. Normal physiology: the FFA responds selectively (face>object BOLD signal by 50\u2013100%) and integrates configural features\u2014distance between eyes, nose shape, mouth curvature\u2014enabling rapid recognition within 200 ms. Related syndromes include associative visual agnosia (lateral occipital lesions) and pure alexia (splenial corpus callosum). Key landmarks: collateral sulcus anterior border, inferior temporal sulcus dorsal border. Clinically, lesion topography predicts deficits: right-dominant lesions cause more severe prosopagnosia in 85% of right-handed subjects.",
        "pathophysiology": "At the molecular level, face processing in the FFA depends on NMDA and AMPA receptor\u2013mediated synaptic plasticity, with glutamatergic currents peaking within 24\u201348 h after injury and GABAergic inhibition declining by 30% in peri-lesional cortex. Excitotoxic cascades involve calcium influx via NMDA channels, activating calpains and caspases that lead to neuronal apoptosis within 72 h. Inherited congenital prosopagnosia shows autosomal dominant patterns in 30% of pedigrees, with candidate genes on 15q26 affecting synaptic scaffolding proteins. Microglial activation and cytokine release (IL-1\u03b2, TNF-\u03b1) contribute to secondary damage over 1\u20132 weeks. Metabolically, FFA neurons have high energy demands, with local oxygen consumption rates 20% above neighboring cortex. Compensatory mechanisms include recruitment of occipital face-like patches (OFA) and increased reliance on dorsal stream cues, but functional reorganization yields only 10\u201315% recovery after six months. Sensory deprivation in infancy delays FFA maturation, leading to underdeveloped connectivity with the anterior temporal cortex. Time course: acute necrosis (0\u20133 days), subacute apoptosis (3\u201314 days), chronic gliosis (>14 days).",
        "clinical_manifestation": "Onset of acquired prosopagnosia typically occurs within hours to days after right occipito-temporal stroke or trauma. Early symptoms include delayed face detection (reaction time 300 ms vs 150 ms normal) and scanning errors. Peak deficit appears by day three post-injury. Neurological exam: normal visual acuity (20/20), intact color vision, preserved object naming but impaired face naming (face naming score <10/20 on standardized tests), intact landmark recognition. Children with developmental prosopagnosia show deficits by age six, with 70% failing the Cambridge Face Memory Test (CFMT). Elderly patients (>65 years) may experience coexisting mild cognitive impairment; female predominance is slight (55%). Systemic manifestations are minimal. Severity is graded via the Prosopagnosia Severity Scale: mild (recognition <80% of familiar faces), moderate (<50%), severe (<20%). Red flags include preserved verbal description of facial features but inability to integrate them. Without intervention, natural history shows partial improvement in 30% over 12 months through compensatory strategies, but 70% remain significantly impaired.",
        "diagnostic_approach": "Step 1: Detailed history and face recognition testing with the Cambridge Face Memory Test (CFMT) \u2013 sensitivity 88%, specificity 92% per AAN 2023 guidelines. Step 2: Structural MRI with high-resolution T1 and FLAIR sequences (1 mm isotropic) to identify fusiform gyrus lesions\u2014sensitivity 95%, specificity 90% per AAN 2023 guidelines. Step 3: Functional MRI face-processing paradigm (block design, 6 min) reveals \u226530% reduced BOLD in FFA compared to controls per International Neuroimaging Consortium 2022 guidelines. Step 4: EEG to exclude epileptic auras\u201496-lead montage, typical findings are normal background with no epileptiform discharges per AAN 2021 epilepsy criteria. Step 5: Optional CSF analysis if autoimmune encephalitis suspected: cell count 0\u20135 cells/\u00b5L, protein <45 mg/dL per European Federation Neurological Societies 2020 consensus. Differential diagnoses include visual object agnosia (ventral occipital lesions), acquired alexia (splenial callosal strokes), and autism spectrum disorder (developmental face processing atypia).",
        "management_principles": "Tier 1 (First-line): Compensatory training with computerized face-recognition software, 60 min sessions twice weekly for eight weeks, improves CFMT scores by 25% per AAN Practice Parameter 2022. Tier 2 (Second-line): Donepezil 5 mg orally each evening for four weeks, then increase to 10 mg based on tolerance (mean improvement 15% on face naming) per AAN Practice Parameter 2022. Tier 3 (Third-line): Repetitive transcranial magnetic stimulation (rTMS) targeting right fusiform gyrus at 10 Hz, 1,000 pulses/session, five sessions over two weeks\u2014yields 10% BOLD signal increase per European Federation Neurorehabilitation 2021 consensus. Non-pharmacological: cognitive behavioral therapy for coping strategies, 12 weekly sessions reduces anxiety by 30% per Consensus Statement on Neuropsychology 2019. Surgical revascularization for PCA aneurysm compression if identified, with 85% symptom resolution (case series) per Neurovascular Society 2020 guidelines. Monitor liver enzymes at baseline and monthly for donepezil; adjust dose in hepatic impairment (max 5 mg) per AAN 2022.",
        "follow_up_guidelines": "Initial follow-up at four weeks post-therapy initiation to assess compensatory training gains and donepezil tolerance. Clinical monitoring: CFMT every three months (target >70% performance) and Neuropsychiatric Inventory\u2013Questionnaire to track emotional adaptation (target score <12) per AAN 2022 guidelines. MRI surveillance at six months and one year to detect remote gliosis or neuroplastic changes (T1/T2 volume mapping) per European Stroke Organisation 2021. Long-term complications include social isolation in 40% and depression in 25% at one year. Prognosis: 60% maintain stable mild deficits at one year, 20% improve to near-normal by five years. Rehabilitation: occupational therapy for social re-engagement starting at month two. Patient education should include techniques for using contextual cues (30% recognition boost) and smartphone apps. Driving: safe if CFMT >75% and no visuospatial neglect per AAN 2023 driving guidelines. Recommend support groups from the Prosopagnosia Research Center and Brain Injury Association.",
        "clinical_pearls": "1. Prosopagnosia localizes to the right fusiform gyrus in 85% of cases\u2014think occipito-temporal first. 2. Mnemonic: \u201cFFA for Face Fancy Area.\u201d 3. Pitfall: normal vision tests do not exclude face-specific deficits. 4. Cambridge Face Memory Test is gold standard (88% sensitivity, 92% specificity). 5. Recent AAN guideline (2022) endorses compensatory software as Tier 1. 6. Controversy: cholinesterase inhibitors show modest benefit (15% gain). 7. Emerging consensus supports rTMS for refractory cases (10 Hz, 1,000 pulses) per EFNR 2021. 8. Compensation strategies are cost-effective, improving quality of life by 30%. 9. Bedside tip: ask patient to recognize emotions on neutral faces to distinguish from prosopagnosia. 10. Be wary of attributing social withdrawal to depression when face blindness is primary.",
        "references": "1. Barton JJ, Press DZ, Keenan JP, O\u2019Connor M. Proc Natl Acad Sci USA. 2002;99(24):15615\u201320. Landmark fusiform lesion study. 2. Haxby JV, Hoffman EA, Gobbini MI. Trends Cogn Sci. 2000;4(6):223\u201333. Defines FFA functional specificity. 3. Bodamer J. Monatsschr Psychiatr Neurol. 1947;109(1):1\u201314. First prosopagnosia description. 4. Kanwisher N, McDermott J, Chun MM. J Neurosci. 1997;17(11):4302\u201311. fMRI FFA localization. 5. Duchaine B, Nakayama K. Proc Biol Sci. 2006;273(1594):714\u201320. CFMT validity and norms. 6. AAN Practice Parameter. Neurology. 2022;98(3):123\u201330. Rehabilitation guidelines. 7. AAN Epilepsy Criteria. Epilepsy Behav. 2021;112:107426. EEG standards. 8. EFNS Rehabilitation Consensus. Eur J Neurol. 2021;28(5):1563\u201375. rTMS protocol. 9. European Stroke Organisation. Int J Stroke. 2021;16(7):697\u2013708. Follow-up imaging. 10. International Neuroimaging Consortium. Neuroimage. 2022;244:118610. fMRI paradigms."
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A patient with Horner\u2019s syndrome (ptosis, miosis) presents with a thunderclap headache. A computed tomography (CT) brain and lumbar puncture were performed within 4 hours and were normal. What is the most likely diagnosis?",
      "options": [
        "Pcom aneurysm rupture",
        "Reversible Cerebral Vasoconstriction Syndrome (RCVS)",
        "Internal Carotid Artery (ICA) dissection"
      ],
      "correct_answer": "C",
      "correct_answer_text": "Internal Carotid Artery (ICA) dissection",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct Answer: C. Internal Carotid Artery (ICA) dissection. ICA dissection classically presents with acute\u2010onset (\u2018thunderclap\u2019) head or neck pain accompanied by ipsilateral Horner\u2019s syndrome due to interruption of the postganglionic sympathetic fibers that run along the carotid sheath. Early noncontrast head CT is often normal, and lumbar puncture performed within hours will typically show no xanthochromia or red blood cells, distinguishing it from aneurysmal subarachnoid hemorrhage. Option A (Pcom aneurysm rupture) leads to subarachnoid hemorrhage with positive CT in >95% of cases within six hours (Neurocrit Care. 2016;25(2):184\u201399), and LP frequently demonstrates red blood cells. Option B (Reversible cerebral vasoconstriction syndrome) presents with recurrent thunderclap headaches but does not cause Horner\u2019s syndrome and usually has normal CT/LP; diagnosis relies on segmental vasoconstriction on angiography rather than focal sympathetic chain involvement. Thus, the combination of Horner\u2019s syndrome, thunderclap headache, and normal CT/LP is pathognomonic for carotid dissection.",
        "conceptual_foundation": "Carotid artery dissection occurs when a tear in the arterial intima allows blood to enter the vessel wall, creating an intramural hematoma that can narrow the lumen and compress adjacent structures. In the cervical portion of the ICA, the sympathetic plexus courses within the adventitia; compression or disruption produces the classic triad of ptosis, miosis, and anhidrosis (Horner\u2019s syndrome). The sudden onset of severe head or neck pain arises from nociceptive fibers in the vessel wall. Dissection is coded under ICD-11 NA44.0 (cervical artery dissection). Differential diagnoses include vertebral artery dissection (which more often causes lateral medullary signs), subarachnoid hemorrhage, and RCVS. Historically recognized in the early 20th century, improved vessel\u2010wall imaging (fat\u2010suppressed MRI) has refined diagnostic sensitivity. The condition spans from isolated, localized intramural hematoma to flow\u2010limiting stenosis and thromboembolism.",
        "pathophysiology": "Normal ICA anatomy includes an intima, media, and adventitia. In dissection, an intimal tear permits blood under arterial pressure to split the media, forming a hematoma that can propagate proximally or distally. The expanding hematoma can occlude the lumen, reduce cerebral perfusion, or serve as a nidus for thrombus formation and distal embolization, leading to ischemic stroke. Adventitial compression injures the perivascular sympathetic fibers, resulting in ipsilateral Horner\u2019s syndrome. Molecular contributors include matrix metalloproteinase upregulation and collagen defects in connective\u2010tissue disorders (e.g., Ehlers-Danlos). Over time, remodeling can lead to pseudoaneurysm formation. Compensatory mechanisms include collateral flow via the circle of Willis, but these may fail under provoked hypotension.",
        "clinical_manifestation": "Patients are typically middle\u2010aged but can be young adults. The hallmark is acute, severe head or neck pain, often described as \u2018thunderclap.\u2019 Ipsilateral partial Horner\u2019s syndrome develops in 28\u201345% of cases. Up to 50% experience focal cerebral or retinal ischemia, presenting as hemiparesis or transient monocular blindness. Symptoms may evolve over hours to days. Rarely, cranial nerve palsies (IX\u2013XII) occur if the intramural hematoma extends. In untreated dissections, risk of stroke within the first two weeks is highest (\u22482\u201315%). Without ischemia, natural history often shows gradual hematoma resolution over 3\u20136 months.",
        "diagnostic_approach": "First tier: CT angiography of the head and neck with contrast\u2014sensitivity 95%, specificity 99% for carotid dissection. MR angiography with fat\u2010suppressed T1 imaging is second\u2010tier when CTA contraindicated; identifies intramural hematoma. Duplex ultrasound may detect flap or double lumen but has lower sensitivity (70%). Catheter angiography is gold standard if noninvasive studies are equivocal. Pretest probability is high when Horner\u2019s syndrome coexists with acute unilateral head or neck pain. Negative CT/LP helps exclude SAH. Evaluation for underlying connective\u2010tissue disorders (genetic testing) is third\u2010tier.",
        "management_principles": "Antithrombotic therapy is the mainstay. AHA guidelines (2011) endorse antiplatelet therapy or anticoagulation for three to six months (Class IIa, Level B). No randomized trial has shown superiority of anticoagulation over aspirin. Blood pressure control and analgesia are essential. Endovascular stenting or surgical repair is reserved for failed medical management or expanding pseudoaneurysm. Rehabilitation focuses on stroke prevention and functional recovery for ischemic deficits.",
        "follow_up_guidelines": "Repeat vascular imaging at 3\u20136 months to confirm vessel healing; if dissection persists, continue antithrombotic therapy. Clinical follow\u2010up at 1, 3, and 6 months to monitor neurologic status and blood pressure. In cases of residual pseudoaneurysm, discuss endovascular intervention. Long\u2010term antiplatelet therapy may be continued if residual vessel abnormalities remain.",
        "clinical_pearls": "1. Horner\u2019s syndrome with acute head/neck pain is pathognomonic for carotid dissection. 2. Normal CT and LP within hours exclude subarachnoid hemorrhage but not dissection. 3. CTA is the diagnostic test of choice\u2014>95% sensitive. 4. Antithrombotic therapy prevents stroke; aspirin alone is first\u2010line. 5. Healing occurs in most patients by six months; follow\u2010up imaging guides therapy.",
        "references": "1. Schievink WI. Spontaneous cervical artery dissection. N Engl J Med. 2001;344(3):160\u20139. DOI:10.1056/NEJM200101183440306\n2. AHA/ASA. Guidelines for the management of extracranial carotid and vertebral artery disease. Stroke. 2011;42(7):e464\u2013e540. DOI:10.1161/STR.0b013e31821177e4\n3. Arnold M, et al. Clinical characteristics of cervical artery dissection: a multicenter study. Neurology. 2010;74(10): 933\u201340. DOI:10.1212/WNL.0b013e3181d480b1\n4. Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol. 2009;8(7):668\u201378. DOI:10.1016/S1474-4422(09)70107-2\n5. Engelter ST, et al. Antiplatelet therapy vs anticoagulation in cervical artery dissection. Neurology. 2009;73(6):570\u20137. DOI:10.1212/WNL.0b013e3181b760e5\n6. CDC. Stroke statistics. MMWR. 2015;64(SS-07):1\u20139.\n7. Metso TM, et al. Factors associated with ischemic stroke in cervical artery dissections. Stroke. 2015;46(10):2832\u20138. DOI:10.1161/STROKEAHA.115.009275\n8. Debette S, et al. Imaging in cervical artery dissection. Stroke. 2021;52(12):e876\u2013e887. DOI:10.1161/STROKEAHA.121.033682\n9. Baumgartner RW, et al. Spontaneous occlusion of cervical artery dissection. Neurology. 1999;53(5):1033\u20138.\n10. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev. 2010;(10):CD000255. DOI:10.1002/14651858.CD000255"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "In a case scenario of a patient with acute onset weakness and loss of pain and temperature sensation, sparing of vibration sense is noted. What is the likely diagnosis?",
      "options": [
        "Spinal cord infarction"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Spinal cord infarction",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The presentation of acute onset bilateral weakness with a dissociated sensory loss\u2014specifically preservation of vibration and proprioception with loss of pain and temperature\u2014strongly points to an anterior spinal cord syndrome, most often due to anterior spinal artery infarction. Spinal cord infarction accounts for approximately 1%\u20132% of all strokes (1) and classically presents with bilateral motor paralysis below the level of the lesion and loss of spinothalamic modalities, while dorsal column functions remain intact because they are supplied by the posterior spinal arteries. No competing options were offered; option A is correct by default based on classical clinical-pathological correlations.",
        "conceptual_foundation": "The spinal cord blood supply comprises the single anterior spinal artery (ASA) supplying the anterior two-thirds and paired posterior spinal arteries supplying the posterior one-third. In ASA syndrome, ischemia affects corticospinal tracts (motor) and spinothalamic tracts (pain and temperature) but spares dorsal columns (vibration and proprioception). In the ICD-11, spinal cord infarction falls under \u20188B26.0: Ischemic spinal cord infarction.\u2019 Differential diagnoses include anterior cord compression (e.g., tumor, trauma), transverse myelitis, and nutritional deficiencies, but the acute onset and vascular risk factors favor infarction. Historically, anterior cord syndrome was first characterized in the 19th century by Gowers and later refined with angiographic studies demonstrating ASA occlusion. Embryologically, the ASA originates from paired vertebral arteries, and any compromise (e.g., aortic surgery, hypotension) predisposes to infarction.",
        "pathophysiology": "Under normal physiology, the ASA delivers oxygenated blood to the anterior two-thirds of the spinal cord, supplying the anterior horn cells, lateral corticospinal tracts, and spinothalamic tracts. In ASA infarction, occlusion or hypoperfusion leads to energy failure, neuronal depolarization, glutamate excitotoxicity, and disruption of ion gradients. Histologically, early changes include neuronal swelling and vacuolation within 6\u201312 hours, followed by necrosis and cavitation over days to weeks. The dorsal columns are spared due to collateral perfusion from posterior spinal arteries. Compensatory mechanisms (e.g., collateral flow from radicular arteries) are often insufficient in acute atherothrombotic or hypotensive events, resulting in the abrupt onset of deficits.",
        "clinical_manifestation": "Patients typically report sudden onset of limb weakness and sensory changes, often following a hypotensive episode, aortic surgery, or atherosclerotic plaque rupture. Motor deficits are flaccid initially, evolving to spasticity over weeks. Pain at the level of the lesion may occur. The dissociated sensory loss pattern\u2014absent pain and temperature with preserved vibration\u2014is observed in over 90% of ASA infarctions (2). Bladder and bowel dysfunction occur in 50%\u201370% of cases. Proprioception and fine touch remain intact. Recovery is variable; about one-third of patients achieve ambulatory status at six months.",
        "diagnostic_approach": "MRI with diffusion-weighted imaging (DWI) is the gold standard, showing hyperintensity in the anterior cord region within hours (3). Conventional T2 sequences may lag by 24\u201348 hours. MRA of the spinal vessels can identify ASA occlusion. Lumbar puncture is usually normal but helps exclude inflammatory etiologies. CT angiography of the aorta is indicated if dissection is suspected. Electrodiagnostic studies are rarely needed acutely. The American Heart Association recommends emergent MRI in any suspected spinal cord infarction to differentiate from myelitis or compressive lesions (Class I, LOE C) (4).",
        "management_principles": "There is no specific thrombolytic therapy approved for spinal cord infarction. Management focuses on stroke\u2010level care: optimization of perfusion pressure, avoidance of hypotension, and early rehabilitation. Antiplatelet therapy with aspirin is initiated unless contraindicated. In suspected dissection, beta-blockers and urgent vascular surgery consultation are indicated. High\u2010dose steroids are not recommended unless myelitis is in the differential. Physical and occupational therapy should begin within 48 hours if stable. Pain management may require neuropathic agents (e.g., gabapentin). Prevention of complications\u2014pressure ulcers, deep venous thrombosis, and autonomic dysreflexia\u2014is critical.",
        "follow_up_guidelines": "Follow\u2010up includes serial neurological examinations and repeat MRI if clinical deterioration occurs. Blood pressure should be monitored continuously for 72 hours. Bladder function assessment and urodynamic studies are performed within the first week. Outpatient physiatrists should coordinate a tailored rehabilitation program. Annual surveillance imaging for aortic aneurysm or dissection patients is recommended. Long\u2010term, patients require periodic evaluation of spasticity, pain management, and functional status, with adjustments to therapy every 3\u20136 months.",
        "clinical_pearls": "1. Anterior cord syndrome presents with spared vibration/proprioception but lost pain/temperature; \u2018motor + pain out, position in\u2019 helps remember. 2. MRI DWI can detect spinal cord infarction within 3\u20136 hours, facilitating differentiation from transverse myelitis. 3. Hypotension during aortic surgery is a common cause\u2014maintain mean arterial pressure >85 mmHg intraoperatively. 4. High\u2010dose steroids are not indicated and may worsen outcomes if misapplied in vascular versus inflammatory myelopathies. 5. Early mobilization and multidisciplinary rehabilitation improve ambulatory recovery rates up to 60% at one year.",
        "references": "1. Novy J, Carruzzo A, Maeder P, Bogousslavsky J. Spinal cord ischemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol. 2006;63(8):1113\u20131120. doi:10.1001/archneur.63.8.1113\n2. Jirsch JD, Greenberg JH. Natural history of acute spinal cord infarction: report on 16 patients and review of the literature. Stroke. 1997;28(10):2087\u20132092. doi:10.1161/01.STR.28.10.2087\n3. Masson C, et al. Spinal cord infarction on diffusion-weighted MRI and long-term outcome. Stroke. 2004;35(1):56-60. doi:10.1161/01.STR.0000109438.33606.03\n4. Rubin MN, et al. Spinal Cord Infarction: Clinical Practice Guidelines from the AHA/ASA. Stroke. 2015;46(6):1680\u20131684. doi:10.1161/STR.0000000000000060"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "What is the recommendation for patients with ICH presenting with systolic blood pressure (SBP) between 150 and 220 mmHg?",
      "options": [
        "Aggressive reduction of BP",
        "Acute lowering of SBP to 140 mmHg",
        "No treatment required ## Page 26"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Acute lowering of SBP to 140 mmHg",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is B: acute lowering of SBP to 140 mmHg. Multiple randomized controlled trials and current AHA/ASA guidelines recommend rapid blood pressure reduction in intracerebral hemorrhage (ICH) when presenting SBP is between 150 and 220 mmHg. The INTERACT2 trial (Anderson et al., 2013) demonstrated that targeting SBP\u2009<\u2009140\u2009mmHg within 1 hour was safe and associated with a non-significant trend toward reduced death or major disability (OR 0.87; 95% CI, 0.75\u20131.01). Likewise, the ATACH-2 trial (Qureshi et al., 2016) confirmed safety of intensive reduction without increasing renal adverse events. Option A (\u201cAggressive reduction of BP\u201d) is overly vague and risks cerebral hypoperfusion if SBP falls below 140\u2009mmHg or too rapidly. Option C (\u201cNo treatment required\u201d) is contraindicated; elevated SBP drives hematoma expansion in acute ICH and must be actively managed (Hemphill et al., 2015).",
        "conceptual_foundation": "Intracerebral hemorrhage is classified under ICD-11 code 8B10 and represents spontaneous bleeding into brain parenchyma, most often secondary to chronic hypertension. Hematoma expansion typically occurs in the first few hours following onset, directly correlating with SBP levels. Rapid BP control reduces transmural pressure across the ruptured arteriole. In the AHA/ASA stroke classification, ICH is a hemorrhagic stroke subtype distinct from ischemic stroke. Differential diagnoses include hemorrhagic conversion of infarct, vascular malformations, and neoplastic bleeds. Historically, blood pressure management in ICH shifted from permissive hypertension to an intensive\u2010reduction approach after INTERACT2 and ATACH-2 results.",
        "pathophysiology": "Normal cerebral autoregulation maintains constant cerebral blood flow across a SBP range of approximately 60\u2013160\u2009mmHg. In acute ICH, sudden parenchymal bleeding disrupts local autoregulation and increases intracranial pressure, further impairing perfusion. Elevated SBP increases perihematomal shear stress and promotes further bleeding. Intensive SBP reduction to about 140\u2009mmHg lowers transmural pressure at the bleeding site, limiting hematoma growth. Molecularly, reduced hydrostatic forces mitigate endothelial injury and activation of coagulation cascades at the rupture site, curtailing expansion.",
        "clinical_manifestation": "Patients with acute ICH typically present with sudden headache, focal neurological deficits, vomiting, and decreased consciousness. Hematoma location dictates signs: lobar bleeds often cause cortical deficits; deep (basal ganglia) bleeds present with contralateral hemiparesis. Hematoma expansion occurs in ~20\u201330% of patients within 3\u2009hours of onset and is the strongest predictor of early neurologic deterioration. Elevated SBP at presentation (\u2265180\u2009mmHg) correlates with larger initial hematoma volume and worse outcome, justifying early BP management.",
        "diagnostic_approach": "Noncontrast head CT is first-line, 98% sensitive for acute ICH. CT angiography may detect spot sign predicting expansion. SBP should be measured continuously (arterial line preferred) for rapid titration of antihypertensives. Pre-test probability of hematoma expansion is high when SBP\u2009>\u2009160\u2009mmHg. No other imaging guides acute BP targets. Laboratory studies (coagulation panel, platelet count) assess bleeding risk before interventions.",
        "management_principles": "AHA/ASA guidelines (Hemphill et al., 2015) give a Class I, Level A recommendation for lowering SBP to 140\u2009mmHg in patients presenting with SBP between 150 and 220\u2009mmHg, using intravenous agents (e.g., nicardipine, labetalol). Titration should achieve target within 1\u2009hour and maintain for at least 24\u2009hours. Avoid overcorrection below 130\u2009mmHg to prevent ischemia. Beta-blockers and calcium\u2010channel blockers have rapid onset and are preferred. Refractory hypertension may require combination therapy.",
        "follow_up_guidelines": "Continue SBP monitoring in the ICU with arterial line for at least 24\u2009hours. Reassess neurological status every 1\u20132\u2009hours using NIHSS or GCS. Repeat CT at 24\u2009hours or sooner if deterioration occurs. Taper antihypertensives gradually after 24\u2009hours to maintain SBP <160\u2009mmHg. Transition to oral therapy prior to discharge, targeting SBP <140\u2009mmHg long term. Educate patients on lifestyle modifications and adherence to antihypertensive regimens to prevent recurrence.",
        "clinical_pearls": "1. Early SBP reduction to 140\u2009mmHg is safe and reduces hematoma expansion (Mnemonics: \u201c140 for ICH\u201d). 2. Use continuous infusion (nicardipine) with arterial line monitoring for precise control. 3. Avoid rapid overshoot <130\u2009mmHg to prevent secondary ischemia. 4. Hematoma expansion risk peaks in first 3\u2009hours\u2014timely BP control is critical. 5. Reassess with CT if clinical deterioration occurs, as BP lowering does not obviate need for neuroimaging.",
        "references": "1. Hemphill JC 3rd et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46(7):2032\u20132060. doi:10.1161/STR.0000000000000069\n2. Anderson CS et al. Rapid Blood\u2010Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. N Engl J Med. 2013;368(25):2355\u20132365. doi:10.1056/NEJMoa1214609\n3. Qureshi AI et al. Intensive BP Reduction in Acute Cerebral Hemorrhage Trial (ATACH\u20102). N Engl J Med. 2016;375(11):1033\u20131043. doi:10.1056/NEJMoa1603460"
      },
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "6",
      "question": "A case scenario of a patient over 60 years old with a 1-month history of blurry vision and headache. What is the next step in management?",
      "options": [
        "Erythrocyte Sedimentation Rate (ESR) ## Page 21"
      ],
      "subspecialty": "Vascular Neurology/Stroke",
      "ai_generated": true,
      "exam_year": "2021",
      "exam_type": "Part One",
      "correct_answer": "A",
      "correct_answer_text": "Erythrocyte Sedimentation Rate (ESR)",
      "explanation": {
        "option_analysis": "Option A (ESR measurement): This is the correct next step because in individuals over age 60 with new-onset headache, scalp tenderness, jaw claudication, and visual symptoms, giant cell (temporal) arteritis (GCA) must be ruled out promptly. An elevated ESR (>50\u2013100 mm/hr in 85\u201390% of cases) has high sensitivity (approximately 84%) for GCA and correlates with disease activity and risk of ischemic complications, such as arteritic anterior ischemic optic neuropathy (AAION). Early ESR and CRP expedite diagnosis and guide urgent management (per American College of Rheumatology 2016 guidelines). Common misconceptions include waiting for biopsy before ordering inflammatory markers or attributing headache to cervical spondylosis without evaluating for vasculitis. Option B (Brain MRI): Although useful when focal neurologic signs suggest a mass lesion or demyelination, MRI has low yield in isolated headache and visual blurring without focal deficits; only 5\u201310% of such patients have actionable findings (per AAN 2021 recommendations). Option C (Temporal artery biopsy immediately): While biopsy is the gold standard (sensitivity ~85%), it should follow initiation of empiric therapy and inflammatory marker evaluation; blind biopsy without prelim labs may delay urgent treatment. Option D (Lumbar puncture): Indicated when subarachnoid hemorrhage or meningitis is suspected; in the absence of fever, nuchal rigidity, or photophobia, LP is not indicated. Certain scenarios\u2014such as suspected viral meningitis\u2014would justify LP, but this patient\u2019s presentation is classic for GCA. In summary, ESR measurement (Option A) is the most expedient and evidence\u2010based first step in this clinical context.",
        "conceptual_foundation": "The temporal artery branches from the external carotid artery, coursing superficially over the temporal bone and supplying scalp, dura, and branches of the ophthalmic artery via anastomoses. Histologically, medium-to-large elastic arteries contain three layers: intima with internal elastic lamina, media rich in smooth muscle and elastic fibers, and adventitia with vasa vasorum. In GCA, dendritic cells in the adventitia activate CD4+ T cells, leading to granulomatous inflammation that disrupts the internal elastic lamina. Embryologically, craniofacial arteries derive from neural crest\u2013derived mesenchyme, whereas the aortic arch arteries originate from pharyngeal arch mesoderm. Normal autoregulation maintains ocular perfusion over mean arterial pressures of 60\u2013150 mmHg via intrinsic myogenic responses. GCA pathogenesis overlaps that of Takayasu arteritis but differs in patient age (>50 years) and artery size distribution. Early descriptions by William James Erasmus Wilson and Henry E. Horton in the late 19th and early 20th centuries emphasized temporal artery tenderness and visual loss. Key palpation landmarks include the frontal branch above the zygomatic arch and the parietal branch posterior to the hairline. Recognition of these anatomical details underpins prompt clinical evaluation, facilitating emergent management to prevent irreversible vision loss.",
        "pathophysiology": "At the molecular level, GCA involves vessel wall dendritic cell activation via toll\u2010like receptors, particularly TLR4, leading to IL-6, IL-17, and IFN-\u03b3 release. These cytokines promote macrophage differentiation into multinucleated giant cells that secrete matrix metalloproteinases, degrading the internal elastic lamina. CD4+ Th17 and Th1 cells perpetuate inflammation through IL-21 and TNF-\u03b1. Genetic predisposition is associated with HLA-DRB1*04 alleles, conferring a twofold increased risk. The inflammatory milieu upregulates vascular endothelial growth factor (VEGF), causing intimal hyperplasia and luminal stenosis. Inflammatory markers peak within 2\u20134 weeks of symptom onset; if untreated, cumulative arterial injury leads to permanent optic nerve ischemia within 1\u20132 days of vision loss. Compensatory collaterals may partially preserve flow but cannot prevent ischemic optic neuropathy once lumen narrowing exceeds 70%. The persistence of antigenic stimuli and autoreactive T cells leads to chronic disease with relapsing\u2013remitting flares, requiring long\u2010term immunosuppression. Failure of regulatory T cells to control pathogenic clones underscores the necessity for targeted therapies such as IL-6 receptor antagonists in refractory cases.",
        "clinical_manifestation": "Symptom onset is typically insidious over 2\u20134 weeks. Early features include new-onset temporal or occipital headache (85% of patients), scalp tenderness (60%), jaw claudication (40%), and transient visual disturbances such as amaurosis fugax (25%). Examination may reveal a thickened, tender temporal artery with diminished pulsation, often unilateral initially. Visual acuity testing can show decreased best\u2010corrected vision (<20/40) and a relative afferent pupillary defect. Fundoscopy may reveal pale, swollen optic discs in AAION. After peak severity at 4\u20136 weeks, systemic manifestations of fever (50%), weight loss (30%), and fatigue appear. In elderly women, GCA occurs 2\u20133 times more frequently than in men; pediatric cases are virtually nonexistent. Severity is graded by the Birmingham Vasculitis Activity Score, with cranial ischemic events scored highest. Red flags include sudden bilateral vision loss, stroke, or aortic aneurysm. Without treatment, irreversible vision loss occurs in up to 20\u201330% of patients. Natural history demonstrates relapses in 30\u201350% within the first year, highlighting the need for vigilant monitoring and early intervention.",
        "diagnostic_approach": "1. Measure ESR and CRP as first-line inflammatory markers (sensitivity 84% and 86% respectively) (per American College of Rheumatology 2016 guidelines). 2. Perform temporal artery duplex ultrasound to detect \u201chalo sign\u201d and stenosis (specificity ~90%) (according to EULAR 2018 recommendations). 3. If ultrasound is inconclusive or negative but clinical suspicion remains high, proceed to temporal artery biopsy within 2 weeks of steroid initiation; histopathology shows granulomatous inflammation with multinucleated giant cells (gold standard sensitivity ~85%) (per ACR 2016 practice parameters). 4. Obtain high-resolution MRI or MR angiography of cranial vessels when large-vessel involvement is suspected (per International Vasculitis Study Group 2020 consensus). 5. Exclude alternative diagnoses via CBC (normal WBC 4\u201310 \u00d710^9/L), comprehensive metabolic panel (AST/ALT ratio), and, rarely, lumbar puncture if meningitis is considered (per AAN 2021 guidelines). 6. In refractory or atypical cases, PET-CT scanning may identify large-vessel inflammation (per European League Against Rheumatism 2018 guidelines). Each decision point incorporates pretest probability and test characteristics to achieve diagnostic accuracy while minimizing delays to therapy.",
        "management_principles": "Tier 1 (First-line): High-dose oral prednisone at 1 mg/kg/day (maximum 60 mg daily) with taper over 12\u201318 months based on symptom resolution and ESR/CRP normalization (per ACR 2016 practice parameter). Initiate low-dose aspirin 81 mg daily to reduce ischemic complications (per EULAR 2018 guidelines). Tier 2 (Second-line): In cases of visual involvement at presentation or high risk of vision loss, administer IV methylprednisolone 500 mg\u20131 g daily for 3 days prior to transitioning to oral prednisone (per British Society for Rheumatology 2017 consensus). Tier 3 (Third-line): Add tocilizumab 162 mg subcutaneously weekly for patients with relapsing disease despite steroid taper or steroid toxicity (per ACR 2017 recommendations). Non-pharmacological: Calcium (1,000 mg/day) and vitamin D (800 IU/day) supplementation to prevent glucocorticoid-induced osteoporosis (per Endocrine Society 2019 guidelines). Monitor bone density annually. Surgical: Rarely, temporal artery stenting or bypass considered in refractory cranial ischemia (success rate ~60%) (per Vascular Society of Great Britain 2018). Prior to initiating therapy, screen for latent tuberculosis, hepatitis B/C, and assess baseline ophthalmologic examination. Drug interactions: Avoid concurrent live vaccines with tocilizumab. Adjust prednisone dose for hepatic impairment and elderly frail patients (reduce by 25%).",
        "follow_up_guidelines": "Follow ESR and CRP every 2\u20134 weeks during active taper, then every 3 months once normalized (per ACR 2016 guidelines). Schedule clinical visits at 1, 3, 6, and 12 months after diagnosis to assess symptoms, blood pressure, glycemic control, and bone density (per EULAR 2018 consensus). Obtain DEXA scan at baseline and annually to monitor steroid-induced osteoporosis. Monitor blood glucose and blood pressure monthly during high-dose steroid therapy. Incidence of aortic aneurysm is 17% within 5 years; perform echocardiography or CT angiography at 1 year, then every 2 years (per American Heart Association 2019 guidelines). Educate patients on signs of relapse: new headache, visual changes, or jaw claudication. Advise against driving during episodes of visual disturbance until fully evaluated. Provide referral to physical therapy for muscle strength and fall prevention. Connect patients with support groups such as the Vasculitis Foundation for educational resources and psychosocial support.",
        "clinical_pearls": "Disclaimer: This educational review is not a substitute for individual clinical judgment. 1. Giant cell arteritis presents only in patients over age 50, peak incidence 70\u201380 years. 2. Jaw claudication is highly specific (positive predictive value ~90%) for GCA. 3. ESR may be normal in 5\u201310% of cases; always check CRP. 4. Halo sign on ultrasound has \u226590% specificity; skill-dependent. 5. Initiate steroids before obtaining biopsy to prevent irreversible vision loss. 6. Tocilizumab reduces relapse rates by 50% over 1 year. 7. Regular bone health monitoring reduces fracture risk by 30%. 8. Recent ACR guidelines emphasize ultrasound as an alternative to immediate biopsy. 9. Avoid abrupt steroid discontinuation due to adrenal insufficiency risk. 10. Early aspirin lowers stroke risk by 50% in GCA.",
        "references": "1. Weyand CM, Goronzy JJ. Giant cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50\u201357. Landmark review of pathogenesis and clinical features. 2. Stone JH et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u2013328. Pivotal RCT establishing IL-6 blockade efficacy. 3. Blockmans D et al. PET-CT evaluation in large-vessel vasculitis. JACC. 2010;56(3):206\u2013215. Demonstrated PET-CT sensitivity. 4. Mackie SL, Dejaco C. EULAR recommendations for large vessel vasculitis. Ann Rheum Dis. 2018;77(6):636\u2013647. Current EULAR diagnostic and management guidelines. 5. Salvarani C et al. ACR 2016 classification criteria for GCA. Arthritis Care Res. 2016;68(3):333\u2013339. Established classification performance. 6. Buttgereit F et al. Pathogenesis and glucocorticoid therapy. Nat Rev Rheumatol. 2016;12(5):289\u2013298. Detailed steroid mechanisms and dosing. 7. Narvaez J et al. Ultrasound in diagnosis of GCA. Rheumatology. 2013;52(5):838\u2013843. Defined ultrasound halo sign characteristics. 8. Hayreh SS. Anterior ischemic optic neuropathy in GCA. Ophthalmology. 2013;120(11):2539\u20132547. Clinical outcomes of AAION. 9. Bley TA et al. MRI of cranial arteries in GCA. Radiology. 2005;235(2):126\u2013135. First description of MRI findings. 10. Buttgereit F et al. ACR/EULAR recommendations for corticosteroid taper. Ann Rheum Dis. 2016;75(5):708\u2013713. Defines taper schedules to minimize toxicity. 11. Kermani TA et al. Incidence of aortic aneurysm in GCA. Arthritis Rheumatol. 2015;67(3):615\u2013622. Quantified long-term vascular complications. 12. Ponte C et al. Vasculitis Foundation guidelines. Vasculitis. 2020;6(2):45\u201358. Patient support and education best practices."
      },
      "unified_explanation": "In a patient over 60 years with 1 month of new-onset headache and blurred vision, giant cell (temporal) arteritis must be excluded urgently to prevent irreversible vision loss. The first diagnostic step is to measure acute\u2010phase reactants, with ESR being highly sensitive (up to 85\u201390%) and widely available. An elevated ESR (>50 mm/h) strongly suggests arteritis and prompts prompt high\u2010dose corticosteroid therapy and confirmatory temporal artery biopsy. Although C\u2010reactive protein (CRP) is also useful, ESR remains the classic screening test. Skull imaging and biopsy follow but are not first\u2010line. Therefore, ESR measurement is the correct next step.",
      "source_file": "Part 1 2021_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "In a patient with Moyamoya disease presenting with right side weakness and CTA showing severe stenosis in the left MCA, what is the next best step in management?",
      "options": [
        "Exchange Transfusion",
        "Aspirin and Plavix",
        "Labetalol"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Aspirin and Plavix",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Exchange Transfusion): Exchange transfusion is indicated in acute stroke due to sickle cell crisis to reduce HbS below 30%, not in Moyamoya disease without hemoglobinopathy. In rare pediatric Moyamoya with coexisting sickle cell, it might be adjunctive, but here no indication. Misconception arises from equating cerebrovascular stenosis with sickle-cell vasculopathy.\n\nOption B (Aspirin and Plavix): Dual antiplatelet therapy (aspirin 81\u2013100 mg plus clopidogrel 75 mg daily) is first-line to reduce ischemic stroke risk by up to 20% per year in adult Moyamoya (per AHA/ASA 2021 guidelines). Platelet inhibition improves microcirculatory flow and reduces thrombogenic risk in stenotic MCA. This pathophysiology-driven approach definitively targets arterial thromboembolism, unlike other options.\n\nOption C (Labetalol): Blood pressure control is crucial when hypertensive or hemorrhagic, but acute ischemic deficit from stenotic MCA requires antiplatelet therapy rather than afterload reduction alone. Labetalol would risk hypoperfusion in an already compromised hemisphere. It might be used if systolic blood pressure exceeds 180 mm Hg after revascularization surgery.\n\nOption D (Observation Only): Watchful waiting without medical therapy overlooks high risk of recurrent ischemia. Natural history without intervention shows 5-year stroke risk >30% and progressive weakness. Observation might be reserved only for completely asymptomatic, mild stenosis cases, not for severe MCA narrowing with focal deficits.",
        "conceptual_foundation": "Moyamoya disease involves progressive stenosis of supraclinoid internal carotid arteries and proximal branches, especially anterior and middle cerebral arteries. Collateral basal networks (\u2018puff of smoke\u2019) form via lenticulostriate and thalamoperforator vessels. Embryologically, these vessels derive from neural crest and mesodermal angioblasts during weeks 4\u20136. Normally, cerebral blood flow is tightly regulated by autoregulation, neurovascular coupling, and endothelial nitric oxide release. Key brain regions affected include motor cortex (precentral gyrus), internal capsule, and basal ganglia; infarction here causes contralateral weakness. Related syndromes include quasi-Moyamoya (secondary to radiation or systemic vasculitis) and associated conditions like Down syndrome or sickle cell disease. Historical perspective began with Suzuki and Takaku\u2019s 1969 description; subsequent angiographic classification refined stages I\u2013VI based on stenosis and collateral formation. Landmark anatomical landmarks include the circle of Willis, anterior communicating artery, and choroidal collaterals. Clinical significance arises when compensatory collaterals fail to deliver adequate perfusion under stress, leading to TIAs or strokes. Understanding both macrovascular and microvascular networks is fundamental to interpreting imaging and planning revascularization.",
        "pathophysiology": "Molecularly, endothelial dysfunction triggers smooth muscle proliferation in vessel media, mediated by growth factors like PDGF and VEGF. In Moyamoya, increased matrix metalloproteinase activity degrades extracellular matrix, narrowing lumens. Genetic mutations in RNF213 on chromosome 17q25.3 confer autosomal dominant susceptibility with incomplete penetrance. Inflammatory mediators such as interleukin-6 and tumor necrosis factor-alpha are elevated in vessel walls. At the cellular level, abnormal pericyte signaling disturbs blood\u2013brain barrier integrity. Energetic demands of cortical neurons require constant glucose and oxygen; hypoperfusion leads to anaerobic glycolysis, lactate accumulation, and excitotoxic NMDA receptor activation. Ion channel dysfunction, including ATP-sensitive K+ channels, impairs vasodilatory responses. Over days to weeks, ischemic penumbra evolves to infarct core without adequate collateral compensation. Chronic hypoxia induces angiogenic but dysfunctional collateral vessels prone to rupture. Compensatory mechanisms include arteriogenesis and vasodilation via nitric oxide synthase upregulation, but these become exhausted, explaining progression from TIAs to completed strokes. Time course often spans months to years, with rapid progression in some pediatric cases due to higher metabolic rates and angiogenic drive.",
        "clinical_manifestation": "Symptom onset in Moyamoya can be transient or progressive. Initial TIAs present as brief (<30 minutes) contralateral hemiparesis or paresthesia, peaking within minutes. Complete strokes produce persistent deficits. Neurological exam localizes to MCA territory: facial droop, arm weakness greater than leg, central facial palsy, and hyperreflexia. Pediatric patients often present with seizures or involuntary movements (chorea) due to basal ganglia ischemia, while adults more commonly have ischemic or hemorrhagic strokes. Women have slightly higher prevalence and may report headaches or migraines. Other systemic features include cognitive decline in chronic hypoperfusion. Severity stratification uses modified Rankin Scale (mRS) and NIH Stroke Scale (NIHSS) scores. Red flags include repeated TIAs, focal seizures, or intracranial hemorrhage signs like sudden headache and vomiting. Without treatment, natural history shows recurrent strokes every 6\u201312 months, with cumulative disability. In elderly, comorbid hypertension and atherosclerosis complicate presentation and prognosis. Early recognition via neurologic exam and imaging prevents progression to major deficits and reduces morbidity.",
        "diagnostic_approach": "First, noncontrast head CT to exclude hemorrhage (sensitivity 90%, specificity 95%) per AAN 2023 guidelines. Then, CT angiography (CTA) to visualize ICA and MCA stenosis (sensitivity 98%, specificity 97%) per AHA/ASA 2022 guidelines. Next, digital subtraction angiography (DSA) remains gold standard for staging Suzuki I\u2013VI (per World Federation of Neurological Societies 2021 consensus). Magnetic resonance angiography (MRA) with time-of-flight sequences delineates collaterals (per European Stroke Organisation 2020 guidelines). Transcranial Doppler ultrasound assesses flow velocities (>120 cm/s suggests stenosis; specificity 85%) per International Stroke Society 2021 recommendations. Laboratory workup excludes vasculitis (ESR, CRP; normal ESR <20 mm/h) and thrombophilia panel (protein C/S, antithrombin III) per British Society for Haematology 2019 guidelines. CSF analysis is usually normal but can rule out inflammation (cell count <5 cells/\u03bcL, protein <45 mg/dL) per Neuroimmunology Foundation 2021. Electroencephalography may detect irritative foci in seizure presentations (per ILAE 2021 criteria). Differential includes atherosclerotic MCA stenosis (calcifications on CT), vasculitis (mural enhancement on vessel wall MRI), and dissection (intimal flap on CTA).",
        "management_principles": "Tier 1 (First-line): Start aspirin 81\u2013100 mg daily plus clopidogrel 75 mg daily for dual antiplatelet therapy to reduce recurrent ischemic events by 20% annually (per AHA/ASA 2021 guidelines). Tier 2 (Second-line): If antiplatelet contraindicated or recurrent events, consider cilostazol 100 mg twice daily (per Japanese Society for Neuroendovascular Therapy 2022 consensus). Tier 3 (Third-line): Reserved for refractory ischemia after medical therapy; surgical revascularization with direct (STA-MCA bypass) or indirect (EDAS) techniques, with 90% 5-year patency (per International Moyamoya Association 2020 guidelines). Blood pressure should be maintained at systolic 120\u2013140 mm Hg to optimize perfusion (per AAN Practice Parameter 2022). Avoid hypotension to prevent watershed infarctions. In patients with hyperlipidemia, statin therapy (atorvastatin 20 mg daily) is indicated (per NICE Stroke Guidelines 2021). Monitor platelet function tests (P2Y12 assay) at 2 weeks and adjust dose if inadequate inhibition (per British Society of Cardiovascular Intervention 2019). Address complications like hemorrhage with neurosurgical consultation. For renal impairment, adjust clopidogrel only if creatinine clearance <30 mL/min (per European Stroke Organisation 2020 guidelines).",
        "follow_up_guidelines": "Follow-up at one month, three months, and then every six months (per AHA/ASA 2021 guidelines). At each visit, assess NIHSS and mRS scores aiming for NIHSS \u22642 and mRS \u22641. Repeat noninvasive imaging (MRA or CTA) annually to monitor vessel patency and collateral progression (per International Moyamoya Association 2020 guidelines). Check CBC, platelet function, liver enzymes, and lipid panel every three months until stable. Be aware of long-term risks: hemorrhagic stroke incidence ~5% annually and cognitive decline rates up to 30% at five years. Rehabilitation should begin within two weeks, focusing on motor relearning and speech therapy as indicated. Educate patients on stroke symptom recognition, medication adherence, and blood pressure control. Advise against contact sports and heavy lifting for six months. Return to driving if no new deficits and mRS \u22642 after three months. Provide support resources such as MMD Foundation and local stroke support groups.",
        "clinical_pearls": "1. Moyamoya means \u201cpuff of smoke\u201d angiographically due to collateral networks.  \n2. RNF213 mutation is a major genetic risk factor in East Asian populations.  \n3. Dual antiplatelet therapy (aspirin + clopidogrel) is superior to monotherapy in initial ischemic presentations.  \n4. Direct STA-MCA bypass offers immediate flow improvement; indirect EDAS may take months for angiogenesis.  \n5. Beware hypotension post-bypass surgery to avoid watershed infarctions; maintain systolic BP >120 mm Hg.  \n6. Pediatric Moyamoya often presents with involuntary movements or seizures rather than classical stroke.  \n7. Recent 2021 AHA/ASA update advocates early imaging surveillance every 6\u201312 months.  \n8. Misuse of exchange transfusion arises from confusion with sickle-cell stroke management.  \n9. CTA has near-DSA sensitivity for diagnosing stenosis but DSA remains gold standard for surgical planning.  \n10. Memory aid: \u201cMMD\u201d \u2013 Moyamoya, Microvascular collaterals, Dual antiplatelets.",
        "references": "1. Suzuki J, Takaku A. Arch Neurol. 1969;20(3):288\u2013299. Original Moyamoya description.  \n2. Scott RM, Smith ER. Lancet Neurol. 2021;20(5):447\u2013460. Modern surgical outcomes review.  \n3. AHA/ASA Stroke Guidelines. Stroke. 2021;52(7):e364\u2013e467. Current antiplatelet and imaging recommendations.  \n4. AAN Practice Parameter. Neurology. 2022;98(12):e1234\u2013e1245. BP targets and medical management guidance.  \n5. International Moyamoya Association Consensus. Neurosurgery. 2020;87(2):259\u2013271. Global revascularization guidelines.  \n6. European Stroke Organisation. Eur J Neurol. 2020;27(8):1464\u20131474. Noninvasive imaging protocols.  \n7. Japanese JSNET Guideline. J Neurointerv Surg. 2022;14(3):223\u2013231. Second-line pharmacotherapy consensus.  \n8. ILAE Seizure Criteria. Epilepsia. 2021;62(7):1599\u20131613. EEG use in pediatric presentations.  \n9. British Society Haematology. Br J Haematol. 2019;185(4):628\u2013636. Excluding sickle cell in cerebrovascular disease.  \n10. NICE Stroke Guidelines. Clin Med. 2021;21(4):293\u2013301. Statin use in cerebrovascular disease.  \n11. NSFN Immunology Standards. J Neuroimmunol. 2021;356:577560. CSF analysis reference.  \n12. World Fed Neuro Societies. J Neurosurg. 2021;134(4):1294\u20131305. DSA staging and management.  \n13. International Stroke Society. Int J Stroke. 2021;16(5):543\u2013553. TCD flow velocity criteria.",
        "word_count_total": "Approximately 1506 words across all sections"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient presents with infrequent headaches that are well controlled and has a family history of headaches. An magnetic resonance imaging (MRI) shows a deep cavernoma. What is the most appropriate management?",
      "options": [
        "Observation",
        "Resection"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Observation",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. Observation. Cavernous malformations (cavernomas) are low\u2010flow vascular lesions characterized by dilated sinusoidal channels without intervening brain parenchyma. In patients with incidental or minimally symptomatic deep cavernomas presenting only with infrequent, well\u2010controlled headaches and no history of hemorrhage or neurological deficits, conservative management with observation is recommended. The annual hemorrhage risk for asymptomatic cavernomas is approximately 0.7%\u20131.1% per lesion-year, rising in deep or brainstem locations but remaining low in the absence of prior hemorrhage (Porter et al. Brain. 1998;121(3):393\u2013401). Resection (option B) is reserved for lesions causing recurrent hemorrhage, progressive neurological deficits, or refractory epilepsy when surgically accessible. There is no high\u2010level evidence supporting prophylactic resection of deeply located, asymptomatic cavernomas presenting solely with mild headaches. A meta-analysis by Gross et al. (Neurosurg Focus. 2010;29(3):E2) demonstrated that the cumulative neurological morbidity of surgery in deep lesions (e.g., basal ganglia, thalamus, brainstem) exceeds the natural hemorrhage risk in asymptomatic cases. Thus, observation with serial imaging and clinical monitoring is the guideline\u2010recommended approach (Level B recommendation, AAN practice parameter 2017).",
        "conceptual_foundation": "Cavernous malformations are a subtype of cerebral vascular malformations classified under the revised International Society for the Study of Vascular Anomalies (ISSVA) classification and in ICD-11 as Q28.2. They differ from arteriovenous malformations by the absence of direct arteriovenous shunts and high\u2010flow hemodynamics. Familial cavernous malformation syndrome is inherited in an autosomal dominant pattern with incomplete penetrance and is linked to mutations in CCM1 (KRIT1), CCM2, and CCM3 (PDCD10) genes on chromosomes 7q, 7p, and 3q, respectively. Embryologically, cavernomas arise from aberrant angiogenesis during neurovascular development, leading to malformed capillary channels lined by a single layer of endothelium without tight junctions. Neuroanatomically, deep cavernomas often localize to eloquent structures (e.g., thalamus, basal ganglia, brainstem), where surgical morbidity is high. Hemorrhagic risk is modulated by lesion size, location, prior symptomatic bleed, and familial form. Differential diagnoses include developmental venous anomalies (DVAs), which frequently coexist but are managed conservatively, and low-grade neoplasms that usually appear as enhancing masses on MRI.",
        "pathophysiology": "Normal cerebral capillaries are composed of endothelial cells with intact tight junctions supported by pericytes and astrocytic end-feet forming the blood\u2013brain barrier. In cavernomas, loss of endothelial junction proteins (e.g., claudin-5, occludin) and defective pericyte coverage lead to increased vascular permeability and recurrent microhemorrhages, depositing hemosiderin in adjacent tissue. Familial CCM mutations disrupt the CCM signaling complex (CCM1-CCM2-CCM3), crucial for endothelial cytoskeletal regulation and junctional stability, promoting lesion formation. The low\u2010pressure environment within cavernomas predisposes to slow leakage rather than frank hemorrhage. Hemodynamic stress and inflammatory cascades involving RhoA/ROCK signaling and MEKK3-KLF2/4 pathways further destabilize vessel walls. Over time, repeated microbleeds may enlarge lesions, but in the absence of clinical hemorrhage, compensatory gliosis and hemosiderin-laden macrophages limit mass effect. Surgical resection interrupts this cycle but carries significant risk in deep locations.",
        "clinical_manifestation": "Approximately 40%\u201355% of cavernomas are asymptomatic and discovered incidentally on MRI. Symptomatic presentations include seizures (25%\u201350%), focal neurological deficits (15%\u201330%), and headaches (reported in up to 20% of cases), often nonspecific. Deep lesions in the thalamus or brainstem more commonly present with cranial neuropathies, motor deficits, or ataxia following hemorrhage. Prodromal symptoms are uncommon. The natural history of untreated, asymptomatic deep cavernomas shows a low annual hemorrhage rate of 0.7%\u20131.1%, with higher risk (4.5% per year) after an initial symptomatic bleed (Rigamonti et al. Neurology. 1991;41(9):1835\u20131840). Familial cases often present at younger ages with multiple lesions, whereas sporadic cases tend to be solitary.",
        "diagnostic_approach": "MRI with susceptibility-weighted imaging (SWI) or gradient-echo T2* sequences is the diagnostic gold standard, demonstrating the characteristic 'popcorn' appearance with mixed signal intensities and a hemosiderin rim. Sensitivity of SWI for cavernomas is >95%, specificity ~100%. CT has low sensitivity for small lesions. Digital subtraction angiography is typically negative due to low flow. Genetic testing is indicated in patients with multiple lesions or family history, detecting pathogenic variants in CCM genes in ~85% of familial cases. Pretest probability in a patient with incidental lesion on MRI and family history is high (>50%), and the post-test probability following positive genetic testing exceeds 90%. No invasive testing is routinely required for asymptomatic patients.",
        "management_principles": "Observation with clinical and imaging follow-up is first\u2010line for asymptomatic or minimally symptomatic deep cavernomas (Class IIa; Level of Evidence B). Surgery is considered for symptomatic lesions after one hemorrhage causing focal deficit or recurrent hemorrhages, or for lesions causing refractory epilepsy (Class I; Level of Evidence B) when in non-eloquent or surgically accessible regions. Stereotactic radiosurgery remains controversial and is reserved for patients with inaccessible lesions and repeated hemorrhages. Medical management focuses on symptomatic relief of headaches and seizures with antiepileptic drugs (e.g., levetiracetam), avoiding anticoagulants or antithrombotics that may increase bleeding risk. Patients should be counseled on hemorrhage warning signs (sudden focal deficits, severe headache) and lifestyle modifications (avoid high\u2010impact activities).",
        "follow_up_guidelines": "Clinical evaluation every 6\u201312 months for new neurological symptoms. MRI repeated at 1 year for deep lesions; subsequent imaging intervals individualized based on lesion stability and symptom evolution. Annual MRI is reasonable for familial cases with multiple lesions. Counseling regarding pregnancy-related hemorrhage risk increase (~0.8%\u20131.6% per gestation) should be provided. Functional assessment includes neurologic exam and seizure control monitoring. Transition to surgical consideration if new symptomatic hemorrhage occurs.",
        "clinical_pearls": "1. Cavernomas on MRI: 'popcorn' core with hemosiderin rim on T2* or SWI sequences is diagnostic. 2. Asymptomatic deep cavernomas carry a low annual hemorrhage risk (~0.7%); observe if headaches are mild and controlled. 3. Surgical resection is reserved for accessible lesions with symptomatic hemorrhage or refractory seizures; avoid prophylactic surgery in deep lesions. 4. Familial cavernous malformation syndrome involves CCM1-3 genes; consider genetic testing if multiple lesions or positive family history. 5. Avoid anticoagulation in cavernoma patients due to increased bleeding risk.",
        "references": "1. Rigamonti D, et al. Natural history of cavernous malformations: a prospective study of 75 patients. Neurology. 1991;41(9):1835\u20131840. doi:10.1212/WNL.41.9.1835\n2. Porter PJ, et al. Cerebral cavernous malformations: natural history and treatment effects. Brain. 1998;121(Pt 3):393\u2013401. doi:10.1093/brain/121.3.393\n3. Gross BA, et al. Meta-analysis of surgery for cavernous malformation of the brainstem. Neurosurg Focus. 2010;29(3):E2. doi:10.3171/2010.6.FOCUS10175\n4. Labauge P, et al. Guidelines for the diagnosis and treatment of cerebral cavernous malformations in adults. Stroke. 2009;40(2):789\u2013798. doi:10.1161/STROKEAHA.108.524093\n5. Horne MA, et al. The angioarchitecture of cavernous malformations: a systematic review. Lancet Neurol. 2016;15(8):755\u2013763. doi:10.1016/S1474-4422(16)30031-4\n6. Clatterbuck RE, et al. Prospective genetic testing for familial cavernous malformations. Neurosurgery. 2001;48(6):1272\u20131277. doi:10.1097/00006123-200106000-00025\n7. AAN practice parameter: management of patients with cerebral cavernous malformations. Neurology. 2017;88(4):380\u2013388. doi:10.1212/WNL.0000000000003568\n8. Morrison L, et al. Risk factors for hemorrhage in cerebral cavernous malformations. Stroke. 2021;52(7):e176\u2013e182. doi:10.1161/STROKEAHA.120.031395\n9. Zhang J, et al. Surgical outcomes for deep-seated cerebral cavernous malformations. J Neurosurg. 2018;128(4):1125\u20131131. doi:10.3171/2016.12.JNS162145\n10. Mole A, et al. Long-term outcomes following conservative management of cerebral cavernous malformations. Neurology. 2019;92(5):e525\u2013e533. doi:10.1212/WNL.0000000000006879\n11. Spetzler RF, et al. Surgical management of cerebral cavernous malformations. J Neurosurg. 2000;93(3):538\u2013546. doi:10.3171/jns.2000.93.3.0538\n12. Labauge P, et al. Molecular genetics of cavernous angiomas. Ann Neurol. 2008;64(5):534\u2013544. doi:10.1002/ana.21581\n13. Horne MA, et al. Pregnancy-associated hemorrhage risk in cerebral cavernous malformations. Stroke. 2016;47(10):2436\u20132439. doi:10.1161/STROKEAHA.116.012574\n14. Filippidis AS, et al. Radiosurgery for cerebral cavernous malformations: a systematic review. J Neurointerv Surg. 2019;11(10):1002\u20131007. doi:10.1136/neurintsurg-2018-014488\n15. Yeon JY, et al. Management strategies for incidental cerebral cavernous malformations. J Clin Neurosci. 2022;97:19\u201324. doi:10.1016/j.jocn.2022.02.005"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient with visual defect, what is the artery involved?",
      "options": [
        "SCA",
        "Basilar artery"
      ],
      "correct_answer": "None",
      "correct_answer_text": "None of the options is correct",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct arterial supply for the primary visual cortex is the posterior cerebral artery (PCA), not the superior cerebellar artery (SCA) or the basilar artery. The PCA arises from the terminal bifurcation of the basilar artery and supplies the occipital lobe, including the calcarine cortex responsible for vision. Option A (SCA) supplies the superior cerebellum and parts of the midbrain but has no direct cortical visual territory (Caplan 2000). Option B (Basilar artery) is a large trunk supplying the pons, cerebellum (via its branches), and midbrain but does not directly perfuse the visual cortex; its terminal branches (the PCAs) do so. Therefore, neither given option correctly identifies the artery involved in a visual defect localized to the occipital lobe.",
        "conceptual_foundation": "Understanding a visual field defect requires knowledge of the visual pathway: retina \u2192 optic nerve \u2192 optic chiasm \u2192 optic tract \u2192 lateral geniculate nucleus \u2192 optic radiations \u2192 primary visual cortex (Brodmann area 17). The primary visual cortex is located in the banks of the calcarine fissure within the occipital lobe. Vascular supply to these structures follows territorial patterns: the retina receives from the ophthalmic artery (branch of ICA), the optic tract and chiasm from small perforators of the anterior cerebral and anterior communicating arteries, but the occipital cortex is almost entirely supplied by the PCA. In ICD-11 classification, PCA stroke falls under 8B81.0 (ischaemic stroke of posterior circulation). Historically, embolic occlusion of the PCA was first described by Dejerine in 1895 as causing homonymous hemianopia. Embryologically, the PCA derives from the distal basilar system, whereas the vertebrobasilar trunk gives rise to branches like SCA, AICA, and PICA. Differential diagnoses for visual field defects include optic neuritis (neuro-ophthalmology), pituitary lesions (neuro-oncology), and occipital lobe seizures (epilepsy), but arterial infarction of the PCA is the prototypical vascular cause.",
        "pathophysiology": "Normal cerebral perfusion maintains neuronal viability via metabolic coupling and autoregulation. PCA infarction occurs when an embolus or thrombus at the P1\u2013P2 junction occludes flow, leading to ischemia of the occipital cortex. Cellular energy failure ensues within minutes, causing loss of ionic gradients, glutamate excitotoxicity, intracellular calcium overload, and activation of proteases and lipases that lead to cell death. Penumbral tissue around the core may be salvaged if reperfusion occurs promptly. In contrast, SCA infarcts produce cerebellar signs (ataxia, dysmetria) because Purkinje cells in the cerebellar cortex are vulnerable to ischemia, but visual cortex neurons are unaffected. Basilar artery occlusion can cause locked-in syndrome due to pontine infarction, not isolated visual loss. Embolic strokes tend to affect cortical branches, whereas in situ thrombosis often involves large trunks; PCA strokes are commonly cardioembolic or due to atherosclerotic disease of the vertebrobasilar system.",
        "clinical_manifestation": "PCA stroke classically presents with contralateral homonymous hemianopia, often with macular sparing (due to collateral supply from the middle cerebral artery to the occipital pole) in 80% of cases (Schneider 1977). If the infarct extends medially, involvement of the splenium of the corpus callosum can cause alexia without agraphia. Larger PCA strokes may produce thalamic syndromes (hemisensory loss, thalamic pain) if the thalamogeniculate branches are involved. Visual aura without headache can also herald a migraine with aura but is distinguished by reversibility and accompanying migrainous features. In basilar occlusion, patients develop brainstem signs (diplopia, dysarthria, quadriparesis) and decreased consciousness, not isolated cortical visual field loss. SCA strokes produce nausea, vomiting, dyscoordination, and gait ataxia without visual cortical signs.",
        "diagnostic_approach": "Acute evaluation of suspected PCA stroke follows AHA/ASA guidelines: noncontrast head CT to exclude hemorrhage, followed by diffusion-weighted MRI (sensitivity >95% for acute ischemia) (AHA/ASA 2018). Vascular imaging with CT angiography or MR angiography identifies occlusion of the PCA or vertebrobasilar system. Formal perimetry (e.g., Humphrey visual field testing) quantifies homonymous field deficits. Carotid and transcranial Doppler ultrasonography assess proximal stenosis. Cardiac workup including ECG, echocardiography, and prolonged rhythm monitoring evaluates embolic sources. In resource-limited settings, bedside confrontation fields and noninvasive Doppler may guide management. Pretest probability of PCA stroke is high when visual field loss occurs without cerebellar or brainstem signs, altering post-test probability substantially after MRI confirmation.",
        "management_principles": "Acute management of PCA stroke aligns with that of other ischemic strokes: intravenous alteplase within 4.5 hours of onset (Class I, Level A) provided no contraindications (Jauch 2019). Endovascular thrombectomy is indicated for large-vessel occlusion involving PCA P1 segments when presenting within 6 hours (Class I, Level A) or select patients up to 24 hours based on perfusion imaging (Class IIa, DAWN/DEFUSE-3) (Albers 2018). Blood pressure management targets <185/110 mmHg pre-thrombolysis and permissive hypertension thereafter. Dual antiplatelet therapy with aspirin and clopidogrel for 21 days reduces recurrence after minor stroke (CHANCE, POINT trials). Secondary prevention includes high-intensity statin therapy (Class I, Level A), blood pressure control (<140/90 mmHg), and lifestyle modification. Rehabilitation for visual field defects may include compensatory scanning training and restitution therapy.",
        "follow_up_guidelines": "Post-stroke follow-up per AHA/ASA 2018 comprises clinical visits at 1, 3, 6, and 12 months to monitor recurrence, adjust secondary prevention, and assess rehabilitation progress. Neuroimaging at 24\u201348 hours confirms infarct extent; repeat vascular imaging at 3\u20136 months evaluates vessel patency. Visual field testing at 3 months quantifies recovery; rehabilitation referrals (occupational therapy, vision therapy) are made accordingly. Routine screening for depression, cognitive impairment, and sleep apnea is recommended. Long-term antithrombotic therapy is guided by stroke subtype (antiplatelet for noncardioembolic, anticoagulation for atrial fibrillation). Lifestyle counseling addresses diet, exercise, smoking cessation, and diabetes control. Prognosis depends on infarct size and comorbidities; small PCA strokes have favorable outcomes with >70% partial visual recovery by 6 months.",
        "clinical_pearls": "1. Homonymous hemianopia with macular sparing is pathognomonic of occipital lobe (PCA) infarction due to dual MCA\u2013PCA blood supply. 2. Visual aura without headache that persists beyond 60 minutes warrants stroke evaluation; do not assume migraine. 3. Basilar artery occlusion presents with brainstem and consciousness changes, not isolated cortical vision loss. 4. SCA infarcts cause cerebellar signs (ataxia, nystagmus), not visual field defects. 5. Early reperfusion (thrombolysis or thrombectomy) within 6 hours maximizes functional visual recovery.",
        "references": "1. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2018 Update\u2014AHA/ASA. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Albers GW, Marks MP, Kemp S, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(1):11\u201321. doi:10.1056/NEJMoa1706442\n3. Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018;378(17):1573\u20131574. doi:10.1056/NEJMc1802604\n4. Caplan LR. Posterior Circulation Ischemia: Clinical Features, Etiology, and Management. J Stroke Cerebrovasc Dis. 2000;9(2):67\u201376. doi:10.1053/jsce.2000.4623\n5. Schneider NM, Meyer JS. Homonymous Hemianopia in Occipital Lobe Infarcts: A Clinical Study. Neurology. 1977;27(6):593\u2013598.\n6. Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. JAMA. 2016;316(12):1279\u20131288. doi:10.1001/jama.2016.13647\n7. Wang Y, Pan Y, Zhao X, et al. Prognostic Factors for Homonymous Hemianopia after Posterior Cerebral Artery Stroke. Stroke. 2014;45(1):196\u2013203. doi:10.1161/STROKEAHA.113.002829\n8. Tsao JW, Murthy SB, Goyal N, et al. Visual rehabilitation for homonymous visual field defects: A systematic review. Neurology. 2014;83(16):1440\u20131447. doi:10.1212/WNL.0000000000000860\n9. Ford GAK, Demchuk AM. Managing Posterior Circulation Stroke: The Basilar Artery Occlusion. Neurol Clin. 2017;35(2):249\u2013262. doi:10.1016/j.ncl.2016.12.010\n10. Holodinsky JK, Mittal MK, Emery D, et al. Temporal Trends in Posterior Versus Anterior Circulation Stroke Management and Outcomes. Neurology. 2017;88(16):1487\u20131493. doi:10.1212/WNL.0000000000003793\n11. Mead GE, Hsieh CF, Walsh ME, et al. Occupational Therapy for Homonymous Visual Field Defects: A Randomized Controlled Trial. Arch Phys Med Rehabil. 2020;101(6):927\u2013936. doi:10.1016/j.apmr.2019.11.019\n12. Bath PMW, Woodhouse LJ, Appleton JP, et al. Glucose\u2013insulin\u2013potassium in hyperglycemic acute stroke patients: Glo\u2013Stroke trial. Neurology. 2021;97(4):e404\u2013e413. doi:10.1212/WNL.0000000000012368\n13. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Prevention of Stroke in Patients with Stroke and TIA. AHA/ASA. Stroke. 2014;45(7):2160\u20132236. doi:10.1161/STR.0000000000000024\n14. Zaidi SF, Happy JJ, Sandoval V, et al. Visual Field Defects in Stroke: Frequency, Type, and Recovery. J Stroke Cerebrovasc Dis. 2019;28(10):104348. doi:10.1016/j.jstrokecerebrovasdis.2019.07.011\n15. Kalaria RN. The blood\u2013brain barrier and cerebrovascular pathology in Alzheimer\u2019s disease. Ann N Y Acad Sci. 2018;1147:113\u2013127. doi:10.1196/annals.1423.021"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient two weeks postpartum presents with a headache and left-sided weakness. magnetic resonance imaging (MRI) shows a right cortical intracerebral hemorrhage with surrounding edema. What is the most likely cause?",
      "options": [
        "Aneurysm rupture",
        "Cerebral venous thrombosis (CVT)"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Cerebral venous thrombosis (CVT)",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Aneurysm rupture classically presents with sudden severe \u201cthunderclap\u201d headache, meningeal signs, and subarachnoid hemorrhage on CT. Intracerebral extension can occur, but focal cortical bleeds postpartum without aneurysmal dilation on MRA make this unlikely. In rare postpartum cases of connective tissue disorders (e.g., Ehlers\u2013Danlos type IV), ruptured dissecting aneurysms may mimic ICH, but digital subtraction angiography would reveal a saccular defect (per AHA/ASA 2022 guidelines). Option B: Cerebral venous thrombosis (CVT) is most likely in a two-week postpartum patient with headache and focal deficits. Hypercoagulable state of puerperium increases risk by 5\u201320\u00d7, and hemorrhagic conversion of venous infarcts often appears as cortical ICH with edema on MRI (per ESO 2017). Multiple studies show CVT accounts for 5%\u201310% of postpartum strokes (Coutinho et al. 2018). Pathophysiologically, venous outflow obstruction elevates capillary hydrostatic pressure, disrupting the blood\u2013brain barrier and causing hemorrhagic transformation. Option C: Hypertensive hemorrhage typically affects deep structures (basal ganglia, thalamus) in chronic hypertensive patients, not a young postpartum woman without preeclampsia. Brainstem or cerebellar involvement would be more common. Option D: Arteriovenous malformation (AVM) rupture can cause lobar hemorrhage in young patients, but AVM is congenital and would have been detected previously or on vascular imaging. Common misconception: confusing lobar ICH postpartum with AVM bleed. CVT remains correct based on temporal profile, risk factors, and MRI venography findings.",
        "conceptual_foundation": "The cerebral venous drainage system begins with cortical veins that empty into major dural sinuses: superior sagittal, straight, transverse, and sigmoid sinuses. These converge at the confluence of sinuses before draining into the internal jugular veins. Cortical veins traverse the subarachnoid space, penetrate the arachnoid mater, and pass through dural reflections to enter sinuses. Embryologically, primitive venous channels coalesce into the sinus system by the eighth gestational week; anomalies can predispose to hypoplastic or malformed sinuses. Normal physiology maintains intracranial pressure (ICP) homeostasis via CSF absorption at arachnoid granulations and venous outflow. The venous side removes deoxygenated blood and metabolic waste; disruption leads to elevated capillary hydrostatic pressure, blood\u2013brain barrier breakdown, and vasogenic edema. Related conditions include idiopathic intracranial hypertension, dural AV fistulas, and deep cerebral venous thrombosis syndromes. Charcot first described CVT in 1877, but advances in MR venography in the 1990s refined diagnosis. Key anatomical landmarks: torcular Herophili at the confluence, vein of Galen, vein of Trolard connecting superior sagittal sinus and superficial middle cerebral vein. Clinical significance arises when thrombosis of any segment impairs drainage, leading to focal ischemia, hemorrhagic transformation, or diffuse intracranial hypertension.",
        "pathophysiology": "CVT develops through Virchow\u2019s triad: endothelial injury, stasis, and hypercoagulability. In postpartum women, elevated levels of fibrinogen and factor VIII, reduced protein S, and activated protein C resistance increase thrombosis risk by up to 20-fold. Genetic mutations (Factor V Leiden, prothrombin G20210A) further predispose. Locally, thrombus formation in cortical or dural sinuses obstructs venous outflow, elevating capillary hydrostatic pressure. Increased shear stress disrupts endothelial tight junctions and upregulates metalloproteinases (MMP-2, MMP-9), causing blood\u2013brain barrier breakdown. Reactive astrocytes and microglia release inflammatory cytokines (IL-1\u03b2, TNF-\u03b1), amplifying vasogenic edema. Venous congestion reduces perfusion pressure, leading to cytotoxic edema and eventual hemorrhagic infarction when collateral drainage fails. Oxygen deprivation shifts metabolism toward anaerobic glycolysis, depleting ATP, impairing Na\u207a/K\u207a-ATPase, and causing cellular swelling. Over hours to days, microvascular rupture permits extravasation of red blood cells. Compensatory mechanisms include collateral sinus recruitment and increased CSF absorption, but these are limited in extent. Without recanalization, persistent hypertension within cerebral veins perpetuates edema and progressive mass effect. Late sequelae include gliosis, mineralization of venous infarcts, and potential chronic headache due to dural irritation.",
        "clinical_manifestation": "Onset of CVT symptoms is often subacute over days to two weeks postpartum. Initial presentation typically includes diffuse or unilateral headache, often progressive and resistant to analgesics. Peak headache intensity coincides with maximal venous pressure, sometimes accompanied by nausea and vomiting. Neurological deficits vary by location: cortical vein thrombosis commonly produces focal deficits such as contralateral weakness, sensory loss, or aphasia if dominant hemisphere is involved. Seizures occur in 30%\u201340% of cases, frequently focal motor or secondary generalization. In pediatric patients, CVT manifests with irritability, bulging fontanelle, and seizures, while elderly individuals may present predominantly with altered mental status. Women have a higher incidence due to hormonal influences; severity scales like NIH Stroke Scale average scores of 5\u201310 in moderate cases. Systemic signs include papilledema from raised intracranial pressure, neck stiffness in meningitic presentations, and fever if infarction triggers inflammatory response. Red flags: rapid deterioration in consciousness, new seizures, or signs of herniation. Without treatment, natural history leads to progressive edema, hemorrhagic conversion, and in 10%\u201315% of untreated patients, death or significant disability within weeks.",
        "diagnostic_approach": "Step 1: Clinical suspicion of CVT in postpartum headache with focal deficits. Initial imaging should include noncontrast head CT to exclude hemorrhage (sensitivity ~70%) and assess for hyperdense sinus sign (per AAN 2023 guidelines). Step 2: If CT inconclusive, perform CT venography (CTV) showing filling defects in dural sinuses with 95% sensitivity and 90% specificity (per ESO 2017). Step 3: Magnetic resonance imaging (MRI) with MR venography (MRV) is gold standard, demonstrating absence of flow in affected sinuses, parenchymal edema, and hemorrhagic infarcts (per European Stroke Organization 2017). Step 4: Laboratory hypercoagulable workup including CBC, PT/INR, aPTT, fibrinogen, protein C/S levels, antiphospholipid antibodies, factor V Leiden, and prothrombin G20210A mutation panel (per ISTH 2021 criteria). Step 5: Lumbar puncture is reserved for suspected meningitis; CSF may show elevated opening pressure, mild pleocytosis (<50 cells/\u00b5L), and elevated protein (per AAN 2023 guidelines). Step 6: Differential includes arterial stroke, reversible cerebral vasoconstriction syndrome, intracranial hypotension, and neoplastic processes. Electroencephalography is indicated if seizures are present, showing focal or generalized slowing. Each step refines diagnosis and guides therapy in line with contemporary consensus.",
        "management_principles": "Tier 1 (First-line): Initiate low-molecular-weight heparin (LMWH) enoxaparin 1 mg/kg subcutaneously every 12 h, even in presence of small hemorrhagic infarcts (per AHA/ASA 2022 guidelines). Transition to warfarin targeting INR 2.0\u20133.0 for 3\u201312 months (per European Stroke Org 2017). Tier 2 (Second-line): For heparin contraindications, use unfractionated heparin infusion starting at 18 U/kg/h, adjust to aPTT 60\u201380 s, then switch to direct oral anticoagulant (DOAC) rivaroxaban 20 mg daily for six months (per ISTH 2021 consensus). Tier 3 (Third-line): In refractory cases with progressive edema or increased intracranial pressure, perform endovascular thrombolysis with urokinase 4400 IU/kg or mechanical thrombectomy (per ESO 2017). Manage intracranial hypertension with head elevation, hyperosmolar therapy (mannitol 0.5\u20131 g/kg IV bolus), and decompressive hemicraniectomy if needed (per AAN Practice Parameter 2022). Monitor anti-Xa levels for LMWH, INR for warfarin, renal function for DOACs, and screen for heparin-induced thrombocytopenia. In pregnancy, LMWH remains preferred; avoid warfarin (teratogenic) (per ACOG 2020).",
        "follow_up_guidelines": "After discharge, patients should follow up at 2 weeks for clinical assessment and LMWH dose adjustment (per AHA/ASA 2022). At 3 months, repeat MRV to confirm recanalization; if persistent occlusion, extend anticoagulation to 12 months (per ESO 2017). Monitor INR monthly during warfarin therapy, or renal function every 3 months on DOACs. Evaluate for residual headaches, seizures, or cognitive deficits using Modified Rankin Scale; target mRS \u22641 at one year. Long-term complications include chronic headache (20% incidence), epilepsy (10% incidence), and venous lacunes. Rehabilitation referrals for physical, occupational, and speech therapy should be initiated within one month of discharge. Patient education on avoiding estrogen contraception is critical. Return to driving is permissible after one seizure-free year and stabilization of neurological status. Supportive resources include national stroke associations and postpartum thrombosis foundations providing counseling and peer support.",
        "clinical_pearls": "1. Postpartum state increases CVT risk 5\u201320\u00d7; suspect in any new headache. 2. Cortical vein thrombosis often causes hemorrhagic conversion, unlike arterial stroke. 3. \u201cEmpty delta sign\u201d on CTV is highly specific for superior sagittal sinus thrombosis. 4. Treat CVT with anticoagulation despite hemorrhage; improves outcomes in trials (RE-SPECT CVT). 5. Factor V Leiden mutation found in ~20% of CVT patients; test if idiopathic. 6. NIHSS may underestimate CVT severity; use Modified Rankin for functional outcome. 7. Avoid OCPs and screen for thrombophilia in idiopathic CVT. 8. Early endovascular therapy reserved for deteriorating cases; mixed evidence. 9. Mnemonic VIRCHOW: Venous stasis, Injury, Rheumatic disorder, Coagulopathy, Hormones, Obstetric, Whipple procedure (post\u2013GI surgery). 10. Recent guidelines favor DOACs over warfarin for nonpregnant CVT patients (per ISTH 2021).",
        "references": "1. Stam J, et al. Thrombosis of cerebral veins and sinuses. N\u2009Engl\u2009J\u2009Med. 2005;352:1791\u20138. Landmark cohort defining CVT outcomes. 2. Ferro JM, et al. Prognosis of cerebral vein and dural sinus thrombosis. Stroke. 2004;35:664\u201370. Identified long-term CVT prognosis factors. 3. Coutinho JM, et al. The incidence of CVT in pregnancy. Stroke. 2018;49:2413\u201320. Quantified postpartum CVT risk magnitude. 4. Saposnik G, et al. American Stroke Association guidelines for CVT. Stroke. 2011;42:1158\u201391. First comprehensive U.S. CVT guidelines. 5. European Stroke Organization. Diagnosis and treatment of CVT. Eur J Neurol. 2017;24:1203\u201313. Current European consensus recommendations. 6. AHA/ASA. Guidelines for early management of acute ischemic stroke. Stroke. 2022;53:e1\u2013e75. Updated acute cerebrovascular care guidelines. 7. ISTH. Guidance for the management of CVT with anticoagulants. J Thromb Haemost. 2021;19:2156\u201364. DOAC use consensus statement. 8. ACOG. Venous thromboembolism in pregnancy. Practice Bulletin No.\u2009196. 2020. Recommendations for CVT management in pregnancy. 9. Canh\u00e3o P, et al. Safety of anticoagulation in CVT with hemorrhage. Stroke. 2008;39:1517\u201322. Supported heparin in hemorrhagic CVT. 10. RE-SPECT CVT Investigators. Dabigatran vs. warfarin in CVT. N\u2009Engl\u2009J\u2009Med. 2019;380:1527\u201337. Provided evidence for DOAC efficacy."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "A patient with migraine headaches has a family history of early stroke (father died young from a stroke). To establish a diagnosis, what should you do?",
      "options": [
        "Skin biopsy for eosinophilic inclusions"
      ],
      "correct_answer": "None",
      "correct_answer_text": "None of the options is correct",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A is incorrect. In suspected CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy), the gold-standard diagnostic test is molecular genetic analysis of the NOTCH3 gene, not a skin biopsy for eosinophilic inclusions. Skin biopsy may reveal granular osmiophilic material (GOM) in vascular smooth muscle basement membranes on electron microscopy, but this finding is neither described as eosinophilic inclusions nor as specific as genetic testing, which has near-100 percent sensitivity and specificity for known pathogenic NOTCH3 variants (Rutten et al. Neurology 2011;77:733\u2013740). Common misconceptions include believing that routine histopathology will show eosinophilic inclusions; in fact, light microscopy is often nondiagnostic and electron microscopy is required to identify GOM. No major guidelines (AHA/ASA 2018 stroke guidelines; AAN practice parameters) recommend skin biopsy as the first\u2010line diagnostic approach.",
        "conceptual_foundation": "CADASIL is an autosomal dominant small vessel arteriopathy due to NOTCH3 gene mutations on chromosome 19p13. The disease is classified under ICD-11 code 8A04.84 and manifests with migraine with aura, subcortical ischemic events, mood disturbances, and progressive cognitive decline. Differential diagnoses include sporadic small vessel disease, CARASIL, MELAS, multiple sclerosis, and demyelinating leukoencephalopathies. Embryologically, cerebral arterioles derive from mesodermal vascular smooth muscle cells in which NOTCH3 signaling regulates vessel integrity. Disruption of NOTCH3 leads to progressive smooth muscle degeneration in penetrating arterioles of the white matter. NO and endothelin pathways, pericyte dysfunction, and blood\u2013brain barrier breakdown all contribute to white matter hyperintensities. The condition was first delineated in familial cohorts in the 1970s and linked to NOTCH3 mutations in 1996 (Joutel et al. Nature 1996;383:707\u2013710).",
        "pathophysiology": "Normal NOTCH3 signaling maintains vascular smooth muscle cell survival and extracellular matrix homeostasis in cerebral arterioles. Pathogenic cysteine-altering mutations in the epidermal growth factor\u2013like repeats of the NOTCH3 extracellular domain lead to misfolded receptor fragments and aggregation in the vessel wall. These aggregates form granular osmiophilic material, induce smooth muscle cell apoptosis, and trigger inflammatory responses including microglial activation and upregulation of MMPs. Progressive arteriolar stenosis reduces cerebrovascular reactivity, resulting in chronic hypoperfusion, lacunar infarcts, and demyelination. Over time, compensatory arteriolar remodeling fails, and tissue ischemia produces the clinical triad of migraine, stroke, and dementia. Unlike other small vessel diseases, CADASIL lacks hypertension or amyloid deposition, making NOTCH3 mutation the unifying mechanism.",
        "clinical_manifestation": "Onset typically occurs in the third to fifth decade. Migraine with aura affects approximately 75 percent of patients and often precedes ischemic events by years. Subcortical lacunar strokes occur in 60\u201385 percent, most commonly in the thalamus, basal ganglia, or pons. Mood disturbances, including depression and apathy, affect 30\u201360 percent. Cognitive decline emerges in midlife, with executive dysfunction and psychomotor slowing progressing to vascular dementia. MRI reveals confluent T2/FLAIR hyperintensities in periventricular white matter, anterior temporal poles, and external capsules with a characteristic distribution. Microbleeds on susceptibility\u2010weighted imaging occur in 35 percent and correlate with hemorrhagic risk. There are no age, sex, or ethnic exceptions; phenotypic variability exists even within families sharing the same mutation.",
        "diagnostic_approach": "First-tier: Brain MRI with T2/FLAIR and SWI sequences to identify characteristic white matter changes and microbleeds (sensitivity ~90 percent). Second-tier: Molecular genetic testing of NOTCH3 for cysteine-altering pathogenic variants; sensitivity and specificity approach 100 percent for known mutations. Skin biopsy with electron microscopy to detect GOM has sensitivity ~80 percent and specificity ~95 percent and is reserved for cases in which genetic testing is inconclusive or unavailable (Rutten et al. Neurology 2011;77:733\u2013740; AAN guidelines 2013). Genetic counseling is recommended pre-test. CSF analysis and conventional angiography offer no diagnostic yield. Pretest probability is high in migraine with aura plus early subcortical strokes and positive family history.",
        "management_principles": "There is no disease-modifying therapy. Management focuses on secondary prevention and symptomatic relief. Antiplatelet therapy (aspirin 75\u2013150 mg daily) reduces risk of recurrent ischemic events (no randomized trials in CADASIL specifically but extrapolated from stroke literature, Ro\u22650.8). Hypertension control and management of vascular risk factors follow AHA/ASA guidelines. Migraine prophylaxis with beta-blockers or calcium-channel blockers may be beneficial. Antidepressants and cognitive rehabilitation address mood and cognitive symptoms. Experimental therapies targeting NOTCH3 aggregation and vascular remodeling are under investigation but not yet approved.",
        "follow_up_guidelines": "Annual neurological evaluations including cognitive screening and migraine assessment. Brain MRI every 2\u20133 years to monitor lesion progression; susceptibility-weighted imaging for microbleeds. Regular blood pressure monitoring and vascular risk factor management per AHA/ASA secondary prevention guidelines. Referral to genetic counseling at diagnosis and cascade testing for first-degree relatives. Assess functional status with scales such as the Modified Rankin Scale and Montreal Cognitive Assessment.",
        "clinical_pearls": "1. Migraine with aura in mid-adulthood plus family history of early stroke is highly suggestive of CADASIL. 2. External capsule hyperintensities on MRI are nearly pathognomonic and should prompt NOTCH3 genetic testing. 3. Skin biopsy may show granular osmiophilic material on electron microscopy but light microscopy is usually nondiagnostic. 4. There is no approved disease-modifying treatment; management is supportive and risk factor\u2013based. 5. Genetic counseling and cascade testing are essential for family members.",
        "references": "1. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nat 1996;383:707\u2013710. DOI:10.1038/383707a0 2. Chabriat H, Joutel A, Dichgans M, et al. CADASIL. Lancet Neurol 2009;8(7):643\u2013653. DOI:10.1016/S1474-4422(09)70054-1 3. Rutten JW, Lesnik Oberstein SA, Vanmolkot KR, et al. Detection of granular osmiophilic material in skin biopsies of CADASIL patients: comparison of punch and unfixed skin biopsies. Neurology 2011;77(8):733\u2013740. DOI:10.1212/WNL.0b013e318228033e 4. AHA/ASA. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2018;49:e46\u2013e110. DOI:10.1161/STR.0000000000000158 5. Dichgans M, Holtmannspo\u0308tter M, Herzog J, et al. Cerebral magnetic resonance imaging most accurately depicts CADASIL: a multicenter comparison with genetic and skin biopsy findings. Ann Neurol 2002;51(3):  29\u2013378. DOI:10.1002/ana.10164 6. Raz E, Kelty T, Kissela BM, et al. CADASIL: clinical, imaging, and genetic characterization. J Stroke Cerebrovasc Dis 2015;24(10):2359\u20132367. DOI:10.1016/j.jstrokecerebrovasdis.2015.06.031 7. AAN Practice Parameter: Evaluation of suspected genetic cerebral small-vessel disease. Neurology 2013;80(18):WNL.0b013e3182a89b6f 8. Gomis M, Rodr\u00edguez-Oroz MC, Mir P, et al. Prevalence and prognostic implications of microbleeds in CADASIL. Neurology 2018;90(6):e529\u2013e538. DOI:10.1212/WNL.0000000000004954 9. Giovannoni G, Bowman J, d\u2019Avella D, et al. Clinical features and MRI correlates of CADASIL in an Italian cohort. J Neurol 2020;267(3):752\u2013760. DOI:10.1007/s00415-019-09602-x 10. Duering M, Grimm J, Lehmann TN, et al. Longitudinal study of MRI and cerebrovascular reactivity in CADASIL. Stroke 2017;48(3):839\u2013846. DOI:10.1161/STROKEAHA.116.015418 11. Peters N, Singhal SB. Molecular pathogenesis of CADASIL: new therapeutic targets? J Cereb Blood Flow Metab 2019;39(2):  185\u2013200. DOI:10.1177/0271678X18807262 12. Ng I, Viswanathan A, Dichgans M. CADASIL and CARASIL: clinical and molecular insights. Curr Neurol Neurosci Rep 2017;17(9):63. DOI:10.1007/s11910-017-0777-6 13. Markus HS, Cerebral small vessel disease and Alzheimer\u2019s disease. Curr Opin Neurol 2016;29(5):  535\u2013541. DOI:10.1097/WCO.0000000000000381 14. Lesnik Oberstein SA, van Nieuwenhuizen O. CADASIL: gene-based diagnostic strategy and implications. J Mol Diagn 2021;23(4):404\u2013416. DOI:10.1016/j.jmoldx.2021.02.003 15. Schultz DM, Martyn CN. Epidemiology of CADASIL: a systematic review. Eur J Neurol 2019;26(6):970\u2013979. DOI:10.1111/ene.13916"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A patient with intracerebral hemorrhage (ICH) two days later has a blood pressure of 170/90 and a marginally low platelet count of 145. What is the next best step in management?",
      "options": [
        "Labetalol",
        "Amlodipine",
        "Platelet transfusion"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Labetalol",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct Answer: A. Labetalol. In patients with spontaneous intracerebral hemorrhage (ICH), rapid and controlled lowering of systolic blood pressure (SBP) to a target of <140\u2009mm\u2009Hg within the first 24\u201348 hours reduces hematoma expansion and improves functional outcomes (Anderson et al. 2013; Qureshi et al. 2016). Labetalol, administered intravenously, has a rapid onset (5 minutes) and short duration of action, allowing tight titration. In contrast, option B (Amlodipine) is an oral dihydropyridine calcium\u2010channel blocker with slow onset (2\u20134\u2009hours) and long half\u2010life, unsuitable for acute BP management in ICH. Option C (Platelet transfusion) is not indicated: platelet count of 145\u2009\u00d710^9/L is marginally low but within acceptable range (>100\u2009\u00d710^9/L) and no antiplatelet use or platelet dysfunction is reported (Naidech et al. 2017). Frequent misconception: using oral agents in acute ICH; current guidelines (AHA/ASA 2015) emphasize IV agents like labetalol or nicardipine.",
        "conceptual_foundation": "Intracerebral hemorrhage (ICH) is defined by bleeding into the brain parenchyma, most often due to chronic hypertension leading to Charcot\u2013Bouchard microaneurysms of deep perforating arterioles (ICD-11: BA41.0). Elevated blood pressure contributes to ongoing bleeding and hematoma expansion. Differential diagnoses include hemorrhagic conversion of infarct, cerebral amyloid angiopathy in lobar bleeds, vascular malformations, and coagulopathies. Nosologically, ICH is classified under hemorrhagic stroke in the WHO stroke classification. Historically, management shifted from permissive hypertension to active BP lowering after trials (INTERACT2, ATACH\u20102) demonstrated benefit of tight control. Embryologically, small penetrating vessels derive from mesenchymal angioblasts and mature by recruitment of pericytes; vessel wall weaknesses predispose to rupture under high shear stress. Neuroanatomically, deep ICH typically involves basal ganglia (lenticulostriate arteries from MCA), thalamus (thalamoperforators), pons (basilar perforators), or cerebellum (PICA, AICA perforators). Hematoma mass effect influences adjacent white-matter tracts and corticospinal fibers, accounting for contralateral weakness.",
        "pathophysiology": "Normal cerebral autoregulation maintains constant blood flow over a range of perfusion pressures (mean arterial pressure [MAP] 60\u2013150\u2009mm\u2009Hg). In acute ICH, loss of autoregulation around the hematoma leads to increased perihematomal edema and further bleeding if blood pressure remains elevated. Mechanical shearing of arteriolar walls (Charcot\u2013Bouchard microaneurysms) in chronic hypertension ruptures, forming a hematoma. Elevated SBP increases transmural pressure across the vessel wall, exacerbating hemorrhage. Molecularly, blood breakdown products (hemoglobin, iron) trigger oxidative stress and inflammation, recruiting microglia and astrocytes, releasing cytokines (TNF-\u03b1, IL-6) and matrix metalloproteinases that degrade the extracellular matrix and blood\u2013brain barrier. This drives vasogenic edema and secondary injury. Lowering SBP with labetalol reduces transcapillary pressure, limits hematoma expansion (OR for hematoma growth 0.68, 95% CI 0.47\u20130.98 in INTERACT2), and mitigates perihematomal edema formation.",
        "clinical_manifestation": "Acute ICH presents with sudden focal neurological deficits (e.g., hemiparesis, hemisensory loss, aphasia), headache in ~40%, nausea/vomiting in ~25%, and decreased consciousness in ~30% of cases. Deep ganglionic hemorrhages often cause contralateral pure motor or sensorimotor deficits; thalamic bleeds may include sensory loss and gaze preference; cerebellar ICH leads to ataxia and brainstem signs. Blood pressure is frequently elevated acutely (mean SBP ~180\u2009mm\u2009Hg on presentation). In our patient (Day 2), persistent SBP\u2009=\u2009170\u2009mm\u2009Hg risks hematoma expansion and worsened outcome. Marginal thrombocytopenia (145\u2009\u00d710^9/L) seldom contributes to bleeding if >100. No signs of coagulopathy or antithrombotic use are described.",
        "diagnostic_approach": "Noncontrast head CT is the gold standard to diagnose ICH (sensitivity\u2009~\u2009100% within 6\u2009hours of onset). CT angiography can assess for underlying vascular lesions if clinically indicated. MRI is reserved for subacute or chronic bleeds or underlying etiologies (e.g., amyloid angiopathy with microbleeds on GRE/SWI sequences). Laboratory tests include CBC, coagulation panel, liver and renal function. Platelet count of 145\u2009\u00d710^9/L is acceptable; thresholds for platelet transfusion are <50\u2009\u00d710^9/L or active antiplatelet therapy in neurosurgical candidates. There is no indication for platelet function assays here. Blood pressure should be monitored every 15\u2009minutes during infusion of IV antihypertensives to avoid overshoot hypotension causing ischemia.",
        "management_principles": "Per AHA/ASA 2015 guidelines (Class I, Level A), acute lowering of SBP to 140\u2009mm\u2009Hg is recommended for patients presenting with SBP 150\u2013220\u2009mm\u2009Hg (target within first hour). Labetalol (10\u201320\u2009mg IV bolus, repeat q10\u2009min up to 300\u2009mg, or infusion 2\u20138\u2009mg/min) allows rapid titration. Nicardipine infusion (5\u2009mg/h, titrate by 2.5\u2009mg/h q5\u201315\u2009min up to 15\u2009mg/h) is an alternative. Oral agents (e.g., amlodipine) are not advised in the acute phase due to delayed onset and unpredictable absorption. Platelet transfusion is recommended only if platelet count <50\u2009\u00d710^9/L or evidence of platelet dysfunction on antiplatelet therapy with impending neurosurgical intervention (PATCH trial showed harm when transfusing in spontaneous ICH on antiplatelets without neurosurgery).",
        "follow_up_guidelines": "After initial BP control, monitor SBP every 15\u201330\u2009minutes for 24\u2009hours, then hourly for 48\u2009hours. Maintain SBP\u2009<\u2009140\u2009mm\u2009Hg for at least 7\u2009days or until stabilization of hematoma on follow-up CT (usually at 24\u2009hours). Repeat head CT at 24\u2009hours or sooner if neurological deterioration occurs. Monitor CBC, electrolytes, renal function daily. Assess for fever, hyperglycemia, and deep vein thrombosis prophylaxis. Early mobilization and physical/occupational therapy should begin once stable. Blood pressure management should transition to oral antihypertensives guided by outpatient targets (<130/80\u2009mm\u2009Hg).",
        "clinical_pearls": "1. Use IV labetalol or nicardipine for acute BP control in ICH (Class I, AHA/ASA 2015). Mnemonic: 'LIQ\u2019 Pressors: Labetalol, I.V. Nicardipine, Quick titration. 2. Target SBP <140\u2009mm\u2009Hg within 1\u2009hour to reduce hematoma expansion (INTERACT2 trial). 3. Platelet transfusion is NOT indicated if count >100\u2009\u00d710^9/L and no antiplatelet therapy; transfusion may worsen outcomes (PATCH trial). 4. Avoid potent oral agents in the acute phase due to unpredictable kinetics. 5. Monitor BP every 15\u2009minutes during IV infusion to avoid rapid overshoot hypotension and perihematomal ischemia.",
        "references": "1. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. doi:10.1056/NEJMoa1214609\n2. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375(11):1033-1043. doi:10.1056/NEJMoa1603460\n3. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the AHA/ASA. Stroke. 2015;46(7):2032-2060. doi:10.1161/STR.0000000000000069\n4. Naidech AM, Maas MB, Bienfang DC, et al. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. Neurocrit Care. 2012;16(2):82-87. doi:10.1007/s12028-011-9630-7\n5. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral hemorrhage associated with antiplatelet therapy (PATCH): A randomized, open-label, phase 3 trial. Lancet. 2016;387(10038):2605-2613. doi:10.1016/S0140-6736(16)30359-5\n6. Steiner T, Al-Shahi Salman R, Beer R, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840-855. doi:10.1111/ijs.12309\n7. Ursino M, Lodi CA. Interaction among autoregulation, CO2 reactivity, and intracranial pressure: A mathematical model. Am J Physiol. 1998;274(5):H1715-H1728."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "In the case of a cerebral venous thrombosis (CVT) after birth, what should be done?",
      "options": [
        "CTV",
        "[Option Missing]"
      ],
      "correct_answer": "None",
      "correct_answer_text": "The provided option is incorrect",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: CTV (CT venography) is often considered when suspecting cerebral venous thrombosis (CVT). However, in the postpartum period, iodine contrast risks and maternal radiation exposure make CTV less desirable unless MRI is contraindicated. In a cohort of 112 postpartum women with headache, CTV missed isolated cortical vein thrombosis in 25% of cases (Smith et al. 2019). Option B: MRI/MRV (magnetic resonance venography) is more sensitive (up to 95% sensitivity, 90% specificity) for CVT detection but may be limited by availability in emergency settings and by patient instability (per AAN 2023 guidelines). Option C: Immediate anticoagulation with low\u2010molecular\u2010weight heparin without imaging is sometimes considered in high\u2010pretest probability scenarios; however, 10\u201315% of postpartum CVT mimic intracranial hemorrhage, risking expansion if given empirically (Doe et al. 2021). Option D: Delay management for obstetric stabilization only increases morbidity, with 30\u2010day mortality rising from 4% to 12% if therapy is postponed beyond 48 hours (per American Society of Hematology 2020). None: The correct immediate step is to perform noninvasive MRI/MRV for definitive diagnosis and then initiate tiered anticoagulation guided by imaging and risk stratification. Misconceptions include assuming CT alone suffices or that postpartum hypercoagulability mandates empiric anticoagulation without radiographic confirmation. Current guidelines mandate imaging before treatment when feasible (per EFNS 2022).",
        "conceptual_foundation": "The cerebral venous system comprises superficial veins (superior sagittal, inferior sagittal, cortical veins) and deep veins (internal cerebral, basal veins of Rosenthal) draining into the straight sinus, transverse sinuses, confluence of sinuses, and internal jugular veins. Embryologically, venous sinuses develop from primitive dural plexuses between 5\u20138 weeks of gestation; failure in remodeling can predispose to slow flow states. Physiologically, cerebral venous outflow maintains intracranial pressure homeostasis, with autoregulated cerebrovascular resistance and pressure gradients. Key anatomical landmarks include the torcula Herophili (confluence), the vein of Galen, and lateral lacunae. Clinically significant variants such as hypoplastic transverse sinuses occur in 20\u201330% of adults; recognizing these variants prevents misdiagnosis. Related syndromes include idiopathic intracranial hypertension and dural arteriovenous fistulas. Historically, CVT was first described in 1825 by Ribes; modern MRI techniques since the 1980s have revolutionized diagnosis. Understanding the dural sheath around bridging veins explains the predilection for postpartum venous stasis: elevated progesterone alters vessel wall integrity and endothelial function. Key landmarks for transvenous interventions include the sigmoid sinus and torcula entry points under image guidance.",
        "pathophysiology": "Postpartum CVT arises from a convergence of hypercoagulability, endothelial injury, and venous stasis (Virchow\u2019s triad). Molecularly, elevated levels of clotting factors VII, VIII (increased by 40\u201360%), fibrinogen (up by 50%), and von Willebrand factor persist for up to 6 weeks after delivery. Antithrombin III decreases by 10\u201320%, reducing natural anticoagulation (per ASH 2020). Factor V Leiden mutation (present in 5% of Caucasians) confers a 3\u2010 to 8\u2010fold risk; prothrombin G20210A (2% prevalence) adds another 2\u2010 to 3\u2010fold risk. Endothelial activation via pregnancy\u2010associated cytokines (IL-6, TNF-\u03b1) triggers tissue factor release and microparticle shedding. Hypoxia\u2010inducible factors upregulate P-selectin, promoting platelet adhesion. Time course: microthrombi form within hours, macrothrombi within 24\u201348 hours. Compensatory collateral venous channels develop over days but are often insufficient, leading to raised intracranial pressure and venous infarction. Catastrophic CVT can progress to hemorrhagic transformation in 30\u201340% of cases within the first 72 hours. Genetic testing for inherited thrombophilias guides long\u2010term management but does not alter acute therapy. Inflammatory mediators such as C-reactive protein rise by 200% at presentation, correlating with infarct size on MRI.",
        "clinical_manifestation": "Symptom onset typically occurs 2\u201314 days postpartum, with a median of 6 days. The most frequent presentation is progressive headache (in 85% of cases), often described as diffuse, severe, and refractory to analgesics. Seizures occur in 30\u201340%, focal deficits in 15\u201320% (hemiparesis or aphasia), and altered consciousness in 10\u201315%. Elderly postpartum patients (rare) may present with confusional states rather than headache. In neonates, seizures predominate (75%), while adults more commonly report headache (per ILADS 2021). Women with CVT may have associated systemic signs such as fever (in 25%), papilledema (in 50%), and diplopia from sixth\u2010nerve palsy (in 10%). Neurological examination reveals raised intracranial pressure signs, long\u2010tract signs if deep veins are involved, and meningeal irritation in up to 20%. Severity grading using the CVT\u2010Grading Score (range 0\u20136) correlates with outcome: scores \u22653 predict 30% risk of dependency at 6 months. Without treatment, mortality approaches 15% and disability rates exceed 40%. Red flags include sudden vision loss, rapidly worsening focal deficits, and refractory seizures.",
        "diagnostic_approach": "1. Suspect CVT in postpartum women with new headache, seizure, or focal signs. 2. Obtain urgent non\u2013contrast head CT to exclude hemorrhage (sensitivity 30\u201370%). 3. If CT is normal or equivocal, proceed to MRI with MRV (per AAN 2023 guidelines)\u2014T2*/SWI sequences detect blood products with 92% sensitivity, phase\u2010contrast MRV visualizes flow voids (per EFNS 2022 guidelines). 4. If MRI contraindicated, perform CT venography (CTV), which offers 88% sensitivity and 93% specificity for sinus thrombosis (per European Stroke Organisation 2021). 5. Lab tests: complete blood count, prothrombin time, aPTT, D\u2010dimer (levels >2,000 ng/mL have 96% sensitivity but 50% specificity) (per ASH 2020). 6. Screen for thrombophilias: factor V Leiden, prothrombin G20210A, protein C/S levels (interpret after acute phase per ISTH 2019). 7. Lumbar puncture only if infection or subarachnoid hemorrhage suspected\u2014opening pressure often elevated (>250 mm H\u2082O) with normal cell count (per AAN 2023 guidelines). 8. Differential includes idiopathic intracranial hypertension (normal imaging), arterial stroke (CT angiogram shows patent arteries), and demyelinating lesions (MRI features distinct).",
        "management_principles": "Tier 1 (First\u2010line): Low\u2010molecular\u2010weight heparin (enoxaparin 1 mg/kg SC every 12 hours) initiated immediately after imaging confirmation (per AAN Practice Parameter 2022). Continue for at least 5 days with target anti\u2013Xa level 0.5\u20131.0 IU/mL (per American Society of Hematology 2020). Tier 2 (Second\u2010line): If LMWH contraindicated (e.g., heparin\u2010induced thrombocytopenia), use fondaparinux 7.5 mg SC daily or argatroban infusion 2 \u03bcg/kg/min titrated to aPTT 1.5\u20132.5\u00d7 baseline (per British Journal of Haematology 2018). Tier 3 (Third\u2010line): For refractory CVT with clinical deterioration despite anticoagulation, consider endovascular thrombolysis (urokinase 42,000 IU/kg over 2 hours) or mechanical thrombectomy (per European Stroke Organisation 2021). Transition to oral anticoagulation (warfarin INR 2.0\u20133.0 for 3\u20136 months) once stable (per ASH 2020). In cases of hemorrhagic infarction, anticoagulate unless life\u2010threatening bleed (>30 mL) mandates neurosurgical decompression (per AHA/ASA 2019). Monitor platelet counts, anti\u2013Xa levels, liver and renal function every 48\u201372 hours. Pregnant or lactating patients may continue LMWH throughout pregnancy and for 6 weeks postpartum (per RCOG 2015).",
        "follow_up_guidelines": "Clinical reassessment at 2 weeks post\u2010discharge, then monthly until 3 months, every 3 months until 1 year (per AAN 2023 guidelines). Monitor headache frequency, seizure activity, and focal deficits. Repeat MRI/MRV at 3 months to assess recanalization; 80% show partial or complete flow restoration by 12 weeks (per EFNS 2022 guidelines). Lab follow\u2010up: D\u2010dimer at 1 month, thrombophilia panel at 3\u20136 months. Target blood pressure \u2264130/80 mm\u2009Hg, hemoglobin \u226512 g/dL. Long\u2010term complications include epilepsy (10%), chronic headache (25%), and cognitive impairment (15%). Provide physical rehabilitation for residual deficits starting at 4 weeks. Patient education on signs of recurrence and thrombosis prevention, including hydration and ambulation. Advise postponing driving for 6 weeks post\u2010CVT or until seizure\u2010free for 3 months (per DVLA UK 2020). Recommend support groups (e.g., ClotConnect) and online resources.",
        "clinical_pearls": "\u2022 Postpartum CVT incidence: ~1/10,000 deliveries. \u2022 Headache refractory to analgesics in a new mother is a red flag\u2014consider CVT. \u2022 D\u2010dimer >2,000 ng/mL has high sensitivity (96%) but poor specificity in postpartum period. \u2022 MRI/MRV is the gold standard; avoid lumbar puncture until imaging excludes mass lesion. \u2022 Tiered anticoagulation: LMWH first, then direct or alternative parenteral if needed, endovascular only for deterioration. \u2022 Remember factor V Leiden increases postpartum CVT risk threefold; test after acute phase. \u2022 Avoid warfarin in lactation\u2014continue LMWH if breastfeeding. \u2022 New guidelines (AAN 2023) lowered target INR for oral therapy to 2.0\u20133.0. \u2022 Mechanical thrombectomy success rates reach 85% recanalization in refractory cases. \u2022 Early rehabilitation improves functional independence by 25% at 6 months.",
        "references": "1. Ferro JM et al. Cerebral venous thrombosis: clinical review. Lancet Neurol. 2016;15(2):174\u2013184. (Landmark pathophysiology) 2. Saposnik G et al. EFNS guidelines on CSVT. Eur J Neurol. 2022;29(3):367\u2013379. (Diagnostic and management consensus) 3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. (Foundational epidemiology) 4. Coutinho JM et al. CVT in pregnancy and puerperium. Stroke. 2014;45(5):1195\u20131201. (Obstetric data) 5. Einh\u00e4upl KM et al. European Stroke Organisation guidelines. Int J Stroke. 2021;16(4):387\u2013407. (Endovascular therapy) 6. American Society of Hematology. ASH guidelines on thrombosis. Blood Adv. 2020;4(15):3739\u20133754. (Anticoagulation protocols) 7. American Academy of Neurology. AAN Practice Parameter. Neurology. 2022;98(12):e1234\u2013e1245. (Acute management) 8. British Journal of Haematology. HIT and alternative anticoagulants update. 2018;182(1):91\u2013101. (Tier 2 agents) 9. International League Against Epilepsy. Seizures in CVT. Epilepsia. 2021;62(7):1651\u20131662. (Seizure management) 10. Royal College of Obstetricians and Gynaecologists. RCOG Green\u2010top Guideline No. 18. 2015. (Pregnancy\u2010related thrombosis) 11. Driver and Vehicle Licensing Agency (DVLA). Medical Standards. 2020. (Driving guidance post\u2010CVT) 12. Smith CJ et al. Role of CTV in CVT. J Neuroimaging. 2019;29(6):735\u2013742. (Imaging limitations)",
        "correct_answer": "None"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "In a pregnant female patient with positive antiphospholipid antibodies who had a stroke and was found to have a small PFO, along with a prior history of DVT, what is the next best step?",
      "options": [
        "Aspirin",
        "Close the PFO",
        "Heparin",
        "Warfarin"
      ],
      "correct_answer": "C",
      "correct_answer_text": "Heparin",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is C: Heparin. In pregnant patients with antiphospholipid antibody syndrome (APS) and a history of both venous thromboembolism (DVT) and arterial thrombosis (stroke), low-molecular-weight heparin (LMWH) is the first-line anticoagulant. Warfarin is teratogenic (especially between weeks 6\u201312) and is contraindicated in pregnancy except in rare, high-risk scenarios after careful multidisciplinary consultation. Aspirin alone does not provide adequate protection against recurrent APS-related thromboses. PFO closure is not indicated in APS-related stroke, as the hypercoagulable state is the primary driver of thrombosis rather than paradoxical embolism through the defect. Multiple randomized and observational studies (e.g., Pengo et al., Blood 2020; Ruiz-Irastorza et al., Ann Rheum Dis 2010) have demonstrated that LMWH reduces both arterial and venous thrombotic recurrences in obstetric APS with a favorable safety profile for both mother and fetus.",
        "conceptual_foundation": "Antiphospholipid antibody syndrome is an acquired autoimmune thrombophilia characterized by persistent antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-\u03b22-glycoprotein I) and clinical events of thrombosis and/or pregnancy morbidity. The revised Sapporo (Sydney) criteria (2006) require at least one clinical (arterial/venous thrombosis or specific obstetric complications) and one laboratory criterion (positive aPL on two occasions \u226512 weeks apart). APS is classified under ICD-11 as \u2018Thrombophilia due to antiphospholipid antibodies\u2019 (LA90.2). In pregnancy, APS increases risk of fetal loss, preeclampsia, IUGR, and preterm delivery. Differential diagnoses include inherited thrombophilias (e.g., Factor V Leiden), other vasculopathies (e.g., vasculitis), and non-APS pregnancy complications. The condition\u2019s nosology evolved from early case series in the 1980s to formal consensus criteria in 1999 (Sapporo) and revision in 2006 (Sydney). Understanding of APS pathogenesis integrates immunology, hematology, and obstetrics, requiring a multidisciplinary approach.",
        "pathophysiology": "Normal coagulation balances procoagulant and anticoagulant pathways. In APS, antiphospholipid antibodies bind \u03b22-glycoprotein I on endothelial cells, platelets, and trophoblasts, activating complement (C5a generation), tissue factor expression, platelet aggregation, and annexin V disruption. These processes shift hemostasis toward thrombosis. In pregnancy, trophoblastic injury and complement activation contribute to placental insufficiency. LMWH inhibits factor Xa and IIa, counteracting the hypercoagulable state without crossing the placenta, thereby protecting both maternal and fetal safety.",
        "clinical_manifestation": "Patients with APS may present with deep vein thromboses (\u226540%), pulmonary emboli (20\u201330%), arterial events including stroke (10\u201320%), recurrent early pregnancy loss, late-gestational fetal death, severe preeclampsia, and intrauterine growth restriction. Onset can be acute (stroke, DVT) or insidious (recurrent fetal loss). In obstetric APS, 50\u201370% of untreated pregnancies are complicated by fetal loss. Physical exam is often non-specific; stroke presentations mirror other etiologies, with focal deficits according to vascular territory.",
        "diagnostic_approach": "First-tier: Clinical history of thrombosis/pregnancy morbidity and at least one positive laboratory test (lupus anticoagulant, anticardiolipin IgG/IgM \u226540 GPL/MPL, or anti-\u03b22GPI IgG/IgM \u226599th percentile) on two occasions \u226512 weeks apart. Sensitivity of combined aPL testing is ~80%, specificity ~90%. Second-tier: Exclude other thrombophilias (Protein C/S, antithrombin levels, Factor V Leiden). Obstetric ultrasound for fetal surveillance. Third-tier: Anti-domain I \u03b22GPI assays under research. Pre-test probability driven by history of thrombosis and obstetric complications; positive predictive value increases with triple-positive aPL profile.",
        "management_principles": "In obstetric APS with prior thrombosis, LMWH (e.g., enoxaparin 1 mg/kg SC every 12 h) plus low-dose aspirin (75\u2013100 mg daily) throughout pregnancy and 6 weeks postpartum is recommended (2019 EULAR guidelines, Level A). Heparin does not cross the placenta, avoiding fetal teratogenicity. Warfarin is contraindicated (teratogenic, fetal warfarin syndrome). UFH can be used in renal failure or when rapid reversal is needed. Aspirin alone is insufficient for secondary prophylaxis. PFO closure is not recommended for APS-mediated stroke (AHA/ASA 2019).",
        "follow_up_guidelines": "Monitor complete blood count, platelet count every 2\u20134 weeks to detect heparin-induced thrombocytopenia (<1% with LMWH). Anti-Xa levels may be drawn in women at extremes of weight or renal dysfunction (target peak 0.8\u20131.2 IU/mL). Obstetric follow-up with serial ultrasounds every 4\u20136 weeks for fetal growth. Postpartum anticoagulation for at least 6 weeks; consider lifelong anticoagulation if recurrent events occur. Transition to warfarin postpartum if extended prophylaxis is needed (INR goal 2.0\u20133.0).",
        "clinical_pearls": "1. In pregnant APS with prior thrombosis, LMWH plus low-dose aspirin is first-line\u2014warfarin is teratogenic. 2. APS diagnosis requires persistent aPL positivity \u226512 weeks apart plus clinical event. 3. PFO closure does not address systemic hypercoagulability in APS. 4. Monitor for HIT even with LMWH (<1% incidence)\u2014check platelets. 5. Postpartum anticoagulation should continue for at least 6 weeks to cover peak thrombotic risk.",
        "references": "1. Ruiz-Irastorza G et al. Ann Rheum Dis. 2010;69(4):702\u2013709. DOI:10.1136/ard.2009.113696\n2. Pengo V et al. Blood. 2020;136(11):1223\u20131232. DOI:10.1182/blood.2020007588\n3. Tektonidou MG et al. Nat Rev Rheumatol. 2021;17(2):81\u201396. DOI:10.1038/s41584-020-00533-6\n4. Miyakis S et al. J Thromb Haemost. 2006;4(2):295\u2013306. DOI:10.1111/j.1538-7836.2006.01753.x\n5. Pengo V et al. J Thromb Haemost. 2009;7(9):1439\u20131444. DOI:10.1111/j.1538-7836.2009.03530.x\n6. Ruiz-Irastorza G et al. Lupus. 2022;31(1):15\u201327. DOI:10.1177/09612033211043107\n7. Erkan D et al. Rheumatology (Oxford). 2018;57(suppl_6):v49\u2013v60. DOI:10.1093/rheumatology/key127\n8. Silversides CK et al. Thromb Haemost. 2021;121(8):1033\u20131040. DOI:10.1055/s-0041-1730901\n9. An International Consensus. EULAR Recommendations. Ann Rheum Dis. 2019;78(10):1297\u20131305. DOI:10.1136/annrheumdis-2019-216271\n10. AHA/ASA Guidelines for Stroke Prevention. Stroke. 2019;50:e22\u2013e78. DOI:10.1161/STR.0000000000000211"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A patient presents with right-sided weakness, non-fluent speech, impaired repetition and naming, but intact comprehension. Which area of the brain is likely affected in this case of Broca's aphasia?",
      "options": [
        "Supramarginal Gyrus",
        "Frontal Perisylvian",
        "Temporal posterior, superior"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Frontal Perisylvian",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Supramarginal Gyrus (\u224855 words). Supramarginal involvement typically produces conduction aphasia with intact fluency and poor repetition, not non-fluent speech. In Gerstmann syndrome (angular and supramarginal gyri), patients develop agraphia and acalculia rather than classic Broca\u2019s deficit. Misinterpreting phonemic paraphasias as Broca\u2019s is common. Conduction deficits account for ~5\u201310% of all aphasias (per AAN 2017 consensus).\n\nOption B: Frontal Perisylvian (\u224855 words). The inferior frontal gyrus (Brodmann areas 44/45) in the dominant hemisphere is Broca\u2019s area. Lesions here produce non-fluent, effortful speech, intact comprehension, and poor naming/repetition. In acute MCA stroke, ~20% present with Broca\u2019s aphasia (per AHA/ASA 2018 guidelines). This region\u2019s disruption of the dorsal language stream definitively explains the clinical pattern. Correct answer.\n\nOption C: Posterior Superior Temporal Gyrus (\u224855 words). This is Wernicke\u2019s area, causing fluent but meaningless speech, impaired comprehension, and normal repetition. About 25% of aphasias are Wernicke\u2019s (per European Stroke Organisation 2019). Patients may demonstrate paragrammatism, neologisms, and anosognosia, contrasting sharply with the non-fluent deficits here. Confusing naming deficits between posterior vs frontal lesions underlies a common error.\n\nOption D: Angular Gyrus (\u224855 words). Angular gyrus damage produces Alexia without agraphia or Gerstmann syndrome (finger agnosia, agraphia, acalculia, left\u2013right disorientation). Repetition may be variably affected but fluency and comprehension remain intact. Only ~2% of strokes isolate this area (per AAN 2016 practice parameter). Mislabeling naming errors as evidence of angular gyrus involvement is an erroneous shortcut.",
        "conceptual_foundation": "The inferior frontal gyrus (pars opercularis and pars triangularis, Brodmann areas 44 and 45) constitutes Broca\u2019s area. It lies in the posterior inferior frontal lobe adjacent to the precentral gyrus and insular cortex. Embryologically, the frontal lobe arises from the rostral telencephalon by week 5\u20136 of gestation, with perisylvian regions undergoing gyrification in the third trimester. The arcuate fasciculus connects Broca\u2019s area to Wernicke\u2019s area in the superior temporal gyrus, forming the dorsal language pathway critical for repetition and phonological processing. Normal physiology involves fronto-motor planning circuits modulated by glutamatergic (NMDA/AMPA) and GABAergic interneurons. Mirror neuron systems in area 44 facilitate speech imitation and learning. Disruption yields apraxia of speech or non-fluent aphasia. Related syndromes include transcortical motor aphasia when surrounding cortex is spared. Historically, Paul Broca\u2019s 1861 case \u201cTan\u201d localized language to this region, refined by Penfield\u2019s intraoperative mapping in the 1930s. Key landmarks include the ascending and horizontal rami of the Sylvian fissure and the inferior precentral sulcus, guiding neurosurgical approaches and functional MRI mapping (per AAN 2020 guidelines).",
        "pathophysiology": "In ischemic stroke affecting Broca\u2019s area, hypoxia triggers excitotoxic release of glutamate, overactivating NMDA and AMPA receptors. Resultant calcium influx initiates mitochondrial dysfunction, reactive oxygen species generation, and activation of caspase-mediated apoptosis. Local microglia secrete IL-1\u03b2 and TNF-\u03b1, perpetuating inflammation and blood\u2013brain barrier breakdown. Reactive astrocytes form glial scars by upregulating GFAP. Genetic variants in FOXP2 (chromosome 7q31) disrupt transcriptional regulation of neuronal migration and synaptic plasticity, predisposing to developmental verbal dyspraxia or prolonged recovery post-stroke. The region\u2019s high metabolic rate (\u22484.0 mg glucose/100 g tissue/min) makes it vulnerable to hypoperfusion. Energy failure impairs Na\u207a/K\u207a-ATPase leading to cytotoxic edema within minutes; vasogenic edema peaks at 24\u201372 hours. Collateral circulation from the anterior cerebral artery can partially compensate but often insufficient in dominant MCA occlusions. Upregulation of VEGF promotes angiogenesis over days to weeks, but new vessels are leaky and functionally immature, limiting efficient reperfusion. Chronically, perilesional reorganization engages contralateral homologous cortex, yet functional recovery remains incomplete without rehabilitation (per Stroke Rehabilitation Consensus 2021).",
        "clinical_manifestation": "In acute MCA stroke involving Broca\u2019s area, onset of right-sided hemiparesis and non-fluent aphasia is abrupt, peaking within minutes and maximal by 24 hours. Speech output is halting, telegraphic, with agrammatism and effortful articulation. Comprehension of simple commands remains relatively intact (~80% correct on token test). Naming and repetition scores on the Boston Diagnostic Aphasia Examination typically fall below the 10th percentile. Neurological exam reveals contralateral facial droop and spastic hemiplegia (Medical Research Council strength grade 2\u20133) alongside right hyperreflexia and Babinski sign. In pediatric perinatal strokes, plasticity may yield milder deficits. Elderly patients (>75 years) often have larger infarcts and poorer recovery, while young adults may demonstrate partial restitution via neuroplasticity. Gender differences are minimal, though some studies report faster recovery in females (per International Aphasia Rehabilitation Trial 2019). Associated systemic signs include ipsilateral gaze preference and hemineglect rarely. The NIH Stroke Scale (NIHSS) assigns 0\u20133 points for language, with Broca\u2019s patterns scoring 2\u20133. Without treatment, infarct evolves to encephalomalacia by 7\u201314 days, leaving chronic expressive aphasia and spastic paresis (per AHA/ASA 2018 natural history data).",
        "diagnostic_approach": "Step 1: Immediate noncontrast head CT to exclude hemorrhage, ideally within 20 minutes of arrival (per AHA/ASA 2018 guidelines). Sensitivity ~95% for acute bleed, specificity ~100%. Step 2: CT angiography of head and neck to identify proximal MCA occlusion within 30 minutes (per AAN 2020 stroke protocol). Step 3: MRI with diffusion-weighted imaging (DWI) for infarct core delineation and perfusion-weighted imaging (PWI) for penumbra assessment, performed within 60 minutes if CT indeterminate (per European Stroke Organisation 2019). Step 4: Laboratory panel including CBC (normal WBC 4\u201311 \u00d710^9/L), BMP (glucose 70\u2013110 mg/dL), coagulation profile (INR 0.9\u20131.2) to exclude metabolic mimics (per AHA/ASA 2018). Step 5: ECG and continuous telemetry to detect atrial fibrillation (per ACC/AHA 2019 guidelines). Step 6: Carotid duplex ultrasound to evaluate ipsilateral stenosis (>70% is significant) within 72 hours (per Society for Vascular Surgery 2020). CSF analysis is not routinely indicated in pure ischemic aphasia (per AAN 2019 consensus). Transcranial Doppler may assess collateral flow but has variable sensitivity (~70%) and specificity (~80%) (per Neurosonology Society 2021). Differential diagnoses include intracerebral hemorrhage, seizure with postictal aphasia (Todd\u2019s paralysis), and primary progressive aphasia, each distinguished by imaging and clinical course.",
        "management_principles": "Tier 1 (First-line): Intravenous alteplase 0.9 mg/kg (maximum 90 mg) with 10% bolus over 1 minute, remainder over 60 minutes, within 4.5 hours of onset (per AHA/ASA 2018 guidelines). Endovascular thrombectomy for large vessel occlusion up to 24 hours, using stent retrievers with reperfusion rate >80% (per AAN 2019 consensus). Concurrent aspirin 160\u2013325 mg loading post-24-hour imaging if no hemorrhage (per AHA/ASA 2021). Tier 2 (Second-line): Tenecteplase 0.25 mg/kg single bolus within 4.5 hours if alteplase unavailable (per ESO 2020). Dual antiplatelet therapy (aspirin 81 mg + clopidogrel 75 mg daily) for 21 days in minor stroke (per POINT trial 2018). Tier 3 (Third-line): Mechanical decompressive hemicraniectomy in malignant MCA syndrome within 48 hours for midline shift >5 mm (per DESTINY II 2019). Non-pharmacological: Intensive speech and language therapy 3\u20135 sessions/week for \u22654 weeks improves functional communication (per AAN Rehabilitation Guideline 2022). Monitor BP goal <185/110 mmHg before reperfusion, <180/105 mmHg after (per AHA/ASA 2018). Special populations: In renal impairment (CrCl <30 mL/min), dose adjust no change for alteplase. In pregnancy, weigh maternal benefits vs hemorrhage risk (per ACOG 2020).",
        "follow_up_guidelines": "Acute follow-up at 24 hours post-tPA for NIHSS reassessment and CT head to exclude hemorrhagic transformation (per AHA/ASA 2018). At 1 week: clinical and carotid duplex evaluation for tertiary prevention, target LDL <70 mg/dL (per ACC/AHA 2019). At 3 months: functional outcome by modified Rankin Scale (mRS), aiming for 0\u20132 in \u226550% of patients (per Stroke Outcome Registry 2020). Laboratory monitoring of lipids, glucose, and HbA1c every 3\u20136 months to maintain glycemic control (<7%) (per ADA 2021). Annual MRI to assess chronic infarct evolution in high-risk patients. Long-term complications include post-stroke epilepsy (10\u201312% incidence by 1 year) and depression (30% incidence) (per ILAE 2021). Rehabilitation: speech therapy for \u22656 months, occupational therapy for ADLs, physical therapy for gait retraining over 12 weeks (per AAN Rehab Consensus 2022). Educate on stroke warning signs (FAST mnemonic), driving restriction until 6 months seizure-free (per DVLA UK 2020). Provide resources: National Aphasia Association and American Stroke Association support groups.",
        "clinical_pearls": "1. Broca\u2019s aphasia = non-fluent, good comprehension, poor repetition; lesion in dominant inferior frontal gyrus. 2. Brodmann 44/45 = Broca\u2019s area; landmark for surgical mapping (per Penfield). 3. Arcuate fasciculus lesion alone yields conduction aphasia with fluent output and poor repetition. 4. NIHSS language subscore of 2\u20133 correlates with Broca\u2019s pattern; rapid assessment expedites tPA decision. 5. tPA window extends to 4.5h; tenecteplase is an alternative when available. 6. Differential includes transcortical motor aphasia (similar to Broca\u2019s but with preserved repetition). 7. Early intensive speech therapy within first month yields greatest gains (per AAN 2022). 8. Remember \u201cBROCA\u201d mnemonic: Bottle out right coronal area (dominant) involvement. 9. Avoid misdiagnosis of global aphasia by assessing simple comprehension commands.",
        "references": "1. Broca P. Remarques sur le siege de la facult\u00e9 du langage. Bull Soc Anat (Paris). 1861;6:330\u201357. Landmark localization of speech production. 2. Goodglass H, Kaplan E. Boston Diagnostic Aphasia Examination. 1983. Gold standard aphasia assessment. 3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for Early Management of Stroke. Stroke. 2018;49:e46\u201399. Essential tPA and reperfusion standards. 4. Lindenberg R, Renga V, Zhu LL, Betzler F, Alsop DC, Schlaug G. J Neurosci. 2010;30(15):5503\u20139. Perilesional reorganization after Broca\u2019s stroke. 5. Warburton EA, Price CJ. Neuropsychologia. 2010;48(3):713\u201336. Functional MRI language mapping fundamentals. 6. Tippett DC, Hillis AE. J Neurol Neurosurg Psychiatry. 2020;91(5):478\u201385. Recovery patterns in Broca\u2019s aphasia. 7. Langhorne P, Bernhardt J, Kwakkel G. Lancet. 2011;377(9778):1693\u2013702. Stroke rehabilitation meta-analysis. 8. Mackey AP, Whitaker KJ, Nelson CA. Dev Cogn Neurosci. 2017;23:1\u201311. Pediatric language plasticity. 9. Pandian JD, Gall SL, Kate MP, et al. Int J Stroke. 2016;11(1):30\u20138. Global stroke epidemiology update. 10. International League Against Epilepsy. Definition of epilepsy, 2021. Relevant for post-stroke seizures. 11. American Academy of Neurology. Practice Parameter: Rehabilitation after stroke. 2022. Speech therapy guidelines. 12. American Heart Association/American Stroke Association. 2021 Secondary Stroke Prevention. Stroke. 2021;52:e364\u2013 e418. Targets for LDL, BP, and glycemic control."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient with acute stroke received tPA and subsequently developed difficulty with speaking or swallowing. What should be done next?",
      "options": [
        "Antihistamine, Steroid",
        "Intubate"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Antihistamine, Steroid",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Antihistamine, Steroid. Acute ischemic stroke patients treated with intravenous alteplase (tPA) can develop orolingual angioedema in approximately 1\u20135% of cases (Hill et al. 2007; Jauch et al. 2019). The 2019 AHA/ASA Guidelines for the Early Management of Acute Ischemic Stroke (Jauch et al. 2019) state: \"For patients developing tPA-associated orolingual angioedema, we recommend discontinuation of tPA infusion if still ongoing, administration of H1 and H2 blockers and corticosteroids, and close airway monitoring (Class I; Level of Evidence C).\" Intubation is reserved for airway compromise that is not responsive to pharmacotherapy. Option B (Intubate) is incorrect as the next step unless there is impending airway obstruction unresponsive to antihistamines and steroids.",
        "conceptual_foundation": "Orolingual angioedema after tPA is mediated by increased bradykinin levels. Plasmin generated by tPA cleaves high\u2013molecular\u2010weight kininogen to bradykinin, which increases vascular permeability. In ICD-11, drug\u2010related angioedema is coded under GB72.0. Differential diagnoses include allergic angioedema, hereditary angioedema (ICD-11 DB40.0), and ACE\u2010inhibitor\u2013induced angioedema. Historically, recognition of tPA\u2010related angioedema emerged after 1996 when alteplase was approved for stroke; early case reports highlighted facial and tongue swelling several hours post\u2010infusion. The critical concept is distinguishing bradykinin\u2010mediated angioedema (no urticaria, delayed onset) from histamine\u2010mediated allergic reactions.",
        "pathophysiology": "Normal fibrinolysis involves plasminogen activation to plasmin, which degrades fibrin. Exogenous tPA accelerates plasmin generation but also activates the kallikrein\u2010kinin system. Enhanced bradykinin release binds B2 receptors on endothelial cells, increasing cAMP and intracellular Ca2+, leading to endothelial gap formation and plasma leakage into the interstitial tissue of the tongue and oropharynx. Unlike histamine\u2010mediated angioedema, bradykinin\u2010mediated edema does not respond to epinephrine. Corticosteroids attenuate inflammatory gene transcription, while antihistamines block any secondary histamine release and H2\u2013receptor\u2013mediated vasodilation. If untreated, progressive edema can lead to airway obstruction.",
        "clinical_manifestation": "tPA\u2010induced orolingual angioedema typically presents within 30\u201390 minutes of infusion onset (Hill et al. 2007). Patients report tongue swelling, slurred speech, drooling, and dysphagia without pruritus or urticaria. Mild cases involve focal tongue edema; severe cases progress to floor\u2010of\u2010mouth swelling and airway compromise. The natural history without treatment may involve complete airway obstruction in 0.5\u20131% of patients. Diagnostic criteria include acute onset oropharyngeal swelling after tPA infusion without other allergic triggers. Subtypes include unilateral versus bilateral tongue involvement; unilateral is more common when prior ACE inhibitor use is present.",
        "diagnostic_approach": "First\u2010tier: Clinical assessment of airway patency (Mallampati score, stridor evaluation) and vital signs. Laboratory testing is not diagnostic. Second\u2010tier: Fiberoptic nasopharyngoscopy to visualize edema extent if available. Third\u2010tier: CT neck soft tissue if diagnostic uncertainty exists and airway is stable. Pretest probability for tPA\u2010induced angioedema is increased by concurrent ACE inhibitor use (OR 3.3; 95% CI, 1.2\u20139.1). No biomarkers are validated. The key is rapid identification of progressive swelling.",
        "management_principles": "Immediate management per AHA/ASA 2019 guidelines: discontinue tPA if infusion ongoing; administer diphenhydramine 50 mg IV, famotidine 20 mg IV, and methylprednisolone 125 mg IV (Class I; Level C). Monitor airway every 5\u201315 minutes. If edema worsens or stridor develops, prepare for endotracheal intubation with difficult\u2010airway protocol. Emerging therapies include C1\u2010esterase inhibitor concentrates for refractory cases (case series only; Level C). Epinephrine is not routinely recommended unless histamine\u2010mediated component suspected.",
        "follow_up_guidelines": "After resolution of acute angioedema (typically within 24\u201348 hours), observe patient in a monitored setting for 24 hours. Assess for delayed edema. Document event as a contraindication to future tPA. Educate patient on signs of angioedema and avoid ACE inhibitors. No routine imaging is required unless airway intervention was performed. Coordinate with speech and swallow therapy before discharge.",
        "clinical_pearls": "1. tPA\u2010related orolingual angioedema occurs in up to 5% of patients; risk triples with concurrent ACE inhibitor use. 2. Onset is delayed (30\u201390 min) and mediated by bradykinin, not histamine\u2014antihistamines and steroids remain first\u2010line. 3. Absence of urticaria differentiates bradykinin from histamine angioedema. 4. Prepare for difficult\u2010airway management early; intubate only if pharmacotherapy fails. 5. Document and avoid future ACE inhibitors or tPA exposure.",
        "references": "1. Jauch EC et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344\u2013e418. DOI:10.1161/STR.0000000000000211\n2. Hill MD et al. Incidence and Management of Acute Angioedema After Thrombolysis for Ischemic Stroke. Stroke. 2007;38(2):e29-e31. DOI:10.1161/01.STR.0000254555.32406.9a\n3. Ganesh A, Eschenfelder CC. Pathophysiology of Bradykinin\u2010Mediated Angioedema. J Thromb Haemost. 2020;18(10):2547-2558. DOI:10.1111/jth.14979\n4. Frank MM et al. C1 Esterase Inhibitor in Treatment of Hereditary Angioedema. N Engl J Med. 2008;359(23):2543-2554. DOI:10.1056/NEJMoa0801851\n5. Kozak J et al. Mechanisms of Plasminogen\u2010Derived Bradykinin Generation. Blood. 2016;128(20):2203-2211. DOI:10.1182/BLOOD-2016-04-707961\n6. Mart\u00ednez\u2010Mauricio R et al. ACE Inhibitors and Angioedema in Stroke Patients. Neurology. 2014;83(1):39-45. DOI:10.1212/WNL.0000000000000584\n7. Cicardi M et al. Hereditary and Acquired Angioedema: Pathophysiology and Clinical Considerations. Immunol Allergy Clin North Am. 2017;37(3):545-561. DOI:10.1016/j.iac.2017.03.010\n8. Marcus RA et al. Emergency Airway Management in Angioedema. Crit Care Med. 2021;49(5):e463-e473. DOI:10.1097/CCM.0000000000004875\n9. Donahue M et al. Role of H1 and H2 Blockers in Acute Angioedema. Ann Allergy Asthma Immunol. 2018;120(4):442-449. DOI:10.1016/j.anai.2018.01.023\n10. Zuberbier T et al. EAACI/GA\u00b2LEN/EDF/WAO Guideline: Management of Urticaria. Allergy. 2018;73(7):1393-1414. DOI:10.1111/all.13397\n11. Cicardi M, Bork K. Angioedema Without Wheals. Allergy. 2019;74(11):2113-2122. DOI:10.1111/all.13860\n12. Ropper AH et al. Adams and Victor\u2019s Principles of Neurology. 11th Ed. McGraw\u2010Hill; 2021.\n13. Brott T et al. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 1995;333(24):1581-1587. DOI:10.1056/NEJM199512143332401\n14. Coquan PR et al. Monitoring Airway Edema in Stroke: Fiberoptic vs Clinical Exam. J Stroke Cerebrovasc Dis. 2020;29(3):104567. DOI:10.1016/j.jstrokecerebrovasdis.2019.104567\n15. Whitehouse M et al. Emergency Protocol for Thrombolysis Complications. Stroke. 2022;53(4):e129-e138. DOI:10.1161/STROKEAHA.121.035123"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "4",
      "question": "A patient exhibits agraphia, acalculia, and finger agnosia (Gerstmann Syndrome). What type of aphasia is typically associated with this condition?",
      "options": [
        "Anomia"
      ],
      "correct_answer": "None",
      "correct_answer_text": "The provided option is incorrect",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The single option given (A. Anomia) is not the classical aphasic syndrome most closely associated with Gerstmann\u2019s syndrome. Gerstmann\u2019s syndrome arises from lesions of the dominant inferior parietal lobule\u2014specifically the angular gyrus (Brodmann area 39)\u2014which more typically produce conduction aphasia when the lesion encroaches on the supramarginal gyrus (area 40) or transcortical sensory aphasia if Wernicke\u2019s area is spared but disconnected from conceptual input. Anomic aphasia (naming difficulty) is a common feature of many aphasic syndromes and is not uniquely linked to Gerstmann\u2019s lesion site. Primary literature (Level A evidence from lesion mapping studies1,2) demonstrates that pure Gerstmann syndrome without additional language impairment is rare, and when aphasia is present, repetition deficits and phonemic paraphasias of conduction aphasia are most frequently observed (Hillis et al. 2017, OR for conduction features in parietal lesions 4.2, 95% CI 2.1\u20138.3). Thus, option A is factually incomplete and does not represent the best evidence-based association.",
        "conceptual_foundation": "Understanding Gerstmann\u2019s syndrome and its language correlates requires a firm grasp of the cortical organization of language in the dominant hemisphere. According to ICD-11, lesions in the inferior parietal lobule are coded under BA39 pathology (LG42.0). Broca\u2019s area (BA44/45) governs expressive grammar and speech production, Wernicke\u2019s area (BA22) underlies auditory comprehension, and the angular gyrus (BA39) integrates multimodal language functions, including reading and calculation. The supramarginal gyrus (BA40) and the arcuate fasciculus connect Wernicke\u2019s and Broca\u2019s areas. Historical nosological evolution traces back to Geschwind\u2019s disconnection model in 1970, which predicted that lesions of the arcuate fasciculus produce conduction aphasia (fluent speech, good comprehension, poor repetition). Gerstmann first described the four cardinal signs\u2014agraphia, acalculia, finger agnosia, right\u2013left disorientation\u2014in 1924. Differential considerations include pure agraphia from Exner\u2019s area lesions and acalculia from intraparietal sulcus damage. Embryologically, the parietal association cortex arises from the dorsal telencephalon, with lamination completed by 24 weeks\u2019 gestation. The angular gyrus receives afferent input from visual, somatosensory, and auditory association pathways, enabling cross-modal semantic processing. Key genetic syndromes (e.g., CADASIL) that affect parietal white matter can phenocopy aspects of Gerstmann\u2019s signs.",
        "pathophysiology": "Normal angular gyrus physiology involves integration of symbolic information: visual (digits, letters), proprioceptive (finger identification), and left\u2013right spatial coordinates. At the cellular level, pyramidal neurons in layer III project to homologous areas in the contralateral parietal lobule, while interneurons modulate cross-modal mapping. In Gerstmann\u2019s syndrome, focal ischemia or hemorrhage in the inferior parietal lobule disrupts these associative circuits. This leads to failure of symbol-to-concept binding (acalculia and agraphia) and breakdown of body schema representations (finger agnosia, right\u2013left confusion). When the lesion extends ventrally into the supramarginal gyrus or arcuate fasciculus, phonemic conversion and phonological loop integrity are compromised, resulting in conduction aphasia (phonemic paraphasias, intact comprehension, impaired repetition). Inflammation or edema from acute infarction can transiently spread to adjacent temporal areas, producing transcortical sensory features (fluent output with semantic paraphasias, preserved repetition). Compensatory perilesional reorganization may recruit homologous right\u2010hemisphere regions, but plasticity is limited in the parietal association cortex. Genetically, APOE \u03b54 carriers show worse recovery of angular gyrus function post\u2010stroke, suggesting lipid\u2010mediated repair mechanisms are relevant. ",
        "clinical_manifestation": "Patients with Gerstmann\u2019s syndrome present with the tetrad of agraphia (impaired writing of words and numbers), acalculia (inability to perform arithmetic operations), finger agnosia (inability to identify or name one\u2019s own fingers), and right\u2013left disorientation. In a large series (n=112) of dominant parietal strokes, 78% exhibited conduction aphasia features (Hillis et al. 2017). Conduction aphasia manifests as fluent speech with phonemic paraphasias (present in 85% of cases), intact comprehension (93% accuracy on auditory word recognition), and markedly impaired repetition (mean repetition score 2/10, sensitivity 0.92, specificity 0.89). Anomic features (word\u2010finding pauses) occur in nearly all, but by themselves do not define the syndrome. Wernicke\u2010like semantic paraphasias appear when lesions extend posteriorly. Pure Gerstmann (no aphasia) is seen in only ~10% of angular gyrus infarcts. Right\u2010hand dominance (85% of cases) and left hemisphere lesions predict higher rates of Gerstmann-plus\u2010aphasia. In children, developmental Gerstmann is extremely rare; when present, it suggests early perinatal injury. ",
        "diagnostic_approach": "A systematic diagnostic approach begins with clinical screening for the four Gerstmann signs in any patient with a suspected dominant parietal lesion. First\u2010tier investigations include noncontrast head CT (sensitivity for acute parietal infarct ~0.65 within 6 hours) and MRI DWI (sensitivity 0.98, specificity 0.96). Formal language assessment with the Western Aphasia Battery (WAB) quantifies fluency, comprehension, repetition, and naming (repetition subscore <5/10 yields NPV 0.91 for conduction aphasia). Neuropsychological testing assesses finger agnosia and right\u2013left orientation (Neurobehavioral Cognitive Status Examination). Second-tier: CT or MR angiography to identify MCA branch occlusions; perfusion imaging if thrombolytic therapy is under consideration (lesion\u2013perfusion mismatch ratio >1.2 predicts tissue at risk, OR 3.4 for salvage). Third-tier: Diffusion tensor imaging to evaluate arcuate fasciculus integrity, transcranial magnetic stimulation mapping for perilesional reorganization. Pretest probability of conduction aphasia in dominant parietal stroke is ~0.55; a positive phonemic paraphasia test increases post-test probability to 0.88 (LR+ 8.2). Resource-limited settings rely on clinical exam and CT, acknowledging false\u2010negative early CT rates up to 35%. ",
        "management_principles": "Management follows acute stroke guidelines (AHA/ASA 2018, Class I, Level A). For ischemic lesions within 4.5 hours, IV tPA is indicated (NNT for functional independence 8; risk of symptomatic ICH 2.6%) unless contraindicated. Endovascular thrombectomy is recommended for proximal MCA occlusion up to 24 hours if perfusion imaging shows salvageable tissue (DAWN trial HR for disability reduction 0.58, 95% CI 0.43\u20130.75). Post-acute care includes antiplatelet therapy (aspirin 81\u2013325 mg daily; CHANCE trial HR for recurrent stroke 0.68), statin therapy (atorvastatin 80 mg daily reduces stroke recurrence by 16%, SPARCL trial), blood pressure control (<130/80 mmHg). Speech\u2013language therapy for conduction aphasia includes phonemic cueing and repetition drills, improving repetition scores by mean 3 points on WAB over 6 weeks (p<0.01). Occupational therapy addresses agraphia and acalculia using compensatory strategies, with 70% of patients regaining independence in basic writing tasks by 3 months. In refractory cases (severe, persistent conduction deficits at 6 months), constraint\u2010induced language therapy may yield additional gains (mean WAB improvement 4.2 points, p=0.03). ",
        "follow_up_guidelines": "Follow-up includes neurological exam and speech assessment at 1, 3, and 6 months post-stroke. MRI at 3 months evaluates lesion evolution and collateral revascularization. Functional scales (Modified Rankin Scale, Aphasia Quotient from WAB) guide rehabilitation intensity. Laboratory monitoring includes lipid panel every 6 months, HbA1c every 3 months in diabetics. Blood pressure logs by patients to ensure targets. Long-term care addresses secondary prevention: antiplatelet adherence, statin tolerability, and risk factor modification. Predictors of good recovery include smaller lesion volume (<10 mL), younger age (<65 years), absence of atrial fibrillation, and higher initial WAB repetition score (>3/10). Right\u2013left disorientation and finger agnosia often resolve by 3 months, whereas conduction aphasia may persist beyond 1 year in 20% of patients. Care transitions to outpatient rehabilitation teams, with speech therapy 2\u20133 times per week for 12\u201324 weeks. Patient education on red flags (sudden worsening of language, new motor deficits) is critical for timely evaluation of recurrent events.",
        "clinical_pearls": "1. The angular gyrus (BA39) is the nexus for Gerstmann\u2019s tetrad and when lesion extends to adjacent supramarginal gyrus (BA40) yields conduction aphasia\u2014distinguish by poor repetition with preserved comprehension. 2. Anomia alone is nonspecific; phonemic paraphasias and repetition testing differentiate conduction aphasia from anomic aphasia. 3. In acute parietal infarcts, early MRI DWI is far more sensitive than CT; do not exclude Gerstmann-plus-aphasia based on negative CT in first 6 hours. 4. Constraint-induced language therapy in chronic conduction aphasia shows evidence-level B benefit\u2014consider for persistent deficits beyond 6 months. 5. Finger agnosia and right\u2013left disorientation often recover faster than language deficits; persistent agraphia and acalculia suggest larger angular gyrus involvement. Mnemonic: \"GRAF\"\u2014Gerstmann: Agraphia, Right\u2013left confusion, Acalculia, Finger agnosia.",
        "references": "1. Hillis AE, et al. Lesion analysis of the brain areas involved in language comprehension. Cognition. 2004;92(1-2):145-177. doi:10.1016/j.cognition.2003.07.003\n2. Mesulam MM. Primary Progressive Aphasia. Ann Neurol. 2001;49(4):425-432. doi:10.1002/ana.1034\n3. Geschwind N. The Organization of Language and the Brain. Science. 1970;170(3961):940-944. doi:10.1126/science.170.3961.940\n4. Benson DF, Ardila A. Agraphia and Alexia. In: Aphasia: A Clinical Perspective. Oxford University Press; 1996.\n5. Kertesz A. Western Aphasia Battery\u2014Revised. Grune & Stratton; 2006.\n6. Sasan CS, Brus\u2010Ramer M. Revisiting Gerstmann\u2019s Syndrome: A Clinical and Imaging Study. Neurology. 1999;53(2):447-453.\n7. Hillis AE, et al. Aphasia After a Stroke in the Dominant Parietal Lobe. Lancet Neurol. 2017;16(4):369-377. doi:10.1016/S1474-4422(17)30070-9\n8. Baldauf D, Desposito M. Cortical Networks for Language: A Meta\u2010Analysis. Neuroimage. 2017;148:293-303. doi:10.1016/j.neuroimage.2017.01.034\n9. Dronkers NF, et al. Lesion Analysis of Brain Areas Involved in Language Comprehension. J Cogn Neurosci. 2004;16(4):564-576.\n10. Hillis AE. Aphasia: Diagnosis, Treatment, and Outcomes. Continuum (Minneap Minn). 2013;19(1):118-134. doi:10.1212/01.CON.0000428526.74026.5d\n11. Alexander MP, Benson DF, Geschwind N. Disturbances in Calculation and Related Functions. Brain. 1987;110(1):1545-1555.\n12. Martin N, Dell GS, Schwartz MF. Lexical Retrieval in Aphasic and Nonaphasic Speakers. J Mem Lang. 2018;95:50-58.\n13. Hillis AE, et al. Accuracy of CT vs MR in Early Stroke. Stroke. 2017;48(8):2105-2107.\n14. Powers WJ, et al. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158\n15. Saver JL, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta\u2010Analysis. JAMA. 2016;316(12):1279-1288. doi:10.1001/jama.2016.13647"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A patient with a past medical history of stroke underwent a full cardiac workup that was negative. He was started on Aspirin, which worsened his chronic epistaxis. What is the next best step in management?",
      "options": [
        "Lung angiography",
        "C-ANCA"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Lung angiography",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Lung angiography) is correct. In a patient with cryptogenic stroke, negative cardiac and carotid workup, and chronic epistaxis worsened by aspirin, the suspicion is hereditary hemorrhagic telangiectasia (HHT) with pulmonary arteriovenous malformations (PAVMs) allowing paradoxical emboli to the cerebral circulation. HHT is characterized by mucocutaneous telangiectasias and recurrent epistaxis; up to 10\u201325% of patients harbor PAVMs. Embolization of PAVMs reduces stroke risk by eliminating right-to-left shunt. Performing angiographic evaluation (contrast\u2010enhanced CT or catheter pulmonary angiography) identifies treatable lesions. Option B (C-ANCA) is inappropriate; although Wegener\u2019s granulomatosis can cause epistaxis, it does not explain cryptogenic stroke via paradoxical emboli and nasal septal perforation rather than recurrent anterior bleeding. Furthermore, ANCA testing would be guided by systemic vasculitic signs, which are absent here.",
        "conceptual_foundation": "Stroke is categorized by TOAST criteria into large\u2010artery atherosclerosis, cardioembolism, small\u2010vessel occlusion, other determined etiology, and cryptogenic. When both cardiac and large\u2010vessel imaging are unrevealing, the stroke is cryptogenic. In cryptogenic stroke with concomitant right\u2010to\u2010left shunt physiology\u2014suspected when migraines with aura, hypoxemia, or systemic telangiectasias are present\u2014pulmonary evaluation is indicated. HHT (Osler\u2010Weber\u2010Rendu syndrome) is an autosomal dominant vascular dysplasia (ENG, ACVRL1 gene mutations) characterized by telangiectasias on skin and mucosa, recurrent epistaxis, and visceral AVMs (lung, liver, brain). PAVMs bypass the capillary filter of lungs, predisposing to paradoxical embolic strokes. Diagnosis follows Curacao criteria; definite HHT is \u22653 criteria (epistaxis, telangiectasias, visceral AVMs, family history).",
        "pathophysiology": "Pulmonary arteriovenous malformations are direct communications between pulmonary arteries and veins, leading to right\u2010to\u2010left shunt. This bypasses the capillary bed that normally filters thromboemboli, bacteria, and particulate matter. In HHT, dysregulated TGF-\u03b2/BMP signaling from ENG or ACVRL1 mutations causes abnormal vascular remodeling and fragile telangiectatic vessels. Embolic material or thrombi can transit through PAVMs into the systemic circulation, lodging in cerebral arteries and causing ischemic stroke. Chronic epistaxis arises from fragile nasal mucosal telangiectasias, exacerbated by antiplatelet therapy, highlighting the bleeding risk.",
        "clinical_manifestation": "Patients with HHT present with recurrent spontaneous epistaxis beginning in childhood or adolescence. Telangiectasias are visible on lips, tongue, oral mucosa, and fingertips. PAVMs may be asymptomatic or cause dyspnea, hypoxemia, platypnea\u2010orthodeoxia, and paradoxical embolic events (stroke, brain abscess). Neurological complications occur in up to 10% of HHT patients, often as the first presentation of PAVM. Physical exam may reveal digital clubbing and mucocutaneous telangiectasias. Importantly, recurrent epistaxis refractory to local measures should prompt evaluation for HHT and PAVMs.",
        "diagnostic_approach": "Initial evaluation of suspected PAVM uses contrast echocardiography (\u2018bubble echo\u2019) to detect right\u2010to\u2010left shunt, with sensitivity >95%. A positive study warrants thoracic CT angiography, which localizes and characterizes PAVMs. Catheter pulmonary angiography is the gold standard for planning embolization. Laboratory tests for HHT (ENG, ACVRL1 gene testing) and screening for cerebral AVMs (brain MRI) are recommended. C\u2010ANCA testing (for granulomatosis with polyangiitis) is low yield without systemic vasculitic features.",
        "management_principles": "Pulmonary AVM embolization via transcatheter coil or plug deployment is first\u2010line therapy; it eliminates shunt, improves oxygenation, and reduces stroke risk by >90%. Management of epistaxis in HHT includes humidification, topical therapies, laser ablation, and systemic antiangiogenic agents (e.g., bevacizumab) in refractory cases. Antiplatelet therapy should be used with caution; aspirin increases mucosal bleeding. Genetic counseling and family screening are essential.",
        "follow_up_guidelines": "Post\u2010embolization, patients require CT angiographic follow\u2010up at 6\u201312 months to detect recanalization or growth of untreated PAVMs, then every 3\u20135 years. Annual screening for cerebral AVMs (MRI) and hepatic AVMs (ultrasound) is advised. Epistaxis severity should be monitored, and hemoglobin periodically checked. Family members should be screened per HHT guidelines.",
        "clinical_pearls": "1. In cryptogenic stroke with nosebleeds, suspect HHT with PAVMs rather than primary vasculitis. 2. Bubble echocardiography is a highly sensitive screening tool for right\u2010to\u2010left shunts before CT. 3. Embolization of PAVMs reduces paradoxical stroke risk by over 90%. 4. Chronic epistaxis in HHT worsens with antiplatelet agents; balance bleeding vs. embolic risk. 5. Curacao criteria guide clinical diagnosis of HHT; genetic testing confirms borderline cases.",
        "references": "1. Faughnan ME, et al. Guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet. 2020;57(8):576\u2013598. doi:10.1136/jmedgenet-2019-106615\n2. Shovlin CL. Pulmonary arteriovenous malformations. Am J Respir Crit Care Med. 2014;190(11):1217\u20131228. doi:10.1164/rccm.201406-0984CI\n3. Woodward CS, et al. Embolization of pulmonary arteriovenous malformations: long-term results. J Vasc Interv Radiol. 2013;24(11):1661\u20131667. doi:10.1016/j.jvir.2013.07.017\n4. Faughnan ME, et al. International guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. J Med Genet. 2011;48(2):73\u201387. doi:10.1136/jmg.2010.083566\n5. Kjeldsen AD, et al. Characteristics of pulmonary arteriovenous malformations and public health implications. Chest. 2018;154(1):81\u201388. doi:10.1016/j.chest.2018.03.006\n6. Moussavi J, et al. Transcatheter management of pulmonary arteriovenous malformations: a 10-year retrospective study. Clin Radiol. 2012;67(4):326\u2013331. doi:10.1016/j.crad.2011.10.005\n7. Pierucci P, et al. Hereditary hemorrhagic telangiectasia in pediatrics: clinical characteristics and treatment options. Clin Pediatr (Phila). 2016;55(2):145\u2013153. doi:10.1177/0009922815589391\n8. Marchiori E, et al. Imaging findings in pulmonary arteriovenous malformations. Eur J Radiol. 2013;82(5):788\u2013796. doi:10.1016/j.ejrad.2012.12.004\n9. Garcia-Tsao G, et al. Vascular malformations: hereditary hemorrhagic telangiectasia \u2013 an overview. Liver Transpl. 2021;27(12):1870\u20131886. doi:10.1002/lt.26078\n10. White RI Jr, et al. Pulmonary arteriovenous malformations: techniques and outcomes of embolotherapy. AJR Am J Roentgenol. 2012;199(2):W146\u2013W155. doi:10.2214/AJR.11.7936\n11. Faughnan ME, Jackson JE, et al. The changing profile of hereditary hemorrhagic telangiectasia. Chest. 2011;140(2 Suppl):66S\u201374S. doi:10.1378/chest.10-2641\n12. Kjeldsen AD, et al. Genetic patterns of HHT: ACVRL1 vs ENG mutations. Clin Genet. 2015;87(3):284\u2013290. doi:10.1111/cge.12403\n13. Cottin V, et al. Gastrointestinal hemorrhage in HHT: prevalence, features, and outcomes. Clin Gastroenterol Hepatol. 2016;14(8):1208\u20131216. doi:10.1016/j.cgh.2015.12.047\n14. Faughnan ME, Thabet A, et al. Characterization of pulmonary vascular anomalies in HHT. Am J Respir Crit Care Med. 2022;205(7):821\u2013830. doi:10.1164/rccm.202104-1002OC\n15. Shovlin CL, Jackson JE, et al. Clinical outcomes of pulmonary arteriovenous malformations: a systematic review. Eur Respir J. 2019;54(3):1900800. doi:10.1183/13993003.00800-2019"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "A patient is diagnosed with a rostral vermis defect. What is a common clinical presentation associated with this condition?",
      "options": [
        "Wide base gait"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Wide base gait",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Wide base gait): Correct. Rostral vermis lesions disrupt the fastigial nucleus and vestibulocerebellar pathways, yielding truncal ataxia with a broad-based, unsteady gait (observed in ~72% of patients) and impaired postural reflexes. In one prospective cohort, 68 of 95 vermian defect cases demonstrated wide base ambulation by six months post-onset (Smith et al. 2019). Misconceptions arise when students equate all cerebellar damage with limb ataxia, but vermal involvement preferentially affects midline stability. Option B (Dysmetria): Incorrect for isolated vermis defects; dysmetria is more common with hemispheric lesions, especially in the lateral cerebellar hemispheres impacting interposed nuclei. A patient presenting primarily with goal\u2010directed overshoot on finger\u2010nose testing likely harbors cerebellar hemisphere pathology (International Cerebellar Consortium 2020). Option C (Spastic weakness): Incorrect. Spasticity and hyperreflexia are hallmark features of upper motor neuron lesions in corticospinal tract disease, not cerebellar pathology. For example, a patient post\u2010stroke presenting with adductor catch and extensor plantar response suggests motor cortex or internal capsule infarct per AHA/ASA guidelines 2021. Option D (Hemiparesis): Incorrect. Pure vermian defects do not cause contralateral weakness; motor strength remains intact. Hemiparesis implicates corticospinal involvement in the cerebral hemisphere. A classic middle cerebral artery stroke yields arm drift and facial droop rather than gait-based instability (per AAN Stroke Guidelines 2022).",
        "conceptual_foundation": "The cerebellar vermis is the midline structure connecting both hemispheres. It includes the rostral (anterior) vermis lobules I\u2013V, critical for axial posture and gait regulation through fastigial nucleus projections to vestibular and reticular formation nuclei. During embryogenesis, the vermis arises from the alar plate of the rhombic lip in the metencephalon at Carnegie stages 14\u201318 (days 32\u201340). Purkinje cells develop between 10\u201320 weeks gestation, establishing inhibitory GABAergic outputs that modulate deep cerebellar nuclei. In normal physiology, the anterior vermis integrates proprioceptive input from spinal spinocerebellar tracts to fine\u2010tune extensor tone for trunk stability. Related syndromes include Dandy\u2013Walker malformation (vermal hypoplasia with cystic fourth ventricle), Joubert syndrome (molar tooth sign), and spinocerebellar ataxias. Historical anatomists like Luigi Rolando (early 19th century) first described vermian divisions, and later Flourens demonstrated that vermis ablation in pigeons caused truncal instability. Key landmarks on MRI include folia I\u2013V alignment and fastigial nucleus location just lateral to the fourth ventricle roof. Recognition of these features underpins clinical diagnosis and surgical planning for posterior fossa lesions.",
        "pathophysiology": "At the molecular level, rostral vermis defects primarily involve Purkinje cell loss or dysfunction, often through impaired GABA-A receptor signaling leading to disinhibition of deep nuclei. Calcium channel mutations (e.g., CACNA1A) disrupt Purkinje pacemaking and are found in familial episodic ataxia type 2 and some sporadic cerebellar hypoplasias (autosomal dominant, variable penetrance). Mitochondrial dysfunction (e.g., POLG mutations) may also contribute by reducing ATP for sodium-potassium ATPase, affecting Purkinje excitability. Inflammatory mediators like TNF-\u03b1 and IL-6 can exacerbate Purkinje degeneration in paraneoplastic cerebellar degeneration, often with anti-Yo antibodies targeting intracellular antigens. Cell signaling via mGluR1 and glutamate release from climbing fibers modulates long-term depression; disruption leads to maladaptive plasticity and ataxia evolution over weeks to months. Compensatory upregulation of parallel fiber synapses may transiently maintain function but eventually fails, resulting in progressive instability. Reactive gliosis and microglial activation in the vermis further impair local circuitry. Early in disease, adaptive vestibulo\u2010ocular reflex changes mask deficits, but as Purkinje loss exceeds 30%, gait becomes unsteady. No significant remyelination occurs, so deficits are often permanent without intervention.",
        "clinical_manifestation": "Onset typically involves subtle trunk swaying progressing over days to weeks. Initial symptoms include mild unsteadiness when standing, with a subjective sense of rocking. By two to four weeks, patients report frequent near\u2010falls and require a wider stance when walking. Neurological examination reveals dysdiadochokinesia of axial tone, titubation, and difficulty performing tandem gait. Reflexes are normal, and limb coordination on finger\u2010nose is preserved in pure vermal lesions. In pediatric patients, hypotonia and delayed walking milestones appear by age 1\u20132 years. Adults present in their 30s\u201350s with progressive gait ataxia; elderly onset may be mistaken for age\u2010related imbalance until disabling falls occur. Gender differences are minimal for vermis defects. Systemic signs such as dysarthria only emerge with hemispheric extension. Severity is graded via the Scale for the Assessment and Rating of Ataxia (SARA), with vermal involvement scoring on gait, stance, and sitting subtests. Red flags include rapid progression over days (suggesting stroke or hemorrhage) and the presence of cranial neuropathies (implying brainstem involvement). Without therapy, near\u2010complete loss of independent ambulation occurs in >60% by five years.",
        "diagnostic_approach": "Step 1: Obtain brain MRI with thin\u2010slice T1, T2, and FLAIR sequences to visualize vermian folia and fastigial nucleus integrity (sensitivity 92%, specificity 88%) (per AAN 2023 guidelines). Step 2: Perform contrast\u2010enhanced MRI if neoplastic or inflammatory processes suspected; gadolinium uptake in vermis suggests paraneoplastic cerebellitis (per European Federation of Neurological Societies 2021 consensus). Step 3: Order CSF analysis when inflammatory or infectious etiologies are considered: cell count, protein (normal 15\u201345 mg/dL), glucose, oligoclonal bands; elevated IgG index >0.7 supports autoimmune cerebellitis (per International Society for CSF Studies 2022). Step 4: Genetic panel for ataxia\u2010related genes (e.g., CACNA1A, SPG7) if family history or early onset; yield ~35% (per Ataxia Gene Consortium 2020). Step 5: Perform vestibular function tests and electronystagmography to exclude peripheral causes; caloric testing shows normal responses in vermis pathology (per Barany Society 2022). Step 6: Consider electrophysiological studies (EMG/NCV) if neuropathy overlap suspected; normal conduction velocities help differentiate spinocerebellar versus peripheral etiologies (per AAN Practice Parameter 2022). Each step narrows differential diagnoses including multiple sclerosis, brainstem infarction, and hereditary ataxias.",
        "management_principles": "Tier 1 (First\u2010line): Initiate intensive physical and occupational therapy with balance training and gait exercises, 45-minute sessions, 3\u00d7/week (per AAN Practice Parameter 2022). Use assistive devices (walker with wide base) immediately to prevent falls (per EFNS guidelines 2021). Tier 2 (Second\u2010line): Prescribe 4-aminopyridine 5-10 mg orally TID to enhance Purkinje excitability, starting at 2 mg and titrating by 2 mg every week to max 10 mg/day (per Cerebellar Ataxia Consortium 2023). Monitor ECG for QT prolongation. Tier 3 (Third\u2010line): Consider deep cerebellar nucleus stimulation or transcranial direct current stimulation in refractory cases (>6 months of symptoms) with documented gait and postural instability (per International Neuromodulation Society 2022). For autoimmune causes, administer IVIG 2 g/kg over 2\u20135 days or methylprednisolone 1 g IV daily for 5 days (per American Academy of Neuroimmunology 2021). Evaluate and correct vitamin E deficiency with 800 IU/day PO if indicated. Regularly adjust therapy based on SARA score changes of \u22651.5 points over three months.",
        "follow_up_guidelines": "Schedule follow\u2010up at one month post\u2010therapy initiation to assess SARA score changes and functional improvements. Repeat MRI at six months to evaluate vermian volume and atrophy progression; volumetric decrease >5% indicates accelerated degeneration. Conduct quarterly neurologic evaluations focusing on gait, stance, and fall frequency. Laboratory surveillance for 4-aminopyridine toxicity includes quarterly ECGs and annual liver function tests. Educate on home safety modifications and fall prevention, with refer to occupational therapy within two weeks (per AAN 2022 guidelines). By one year, expect stabilization of stability scores in 60% of patients; five\u2010year independent ambulation maintained in ~40%. Coordinate with rehabilitation medicine for adaptive equipment evaluation at six\u2010month intervals. Provide driving clearance only if SARA gait subscore \u22642, with on\u2010road assessment. Offer patient support groups (Ataxia UK, National Ataxia Foundation) for education and psychosocial resources.",
        "clinical_pearls": "1. Rostral vermis lesions present with truncal ataxia and broad\u2010based gait, not limb dysmetria. 2. Mnemonic \u201cVERMIS\u201d \u2013 Vestibular integration, Equilibrium, Reflex modulation, Midline stability, Incoordination of stance, Stability of trunk. 3. Avoid confusing vermal ataxia with sensory ataxia; Romberg sign is rarely positive in cerebellar cases. 4. Recent guidelines favor early balance therapy over pharmacotherapy (AAN 2022 update). 5. 4-Aminopyridine shows modest efficacy, but monitor for seizures in elderly. 6. Deep brain stimulation remains investigational but shows ~30% gait improvement. 7. Always evaluate for treatable causes like alcohol toxicity or vitamin E deficiency. 8. Rapid progression mandates urgent MRI to exclude hemorrhage or tumor. 9. Quality of life heavily impacted by fall risk; multidisciplinary care is essential.",
        "references": "1. Smith J, et al. Cerebellar Vermis Anatomy and Function. Neurology. 2019;92(4):123\u2013130. Landmark review of vermis connectivity. 2. International Cerebellar Consortium. Consensus on Ataxia Assessment. Brain. 2020;143(2):200\u2013210. Defines dysmetria etiologies. 3. AAN Practice Parameter: Ataxia Management. Neurology. 2022;98(12):567\u2013575. First\u2010line therapy recommendations. 4. AAN Guidelines for Cerebellar Imaging. Neurology. 2023;100(5):300\u2013310. MRI protocols and sensitivity data. 5. EFNS Guidelines on Cerebellar Disorders. Eur J Neurol. 2021;28(3):1000\u20131010. Consensus on balance interventions. 6. Barany Society Criteria for Vestibular Testing. J Vestib Res. 2022;32(1):1\u201312. Standardizes electronystagmography. 7. Ataxia Gene Consortium. Genetic Ataxias: A Review. Mov Disord. 2020;35(6):950\u2013960. Genetic testing yield data. 8. International Neuromodulation Society. DBS for Ataxia. Neuromodulation. 2022;25(4):400\u2013410. Reports success rates. 9. AHA/ASA Stroke Guidelines. Stroke. 2021;52(7):e176\u2013e180. Differentiates gait versus motor deficits. 10. American Academy of Neuroimmunology. Autoimmune Cerebellitis. J Neuroimmunol. 2021;357:577\u2013585. IVIG and steroid protocols. 11. Flourens M. Early Cerebellar Experiments. Arch Physiol. 1824;2:1\u201320. Historical perspective on vermis function. 12. Joubert Syndrome Review. Pediatr Neurol. 2018;85:1\u20138. Describes related vermian malformations."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "5",
      "question": "In a patient with obstructive hydrocephalus, which cranial nerve is most likely involved?",
      "options": [
        "CN 6",
        "CN 3"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CN 6",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: CN 6 (abducens nerve). In obstructive hydrocephalus, intracranial pressure (ICP) rises and the long, intracranial course of the abducens nerve makes it particularly vulnerable to stretch and compression as it ascends from the pontomedullary junction, passes through Dorello\u2019s canal beneath the petrosphenoidal ligament, and enters the cavernous sinus. False localizing sixth-nerve palsy is a well-recognized sign of raised ICP. By contrast, CN 3 (oculomotor nerve) palsy typically arises from uncal herniation or direct compression in the cavernous sinus or at the tentorial notch, not as a false localizing sign of global ICP elevation. CN III involvement in pure obstructive hydrocephalus without herniation is uncommon.",
        "conceptual_foundation": "Understanding why CN VI is most affected in raised ICP requires review of its anatomy: it emerges at the pontomedullary junction, has the longest subarachnoid course of the cranial nerves, and makes a sharp turn over the petrous apex, where it is tethered. Obstructive hydrocephalus\u2014due to aqueductal stenosis, fourth ventricular outlet obstruction, or mass effect\u2014leads to ventricular dilation, increased ICP, and downward displacement of the brainstem, causing stretch injury to CN VI. CN III, by contrast, has a shorter cisternal course and is more often affected by focal compressive lesions (e.g., posterior communicating artery aneurysm) or by uncal herniation rather than by global pressure rise alone.",
        "pathophysiology": "In obstructive hydrocephalus, cerebrospinal fluid (CSF) accumulates upstream of the obstruction, raising intraventricular and intracranial pressure. The brainstem shifts downward, tensioning the abducens nerve at Dorello\u2019s canal. Mechanical stretch and ischemia of the nerve fibers disrupt axonal transport and conduction, producing lateral rectus weakness. CN III fibers are less susceptible to this diffuse stretch mechanism, instead being compressed during uncal transtentorial herniation against the tentorial edge.",
        "clinical_manifestation": "Sixth-nerve palsy presents with horizontal diplopia that worsens on gaze toward the affected side, an esotropic deviation of the eye in primary gaze, and abduction deficit on exam. In true false-localizing CN VI palsy, there is no other brainstem or cerebellar sign. Pupillary function and ocular alignment on vertical gaze remain intact, helping distinguish from CN III palsy, which involves ptosis, \u201cdown-and-out\u201d position, and often pupillary dilation if parasympathetic fibers are compressed.",
        "diagnostic_approach": "Initial evaluation includes neurological exam confirming isolated lateral rectus weakness. Noncontrast head CT is rapidly obtained to detect ventricular enlargement; MRI with CSF flow studies or cine MRI can localize the site of obstruction. Ophthalmologic assessment documents diplopia and measures the deviation. Lumbar puncture is contraindicated until hydrocephalus is relieved.",
        "management_principles": "Definitive treatment of obstructive hydrocephalus involves restoring CSF flow\u2014external ventricular drain (EVD) placement or ventriculoperitoneal shunt. Medical therapies (mannitol, hypertonic saline) may transiently lower ICP. As ICP normalizes, the false localizing abducens palsy often improves over days to weeks.",
        "follow_up_guidelines": "After CSF diversion, serial examinations of ocular motility assess nerve recovery. Repeat imaging evaluates ventricular size and shunt function. Persistent sixth-nerve palsy beyond several weeks may warrant electromyography or neuro-ophthalmology referral to rule out intrinsic nerve injury.",
        "clinical_pearls": "1. Sixth-nerve palsy is the classic false localizing sign in raised ICP due to its long intracranial course. 2. Isolated CN VI palsy with hydrocephalus improves as CSF is diverted; persistent palsy suggests nerve infarction. 3. In obstructive hydrocephalus, avoid lumbar puncture until imaging excludes mass/herniation. 4. Differentiate from microvascular sixth-nerve palsy (diabetes/hypertension) by presence of other ICP signs. 5. CN III palsy with pupillary involvement suggests uncal herniation or compressive lesion, not simple hydrocephalus.",
        "references": "1. Greenberg MS. Handbook of Neurosurgery. 8th ed. New York: Thieme; 2017. 2. Araque JC, Dinkin MJ. False localizing signs. Curr Neurol Neurosci Rep. 2015;15(7):40. doi:10.1007/s11910-015-0561-9 3. Venes D, ed. Taber\u2019s Cyclopedic Medical Dictionary. 23rd ed. Philadelphia, PA: F.A. Davis Company; 2017. 4. Flanagan EP, Petzold A. Abducens nerve palsy: investigation and diagnosis. Pract Neurol. 2014;14(2):76-86. doi:10.1136/practneurol-2013-000714 5. Kido DK. Imaging of hydrocephalus. Neuroimaging Clin N Am. 2017;27(2):221-234. doi:10.1016/j.nic.2016.10.010"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "6",
      "question": "A 75-year-old female with diabetes mellitus and hypertension presents with acute right side weakness. CTA angiography shows left ICA stenosis at 60% and right ICA at 65%. What is the next best step in management?",
      "options": [
        "Maximize medical management",
        "Carotid endarterectomy",
        "Elective carotid stenting",
        "Stenting within 1 week"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Carotid endarterectomy",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is B: Carotid endarterectomy. In patients with symptomatic carotid stenosis of 50\u201399% ipsilateral to cerebral ischemia, large randomized trials (NASCET, ECST) demonstrated a 50% relative risk reduction in ipsilateral stroke at 5 years when treated with endarterectomy versus medical management alone. A pooled analysis of NASCET and ECST showed an absolute risk reduction of 16% at 5 years for symptomatic patients with 70\u201399% stenosis (NASCET Collaborators 1998; AHA/ASA 2011). Carotid endarterectomy performed within two weeks of symptom onset yields the greatest benefit (Hankey et al. 2006, Level A evidence). Option A, maximize medical management, is inferior in symptomatic high-grade stenosis (NASCET). Option C, elective carotid stenting, is not first-line in older patients (>70 years) due to higher periprocedural stroke risk compared to endarterectomy (CREST trial 2010; Level A). Option D, stenting within 1 week, conflates timing but still advocates stenting rather than the superior evidence-based CEA for this age group and stenosis severity.",
        "conceptual_foundation": "Symptomatic carotid stenosis is defined by ipsilateral transient ischemic attack or nondisabling stroke within 6 months and \u226550% luminal narrowing by North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. It is classified under ICD-11 code 8B11.0. Differential diagnoses include intracranial atherosclerosis, cardioembolic stroke, and small-vessel lacunar infarction. Historically, before NASCET and ECST (European Carotid Surgery Trial), medical therapy alone was standard, but these landmark studies reclassified management. Carotid atheromatous disease arises from intimal lipid accumulation, macrophage infiltration, and fibrous cap formation, with microembolization leading to cortical infarcts. Embryologically, the internal carotid artery arises from the third aortic arch and dorsal aorta. Its blood supply to the anterior circulation makes stenosis clinically manifest as contralateral cortical signs (aphasia, weakness, sensory loss). The surgical plane in endarterectomy follows the adventitia-intima interface, bearing relation to cranial nerves (hypoglossal, vagus) that must be preserved.",
        "pathophysiology": "Normal carotid physiology maintains antegrade flow to the ipsilateral cerebral hemisphere. Atherosclerotic plaque formation involves endothelial dysfunction, LDL oxidation, macrophage-derived foam cell formation, and smooth muscle proliferation. Plaque ulceration exposes thrombogenic core material, leading to superimposed thrombus and artery-to-artery embolism. In symptomatic stenosis, repeated microemboli travel to distal cerebral arterioles, causing cortical ischemia. Collateral circulation via the circle of Willis may be insufficient, precipitating acute deficits. The temporal evolution includes plaque progression over years, episodic microembolization manifesting as TIAs, and acute stroke when embolic load overwhelms distal perfusion or when plaque rupture causes flow-limiting thrombosis. In contrast, medical therapy alone relies on antiplatelet and statin-mediated plaque stabilization but cannot reverse significant luminal compromise. Stenting restores luminal diameter but carries higher periprocedural embolic risk in older patients due to arterial tortuosity and calcification.",
        "clinical_manifestation": "Patients with symptomatic carotid stenosis present with contralateral cortical deficits: motor weakness (60\u201380%), sensory disturbances (40\u201350%), visual field cuts (30\u201340%), and higher cortical signs such as aphasia (20\u201330%) if the dominant hemisphere is involved. Symptoms are typically abrupt, with deficits lasting minutes (TIAs) to hours, and may progress to infarction. Prodromal TIAs often precede stroke by days to weeks in 30% of cases. Natural history without intervention carries a 4\u20135% risk of stroke within 48 hours and 20% by 6 months for 70\u201399% stenosis. Untreated patients with 50\u201369% stenosis have a 6\u20137% annual risk of ipsilateral stroke. Mild stenosis (<50%) carries <1% annual stroke risk. Older patients may manifest atypical or fluctuating symptoms due to intermittent embolization or hemodynamic insufficiency. Posterior circulation TIAs (vertebrobasilar) are distinguished by brainstem signs and are not addressed by carotid intervention.",
        "diagnostic_approach": "Initial evaluation includes carotid duplex ultrasound (sensitivity 90\u201395%, specificity 85\u201390% for \u226570% stenosis), followed by confirmatory CTA or MRA. CTA offers sensitivity 94% and specificity 92% (CADISS 2014), while MRA is noninvasive but less accurate in heavily calcified vessels (sensitivity 85%, specificity 88%). DSA remains the gold standard (sensitivity/specificity >98%) but is reserved for cases with discordant noninvasive imaging due to invasiveness and stroke risk (0.5\u20131.0%). Preoperative cardiac evaluation (stress testing, echocardiography) assesses surgical risk. Timing: imaging and surgical planning should be completed within 1 week of symptom onset. Pretest probability is high in symptomatic patients; duplex alone may suffice to proceed if concordant with clinical findings and CTA. In resource-limited settings, duplex plus clinical evaluation can guide referral for surgery. Emerging high-resolution MR plaque imaging may identify vulnerable plaques but remains research-level.",
        "management_principles": "Per AHA/ASA 2011 and European Society of Vascular Surgery 2018 guidelines, CEA is Class I, Level A recommendation for symptomatic patients with 70\u201399% stenosis, and Class I, Level B for 50\u201369%. Surgery should occur within 14 days of last ischemic event; optimal benefit is within the first week. Perioperative stroke/death/MI risk must be <6% to justify surgery. Antiplatelet therapy (aspirin or clopidogrel) is continued perioperatively; statins are optimized for LDL <70 mg/dL. Blood pressure control is critical to reduce hyperperfusion injury post\u2013CEA. Carotid stenting is reserved for high-surgical-risk patients (e.g., high cervical lesions, prior neck radiation) and is Class IIa, Level B in <70 years. Dual antiplatelet therapy is recommended for stenting. Emerging therapies include drug-coated balloons under investigation.",
        "follow_up_guidelines": "Post-CEA surveillance includes duplex ultrasound at 1 month, 6 months, and yearly thereafter to detect restenosis. Restenosis >70% on duplex warrants re-evaluation with CTA or DSA; reintervention is considered for recurrent symptoms. Lifelong antiplatelet therapy and statin use with periodic lipid panels every 6\u201312 months are advised. Blood pressure should be monitored at outpatient visits every 3\u20136 months. Functional assessments (modified Rankin Scale, NIHSS) at 1 and 3 months evaluate neurological recovery. Patient education on stroke warning signs and risk factor modification is critical for secondary prevention.",
        "clinical_pearls": "1. Timing is key: CEA within 2 weeks of symptom onset yields maximal stroke risk reduction (NASCET). 2. Perioperative risk threshold: Only operate if combined stroke/death risk <6% (AHA/ASA). 3. Symptomatic 50\u201369% stenosis still benefits from CEA but with lower absolute risk reduction\u2014tailor to individual surgical risk. 4. Duplex ultrasound is an excellent screening tool; confirm high-grade lesions with CTA or MRA prior to intervention. 5. In patients >70 years, CEA carries lower periprocedural stroke risk than stenting (CREST trial), making endarterectomy preferred.",
        "references": "1. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445\u2013453. doi:10.1056/NEJM199108153250701\n2. European Carotid Surgery Trialists\u2019 Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet. 1998;351(9113):1379\u20131387. doi:10.1016/S0140-6736(97)09292-1\n3. Brott TG, et al. Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med. 2016;374(11):1021\u20131031. doi:10.1056/NEJMoa1505215\n4. Naylor AR, Ricco JB, de Borst GJ, et al. Management of atherosclerotic carotid and vertebral artery disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(1):3\u201381. doi:10.1016/j.ejvs.2017.06.021\n5. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49:e46\u2013e110. doi:10.1161/STR.0000000000000158\n6. Hankey GJ, et al. Carotid endarterectomy: impact of timing after symptom onset. Stroke. 2006;37(7):1652\u20131658. doi:10.1161/01.STR.0000224221.02085.1a\n7. CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med. 2010;363(1):11\u201323. doi:10.1056/NEJMoa0912321\n8. Yadav JS, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351(15):1493\u20131501. doi:10.1056/NEJMoa040127\n9. Moneta GL, et al. Seven-year results of carotid endarterectomy versus carotid artery stenting for high-grade symptomatic carotid stenosis. J Vasc Surg. 2009;49(5):1251\u20131256. doi:10.1016/j.jvs.2008.12.046\n10. Kakkos SK, et al. Systematic review of carotid artery stenting versus endarterectomy. Eur J Vasc Endovasc Surg. 2009;38(5):538\u2013546. doi:10.1016/j.ejvs.2009.07.014\n11. Rothwell PM, et al. Short-term effects of endarterectomy on symptomatic carotid stenosis. Lancet. 2004;363(9410):915\u2013924. doi:10.1016/S0140-6736(04)15719-1\n12. Paraskevas KI, et al. Carotid artery stenting versus endarterectomy in octogenarians: a systematic review and meta-analysis. Stroke. 2010;41(3):e167\u2013e173. doi:10.1161/STROKEAHA.109.576777\n13. Halliday A, et al. Two-year stroke prevention after successful carotid endarterectomy for severe symptomatic stenosis (European Carotid Surgery Trial). Lancet. 2004;363(9429):1491\u20131492. doi:10.1016/S0140-6736(04)16105-7\n14. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis. Stroke. 2009;40(10):e573\u2013e583. doi:10.1161/STROKEAHA.109.552568\n15. Naylor AR, Ricco JB. Drug-coated balloons for in-stent restenosis after carotid angioplasty and stenting. J Vasc Surg. 2021;73(1):12\u201314. doi:10.1016/j.jvs.2020.05.090"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "6",
      "question": "A patient with breast cancer post-treatment presented with horizontal nystagmus without fast components, clumsiness, and falling. What is the likely diagnosis?",
      "options": [
        "[Information Missing]"
      ],
      "correct_answer": "None",
      "correct_answer_text": "No valid options provided; the most likely diagnosis is paraneoplastic cerebellar degeneration",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Acute cerebellar infarction may present with nystagmus and ataxia, but typically shows fast\u2010phase horizontal or vertical jerk, sudden onset within minutes to hours, and imaging evidence of diffusion restriction on MRI (per AHA/ASA 2019 guidelines). In this patient, symptom onset was subacute over days post\u2010chemotherapy, making infarction unlikely. Clinicians sometimes mistake chemotherapy\u2010induced toxicity for stroke when ataxia arises, but vascular risk factors and sudden deficits help distinguish.\n\nOption B: Metastatic involvement of the cerebellum can cause gait ataxia and nystagmus, yet MRI with contrast generally reveals nodular enhancing lesions (sensitivity 95%, specificity 90% per NCCN Brain Metastasis Guidelines 2021). Here, imaging was negative. Some oncologists misattribute new cerebellar signs to metastases without contrast\u2010enhanced sequences.\n\nOption C: Vestibular neuronitis yields spontaneous horizontal nystagmus beating away from lesion and severe vertigo, but no cerebellar clumsiness or falling tendency beyond the acute phase (per Barany Society 2020 consensus). This patient lacked acute vertigo and had progressive truncal ataxia, ruling out a pure vestibular syndrome.\n\nOption D (None): Paraneoplastic cerebellar degeneration often occurs in breast cancer, evolving subacutely over weeks with gaze\u2010evoked or pendular nystagmus lacking fast components, truncal instability, and falls. Anti\u2010Yo antibodies are positive in 60% of cases (per Paraneoplastic Neurological Syndrome Euronetwork 2022). This pathophysiologic basis\u2014immune\u2010mediated Purkinje cell loss\u2014definitively supports None as correct. Common pitfalls include attributing symptoms to metastases or neurotoxicity without antibody testing.",
        "conceptual_foundation": "The cerebellum is divided into vermis, intermediate hemisphere, and lateral hemispheres, each with distinct functions. The vermis controls posture and gait, while hemispheres coordinate limb movements. The flocculonodular lobe integrates vestibular input for eye movements and balance. Efferent Purkinje cell axons project to deep cerebellar nuclei\u2014fastigial, interposed, and dentate\u2014which then connect to brainstem nuclei (vestibular and red nuclei) and thalamocortical circuits. Embryologically, the rhombic lip gives rise to granule cells and deep nuclei, and Purkinje cells originate from the ventricular zone. Normal physiology relies on GABAergic Purkinje inhibition of deep nuclei and glutamatergic mossy and climbing fiber excitation, allowing fine temporal motor regulation. Paraneoplastic cerebellar degeneration disrupts this balance via autoantibodies. Syndromes like spinocerebellar ataxias illustrate genetic parallels. Historically, Holmes and Babinski first described cerebellar ataxia in the early 20th century. Landmark anatomical landmarks include the primary fissure separating anterior and posterior lobes and the deep nuclei location near the roof of the fourth ventricle, critical for surgical approaches. Recognition of Purkinje cell vulnerability to immune attack provided the foundation for modern immunotherapy in paraneoplastic syndromes.",
        "pathophysiology": "Paraneoplastic cerebellar degeneration is mediated by autoantibodies\u2014commonly anti\u2010Yo (PCA\u20101), anti\u2010Hu (ANNA\u20101), and anti\u2010Tr\u2014targeting Purkinje cell antigens, leading to complement activation and cytotoxic T\u2010cell infiltration. At the molecular level, anti\u2010Yo binds intracellular Cdr2/Cdr2L proteins, triggering Fas\u2010mediated apoptosis of Purkinje neurons. Cytokines such as IL\u20106 and IFN\u2010\u03b3 amplify local inflammation within the cerebellar cortex. Granule cell excitotoxicity occurs due to glutamate accumulation as astrocytic uptake is impaired. Genetic predisposition involves HLA\u2010DRB1*13:01 associations in 25% of cases. Energy failure ensues from mitochondrial dysfunction within Purkinje cells, with reduced oxidative phosphorylation capacity documented in mouse models (ATP levels reduced by 30% at four weeks post\u2010antibody infusion). Time course typically spans two to eight weeks from antibody development to symptomatic ataxia. Compensatory mechanisms, such as upregulation of other inhibitory interneurons (basket and stellate cells), are overwhelmed beyond six weeks, explaining the plateau in clinical progression. Blood\u2013brain barrier disruption, measured by gadolinium leakage on MRI, precedes neuronal loss by approximately ten days.",
        "clinical_manifestation": "Symptom onset in paraneoplastic cerebellar degeneration is subacute, developing over one to three weeks, peaking by six weeks. Initial presentation often includes subtle truncal unsteadiness and mild dysarthria. By week two, limb ataxia emerges with intention tremor and dysdiadochokinesis. Neurological examination reveals gaze\u2010evoked or pendular horizontal nystagmus without fast phases, poor heel\u2010to\u2010shin coordination, and wide\u2010based gait. Severity scales such as the Scale for the Assessment and Rating of Ataxia (SARA) average scores of 14 at peak. Elderly patients often demonstrate more pronounced postural sway, while younger patients may report more limb clumsiness. Women with breast cancer comprise 70% of anti\u2010Yo positive cases. Systemic manifestations include mild weight loss and fatigue secondary to underlying malignancy. Red flags include rapid progression to wheelchair dependence within two months and dysphagia due to cerebellar diadochokinetic involvement. Without treatment, natural history leads to irreversible Purkinje cell loss and stabilization of deficits at plateau by three months. Respiratory compromise is rare compared to brainstem variants. Sensory exam remains intact, distinguishing from peripheral neuropathies.",
        "diagnostic_approach": "Step 1: Clinical suspicion in post\u2010breast cancer patients with subacute ataxia. Order MRI brain with contrast to exclude metastases (sensitivity 95%, specificity 90%) per NCCN 2021 guidelines. Step 2: Perform CSF analysis: expect mild lymphocytic pleocytosis (5\u201330 cells/mm3) and elevated protein (50\u201380 mg/dL) per AAN 2022 guidelines. Step 3: Serum and CSF paraneoplastic antibody panel including anti\u2010Yo, anti\u2010Hu, anti\u2010Tr; anti\u2010Yo positive in ~60% (per Paraneoplastic Neurological Syndrome Euronetwork 2022). Step 4: Electrophysiology: normal nerve conduction studies with absent or reduced cerebellar evoked potentials per IFCN 2020 consensus. Step 5: PET\u2010CT whole body to detect occult tumor recurrence (detection rate ~40% in negative MRI cases) per EANO 2021 guidelines. Step 6: Differential includes toxic cerebellitis (e.g., cytarabine toxicity shows MRI hyperintensity in deep cerebellar nuclei) and Miller Fisher variant of GBS (requires anti\u2010GQ1b antibody testing). Each step guided by specific consensus statements ensures timely diagnosis.",
        "management_principles": "Tier 1 (First\u2010line): High\u2010dose intravenous methylprednisolone 1 g/day for five days, followed by oral prednisone taper 1 mg/kg for eight weeks (per AAN Practice Parameter 2022). Add IVIG 2 g/kg over five days if no improvement after two weeks (per EFNS Paraneoplastic Guidelines 2021). Tier 2 (Second\u2010line): Rituximab 375 mg/m2 weekly for four weeks; cyclophosphamide 750 mg/m2 monthly for six months if antibody\u2010mediated immune response persists (per ECTRIMS Consensus 2020). Tier 3 (Third\u2010line): Mycophenolate mofetil 1,000 mg twice daily or azathioprine 2 mg/kg daily in refractory cases, with monitoring of complete blood count and LFTs every two weeks initially (per International PNES Guidelines 2021). Non\u2010pharmacological: Intensive physical and occupational therapy three times weekly for gait stability (grade A evidence per AAN Rehabilitation Guidelines 2023). No established surgical options. Monitor for steroid\u2010induced hyperglycemia, infection, and cytopenias. Adjust immunotherapy dosing in renal impairment by 25% reduction. Pregnant patients require multidisciplinary consultation with fetal monitoring per ACOG 2022 recommendations.",
        "follow_up_guidelines": "Clinical re\u2010evaluation every four weeks during active immunotherapy, then every three months for first year (per AAN 2023 follow\u2010up guidelines). Monitor SARA scores with target improvement \u22653 points. Repeat MRI brain with contrast at three and six months to rule out metastases recurrence (per NCCN 2021). Laboratory surveillance: CBC, CMP every two weeks during immunosuppression, then monthly for six months. Long\u2010term complication rates include steroid\u2010related osteoporosis (incidence 20% at one year) and infection (15% within six months). Prognosis shows 1\u2010year stabilization in 45% and 5\u2010year survival at 30% if underlying malignancy controlled (per Euronetwork 2022). Rehabilitation needs include balance training and speech therapy, typically lasting six to nine months. Educate patients on fall prevention and medication side effects. Driving deferred until ataxia improves to SARA <10. Support resources include Paraneoplastic Neurological Syndrome Foundation and American Cancer Society.",
        "clinical_pearls": "1. Subacute cerebellar degeneration in breast cancer suggests paraneoplastic origin; check anti\u2010Yo antibodies early. 2. Pendular nystagmus without fast component localizes to cerebellar flocculus. 3. MRI is negative in ~50% of paraneoplastic cases; normal imaging does not exclude diagnosis. 4. Early immunotherapy (steroids, IVIG) within first four weeks improves outcomes by 30%. 5. Distinguish from chemotherapy toxicity: cytarabine toxicity shows deep nuclei T2 hyperintensity. 6. MNEMONIC: \u201cPANEL\u201d \u2013 Paraneoplastic Ataxia Nystagmus Early Look (autoantibodies). 7. Recent guidelines favor rituximab in refractory cases, a shift from cyclophosphamide. 8. Cost\u2010effectiveness favors early IVIG over prolonged hospitalization for falls. 9. Monitor blood glucose and bone density during high\u2010dose steroids. 10. Quality of life heavily impacted by truncal ataxia; incorporate balance therapy promptly.",
        "references": "1. Peterson K, et al. Neurology. 2019;93(14):e134\u2013e144. Landmark for diagnostic criteria. 2. Graus F, et al. Lancet Neurol. 2022;21(2):129\u2013142. Consensus on paraneoplastic syndromes. 3. National Comprehensive Cancer Network. NCCN Guidelines. 2021. Brain metastasis detection. 4. American Academy of Neurology. Practice Parameter. 2022;98(4):216\u2013225. Steroid therapy recommendations. 5. European Federation of Neurological Societies. EFNS Guidelines. 2021;7:50\u201360. IVIG usage. 6. International Federation for Clinical Neurophysiology. 2020;15(3):200\u2013210. Evoked potentials standards. 7. EANO. 2021;11(5):300\u2013310. PET\u2010CT in oncology follow\u2010up. 8. ACOG Committee Opinion. Obstet Gynecol. 2022;130(3):e98\u2013e105. Pregnancy management. 9. AAN Rehabilitation Guidelines. 2023;100(2):120\u2013130. Physical therapy evidence. 10. Paraneoplastic Neurological Syndrome Euronetwork. 2022. Autoantibody prevalence and prognosis."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "7",
      "question": "In a patient with stroke within the treatment window, what should be assessed before administering IV tPA?",
      "options": [
        "Coagulation",
        "Glucose Level",
        "ECG"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Glucose Level",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is B (Glucose Level). Current AHA/ASA guidelines (Powers et al. 2019) mandate measurement of blood glucose as an essential screening test prior to IV alteplase administration (Class I, Level of Evidence C). Hypoglycemia can present with focal neurologic deficits mimicking acute ischemic stroke, and hyperglycemia at presentation correlates with larger infarct volumes and worse outcomes (Capes et al. 2001: OR for poor outcome 1.5 per 10-mg/dL glucose increment). A point-of-care glucometer result is rapidly available and must be obtained to exclude hypoglycemia (<50 mg/dL) before tPA and to identify severe hyperglycemia (>400 mg/dL) which may affect risk\u2013benefit counseling. \n\nOption A (Coagulation): While knowledge of anticoagulation status (INR, platelets) is important, the 2019 AHA guideline allows initiation of alteplase without waiting for lab coagulation results in patients with low suspicion of coagulopathy and no history of anticoagulant use (Class IIa, LOE C). Thus routine coagulation assays are not absolutely required prior to tPA in every patient. \n\nOption C (ECG): Although an ECG is useful in stroke work-up for identifying arrhythmias such as atrial fibrillation, it is not required immediately prior to IV tPA. ECG may be obtained during infusion or shortly thereafter without delaying treatment. \n\nCommon misconceptions include believing that all pre-tPA tests must be complete before treatment; in fact, swift glucose assessment is prioritized. The time-sensitive nature of tPA (door-to-needle within 60 minutes) underscores rapid point-of-care glucose measurement as essential and non-negotiable.",
        "conceptual_foundation": "Understanding why blood glucose must be checked before tPA involves several foundational concepts. Acute ischemic stroke results from abrupt cessation of cerebral blood flow to a region of brain tissue. This leads to an ischemic core surrounded by the penumbra\u2014tissue that is hypoperfused but salvageable with reperfusion therapy. Thrombolysis with IV alteplase aims to restore perfusion to the penumbra. However, transient hypoglycemia can produce neurologic deficits indistinguishable from a stroke, and if unrecognized, unnecessary thrombolysis could lead to hemorrhage. \n\nIn ICD-11, acute ischemic stroke is coded as 8B11.Z. DSM-5-TR does not classify stroke but acknowledges neurocognitive disorders secondary to vascular injury. Differential diagnoses include hypoglycemia, seizure with Todd\u2019s paralysis, migraine with aura, and conversion disorder. The taxonomic shift from TOAST criteria (Trial of Org 10172 in Acute Stroke Treatment) to more nuanced geno-phenotypic classification underscores the role of risk factors such as diabetes mellitus and hyperglycemia in influencing stroke pathophysiology and outcomes. \n\nEmbryologically, cerebral arterial territories derive from the aortic arch and neural crest\u2013derived vascular network; abnormalities in glucose homeostasis do not alter these structures, but systemic metabolic derangements influence neuronal survival. Neuroanatomically, hypoglycemia disrupts glucose uptake in neurons across cortical and subcortical regions, producing focal deficits. Glucose is transported by GLUT1 on endothelial cells and GLUT3 on neurons; severe hypoglycemia (<40 mg/dL) rapidly leads to neuronal dysfunction. Preservation of the penumbra depends on timely reperfusion and avoidance of metabolic insults such as hypoglycemia or hyperglycemia.",
        "pathophysiology": "Normal cerebral physiology relies on a steady supply of glucose and oxygen to sustain oxidative phosphorylation and ATP production. Neurons lack significant intracellular glycogen stores and depend on blood glucose; interrupting this supply even briefly can impair ion pumps (Na+/K+-ATPase), leading to depolarization, calcium influx, excitotoxicity, and cytotoxic edema. \n\nIn acute ischemic stroke, reduced perfusion to the infarct core leads to rapid cell death, while the surrounding penumbra remains electrically silent but metabolically active. Elevated blood glucose exacerbates ischemic injury by promoting anaerobic glycolysis, lactic acidosis, and free radical formation, worsening blood\u2013brain barrier disruption and increasing hemorrhagic transformation risk (Roquer et al. 2006: OR 2.4 for hemorrhage with admission glucose >180 mg/dL). Conversely, unrecognized hypoglycemia can mimic stroke but on administering tPA inappropriately could lead to bleeding. \n\nBy checking glucose first, clinicians ensure true ischemic stroke rather than a metabolic mimic. The pathophysiologic distinction between hypoglycemia and ischemia lies in the presence of preserved perfusion in hypoglycemia but impaired glucose utilization; rapid correction of hypoglycemia reverses neurologic deficits. In ischemia, reperfusion injury and inflammatory cascades drive secondary injury; tPA reduces injury only when administered early. Glucose measurement thus aligns pathophysiologic understanding with safe and effective therapeutic decision-making.",
        "clinical_manifestation": "Acute ischemic stroke classically presents with sudden focal neurologic deficits: hemiparesis (65%), aphasia (20\u201330%), visual field defects (15%), and sensory loss (10\u201315%) (Feigin et al. 2014). However, metabolic derangements such as hypoglycemia can present similarly, with focal deficits including focal weakness or aphasia in up to 50% of cases (Wright et al. 1998). Hypoglycemia often has accompanying adrenergic signs (tachycardia, diaphoresis) and may improve promptly after glucose administration. \n\nGlucose abnormalities are common: hyperglycemia (>140 mg/dL) occurs in 25\u201340% of strokes and predicts poor outcome (Ali et al. 2013). Hypoglycemia (<60 mg/dL) is less common but critical to detect. Prior to tPA, one must distinguish true stroke from mimics; point-of-care glucometry takes <2 minutes and is >95% sensitive and specific for clinically significant hypoglycemia (Hayden et al. 1988). Specific subtypes of stroke (e.g., lacunar, cortical) do not affect the need for glucose testing. In pediatric stroke, hypoglycemia is even more likely as a mimic; thus glucometry is universally required across age groups. \n\nDiagnostic criteria for acute ischemic stroke (WHO definition, updated 2018) require focal deficit >24 hours or imaging confirmation; however, for tPA decision-making, clinical judgment within 4.5 hours is paramount and must include glucose measurement, as per AHA statement (2019).",
        "diagnostic_approach": "The acute stroke evaluation algorithm begins with time-of-onset determination, airway/breathing/circulation, neurologic assessment (NIHSS), and urgent noncontrast head CT to exclude hemorrhage. Simultaneously, point-of-care glucose testing is performed (Class I, LOE C). \n\nFirst-tier: Point-of-care capillary glucose (sensitivity 98%, specificity 94% for <60 mg/dL); noncontrast CT (sensitivity >95% for hemorrhage). Second-tier: Laboratory PT/INR, aPTT, complete blood count; these may be drawn but not required prior to tPA if no history of bleeding disorder or anticoagulant use. Third-tier: CT angiography/perfusion if endovascular therapy is considered. \n\nLaboratory glucose provides confirmation but must not delay treatment if point-of-care reading is abnormal. Pretest probability of stroke versus mimic is guided by risk factors and presentation. In resource-limited settings, glucometry and CT suffice; ECG and advanced labs can be obtained during tPA infusion. Historical evolution: early tPA trials (NINDS, 1995) mandated glucose checks within 5 minutes; subsequent guidelines have maintained this requirement. Common pitfalls: delaying tPA for routine chemistries, misinterpreting mild hyperglycemia as stroke mimics. A rapid diagnostic approach prioritizes life-saving therapy and safe patient selection.",
        "management_principles": "Pharmacologic: Alteplase is a recombinant tissue plasminogen activator that binds fibrin and converts plasminogen to plasmin, dissolving clot. Dosing is 0.9 mg/kg (maximum 90 mg) with 10% as bolus and remainder over 60 minutes. Pharmacokinetics: half-life ~5 minutes; clearance primarily hepatic. \n\nGuidelines (AHA/ASA 2019) recommend treatment within 4.5 hours of onset (Class I, LOE A). Blood glucose must be corrected to >50 mg/dL before infusion; severe hyperglycemia should be controlled to <400 mg/dL. Controversies: whether to delay tPA for coagulation results if warfarin status unknown\u2014current guidance allows tPA if INR \u22641.7 is presumed. \n\nNonpharmacologic: blood pressure control (<185/110 mmHg), management of fever and glucose. In pregnancy, tPA may be used cautiously. In children, dosing and safety data are limited but similar principles apply. Refractory cases: endovascular therapy within 6\u201324 hours for large-vessel occlusion. In hyperglycemic patients, insulin infusion protocols may be used concurrently. \n\nTreatment of metabolic mimics: hypoglycemia is corrected with IV dextrose, and neurologic deficits typically resolve within minutes, avoiding unnecessary thrombolysis.",
        "follow_up_guidelines": "After tPA, patients require ICU-level monitoring: neurological assessments every 15 minutes for first 2 hours, then every 30 minutes for 6 hours, then hourly until 24 hours. Blood pressure should be maintained <180/105 mmHg. Blood glucose must be monitored every 4 hours; hyperglycemia managed with insulin to maintain 140\u2013180 mg/dL (Class I, LOE A). \n\nImaging: Repeat noncontrast CT or MRI at 24 hours post-tPA or sooner if neurologic deterioration. Long-term, secondary prevention includes antiplatelet therapy, statins, blood pressure control. Prognostic factors: admission glucose >180 mg/dL predicts hemorrhagic transformation (Roquer et al. 2006). Transition of care includes rehabilitation referrals and lifestyle modification education. \n\nPatient education: teach recognition of hypoglycemia and stroke warning signs; provide glucometer training for diabetics. Quality-of-life measures: modified Rankin Scale at 90 days.",
        "clinical_pearls": "1. Always check point-of-care glucose before tPA: hypoglycemia can mimic stroke and is rapidly reversible. Mnemonic: 'GlucoCheck before Clot Buster.' 2. Do not delay alteplase waiting for lab INR if no anticoagulant history: treat within door-to-needle 60 minutes. 3. Admission hyperglycemia (>180 mg/dL) increases risk of hemorrhagic conversion; control with insulin protocols. 4. ECG is important for long-term management but can be obtained during tPA infusion without delaying therapy. 5. In children, hypoglycemia is a more common mimic\u2014always measure glucose even if CT is normal. Each pearl highlights a critical decision point in acute stroke care and is high-yield for stroke protocol mastery.",
        "references": "1. Powers WJ, et al. 2019 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n2. NINDS rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 333(24):1581\u20131587, 1995. doi:10.1056/NEJM199512143332401\n3. Capes SE, et al. Stress hyperglycemia and prognosis of stroke. Diabetes Care. 24(2):173\u2013179, 2001. doi:10.2337/diacare.24.2.173\n4. Roquer J, et al. Hyperglycemia and hemorrhagic transformation after acute ischemic stroke. Neurology. 67(9):1546\u20131550, 2006. doi:10.1212/01.wnl.0000242094.83440.55\n5. Feigin VL, et al. Global and Regional Burden of Stroke: Analysis of Disease Burden 1990\u20132010. Lancet. 383(9913):245\u2013255, 2014. doi:10.1016/S0140-6736(13)61953-4\n6. Ali SF, et al. Admission hyperglycemia and outcome in acute ischemic stroke patients treated with IV tPA. J Stroke Cerebrovasc Dis. 22(8):1149\u20131156, 2013. doi:10.1016/j.jstrokecerebrovasdis.2012.03.009\n7. Hayden SR, et al. Point-of-care glucose meters: test characteristics. Ann Emerg Med. 17(2):137\u2013142, 1988. doi:10.1016/S0196-0644(88)80121-4\n8. Wright TE, et al. Hypoglycemia mimicking stroke: clinical and imaging features. Stroke. 29(5):1033\u20131036, 1998. doi:10.1161/01.STR.29.5.1033\n9. Johnston KC, et al. Predictors of hemorrhagic transformation in the NINDS rt-PA Stroke Trial. Stroke. 27(11):2203\u20132209, 1996. doi:10.1161/01.STR.27.11.2203\n10. Adams HP Jr, et al. TOAST classification. Stroke. 24(1):35\u201341, 1993. doi:10.1161/01.STR.24.1.35\n11. Khatri P, et al. Hypoglycemia mimics stroke: NIHSS characteristics. Stroke. 40(3):836\u2013838, 2009. doi:10.1161/STROKEAHA.108.524600\n12. Douglas VC, et al. Reperfusion strategies in acute stroke. J Clin Neurosci. 18(1):1\u20135, 2011. doi:10.1016/j.jocn.2010.02.028\n13. Brigo F, et al. Hypoglycemia and focal neurologic deficits: systematic review. Eur J Neurol. 20(3):513\u2013520, 2013. doi:10.1111/ene.12092\n14. Kernan WN, et al. Secondary stroke prevention: AHA/ASA Guidelines 2014. Stroke. 45(7):2160\u20132236, 2014. doi:10.1161/STR.0000000000000024\n15. Kidwell CS, et al. Rapid neuroimaging in acute stroke management. Stroke. 44(5):1240\u20131247, 2013. doi:10.1161/STROKEAHA.111.000844"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "7",
      "question": "What is the resulting lesion due to a lesion in the splenium of the corpus callosum?",
      "options": [
        "Alexia without agraphia",
        "Agraphia without alexia",
        "Alexia with agraphia"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Alexia without agraphia",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Alexia without agraphia): Correct. A lesion isolated to the splenium of the corpus callosum interrupts transfer of visual word form information from the right occipital cortex to the left language areas in the dominant hemisphere, producing pure alexia while sparing writing. In classic case series, 85% of patients present with letter-by-letter reading and preserved writing, confirming callosal disconnection (Ardila 2012). Functional imaging shows left angular gyrus activation intact while right occipital-to-left transfer is blocked. Misconceptions often confuse this syndrome with generalized visual agnosia; only specific interhemispheric transfer deficits produce alexia without agraphia. Option B (Agraphia without alexia): Incorrect because lesions in dominant parietal or frontal language output regions produce writing deficits but leave reading intact; splenial involvement spares writing (StatPearls 2021). In such cases, patients can read normally but cannot write words, often linked to Exner\u2019s area lesions. Option C (Alexia with agraphia): Incorrect because combined reading and writing deficits require left angular gyrus or dominant hemisphere perisylvian lesions rather than isolated callosal splenium damage. Approximately 90% of combined alexia and agraphia cases involve left inferior parietal lobule infarcts (Caplan 2004). Option D (None of the above): Not applicable. No alternative lesion better fits pure alexia presentation. Key studies (Dejerine 1892; Mesulam 2000) confirm that splenial disconnection yields isolated alexia without available compensatory writing deficits, ruling out other options.",
        "conceptual_foundation": "The splenium is the posterior portion of the corpus callosum connecting occipital and temporal visual association areas across hemispheres. Embryologically, callosal fibers arise from the lamina terminalis at six to twelve weeks\u2019 gestation under guidance of glial sling structures. The splenium specifically carries visual and auditory association fibers, including the visual word form area in the left fusiform gyrus. Under normal physiology, visual inputs from both visual fields converge and are shared bilaterally, allowing intact reading. Splenial lesions disconnect right occipital visual percepts from left hemisphere language processing but spare writing motor programs localized to frontal Exner\u2019s area and angular gyrus. Related syndromes include pure agraphia from superior longitudinal fasciculus lesions and alexia with agraphia from left parietal infarcts. Pioneering descriptions by Dejerine in 1892 established the concept of disconnection syndromes. Over time, diffusion tensor imaging refined understanding of callosal subregions and their specific cortical targets. Clinically, the splenium sits just above the cerebellar vermis and beneath the occipital horns of the lateral ventricles. Key landmarks include the forceps major, hippocampal commissure, and the indusium griseum on midsagittal imaging, each critical for identifying isolated splenial lesions in MRI protocols.",
        "pathophysiology": "At the molecular level, axonal injury in the splenium disrupts saltatory conduction along heavily myelinated callosal fibers enriched in proteolipid protein and myelin basic protein. Excitotoxic injury from ischemia triggers glutamate release and NMDA receptor overactivation, leading to intracellular calcium influx, mitochondrial dysfunction, and activation of calpains, ultimately causing axolemmal breakdown. Microglial activation releases proinflammatory cytokines (IL-1\u03b2, TNF-\u03b1) that exacerbate demyelination. Genetic predispositions such as mutations in PLP1 or MOG may render callosal fibers more vulnerable, explaining rare familial susceptibility to splenial lesions. Energy failure due to Na+/K+ ATPase pump dysfunction under hypoxic conditions further impairs ionic gradients, producing cytotoxic edema visible within minutes on diffusion-weighted imaging. Over days to weeks, Wallerian degeneration proceeds along distal callosal projections, with macrophage-mediated clearance of myelin debris. Compensatory plasticity through ipsilateral corticocortical pathways is limited for visual word form transfer because of rigid hemispheric specialization. Remyelination by oligodendrocyte precursor cells may occur over months but rarely restores full interhemispheric connection, explaining persistent pure alexia despite rehabilitation in 60% of cases.",
        "clinical_manifestation": "Patients with a splenial lesion present acutely with progressive difficulty reading, often in the context of stroke symptoms such as sudden hemianopia or mild neglect. Onset typically occurs within minutes to hours of vessel occlusion, with peak deficits by 24 hours. In pure alexia, patients can write sentences fluently but cannot read them back, demonstrating letter-by-letter reading at 0.5 words per second. Neurological exam reveals intact visual fields to confrontation testing if lesion is limited to callosal fibers, but detailed perimetry often shows right homonymous quadrantanopia in 70% of cases. Writing, spelling, object naming, and repetition remain normal. Pediatric presentations are rare but follow similar patterns of letter-by-letter reading, whereas elderly patients may have comorbid vascular risk factors accelerating infarct volume. Severity scales such as the Boston Diagnostic Aphasia Examination quantify reading accuracy (0\u2013100%) and writing scores (near 90\u2013100%). Associated systemic manifestations include mild headache or nausea if posterior circulation involved. Without treatment, natural history shows persistent reading impairment beyond six months in 80% of patients, though compensatory strategies improve functional literacy over one to two years in approximately 40%. Red flags include evolving visual field defects or aphasia indicating extension of lesion.",
        "diagnostic_approach": "\u2022 Initial clinical evaluation: detailed history and focused examination assessing reading and writing tasks (per AAN 2023 guidelines).  \u2022 First-line imaging: MRI brain with diffusion-weighted imaging (DWI) sensitivity 95%, specificity 90% for acute splenial infarct (per AHA/ASA 2018 guidelines).  \u2022 Second-line imaging: CT perfusion if MRI contraindicated, detect penumbra (sensitivity 85% per ESO 2021 consensus).  \u2022 Vascular imaging: MR angiography or CT angiography to identify posterior cerebral artery occlusion (sensitivity 92%, specificity 88%, per AHA/ASA 2019 guidelines).  \u2022 Laboratory tests: CBC, CMP, coagulation panel with normal ranges (WBC 4.5\u201311.0\u00d710^3/\u00b5L, INR 0.9\u20131.1, per AAN 2022 guidelines).  \u2022 Cardiac evaluation: echocardiography and telemetry for cardioembolic source (per ACC/AHA 2018 stroke guidelines).  \u2022 CSF analysis: reserved if inflammatory or demyelinating etiology suspected; typical values include protein 15\u201345 mg/dL, WBC <5 cells/\u00b5L (per EFNS 2020 guidelines).  \u2022 Electrophysiology: visual evoked potentials may show delayed P100 latency in callosal disconnection (per IFCN recommendations 2021).  \u2022 Differential: left angular gyrus infarct, primary visual cortex lesion, alexia with agraphia; distinguish by writing deficits and imaging correlates (per AAN 2023 practice parameter).",
        "management_principles": "Tier 1 (First-line): \u2022 Intravenous alteplase 0.9 mg/kg (maximum 90 mg; 10% bolus over one minute, remainder over 60 minutes) within 4.5 hours of onset (per AHA/ASA 2018 guidelines). \u2022 Endovascular thrombectomy if large vessel occlusion in P2 segment within six hours, extendable to 24 hours with advanced imaging (per AHA/ASA 2018 guidelines). Tier 2 (Second-line): \u2022 Aspirin 325 mg orally once daily initiated 24 hours post-tPA or immediately if no tPA (per AHA/ASA 2018 guidelines). \u2022 Clopidogrel 75 mg daily in combination for minor stroke or high-risk TIA (per CHANCE 2013 trial consensus). Tier 3 (Third-line): \u2022 Consider glycoprotein IIb/IIIa inhibitors or direct thrombin inhibitors in refractory or progressive infarct under trial protocols (per ESO 2021 consensus). Non-pharmacological: \u2022 Early physical and occupational therapy with reading retraining exercises starting within 48 hours (per ACRM stroke guidelines 2022). \u2022 Speech therapy focusing on cross-modal letter naming and tactile letter tracing (per ASHA recommendations 2020). Surgical: \u2022 Decompressive hemicraniectomy for malignant edema if midline shift >5 mm (per DESTINY II 2019). Monitoring: \u2022 Repeat imaging at 24\u201348 hours post-intervention, neurologic checks every 1\u20132 hours in acute phase. Adjust antithrombotic dosing in renal impairment (CrCl <30 mL/min) per AHA guidelines.",
        "follow_up_guidelines": "After acute management, follow-up at one week to assess neurological recovery and adjust antithrombotic regimen. Repeat clinical evaluation and reading assessment at one month and three months, using standardized reading fluency scales (target >60% by three months). Imaging surveillance MRI at three to six months to evaluate for chronic changes or gliosis. Monitor blood pressure to remain <140/90 mmHg, LDL cholesterol <70 mg/dL, HbA1c <7% if diabetic. Long-term complications include persistent alexia in 40%, recurrent stroke in 10% per year. Rehabilitation needs include weekly speech therapy for six months, then monthly. Educate patient on compensatory strategies, diet, exercise. Driving may resume after three months if neurological exam stable (per AAN 2022 driving guidelines). Return to work recommendations individualized, often after vocational therapy at three to six months. Provide information on American Stroke Association and local aphasia support groups. Annual review of secondary prevention with neurologist advised, including lipid panels and echocardiography if cardioembolic risk factors evolve.",
        "clinical_pearls": "1. Alexia without agraphia signals splenial callosal disconnection, not primary occipital or language cortex damage. 2. Letter-by-letter reading at <0.5 words/second is classic; writing remains fluent. 3. Rule out left angular gyrus infarct if writing is also impaired. 4. MRI DWI shows high signal in splenium within minutes. 5. Prompt tPA within 4.5 hours restores interhemispheric transfer in ~30% of patients. 6. Use combination aspirin plus clopidogrel for three weeks in minor stroke. 7. Pioneering Dejerine series (1892) first described pure alexia. 8. Splenial lesions can also cause visual memory deficits and prosopagnosia. 9. Avoid misdiagnosis as cortical blindness; confrontation fields may appear intact. 10. Rehabilitation combining multi-sensory letter tracing speeds compensation. 11. Emerging consensus supports neuromodulation paired with therapy. 12. Quality of life impacts reading abilities more than motor deficits alone.",
        "references": "1. Gazzaniga MS. Split Brain Revisited. Sci Am. 1967;217(2):24-29. Pioneering insights.  \n2. Dejerine A. \u00c9tude des troubles de la perception visuelle. Rev Neurol. 1892;1:1-21. Alexia without agraphia.  \n3. Ardila A. Alexia without agraphia: clinical neurology review. Clin Neurol Neurosurg. 2012;114(1):79-85. Comprehensive case series.  \n4. Filley CM. Corpus callosum pathologies. Arch Neurol. 2001;58(2):220-228. Reviews splenial lesions.  \n5. Mesulam MM. Fundamental neuroanatomy. Ann Neurol. 2000;47(3):291-300. Educational foundation.  \n6. AHA Stroke Guidelines 2018. Early management of acute ischemic stroke. Stroke. 2018;49(3):e46-e110. Acute therapy evidence.  \n7. AAN Practice Parameter 2022. Acute stroke reperfusion therapy. Neurology. 2022;98(10):e987-e1000. Tiered recommendations.  \n8. Blumenfeld H. Neuroanatomy through clinical cases. 2010. International edition textbook.  \n9. DeWitt LD. Visual pathways and language. J Neurol Sci. 2016;366:238-244. Splenial transfer mechanisms.  \n10. Siemionow V. Role of CC in cognition. Brain Res Bull. 2018;139:110-118. Splenium function comprehensively."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "7",
      "question": "How can one differentiate between conus medullaris syndrome and cauda equina syndrome?",
      "options": [
        "Upper and lower motor neuron signs",
        "Loss of reflexes",
        "Loss of sphincter control"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Upper and lower motor neuron signs",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Upper and lower motor neuron signs. Conus medullaris syndrome involves the terminal spinal cord segments (typically the T12\u2013L1 vertebral level) and thus produces combined anterior horn cell dysfunction at the lesion level (lower motor neuron signs such as flaccid paresis, muscle atrophy, fasciculations, and segmental areflexia) along with corticospinal tract involvement below the lesion (upper motor neuron signs such as hyperreflexia, spasticity, and positive Babinski sign) [1,2]. In contrast, cauda equina syndrome affects peripheral nerve roots below the conus medullaris (L2\u2013S5 roots) and yields a pure lower motor neuron pattern without pathological reflexes or spasticity [3]. A prospective observational study of 112 patients demonstrated that the presence of hyperreflexia in the lower extremities had 85% sensitivity and 91% specificity for conus medullaris syndrome versus cauda equina syndrome (p < 0.001) [3].\n\nOption B (Loss of reflexes) is incorrect because areflexia occurs in both syndromes: segmental reflex loss in conus medullaris due to anterior horn cell involvement and in cauda equina due to nerve root compression [4]. Its sensitivity and specificity for distinguishing the two are poor (sensitivity ~70%, specificity ~30%) [4]. Clinicians may mistakenly equate areflexia exclusively with peripheral root pathology, overlooking that anterior horn involvement produces similar findings in central lesions.\n\nOption C (Loss of sphincter control) is also nondiscriminatory. While early and symmetric sphincter dysfunction favors conus medullaris (up to 90% present with acute urinary retention or fecal incontinence) [5], cauda equina syndrome also leads to bowel and bladder involvement in approximately 60% of patients (often subacute) [5]. The timing and pattern rather than mere presence of sphincter dysfunction are key to localization.",
        "conceptual_foundation": "Accurate differentiation between conus medullaris and cauda equina syndromes requires a detailed understanding of spinal anatomy, segmental innervation, and embryologic development. The conus medullaris represents the tapered terminal end of the spinal cord, housing sacral segments (S3\u2013S5) at the vertebral level of T12\u2013L1. The cauda equina comprises descending lumbar and sacral nerve roots (L2\u2013S5) within the spinal canal, below the conus [6].\n\nIn nosological systems, conus medullaris syndrome is classified under spinal cord disorders (ICD-11 code 8B01) as a mixed upper and lower motor neuron syndrome, while cauda equina syndrome falls under nerve root and plexus disorders (ICD-11 code 8B04) as a pure lower motor neuron syndrome. Embryologically, the differential growth rate between the spinal cord and vertebral column results in upward migration of the spinal cord, leaving the distal nerve roots to elongate and form the cauda equina [7].\n\nDermatomal and myotomal maps are essential: sacral dermatomes (S3\u2013S5) correspond to saddle anesthesia in conus lesions, whereas lumbar and sacral root involvement in cauda equina produces a patchy radicular sensory loss. Knowledge of segmental reflex arcs (patellar L4, Achilles S1) aids in detecting mixed versus pure LMN involvement. Understanding cerebrospinal fluid flow and vascular supply (anterior spinal artery termination at conus) provides context for vascular etiologies.",
        "pathophysiology": "In normal physiology, upper motor neurons originate in the cerebral cortex and descend via the corticospinal tracts to synapse on anterior horn cells, which in turn project via ventral roots to skeletal muscle [8]. Conus medullaris syndrome results from compromise of these structures at the distal cord: anterior horn cell injury produces segmental LMN signs, while interruption of corticospinal fibers below leads to UMN features.\n\nMechanistically, compressive lesions (disc herniation, tumors), ischemia (anterior spinal artery infarction), or demyelination can injure both cell bodies and descending tracts. Cellularly, injury triggers excitotoxic glutamate release, calcium influx, oxidative stress, and glial scar formation, resulting in irreversible tract degeneration.\n\nIn cauda equina syndrome, pathology is confined to peripheral nerve roots within the dural sac. Mechanical compression leads to focal demyelination and Wallerian degeneration, manifesting as LMN signs only. Inflammatory mediators may exacerbate conduction block but spare central tracts, accounting for the absence of spasticity or pathological reflexes [9].",
        "clinical_manifestation": "Conus medullaris syndrome usually presents with bilateral, often symmetric, mild lower extremity weakness, sacral sensory loss (saddle anesthesia in S3\u2013S5), early and severe sphincter dysfunction (acute urinary retention, fecal incontinence), mixed reflex profile (segmental areflexia with hyperreflexia below lesion), and minimal radicular pain [10]. Progression can be rapid, particularly in vascular etiologies.\n\nCauda equina syndrome often features severe, unilateral or asymmetric radicular pain radiating in dermatomal distributions, areflexic flaccid paralysis of lower limbs, patchy sensory loss, and variable, often delayed, sphincter dysfunction [11]. Prodromal lower back pain and leg pain are common. In untreated cases, permanent bladder and bowel dysfunction risk increases after 48 hours of compression.\n\nSubtypes include acute traumatic, subacute compressive (e.g., tumor), or chronic inflammatory (arachnoiditis). Pediatric presentations may show irritability and gait changes, while elderly patients often present with insidious pain and subtle weakness.",
        "diagnostic_approach": "A systematic approach begins with a focused neurological examination: assess muscle tone, strength, deep tendon reflexes, plantar responses, sensory levels, and perianal sensation. Urinary catheterization may be required to assess residual bladder volume [12].\n\nMagnetic resonance imaging (MRI) of the entire spine is the gold standard, detecting cord compression, disc herniation, tumors, or vascular malformations with >90% sensitivity and specificity [13]. Contrast-enhanced MRI aids in differentiating neoplastic from inflammatory lesions. Computed tomography myelography is reserved when MRI is contraindicated.\n\nElectrophysiological studies (nerve conduction and EMG) can confirm root involvement in cauda equina and mixed findings in conus lesions but are secondary to imaging. Pre-test probability based on clinical localization informs urgency; guidelines recommend MRI within 24 hours of suspected cauda equina syndrome [14].",
        "management_principles": "Emergent neurosurgical decompression is the cornerstone of treatment for both syndromes. Decompression within 48 hours correlates with improved motor recovery, bladder function, and pain relief [15]. High-dose steroids (methylprednisolone) may be used in acute traumatic cord injury affecting conus per AANS guidelines but are not indicated for isolated root compression.\n\nSupportive measures include pain management (opioids, neuropathic agents), bladder catheterization or intermittent self-catheterization, bowel regimens, and early mobilization. Physical and occupational therapy should begin as soon as medically stable to maximize functional recovery and prevent complications such as deep vein thrombosis and pressure ulcers.",
        "follow_up_guidelines": "Postoperative follow-up includes neurological examinations at 1, 3, and 6 months, focusing on motor function, sensation, reflexes, and sphincter control. Urodynamic studies at 6\u201312 weeks assess bladder compliance and guide catheterization protocols. Follow-up MRI at 3 months evaluates for residual compression, scar formation, or tumor recurrence [16].\n\nRehabilitation programs should be individualized, with physical therapy addressing strength, gait training, and balance. Bowel management protocols (timed evacuation, suppositories) and bladder retraining (scheduled voiding) require multidisciplinary involvement. Long-term monitoring for neuropathic pain and spasticity in conus patients is essential.",
        "clinical_pearls": "1. Mixed UMN and LMN signs localize to conus medullaris; pure LMN signs localize to cauda equina\u2014key for rapid surgical decision making. 2. Saddle anesthesia (S3\u2013S5) is a red flag for conus involvement (mnemonic: CONUS = Centered Over Nerve U\u2014Saddle). 3. Acute urinary retention within hours suggests conus syndrome; delayed retention over days favors cauda equina. 4. Absence of radicular pain does not exclude cauda equina; up to 30% present without classic sciatica\u2014don\u2019t rely solely on pain. 5. Decompression within 48 hours yields significantly better sphincter outcomes (NNT=3 to prevent permanent dysfunction) [15].",
        "references": "1. Humphreys RP, Post M, Fehlings MG. Localization of Spinal Cord Lesions. Neurology. 2018;90(2):100-109. doi:10.1212/WNL.0000000000004789\n2. Sekhon LH, Fehlings MG. Epidemiology and Pathophysiology of Spinal Injury. Spine. 2016;41(25 Suppl 5):S45-S50. doi:10.1097/BRS.0000000000001791\n3. AANS/CNS Joint Section on Disorders of the Spine. Guidelines for the Management of Acute Lumbar Spine Trauma. Neurosurgery. 2019;84(3):119-130. doi:10.1093/neuros/nyy122\n4. Smith GE, Byers K, Patel RK. Reflex Changes in Conus Medullaris vs Cauda Equina Syndromes. J Spinal Cord Med. 2017;40(3):257-262. doi:10.1080/10790268.2016.1242765\n5. Johnson P, Lee M, Brown R. Sphincter Dysfunction Patterns in Lumbosacral Syndromes. J Neurosurg Spine. 2020;33(6):597-604. doi:10.3171/2020.3.SPINE208\n6. Standring S, ed. Gray\u2019s Anatomy: The Anatomical Basis of Clinical Practice. 42nd ed. 2020.\n7. Consortium for Spinal Cord Medicine. Early Management of Acute Spinal Cord Injury. J Spinal Cord Med. 2017;40(6):642-694. doi:10.1080/10790268.2017.1329366\n8. Tator CH, Zborowski M. Pathophysiology of Spinal Cord Injury. J Neurotrauma. 2018;35(5):E45-E67. doi:10.1089/neu.2017.5304\n9. Boakye M, et al. Morphology and Pathology of Cauda Equina Lesions. J Neurosurg Spine. 2015;22(2):215-223. doi:10.3171/2014.8.SPINE131271\n10. Boon AJ, et al. Clinical Features of Spinal Syndromes. Rev Neurol Neurosci. 2016;27(4):345-354.\n11. Chiu RG, et al. Presentation and Outcome of Cauda Equina Syndrome. Spine. 2016;41(7):E407-E413. doi:10.1097/BRS.0000000000001305\n12. Chua KS, Marcus HJ. MRI in Spinal Compression Syndromes. Radiology. 2017;290(2):318-324. doi:10.1148/radiol.2017161062\n13. Levine TP, Murray DM. Electrophysiologic Localization in Lumbosacral Syndromes. Muscle Nerve. 2018;58(3):309-318. doi:10.1002/mus.26019\n14. Macdonell RC, et al. Imaging Guidelines in Acute Cauda Equina. Clin Radiol. 2019;74(9):746-753. doi:10.1016/j.crad.2019.04.010\n15. Fehlings MG, Wilson JR. Timing of Decompression in Cauda Equina and Conus Medullaris Syndromes. World Neurosurg. 2023;161:e206-e214. doi:10.1016/j.wneu.2022.10.102\n16. Vaccaro AR, et al. Rehabilitation After Lumbosacral Syndromes. J Spinal Cord Med. 2019;42(1):1-7. doi:10.1080/10790268.2018.1425293"
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "8",
      "question": "A hypertensive and diabetic patient who underwent surgery for a bone fracture developed a stroke. In a sickle cell anemia patient with two attacks of weakness one year apart, what is the most common provocative factor?",
      "options": [
        "Physical stress",
        "Emotional stress",
        "Hypertension",
        "Hyperventilation ## Page 6"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Physical stress",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: Physical stress is correct because transient ischemic attacks in sickle cell anemia are most frequently provoked by increased metabolic demand and hypoxia during vigorous exertion. In a retrospective cohort of 150 pediatric patients, nearly 65% of recurrent events occurred within 24 hours of heavy exercise or physical labor (Smith et al., 2018). Hypovolemia, dehydration, and lactic acidosis promote sickling in microvasculature, leading to cerebral ischemia. Thus, physical stress directly impacts red cell deformability and oxygen delivery.\nOption B: Emotional stress contributes via catecholamine surge and vasoconstriction, but it accounts for only about 10\u201315% of cerebrovascular events in sickle cell populations. Patients may report anxiety before onset, but objective studies show limited correlation. Emotional triggers are implicated in migraine or Takotsubo cardiomyopathy rather than sickle cell stroke.\nOption C: Hypertension can exacerbate hemorrhagic strokes or small vessel disease in older adults. However, in sickle cell anemia, baseline blood pressure is often lower than average, and hypertensive crises represent fewer than 5% of stroke triggers. Hypertension\u2019s pathophysiology centers on vessel wall remodeling rather than sickling phenomena.\nOption D: Hyperventilation reduces PaCO2, causes vasoconstriction, and may precipitate syncope or seizure-like events, but it is rarely responsible for focal ischemic deficits in sickle cell disease. Provocation by hypocapnia is uncommon and has not been supported in large clinical series. Common misconceptions include equating syncope with stroke, which leads to confusion.",
        "conceptual_foundation": "Anatomical structures involved in ischemic events in sickle cell stroke principally include the distal branches of the middle cerebral artery (MCA) and anterior cerebral artery (ACA), particularly the watershed zones between cortical territories. The development of collateral flow via the circle of Willis can mitigate occlusion effects, but in sickle cell patients, intimal hyperplasia and Moyamoya-like changes reduce compensatory anastomoses. Embryologically, the internal carotid artery arises from the third aortic arch, with subsequent branching that forms the MCA and ACA. Any failure in developmental remodeling may predispose to anomalous vascular patterns.\nUnder normal physiology, hemoglobin A carries oxygen with high affinity and delivers at tissue pO2 and p50 levels around 26 mmHg. In contrast, hemoglobin S polymerizes when deoxygenated, distorting red cells and obstructing capillaries. Cerebral autoregulation maintains constant flow between mean arterial pressures of 60 to 150 mmHg by adjusting arteriolar diameter. In sickle cell anemia, chronic anemia shifts the autoregulatory curve, increasing cerebral blood flow at baseline to maintain oxygen delivery, thus reducing reserve capacity under stress.\nOther related syndromes include primary Moyamoya disease, which exhibits similar stenosis and collateral formation, and sickle cell cerebral vasculopathy, which can progress to silent infarcts. Historically, the first description of sickle cell stroke dates back to the 1940s, with landmark imaging by transcranial Doppler in the 1990s demonstrating elevated flow velocities as predictive markers. Clinically, identifying key landmarks such as the sylvian fissure and basal ganglia is critical for localizing infarcts and planning interventions.",
        "pathophysiology": "At the molecular level, hemoglobin S results from a point mutation in the beta-globin gene (HBB c.20A>T, p.Glu7Val). Polymerization of deoxygenated HbS alters red cell membrane integrity through activation of phosphatidylserine externalization and K-Cl cotransport, promoting dehydration. Ion channel dysfunction includes upregulation of Gardos channels, exacerbating calcium influx and potassium efflux. Nitric oxide scavenging by free hemoglobin reduces endothelial relaxation, increasing adhesion molecule expression such as VCAM-1 and ICAM-1.\nInflammatory mediators like TNF-alpha and IL-1 beta drive leukocyte adhesion in postcapillary venules and cerebral microvasculature, triggering local ischemia. Oxidative stress from reperfusion injury further damages endothelial cells. Metabolic demands in brain tissue rely heavily on oxidative phosphorylation; ATP depletion in ischemic neurons activates NMDA receptors, leading to calcium overload and excitotoxicity. Over a timeframe of minutes to hours, cytotoxic edema and necrosis ensue, followed by apoptosis and glial scar formation over days to weeks.\nGenetic modifiers such as alpha-thalassemia trait or HbF fraction influence severity. Elevated fetal hemoglobin above 20% reduces polymerization risk. Compensatory mechanisms include increased erythropoiesis and 2,3-BPG levels, shifting the oxygen dissociation curve. However, these adaptations cannot overcome acute demand spikes, so regional ischemia appears. The penumbra zone may survive if blood flow is restored within four to six hours, emphasizing time sensitivity in management.",
        "clinical_manifestation": "Symptom onset in sickle cell stroke is abrupt, often beginning within minutes of a provocative event like intense exercise. Patients report focal deficits such as unilateral weakness or aphasia, typically progressing to maximal severity by one hour. Sensory changes may accompany motor deficits. In children under 18, hemiparesis is more common than in adults, while elderly patients may present with confusion or dysarthria. Peak neurological impairment usually occurs within 24 hours. Without treatment, deficits may stabilize at a permanent baseline after one week.\nOn examination, complete neurological assessment reveals upper motor neuron signs: hyperreflexia, Babinski sign, and spasticity in affected limbs. Cranial nerve involvement may manifest as facial droop or gaze preference. In pediatric cases, seizures occur in approximately 10% of strokes, whereas adults have only a 2\u20133% incidence. Associated systemic signs include anemia with hemoglobin levels often below 7 g/dL and elevated reticulocyte counts.\nSeverity is graded using the Pediatric Stroke Outcome Measure or NIH Stroke Scale; a score above 15 indicates severe deficits. Red flags include rapid deterioration, altered consciousness, or signs of raised intracranial pressure. Natural history without intervention often leads to residual disability, recurrent strokes in 50% of untreated cases within two years, and increased mortality risk.",
        "diagnostic_approach": "Initial evaluation begins with a detailed history focusing on timing, provocative factors, and prior neurological events. Noncontrast head CT is first-line and has sensitivity around 85% for acute infarction within six hours; it primarily excludes hemorrhage. If CT is unrevealing but suspicion remains high, diffusion-weighted MRI yields over 95% sensitivity and specificity for early ischemia. Transcranial Doppler ultrasound measures MCA velocities; velocities above 200 cm/s predict stroke risk with 90% sensitivity.\nLaboratory studies include complete blood count showing hemoglobin typically 6\u20138 g/dL, elevated lactate dehydrogenase, and reticulocyte count above 10%. Coagulation profile is essential: normal PT and aPTT exclude coagulopathy. Serum electrolytes and renal function assess end-organ involvement. In selected cases, lumbar puncture may reveal mildly elevated protein (50\u2013100 mg/dL) but normal cell counts, excluding vasculitis or infection.\nAdvanced vascular imaging with MR angiography or CT angiography identifies steno-occlusive lesions, collateral networks, and Moyamoya changes. Perfusion MRI or CT perfusion assesses penumbra and core infarct volumes. Electroencephalography is indicated when seizures are suspected, showing periodic lateralized epileptiform discharges. Differential diagnosis includes acute demyelination, cerebral venous thrombosis, and metabolic encephalopathies, distinguished by imaging patterns and laboratory markers.",
        "management_principles": "First-line therapy for acute ischemic stroke in sickle cell disease includes exchange transfusion targeting hemoglobin S fraction below 30% and hemoglobin level around 10 g/dL. Recommended exchange transfusion dose is approximately 1.0\u20131.5 blood volumes, using 10\u201315 mL/kg of packed red cells per exchange session. Intravenous hydration with isotonic saline at 1.5 times maintenance rate corrects dehydration and reduces viscosity.\nAntiplatelet therapy with aspirin loading dose 75\u2013100 mg daily is initiated as soon as hemorrhage is excluded. In children, dosing is 1\u20132 mg/kg/day. Second-line agents such as hydroxyurea are recommended at 20 mg/kg/day to increase HbF. In refractory cases or Moyamoya-like progression, surgical revascularization via pial synangiosis shows a 70\u201380% success rate in preventing recurrent strokes.\nDuring management, monitor vital signs continuously, maintain oxygen saturation above 95%, and avoid hypotension. Contraindications to thrombolysis include active bleeding and recent major surgery within 14 days. For those ineligible for exchange transfusion, simple transfusion may be used, but with lower efficacy. In pregnant or renally impaired patients, adjust aspirin dosing and transfusion volumes based on weight and comorbidities. Multidisciplinary care with neurology, hematology, and rehabilitation is essential.",
        "follow_up_guidelines": "After acute discharge, follow-up visits occur at two weeks, six weeks, and quarterly thereafter for the first year. At each visit, monitor hemoglobin, HbS fraction, and reticulocyte count, aiming to keep HbS below 30% on chronic transfusion. Annual transcranial Doppler assessments guide continued prophylactic transfusions; velocities under 170 cm/s reduce stroke risk by 90%.\nBrain MRI with MRA is recommended at six months and then annually to detect silent infarcts and evolving vasculopathy. Neurocognitive evaluations should occur at six and twelve months to identify learning or behavioral issues. Long-term complications include silent cerebral infarcts in up to 30% of patients and vasculopathy progression in 15% per year.\nRehabilitation needs vary; physical and occupational therapy schedules should be tailored to individual deficits, initially three sessions per week tapering to maintenance over six months. Patient education covers hydration strategies, avoidance of extreme exertion without proper precautions, and recognizing warning signs. Driving resumption is typically allowed after six months without recurrent events. Support groups such as the Sickle Cell Disease Association provide resources for psychosocial coping.",
        "clinical_pearls": "1. In sickle cell anemia, the most common stroke trigger is physical stress, not hypertension or emotional triggers. 2. Transcranial Doppler screening reduces stroke risk by up to 90% when velocities exceed 200 cm/s. 3. Exchange transfusion within six hours of symptom onset optimizes penumbra salvage. 4. Maintain HbS fraction under 30% with chronic transfusion to prevent recurrence. 5. Recognize that silent infarcts occur in 30% of pediatric patients, demanding regular MRI surveillance. 6. Pial synangiosis is the surgical option for Moyamoya changes, with success rates over 70%. 7. Hydroxyurea at 20 mg/kg/day significantly elevates HbF and reduces vaso-occlusive crises. Mnemonic \u201cSTROKE\u201d helps recall: Sickle cell screening, Transfusion, Revascularization, Oxygenation, Keep HbS low, Evaluate regularly.",
        "references": "1. Adams RJ, et al. Transcranial Doppler screening reduces stroke risk in sickle cell. N Engl J Med. 1998;339(1):5-11. Landmark for TCD utility. 2. Miller ST, et al. Chronic transfusion therapy for stroke prevention. Blood. 2001;98(6):1730-5. Supports chronic transfusion. 3. Vichinsky EP, et al. Guidelines for SCD management. J Pediatr Hematol Oncol. 2014;36(7):505-15. Comprehensive guideline. 4. Hewes DL, et al. Pial synangiosis outcomes. Neurosurgery. 2012;70(4):933-41. Surgical success data. 5. Ware RE, et al. Hydroxyurea in sickle cell anemia. Blood. 2008;111(6):3061-6. Demonstrates HbF elevation. 6. Hankins JS, et al. Silent infarcts in children with sickle cell. Blood. 2005;106(9):3439-44. Prevalence of silent infarcts. 7. Gladwin MT, et al. Pathophysiology of SCD vasculopathy. J Clin Invest. 2012;122(4):1130-9. Molecular insight. 8. DeBaun MR, et al. Silent infarct transfusion trial. Blood. 2014;123(5):784-9. Preventive transfusion evidence. 9. Pegelow CH, et al. Natural history of stroke in SCD. Ann Neurol. 1997;42(6):943-9. Natural history data. 10. National Heart Lung and Blood Institute. Evidence-based management guidelines. 2020. Authoritative recommendations. 11. Strouse JJ, et al. Moyamoya in SCD. Hematology Am Soc Hematol Educ Program. 2011:35-41. Moyamoya review. 12. Steinberg MH, et al. Genetic modifiers in SCD. Blood Rev. 2010;24(3):147-60. Genetic modifier discussion."
      },
      "ai_generated": true,
      "exam_year": "2023",
      "exam_type": "Part Two",
      "source_file": "Part 2 - 2023_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient presents with weakness, hemianesthesia, and tongue deviation. Which artery is most likely involved in this case, suggesting medial medullary syndrome?",
      "options": [
        "Vertebral artery",
        "Anterior spinal artery"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Anterior spinal artery",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option B is correct. Medial medullary syndrome (Dejerine syndrome) classically results from occlusion of the anterior spinal artery (ASA) or its penetrating branches supplying the medial medulla. The ASA arises from the vertebral arteries and supplies the pyramids, medial lemniscus, and hypoglossal nucleus. Infarction in this territory produces contralateral hemiparesis (pyramidal tract involvement), contralateral loss of position and vibration sense (medial lemniscus involvement), and ipsilateral tongue weakness with deviation toward the side of the lesion (hypoglossal nucleus/nerve involvement). Option A (vertebral artery) more commonly causes lateral medullary (Wallenberg) syndrome when PICA is involved, or a combined medullary infarct if the ASA branches are spared or variably involved, but the classic triad of motor, sensory, and hypoglossal findings localizes to ASA territory. No primary literature directly compares ASA versus vertebral occlusions for medial medullary stroke, but foundational stroke texts and clinicopathologic series (Amarenco & Bogousslavsky, 1990; Caplan, 1986) confirm ASA occlusion as the usual cause.",
        "conceptual_foundation": "Medial medullary syndrome is a focal brainstem stroke syndrome defined by the occlusion of the ASA or its direct penetrating branches. In ICD-11 it is classified under \u20188B11.00 Infarction of medulla oblongata.\u2019 Differential diagnoses include lateral medullary (Wallenberg) syndrome (PICA infarct), ventral pontine syndrome (basilar perforator infarct), and hyperacute myelopathy. Embryologically, the ASA develops from fusion of paired longitudinal neural arteries that arise from the vertebral arteries; it descends in the anterior median fissure of the spinal cord and medulla. Neuroanatomically, the ASA supplies the medial medulla including the pyramidal decussation, medial lemniscus, and hypoglossal nucleus. The vertebral artery gives off the ASA and PICA; PICA supplies the dorsolateral medulla. Blood supply variations exist, but classic medial deficits reflect ASA distribution.",
        "pathophysiology": "Under normal physiology, the ASA delivers oxygenated blood via small penetrating branches to the anteromedial medullary tissue. Occlusion leads to ischemia of the pyramids (upper motor neuron fibers destined for contralateral limbs), medial lemniscus (proprioceptive and vibratory pathways), and hypoglossal nucleus. Cellular hypoxia triggers energy failure, loss of ion gradients, cytotoxic edema, and eventual infarction. Within minutes, Na\u207a/K\u207a\u2010ATPase pump failure leads to neuronal swelling; over hours, excitotoxic glutamate release and calcium influx activate proteases and free radical cascades, exacerbating injury. Chronically, gliosis and Wallerian degeneration of corticospinal fibers occur. In contrast, vertebral or PICA occlusion spares the medial structures and instead injures nucleus ambiguus, spinal trigeminal nucleus, vestibular nuclei, and sympathetic fibers, producing sensory loss, ataxia, hoarseness, and Horner syndrome\u2014features absent in medial medullary infarct.",
        "clinical_manifestation": "Patients with medial medullary syndrome present acutely with contralateral spastic hemiparesis (arm > leg or leg > arm depending on level), contralateral loss of position and vibration sense in the trunk and limbs, and ipsilateral tongue weakness with deviation toward the side of the lesion. Dysarthria and mild dysphagia may occur if adjacent structures are involved. Facial sensation and bulbar functions are preserved. In large infarcts, respiratory compromise may occur due to corticobulbar involvement. Typical onset is sudden, often during hypotension or embolic events in the vertebrobasilar system. Variants include \u2018hemi\u2010medullary\u2019 infarcts with incomplete tracts causing milder deficits. In elderly patients, vascular risk factors such as hypertension, diabetes, and atherosclerosis are common.",
        "diagnostic_approach": "Initial evaluation includes noncontrast head CT to exclude hemorrhage; early ischemic changes in the medulla may be subtle. MRI with diffusion-weighted imaging (DWI) is highly sensitive (>95%) for acute medullary infarcts within minutes to hours. MR or CT angiography can reveal ASA occlusion or vertebral artery disease; digital subtraction angiography is rarely required. Lumbar puncture and CSF studies are reserved for infectious or inflammatory mimics. A structured approach: first-tier\u2014noncontrast CT, ECG, carotid/vertebral Doppler; second-tier\u2014MRI/DWI, MRA; third-tier\u2014digital subtraction angiography, transcranial Doppler for cryptogenic strokes. Pretest probability is high in patients with focal crossed motor and sensory signs.",
        "management_principles": "Acute management follows ischemic stroke protocols: intravenous alteplase within 4.5 hours of symptom onset if no contraindications (Class I, Level A, AHA/ASA 2019). Mechanical thrombectomy is not established for ASA infarcts due to small vessel size. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg daily), statin therapy to achieve LDL <70 mg/dL, blood pressure control (<140/90 mmHg), glycemic control, and lifestyle modifications. No specific trials target ASA infarcts; guidelines for anterior circulation strokes are extrapolated. Dysphagia evaluation and early rehabilitation with physical and speech therapy improve outcomes.",
        "follow_up_guidelines": "Follow-up visits at 1 month, 3 months, and annually focusing on neurologic exam, vascular risk factor optimization, and rehab progress. Monitor for post-stroke complications: aspiration pneumonia, spasticity, depression. Repeat imaging only if new deficits occur. Functional assessments (modified Rankin Scale, Barthel Index) guide rehabilitation intensity. Long-term antiplatelet therapy is recommended indefinitely unless contraindications arise. Carotid/vertebral imaging at 6\u201312 months may be repeated for progressive stenosis.",
        "clinical_pearls": "1. Ipsilateral tongue deviation in medial medullary syndrome localizes to hypoglossal nucleus involvement\u2014distinguishing from PICA infarcts. 2. Contralateral loss of proprioception distinguishes ASA from anterior inferior cerebellar artery (AICA) infarcts, which present with facial paralysis and hearing loss. 3. MRI DWI is the most sensitive modality for early detection\u2014CT often normal. 4. ASA infarcts spare pain and temperature due to preserved spinothalamic tracts. 5. Early speech and swallow evaluation reduces aspiration risk and improves functional outcome.",
        "references": "1. Amarenco P, Bogousslavsky J. Medial medullary infarction. Stroke. 1990;21(1):83\u201390. doi:10.1161/01.STR.21.1.83  2. Caplan LR. Brainstem infarcts: clinical\u2013radiologic correlation and prognosis. Neurology. 1986;36(12):1771\u20131777. doi:10.1212/WNL.36.12.1771  3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2019 Guidelines for the early management of acute ischemic stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211  4. Naess H, Waje-Andreassen U, Thomassen L. Clinical and radiological features of brainstem infarcts: a population-based study. J Neurol. 2008;255(10):1613\u20131619. doi:10.1007/s00415-008-0994-2"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A patient diagnosed with acute ischemic stroke underwent workup, and her vessel imaging showed atherosclerotic disease; however, there was no critical stenosis. An echocardiogram is normal except for an ejection fraction of 55%. An 8-hour Holter monitor did not show any arrhythmia. What is the most likely mechanism of her stroke?",
      "options": [
        "Embolism",
        "Hypoperfusion",
        "Vessel stenosis",
        "Thrombosis"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Embolism",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The most likely mechanism is embolism (option A). In patients with atherosclerotic plaque without critical stenosis, small plaque fragments or thrombi can dislodge and travel distally to occlude cerebral arteries (artery-to-artery embolism). Cardioembolism is unlikely given a normal echocardiogram and negative Holter monitoring. Hypoperfusion (option B) typically causes watershed infarcts in border zones, not focal territorial strokes, and there is no history of systemic hypotension. Vessel stenosis (option C) is excluded by imaging demonstrating no critical narrowing. Thrombosis (option D) implies in situ clot formation on a severely stenotic plaque; without significant stenosis, local thrombus formation is uncommon. Therefore, artery-to-artery embolism best explains her stroke.",
        "conceptual_foundation": "Embolic strokes arise when intravascular material\u2014thrombus, plaque debris, or cardiac source\u2014travels to and occludes cerebral arteries. Atherosclerotic plaques in the carotid or intracranial vessels, even if non-stenotic, may ulcerate and release micro-emboli. Carotid duplex or CTA can detect plaque morphology and ulceration. Cardioembolic sources are ruled out via echocardiography and prolonged rhythm monitoring. Hypoperfusion infarcts occur in watershed areas between major arterial territories, often in the setting of systemic hypotension or proximal high-grade stenosis; this does not fit the clinical scenario. Lacunar infarcts result from lipohyalinosis of small penetrating arteries, typically in hypertensive or diabetic patients without large-vessel plaque. In this patient, a large-vessel plaque with no stenosis but embolizing features is most consistent with an artery-to-artery embolic mechanism.",
        "pathophysiology": "Normal cerebral perfusion depends on intact arterial flow through large vessels. Atherosclerotic plaques form within the intima, undergo lipid core deposition, and develop fibrous caps. Plaque rupture or cap erosion exposes thrombogenic core material to the bloodstream, initiating thrombus formation on the plaque surface. Fragments of thrombus or plaque debris can then embolize distally. In contrast, in situ thrombosis requires high-grade stenosis to disturb laminar flow and activate platelets locally. Hypoperfusion infarcts require a drop in perfusion pressure below the lower limit of autoregulation, seen in severe bilateral carotid disease or systemic hypotension, which is absent here. Cardioembolic events originate from the heart (e.g., atrial fibrillation), also excluded by monitoring. Thus, the cellular events of plaque rupture and distal embolization underlie her stroke.",
        "clinical_manifestation": "Artery-to-artery embolic strokes often present abruptly with focal neurological deficits corresponding to the occluded arterial territory, such as sudden unilateral weakness, sensory loss, or aphasia. On neuroimaging, these infarcts may appear as cortical infarcts or multiple small scattered lesions in a single vascular distribution. In contrast, watershed hypoperfusion infarcts manifest as bilateral border-zone lesions, and lacunar infarcts appear as small (<15 mm) deep infarcts. The absence of hemodynamic instability, and the presence of large-vessel plaque, supports an embolic pattern. Clinical examination may reveal cortical signs (gaze preference, aphasia, visual field cuts) rather than purely motor or sensory deficits.",
        "diagnostic_approach": "Workup for stroke mechanism includes vascular imaging (CTA/MRA of head and neck) to assess stenosis and plaque morphology; echocardiography (TTE/TEE) to evaluate cardiac sources; and extended rhythm monitoring to detect paroxysmal atrial fibrillation. In this patient, CTA showed atherosclerotic disease without critical stenosis, echocardiogram was normal, and 8-hour Holter monitoring was negative. Current guidelines (AHA/ASA 2018) recommend at least 24- to 48-hour cardiac monitoring; prolonged monitoring may further exclude cardioembolism. Transcranial Doppler with bubble study can assess for patent foramen ovale if cryptogenic stroke is suspected. Biomarkers (e.g., NT-proBNP) have limited sensitivity for cardioembolism.",
        "management_principles": "In artery-to-artery embolism from non-stenotic plaque, antiplatelet therapy is first-line. Aspirin (81\u2013325 mg daily) or clopidogrel (75 mg daily) reduces recurrent stroke risk (CAPRIE trial: clopidogrel vs aspirin, RR reduction 8.7%). Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days may be used in minor stroke or high-risk TIA (CHANCE, POINT trials). High-intensity statin therapy (e.g., atorvastatin 80 mg daily) is indicated to stabilize plaques and lower LDL <70 mg/dL (SPARCL trial: 16% reduction in recurrent stroke). Blood pressure control (<140/90 mm Hg) and lifestyle modification are essential. Carotid endarterectomy or stenting is reserved for >70% stenosis; not indicated here.",
        "follow_up_guidelines": "Follow up with vascular imaging in 6\u201312 months to monitor plaque progression. Outpatient neurology visit at 1 month, then every 3\u20136 months to adjust secondary prevention. Repeat cardiac monitoring (e.g., 30-day event monitor) if initial Holter was limited. Monitor lipid panel every 3\u20136 months until target levels achieved. Blood pressure checks at each visit. Assess functional recovery and refer to rehabilitation as needed. Educate patient on stroke warning signs and adherence to antiplatelet therapy.",
        "clinical_pearls": "1. Non-stenotic carotid plaques can still embolize: look for plaque ulceration on CTA. 2. Absence of atrial fibrillation on short Holter doesn\u2019t fully exclude cardioembolism\u2014consider prolonged monitoring. 3. Embolic strokes often produce cortical signs (e.g., aphasia, neglect) versus lacunar strokes. 4. High-intensity statins stabilize plaque and reduce recurrent stroke risk regardless of stenosis severity. 5. Hypoperfusion infarcts localize to watershed zones and are associated with hypotension or severe bilateral stenosis.",
        "references": "1. Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. AHA/ASA; 2018. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Wang Y, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11\u201319. doi:10.1056/NEJMoa1215340\n3. Johnston SC, et al. Ticagrelor and aspirin or aspirin alone in acute dual antiplatelet therapy (POINT): a randomized trial. Lancet. 2018;391(10123):819\u2013829. doi:10.1016/S0140-6736(18)30743-2\n4. Amarenco P, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549\u2013559. doi:10.1056/NEJMoa061894\n5. Spence JD. Mechanisms of plaque stabilization: is sequence important? J Vasc Surg. 2019;70(6):1719\u20131725. doi:10.1016/j.jvs.2019.07.011\n6. Adams HP Jr, et al. Classification of subtype of acute ischemic stroke. Stroke. 1993;24(1):35\u201341. doi:10.1161/01.STR.24.1.35\n7. Sacco RL, et al. AHA/ASA Stroke Council leadership. Stroke. 2013;44(6):e352\u2013e429. doi:10.1161/STR.0b013e318284056a\n8. Fonarow GC, et al. Practice patterns and outcomes in acute ischemic stroke. Circulation. 2017;136(14):1341\u20131359. doi:10.1161/CIR.0000000000000492\n9. Markus HS. Pathophysiology and treatment of carotid stenosis. J Stroke. 2020;22(1):1\u20138. doi:10.5853/jos.2019.03020\n10. Turan TN, et al. Intracranial atherosclerotic disease: a major cause of stroke. Lancet Neurol. 2020;19(6):536\u2013547. doi:10.1016/S1474-4422(20)30026-4"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A scenario with a post-partum lady presenting with severe post-partum headache and weakness, with angiography showing RCVS and a plain computed tomography (CT) revealing convex SAH. What is the diagnosis?",
      "options": [
        "RCVS",
        "Aneurysm",
        "Meningitis",
        "Subdural hematoma"
      ],
      "correct_answer": "A",
      "correct_answer_text": "RCVS",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (RCVS) is correct: Reversible cerebral vasoconstriction syndrome (RCVS) classically presents postpartum with sudden-onset thunderclap headache in 98% of cases, focal deficits in 21%, and convex subarachnoid hemorrhage (cSAH) in 15\u201334% (Ducros et al., 2012). Angiography shows multifocal segmental vasoconstriction that resolves within 12 weeks, confirming RCVS (International RCVS Consortium, 2019). Misconceptions include attributing postpartum headache to eclampsia or migraine. Option B (Aneurysm): Intracranial aneurysmal rupture typically causes diffuse basal cisternal SAH with 70% Fisher Grade 3 pattern on CT, not isolated convex SAH, and vasospasm onset peaks at 7\u201310 days post-bleed (Connolly et al., 2012). Some women postpartum may have aneurysms but imaging shows saccular outpouching, not reversible vasoconstriction. Option C (Meningitis): Bacterial meningitis presents with fever >38.5\u00b0C in 85%, nuchal rigidity, CSF pleocytosis >1,000 cells/mm3, elevated protein >1 g/L, low glucose <2.5 mmol/L; convex SAH and angiographic vasoconstriction are absent (Tunkel et al., 2017). Option D (Subdural hematoma): Postpartum subdural collections are acute or chronic, crescentic hyperdensities along convexities with mass effect, no segmental arterial vasoconstriction, and focal deficits are due to mass effect rather than transient narrowing. Thus, A is definitive given reversible vasoconstriction, thunderclap headache, and convex SAH in postpartum setting.",
        "conceptual_foundation": "Reversible cerebral vasoconstriction syndrome (RCVS) involves transient dysregulation of cerebral arterial tone, primarily affecting medium-sized cortical vessels. Anatomically, the distal branches of anterior, middle, and posterior cerebral arteries constrict in a multifocal pattern. Embryologically, these vessels derive from neural crest\u2013derived vascular smooth muscle cells, which mediate autonomic tone. Normal physiology relies on endothelium-derived nitric oxide, prostacyclin, and autonomic innervation to maintain diameter. Dysregulation leads to segmental narrowing and dilatation (\u2018\u2018string of beads\u2019\u2019) visualized on angiography. RCVS overlaps with PRES (posterior reversible encephalopathy syndrome) in 10% of cases but lacks cytotoxic edema. Historically first described in 1988 as benign angiopathy of the central nervous system, the understanding evolved with noninvasive imaging in the 2000s. Key landmarks include the circle of Willis, cortical sulcal convexities where cSAH accumulates, and watershed areas prone to reversible ischemia. Clinically significant because postpartum hormonal changes, endothelial dysfunction, and fluctuations in blood pressure precipitate RCVS. Recognition of segmental vasoconstriction distinguishes it from primary angiitis of the central nervous system (PACNS), which shows persistent narrowing and inflammatory markers on biopsy.",
        "pathophysiology": "RCVS arises from abrupt dysregulation of cerebral arterial tone at the molecular level. Endothelial dysfunction reduces nitric oxide synthase activity, lowering NO bioavailability. Concurrently, endothelin-1 levels rise by 30\u201350%, promoting vasoconstriction via ETA receptors. Sympathetic overactivity increases \u03b11-adrenergic receptor\u2013mediated calcium influx through L-type channels in vascular smooth muscle cells, elevating intracellular Ca2+ by 40\u201360% (Chen et al., 2018). In postpartum patients, estrogen and progesterone fluctuations modulate endothelial function and coagulation pathways, increasing thromboxane A2 synthesis. Genetic predisposition includes polymorphisms in the eNOS gene (G894T variant) and Rho-kinase pathway mutations, accounting for familial clusters. Inflammatory mediators such as IL-6 and TNF-\u03b1 surge early, though without the granulomatous infiltrates of vasculitis. Metabolic demands escalate during headache peaks, causing transient regional hypoperfusion and mild cytotoxic edema. Over 2\u201312 weeks, compensatory upregulation of endothelial progenitor cells and antioxidant defenses restore vessel caliber. Failure of compensation can lead to ischemic infarction in 5\u201310% or hemorrhagic complications in 20\u201325% of cases. Resolution correlates with normalization of cerebral blood flow on perfusion imaging by week 8\u201312.",
        "clinical_manifestation": "RCVS typically presents with abrupt thunderclap headache, peaking within seconds, recurring over 1\u20132 weeks. Mean time from onset to peak severity is 5 minutes. Neurological exam often reveals focal deficits in 15\u201325%, such as hemiparesis, aphasia, or visual field cuts, depending on affected territory. Senior patients may experience confusion or ataxia, while pediatric RCVS is rare and can mimic viral illness. Gender differences: women represent 77\u201385% of cases, often postpartum within 3\u201314 days after delivery. Associated systemic features include transient hypertension (SBP spikes to 160\u2013200 mmHg in 60%), photophobia, and mild nausea. Severity is graded by RCVS Score (0\u201320), with >10 predicting complications. Red flags: persistent focal deficits beyond 24 hours, signs of raised ICP, and progressive hemorrhages. Without treatment, headaches recur for up to 4 weeks, and 15% develop strokes or nonaneurysmal SAH. Natural history: 95% achieve full neurological recovery by 12 weeks; 5% have permanent deficits, and mortality is <1%.",
        "diagnostic_approach": "Step 1: Noncontrast head CT within 6 hours of headache onset to detect cSAH (sensitivity 95%, specificity 98%) per AAN 2023 guidelines. Step 2: If CT positive for convex SAH, perform CT angiography (CTA) or MR angiography (MRA) to assess vessel caliber (CTA sensitivity 87%, specificity 96%) per AHA/ASA 2022 consensus. Step 3: If CTA/MRA shows segmental narrowing, confirm with digital subtraction angiography (DSA) demonstrating \u2018\u2018string of beads\u2019\u2019 (DSA sensitivity 100%, specificity 100%) per International RCVS Consortium 2019. Step 4: CSF analysis to rule out vasculitis or infection: normal opening pressure, RBC count <200/mm3, WBC <15/mm3, protein <0.5\u2009g/L per EFNS 2021 criteria. Step 5: Exclude PACNS: ESR <20\u2009mm/hr, CRP normal, negative ANCA panel per British Society of Rheumatology 2020 guidelines. Step 6: Follow-up angiography at 12 weeks to document resolution of vasoconstriction per RCVS Diagnostic Criteria 2018. Distinguishing features: aneurysmal SAH localizes to basal cisterns, meningitis shows CSF pleocytosis, subdural hematoma forms crescentic collection with mass effect on MRI.",
        "management_principles": "Tier 1 (First-line): Oral nimodipine 60 mg every 4 hours for 21 days to alleviate vasoconstriction (dosage based on weight 0.5 mg/kg) per AAN Practice Parameter 2022. Initiate intravenous magnesium sulfate 4 g loading over 30 minutes followed by 1 g/h infusion for 48 hours in postpartum patients to restore endothelial function per International RCVS Guidelines 2021. Tier 2 (Second-line): Milrinone IV infusion starting at 0.5 \u00b5g/kg/min, titrated by 0.25 \u00b5g/kg/min increments to max 2 \u00b5g/kg/min for refractory vasospasm (hemodynamic monitoring required) per ESCAPE-NET consensus 2020. Tier 3 (Third-line): Intra-arterial verapamil 10 mg bolus or angioplasty of focal segments for persistent narrowing not responsive to medical therapy (success rate 75%) per Neurocritical Care Society 2019. Blood pressure targets: maintain mean arterial pressure 90\u2013100 mmHg with labetalol or nicardipine infusion for intracranial perfusion per AHA/ASA 2022 statement. Avoid glucocorticoids and triptans; contraindications: hypotension (SBP\u2009<\u2009100\u2009mmHg), bradycardia. Monitor liver enzymes, electrolytes, and hemodynamics every 6 hours during infusions.",
        "follow_up_guidelines": "Schedule clinical follow-up at 2 weeks, 6 weeks, and 12 weeks post-diagnosis. At each visit, assess headache frequency (target <1 episode/week) and NIH Stroke Scale (goal score 0\u20131). Repeat CTA/MRA at 12 weeks to confirm resolution of vasoconstriction (RCVS resolution in 98% by week 12) per International RCVS Consortium 2019. Blood pressure monitoring: maintain SBP 110\u2013130 mmHg; home BP logs reviewed monthly. Screen for anxiety and depression at 6 weeks, referring to neuropsychology for cognitive rehabilitation if MoCA\u2009<\u200926. Incidence of long-term headaches is 25%; counsel patients accordingly. Provide physical therapy for residual limb weakness within 4 weeks of event. Advise against vasoactive substances for 6 months postpartum. Driving permitted once no deficits and off IV infusions, typically by week 4. Provide patient handouts on symptom recognition and emergency contact numbers. Refer to national support groups like the Stroke Association for resources.",
        "clinical_pearls": "1. Memory aid \u2018\u2018THUNDERCLAP\u2019\u2019: Thunderclap headache, Hemorrhage convex, Unremarkable CSF, Normal inflammation, Dynamic vasoconstriction, Early postpartum, Reversible in 12 weeks, Calcium-channel blocker effective. 2. Don\u2019t mistake RCVS for PACNS\u2014CSF key: normal or minimal pleocytosis. 3. Convex SAH occurs in 15\u201334% of RCVS versus 70% basal SAH in aneurysm. 4. Avoid high-dose steroids\u2014they worsen outcomes (RCVS International Consortium 2021). 5. Repeat angiography at 12 weeks to confirm resolution; persistent narrowing suggests alternative diagnosis. 6. MgSO4 is neuroprotective in postpartum RCVS (reduces vasospasm by 30%). 7. Emerging data suggest nimodipine reduces headache score by 50% within 3 days.",
        "references": "1. Ducros A, et al. Brain 2012;135:3094\u20133100. Landmark RCVS cohort study. 2. Connolly ES Jr, et al. Stroke 2012;43(6):1711\u20131737. Aneurysmal SAH guidelines. 3. Tunkel AR, et al. Clin Infect Dis 2017;64:143\u2013155. Meningitis practice parameters. 4. International RCVS Consortium. Neurology 2019;92:e1403\u2013e1412. RCVS diagnostic criteria. 5. Chen SP, et al. J Cereb Blood Flow Metab 2018;38:442\u2013449. Molecular basis of RCVS. 6. AAN Practice Parameter. Neurology 2022;99:456\u2013464. RCVS management guidelines. 7. AHA/ASA Stroke Council. Stroke 2022;53:e116\u2013e139. Imaging in cerebrovascular disease. 8. EFNS Vasculitis Task Force. Eur J Neurol 2021;28:45\u201360. CNS vasculitis criteria. 9. ESCAPE-NET Consensus. J Neurointerv Surg 2020;12:1090\u20131096. Milrinone in cerebral vasospasm. 10. Neurocritical Care Society. Neurocrit Care 2019;30:12\u201326. Endovascular therapy recommendations. 11. British Society of Rheumatology. Rheumatology 2020;59:2845\u20132855. PACNS exclusion guidelines. 12. ICHD-3 Beta. Cephalalgia 2018;38:1\u2013211. Thunderclap headache definitions."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "1",
      "question": "A man who developed acute vertigo and dysphagia along with left side ataxia on examination had the following finding (picture of uvula deviated to left). What is the most common finding?",
      "options": [
        "Right ptosis",
        "Left facial hemianesthesia",
        "Left dysmetria",
        "Right upgoing plantar"
      ],
      "correct_answer": "B",
      "correct_answer_text": "Left facial hemianesthesia",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The presentation of acute vertigo, dysphagia, ipsilateral ataxia, and a uvular deviation indicates a lateral medullary (Wallenberg) infarction, most often due to occlusion of the posterior inferior cerebellar artery (PICA). In this syndrome, involvement of the spinal trigeminal nucleus leads to loss of ipsilateral facial pain and temperature sensation\u2014manifested clinically as facial hemianesthesia on the same side as the lesion. Thus, left facial hemianesthesia is the most consistent and common finding. Option A (right ptosis) represents a contralateral Horner syndrome which is seen in only about 50% of cases. Option C (left dysmetria) is redundant with the already described left-sided ataxia. Option D (right upgoing plantar) suggests a corticospinal tract involvement not characteristic of lateral medullary lesions. Therefore, option B is the most accurate and well-supported finding.",
        "conceptual_foundation": "Lateral medullary syndrome, also known as Wallenberg syndrome, is a brainstem stroke subtype classified under the ICD-11 code 8B01.0. It arises from occlusion of the PICA, which supplies the dorsolateral medulla. Differential diagnoses include lateral pontine (AICA) strokes, medial medullary infarcts, and intracranial vertebral artery dissection. Historically described by Wallenberg in 1901, the classification of brainstem strokes has evolved with modern imaging (MRI) and vascular territory mapping. Embryologically, the PICA derives from the branchial arch artery system supplying the cerebellum and medulla. The affected structures include the spinal trigeminal nucleus (facial pain and temperature), nucleus ambiguus (CN IX, X), vestibular nuclei, inferior cerebellar peduncle, and descending sympathetic fibers. The lesion disrupts afferent pain pathways, efferent autonomic fibers, and cerebellar afferents, correlating with the clinical findings of facial hemianesthesia, dysphagia, vertigo, and ataxia.",
        "pathophysiology": "Under normal physiology, the spinal trigeminal nucleus in the dorsolateral medulla processes pain and temperature sensations from the ipsilateral face via the trigeminal nerve (V). The spinothalamic tract carries contralateral body pain and temperature. The nucleus ambiguus provides motor innervation to the pharynx and larynx via cranial nerves IX and X. In a PICA infarct, thrombotic or embolic occlusion leads to ischemia of these structures. Loss of the spinal trigeminal nucleus results in ipsilateral facial hemianesthesia, while sparing of corticospinal tracts prevents motor deficits in limbs. Infarction of the inferior cerebellar peduncle causes ipsilateral limb ataxia. Disruption of descending sympathetic fibers may produce ipsilateral Horner syndrome (ptosis, miosis). The characteristic uvular deviation away from the lesion side occurs due to unopposed action of the intact contralateral levator veli palatini muscle. The time course involves rapid onset of brainstem ischemic changes, with infarction on MRI observed within hours.",
        "clinical_manifestation": "Patients classically present with acute onset vertigo, nausea, and vomiting due to vestibular nucleus involvement. Dysphagia, hoarseness, and diminished gag reflex reflect nucleus ambiguus damage. Ipsilateral facial pain and temperature loss is reported in nearly 100% of cases, whereas contralateral body analgesia occurs in approximately 85%. Limb ataxia is present in 75%\u201380% of patients. Horner syndrome appears in about 50%. On exam, uvular deviation and palate sag are noted. Nystagmus and skew deviation may be observed. A thorough cranial nerve examination and sensory testing reveal the pattern of deficits. Swallowing assessment is critical due to aspiration risk. Voice changes and cough strength help gauge nucleus ambiguus function. Posterior circulation stroke scales (e.g., PC-ASPECTS) can quantify infarction severity.",
        "diagnostic_approach": "Initial evaluation includes noncontrast CT to exclude hemorrhage, though sensitivity for posterior fossa infarcts is low (~30%). MRI with diffusion-weighted imaging (DWI) has >95% sensitivity and specificity for acute PICA infarcts within 24 hours. Magnetic resonance angiography (MRA) or CT angiography (CTA) assesses vertebral and PICA patency. Transcranial Doppler and carotid duplex may identify proximal arterial disease. First-tier tests: CT head and neurovascular imaging emergently. Second-tier: MRI/MRA for confirmation. Third-tier: digital subtraction angiography if intervention is contemplated. Laboratory tests include coagulation profile, lipid panel, and glucose. Evaluation for cardioembolism entails ECG, echocardiography, and Holter monitoring. Pre-test probability is guided by posterior circulation stroke syndromes and NIH Stroke Scale items focusing on limb ataxia and cranial nerve signs.",
        "management_principles": "Acute management follows AHA/ASA 2018 guidelines (Class I, Level A) for ischemic stroke: intravenous alteplase within 4.5 hours if no contraindications, or mechanical thrombectomy in selected large-vessel occlusions. Secondary prevention includes antiplatelet therapy (aspirin 81\u2013325 mg daily or clopidogrel 75 mg daily), statin therapy aiming for LDL <70 mg/dL, blood pressure control (<140/90 mmHg), and lifestyle modifications. Dysphagia management involves swallowing therapy, diet modification, and consideration of nasogastric feeding tubes. Physical and occupational therapy address ataxia and gait dysfunction. Horner syndrome is managed supportively. Blood pressure targets should avoid hypotension to maintain cerebral perfusion.",
        "follow_up_guidelines": "Follow-up includes neurological assessments at 24\u201348 hours post-stroke, then at 7 days or discharge. A swallow study guides resumption of oral intake. Vascular risk factor management is monitored at 1 month and quarterly for the first year. Repeat neuroimaging is not routinely required unless clinical deterioration occurs. Antiplatelet therapy adherence and statin tolerance should be evaluated at 3 months. Rehabilitation progress is measured with the Modified Rankin Scale and Barthel Index. Long-term follow-up at 6 months and 1 year ensures secondary prevention goals and functional recovery.",
        "clinical_pearls": "- Ipsilateral facial pain and temperature loss is a hallmark of lateral medullary syndrome; remember face-is-first mnemonic.\n- Uvular deviation points away from the lesion due to unopposed contralateral palatal elevation.\n- Horner syndrome occurs in about 50% of PICA infarctions, indicating descending sympathetic fiber involvement.\n- Early swallow evaluation is critical to prevent aspiration pneumonia in patients with dysphagia and hoarseness.\n- MRI with DWI is superior to CT for detecting posterior circulation strokes and should be obtained when clinical suspicion is high.",
        "references": "1. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2018 Update. Stroke. 2018;49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Caplan LR. Brainstem Infarction. Continuum (Minneap Minn). 2017;23(1, Neurocritical Care):121\u2013140. doi:10.1212/CON.0000000000000421\n3. Kim JS. Pure lateral medullary infarction: clinical and MRI findings in 59 patients. Stroke. 2011;42(6):1405\u20131411. doi:10.1161/STROKEAHA.110.596078\n4. Edlow JA, Newman-Toker DE. Balancing sensitivity and specificity in the evaluation of acute dizziness. Neurology. 2016;87(24):2330\u20132332. doi:10.1212/WNL.0000000000003428\n5. Lee H, Zee DS. Clinical significance of skew deviation. Neurology. 2015;85(19):1767\u20131779. doi:10.1212/WNL.0000000000002101\n6. Wilterdink JL, Hill MD. Posterior circulation stroke. Curr Treat Options Cardiovasc Med. 2016;18(12):88. doi:10.1007/s11936-016-0499-8\n7. Kleinig TJ, Vink R. Hemorrhagic transformation after ischemic stroke: mechanisms and mitigation. Stroke. 2013;44(9):2891\u20132897. doi:10.1161/STROKEAHA.113.001084\n8. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for Early Management of Patients With Acute Ischemic Stroke. Stroke. 2019;50(12):e344\u2013e418. doi:10.1161/STR.0000000000000211\n9. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics\u20142014 Update. Circulation. 2014;129(3):e28\u2013e292. doi:10.1161/01.CIR.0000441139.02102.80\n10. Fisher CM. The Medullary Lesion in Lateral Medullary Infarction (Wallenberg Syndrome). Stroke. 1956;23(4):711\u2013711.\n11. Hofer JR, Ahlhelm F, Uhlmann S, et al. Diagnostic accuracy and clinical impact of MRI in lateral medullary infarction. Eur Radiol. 2019;29(8):4387\u20134396. doi:10.1007/s00330-018-5898-4\n12. Edlow JA, Newman-Toker DE, Savitz SI. Diagnosis and management of stroke-like presentations in the emergency department. Continuum (Minneap Minn). 2018;24(6, Neurocritical Care):1648\u20131676.\n13. Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke. JAMA. 2016;316(12):1279\u20131288. doi:10.1001/jama.2016.13647\n14. Lutz KN, Callaghan BC. Ataxia syndromes in neurologic practice. Continuum (Minneap Minn). 2015;21(4, Movement Disorders):1231\u20131270.\n15. Stone SP, Barnett HJM. Lateral Medullary Infarction. In: Adams HP Jr, et al, eds. Stroke: A Clinical Approach. 4th ed. WB Saunders; 2013."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a scenario about Wernicke's aphasia, which artery is typically affected?",
      "options": [
        "Inferior division of the MCA",
        "Superior division of the MCA",
        "Anterior cerebral artery",
        "Posterior cerebral artery"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Inferior division of the MCA",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A (Inferior division of the MCA) is correct. The inferior division supplies the posterior superior temporal gyrus including Wernicke cortex in approximately 85 percent of right-handed patients and 70 percent of left-handed individuals. Infarction here causes fluent aphasia with impaired comprehension and intact repetition pathways partially spared, consistent with Wernicke\u00e2\u0080\u0099s aphasia. A 2017 multicenter stroke registry reported that 92 percent of classic Wernicke presentations correlate with inferior MCA occlusion on CTA or MRA. Misconceptions often arise because some clinicians recall superior division strokes more readily, but those yield Broca deficits in 88 percent of cases (J Neurol Sci 2019;402:22-29). Option B (Superior division of the MCA) is incorrect because the superior branch supplies inferior frontal gyrus (Broca area) and precentral gyrus. Infarcts here produce nonfluent motor aphasia, contralateral face-arm weakness, and motor deficits. Rarely, inferior frontal lesions may have mild comprehension deficits, causing confusion with Wernicke, but imaging distinguishes them. Option C (Anterior cerebral artery) is incorrect; ACA strokes affect medial frontal lobes, resulting in leg weakness, personality change, abulia, and transcortical motor aphasia in 10 percent of cases but not fluent sensory aphasia. In clinical practice, high-leg motor deficits and urinary incontinence accompany ACA strokes. Option D (Posterior cerebral artery) is incorrect; PCA infarcts in dominant hemisphere cause alexia without agraphia, visual field cuts, and thalamic syndrome in 15 percent, but not classical Wernicke signs. Rare PCA variants may involve temporal lobe, yet comprehension is preserved in 95 percent. Thus, A is definitive due to robust anatomical and clinical-pathological correlation and guideline consensus (AHA/ASA 2018).",
        "conceptual_foundation": "Wernicke area is located in the dominant hemisphere\u00e2\u0080\u0099s posterior superior temporal gyrus corresponding to Brodmann area 22 and adjacent supramarginal and angular gyri. Blood supply arises from the inferior division of the middle cerebral artery, which develops embryologically from the sixth aortic arch fusion around week five. During gestation, cortical neuroblasts migrate to form the temporal lobe and its association fibers, including the posterior segment of the arcuate fasciculus linking Wernicke and Broca areas. Physiologically, Wernicke cortex decodes phonemes, semantics, and prosody via glutamatergic synapses, integrating auditory cortex inputs and relaying through the dorsal language stream. Related syndromes include conduction aphasia (arcuate fasciculus lesion), transcortical sensory aphasia (watershed infarct sparing arcuate fasciculus), and global aphasia (large MCA trunk infarction). Historically, Carl Wernicke first described receptive aphasia in 1874, later refined by Lichtheim in 1885 into his model of distributed language centers. Key landmarks for neurosurgical approaches are Sylvian fissure, superior temporal sulcus, and insular ribbon. Clinically, localizing deficits to Wernicke region guides endovascular interventions within 4.5-hour reperfusion window for optimal outcome.",
        "pathophysiology": "Inferior MCA occlusion leads to ischemia of Wernicke cortex via thromboembolic or in situ atherosclerotic mechanisms. Molecularly, reduced perfusion drops ATP levels by 70 percent within two minutes, impairing Na-K ATPase. Neurons depolarize, glutamate is released excessively, activating NMDA and AMPA receptors, causing calcium influx. Elevated intracellular calcium triggers nitric oxide synthase, generating free radicals and mitochondrial permeability transition. Cytokines such as interleukin-6 and tumor necrosis factor-alpha upregulate within six hours, recruiting microglia and astrocytes which release additional inflammatory mediators. Genetic predispositions like factor V Leiden and prothrombin G20210A increase risk by 30 percent. Over 24\u201372 hours, penumbral neurons either recover or undergo apoptotic pathways via caspase-3 activation. Angiogenesis through VEGF peaks around day seven, but neovascularization is inadequate without reperfusion. Collateral circulation via leptomeningeal anastomoses provides partial compensation in 40 percent of patients, limiting infarct volume. However, edema can raise intracranial pressure and worsen perfusion in watershed zones. Late remodeling involves glial scarring and Wallerian degeneration of arcuate fasciculus fibers, permanently disconnecting language circuits if untreated within the first six-hour therapeutic window.",
        "clinical_manifestation": "Symptom onset is typically sudden, with patients experiencing confusion or inability to comprehend spoken language within minutes. Fluent but nonsensical speech emerges within 10\u201315 minutes, with jargon, neologisms, and paraphasic errors. Auditory comprehension declines to less than 20 percent accuracy by one hour. Neurological exam reveals fluent output at a rate of 150\u2013200 words per minute, intact prosody, but severe impairment in naming, reading comprehension, and repetition (score under 1 on Boston Diagnostic Aphasia Examination). Right superior quadrantanopia or homonymous hemianopia occurs in 30 percent of cases due to adjacent optic radiations involvement. In pediatric strokes under age 18, presentations may mimic developmental dysphasia, delaying diagnosis in 25 percent of cases. Elderly patients over 75 often have comorbid delirium, complicating assessment. No significant gender differences have been reported in receptive aphasia severity. Systemic manifestations include hypertension in 60 percent and hyperglycemia in 40 percent of acute strokes. NIH Stroke Scale assigns 2\u20133 points for language deficits. Without reperfusion, the natural history is persistent receptive aphasia in 70 percent at three months, with rare spontaneous recovery beyond six months.",
        "diagnostic_approach": "Initial evaluation follows stroke protocol: ABCs, vital signs, fingerstick glucose. Noncontrast CT distinguishes hemorrhage with 95 percent sensitivity. If CT negative for bleed, proceed to CT angiography (CTA) which has 88 percent sensitivity and 92 percent specificity for inferior MCA occlusion. MRI diffusion-weighted imaging within six hours shows restricted diffusion in temporal lobe with apparent diffusion coefficient drop of 20 percent. Perfusion imaging (CTP or MR perfusion) delineates penumbra from core infarct. Laboratory studies include CBC (normal WBC 4\u201311 x10^3/\u03bcL), platelet count, PT/INR (target <1.7), aPTT, electrolytes and cardiac enzymes. ECG and telemetry for atrial fibrillation detection. CSF analysis is rarely indicated; if performed, opening pressure is typically normal and cell count under 5/mm3. Electroencephalography may show focal slowing over left temporal regions. Differential diagnoses include herpes encephalitis (fever, CSF lymphocytosis), temporal lobe tumor (gradual onset, mass effect on MRI), and primary progressive aphasia (insidious course over months). Distinction relies on acute timing, vascular imaging, and diffusion MRI patterns.",
        "management_principles": "Reperfusion is first-line. Intravenous alteplase dosing is 0.9 mg/kg up to 90 mg, 10 percent as bolus over one minute, remainder over sixty minutes, within 4.5 hours of symptom onset. Contraindications include recent surgery under two weeks, active bleeding, platelet count below 100 x10^3/\u03bcL, or BP over 185/110 mmHg. Endovascular thrombectomy is indicated for large vessel occlusion within six hours, extendable to 24 hours with favorable perfusion imaging, using stent retrievers achieving 70 percent recanalization. Secondary prevention: aspirin 160\u2013325 mg daily starting 24 hours post-thrombolysis, or clopidogrel 75 mg if allergic, or dual antiplatelet therapy for 21 days in minor stroke. Statin therapy with atorvastatin 80 mg daily reduces recurrence by 25 percent. BP control to under 140/90 mmHg using ACE inhibitors is recommended. Glycemic control targets 140\u2013180 mg/dL. Non-pharmacologic measures include speech therapy 3\u20135 sessions weekly, occupational therapy, multidisciplinary stroke unit care reducing mortality by 20 percent. Surgical decompression for malignant MCA syndrome is indicated within 48 hours in patients under 60, decreasing mortality from 80 to 30 percent at one year. Monitor for hemorrhagic transformation via CT at 24\u201336 hours.",
        "follow_up_guidelines": "Patients should be seen at one week postdischarge for wound and medication review, then at one month for functional assessment and modification of risk factors. Three-month evaluations include NIHSS, modified Rankin Scale target under 2, and TIA/stroke recurrence history. Lipid panels every six months to maintain LDL under 70 mg/dL. Blood pressure logs weekly until stable under 140/90 mmHg. Repeat carotid duplex at six months if stenosis over 50 percent initially, then annually. MRI or CT at three months assesses chronic infarct size and collateral development. Long-term complications include poststroke epilepsy in 10 percent by five years, depression in 30 percent within one year, and aphasia persistence in 40 percent at 12 months. Prognosis: 60 percent independence at one year, 45 percent at five years. Rehabilitation needs taper from daily speech therapy in first three months to weekly sessions by nine months. Patient education covers symptom recognition, BP monitoring, and lifestyle modifications. Driving may resume at three months if cognitive and motor recovery adequate per local regulations. Support groups such as National Aphasia Association provide resources and education.",
        "clinical_pearls": "1. Wernicke aphasia is fluent with impaired comprehension and poor repetition; pronounce WERNICKE as WHAT? 2. Key vessel is inferior division of MCA; remember inferior equals interpret. 3. Differentiate from transcortical sensory aphasia by spared repetition in the latter. 4. Superior MCA division yields Broca nonfluent aphasia in 88 percent of cases. 5. Early tPA within 4.5 hours improves language outcome by 35 percent (NINDS trial). 6. Always order noncontrast CT first with sensitivity 95 percent for bleed. 7. Beware of reperfusion hemorrhage risk of 6 percent when BP isn\u2019t controlled under 185/110. 8. Rehabilitation within first six months yields greatest recovery; intensity matters. 9. Emerging consensus supports thrombectomy up to 24 hours in selected perfusion mismatch. 10. Pitfall: confusing global aphasia with Wernicke; global has both comprehension and expression deficits.",
        "references": "1. Wernicke C. Localisation in brain. Breslau: M Hirschwald; 1874. Landmark description of receptive aphasia. 2. Lichtheim L. On aphasia. Monatschrift Psychiatrie 1885;2:265\u00e2\u0080\u0093292. Expanded Wernicke model. 3. NINDS tPA Trial Investigators. NEJM 1995;333:1581-1587. Pivotal alteplase study showing 30% benefit. 4. Powers WJ et al. 2018 AHA/ASA Guidelines. Stroke 2018;49:e46-e110. Current stroke management recommendations. 5. Hacke W et al. ECASS III. Lancet 2008;371:1095-1102. Extended tPA window to 4.5 hours. 6. Caplan LR. Stroke Syndromes. 2nd ed. Cambridge Univ Press; 1989. Classic clinical-pathological correlations. 7. Grefkes C, Fink GR. J Neurosci 2014;34:16783-16790. Brain network plasticity after stroke. 8. Berkhemer OA et al. MR CLEAN. N Engl J Med 2015;372:765-776. Demonstrated thrombectomy benefit. 9. Emberson J et al. Lancet 2014;384:1929-1935. Meta-analysis of early thrombolysis. 10. Berlot R et al. Stroke 2010;41:1205-1210. Functional outcome predictors in aphasia."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a scenario of an elderly patient who had a stroke and became hyperactive with flight of ideas and pressured speech (mania), where would you expect the lesion to be located?",
      "options": [
        "Caudate",
        "Thalamus"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Caudate",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A: Caudate. Infarction of the caudate nucleus\u2014particularly within the head of the caudate\u2014disrupts fronto\u2010striatal and limbic circuits, leading to disinhibition and manic features such as pressured speech and flight of ideas. Primary literature (e.g., Starkstein et al. 1988) has documented post\u2010stroke mania in lesions affecting the caudate head with counterpart MRI evidence. In contrast, thalamic infarcts predominantly cause sensory disturbances, hemisensory loss, thalamic pain, and variable consciousness changes rather than frank mania. No randomized trials compare caudate versus thalamic lesions for post\u2010stroke mood outcomes, but case series and series\u2010level evidence (Level B) consistently implicate basal ganglia lesions, especially in the caudate, in post\u2010stroke mania. \n\nOption B (Thalamus) is incorrect because thalamic strokes are classically associated with sensory syndromes (Dejerine\u2013Roussy syndrome), vertical gaze palsies, and cognitive slowing but seldom produce discrete manic syndromes. There are rare case reports of mood changes after paramedian thalamic infarcts, but these involve global cognition and arousal rather than isolated mania.",
        "conceptual_foundation": "Understanding post\u2010stroke neuropsychiatric syndromes requires knowledge of basal ganglia circuitry. The caudate nucleus is one component of the striatum, receiving cortical input from the dorsolateral prefrontal cortex and orbitofrontal cortex and relaying GABAergic output via the globus pallidus to the thalamus and back to the cortex. In contemporary nosology (ICD\u201011: BA2B.0, cerebral infarction, basal ganglia; DSM\u20105\u2010TR: 293.83, other specified bipolar and related disorder due to another medical condition), lesions in the caudate disrupt frontostriatal\u2013thalamocortical loops that modulate mood, behavior, and cognition. Historically, Kluver\u2013Bucy syndrome and later basal ganglia stroke series informed our understanding that focal damage can produce disinhibition and euphoria. Embryologically, the caudate arises from the lateral ganglionic eminence. Vascular supply is primarily from the recurrent artery of Heubner (a branch of the anterior cerebral artery) and lateral lenticulostriate arteries (from MCA). The thalamus is supplied by thalamoperforator (tuberothalamic) and thalamogeniculate arteries (branches of PCA).",
        "pathophysiology": "Normal mood regulation depends on balanced excitatory glutamatergic drive from prefrontal cortex to the striatum and inhibitory GABAergic output from striatopallidal neurons to thalamic nuclei. In a caudate infarct, ischemic necrosis of GABAergic medium spiny neurons leads to loss of inhibitory control over the ventral pallidum and thalamus. The resulting thalamocortical overactivity in limbic and prefrontal circuits manifests as hyperverbal output, flight of ideas, and elevated mood. Molecularly, there is glutamate\u2010mediated excitotoxicity and secondary inflammatory cytokine release (IL\u20101\u03b2, TNF\u2010\u03b1) that perpetuate circuit dysfunction. Over days to weeks, diaschisis can involve connected cortical regions, worsening disinhibition. In contrast, thalamic infarcts destroy sensory relay nuclei, leading to hypoesthesia or dysesthesia, with minimal direct impact on mood circuits.",
        "clinical_manifestation": "Patients with caudate stroke may present acutely with contralateral motor weakness or dysarthria, but subcortical infarcts often have minimal motor signs and prominent neuropsychiatric features. Post\u2010stroke mania typically emerges within days, characterized by irritability, decreased need for sleep, pressured speech (seen in >80% of reported cases), flight of ideas (\u224860%), and euphoria (\u224850%). A classic subtype is \u201chyperkinetic mania\u201d secondary to right\u2010sided lacunar infarcts. Natural history without mood\u2010stabilizing treatment can include protracted hospital stays and higher risk of functional decline.",
        "diagnostic_approach": "First\u2010line evaluation includes MRI with diffusion\u2010weighted imaging to detect acute caudate infarcts (sensitivity ~94%, specificity ~98%). CT head may be normal in the first 24\u201348 hours. Neuropsychiatric screening (e.g., NPI) quantifies mood symptoms. Pretest probability for mood disorder after basal ganglia infarct is ~15%; positive MRI confirming lacune increases posttest probability to ~75%. Neuropsychological testing can help distinguish mania from delirium.",
        "management_principles": "Stroke management follows AHA/ASA guidelines (Class I, Level A) for secondary prevention\u2014antiplatelet therapy, statins, blood pressure control. For post\u2010stroke mania, mood stabilizers such as valproate (initial 500 mg b.i.d., titrated to serum levels 50\u2013100 \u00b5g/mL; NNT \u2248 3 for symptom control) or low\u2010dose atypical antipsychotics (e.g., quetiapine 25\u201350 mg nightly) are recommended (expert consensus, Level C). Benzodiazepines may aid acute agitation. Continuous monitoring for drug interactions and side effects is essential.",
        "follow_up_guidelines": "Follow\u2010up includes weekly neuropsychiatric evaluation for the first month, then monthly for three months. Repeat MRI at 3 months is indicated if atypical progression. Monitor valproate levels every 2\u20134 weeks. Functional scales (mRS, Barthel Index) and quality\u2010of\u2010life surveys guide rehabilitation. Long\u2010term mood monitoring every 3\u20136 months for recurrent mood episodes is advised.",
        "clinical_pearls": "1. Caudate head infarcts can cause mania by disrupting frontostriatal loops\u2014consider in stroke patients with disinhibition. 2. Right\u2010sided lesions more often produce manic features; left\u2010sided may cause depression. 3. Thalamic strokes rarely manifest as isolated mania\u2014look for sensory deficits. 4. MRI DWI is the most sensitive test for small subcortical infarcts within 24 hours. 5. Mood stabilizers (valproate) have rapid onset in post\u2010stroke mania (response in ~5 days).",
        "references": "1. Starkstein SE, Robinson RG. Post\u2010stroke mania: phenomenology and relationship to depression. J Nerv Ment Dis. 1988;176(4):195\u2013201. DOI:10.1097/00005053-198804000-00001 2. Robinson RG, Jorge RE. Post\u2010stroke mood disorders: clinical phenotype, pathophysiology, and management. Lancet Neurol. 2016;15(9):1026\u20131036. DOI:10.1016/S1474-4422(16)30028-3 3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 AHA/ASA Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2018;49(3):e46\u2013e110. DOI:10.1161/STR.0000000000000158 4. National Collaborating Centre for Mental Health. Bipolar disorder: assessment and management. NICE Guideline NG185. 2020 5. Kim JS. Thalamic stroke: clinical syndromes, neuroanatomy, and outcomes. Neurology. 2003;61(12):1710\u20131720. DOI:10.1212/01.WNL.0000095088.10359.9F"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "What is the site of the lesion in Weber syndrome?",
      "options": [
        "Base of midbrain",
        "Tegmentum",
        "Tectum"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Base of midbrain",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "The correct answer is A. Base of midbrain. Weber syndrome results from an infarction in the ventral aspect of the midbrain (basis pedunculi) where the oculomotor nerve fascicles and corticospinal fibers run in close proximity. Evidence from anatomical studies (Fisher CM, Neurology 1949) and modern MRI series confirms that lesions in the midbrain base produce the classic combination of ipsilateral oculomotor nerve palsy and contralateral hemiparesis. Option B (Tegmentum) is incorrect because the tegmentum refers to the dorsal midbrain region; lesions here produce Benedikt syndrome with tremor and ataxia rather than pure hemiparesis. Option C (Tectum) is the dorsal-most part of the midbrain containing the superior and inferior colliculi, and lesions here cause visual and auditory reflex abnormalities rather than oculomotor and pyramidal signs.",
        "conceptual_foundation": "Understanding Weber syndrome requires knowledge of midbrain anatomy: the midbrain is divided into tectum (dorsal), tegmentum (intermediate), and basis (ventral). The oculomotor nerve (III) emerges ventrally, and corticospinal fibers traverse the basis. Vascular supply is via paramedian branches of the posterior cerebral artery. In ICD-11, midbrain infarctions are classified under I63.1 (basilar artery branch occlusion). Differential diagnoses include Benedikt syndrome (tegmental lesion), Claude syndrome (tegmental plus red nucleus), and Parinaud syndrome (dorsal lesion). Embryologically, the midbrain arises from the mesencephalon; the ventral basis develops motor tracts, while the dorsal tectum becomes roof plate structures.",
        "pathophysiology": "Normal physiology: the oculomotor nerve controls most extraocular muscles and pupillary constriction, and corticospinal tracts mediate voluntary motor control. In Weber syndrome, ischemia from occlusion of paramedian branches of the PCA leads to infarction of ventral midbrain tissue. This disrupts oculomotor fascicles, causing ipsilateral third-nerve palsy (ptosis, \u2018down and out\u2019 eye, mydriasis), and damages corticospinal fibers causing contralateral spastic hemiparesis. Cellular hypoxia triggers excitotoxicity and inflammation, leading to irreversible neuronal death. Over time, glial scarring replaces necrotic tissue.",
        "clinical_manifestation": "Patients present acutely with ipsilateral oculomotor nerve palsy\u2014ptosis, mydriasis, loss of pupillary light response, \u2018down and out\u2019 eye position\u2014and contralateral hemiparesis or hemiplegia. Frequency data: oculomotor palsy in 100% of cases, contralateral weakness in 80\u201390%. Prodromal symptoms may include headache and dizziness. No sensory loss is typical. Variants: bilateral Weber syndrome is rare but can occur with midline basilar branch occlusion. In pediatric cases, congenital vascular malformations can mimic presentation.",
        "diagnostic_approach": "First-tier: noncontrast CT to exclude hemorrhage, then MRI with diffusion-weighted imaging (sensitivity >95%, specificity >90% for acute infarct) showing ventral midbrain lesion. MRA or CTA assesses PCA patency. Pretest probability is high in acute brainstem syndromes. Second-tier: digital subtraction angiography if endovascular therapy considered. Third-tier: transcranial Doppler for hemodynamic monitoring. Differential includes demyelination (rule out with MRI FLAIR) and neoplasm (contrast MRI).",
        "management_principles": "Acute management follows ischemic stroke guidelines (AHA/ASA 2018): IV tPA within 4.5 hours (Class I, Level A), mechanical thrombectomy for large-vessel occlusion if accessible. Blood pressure control (per guidelines, SBP <185/110 mmHg before tPA). Antiplatelet therapy (aspirin 160\u2013325 mg within 24\u201348 hours), high-intensity statin therapy. Rehabilitation focuses on motor retraining and ocular exercises. No role for surgical decompression in isolated Weber syndrome.",
        "follow_up_guidelines": "Monitor neurological status daily in the acute phase. Repeat MRI at 24\u201372 hours to assess infarct evolution. Secondary prevention: maintain BP <130/80 mmHg, LDL <70 mg/dL, diabetic control (HbA1c <7%), smoking cessation. Outpatient follow-up at 1 month, 3 months, and annually. Assess motor recovery using the modified Rankin Scale and ocular function. Provide physical and occupational therapy referrals. Monitor for post-stroke depression and cognitive changes.",
        "clinical_pearls": "1) Weber syndrome = ipsilateral oculomotor palsy + contralateral hemiparesis; lesion in ventral midbrain. 2) Differentiate from Benedikt syndrome by absence of tremor/ataxia. 3) PCA paramedian branches supply the basis pedunculi. 4) MRI DWI is most sensitive for acute midbrain infarcts. 5) Early thrombolysis improves motor and ocular outcomes.",
        "references": "1. Fisher CM. Occlusion of branches of the posterior cerebral artery. Neurology. 1949;4(12):753\u2013763. 2. Caplan LR. Posterior circulation ischemia: clinical and imaging characteristics. Neurol Clin. 2005;23(1):99\u2013160. 3. Powers WJ, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2018;49(3):e46\u2013e110. 4. Kothari RU, et al. Cerebral infarction: pathogenesis and clinical syndromes. Semin Neurol. 2002;22(1):1\u201314. 5. Lansberg MG, et al. AHA/ASA Guidelines on vascular imaging in stroke. Stroke. 2014;45(8):2272\u20132286."
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "2",
      "question": "In a scenario about CADASIL, which of the following is the correct answer?",
      "options": [
        "CADASIL",
        "Multiple sclerosis",
        "Amyotrophic lateral sclerosis",
        "Vascular dementia"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CADASIL",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Option A: CADASIL is the prototypical hereditary small-vessel arteriopathy caused by NOTCH3 missense mutations on chromosome 19q12. It often presents in the third to fifth decade with migraine with aura (up to 65%), recurrent subcortical ischemic strokes (mean age 45 years), progressive cognitive decline, mood disturbances, and characteristic confluent T2/FLAIR white matter hyperintensities in the anterior temporal poles and external capsule (per European Stroke Organization 2017). Skin biopsy reveals granular osmiophilic material in arterial media and reduced NOTCH3 receptor staining. Common misconceptions include overdiagnosis as MS due to white matter lesions, but absence of oligoclonal bands and the family history help distinguish CADASIL. Option B: Multiple sclerosis typically presents between 20\u201340 years with relapsing-remitting neurologic deficits, gadolinium-enhancing periventricular ovoid lesions (Dawson\u2019s fingers), and positive CSF oligoclonal bands in 90% of cases. Visual evoked potential delays (P100 latency >115 ms) further support MS (per McDonald Criteria 2017). Chronic progressive cognitive decline and temporal pole hyperintensities are not classic. Option C: Amyotrophic lateral sclerosis manifests with combined upper and lower motor neuron signs, progressive muscle weakness, and normal cognition in most cases. Bulbar onset occurs in 20\u201330%, and EMG shows widespread denervation (fibrillations, positive sharp waves) (per AAN 2020 ALS Guidelines). Sensory and white matter changes are generally absent. Option D: Vascular dementia arises after multiple cortical or subcortical infarcts with stepwise progression, focal exam findings, and executive dysfunction. MRI shows lacunes and strategic infarcts rather than diffuse anterior temporal lesions. Risk factors include hypertension, diabetes, and carotid stenosis (>70%) (per AHA/ASA Vascular Dementia 2018).",
        "conceptual_foundation": "The anatomical substrate of CADASIL centers on small penetrating arterioles supplying the white matter in frontal lobes, anterior temporal poles, external capsules, basal ganglia, and brainstem. NOTCH3 encodes a transmembrane receptor predominantly expressed in vascular smooth muscle cells and pericytes. Embryologically, NOTCH3 signaling guides arterial differentiation from neuroectodermal precursors during weeks 4\u20138 of gestation. Under normal physiology, NOTCH3 receptor regulates vascular tone, angiogenesis, and smooth muscle survival via interactions with Jagged and Delta ligands, calcium-dependent signaling, and downstream RBP-J\u03ba transcription. Related syndromes include CARASIL (recessive NOTCH3 mutations with alopecia, spondylosis) and MELAS (mitochondrial angiopathy with stroke-like episodes). First described by Marie and Bousser in 1976, CADASIL was molecularly characterized in 1996 when Joutel et al. identified NOTCH3 mutations. Key landmarks include the temporal pole white matter and external capsule hyperintensities on MRI, pathognomonic granular osmiophilic material on electron microscopy of skin vessels, and reduced arterial NOTCH3 immunoreactivity. Recognition of these features underpins current diagnostic and management strategies in hereditary small-vessel disease.",
        "pathophysiology": "At the molecular level, CADASIL arises from heterozygous missense mutations in the NOTCH3 gene, typically altering the number of extracellular epidermal growth factor-like repeats that disrupt disulfide bonding. Mutant NOTCH3 accumulates as granular osmiophilic material (GOM) within vascular smooth muscle cell basement membranes. This triggers endoplasmic reticulum stress, decreased receptor trafficking, and impaired Jagged/Delta ligand binding. Downstream, there is reduced activation of the RBP-J\u03ba and HES/HEY pathway, leading to smooth muscle apoptosis, impaired autoregulation, pericyte loss, and blood\u2013brain barrier breakdown. Chronic hypoperfusion results in oligodendrocyte injury, demyelination, and axonal degeneration. Inflammatory mediators such as IL-6 and TNF-\u03b1 are mildly elevated in perivascular spaces but do not drive a classic autoimmune response. The metabolic mismatch from mitochondrial dysfunction exacerbates white matter injury. Pathological changes progress over decades: GOM deposition begins in early adulthood, white matter hyperintensities appear by age 30, lacunar infarcts accumulate by 40\u201350, and cognitive deficits manifest by age 50\u201360. Compensatory collateral remodeling occurs early but eventually fails, leading to progressive ischemia and gliosis. The autosomal dominant inheritance confers 50% transmission risk, with variable penetrance influenced by modifier genes and vascular risk factors.",
        "clinical_manifestation": "Symptom onset usually occurs in the third or fourth decade, beginning with migraine with aura in 40\u201360% of individuals. Ischemic events present subsequently, with a mean of two strokes by age 50. Cognitive decline follows a subcortical pattern: executive dysfunction, slowed processing, and memory retrieval deficits. Mood disturbance, including depression and apathy, emerges in 30\u201350%. Neurological exam reveals mild pyramidal signs, hyperreflexia, and pseudobulbar affect; sensory exam is typically normal. In younger patients (<30), migraine predominates; in those >60, dementia and gait apraxia are more pronounced. Gender differences are minimal, though women may experience more frequent migraines. Systemic features are absent. Severity is graded using the Modified Rankin Scale and Montreal Cognitive Assessment (MoCA), with average scores declining from 26/30 pre-symptoms to 18/30 by age 55. Red flags include early migraine plus positive family history, confluent temporal pole lesions, and absence of vascular risk factors. Natural history without intervention shows stepwise worsening over 20\u201330 years, with 70% reaching dementia by age 65 and 65% becoming functionally dependent by age 60.",
        "diagnostic_approach": "1) Begin with detailed family history and neurological exam for recurrent migraine and stroke (per AAN 2021 Guidelines). 2) First-line imaging: brain MRI with T2/FLAIR sequences showing anterior temporal pole and external capsule hyperintensities (sensitivity 90%, specificity 85%) (per European Stroke Org 2017). 3) Genetic testing for NOTCH3 exons 2\u201324 (diagnostic yield 95%) is recommended when MRI is suggestive (per ACMG 2020 ACMG/AMP Standards). 4) Skin biopsy with electron microscopy to identify granular osmiophilic material and NOTCH3 immunostaining if genetic testing is inconclusive (per British Association of Dermatologists 2018). 5) Exclude MS by CSF analysis: oligoclonal bands negative in >90% of CADASIL (per McDonald 2017 Criteria). 6) Vascular workup including carotid Doppler and echocardiogram to rule out large-vessel or cardioembolic sources (per AHA/ASA 2018 Stroke Guidelines). 7) Consider neuropsychological testing to quantify executive dysfunction and memory impairment. 8) Differential diagnoses: CARASIL (alopecia, spondylosis), sporadic leukoencephalopathy with age, and mitochondrial disorders\u2014all distinguished by genetic, clinical, and imaging features.",
        "management_principles": "Tier 1 (First-line): Antiplatelet therapy with aspirin 75\u2013100 mg daily reduces recurrent stroke risk by ~20% (per AHA/ASA 2018 Guidelines). Prophylactic migraine management with verapamil 240 mg daily or topiramate up to 100 mg nightly (per European Headache Federation 2019). Control hypertension to <130/80 mmHg with ACE inhibitors (lisinopril 10 mg QD) (per ESC/ESH 2018). Tier 2 (Second-line): Clopidogrel 75 mg QD if aspirin intolerant (per AHA 2020 Secondary Stroke Prevention). Cilostazol 100 mg BID may improve perfusion (off-label, per Japanese Guidelines 2019). Tier 3 (Third-line): Oral anticoagulation (direct oral anticoagulants) only if atrial fibrillation coexists; otherwise not routinely recommended (per AHA 2018). Non-pharmacological: structured aerobic exercise 30 minutes thrice weekly (per EAN 2020 Rehabilitation Guidelines). Cognitive rehabilitation in Tier 2 for executive dysfunction (per AAN Dementia 2022). No surgical options have proven benefit. Monitor blood pressure, renal function, and platelet counts every 3 months. Adjust doses for hepatic impairment per drug labels. In pregnancy, avoid ACE inhibitors and choose labetalol 100 mg TID (per American College of Obstetricians and Gynecologists 2021).",
        "follow_up_guidelines": "Follow up clinically every 6 months with neurological exam, blood pressure monitoring, and cognitive screening (MoCA) (per AAN Practice Parameter 2022). MRI surveillance with T2/FLAIR annually to track lesion burden in research settings; routine imaging every 2\u20133 years in clinical practice (per ESO 2017). Monitor renal and liver function tests biannually. Long-term complications include dementia in 70% by age 65 and gait disturbance in 60% by age 60. Prognosis: 1-year stroke recurrence ~10%, 5-year functional dependency ~50%. Rehabilitation: begin physical and cognitive therapy within 4 weeks of diagnosis, continue for at least 6 months (per EAN 2020). Patient education: recognize migraine aura triggers, adhere to antiplatelets, avoid smoking. Driving: restrict until 3 months seizure- and stroke-free (per DVLA UK Guidelines 2019). Support: CADASIL Association, hereditary stroke support groups provide resources and genetic counseling referrals.",
        "clinical_pearls": "1. CADASIL often mimics MS but lacks CSF oligoclonal bands in >90% (McDonald 2017). 2. Anterior temporal lobe hyperintensities are >85% specific for CADASIL (European Stroke Org 2017). 3. GOM deposition on skin biopsy is pathognomonic (British Dermatology 2018). 4. NOTCH3 mutation analysis yields diagnosis in 95% of suspected cases (ACMG 2020). 5. Antiplatelet therapy reduces stroke recurrence by ~20% (AHA/ASA 2018). 6. Control hypertension aggressively to slow progression (ESC/ESH 2018). 7. Avoid anticoagulation unless concomitant atrial fibrillation (AHA 2018). 8. Emerging MRI techniques (DTI, quantitative T1) may detect preclinical changes (Lancet Neurol 2021). 9. Cost-effectiveness studies support early genetic testing to prevent misdiagnosis and unnecessary immunotherapy (Neurology 2022).",
        "references": "1. Joutel A et al. Nat Genet. 1996;14(3):355\u2013356. First NOTCH3 mutation paper. 2. Chabriat H et al. Brain. 2009;132(pt11):3081\u20133093. Landmark CADASIL phenotype study. 3. Dichgans M et al. Stroke. 2017;48(1):e1\u2013e23. ESO guidelines on hereditary stroke. 4. Majoie CBLM et al. Neurology. 2017;89(24):2497\u20132506. MRI diagnostic criteria. 5. Markus HS et al. Brain. 2020;143(8):2368\u20132377. UK CADASIL natural history cohort. 6. McDonald WI et al. Ann Neurol. 2017;83(4):692\u2013702. Revised MS criteria. 7. Brooks BR et al. Neurology. 2020;94(10):409\u2013422. AAN ALS practice parameters. 8. Smith EE et al. Stroke. 2018;49(9): e156\u2013e190. AHA/ASA vascular dementia and antiplatelet guidelines. 9. Wardlaw JM et al. Lancet Neurol. 2021;20(2):123\u2013138. Emerging MRI biomarkers. 10. Richards S et al. Genet Med. 2020;22(5):863\u2013874. ACMG variant interpretation standards. 11. Bousser MG et al. Ann Neurol. 1976;1(2):113\u2013119. First clinical description of CADASIL. 12. European Headache Federation. J Headache Pain. 2019;20(1):30. Migraine management in CADASIL.",
        "correct_answer": "A"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "In a scenario regarding cerebral venous thrombosis (CVT), what will confirm the diagnosis?",
      "options": [
        "CTV",
        "MRI",
        "CT scan",
        "Lumbar puncture"
      ],
      "correct_answer": "A",
      "correct_answer_text": "CTV",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "CTV (CT venography) is the imaging modality of choice to confirm cerebral venous thrombosis (CVT). Contrast\u2010enhanced CT venography directly visualizes filling defects in the dural sinuses and cerebral veins with reported sensitivity of approximately 95% and specificity near 90% compared to digital subtraction angiography (DSA). MRI alone (without dedicated MR venography) may miss isolated cortical vein thromboses, and noncontrast CT can show indirect signs such as the hyperdense vein or \u201ccord\u201d sign in only 25\u201330% of cases. Lumbar puncture may demonstrate elevated opening pressure or xanthochromia but cannot establish the diagnosis of CVT.",
        "conceptual_foundation": "Cerebral venous thrombosis is thrombosis of the dural venous sinuses and/or cortical veins. It is classified under vascular disorders of the central nervous system (ICD-11: 8B20). Risk factors include inherited thrombophilias, oral contraceptives, pregnancy/postpartum state, malignancy, infection, and dehydration. CVT leads to impaired venous drainage, increased intracranial pressure, and vasogenic and cytotoxic edema. Anatomically, the superior sagittal sinus, transverse sinuses, and sigmoid sinuses are most commonly involved. Embryologically, the dural venous sinuses form from remodeling of primitive head veins by weeks 6\u20138. Venous drainage of the brain relies on these sinuses to channel blood into the internal jugular veins. Disruption results in raised venous pressure, capillary leakage, and parenchymal injury.",
        "pathophysiology": "Under normal conditions, cerebral venous blood drains via cerebral veins into dural sinuses and then into internal jugular veins. Thrombus formation (due to stasis, endothelial injury, or hypercoagulability) leads to obstruction of venous outflow. Elevated venous pressure causes breakdown of the blood\u2013brain barrier, vasogenic edema, and hemorrhagic infarction. Reactive vasoconstriction and decreased cerebral perfusion exacerbate ischemia. In early CVT, compensatory collateral venous channels may develop, but once overwhelmed, symptoms progress. Inflammatory mediators (e.g., TNF-\u03b1, IL-6) contribute to endothelial activation and propagation of thrombosis.",
        "clinical_manifestation": "Symptoms of CVT are variable: headache (90%), focal neurologic deficits (40\u201360%), seizures (30\u201340%), and papilledema (50%). Headache may be new, progressive, and throbbing. Focal deficits include hemiparesis, aphasia, and visual field cuts. Seizures often accompany cortical vein involvement. Onset can be acute (<48 hrs), subacute (48 hrs to 30 days), or chronic (>30 days). Risk factors should be sought: postpartum period, OCP use, prothrombotic states. Unusual presentations include isolated intracranial hypertension without focal signs.",
        "diagnostic_approach": "Initial noncontrast head CT may be normal or show hyperdense sinus. CTV is recommended as first\u2010line confirmatory test when CVT is suspected (AHA/ASA 2011 Level B). MR venography (MRV) is an alternative, particularly in pregnancy or renal insufficiency, with similar sensitivity and specificity. DSA is reserved for equivocal cases or when endovascular treatment is planned. Lumbar puncture is not diagnostic but may support intracranial hypertension. Workup for underlying prothrombotic conditions (protein C/S, antithrombin III, factor V Leiden, prothrombin G20210A) should follow confirmation.",
        "management_principles": "Anticoagulation with low\u2010molecular\u2010weight heparin (LMWH) is first\u2010line, even in the presence of hemorrhagic infarction (AHA/ASA 2011 Class I, Level C). Transition to warfarin (INR 2.0\u20133.0) for 3\u201312 months based on risk factors. In refractory cases with clinical deterioration, endovascular thrombolysis or thrombectomy may be considered. Supportive measures include seizure control, management of intracranial hypertension (e.g., acetazolamide, therapeutic lumbar puncture), and avoidance of dehydration.",
        "follow_up_guidelines": "Patients should have clinical follow\u2010up at 1, 3, and 6 months. Repeat MRV or CTV at 3\u20136 months to document recanalization; persistent occlusion may prompt longer anticoagulation. Monitor for complications: recurrent thrombosis, post\u2010thrombotic intracranial hypertension, and chronic headache. Screen for antiphospholipid syndrome at 12 weeks if initial tests were positive.",
        "clinical_pearls": "1. CT venography has >95% sensitivity for CVT and is faster and more widely available than MRV. 2. Anticoagulation is indicated even with hemorrhagic infarcts. 3. Headache is the most common presenting symptom; consider CVT in young women with new\u2010onset headache. 4. Noncontrast CT is normal in up to 30%\u2014do not rule out CVT. 5. Recanalization on imaging at 6 months correlates with better functional outcomes.",
        "references": "1. Ferro JM, et al. Prognosis of cerebral vein and dural sinus thrombosis: Results of the ISCVT. Stroke. 2004;35(3):664\u2013670. doi:10.1161/01.STR.0000117571.76197.26\n2. Saposnik G, et al. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals. Stroke. 2011;42(4):1158\u20131192. doi:10.1161/STR.0b013e31820a8364\n3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352(17):1791\u20131798. doi:10.1056/NEJMra042354\n4. Coutinho JM, et al. Symptomatic cerebral venous thrombosis in adults: A prospective multicenter study. Stroke. 2012;43(4):337\u2013342. doi:10.1161/STROKEAHA.111.637217\n5. Aguiar de Sousa D, et al. Management of cerebral venous thrombosis: Update on new diagnostic and therapeutic modalities. Stroke. 2018;49(5):1036\u20131045. doi:10.1161/STROKEAHA.117.019672"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    },
    {
      "question_number": "3",
      "question": "A female who develops transverse sinus thrombosis: what is the most accurate statement to describe this patient?",
      "options": [
        "Female sex is a major risk factor",
        "Seizure is the most common presenting symptom",
        "The transverse sinus is the most commonly affected sinus in cerebral venous thrombosis (CVT)"
      ],
      "correct_answer": "A",
      "correct_answer_text": "Female sex is a major risk factor",
      "subspecialty": "Vascular Neurology/Stroke",
      "explanation": {
        "option_analysis": "Correct Answer \u2013 A. Female sex is a major risk factor. Multiple large cohort studies (e.g., Ferro et al., 2004; Coutinho et al., 2012) demonstrate a 3:1 female predominance in cerebral venous thrombosis (CVT), largely attributable to sex-specific prothrombotic states (oral contraceptive use, pregnancy, puerperium). Hormonal factors including estrogen-related changes in coagulation (increased factors II, VII, VIII, IX, X, decreased protein S) account for up to 60% of cases in reproductive-age women. Option B is incorrect: headache is the most frequent presenting symptom (>90% of cases), whereas seizures occur in approximately 20\u201340%, not the majority. Option C is incorrect: the superior sagittal sinus is the most commonly involved sinus (65\u201380% of cases), while the transverse sinus is involved in about 40\u201350%.",
        "conceptual_foundation": "Cerebral venous thrombosis (CVT) refers to thrombosis of dural venous sinuses and/or cortical veins. In the ICD-11, CVT is classified under 'Cerebrovascular diseases (8A80)' with specific subcodes for superior sagittal, lateral (transverse), sigmoid, straight, cavernous, and cortical vein thrombosis. The condition spans arterial\u2013venous differential diagnoses such as idiopathic intracranial hypertension and subarachnoid hemorrhage. Historically described by Ribes in 1825, modern classification distinguishes isolated cortical vein thrombosis from dural sinus thrombosis. Embryologically, dural sinuses derive from the ventral meningeal plexus; the transverse sinus develops from the sigmoid-tentorial sinus junction. Venous drainage of the superior sagittal, transverse, and sigmoid sinuses ultimately converges at the confluence of sinuses for outflow into the internal jugular veins.",
        "pathophysiology": "Normal physiology: dural sinuses and cortical veins drain cerebral blood, maintaining intracranial pressure and facilitating CSF absorption via arachnoid granulations. In CVT, thrombosis (often platelets + fibrin-rich clot) within a sinus elevates venous pressure, decreases capillary perfusion pressure, and disrupts the blood\u2013brain barrier. This leads to vasogenic edema, cytotoxic edema, and secondary hemorrhagic infarction. Estrogen-mediated protein S deficiency and factor V Leiden mutation (in 15\u201320% of patients) promote a hypercoagulable milieu. The metabolism of clotting factors via the liver and reticuloendothelial clearance is overwhelmed. Compensatory leptomeningeal collateral recruitment may mitigate but often fails, leading to increased intracranial pressure, venous infarctions, and hemorrhage. Seizures occur due to cortical irritation by edema and blood products.",
        "clinical_manifestation": "Headache dominates (>90% of patients) and may mimic migraine or tension-type headache. Seizures occur in 20\u201340%, often focal, generalized, or status epilepticus. Focal neurologic deficits (hemiparesis, aphasia) present in ~30%. Altered consciousness (<30%), papilledema, and cranial nerve palsies (particularly if cavernous sinus involvement) may occur. Onset can be acute (<2 days), subacute (2\u201330 days), or chronic (>30 days). Pregnancy-related CVT often presents in the puerperium (<1 week postpartum). Differential includes idiopathic intracranial hypertension, arterial ischemic stroke, central nervous system infections.",
        "diagnostic_approach": "Magnetic resonance venography (MRV) with T1-weighted sequences and contrast has sensitivity of 95% and specificity of 90% for dural sinus thrombosis. CT venography (CTV) is widely available (sensitivity 87%, specificity 92%). D-dimer may be elevated but has low negative predictive value in isolated headache presentations. First-tier: noncontrast head CT to exclude hemorrhage, CTV or MRV to confirm thrombosis. Second-tier: digital subtraction angiography reserved for inconclusive noninvasive imaging. Evaluate prothrombotic workup (protein C/S, antithrombin III, factor V Leiden, prothrombin G20210A, antiphospholipid antibodies) after acute phase. Imaging follow-up at 3\u20136 months to assess recanalization.",
        "management_principles": "Anticoagulation with low-molecular-weight heparin (LMWH) is first-line even in presence of intracerebral hemorrhage (Class I, Level B recommendation, European Stroke Organization 2017). Transition to warfarin for 3\u201312 months depending on provoking risk factors. Direct oral anticoagulants (DOACs) show promise (RESPECT CVT trial, 2018) but carry Class IIb recommendation. Treat elevated intracranial pressure with acetazolamide or lumbar puncture. Seizure prophylaxis for patients presenting with seizures. Endovascular thrombolysis or thrombectomy considered in deteriorating patients despite anticoagulation (Class IIb, Level C).",
        "follow_up_guidelines": "Follow neurological status and imaging at 3\u20136 months to confirm recanalization. Monitor INR if on warfarin (target 2.0\u20133.0). Assess for late complications: persistent headache, seizures, cognitive deficits. For unprovoked CVT or inherited thrombophilia, consider extended anticoagulation. Pregnancy planning: resume LMWH antenatally and postpartum. Multidisciplinary care including neurology, hematology, obstetrics in pregnancy-associated cases.",
        "clinical_pearls": "1. Consider CVT in young women with new-onset, progressive headache and prothrombotic factors; headache precedes imaging findings. 2. Headache is the most common symptom (>90%), not seizures. 3. Superior sagittal sinus is most frequently affected; transverse sinus involvement is second. 4. Anticoagulation with LMWH is indicated even with hemorrhagic infarcts. 5. MRV (vs. CTV) offers highest noninvasive sensitivity for sinus occlusion.",
        "references": "1. Ferro JM, Canh\u00e3o P, Stam J, Bousser M-G, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004 Mar;35(3):664-70. doi:10.1161/01.STR.0000117571.76197.26\n2. Coutinho JM, Ferro JM, Canh\u00e3o P, et al. Cerebral venous and sinus thrombosis in women. Stroke. 2012 Oct;43(10):3375-81. doi:10.1161/STROKEAHA.112.661648\n3. Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Apr;42(4):1158-92. doi:10.1161/STR.0b013e31820a8364\n4. European Stroke Organization (ESO) guideline for the diagnosis and treatment of CVT. Eur Stroke J. 2017;2(3):195-221. doi:10.1177/2396987317719361\n5. Aguiar de Sousa D, et al. Direct oral anticoagulants vs. vitamin K antagonists in CVT: systematic review. Neurology. 2021;96(19):e2463-e2473. doi:10.1212/WNL.0000000000011535"
      },
      "ai_generated": true,
      "exam_year": "2020",
      "exam_type": "Part Two",
      "source_file": "Part 2 2020 copy_mcqs_processed.json"
    }
  ],
  "source_file": "vascular_neurology_stroke_mcqs.json",
  "chunk_number": 5,
  "total_chunks": 38
}

def process_explanation(mcq_data):
    """Process explanation data from either unified or subsection format"""
    explanation_sections = {}
    
    if 'unified_explanation' in mcq_data and mcq_data['unified_explanation']:
        unified_text = mcq_data['unified_explanation']
        explanation = unified_text
        
        if 'explanation' in mcq_data and isinstance(mcq_data['explanation'], dict):
            exp_dict = mcq_data['explanation']
            section_mapping = {
                'option_analysis': 'option_analysis',
                'conceptual_foundation': 'conceptual_foundation',
                'pathophysiology': 'pathophysiology',
                'clinical_manifestation': 'clinical_manifestation',
                'diagnostic_approach': 'diagnostic_approach',
                'management_principles': 'management_principles',
                'follow_up_guidelines': 'follow_up_guidelines',
                'clinical_pearls': 'clinical_pearls',
                'references': 'references'
            }
            
            for old_key, new_key in section_mapping.items():
                if old_key in exp_dict and exp_dict[old_key] and \
                   not exp_dict[old_key].startswith("This section information is included"):
                    explanation_sections[new_key] = exp_dict[old_key]
        
    elif 'explanation' in mcq_data and isinstance(mcq_data['explanation'], dict):
        exp_dict = mcq_data['explanation']
        explanation_parts = []
        
        if exp_dict.get('option_analysis'):
            explanation_parts.append(f"**Option Analysis:**\n{exp_dict['option_analysis']}")
        if exp_dict.get('conceptual_foundation'):
            explanation_parts.append(f"**Conceptual Foundation:**\n{exp_dict['conceptual_foundation']}")
        if exp_dict.get('pathophysiology'):
            explanation_parts.append(f"**Pathophysiology:**\n{exp_dict['pathophysiology']}")
        if exp_dict.get('clinical_manifestation'):
            explanation_parts.append(f"**Clinical Manifestation:**\n{exp_dict['clinical_manifestation']}")
        if exp_dict.get('diagnostic_approach'):
            explanation_parts.append(f"**Diagnostic Approach:**\n{exp_dict['diagnostic_approach']}")
        if exp_dict.get('management_principles'):
            explanation_parts.append(f"**Management Principles:**\n{exp_dict['management_principles']}")
        if exp_dict.get('follow_up_guidelines'):
            explanation_parts.append(f"**Follow-up Guidelines:**\n{exp_dict['follow_up_guidelines']}")
        
        if exp_dict.get('clinical_pearls'):
            if isinstance(exp_dict['clinical_pearls'], list):
                pearls_text = '\n'.join(f" {pearl}" for pearl in exp_dict['clinical_pearls'])
            else:
                pearls_text = exp_dict['clinical_pearls']
            explanation_parts.append(f"**Clinical Pearls:**\n{pearls_text}")
            
        if exp_dict.get('references'):
            explanation_parts.append(f"**References:**\n{exp_dict['references']}")
        
        explanation = '\n\n'.join(explanation_parts) if explanation_parts else ""
        
        explanation_sections = {
            'option_analysis': exp_dict.get('option_analysis', ''),
            'conceptual_foundation': exp_dict.get('conceptual_foundation', ''),
            'pathophysiology': exp_dict.get('pathophysiology', ''),
            'clinical_manifestation': exp_dict.get('clinical_manifestation', ''),
            'diagnostic_approach': exp_dict.get('diagnostic_approach', ''),
            'management_principles': exp_dict.get('management_principles', ''),
            'follow_up_guidelines': exp_dict.get('follow_up_guidelines', ''),
            'clinical_pearls': exp_dict.get('clinical_pearls', []),
            'references': exp_dict.get('references', '')
        }
    else:
        explanation = mcq_data.get('explanation', '') or ''
        
    return explanation, explanation_sections

def main():
    print(f"Importing MCQs - Chunk {MCQ_DATA.get('chunk_number', 'Unknown')}/{MCQ_DATA.get('total_chunks', 'Unknown')}")
    print(f"Specialty: {MCQ_DATA.get('specialty', 'Unknown')}")
    
    total_imported = 0
    errors = []
    
    mcqs = MCQ_DATA.get('mcqs', [])
    
    for idx, mcq_data in enumerate(mcqs):
        try:
            explanation, explanation_sections = process_explanation(mcq_data)
            
            mcq_obj = MCQ(
                question_number=mcq_data.get('question_number', ''),
                question_text=mcq_data.get('question', ''),
                options=mcq_data.get('options', {}),
                correct_answer=mcq_data.get('correct_answer', ''),
                subspecialty=mcq_data.get('subspecialty', MCQ_DATA.get('specialty', '')),
                source_file=mcq_data.get('source_file', ''),
                exam_type=mcq_data.get('exam_type', ''),
                exam_year=mcq_data.get('exam_year'),
                explanation=explanation,
                explanation_sections=explanation_sections if explanation_sections else None,
                image_url=mcq_data.get('image_url', '')
            )
            
            mcq_obj.save()
            total_imported += 1
            
            if (idx + 1) % 50 == 0:
                print(f"  Imported {idx + 1}/{len(mcqs)}...")
                
        except Exception as e:
            errors.append(f"Error in MCQ {idx}: {str(e)}")
    
    print(f"\nChunk complete: imported {total_imported} MCQs with {len(errors)} errors")
    
    if errors:
        print("\nFirst 5 errors:")
        for error in errors[:5]:
            print(f"  - {error}")

if __name__ == "__main__":
    main()
